<SEC-DOCUMENT>0001628280-23-037360.txt : 20231107
<SEC-HEADER>0001628280-23-037360.hdr.sgml : 20231107
<ACCEPTANCE-DATETIME>20231107161432
ACCESSION NUMBER:		0001628280-23-037360
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231107
DATE AS OF CHANGE:		20231107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyell Immunopharma, Inc.
		CENTRAL INDEX KEY:			0001806952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				833006753
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40502
		FILM NUMBER:		231384092

	BUSINESS ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 695-0677

	MAIL ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lyel-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:8759b030-35fe-4fde-9a5a-bde7fe691e10,g:0b784d50-2a9f-447e-ae11-ec2a3c5830c1,d:cccf8cd82c034620b68745752f617ca9--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:lyel="http://lyell.com/20230930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lyel-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001806952</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-26">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lyel-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">lyel:AdjustmentToRevenueRelatedToChangeInEstimateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>lyel:entity</xbrli:measure></xbrli:unit><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyel:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyel:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GoldmanSachsAndBofAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-04</xbrli:startDate><xbrli:endDate>2022-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lyel:LyellImmunopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-06</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-06</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-99 f-100 f-98 f-101" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship></ix:resources></ix:header></div><div id="icccf8cd82c034620b68745752f617ca9_1"></div><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September&#160;30, 2023</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Lyell Immunopharma, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">83-1300510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(State or other jurisdiction of</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">201 Haskins Way</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">695-0677</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:37.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">LYEL</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:6pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of November&#160;2, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">251,868,968</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_13">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.72pt;padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_25">Condensed Consolidated Statements of Stockholders</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_25">&#8217;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_25"> Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_34">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_94">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_94">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_124">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_127">31</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_130">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_133">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_133">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_136">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_136">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_136">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_166">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_166">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_166">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_169">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_169">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_169">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_172">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_172">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_172">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_175">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_175">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_175">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_178">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_178">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_178">71</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_181">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_181">72</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned nonclinical studies and clinical trials, results of nonclinical studies and clinical trials, research and development costs, planned regulatory submissions, regulatory approvals and the timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the accuracy and timing of our estimates regarding expenses, revenue opportunities, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, progress, results and costs of developing LYL797, LYL845, LYL119 or any other product candidates we may develop, and conducting nonclinical studies and clinical trials, including for LYL797, LYL845 and LYL119;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and costs involved in obtaining and maintaining regulatory approvals of LYL797, LYL845, LYL119 or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including any expectations regarding seeking special designations for our product candidates for various diseases;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our plans relating to the commercialization of LYL797, LYL845, LYL119 or any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales force;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size of the market opportunities for LYL797, LYL845, LYL119 or any other product candidates we may develop in each of the diseases we may target;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reliance on third parties to conduct nonclinical research activities for LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the characteristics, safety, efficacy and therapeutic effects of LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our estimates of the number of patients in the United States who suffer from the diseases we target and the number of subjects that will enroll in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the progress and focus of our current and planned clinical trials of our product candidates, and the reporting of data from those trials, including the timing thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability of our clinical trials to demonstrate the safety and efficacy of LYL797, LYL845, LYL119 or any other product candidates we may develop, and other clinical trial results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of competing therapies that are, or may become, available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developments relating to our competitors and our industry, including any existing or future competing product candidates or therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our plans relating to the further development and manufacturing of LYL797, LYL845, LYL119 or any other product candidates we may develop, including additional indications that we may pursue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our potential and ability to successfully manufacture and supply LYL797, LYL845, LYL119 or any other product candidates we may develop for clinical trials and for commercial use, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the rate and degree of market acceptance, as well as the pricing and reimbursement, of LYL797, LYL845, LYL119 or any other product candidates we may develop, if approved;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our continued reliance on third parties to assist us in conducting additional clinical trials of LYL797, LYL845, LYL119 or any other product candidates we may develop, and our potential reliance on third parties for the manufacture of our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of protection we are able to establish and maintain for intellectual property rights, including covering our product candidates and technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our expectations regarding the impact of inflation, macroeconomic conditions and geopolitical conflicts on our business and operations, including on our manufacturing suppliers, collaborators, contract research organizations (CROs) and employees; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our anticipated use of our existing cash, cash equivalents and marketable securities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our expectations related to the costs, timing and estimated financial impact of our planned reduction in workforce in the fourth quarter of 2023, including the estimated charges associated with the reduction in workforce.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A, and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in these forward-looking statements. Except as required by applicable law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those projected in these forward-looking statements, even if new information becomes available in the future. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="icccf8cd82c034620b68745752f617ca9_16"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Financial Statements.</span></div><div><span><br/></span></div><div id="icccf8cd82c034620b68745752f617ca9_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">286,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">123,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">289,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">516,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">11,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">586,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">651,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-38">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-39">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">22,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">70,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-42">32,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-43">44,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">108,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">123,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">40,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">43,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">4,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">794,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">937,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">LIABILITIES AND STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">4,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">3,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">29,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">28,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:SuccessPaymentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:SuccessPaymentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">35,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">37,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">58,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">63,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">3,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">4,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">97,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">104,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-68"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-71">10,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-75">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-79">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-81">500,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-83">251,869</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-85">249,567</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-86">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-87">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-88">1,647,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-89">1,608,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-90">1,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-91">7,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">949,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">767,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">697,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">833,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Total liabilities and stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">794,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">937,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-98">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-99">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-100">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-101">36,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">43,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">41,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">135,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">121,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">15,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">26,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">53,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">90,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-110">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-111">1,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-112">2,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-113">3,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">59,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">66,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-116">187,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-117">208,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">59,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">66,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">187,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">172,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-122">6,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-123">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-124">16,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-125">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">1,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">1,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">2,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">1,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">12,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">8,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">5,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">2,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">50,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">70,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">181,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">174,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other comprehensive loss:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-142">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-143">1,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-144">6,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-145">8,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-146">49,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-147">71,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-148">175,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-149">183,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-150"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-151">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-152"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-154"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-155">0.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-156"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-157">0.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Weighted-average shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-158"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-159">251,318</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-160"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-161">248,320</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-162"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-163">250,377</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-164"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-165">246,285</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">(1)&#160;&#160;&#160;&#160;Including related-party revenue of <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-166"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-167">zero</ix:nonFraction></ix:nonFraction> for both the three months ended September&#160;30, 2023 and 2022, and <ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-168">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-169">36,299</ix:nonFraction> for the nine months ended September&#160;30, 2023 and 2022, respectively.</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended September 30, 2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of June&#160;30, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-170">251,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-171">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">1,637,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">2,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">898,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">736,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-176">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-177">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-178">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-179">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-180">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-181">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-182">10,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">10,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-184">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-185">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">50,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">50,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of September&#160;30, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-188">251,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-189">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">1,647,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">1,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">949,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">697,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Nine Months Ended September 30, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-194">249,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-195">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">1,608,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">7,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">767,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">833,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-200">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-201">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-202">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-203">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-204">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-205">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-206">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-207">334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-208">334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-209">38,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">38,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-211">6,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-212">6,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-213">181,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">181,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of September&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-215">251,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-216">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-217">1,647,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">1,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">949,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">697,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.666%"><tr><td style="width:1.0%"></td><td style="width:40.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended September 30, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-221">247,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-222">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">1,565,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">8,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">688,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">868,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-227">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-228">5,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-229">5,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-230">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-231">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-232">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-233">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-234">19,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-235">19,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-236">1,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-237">1,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">70,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">70,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-240">249,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-241">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">1,589,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">9,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">759,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">820,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.555%"><tr><td style="width:1.0%"></td><td style="width:40.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-246">242,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-247">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">1,515,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">1,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">584,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">929,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-252">3,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-253">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-254">9,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-255">9,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-256">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-257">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-258">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-259">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-260">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-261">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-262">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-263">63,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-264">63,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-265">8,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-266">8,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">174,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-268">174,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-269">249,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-270">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">1,589,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">9,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-273">759,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-274">820,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-275">181,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-276">174,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-277">38,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-278">63,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-279">15,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-280">12,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">12,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-282">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net amortization and accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-283">6,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-284">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Change in fair value of success payment liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lyel:FairValueAdjustmentOfSuccessPaymentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-285">3,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:FairValueAdjustmentOfSuccessPaymentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-286">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-cash lease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:NonCashLeaseIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-287">1,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:NonCashLeaseIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-288">1,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Loss on property and equipment disposals, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="f-289">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-290">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Change in fair value of equity warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-292">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Prepaid expenses, other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-293">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-294">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-295">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-296">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-297">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-298">5,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-300">36,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-302">3,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-303">337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-304">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-305">123,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-306">129,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-307">2,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-308">19,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-309">220,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-310">346,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-311">507,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-312">308,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-313">284,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-314">58,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-315">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-316">9,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="f-317">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-318">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-319">334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-320">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-321">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-322">9,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-323">162,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-324">177,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-325">123,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-326">294,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-327">286,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-328">116,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Represented by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-329">286,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-330">116,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-331">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-332">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-333">286,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-334">116,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">SUPPLEMENTAL CASH FLOW INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-335">8,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-336">8,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash received for amounts related to tenant improvement allowances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="3" id="f-338">3,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-339">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-340">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="icccf8cd82c034620b68745752f617ca9_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-341" continuedAt="f-341-1" escape="true">Organization</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="f-341-1" continuedAt="f-341-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in June 2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex&#160;vivo</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-341-2"> genetic and epigenetic T&#8209;cell reprogramming technologies. The Company&#8217;s primary activities since incorporation have been to develop T&#8209;cell therapies, perform research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions, execute clinical trials, raise capital and provide general and administrative support for these activities.</ix:continuation> </span></div><div id="icccf8cd82c034620b68745752f617ca9_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-342" continuedAt="f-342-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-342-1" continuedAt="f-342-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-343" continuedAt="f-343-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-343-1">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-344" escape="true">All significant intercompany transactions and balances have been eliminated in consolidation.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s audited financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of September&#160;30, 2023 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-345" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#8220;GSK&#160;Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#8220;GSK&#8221;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-346">35.3</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-347">35.3</ix:nonFraction>&#160;million and resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-348"><ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-349">0.14</ix:nonFraction></ix:nonFraction> reduction in the Company&#8217;s basic and diluted net loss per common share for the nine months ended September&#160;30, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-342-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-350" continuedAt="f-350-1" escape="true">Concentrations of Credit Risk and Off-balance Sheet Risk</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-350-1">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" id="f-351" escape="true">The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="lyel:SignificantAccountingPoliciesPolicyTextBlock" id="f-352" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-353" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="icccf8cd82c034620b68745752f617ca9_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-354" continuedAt="f-354-1" escape="true">License, Collaboration and Success Payment Agreements</ix:nonNumeric></span></div><ix:continuation id="f-354-1" continuedAt="f-354-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fred Hutch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#8220;CARs&#8221;) and/or T-cell receptors (&#8220;TCRs&#8221;), subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay Fred Hutch annual license maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" format="ixt:num-dot-decimal" scale="0" id="f-355">50,000</ix:nonFraction> on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#8220;Fred Hutch Collaboration Agreement&#8221;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsResearchPayments" format="ixt:num-dot-decimal" scale="6" id="f-356">12.0</ix:nonFraction>&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a <ix:nonNumeric contextRef="c-57" name="lyel:CollaborativeArrangementRightsAndObligationsResearchTerm" format="ixt-sec:durwordsen" id="f-357">six-year</ix:nonNumeric> term. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-358">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-359">0.4</ix:nonFraction>&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended September&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-360">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-361">1.4</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from <ix:nonFraction unitRef="number" contextRef="c-62" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-362">10</ix:nonFraction>x to <ix:nonFraction unitRef="number" contextRef="c-63" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-363">50</ix:nonFraction>x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $<ix:nonFraction unitRef="usdPerShare" contextRef="c-64" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-364">1.83</ix:nonFraction> per share issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The aggregate success payments to Fred Hutch are not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-365">200.0</ix:nonFraction>&#160;million, which would only occur upon a <ix:nonFraction unitRef="number" contextRef="c-63" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-366">50</ix:nonFraction>x increase in value. Each threshold is associated with a success payment, ascending from $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-367">10.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-368">18.29</ix:nonFraction> per share to $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-369">200.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-63" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-370">91.44</ix:nonFraction> per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the <ix:nonNumeric contextRef="c-57" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" format="ixt-sec:durwordsen" id="f-371">nine-year</ix:nonNumeric> anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="f-372" continuedAt="f-372-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-373">10</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-374">20</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-375">30</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-376">40</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-377">50</ix:nonFraction>x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-65" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-378">18.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-379">36.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-380">54.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-381">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-382">91.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-383">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-384">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-385">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-386">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-387">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-354-2" continuedAt="f-354-3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the <ix:nonNumeric contextRef="c-57" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" format="ixt-sec:durwordsen" id="f-388">one-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO and each <ix:nonNumeric contextRef="c-57" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" format="ixt-sec:durwordsen" id="f-389">two-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of September&#160;30, 2023, <ix:nonFraction unitRef="usd" contextRef="c-70" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:fixed-zero" scale="0" id="f-390">no</ix:nonFraction> success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payment liability was estimated at fair value at inception and at each subsequent reporting period and the associated expense was accreted over the service period of the success payment obligations as research and development expense through 2022. As of December&#160;31, 2022, the Company&#8217;s associated success payment liability was fully accreted to fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and nine months ended September&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other income (expense), net, as the requisite service obligation had been met. The success payment liability was $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-391">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-392">2.5</ix:nonFraction>&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-393">1.5</ix:nonFraction>&#160;million and expense of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-394">1.4</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and a gain of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-395">2.1</ix:nonFraction>&#160;million and expense of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-396">0.8</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" format="ixt:num-dot-decimal" scale="0" id="f-397">50,000</ix:nonFraction> on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments to Stanford of up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-398">3.7</ix:nonFraction>&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-399">2.5</ix:nonFraction>&#160;million collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#8209;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#8220;Stanford Collaboration Agreement&#8221;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a <ix:nonNumeric contextRef="c-75" name="lyel:CollaborativeArrangementRightsAndObligationsResearchTerm" format="ixt-sec:durwordsen" id="f-400">four-year</ix:nonNumeric> term. The Company is committed to fund aggregate research performed by Stanford of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsResearchPayments" format="ixt:num-dot-decimal" scale="6" id="f-401">12.0</ix:nonFraction>&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-402"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-403">0.8</ix:nonFraction></ix:nonFraction>&#160;million in expense in connection with the Stanford Collaboration Agreement for both the three months ended September&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-404"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-405">2.3</ix:nonFraction></ix:nonFraction>&#160;million for both the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from <ix:nonFraction unitRef="number" contextRef="c-80" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-406">10</ix:nonFraction>x to <ix:nonFraction unitRef="number" contextRef="c-81" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-407">50</ix:nonFraction>x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-408">1.83</ix:nonFraction> issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s IPO. The aggregate success payments to Stanford are not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-409">200.0</ix:nonFraction>&#160;million, which would only occur upon a <ix:nonFraction unitRef="number" contextRef="c-81" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-410">50</ix:nonFraction>x increase in value. Each threshold is associated with a success payment, ascending from $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-411">10.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-412">18.29</ix:nonFraction> per share to $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-413">200.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-414">91.44</ix:nonFraction> per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the <ix:nonNumeric contextRef="c-75" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" format="ixt-sec:durwordsen" id="f-415">nine-year</ix:nonNumeric> anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><ix:continuation id="f-372-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-416">10</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-417">20</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-418">30</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-419">40</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-420">50</ix:nonFraction>x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-421">18.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-422">36.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-423">54.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-424">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-425">91.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-426">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-427">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-428">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-429">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-430">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-354-3" continuedAt="f-354-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the above outlined multiples. The valuation measurement dates are triggered by the following events: the <ix:nonNumeric contextRef="c-75" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" format="ixt-sec:durwordsen" id="f-431">one-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO and each <ix:nonNumeric contextRef="c-75" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" format="ixt-sec:durwordsen" id="f-432">two-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of September&#160;30, 2023, <ix:nonFraction unitRef="usd" contextRef="c-88" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:fixed-zero" scale="0" id="f-433">no</ix:nonFraction> success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the success payments to Stanford as of September&#160;30, 2023 and December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-434">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-435">3.3</ix:nonFraction>&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="f-436">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="f-437">1.9</ix:nonFraction>&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-438">1.2</ix:nonFraction>&#160;million and expense of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-439">1.0</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and a gain of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-440">1.2</ix:nonFraction>&#160;million and expense of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-441">1.4</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into the GSK Agreement with GSK for potential T&#8209;cell therapies that apply the Company&#8217;s platform technologies and cell therapy innovations with TCRs or CARs under distinct collaboration programs. The GSK Agreement defined two initial collaboration targets, LYL331 and LYL132, and allowed GSK to nominate seven additional targets through July 2024, though no additional targets were nominated over the life of the GSK Agreement. The Company was expected to perform research and development services for each selected target up until a defined point (the &#8220;GSK Option Point&#8221;), at which time GSK would decide whether or not to exercise an option to obtain a license from the Company (&#8220;License Option&#8221;) and take over the future development and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, GSK exercised the License Option on LYL331 (NY-ESO-1 TCR with c-Jun) and assumed sole responsibility for future development and commercialization of the program at its own cost and expense. The investigational new drug (&#8220;IND&#8221;) application for LYL132 was cleared in January 2022, though no patients were treated, and the IND for LYL331 was not submitted to the U.S. Food and Drug Administration. GSK terminated the GSK Agreement effective December&#160;24, 2022, and Lyell has also discontinued any further work on these programs. There are no future performance obligations associated with the GSK Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-442">45.0</ix:nonFraction>&#160;million under the GSK Agreement. In connection with the GSK Agreement, in May 2019, the Company also entered into a stock purchase agreement with GSK, pursuant to which the Company agreed to sell <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="lyel:StockPurchaseAgreementSharesSold" format="ixt:num-dot-decimal" scale="0" id="f-443">30,253,189</ix:nonFraction> shares of Series&#160;AA convertible preferred stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="lyel:StockPurchaseAgreementSharesSoldPricePerShare" scale="0" id="f-444">6.78</ix:nonFraction> per share, which was above the issuance date estimated fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="lyel:StockPurchaseAgreementFairValueOfStockPerShare" scale="0" id="f-445">4.84</ix:nonFraction> per share. The difference between the per share values resulted in $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="lyel:RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" format="ixt:num-dot-decimal" scale="6" id="f-446">58.6</ix:nonFraction>&#160;million additional deemed consideration, bringing the total upfront consideration of the GSK Agreement to $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-447">103.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GSK Agreement was deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;)&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, because GSK engaged the Company to initially provide research and development services, which were outputs of its ongoing activities, in exchange for consideration. In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the GSK Agreement due to GSK and the Company mutually agreeing to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-448">35.3</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-449">35.3</ix:nonFraction>&#160;million and resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-450"><ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-451">0.14</ix:nonFraction></ix:nonFraction> reduction in the Company&#8217;s basic and diluted net loss per common share for the nine months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-452"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-453">no</ix:nonFraction></ix:nonFraction> revenue related to the research and development services related to the two initial targets for both the three months ended September&#160;30, 2023 and 2022, and <ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-454">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-455">36.3</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. As of September&#160;30, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-456"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-457"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-458"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-459">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to the license contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PACT</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a commitment agreement (&#8220;PACT Commitment Agreement&#8221;) with PACT Pharma, Inc. (&#8220;PACT&#8221;) to jointly develop and test an anti-cancer T-cell therapy against solid tumors, in connection with which it also purchased PACT Series&#160;C-1 convertible preferred stock, which was recorded in other investments at $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-460">36.4</ix:nonFraction>&#160;million in the Company&#8217;s Condensed Consolidated Balance Sheet. In December 2021, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-461">36.4</ix:nonFraction>&#160;million impairment expense for its investment in PACT. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company filed a demand for arbitration seeking, among other things, rescission of the PACT Commitment Agreement. On October&#160;1, 2022, the Company entered into a settlement agreement to resolve its </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><ix:continuation id="f-354-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding legal dispute with PACT, pursuant to which PACT issued shares of PACT&#8217;s Series&#160;D convertible preferred stock to the Company in exchange for the Company&#8217;s tender of its PACT Series&#160;C-1 convertible preferred stock. The settlement agreement also included the termination of the commitment agreement with PACT. The Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-462">2.9</ix:nonFraction>&#160;million in October 2022 for the estimated fair value of the PACT Series&#160;D convertible preferred stock, which was included in other investments in the Company&#8217;s Condensed Consolidated Balance Sheet as of December&#160;31, 2022. In connection with the preparation of the financial statements for the nine months ended September&#160;30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment of the PACT Series&#160;D convertible preferred stock investment, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-463">2.9</ix:nonFraction>&#160;million impairment expense for the nine months ended September&#160;30, 2023. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></ix:continuation></div><div id="icccf8cd82c034620b68745752f617ca9_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-464" continuedAt="f-464-1" escape="true">Cash Equivalents and Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="f-464-1" continuedAt="f-464-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-465" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-466" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-467">168,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-468">168,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-469">249,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-470">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-471">492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-472">249,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-473">69,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-475">544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-476">68,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-477">89,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-479">151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-480">89,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-481">577,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-482">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-483">1,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-484">576,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-485">264,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-486">289,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-487">22,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-488">576,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-489">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-490">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-491">277,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-493">5,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-494">271,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-495">135,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-496">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-497">1,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-498">134,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-499">221,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-500">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-501">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-502">220,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-503">702,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-504">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-505">7,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-506">694,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-507">107,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-508">516,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-509">70,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-510">694,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of securities held by the Company in an unrealized loss position for less than 12&#160;months were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-511">247.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-512">287.8</ix:nonFraction>&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The fair values of securities held by the Company in an unrealized loss position for greater than 12&#160;months were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-513">104.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-514">278.7</ix:nonFraction>&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. As of September&#160;30, 2023 and December&#160;31, 2022, all of the Company&#8217;s marketable securities had a maturity date of <ix:nonNumeric contextRef="c-111" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-515"><ix:nonNumeric contextRef="c-112" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-516">two years</ix:nonNumeric></ix:nonNumeric> or less, were available for use and were classified as available&#8209;for&#8209;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both September&#160;30, 2023 and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><ix:continuation id="f-464-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September&#160;30, 2023 and 2022 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three and nine months ended September&#160;30, 2023 and 2022 were also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note&#160;6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding cash equivalents and marketable securities.</span></ix:continuation></div><div id="icccf8cd82c034620b68745752f617ca9_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="lyel:OtherInvestmentsTextBlock" id="f-517" continuedAt="f-517-1" escape="true">Other Investments</ix:nonNumeric></span></div><ix:continuation id="f-517-1" continuedAt="f-517-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company makes minority ownership strategic investments. As of September&#160;30, 2023 and December&#160;31, 2022, the aggregate carrying amounts of the Company&#8217;s strategic investments in non-publicly traded companies were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-518">32.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-519">44.9</ix:nonFraction>&#160;million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of September&#160;30, 2023 and December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="f-520">17.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="f-521">5.0</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the acquisition of each of the Company&#8217;s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of September&#160;30, 2023 and December&#160;31, 2022, the Company held an interest in <ix:nonFraction unitRef="entity" contextRef="c-3" decimals="INF" name="lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" format="ixt-sec:numwordsen" scale="0" id="f-522"><ix:nonFraction unitRef="entity" contextRef="c-4" decimals="INF" name="lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" format="ixt-sec:numwordsen" scale="0" id="f-523">two</ix:nonFraction></ix:nonFraction> entities that were concluded to be variable interests for which the Company was not the primary beneficiary. As of September&#160;30, 2023 and December&#160;31, 2022, the carrying value and maximum exposure to loss of the Company&#8217;s variable interests were $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-524"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:num-dot-decimal" scale="6" id="f-525">13.0</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:num-dot-decimal" scale="6" id="f-526"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-527">15.9</ix:nonFraction></ix:nonFraction>&#160;million, respectively, which is recorded in other investments in the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received shares of PACT&#8217;s Series&#160;D non-voting convertible preferred stock (See Note&#160;3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company recognized its investment in PACT preferred stock at its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-528">2.9</ix:nonFraction>&#160;million on October&#160;1, 2022, which was included in the Company&#8217;s Condensed Consolidated Balance Sheet within other investments as of December&#160;31, 2022. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-517-2">For the nine months ended September&#160;30, 2023 and the three and nine months ended September&#160;30, 2022, the Company performed qualitative assessments of potential indicators of impairment and determined that indicators existed for certain of its other investments. The Company did not identify any impairments for the three months ended September&#160;30, 2023. The Company did identify impairments for the nine months ended September&#160;30, 2023 and for the three and nine months ended September&#160;30, 2022. While there was no single event or factor in each instance, the Company considered the underlying companies&#8217; operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies&#8217; inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-529">2.9</ix:nonFraction>&#160;million impairment expense for the PACT Series&#160;D convertible preferred stock investment and a $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-530">10.0</ix:nonFraction>&#160;million impairment expense for one investment for the nine months ended September&#160;30, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-531"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-532">5.0</ix:nonFraction></ix:nonFraction>&#160;million impairment expense for one investment for the three and nine months ended September&#160;30, 2022, which were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as reductions to the investment balances within other investments on the Condensed Consolidated Balance Sheets.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-533" continuedAt="f-533-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-533-1" continuedAt="f-533-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-534" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-535">168,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-538">168,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-540">249,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-542">249,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-544">68,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-546">68,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-548">89,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-550">89,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-551">168,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-552">407,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-554">576,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-557">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-558">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-561">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-562">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-563">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-566">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-568">271,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-570">271,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-572">134,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-574">134,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-576">220,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-578">220,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-579">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-580">626,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-582">694,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-585">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-586">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-589">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-590">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Level&#160;3 financial instruments fair values are estimated using valuation models, including Monte Carlo simulations for the Company&#8217;s success payment liabilities. Monte Carlo simulations model the future movement of stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the estimated fair value of the success payment liabilities: fair value of the Company&#8217;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-591" continuedAt="f-591-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-592">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-593">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-594">4.26</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-154" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-595">5.42</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-596">3.58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-156" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-597">4.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-157" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-598">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-599">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-159" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-600">0.71</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-160" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-601">4.22</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-602">0.46</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-162" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-603">4.97</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-533-2"><ix:continuation id="f-591-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-604">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-605">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-606">4.21</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-607">5.42</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-608">3.58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-609">4.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-610">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-611">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-612">0.71</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-613">6.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-614">0.46</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-615">6.75</ix:nonFraction></span></div></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#8217;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-616" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-617">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-618">3,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at September&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-619">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in the fair value associated with the Fred Hutch success payment liabilities of approximately $(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" scale="6" id="f-620">2.1</ix:nonFraction>)&#160;million is recorded in other income (expense), net. The change in the fair value of approximately $(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" scale="6" id="f-621">1.2</ix:nonFraction>)&#160;million associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received non-voting PACT Series&#160;D convertible preferred stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-622">2.9</ix:nonFraction>&#160;million (See Note&#160;3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In connection with the preparation of the financial statements for the nine months ended September&#160;30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment of the PACT Series&#160;D convertible preferred stock investment, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-623">2.9</ix:nonFraction>&#160;million impairment expense for the nine months ended September&#160;30, 2023. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></div></ix:continuation><div id="icccf8cd82c034620b68745752f617ca9_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-624" continuedAt="f-624-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="f-625" continuedAt="f-625-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-624-1" continuedAt="f-624-2"><ix:continuation id="f-625-1" continuedAt="f-625-2">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</ix:continuation></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-624-2"><ix:continuation id="f-625-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-626" escape="true"><ix:nonNumeric contextRef="c-1" name="lyel:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-627" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining three months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-628">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-629">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-630">11,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-631">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-632">12,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-633">35,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-634">86,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-635">21,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-636">64,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of September&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-637">6,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-638">58,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-639">64,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-640"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-641">2.3</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-642">6.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-643">7.0</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September&#160;30, 2023 and 2022. Variable lease costs for operating leases were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-644"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-645">1.3</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-646">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-647">3.8</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-648">7.0</ix:nonNumeric>&#160;and <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-649">7.8</ix:nonNumeric>&#160;years as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted&#8209;average discount rates for operating leases were <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-650"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-651">8.5</ix:nonFraction></ix:nonFraction>% as of both September&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-179" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-652">11,000</ix:nonFraction> square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-653"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-654">0.2</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-655"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-656">0.6</ix:nonFraction></ix:nonFraction> million for both the nine months ended September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-184" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-657">18,000</ix:nonFraction> square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-658">4.6</ix:nonFraction>&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-659"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-660">0.5</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-661"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-662">1.4</ix:nonFraction></ix:nonFraction> million for both the nine months ended September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div></ix:continuation></ix:continuation><div id="icccf8cd82c034620b68745752f617ca9_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-663" continuedAt="f-663-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-663-1" continuedAt="f-663-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-664">10.0</ix:nonFraction>&#160;million shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-665">0.0001</ix:nonFraction> per share. As of September&#160;30, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-666"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-667">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-668">500.0</ix:nonFraction>&#160;million shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-669">0.0001</ix:nonFraction> per share. As of September&#160;30, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-670">251,868,968</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-671">249,567,343</ix:nonFraction> shares of the Company&#8217;s common stock outstanding, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-663-2">On August&#160;4, 2022, the Company entered into an Equity Distribution Agreement with Goldman Sachs &amp; Co. LLC (&#8220;Goldman Sachs&#8221;) and BofA Securities, Inc. (&#8220;BofA&#8221;, and together with Goldman Sachs, the &#8220;Agents&#8221;) with respect to an at-the-market offering program (the &#8220;Equity Distribution Agreement&#8221;). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agents shares of the Company&#8217;s common stock having an aggregate offering amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="INF" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-672">200.0</ix:nonFraction>&#160;million (the &#8220;Placement Shares&#8221;). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 of the Securities Act of 1933, as amended. The Company will pay commissions to the Agents of up to <ix:nonFraction unitRef="number" contextRef="c-190" decimals="INF" name="lyel:PercentageOfCommissionFromEachSaleOfShares" scale="-2" id="f-673">3.0</ix:nonFraction>% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither the Company nor the Agents are obligated to sell any shares and, to date, the Company has not made any sales under the Equity Distribution Agreement.</ix:continuation></span></div><div id="icccf8cd82c034620b68745752f617ca9_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-674" continuedAt="f-674-1" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-674-1" continuedAt="f-674-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;), which on the date of the underwriting agreement related to the Company&#8217;s IPO became effective with an initial reserve of <ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-675">26,662,087</ix:nonFraction> shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of <ix:nonNumeric contextRef="c-192" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-676">ten years</ix:nonNumeric>, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;<ix:nonFraction unitRef="number" contextRef="c-192" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-677">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#8217;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2023, the Company reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-678">12,478,367</ix:nonFraction> shares of common stock for issuance under the 2021 Plan representing <ix:nonFraction unitRef="number" contextRef="c-193" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="f-679">5</ix:nonFraction>% of the total common shares outstanding as of December&#160;31, 2022. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#8217;s board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed <ix:nonNumeric contextRef="c-194" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-680">ten years</ix:nonNumeric>. Generally, awards granted by the Company vest over <ix:nonNumeric contextRef="c-192" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-681">four years</ix:nonNumeric> but may be granted with different vesting terms. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-682">22,478,430</ix:nonFraction> shares were available for future issuance pursuant to the 2021 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s IPO with an initial reserve of <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-683">2,470,000</ix:nonFraction> shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-684">15</ix:nonFraction>% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-685">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of <ix:nonNumeric contextRef="c-197" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-686">ten years</ix:nonNumeric>, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;<ix:nonFraction unitRef="number" contextRef="c-197" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-687">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;<ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-688">4,940,000</ix:nonFraction> shares; provided, however, that the Company&#8217;s board of directors may act to provide a lesser increase in number of shares. The Company&#8217;s board of directors elected to reserve <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-689">no</ix:nonFraction> additional shares under the 2021 ESPP for the year beginning January&#160;1, 2023. The Company may specify offerings with durations not more than <ix:nonNumeric contextRef="c-197" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" format="ixt-sec:durmonth" id="f-690">27</ix:nonNumeric>&#160;months and may specify shorter purchase periods within each offering. Under the 2021 ESPP, <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-691"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-692">no</ix:nonFraction></ix:nonFraction> shares were issued for both the three months ended September&#160;30, 2023 and 2022, and <ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-693">542,921</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-694">283,574</ix:nonFraction> shares were issued for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-695">3,905,099</ix:nonFraction> shares were available for future issuance pursuant to the 2021 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#8209;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-674-2" continuedAt="f-674-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed <ix:nonNumeric contextRef="c-204" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-696">ten years</ix:nonNumeric>. Generally, awards granted by the Company vest over <ix:nonNumeric contextRef="c-204" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-697">four years</ix:nonNumeric>, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While <ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-698">no</ix:nonFraction> shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-699" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-700">4,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-701">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-702">14,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-703">12,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-704">5,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-705">14,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-706">24,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-707">51,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-708">10,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-709">19,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-710">38,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-711">63,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2023, total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-712">76.5</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-713">2.79</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="f-714" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-715">872,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-214" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-716">5.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-717">2,559,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-718">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-719">414,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-720">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-721">240,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-722">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of September&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-723">2,777,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-724">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-725" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-726">53,849,045</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-727">5.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-217" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-728">7.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-729">24,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-730">12,276,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-731">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-732">1,478,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-733">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-734">4,196,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-735">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-736">60,449,815</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-737">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-738">7.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-739">7,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-740">32,422,027</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-741">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-742">6.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-743">7,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><ix:continuation id="f-674-3" continuedAt="f-674-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-744" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-745">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-746">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-747">88.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-748">85.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-749">6.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-750">5.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-751">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-752">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-674-4">The weighted-average grant date fair value of options granted for the nine months ended September&#160;30, 2023 and 2022 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-753">1.69</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-754">4.33</ix:nonFraction> per share, respectively.</ix:continuation> </span></div><div id="icccf8cd82c034620b68745752f617ca9_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-755" continuedAt="f-755-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-755-1">Basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include unvested RSAs, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSAs and unvested RSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.</ix:continuation> </span></div><div id="icccf8cd82c034620b68745752f617ca9_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-756" continuedAt="f-756-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-756-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#8217;s obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both September&#160;30, 2023 and December&#160;31, 2022.</span></div></ix:continuation><div id="icccf8cd82c034620b68745752f617ca9_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-757" continuedAt="f-757-1" escape="true">Related-party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-757-1" continuedAt="f-757-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma (&#8220;Sonoma Sublease&#8221;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-185" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-758">18,000</ix:nonFraction> square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#8217;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-759">4.6</ix:nonFraction>&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both September&#160;30, 2023 and December&#160;31, 2022, there were accrued liabilities and other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-760"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-761">0.5</ix:nonFraction></ix:nonFraction>&#160;million, and as of September&#160;30, 2023 and December&#160;31, 2022, other non-current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-762">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-763">3.5</ix:nonFraction>&#160;million, respectively, in connection with the Sonoma Sublease. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-764" continuedAt="f-764-1" escape="true">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, </ix:nonNumeric></span><ix:continuation id="f-764-1" continuedAt="f-764-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span></ix:continuation></div><div style="margin-top:6pt"><ix:continuation id="f-764-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-765">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-766">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-767">1,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-768">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-769">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-770">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-771">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-772">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was party to the GSK Agreement with GSK, which is a holder of more than <ix:nonFraction unitRef="number" contextRef="c-220" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-773">10</ix:nonFraction>% of the Company&#8217;s outstanding common stock. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. GSK terminated the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-757-2">GSK Agreement effective December&#160;24, 2022. The Company had <ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-774"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-775">no</ix:nonFraction></ix:nonFraction> current or non-current deferred revenue in connection with the GSK Agreement as of both September&#160;30, 2023 and December&#160;31, 2022. Revenue recognized in connection with the GSK agreement was <ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-776"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-777">zero</ix:nonFraction></ix:nonFraction> for both the three months ended September&#160;30, 2023 and 2022, and <ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-778">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-779">36.3</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</ix:continuation> </span></div><div id="icccf8cd82c034620b68745752f617ca9_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-780" continuedAt="f-780-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-780-1">On November 6, 2023, the Company committed to and commenced a reduction in its workforce of approximately <ix:nonFraction unitRef="number" contextRef="c-227" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-781">25</ix:nonFraction>% to reduce operating costs and improve operating efficiency. The reduction in workforce is expected to be completed in the fourth quarter of 2023. In connection with this reduction in workforce, the Company estimates that it will incur charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-782">6</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-783">7</ix:nonFraction> million for severance payments, employee benefits and related costs, primarily in the fourth quarter of 2023. Substantially all of the estimated charges are expected to result in future cash expenditures.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited Condensed Consolidated Financial Statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several factors, including those set forth in the section titled &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form 10-Q. See also the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="icccf8cd82c034620b68745752f617ca9_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing our proprietary ex vivo genetic and epigenetic T&#8209;cell reprogramming technologies. Our investigational therapies use the patient&#8217;s own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to defeat solid tumors. Our innovative reprogramming technologies address what we believe are the primary barriers that limit consistent and long-lasting responses to T&#8209;cell therapy in solid tumors: T&#8209;cell exhaustion and lack of durable stemness. Our technologies are designed to generate T cells with the ability to persist and self&#8209;renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. Our goal is to provide patients with T cells that are potent and long-lasting to achieve durable antitumor responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technologies can be applied in a target agnostic manner to multiple T&#8209;cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T&#8209;cell receptor (TCR) therapies. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our technologies with the aim to develop T&#8209;cell therapies with improved and durable clinical outcomes. Our growing pipeline of promising cell product candidates targets solid tumor indications with large unmet needs that are collectively responsible for approximately 180,000 deaths in the U.S. annually. Each of our programs provide opportunities to expand into additional indications beyond the patient populations we are initially targeting. Our lead product candidates are summarized in the table below:</span></div><div style="margin-top:6pt;text-align:center"><img src="lyel-20230930_g1.jpg" alt="Pipeline Graphic - 10.25.23.jpg" style="height:289px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in June 2018. Our primary activities to date have included developing T-cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of our product candidate development efforts, organizing and staffing our company, business planning, establishing our intellectual property portfolio, making regulatory submissions, executing clinical trials, raising capital and providing general and administrative support for these activities. We are early in our research and development efforts and are in Phase&#160;1 clinical development of LYL797, our ROR1 targeted CAR T-cell product candidate, and LYL845, our TIL product candidate. Two additional product candidates that each include novel genetic and epigenetic reprogramming technologies are in preclinical development: LYL119, a ROR1 targeted CAR T-cell product candidate and a second generation TIL product candidate. We do not have any products approved for sale. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Programs and Operational Updates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Programs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing four wholly-owned product candidates, including two product candidates in Phase&#160;1 clinical development, LYL797 and LYL845. Two additional product candidates, LYL119 and a second generation TIL product candidate, are in preclinical development. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL797 - A genetically and epigenetically reprogrammed ROR1-targeted CAR T-cell product candidate designed for differentiated potency and durability targeting multiple solid tumor indications.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are applying our c-Jun and Epi&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies to our lead CAR T&#8209;cell product candidate, LYL797, which is expected to be an intravenously&#8209;administered CAR T&#8209;cell product targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) protein. ROR1 is a fetal protein expressed during embryogenesis and is believed to be important in cell migration, polarity and survival. It is expressed in several cancer types, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian cancer and chronic lymphocytic leukemia, and is generally associated with a poor prognosis. LYL797 contains a CAR with a 4-1BB/CD3&#950; intracellular domain, a transmembrane domain, an optimized spacer domain and a single-chain variable fragment (scFv) derived from an R12 rabbit monoclonal antibody that recognizes and binds with high specificity to human ROR1. LYL797 also incorporates c-Jun overexpression and a proprietary optimized truncated version of human EGFR (EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">opt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) used for tracking the CAR T cells in the peripheral blood post treatment and can also be used as a safety measure with the administration of cetuximab, if needed. LYL797 is manufactured utilizing our proprietary Epi&#8209;R technology. Our Epi-R manufacturing protocols comprise proprietary media, optimized cytokine compositions and well-defined cell activation and expansion protocols used during our manufacturing process.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing LYL797 for the treatment of ROR1-positive TNBC and NSCLC. Literature indicates that significant subsets of patients with common cancers express ROR1, including TNBC (~60%) and NSCLC (~40%), two of the highest ROR1&#8209;expressing solid tumor indications and, to date, results from our own ROR1 screening program are consistent with what is reported in the literature. If successful, we may expand into other ROR1-positive cancers with a lower incidence of ROR1 expression, including potentially hormone-receptor positive breast cancer, ovarian and other solid tumors. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Enrollment in the Phase&#160;1 clinical trial of LYL797 is ongoing. The study includes patients with relapsed or refractory TNBC or NSCLC.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initial clinical and translational data from at least 20 patients in the Phase&#160;1 trial of LYL797 are expected in the first half of 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The Phase 1 clinical trial is designed as an open label, dose escalation and expansion trial in patients with relapsed/refractory TNBC who have failed at least two lines of therapy and patients with relapsed/refractory NSCLC who have failed at least one line of therapy. All patients enrolled have tumor specimens positive for ROR1 protein expression by immunohistochemistry. The study will enroll at least 15 patients each with relapsed or refractory TNBC or with NSCLC in the expansion phase of the study.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A CAR T-cell manufacturing proof-of-concept collaboration with Cellares was initiated as part of an overall manufacturing strategy to build scale and reduce cost. Under the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell&#8217;s LYL797 CAR T-cell therapy, using Cellares&#8217; Cell Shuttle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initial results from Lyell&#8217;s ROR1 screening program indicated that expression of ROR1 in TNBC and NSCLC, 53% (N=77) and 33% (N=18), respectively, is consistent with what has been reported in the literature. The screening program is designed to support Lyell&#8217;s current and future clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented a LYL797 Trial in Progress poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego on November 1-5, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL845 - A novel epigenetically reprogrammed TIL product candidate designed for differentiated potency and durability targeting multiple solid tumor indications. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are applying our Epi&#8209;R technology to our lead TIL product candidate, LYL845, which is expected to be an intravenously&#8209;administered autologous TIL therapy for multiple solid tumors. Our Epi&#8209;R manufacturing protocols comprise proprietary media, optimized cytokine compositions and well-defined cell activation and expansion protocols used during our manufacturing process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TIL have previously shown clinical benefit in patients with advanced melanoma and other solid tumors with high mutational burden. Published data from third-party TIL trials show that treating metastatic melanoma patients with TIL can result in complete and durable responses. Response rates to TIL therapy in patients with other advanced solid tumors such as lung, colorectal and breast have been much lower than those observed in advanced melanoma. Broad TIL efficacy has been limited by poor enrichment of tumor-reactive T cells and the poor quality and limited growth potential of expanded T&#160;cells. Failure to maintain polyclonality of TIL during production may also limit their ability to eradicate cancer cells given the inherent heterogeneous nature of solid tumors. LYL845 incorporates our Epi&#8209;R technology that has been shown to generate TIL product with characteristics that have previously been associated with improved response rate, including a higher percentage of cytotoxic T cells and stemness phenotypes. We have also demonstrated that our Epi-R process led to enhanced T-cell potency and maintenance of tumor-reactive polyclonality in nonclinical experiments. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing LYL845 for advanced melanoma, NSCLC and colorectal cancer (CRC). Based on our success with those indications, we may include patients with other solid tumors, potentially including head and neck, cervical, breast and pancreatic cancer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment in the Phase&#160;1 clinical trial for LYL845 is ongoing. The study includes patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial clinical data from the Phase&#160;1 trial of LYL845 are expected in 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase&#160;1 clinical trial is designed as an open label, dose escalation and expansion trial in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC. The study will enroll at least 15 patients each with advanced melanoma, and relapsed or refractory NSCLC or CRC in the expansion phase of the study. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical data on the Epi-R P2 manufacturing process designed to shorten TIL manufacturing time without impacting cell number and phenotype was presented at SITC. Epi-R P2 is expected to be incorporated into the Phase 1 trial in 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented a LYL845 Trial in Progress poster was presented at SITC. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL119 - An innovative ROR1 CAR T-cell product designed for enhanced cytotoxicity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key pillar of our strategy is to continually innovate to develop and advance novel, breakthrough technologies that address key barriers to successful cell therapy for solid tumors. We have advanced a new genetic reprogramming technology, NR4A3 knockout, and a new epigenetic reprogramming technology, Stim&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that are both incorporated in our next CAR T-cell product candidate, LYL119. These technologies are stackable and complementary to c-Jun and Epi&#8209;R and are designed to further improve the antitumor potency and durability of T cells. LYL119 is being advanced with the goal of potentially creating even greater benefit for patients with ROR1-positive solid tumors. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An investigational new drug (IND) application is expected to be submitted for LYL119 in the first half of 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An abstract highlighting preclinical development of LYL119 was presented at SITC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">T&#8209;cell rejuvenation technologies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and others have documented the impact of aging on T&#8209;cell function, which begins to decline after puberty, and at an increasingly accelerated rate after age 65. Morbidity and mortality from cancer also increase with age. Thus, we are working to advance another novel reprogramming technology that focuses on rejuvenation of antitumor T cells. We are developing a method to maintain T&#8209;cell identity while reducing the epigenetic age of the cells. This technology is currently in the research stage. We have generated data illustrating the ability to &#8220;turn back&#8221; the epigenetic clock in a process called cellular rejuvenation, without changing the T&#8209;cell&#8217;s identity as would occur in the setting of induced pluripotent stem cell-derived T cells.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data demonstrating that T cells rejuvenated with Lyell&#8217;s technology have improved expansion capacity and increased expression of biomarkers associated with T-cell stemness, and also exhibit improved antitumor properties compared with non-rejuvenated T-cell controls in sequential cell-killing assays, were presented at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting on June 14th in Boston, MA. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An abstract highlighting rejuvenation of TIL through partial reprogramming was presented at SITC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Manufacturing Capabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe it is critically important to control and continuously monitor all aspects of the cell therapy manufacturing process to mitigate risks, including challenges in managing production, supply chain, patient specimen chain of custody and quality control. As we developed our technologies, we made a strategic decision to invest in building our own manufacturing facility to control our supply chain, maximize efficiencies in cell product production time, optimize cost and quality, and have the ability to rapidly incorporate disruptive advancements and new innovations. Controlling </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing also enables us to protect proprietary aspects of our reprogramming technologies. We view our manufacturing team and capabilities as a significant competitive advantage.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LyFE&#8482; manufacturing center located in Bothell, Washington is approximately 73,000 square feet and is comprised of manufacturing suites, laboratories and offices. LyFE is commissioned and designed to be in compliance with U.S. and European Union current Good Manufacturing Practices (cGMP) standards and has a flexible and modular design enabling CAR T-cell, TIL, TCR T-cell and cGMP viral vector production to control and de-risk the manufacturing sequence and timing of the major components of our supply chain. Owning our own facility has enabled seamless collaboration across research, process development and manufacturing for high-quality reproducibility at manufacturing scale.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently producing clinical supply for our Phase&#160;1 trials at LyFE. At full staffing and capacity, we expect to be able to manufacture approximately 500 infusions per year depending on product candidate mix. While we believe this capacity is sufficient to support our pipeline programs into pivotal trials and, if approved, early commercialization, we are also evaluating third-party manufacturing options, such as the recently initiated CAR T-cell proof-of-concept collaboration with Cellares, as part of an overall manufacturing strategy to build scale and reduce cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Environment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and operations may be affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as the effects of the ongoing geopolitical conflicts in Ukraine, tensions in U.S.-China relations, escalating armed conflicts and turmoil in the Middle East, the lingering effects of the COVID-19 pandemic, inflationary pressures, interest rate environment, instability in the banking industry and overall market volatility. Fiscal year 2022 and the first half of 2023 were marked by significant market uncertainty, increasing inflationary pressures, banking upheaval, supply constraints and lingering effects from the COVID-19 pandemic. Although some of these negative impacts improved throughout the fiscal year, these market dynamics may continue for the rest of 2023, and these and similar adverse market conditions may negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of trends, uncertainties and other factors that could impact our operating results, see the section entitled &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reduction in Workforce</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, we committed to and commenced a reduction in our workforce of approximately 25% to reduce operating costs and improve operating efficiency. The restructuring prioritized investment in our clinical stage programs and core research platforms and streamlined operations. The reduction in workforce is expected to be completed in the fourth quarter of 2023. In connection with this reduction in workforce, we estimate that we will incur charges of approximately $6 million to $7 million for severance payments, employee benefits and related costs, primarily in the fourth quarter of 2023. Substantially all of the estimated charges are expected to result in future cash expenditures. The estimated charges that we expect to incur are subject to a number of assumptions, and actual results may differ materially from these estimates. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction in workforce. </span></div><div id="icccf8cd82c034620b68745752f617ca9_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale and have never generated any revenue from product sales.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated revenue primarily from the recognition of the upfront payment under the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (GSK Agreement) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together, GSK). GSK terminated the GSK Agreement effective December 2022, and we do not expect further revenue from the collaboration. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10&#8209;Q, for additional details regarding termination of the GSK Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate additional revenue from other collaborations, strategic alliances, licensing agreements, product sales, or a combination of these.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, research and development expenses consist of costs incurred by us for the discovery and development of our technology platforms and product candidates and include costs incurred in connection with strategic collaborations, costs to license technology, personnel-related costs, including stock-based compensation expense, facility and technology related costs, research and laboratory expenses, as well as other expenses, which include consulting fees and other costs. Upfront payments and milestones paid to third parties in connection with technology platforms that have not reached technological feasibility and do not have an alternative future use are expensed as incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses also include non-cash expenses related to the change in the estimated fair value of the success payment obligations over their respective requisite service terms granted to Fred Hutchinson Cancer Center (Fred&#160;Hutch) and The Board of Trustees of the Leland Stanford Junior University (Stanford). As of December&#160;31, 2022, Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and nine months ended September&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other income (expense), net, as the requisite service obligation had been met. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10&#8209;Q. Research and development expenses related to our success payment liabilities are unpredictable and may vary significantly from quarter&#8209;to&#8209;quarter and year&#8209;to&#8209;year due to changes in our assumptions used in the calculation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deploy our employee and infrastructure resources across multiple research and development programs for identifying and developing product candidates and establishing manufacturing capabilities. Due to the stage of development and number of ongoing programs and our ability to use resources across several programs, most of our research and development costs are not recorded on a program-specific basis. These include costs for personnel, laboratory and other indirect facility and operating costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities account for a significant portion of our operating expenses. We anticipate that our research and development expenses will increase over the foreseeable future as we expand our research and development efforts including completing nonclinical studies, commencing planned clinical trials, conducting and completing current and planned clinical trials, seeking regulatory approvals of our product candidates, identifying new product candidates and incurring costs to acquire and license technology platforms. A change in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our product candidates. Because we are early in our research and clinical development efforts of our product candidates, and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the nonclinical development, clinical development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses may vary significantly based on factors such as:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and scope of nonclinical and IND-enabling studies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of trials required for approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the duration of patient participation in the trials and follow-up;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of manufacturing our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the phase of development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy and safety profile of our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which we establish additional collaboration or license agreements; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether we choose to partner any of our product candidates and the terms of such partnership.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative costs include personnel-related expenses, including stock-based compensation expense for personnel in executive, legal, finance and other administrative functions, legal costs, transaction costs related to collaboration and licensing agreements, as well as fees paid for accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include those related to corporate, dispute and patent matters.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase over the foreseeable future to support our continued research and development activities, operations generally, future business development opportunities, consulting fees, as well as due to the increased costs of operating as a public company such as costs related to accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission (SEC) requirements, director and officer insurance costs and investor and public relations costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income, net consists primarily of service and occupancy fees received associated with subleases as well as losses on the retirement of property and equipment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists primarily of interest earned on our cash, cash equivalents and marketable securities balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of the change in fair value associated with our success payment liabilities to Fred Hutch for three and nine months ended September&#160;30, 2023 and primarily of changes in the fair value of an equity warrant investment held for the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Other Investments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other investments consists of a reduction in the value of certain other investments.</span></div><div id="icccf8cd82c034620b68745752f617ca9_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three and Nine Months Ended September&#160;30, 2023 and 2022</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"></td><td style="width:29.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(36,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">43,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">41,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">121,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">15,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">26,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(10,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">53,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(37,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">59,064&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,440&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,376)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">187,617&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">208,571&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(20,954)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(59,039)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(66,437)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,398&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(187,500)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(172,274)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(15,226)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,608&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,251&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,357&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">16,369&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,769&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(12,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,186&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,817)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,798&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,447)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,245&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(50,853)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(70,254)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(181,702)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(174,721)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(6,981)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was approximately zero for both the three months ended September&#160;30, 2023 and 2022, and $0.1&#160;million and $36.3&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The GSK Agreement was terminated in December 2022 and, therefore, no further research and development pursuant to the GSK Agreement was performed in the first nine months of 2023, which drove the decrease in revenue of $36.2&#160;million for the nine months ended September&#160;30, 2023. The revenue for the nine months ended September&#160;30, 2022 was primarily due to a $35.3&#160;million revenue adjustment recorded in 2022 due to a change in estimate in connection with the GSK Agreement following a mutual agreement with GSK to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements &#8211; GSK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional information about the termination of the GSK Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our research and development expenses for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:28.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Personnel</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">16,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">61,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">50,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Facilities and technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">39,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">39,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research activities, collaborations and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">29,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">43,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">41,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">121,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $43.8&#160;million and $41.6&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively. The increase of $2.2&#160;million was primarily due to an increase of $3.4&#160;million in personnel&#8209;related expenses mainly due to an increase in headcount to expand our research, development and manufacturing capabilities; an increase of $3.2&#160;million in research activities, collaborations and outside services primarily driven by an increase in research and laboratory costs mainly due to clinical trials, partially offset by a reduction in professional services and collaborations and license expenses primarily related to the completion of certain sponsored research agreements; a decrease of $3.7&#160;million associated with our success payment liabilities driven by the decrease in our stock price, with $1.4&#160;million of the change due to recognizing the Fred Hutch success payment liability fair value change in other income (expense), net for the three months ended September&#160;30, 2023; and a decrease of $0.7&#160;million in facilities and technology costs primarily related to lower software implementation costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $136.0&#160;million and $121.2&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The increase of $14.8&#160;million was primarily due to an increase of $11.2&#160;million in personnel-related expenses, that was mainly due to an increase in headcount to expand our research, development and manufacturing capabilities to support increases in clinical trial enrollment; an increase of $6.6&#160;million in research activities, collaborations and outside services primarily driven by an increase in research and laboratory costs mainly due to clinical trials, partially offset by a reduction professional services and collaboration and license expenses primarily related to the completion of certain sponsored research agreements; an increase of $0.4&#160;million in facilities and technology costs primarily related to increased infrastructure to support our expansion in research and development, manufacturing capabilities and associated headcount growth; and a decrease of $3.4&#160;million in expense associated with our success payment liabilities driven by the decrease in our stock price, with $0.8&#160;million of the change due to recognizing the Fred Hutch success payment liability fair value change in other income (expense), net for the nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $15.5&#160;million and $26.1&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively. The decrease of $10.6&#160;million was primarily due to a decrease of $8.7&#160;million in stock-based compensation expense, primarily related to significant awards being fully expensed, a decrease of $1.4&#160;million in outside services primarily due to a decrease in legal and consulting expenses and a decrease of $0.7 million in other administrative expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $53.8&#160;million and $91.0&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The decrease of $37.1&#160;million was primarily due to a decrease of $27.0&#160;million in stock-based compensation expense, primarily related to significant awards being fully expensed, a decrease of $8.2&#160;million in outside services attributed to lower legal and consulting expenses and a decrease of $2.0&#160;million in other administrative expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income, net was $0.3&#160;million and $1.3&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and $2.1&#160;million and $3.5&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net was $6.6&#160;million and $2.3&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and $16.4&#160;million and $3.6&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The increase in interest income, net was primarily driven by higher interest rates in 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net was $1.6&#160;million and $(1.1)&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and $2.4&#160;million and $(1.0) million for the nine months ended September&#160;30, 2023 and 2022, respectively. The changes in other income (expense), net were primarily due to the change in fair value associated with our success payment liabilities to Fred Hutch for the three and nine months ended September&#160;30, 2023; the fair value changes of Fred Hutch success payment liabilities are recognized in other income (expense), net for the three and nine months ended September&#160;30, 2023 as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration as of December 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Other Investments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023, the $12.9 million impairment of other investments consisted of the full impairment of two of our other investments. For the three and nine months ended September&#160;30, 2022, the $5.0 million impairment consisted of the full impairment of one of our other investments. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10&#8209;Q, for additional details regarding the impairments of other investments.</span></div><div id="icccf8cd82c034620b68745752f617ca9_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily through the sale and issuance of convertible preferred stock, the sale of common stock in connection with our initial public offering (IPO) and business development activities. As of September&#160;30, 2023, we had $598.2&#160;million in cash, cash equivalents and marketable securities. Since our inception, we have incurred significant operating losses. We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product for a number of years, if ever. We had an accumulated deficit of $949.2&#160;million as of September&#160;30, 2023. From June 29, 2018 (inception) through September&#160;30, 2023, we raised an aggregate of $1,405.7&#160;million in gross proceeds from the sales of our convertible preferred stock prior to the IPO and sales of our common stock in the IPO.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2022, we entered into an Equity Distribution Agreement (the Equity Distribution Agreement) with Goldman Sachs &amp; Co. LLC (Goldman Sachs) and BofA Securities, Inc. (BofA, and together with Goldman Sachs, the Agents) with respect to an at-the-market offering program. In accordance with the terms of the Equity Distribution Agreement, we may offer and sell from time to time, through the Agents, shares of our common stock having an aggregate offering amount of up to $200.0&#160;million (the Placement Shares). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 of the Securities Act of 1933, as amended (the Securities Act). We will pay commissions to the Agents of up to 3.0% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither us nor the Agents are obligated to sell any shares and, to date, we have not made any sales under the Equity Distribution Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur additional expenses and operating losses in the foreseeable future as we conduct and expand our research and development efforts, including conducting nonclinical studies and clinical trials, developing new product candidates, establishing manufacturing capabilities and funding our operations generally. Based on our current operating </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our working capital and capital expenditure needs into 2027. However, we anticipate that we will need to raise additional capital in the future to fund our operations, including further development of our product candidates and the commercialization of any approved product candidates. In addition, we regularly consider fund-raising opportunities and may decide, from time to time, to raise additional capital, including pursuant to the Equity Distribution Agreement, based on various factors, including market conditions and our plans of operation. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. For example, although we committed to implementing a reduction in workforce in the fourth quarter of 2023 to reduce our operating costs and improve operating efficiency, we may not achieve the expected benefits of our cost preservation efforts on the expected timeline, or at all, and we could otherwise consume capital more rapidly than we currently anticipate. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, timing, progress, costs and results of discovery, nonclinical development and clinical trials for our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of clinical trials required for regulatory approvals of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs, timing and outcome of regulatory review of any of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">advances in our genetic and epigenetic reprogramming technologies, as well as other research and development efforts;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of manufacturing clinical and commercial supplies of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the need to build additional manufacturing facilities or expand the capacity of our existing one or find suitable third-party manufacturing partners;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain existing, and establish new, collaborations, licenses, product acquisitions or other strategic transactions and the fulfillment of our financial obligations under any such agreements, including the timing and amount of any success payments, future contingent payments, milestone, royalty or other payments due under any such agreement;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses to attract, hire and retain skilled personnel;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs of operating as a public company;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the need to expand our operational, financial and management systems;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any potential disputes or litigation and our related responses; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which we acquire or invest in businesses, products and technology platforms.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we complete nonclinical and clinical development and receive regulatory approval of our product candidates and can generate significant revenue from product sales, if ever, we expect to finance our operations from the sale of additional equity or debt financings, or other capital that may come in the form of strategic collaborations, licensing, or other arrangements. In the event that additional capital is required, we may not be able to raise it on terms acceptable to us, or at all. If we raise additional funds through the issuance of equity or convertible debt securities, including pursuant to the Equity Distribution Agreement, it may result in dilution to our existing stockholders. Debt financing or preferred equity financing, if available, may result in increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations. If we raise funds through strategic collaboration, licensing or other arrangements, we may relinquish significant rights or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potentially unfavorable global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide, actual or perceived changes in interest rates and economic inflation, the current or anticipated impact of geopolitical instability and otherwise. If we are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to raise additional capital when desired, our business, results of operations and financial condition would be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate our liquidity and capital resources to ensure that we can adequately and efficiently finance our operations. As of September&#160;30, 2023, our material cash requirements consisted primarily of paying salaries and benefits, conducting clinical trials and research, improving our manufacturing capabilities, providing the technology and facilities necessary to support our operations, funding operating lease obligations and other payments related to our collaborative agreements, including anticipated success payments and license fees. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q, for additional information.</span></div><div id="icccf8cd82c034620b68745752f617ca9_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(123,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(129,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">284,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(58,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">162,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(177,704)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023, net cash used in operating activities was $123.1&#160;million, reflecting our net loss of $181.7&#160;million, partially offset by non-cash items primarily related to stock-based compensation expense of $38.6&#160;million, depreciation and amortization expense of $15.2&#160;million and impairment of other investments of $12.9&#160;million. Non-cash net amortization and accretion on marketable securities of $6.2&#160;million also contributed to net cash used in operating activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, net cash used in operating activities was $129.3 million, primarily reflecting our net loss of $174.7&#160;million, partially offset by non-cash items mainly related to stock-based compensation expense of $63.6&#160;million, depreciation and amortization of $13.0&#160;million and impairment of other investments of $5.0&#160;million. Non-cash deferred revenue of $36.3&#160;million and accrued liabilities and other current liabilities of $5.8&#160;million also contributed to net cash used in operating activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023, cash provided by investing activities was $284.7&#160;million, consisting of net maturities, sales and purchases of marketable securities of $287.4&#160;million offset by purchases of property and equipment of $2.7&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, cash used in investing activities was $58.2&#160;million, consisting of net maturities, sales and purchases of marketable securities of $38.5&#160;million and purchases of property and equipment of $19.7&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023, cash provided by financing activities was $1.0&#160;million, consisting of proceeds from the employee stock purchase plan of $1.2&#160;million and proceeds from the exercise of stock options of $0.2&#160;million, partially offset by taxes paid related to the net share settlement of equity awards of $0.3&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, cash provided by financing activities was $9.8&#160;million, consisting of proceeds from the exercise of stock options of $9.3&#160;million and proceeds from the employee stock purchase plan of $0.9&#160;million, partially offset by $0.4&#160;million in taxes paid related to the net share settlement of equity awards.</span></div><div id="icccf8cd82c034620b68745752f617ca9_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we did not have, and we do not currently have, any off-balance sheet arrangements as defined under the applicable rules and regulations of the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited Condensed Consolidated Financial Statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these unaudited Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as compared to those described in our Annual Report on Form 10&#8209;K for the year ended December&#160;31, 2022 (Annual Report).</span></div><div id="icccf8cd82c034620b68745752f617ca9_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Our primary risks include interest rate sensitivities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash equivalents of $264.5&#160;million as of September&#160;30, 2023, which consisted of money market funds and highly liquid investments purchased with original maturities of three months or less from the purchase date. We also had marketable securities of $311.9&#160;million as of September&#160;30, 2023. The primary objective of our investment activities is to preserve capital to fund our operations, and we currently do not hedge our interest rate risk exposure. Because our marketable securities are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material effect on our unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q. We had no debt outstanding as of September&#160;30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees and operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. We therefore are not currently exposed to significant market risk related to changes in foreign currency exchange rates. However, we have contracted with and may continue to contract with non-U.S. vendors who we may pay in their local currency. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. To date, foreign currency transaction gains and losses have not been material to our Condensed Consolidated Financial Statements, and we have not had a formal hedging program with respect to foreign currency. We believe a hypothetical 10% change in exchange rates during any of the periods presented would not have a material effect on our unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and our clinical trial costs. We believe that inflation has not had a material effect on our unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div id="icccf8cd82c034620b68745752f617ca9_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September&#160;30, 2023, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during the quarter ended September&#160;30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="icccf8cd82c034620b68745752f617ca9_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have been or may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not party to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by a government authority.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of outcome, any such proceedings or claims is subject to inherent uncertainties and can have an adverse impact on us because of defense and settlement costs, diversion of time and resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div id="icccf8cd82c034620b68745752f617ca9_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information contained in this Quarterly Report on Form 10-Q, including our unaudited Condensed Consolidated Financial Statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. The risk factors set forth below that are marked with an asterisk (*) contain substantive changes to the similarly titled risk factors included in, or did not appear as separate risk factors in, Item&#160;1A of our Annual Report, which was filed with the SEC on February 28, 2023.</span></div><div id="icccf8cd82c034620b68745752f617ca9_139"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, follows this summary. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are an early clinical stage biopharmaceutical company and have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our success payment obligations in our success payment agreements may result in dilution to our stockholders or may be a drain on our cash resources to satisfy the payment obligations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are early in our research and clinical development efforts of our product candidates. If we are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidates and technology platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business could continue to be adversely affected by the effects of health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently manufacture drug products for our clinical trials ourselves. Delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates, or in expanding our manufacturing capacity or finding suitable third-party manufacturing partners, could delay our development plans and thereby limit our ability to generate product revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, including risks associated with supply chain complexity related to patient materials, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If a sole clinical or commercial manufacturing facility or any of our contract manufacturing organizations are damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We rely on third parties to conduct, supervise and monitor a significant portion of our research and nonclinical studies and clinical trials for our product candidates, and, if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We depend on the enrollment and retention of patients in our current and planned clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approvals, commercialization or payor coverage of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical development involves a lengthy and expensive process with an uncertain outcome.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span></div><div id="icccf8cd82c034620b68745752f617ca9_142"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early clinical stage biopharmaceutical company and have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove safe and effective, gain regulatory approval or become commercially viable. We are an early clinical stage biopharmaceutical company, and we do not have any products approved by regulatory authorities and have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses. Since our inception, we have not generated any revenue from product sales and have incurred significant net losses. Substantially all of our net losses since inception have resulted from our research and development programs and general and administrative costs associated with our operations. As of September&#160;30, 2023, we had an accumulated deficit of $949.2&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenue from product sales for the foreseeable future, if at all. We also expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates, expand our manufacturing capabilities, in-license or acquire additional technologies and potentially begin to commercialize product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period&#8209;to&#8209;period comparison of our results of operations may not be a good indication of our future performance. If any of our product candidates fails in research and development or clinical trials or does not gain regulatory approval, or, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur additional expenses and operating losses in the foreseeable future, if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue nonclinical development of our current and future product candidates and initiate additional nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commence and continue clinical trials of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">advance our genetic and epigenetic reprogramming technologies as well as other research and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek regulatory approval of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our manufacturing and process development capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our operational, financial and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acquire and license technology or technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue to develop, protect and defend our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a rapidly evolving field and, having commenced operations in June 2018, have a limited operating history, which makes it difficult to evaluate our business and prospects. Our primary activities to date have included developing T&#8209;cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of our product candidate development efforts, organizing and staffing the company, business planning, establishing our intellectual property portfolio, regulatory submissions and other preparations to initiate and execute clinical trials, raising capital and providing general and administrative support for these activities. Any predictions about our future success, performance or viability, may not be as accurate as they could be if we had a longer operating history or approved products on the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, any of our quarterly or annual periods&#8217; results are not indicative of future operating performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenues from product sales. Our ability to generate revenues from product sales and achieve profitability will depend on our ability to successfully develop and subsequently obtain regulatory approval for and commercialize our product candidates. Our ability to generate revenues and achieve profitability also depends on a number of additional factors, including our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete our research activities to identify the technologies and product candidates to further investigate in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete development activities, including the necessary clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit regulatory submissions to the FDA, the European Medicines Agency (EMA) or other agencies and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain coverage and adequate reimbursement from third parties, including government and private payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">set commercially viable prices for our products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop manufacturing and distribution processes for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">produce commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintain adequate supply of our product candidates, including the starting materials and reagents needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintain the supply of our product candidates in a manner that is compliant with global legal requirements or to the extent necessary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish and maintain manufacturing relationships with reliable third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">achieve market acceptance of our products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">protect our rights in our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves in the markets in which we choose to commercialize on our own; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">find suitable distribution partners to help us market, sell and distribute our approved products in other markets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues for any product for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. In addition, we anticipate incurring significant costs associated with commercializing any approved product. As a result, even if we generate revenue from product sales, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to expend substantial resources for the foreseeable future to advance and expand our research pipeline, conduct nonclinical studies and pursue clinical development and manufacturing of our product candidates. We also expect to continue to expend resources for the development of our technology platforms. These expenditures will include costs associated with research and development, potentially acquiring or licensing new technologies, conducting nonclinical studies and clinical trials and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. We will also need to make significant expenditures to develop a commercial organization capable of sales, marketing and distribution for any products, if any, that we intend to sell ourselves in the markets in which we choose to commercialize. In addition, we may be required to make substantial payments related to our success payment agreements and other contingent consideration payments under our license and collaboration agreements. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the discovery, development and commercialization of our existing and potential product candidates, and other unanticipated costs may arise.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we had $598.2&#160;million in cash, cash equivalents and marketable securities. As a result of expense timing, as well as diligent expense management, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our working capital and capital expenditure needs into 2027. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital to complete clinical development of any of our current programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds. Additional funds may not be available when we need them on terms that are acceptable to us, or at all, and our ability to raise additional capital may be adversely impacted by potentially unfavorable global economic conditions or conditions in the biotechnology sector of the market, including disruptions to, or volatility in the credit and financial markets in the United States and worldwide, actual or perceived changes in interest rates and economic inflation, the current or anticipated impact of geopolitical instability and otherwise. If adequate funds are not available to us on a timely basis, including pursuant to the Equity Distribution Agreement, we may be required to delay, limit, reduce or terminate nonclinical studies, clinical trials or other development activities for our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success payment obligations in our success payment agreements may result in dilution to our stockholders or may be a drain on our cash resources to satisfy the payment obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to make success payments payable in cash or publicly-tradeable shares of our common stock at our discretion pursuant to our success payment agreements with Fred Hutch and Stanford. On each contractually prescribed measurement date, we may be required to make success payments based on increases in the per share fair value of our common stock. The total amount of success payments that we may become obligated to make is currently $400.0&#160;million and may increase in the future due to amendments of our existing success payment agreements. For information related to our success payment obligations, see Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form&#160;10&#8209;Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to satisfy our obligations to make these success payments, if and when they are triggered, we may issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash to satisfy the success payment obligation in cash, which may adversely affect our financial position. In addition, these success payments may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third-party line of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success payment agreements may cause operating results to fluctuate significantly from quarter to quarter and year to year, which may reduce the usefulness of our consolidated financial statements.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success payment obligations are recorded as liabilities on our Condensed Consolidated Balance Sheets. Under U.S. generally accepted accounting principles (GAAP), we are required to estimate the fair value of these liabilities as of each quarter end and changes in the estimated fair value are accreted to research and development expense over the service period of the collaboration agreement. Once the requisite service obligation to earn the potential success payment consideration is met under our continued collaboration agreements, the change in the success payment liabilities fair value is recognized in other income or expense, net. For example, in December 2022, Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration; accordingly in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 and future periods, the change in the success payments liability fair value is recognized in other income or expense, net.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may lead to increases or decreases in the estimated fair value of our success payment liabilities include, among others, changes in the value of the common stock, changes in volatility and changes in the risk-free rate. As a result, our operating results and financial condition as reported by GAAP may fluctuate significantly from quarter to quarter and from year to year and may reduce the usefulness of our GAAP consolidated financial statements. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div id="icccf8cd82c034620b68745752f617ca9_145"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are early in our research and clinical development efforts. If we are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our research and clinical development efforts of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. We have not yet demonstrated our ability to successfully complete any clinical trials (including any Phase&#160;3 or other pivotal clinical trials), obtain regulatory approvals, manufacture a commercial&#8209;scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We have invested substantial resources in developing our technology platforms and our product candidates, conducting nonclinical studies, commencing clinical trials and building our manufacturing facilities and capabilities, each of which will be required prior to any regulatory approval and commercialization. Our ability to generate revenue from product sales, which we do not expect will occur for several years, if ever, will depend heavily on the successful research and development and eventual commercialization of one or more product candidates. The success of our efforts to identify and develop product candidates will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timely and successful completion of our nonclinical studies and research activities to identify and develop product candidates to investigate in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">submission of INDs to the FDA to proceed with clinical trials, or comparable applications to foreign regulatory authorities that allow the commencement of our planned clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successful enrollment and completion of clinical trials in compliance with Good Clinical Practice (GCP) requirements with positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of efficacy observed with our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of adverse events experienced with any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully developing, or making arrangements with third parties for, manufacturing and distribution processes for our product candidates and for commercial manufacturing and distribution for any of our product candidates that receive regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">receipt of timely regulatory approvals from applicable authorities for our product candidates for their intended uses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">protecting our rights in our intellectual property portfolio, including by obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establishing capabilities and infrastructure to obtain the tumor tissues needed to develop and, if successful, commercialize approved products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">manufacturing our product candidates at an acceptable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">launching commercial sales of our products, if approved by applicable regulatory authorities, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acceptance of our products, if approved by applicable regulatory authorities, by patients and the medical community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">effectively competing with other marketed therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining compliance with regulatory requirements, including the cGMP requirements;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining a continued acceptable benefit/risk profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates and technology platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking to identify and develop a broad pipeline of product candidates using our proprietary technology platforms. The scientific research that forms the basis of our efforts to develop product candidates with our technology platforms is still ongoing. We are not aware of any FDA approved therapeutics utilizing similar technology. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our technology platforms are both preliminary and limited. Additionally, although LYL797 and LYL845 are in Phase 1 clinical development, our current clinical data are limited, and nonclinical data from murine tumor models and in vitro experiments with tumor cell lines may not translate into humans or may not accurately predict the safety and efficacy of our product candidates in humans. As a result, we are exposed to a number of unforeseen risks, and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the novelty of our technology platforms, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of relevant experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates developed using our technology platforms, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. There can be no assurance as to the length of clinical development, the number of patients that the FDA may require to be enrolled in clinical trials to establish the safety, purity and potency of our product candidates or the acceptability to the FDA of data generated in these clinical trials to support marketing approvals. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel and, if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, manufacturing, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors and our inability to find suitable replacements could result in delays in product development and harm our business. We conduct substantially all of our operations at our facilities in the San Francisco, Seattle and Bothell metropolitan areas. These regions are headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in these markets is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity that vests over time. The value to employees of equity incentives that vest over time may be significantly affected by factors beyond our control, including market conditions and volatility, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, we may nevertheless experience attrition from members of our management, scientific and development teams. For example, over the past twelve months, there have been departures of executive officers, including most recently our chief medical officer. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior managers as well as junior, mid-level and senior scientific and medical personnel. Our recently announced reduction in workforce may yield unintended consequences and costs, such as difficulty retaining and motivating remaining employees, increased difficulty in our day-to-day operations and loss of institutional knowledge and expertise and difficulty in attracting and hiring qualified employees in the future. We may also be subject to reputational risks and litigation risks and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any litigation or adversarial proceedings could be costly and time-consuming to defend.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been and may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by us or third parties in connection with commercial disputes or employment claims made by our current or former employees. Litigation or adversarial proceedings might result in substantial costs and may divert management&#8217;s attention and resources, which might seriously harm our business, reputation, overall financial condition and operating results. For example, in February 2021, we filed a demand for arbitration seeking, among other things, rescission of each of the joint-development agreement and stock purchase agreement with PACT Pharma, Inc. (PACT) and recovery of the consideration paid thereunder and in October 2022, we entered into a settlement agreement with PACT to resolve the outstanding legal dispute. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims and might not continue to be available on terms acceptable to us. Any claim brought by us or against us that is uninsured or underinsured could result in unanticipated costs, thereby harming our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain our company culture as we grow, our success and our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our culture has been a key contributor to our success to date. Any failure to preserve our culture could negatively affect our ability to retain and recruit personnel, which is critical to our growth, and to effectively focus on and pursue our objectives. As we grow and are required to implement more complex organizational management structures, we may find it increasingly difficult to maintain the beneficial aspects of our culture. If we fail to maintain our company culture, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no marketing, sales and distribution capabilities. To support commercial marketing and distribution of any of our product candidates that complete clinical development and are approved, we would either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner or outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could continue to be adversely affected by the effects of health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could continue to be adversely affected by health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations. For example, health epidemics, including the COVID-19 pandemic, have in the past and could again in the future result in quarantines, stay-at-home orders, remote work policies or other similar events that may disrupt businesses, delay our research and development programs and timelines, negatively impact productivity and increase risks associated with cybersecurity, the future magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations. These types of events presented substantial public health and economic challenges around the world and affected employees, patients, communities and business operations, as well as the United States and international economy </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and financial markets. In this regard, the COVID-19 pandemic and government measures taken in response have had a significant impact in the last three years, both direct and indirect, on businesses and commerce, as significant reductions in business-related activities have occurred, supply chains have been disrupted, availability and cost of materials have been affected and manufacturing and clinical development activities have been impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of the COVID-19 pandemic and actual or perceived changes in interest rates and economic inflation), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability and swings in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of supply chain disruptions, labor shortages, fluctuations in currency exchange rates, changes in interest rates, military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to geopolitical conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions, including disruption to enrollment within our ongoing trials and our ability to purchase necessary supplies on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, later in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. While the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program, and there is no guarantee that such programs will be sufficient. Additionally, it is uncertain whether the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations as a result of the matters relating to SVB, Signature Bank and Silvergate Capital Corp, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners or industry as a whole may be adversely impacted in ways that we cannot predict at this time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships and, in turn, us. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div><span><br/></span></div><div id="icccf8cd82c034620b68745752f617ca9_148"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently manufacture drug products for our clinical trials ourselves. Delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates, or in expanding our manufacturing capacity, could delay our development plans and thereby limit our ability to generate product revenues.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our own manufacturing facility in Bothell, Washington. The facility is designed to support the production of nonclinical and clinical development product candidates and early commercialization of products, and ongoing facility and equipment qualification to support clinical production is required. If we are not able to further qualify our existing facility or the appropriate regulatory approvals for the facility are delayed, or if we are unable to otherwise expand our manufacturing capacity, we may be unable to manufacture sufficient quantities of our product candidates, if at all, which would limit our development activities and our opportunities for growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing facility will be subject to ongoing, periodic inspection by the FDA, EMA or other applicable regulatory agencies to ensure compliance with cGMPs and current Good Tissue Practices (cGTPs). Our failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or, in the future, commercial use. This may result in the termination of or a hold on a clinical trial or may delay or prevent filing or approval of commercial marketing applications for our product candidates. We also may encounter problems with the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">achieving adequate or clinical-grade materials that meet regulatory agency standards or specifications with consistent and acceptable production yield and costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining continuity among our key manufacturing-related electronic systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">shortages of qualified personnel, raw materials or key contractors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing advanced manufacturing techniques and process controls is required to fully utilize our facility. Without further investment, advances in manufacturing techniques may render our facility and equipment inadequate or obsolete. We may also require further investment to build additional manufacturing facilities or expand the capacity of our existing ones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing commercially viable manufacturing processes for cellular therapies is a difficult and uncertain task and requires significant expertise and capital investment. We are developing and implementing manufacturing processes for our product candidates. In particular, for autologous cell therapies, the starting material is the patient&#8217;s own cells, which inherently adds complexity and variability to the manufacturing process. In addition, our ability to consistently and reliably manufacture our cellular therapy product candidates is essential to our success, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including cost overruns, potential problems with process scale-up, process reproducibility, stability issues, consistency and timely availability of reagents or raw materials. Furthermore, our manufacturing processes may have significant dependencies on third parties, which will pose additional risks to our manufacturing capabilities. Additionally, we do not yet have sufficient information to reliably estimate the cost </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the factors mentioned above, the overall process of manufacturing cellular therapies is extremely susceptible to product loss due to low cell viability, contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, impact to key product quality attributes and other supply disruptions. Product defects can also occur unexpectedly. These deviations and disruptions could delay our programs. If we are not able to capably manage this complexity and variability, our ability to timely and successfully provide our product candidates to patients could be delayed. In addition, the complexities of utilizing a patient&#8217;s own cells as the starting material requires that we have suitable cells capable of yielding a viable cellular therapy product, which may not be possible for severely immune-compromised or heavily pre-treated patients.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of successfully manufacturing products for clinical testing and commercialization may be particularly challenging, even if such products otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with microbes, viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated, unusable product or necessitate the closing of a manufacturing facility for an extended period of time to allow us to investigate and remedy the contamination. These types of contaminations could result in delays in the manufacture of products, which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in supply that could delay the development of our product candidates. If we are unable to obtain sufficient supply of our product candidates, whether due to production shortages or other supply interruptions resulting from any lingering effects of the COVID-19 pandemic, the Russia-Ukraine conflict or otherwise, our clinical trials or regulatory approvals may be delayed. We may also have to write off inventory, incur other charges and expenses for supply of product that fails to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, parts of the supply chain may have long lead times or may come from a small number of suppliers. If we are not able to appropriately manage our supply chain, our ability to successfully produce our product candidates could be delayed or harmed. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, health epidemics and numerous other factors. If any of these events were to occur and impact our manufacturing facilities, our business would be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our sole clinical or commercial manufacturing facility or any of our contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a single manufacturing facility in Bothell, Washington and may rely on third-party contract manufacturing organizations to meet our current and future manufacturing needs. If our manufacturing facility or any facility in our manufacturing network, or the equipment in these facilities, is either damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity, if at all. In the event of a temporary or protracted loss of a facility or its equipment, we may not be able to transfer manufacturing to a third party in the time required to maintain supply. Even if we are able to transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could substantially delay our clinical trials or commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on third parties to manufacture our current or future product candidates. We may be unable to identify manufacturers for our product candidates or the materials required to develop the cellular therapy on acceptable terms or at all because the number of potential manufacturers is limited. We are currently evaluating third&#8209;party manufacturing options, including an automated manufacturing platform from Cellares for the manufacture of our LYL797 CAR T-cell therapy. Engaging a third-party manufacturer will require testing and regulatory interactions, and a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. Such potential third-party manufacturers may be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the facilities used by manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state agencies to ensure strict compliance with government regulations and corresponding foreign standards, and we do not have control over third-party manufacturers&#8217; compliance with cGMPs for the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to obtain and/or maintain regulatory approval for our product candidates manufactured in these facilities. In addition, we have no control over the ability of our third-party manufacturers to maintain adequate control, quality assurance and qualified personnel required to meet our clinical and commercial needs, if any. If the FDA or a comparable foreign regulatory authority does not approve the manufacture of our product candidates at these facilities or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that any approvals we have obtained could be revoked, which would adversely affect our business and reputation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products. Also, our third-party manufacturers could breach or terminate their agreement with us because of their own financial difficulties or business priorities at a time that is costly or otherwise inconvenient for us. If we were unable to find adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our third-party manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials. As a result, we may be required to outsource aspects of our manufacturing supply chain. Many of the specialty raw materials may be manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidates in a timely and competitive manner, or at all. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, those suppliers may not have the capacity to support commercial products manufactured by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection, or medical crises such as widespread contamination. We may not be able to contract with these companies on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing. In addition, some raw materials are currently available from a single supplier, or a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. These factors could cause the delay of studies or trials, regulatory submissions, required approvals or commercialization of product candidates that we develop, cause us to incur higher costs and prevent us from commercializing our product candidates successfully.</span></div><div id="icccf8cd82c034620b68745752f617ca9_151"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on third parties to conduct, supervise and monitor a significant portion of our research and nonclinical studies and clinical trials for our product candidates, and, if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GCP-compliant clinical trials on our product candidates properly and on time. For example, we are relying on CROs to conduct significant parts of our LYL797 and LYL845 Phase&#160;1 clinical trials. Negotiating budgets and contracts with CROs and study sites may result in delays to our development timelines and increased costs. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any third parties conducting our clinical trials or nonclinical studies will not be our employees, and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials or nonclinical studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on these parties for execution of our nonclinical studies and clinical trials, and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP conditions. Our failure to comply with these regulations may require us to add patients to or repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with the third parties that we currently use or that we may use in the future terminates, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. As a result, delays occur, which can materially impact our ability to meet desired research and clinical development timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do and will continue to or intend to rely on outside scientists and clinical trial investigators and their third-party research institutions for research and development and early clinical testing of our product candidates. These scientists, investigators and institutions may have other commitments or conflicts of interest, which could limit our access to their expertise and harm our ability to leverage our technology platforms.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our third-party research institution collaborators for some research capabilities. However, the research we are funding constitutes only a small portion of the overall research of each research institution. Other research being conducted by these institutions may at times receive higher priority than research on the programs we are funding. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">typically have less control of the research, clinical trial protocols and patient enrollment than we might with activity led by our employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outside scientists and clinical trial investigators who conduct the research and development upon which portions of our product candidate pipeline depends are not our employees; rather, they serve as either independent contractors or the primary investigators under research collaboration agreements that we have with their sponsoring academic or research institution. Such scientists and collaborators may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if an actual or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. These factors could adversely affect the timing of the clinical trials, the timing of receipt and reporting of clinical data, the timing of our IND submissions and our ability to conduct our current and planned clinical trials. It is also possible that some of our valuable proprietary knowledge may become publicly known through these scientific advisors if they breach their confidentiality agreements with us, which would cause competitive harm to, and have an adverse effect on, our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into research and development collaborations in the past, and may in the future, enter into additional license and collaboration arrangements. Any collaboration arrangement that we enter into is subject to numerous risks, which may include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator has significant discretion in determining the efforts and resources that they will apply to a program or product candidate under the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may delay or halt clinical trials, provide insufficient funding for a clinical trial, preferentially enroll patients on a portion of a clinical trial not testing our product candidates, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not commit sufficient resources to marketing and distribution of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaboration may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, failure by any collaborator to meet its obligations under our collaboration agreements or to apply sufficient efforts at developing and commercializing collaboration products may adversely affect our business, financial condition and our results of operations. For example, we were previously party to a research and development collaboration with GSK for our NY-ESO-1 program and other potential product opportunities and, effective December 2022, GSK terminated the agreement and discontinued its development of product candidates targeting NY-ESO-1, including the second&#8209;generation product candidates that incorporated our genetic and epigenetic reprogramming technologies. No patients had been treated with these product candidates and, given the early stage of these second&#8209;generation programs, the termination was not based on any clinical efficacy or safety data from these programs. We have also discontinued any further work on these programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates, our research and any future product candidates that we may pursue. Such alliances will be subject to many of the risks set forth above. Moreover, any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these risks, we may not be able to realize the benefit of our existing collaboration or any future collaborations or licensing agreements we may enter into. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of potential future collaborations, licenses, product acquisitions or other strategic transactions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may desire to enter into in the future, collaborations, licenses or other strategic transactions for the acquisition of products or business opportunities, in each case where we believe such arrangement will complement or augment our existing business. These relationships or transactions, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, reduce the potential profitability of the products that are the subject of the relationship or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and transactions and the negotiation process is time-consuming and complex, and there can be no assurance that we can enter into any of these transactions even if we desire to do so. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates or programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate a positive benefit/risk profile. Any delays in entering into new strategic alliance agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we license products or acquire businesses, we may not be able to realize the benefit of these transactions if we are unable to successfully integrate them with our existing operations and company culture. There are other risks and uncertainties involved in these transactions, including unanticipated liabilities related to acquired intellectual property rights, products or companies and disruption in our relationship with collaborators or suppliers as a result of such a transaction. We cannot be certain that, following an acquisition or license, we will achieve the financial or strategic results that would justify the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the enrollment and retention of patients in our current and planned clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful and timely completion of clinical trials require that we enroll and retain a sufficient number of patient candidates. Any clinical trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, manufacturing failures resulting in patients being unable to be treated, patient withdrawal or adverse events.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These types of developments could cause us to delay the trial or halt further development. For example, we announced in 2022 that enrollment for the Phase 1 trial of LYL797 had been slower than anticipated due to delays in clinical site activations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for diseases in which there is an approved standard of care is challenging, as patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care do not enroll in clinical trials. This may limit the number of eligible patients able to enroll in our clinical trials who have the potential to benefit from our product candidates and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these prior treatment regimens may render our therapies less effective in clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, healthcare and hospital resources, including both front-line and administrative staff, may continue to be negatively impacted by the lingering effects of the COVID-19 pandemic and other macroeconomic factors, which may delay enrollment in our current and planned clinical trials. For example, some patients may not be able to comply with clinical trial protocols due to lack of healthcare support or potential interruptions of healthcare services. Our ability to recruit and retain patients, principal investigators and site staff may also be hindered, which would adversely affect our trial operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment depends on many additional factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size and nature of the patient population;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eligibility criteria for the trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the proximity of patients to clinical sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the design of the clinical protocol;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to obtain and maintain patient consents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">perceived risks and benefits of the product candidate under evaluation, including any perceived risks associated with genetically modified product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of competing clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of new drugs approved for the indication that the clinical trial is investigating; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available approved or investigational therapies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions. Our ability to enroll clinical trials or our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. Additionally, our commercial opportunities will be reduced or eliminated if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of our current or future target diseases. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by applicable regulatory authorities. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.</span></div><div id="icccf8cd82c034620b68745752f617ca9_154"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulation and Legal Compliance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the first phase of clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for commercial sale, and we are in the first phase of clinical development of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. The future success of our business is substantially dependent on our ability to obtain regulatory approval for our product candidates for the indications we seek, and, if approved, to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successfully commercialize one or more product candidates in a timely manner. Each of our programs and product candidates will require clinical development, regulatory approval, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence from and to the satisfaction of the FDA and foreign regulatory authorities, that the product candidate is safe, pure and potent for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of nonclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval. Furthermore, the regulatory approval process for novel product candidates, such as T-cell product candidates and next-generation T-cell programs, can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on the successful development of our cellular therapies in general and our development product candidates, in particular. Because these programs represent a new approach to the treatment of cancer, developing and, if approved, commercializing our product candidates subject us to a number of challenges. Moreover, we cannot be sure that the manufacturing processes used in connection with our cellular therapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, scalable or profitable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to oversight by the FDA and by institutional review boards (IRBs) under guidelines promulgated by the National Institutes of Health (NIH), gene therapy clinical trials, such as those for LYL797 which evaluates T cells expressing a synthetic CAR and overexpressing c-Jun, are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA decides whether trials of cell therapies that involve genetic engineering may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment mechanics. The FDA or other applicable regulatory authorities may ask for specific post-marketing requirements, and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt this </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">novel therapy, may decide the therapy is too complex to adopt without appropriate training or not cost-efficient and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in research, nonclinical studies and early clinical trials does not ensure that later clinical trials will generate similar results and otherwise provide adequate data to demonstrate the efficacy and safety of an investigational product. Likewise, a number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in late-stage clinical trials, even after seeing promising results in earlier nonclinical studies or clinical trials. Thus, even if the results from our initial research and nonclinical activities appear positive, we do not know whether subsequent late-stage clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, final study results may not be consistent with interim study results. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our product candidates, the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the first phase of clinical development of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. The risk of failure of our product candidates is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical testing that will be required for any product candidates we choose to advance is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process. Even if our current and planned clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted indications or support continued clinical development of such product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through nonclinical and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not fully enrolled or completed any clinical trials required for the approval of our product candidates. We may experience delays in initiating, enrolling or conducting our current and planned clinical trials, and we do not know whether clinical trials will begin or enroll subjects on time, will need to be redesigned, will achieve expected enrollment rates or will be completed on schedule, if at all. Obtaining sufficient and specific tumor tissues is needed for our Phase&#160;1 clinical trials of LYL797 and LYL845 in multiple solid tumor indications. Our inability to obtain the specific tumor tissues or sufficient amount of tumor tissues in a timely manner or at all could delay or preclude our ability to execute and complete the clinical trials. There can be no assurance that the FDA or comparable foreign regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities will not put clinical trials of any of our product candidates on clinical hold in the future. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including in connection with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability to generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in reaching agreement with the FDA or other regulatory authorities as to the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining regulatory authorization to commence a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reaching an agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining IRB or ethics committee approval at each trial site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">recruiting suitable patients to participate in a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">having patients complete a clinical trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to perform in accordance with applicable regulatory requirements, including the FDA&#8217;s GCP requirements, or applicable regulatory requirements in other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">adding a sufficient number of clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspensions or terminations by IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including those described above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial or the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict with any certainty whether or when we might complete a given clinical trial, if at all. If we experience delays or quality issues in the conduct, completion or termination of any clinical trial of our product candidates, the approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we may experience in our clinical trials, we may not continue the development of nor receive approval to market any product candidates, which could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevent us from ever generating product revenues or achieving profitability. For example, previous clinical trials utilizing CAR T&#160;cells to treat hematologic tumors have shown an increased risk of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Adverse events may also be associated with the lymphodepletion or IL-2 regimen utilized with cellular therapies. Additionally, ROR1 is expressed on a number of normal tissues. As a result, ROR1 could cause on-target, off-tumor toxicity. c-Jun is also potentially an oncogene and could cause healthy cells to transform into malignant cells. Results of our trials could reveal an unacceptably high severity and incidence of side effects, or side effects outweighing the benefits of our product candidates. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The side effects experienced could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our product candidates receives regulatory approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may withdraw or limit approvals of such products and require us to take our approved product off the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy (REMS) plan to ensure that the benefits of the product outweigh its risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to change the dose or the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to limitations on how we may promote or manufacture the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sales of the product may decrease significantly;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, topline or preliminary data from our nonclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Further, modifications or improvements to our manufacturing processes for a therapy may result in changes to the characteristics or behavior of the product candidate that could cause our product candidates to perform differently and affect the results of our ongoing clinical trials. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose preliminary or interim data from our nonclinical studies and clinical trials. Preliminary or interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Additionally, disclosure of preliminary or interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. If the interim, topline or preliminary data we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of our potential product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval of our product candidates, our business will be substantially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T-cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize any drug product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe, pure and potent for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional nonclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the approval policies or regulations of the FDA or comparable foreign authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if physicians experience unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, testing, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor the safety and efficacy of the product if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations, as well as, for the manufacture of certain of our product candidates, the FDA&#8217;s cGTPs for the use of human cellular and tissue products to prevent the introduction, transmission or spread of communicable diseases. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs, cGTPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, quality control and distribution.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include issuing warning letters or untitled letters, imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we have any product candidate approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. In the United States, the FDA and the Federal Trade Commission (FTC) strictly regulate the promotional claims that may be made about pharmaceutical products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false in any particular way and adequately substantiated by clinical data. The promotion of a drug product in a manner that is false, misleading, unsubstantiated or for unapproved (or off-label) uses may result in enforcement letters, inquiries and investigations and civil and criminal sanctions by the FDA, FTC and other regulatory authorities. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions and may result in false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government has also required that companies enter into consent decrees and/or imposed permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue, or require us to issue, safety-related communications, such as safety alerts, field alerts, &#8220;Dear Doctor&#8221; letters to healthcare professionals, or import alerts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">impose civil or criminal penalties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend, limit or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend any of our nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">impose restrictions on our operations, including closing our and our contract manufacturers&#8217; facilities; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, during the Trump administration several executive actions were taken, including the issuance of a number of Executive Orders, that imposed significant burdens on, or otherwise delayed, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how similar orders in the future would be implemented, and the extent to which they would impact the FDA&#8217;s ability to exercise its regulatory authority. If executive actions are taken that impose restrictions on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to applicable fraud and abuse, including anti-kickback and false claims, transparency, health information privacy and security and other healthcare laws. Failure to comply with such laws, may result in substantial penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute any product candidates for which we obtain marketing approval. The healthcare laws that may affect us include: the federal fraud and abuse laws, including the federal anti-kickback, and false claims and civil monetary penalties laws; federal data privacy and security laws, including the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act; and federal transparency laws related to ownership and investment interests and payments and/or other transfers of value made to or held by physicians (including doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. In addition, many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. Moreover, several states require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenditures. Additionally, some state and local laws require the registration of biopharmaceutical sales representatives in the jurisdiction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of non-compliance with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished profits and lower future earnings. For additional detail on healthcare laws that may affect our business, see &#8220;Other Healthcare Laws&#8221; in the business section of our Annual Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare policies, laws and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives, as well as executive, judicial and Congressional challenges to existing healthcare laws that have significantly affected, and could continue to significantly affect, the healthcare industry. For example, there have been efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), some of which have been successful. While the U.S. Supreme Court dismissed in June 2021 a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress, such efforts may continue. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there continues to be heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs and review the relationship between pricing and manufacturer patient programs. For example, President Biden issued an executive order in July 2021 supporting legislation to enact drug pricing reforms and, in response, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of, and access to, prescription drugs. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things: (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. Additionally, the IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions will take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center, which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a procedure is safe, effective and medically necessary; appropriate for the specific patient; cost effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, a significant trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. As such, cost containment reform efforts may result in an adverse effect on our operations. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Similarly, because our product candidates will be physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to be cleared or approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough FDA employees and stop critical activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. In February 2022, the FDA resumed on-site inspections of domestic manufacturing facilities, subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, in April 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized or deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to health epidemics. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div id="icccf8cd82c034620b68745752f617ca9_157"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements to protect the intellectual property related to our technology and product candidates. We own or possess certain intellectual property, and other intellectual property are owned or possessed by our partners and are in-licensed to us. When we refer to &#8220;our&#8221; technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license, many of which are critical to our intellectual property protection and our business. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by the U.S. Patent and Trademark Office (USPTO) and non-U.S. patent offices in granting patents are not always applied uniformly or predictably. There is also no assurance that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity, enforceability or patentability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity, enforceability or patentability of such claim. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if patents have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable. Even if unchallenged, our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other intellectual property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also desire to seek licenses from third parties who own or have rights to intellectual property that may be useful for providing exclusivity for our product candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to obtain such licenses from third parties on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the USPTO and various foreign governmental or inter-governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during and after the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete, irreversible loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States patent applications containing or that at any time contained a claim not entitled to a priority date before March&#160;16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011). The first to file system requires us to be cognizant going forward of the time from invention to filing of a patent application. Because patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our partners were the first to file any patent application related to a product candidate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our registered or unregistered trademarks or trade names may be challenged, infringed or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trade names, which we view as valuable to building name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties have adopted or may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion and/or litigation. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce, protect or defend our proprietary rights related to trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first nonprovisional effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. While the patent term of certain patents can also be extended with respect to a specific product to recapture time lost in clinical trials and regulatory review by the FDA, a patent&#8217;s life also can be shortened by a terminal disclaimer over an earlier filed patent or patent application. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, enforcing and defending patents on all of our product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights in certain countries outside the United States may be less extensive than those in the United States. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we and our partners may not be able to prevent third parties from practicing our inventions in countries outside the United States, or from selling or importing infringing products made using our inventions in other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patents to develop their own products and, further, may export otherwise-infringing products to territories where we and our partners have patent protection but where enforcement is not as strong as that in the U.S. These infringing products may compete with our product candidates in jurisdictions where we or our partners have no issued patents or where we do not have exclusive rights under the relevant patents, or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our partners to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us or our partners. We or our partners may not prevail in any lawsuits that we or our licensors initiate, and even if we or our licensors are successful, the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, we or our partners may have limited remedies, which could materially diminish the value of such patent. If we or our partners are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing or misappropriating the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on us and our partners not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including patent infringement lawsuits, interference or derivation proceedings, oppositions, and inter partes and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in the fields in which we are developing, and may develop, product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of third parties&#8217; patent rights, as it may not always be clear to industry participants, including us, which patents cover various types of products, methods of making or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert infringement or misappropriation claims against us based on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, patent applications covering our product candidates could have been filed by others without our knowledge, since these applications generally remain confidential for some period of time after their filing date. Even pending patent applications that have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. In addition, we may have analyzed patents or patent applications of third parties that we believe are relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or potentially result in any of our product candidates or our activities infringing their claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving that a patent is invalid is difficult and even if we are successful in the relevant proceedings, we may incur substantial costs, and the time and attention of our management and scientific personnel could be diverted from other activities. If one or more claims of any issued third-party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until the relevant patent expired. Alternatively, we may desire or be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property licensed to us. If we are unable to obtain a necessary license on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third-party&#8217;s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defending against intellectual property claims, regardless of their merit, could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle before a final judgment, any litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions and other interim proceedings in the litigation and these announcements may have negative impact on the perceived value of our product candidates, programs or intellectual property. In the event of a successful intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. In addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, and the parties making claims against us may obtain injunctive or other equitable relief, which could impose limitations on the conduct of our business. We may also elect to enter into license agreements in order to settle patent infringement claims prior to litigation, and any of these license agreements may require us to pay royalties and other fees that could be significant. As a result of all of the foregoing, any actual or threatened intellectual property claim could prevent us from developing or commercializing a product candidate or force us to cease some aspect of our business operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold rights under license agreements with our partners. Our discovery and development technology platforms are built, in part, around intellectual property rights in-licensed from our partners. Under our existing license agreements, we are subject to various obligations, which may include diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales. If there is any conflict, dispute, disagreement or issue of nonperformance between us and our counterparties regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations, we may be liable to pay damages and our counterparties may have a right to terminate the affected license. The termination of any license agreement with one of our partners could adversely affect our ability to utilize the intellectual property that is subject to that license agreement in our discovery and development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected product candidates and our ability to commercialize the affected product candidates. Furthermore, disagreements under any of these license agreements may arise, including those related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether and the extent to which our technology and processes may infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These disagreements may harm our relationship with the partner, which could have negative impacts on other aspects of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, to develop our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations, manufacturing methods or technologies to work effectively and efficiently, and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms; such failure would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired or licensed, or may require in the future, intellectual property rights that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. Our patent applications cannot be enforced against third parties practicing the technology claimed in these applications unless and until a patent issues from the applications, and then only to the extent the issued claims cover the technology. In the future, we or our partners may elect to initiate legal proceedings to enforce or defend our or our partners&#8217; intellectual property rights, to protect our or our partners&#8217; trade secrets or to determine the validity or scope of our intellectual property rights. Any claims that we or our partners assert against perceived infringers could also provoke these parties to assert counterclaims against us or our partners alleging that we or our partners infringe their intellectual property rights or that our intellectual property rights are invalid. In patent litigation in the United States, defendant counterclaims alleging noninfringement, invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert noninfringement, invalidity or unenforceability of a patent. The outcome following legal assertions of noninfringement, unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity of patent rights, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference, derivation or opposition proceedings provoked by third parties, brought by us or our partners, or brought by the USPTO or any non-U.S. patent authority may be necessary to determine the priority of inventions or matters of inventorship with respect to our patents or patent applications. We or our partners may also become involved in other proceedings, such as reexamination or opposition proceedings, inter partes review, post-grant review or other pre-issuance or post-grant proceedings in the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property of others. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. An unfavorable outcome in any of these proceedings could require us or our partners to cease using the related technology and commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our partners a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any intellectual property proceedings can be expensive and time-consuming. Our or our partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our partners can. Accordingly, despite our or our partners&#8217; efforts, we or our partners may not be able to prevent third parties from infringing upon or misappropriating our intellectual property rights, particularly in countries where the laws may not protect our rights as fully as in the U.S. Even if we are successful in the relevant proceedings, we may incur substantial costs, and the time and attention of our management and scientific personnel could be diverted from other activities. In addition, in an infringement proceeding, a court may decide that one or more of our patents is invalid or unenforceable, in whole or in part, may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question and/or may require us to pay the other party attorneys&#8217; fees. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be adversely affected and our business could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our product candidates, thus eroding our competitive position in the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets can be difficult to protect. We seek to protect our proprietary, confidential technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the U.S. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations and/or wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise breached non-compete or non-solicit obligations with respect to such individuals&#8217; prior employers, or used or disclosed confidential information of these third parties or such individuals&#8217; former employers. Dealing with such claims and negotiating with potential claimants could result in substantial cost and be a distraction to our management and employees. In addition, litigation may be necessary to defend against these claims, and even if we are successful in defending against these claims, such litigation could result in further costs to us and distraction to our management and employees.</span></div><div id="icccf8cd82c034620b68745752f617ca9_160"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our organizational documents:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish that our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered three-year terms;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that our directors may be removed only for cause;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eliminate cumulative voting in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">permit stockholders to take actions only at a duly called annual or special meeting and not by unanimous written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prohibit stockholders from calling a special meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors, by a majority vote, to amend certain provisions of the bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, which is generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees, or stockholders to us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation and bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim governed by the internal affairs doctrine.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, to prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. However, these provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents or our other stockholders, which may discourage such lawsuits against us and such other persons, or may result in additional expense to a stockholder seeking to bring a claim against us. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls over financial reporting or identify additional material weaknesses in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may significantly harm our business and the value of our common stock.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act (Section&#160;404) requires that we evaluate and determine the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Our independent registered public accounting firm is also required to attest to the effectiveness of our internal control over financial reporting. These assessments need to include the disclosure of any material weaknesses in such internal control. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. We and our independent auditors have previously identified a material weakness in our internal control over financial reporting, and we cannot assure you that we will not identify other material weaknesses in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may not have identified all material weaknesses, and our current controls and any new controls that we develop may become inadequate because of changes in personnel or conditions in our business or otherwise. Accordingly, we cannot assure you that any future material weaknesses will not result in a material misstatement of our consolidated financial statements and/or our failure to meet our public reporting obligations. In addition, if we and/or our independent registered public accounting firm are unable to conclude that our internal control over financial reporting is effective in the future, investor confidence in the accuracy and completeness of our consolidated financial statements would be adversely affected, which could significantly harm our business and the value of our common stock. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div id="icccf8cd82c034620b68745752f617ca9_163"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act, and we must maintain disclosure controls and procedures designed to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement, causing us to fail to make a required related party transaction disclosure or identify a potential conflict of interest. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and may continue to be, volatile, which could result in substantial losses for investors.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and may continue to be, volatile and may fluctuate substantially as a result of a variety of factors, many of which are beyond our control. Some of the factors that may cause the market price of our common stock to fluctuate are listed below and other factors described in this &#8220;Risk Factors&#8221; section:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and results of nonclinical studies and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of existing or new competitive product candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">results of clinical trials or regulatory approvals of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commencement or termination of collaborations for our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developments or disputes including those concerning patent applications, issued patents, or other proprietary rights;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any lingering effects of the COVID-19 pandemic on our business and on global economic conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor discord or disruption, geopolitical events, social unrest, war, including repercussions of the military conflict between Russia and Ukraine, tensions in U.S.-China relations, escalating armed conflicts and turmoil in the Middle East, terrorism, political instability, acts of public violence, boycotts, hostilities and social unrest and other health pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of expenses related to any of our research programs or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">actual or anticipated changes in our estimates as to our financial results or development timelines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether our financial results, forecasts and development timelines meet the expectations of securities analysts or investors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sales of our common stock by us, our insiders, or other stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market conditions in the healthcare sector;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">general economic, industry and market conditions beyond our control, such as inflationary pressures, labor shortages and supply chain disruptions, bank failures and other macroeconomic factors and associated economic downturn; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, stock markets in general, and the market for biotechnology companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors have affected and may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they publish negative or neutral evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts covering our business initiate coverage with a neutral or sell rating or downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders could cause the price of our common stock to decline.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time, sales of a substantial number of shares of our common stock in the public market could occur, or there could be a perception in the market that the holders of a large number of shares of common stock intend to sell shares, and any such event could reduce the market price of our common stock. As of September&#160;30, 2023, we have 251,868,968 shares of common stock outstanding. Substantially all of the shares of our common stock outstanding and shares issued upon the exercise of stock options outstanding under our equity incentive plans, subject to applicable securities law restrictions, may be able to be sold in the public market. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, certain holders of shares of our common stock have rights, subject to conditions, to require us to file registration statements with the SEC covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing securities issued in any such transactions. Because our decision to issue debt or equity securities in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. In August 2022, we entered into an Equity Distribution Agreement pursuant to which we may offer and sell, from time to time, up to $200.0&#160;million in shares of our common stock. To the extent that we raise additional capital through the sale of equity or debt securities, including pursuant to the Equity Distribution Agreement, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships, alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or our products, or grant licenses on terms unfavorable to us. Certain of the foregoing transactions may require us to obtain stockholder approval, which we may not be able to obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are no longer an &#8220;emerging growth company&#8221;, and the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; no longer apply, which increases our costs as a result of being a public company and demands on management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2022, we are no longer classified as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). As such, we will incur significant additional expenses that we did not previously incur in complying with the Sarbanes-Oxley Act and rules implemented by the SEC. For instance, the cost of compliance with Section 404 has required, and will continue to require, us to incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements, which could divert management attention and adversely affect our business, operating results and financial condition. Moreover, if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, investor perceptions of our company may suffer if, in the future, material weaknesses are found, and this could cause a decline in the market price of our stock. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material effect on our stated operating results. If we are unable to implement these changes effectively or efficiently, it could harm our operations, financial reporting or financial results and could result in an adverse opinion on internal control from our independent registered public accounting firm.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a &#8220;large accelerated filer,&#8221; we were required to hold a say-on-pay vote and a say-on-frequency vote at our 2023 annual meeting of stockholders. As a result, we required additional attention from management with respect to our disclosures and have incurred and will incur increased costs, including higher legal fees, accounting fees, consultant fees and fees associated with investor relations activities, among others, and, as a result, our business, operating results and financial condition could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions, strategic investments, partnerships or alliances could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value and adversely affect our operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek to acquire or invest in businesses, products or technologies that we believe could complement or expand our technology platforms, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions or strategic investments may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions or investments, whether or not such transactions are completed. In addition, we have only limited experience in acquiring or investing in other businesses, and we may not successfully identify desirable targets, or if we acquire additional businesses, we may not be able to integrate them effectively following the acquisition. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, as well as unfavorable accounting treatment and exposure to claims and disputes by third parties, including intellectual property claims. We also may not generate sufficient financial returns to offset the costs and expenses related to any acquisitions. In addition, if an acquired business fails to meet our expectations, our business, operating results and financial condition may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company require our management to devote substantial time to compliance initiatives and corporate governance practices and could divert management&#8217;s attention and strain our resources.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. Section&#160;404, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">listing requirements and rules of The Nasdaq Stock Market LLC (Nasdaq Listing Rules) and other applicable U.S. rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We continue to need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company, and our management and other personnel will continue to need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have and will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, the rules and regulations applicable to us as a public company have made it more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (the Tax Act), the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) and the recently enacted IRA made many significant changes to the U.S. tax laws. For example, the Tax Act made broad and complex changes to the U.S. tax code, including, among other things, reducing the federal corporate tax rate. Additionally, beginning in 2022, the Tax Act required the capitalization of research and experimentation expenses with amortization periods over five and fifteen years pursuant to Section 174 of the U.S. Internal Revenue Code of 1986, as amended (the Code). If the requirement to capitalize Section 174 expenditures is not modified, it may impact our effective tax rate and our cash tax liability in future years. We expect further guidance regarding Section 174 may be forthcoming from the Financial Accounting Standards Board and the SEC, as well as regulations, interpretations and rulings from federal and state agencies, which could impact our consolidated financial statements. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to any such tax legislation may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations and the deductibility of expenses under the Tax Act or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Act, as modified by the CARES Act, our net operating losses (NOLs) generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. There is variation in how states have responded and may continue to respond to the Tax Act and CARES Act. In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We may have experienced ownership changes in the past, including as a result of our IPO, and may experience future ownership changes as a result of subsequent shifts in our stock ownership (some of which may be outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset post-change taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems, and those of our partners, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed and our business could be otherwise adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any material system failure, accident or security breach to date, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs, and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection and other losses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with third parties may include indemnification provisions under which we agree to indemnify them for losses suffered or incurred as a result of claims of intellectual property infringement or other liabilities relating to or arising from our contractual obligations. Large indemnity payments could harm our business and financial condition. Although we normally contractually limit our liability with respect to such obligations, we may still incur substantial liability. Any dispute with a third party with respect to such obligations could have adverse effects on our relationship with that third party and relationships with other existing or new partners, harming our business.</span></div><div id="icccf8cd82c034620b68745752f617ca9_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="icccf8cd82c034620b68745752f617ca9_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="icccf8cd82c034620b68745752f617ca9_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="icccf8cd82c034620b68745752f617ca9_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023, none of our directors or executive officers <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-784"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-785">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-786"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-787">terminated</ix:nonNumeric></ix:nonNumeric> a Rule&#160;10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement as defined in Item 408(a) and (c) of Regulation&#160;S-K, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended and Restated Bylaws</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2023, our board of directors approved an amendment and restatement of our Amended and Restated Bylaws, effective as of such date (the Amended Bylaws). Among other matters, the Amended Bylaws (i) revises the procedures and disclosures for the nomination of directors in accordance with Rule 14a-19 of the Securities Exchange Act of 1934, as amended, including that the stockholder proposing business or nominating directors provide certain additional information regarding the stockholder and the proposal or nominee, as applicable, and any candidate for the board of directors nominated by a stockholder must provide certain additional information and representations; (ii) updates certain provisions in accordance with certain amendments to the Delaware General Corporation Law, including when additional notice need not be given of an adjourned meeting, board meeting quorum requirements and the elimination of the requirement that the stockholder list be made available for inspection during a meeting of stockholders; and (iii) makes other administrative, modernizing, clarifying and conforming changes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing summary of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended Bylaws, a copy of which is filed as Exhibit 3.2 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reduction in Workforce</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, we committed to and commenced a reduction in our workforce of approximately 25% to reduce operating costs and improve operating efficiency. The restructuring prioritized investment in our clinical stage programs and core research platforms and streamlined operations. The reduction in workforce is expected to be completed in the fourth quarter of 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this reduction in workforce, we estimate that we will incur charges of approximately $6 million to $7 million for severance payments, employee benefits and related costs, primarily in the fourth quarter of 2023. Substantially all of the estimated charges are expected to result in future cash expenditures. The estimated charges that we expect to incur are subject to a number of assumptions, and actual results may differ materially from these estimates. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction in workforce. This disclosure is provided in this Part II, Item 5 in lieu of disclosure under Item 2.05 of Form 8-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_178"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">File Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Exhibit/<br/>Appendix<br/>Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Filing<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521195237/d136326dex41.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-257249</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/21/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.2*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx32.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521185918/d168165dex41.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-256470</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/09/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165dex42.htm">Amended and Restated Investors' Rights Agreement, by and among the Registrant and certain of its stockholders, dated March&#160;5,&#160;2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-256470</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">05/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx101.htm">Offer Letter by and between the Registrant and Matthew Lang, dated May 12, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10.2*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx102.htm">N</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx102.htm">on-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx102.htm">Employee Director Com</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx102.htm">pensation Policy</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">32.1*&#171;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230930x10qxexx321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#171;&#160;&#160;&#160;&#160;The certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><div id="icccf8cd82c034620b68745752f617ca9_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icccf8cd82c034620b68745752f617ca9_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lyell Immunopharma, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date: November&#160;7, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">/s/ CHARLES NEWTON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Chief Financial Officer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>lyel-20230930x10qxexx32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia13b75862b5b44f29e162c4f6deb7601_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 3.2</font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDED AND RESTATED BYLAWS<br><br>OF<br><br>LYELL IMMUNOPHARMA, INC. <br>(A DELAWARE CORPORATION)</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">June 21, 2021</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(as amended November&#160;3, 2023)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="ia13b75862b5b44f29e162c4f6deb7601_4"></div><hr style="page-break-after:always"><div style="min-height:105.84pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I&#160;&#160;&#160;&#160;OFFICES</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Registered Office</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Other Offices</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II&#160;&#160;&#160;&#160;CORPORATE SEAL</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Corporate Seal</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III&#160;&#160;&#160;&#160; STOCKHOLDERS' MEETINGS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Place of Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Annual Meetings.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Special Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Notice of Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Quorum and Vote Required</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;Adjournment and Notice of Adjourned Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Voting Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;Joint Owners of Stock</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;List of Stockholders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Action without Meeting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Remote Communication&#59; Delivery to the Corporation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Organization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IV&#160;&#160;&#160;&#160;DIRECTORS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Number and Term of Office</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 17.&#160;&#160;&#160;&#160;Powers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 18.&#160;&#160;&#160;&#160;Vacancies&#59; Newly Created Directorships</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 19.&#160;&#160;&#160;&#160;Resignation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 20.&#160;&#160;&#160;&#160;Removal</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 21.&#160;&#160;&#160;&#160;Meetings.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 22.&#160;&#160;&#160;&#160;Quorum and Voting.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 23.&#160;&#160;&#160;&#160;Action without Meeting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 24.&#160;&#160;&#160;&#160;Fees and Compensation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 25.&#160;&#160;&#160;&#160;Committees.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:76.5pt;padding-right:2.75pt;text-align:justify;text-indent:-76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 26.&#160;&#160;&#160;&#160;Duties of Chairperson of the Board of Directors and Lead Independent Director</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 27.&#160;&#160;&#160;&#160;Organization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V&#160;&#160;&#160;&#160;OFFICERS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 28.&#160;&#160;&#160;&#160;Officers Designated</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 29.&#160;&#160;&#160;&#160;Tenure and Duties of Officers.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 30.&#160;&#160;&#160;&#160;Delegation of Authority</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 31.&#160;&#160;&#160;&#160;Resignations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 32.&#160;&#160;&#160;&#160;Removal</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-i-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:105.84pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:76.5pt;padding-right:2.75pt;text-align:justify;text-indent:-76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VI&#160;&#160;&#160;&#160; EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 33.&#160;&#160;&#160;&#160;Execution of Corporate Instruments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 34.&#160;&#160;&#160;&#160;Voting of Securities Owned by the Corporation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII SHARES OF STOCK</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 35.&#160;&#160;&#160;&#160;Form and Execution of Certificates</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 36.&#160;&#160;&#160;&#160;Lost Certificates</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 37.&#160;&#160;&#160;&#160;Transfers.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 38.&#160;&#160;&#160;&#160;Fixing Record Dates.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 39.&#160;&#160;&#160;&#160;Registered Stockholders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 40.&#160;&#160;&#160;&#160;Additional Powers of the Board</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VIII OTHER SECURITIES OF THE CORPORATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 41.&#160;&#160;&#160;&#160;Execution of Other Securities</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IX&#160;&#160;&#160;&#160; Dividends</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 42.&#160;&#160;&#160;&#160;Declaration of Dividends</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 43.&#160;&#160;&#160;&#160;Dividend Reserve</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE X&#160;&#160;&#160;&#160;Fiscal Year</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 44.&#160;&#160;&#160;&#160;Fiscal Year</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XI&#160;&#160;&#160;&#160;Indemnification</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 45.&#160;&#160;&#160;&#160;Indemnification of Directors, Executive Officers, Other Officers, Employees and Agents.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XII Notices</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 46.&#160;&#160;&#160;&#160;Notices.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XIII Amendments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 47.&#160;&#160;&#160;&#160;Amendments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XIV&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 48.&#160;&#160;&#160;&#160;Loans to Officers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-ii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ia13b75862b5b44f29e162c4f6deb7601_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDED AND RESTATED BYLAWS<br><br>OF<br><br>LYELL IMMUNOPHARMA, INC.<br>(A DELAWARE CORPORATION)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.7pt"><br><br>OFFICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Registered Office.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The registered office of Lyell Immunopharma, Inc. (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in the State of Delaware and the name of its registered agent at such address shall be as set forth in the Amended and Restated Certificate of Incorporation of the Corporation, as the same may be amended or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Other Offices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Corporation may also have and maintain an office or principal place of business at such place as may be fixed by the board of directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the Corporation may require.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.04pt"><br><br>CORPORATE SEAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Corporate Seal.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Board of Directors may adopt a corporate seal. If adopted, the corporate seal shall consist of the name of the Corporation and the inscription, &#8220;Corporate Seal-Delaware.&#8221; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:0.38pt"><br><br>STOCKHOLDERS&#8217; MEETINGS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Place of Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Meetings of the stockholders of the Corporation may be held at such place, if any, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Section 14 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Annual Meetings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The annual meeting of the stockholders of the Corporation, for the purpose of election of directors and for such other business as may properly come before it, shall be held on such date, time and place as may be designated from time to time by the Board of Directors. The Board or any director or officer of the corporation to whom the Board of Directors delegates authority may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by the Board of Directors. Nominations of persons for election to the Board of Directors and proposals of business to be considered by the stockholders may be made at an annual meeting of stockholders&#58; (i) by or at the direction of the Board of Directors or a duly authorized committee thereof&#59; or (ii) by any stockholder of the Corporation who was a stockholder of record (and, with respect to any beneficial owner, if different, on whose behalf such business is proposed or such nomination or nominations are made, only if such beneficial owner was the beneficial owner of shares of the Corporation) at the time of giving the stockholder&#8217;s notice provided for in Section 5(b) below and who is a stockholder of record at the time of the annual meeting of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">stockholders, who is entitled to vote at the meeting and who complied with the notice procedures set forth in this Section 5. For the avoidance of doubt, clause (ii) above shall be the exclusive means for a stockholder to make nominations and submit other business (other than matters properly included in the Corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)) before an annual meeting of stockholders. A stockholder may not designate any substitute nominees unless the stockholder provides timely notice of such substitute nominee(s) in accordance with this Section 5, in the case of an annual meeting, or Section 6, in the case of a special meeting (and such notice contains all of the information, representations, questionnaires and certifications with respect to such substitute nominee(s) that are required by these Amended and Restated Bylaws, as the same may be amended or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with respect to nominees for director).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">At an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under the DGCL, the Certificate of Incorporation and these Bylaws, and only such nominations shall be made and such business shall be conducted as shall have been properly brought before the meeting in accordance with the procedures below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (ii) of Section&#160;5(a), the stockholder must deliver written notice to the Secretary of the Corporation at the principal executive offices of the Corporation on a timely basis as set forth in Section 5(b)(ii) and must update and supplement the information in contained in such written notice on a timely basis as set forth in Section 5(c). Such stockholder&#8217;s notice shall set forth&#58; (A) as to each nominee such stockholder proposes to nominate at the meeting&#58; (1) the name, age, business address and residence address of such nominee&#59; (2) the principal occupation or employment of such nominee&#59; (3) the class or series and number of shares of each class or series of capital stock of the Corporation that are owned of record and beneficially by such nominee and list of any pledge of or encumbrances on such shares&#59; (4) the date or dates on which such shares were acquired and the investment intent of such acquisition&#59; (5) the questionnaire, representation and agreement required by Section 5(b)(iv)(D), completed and signed by such nominee, and (6) such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved and whether or not proxies are being or will be solicited), or that is otherwise required to be disclosed or provided to the Corporation pursuant to Section 14 of the 1934 Act (including such person&#8217;s written consent to being named in a proxy statement and associated proxy card as a nominee of the stockholder and to serving as a director if elected)&#59; and (B) all of the information required by Section 5(b)(iv). The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the Corporation and to determine the independence of such proposed nominee (as defined by any applicable stock exchange listing requirements or applicable law) or of any committees or sub-committee of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or that the Board determines, in its sole discretion, could be material to a reasonable stockholder&#8217;s understanding of the background, qualifications, experience, independence, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> lack thereof, of such proposed nominee. The number of nominees a stockholder may nominate for election at the annual meeting on its own behalf (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Other than proposals sought to be included in the Corporation&#8217;s proxy materials pursuant to Rule 14a-8 under the 1934 Act, for business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of Section&#160;5(a), the stockholder must deliver written notice to the Secretary of the Corporation at the principal executive offices of the Corporation on a timely basis as set forth in Section 5(b)(iii), and must update and supplement such written notice on a timely basis as set forth in Section 5(c). Such stockholder&#8217;s notice shall set forth&#58; (A) as to each matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these Bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting, and any material interest (including any anticipated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the Corporation&#8217;s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent&#59; and (B) the information required by Section 5(b)(iv). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">To be timely, the written notice required by Section 5(b)(i) or 5(b)(ii) must be received by the Secretary of the Corporation at the principal executive offices of the Corporation not later than the close of business on the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day nor earlier than the 120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">day prior to the first anniversary of the immediately preceding year&#8217;s annual meeting&#59; provided, however, that, subject to the last sentence of this Section 5(b)(ii), in the event that (A) the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year&#8217;s annual meeting, notice by the stockholder to be timely must be so received not earlier than the 120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such annual meeting and not later than the close of business on the later of the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such annual meeting or the tenth day following the day on which public announcement of the date of such meeting is first made by the Corporation or (B) the Corporation did not have an annual meeting in the preceding year, notice by the stockholder to be timely must be so received not later than the tenth day following the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment, recess or postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">The written notice required by Sections 5(b)(i) or 5(b)(ii) shall also set forth, as of the date of the notice and as to the stockholder giving the notice, the beneficial owner, if any, on whose behalf the nomination or proposal is made and any affiliate who controls either of the foregoing stockholder or beneficial owner, directly or indirectly (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Proponent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Proponents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58; (A) the name and address of each Proponent, including, if applicable, such name and address as they appear on the Corporation&#8217;s books and records&#59; (B) the class, series and number of shares of each class or series of the capital stock of the Corporation that are directly or indirectly owned of record or beneficially (within the meaning of Rule 13d-3 under the 1934 Act) by each Proponent (provided, that for purposes of this Section 5(b)(iv), such Proponent shall in all events be deemed to beneficially own all shares of any class or series of capital stock of the Corporation as to which such Proponent or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future)&#59; (C) a description of any agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal (and&#47;or the voting of shares of any class or series of capital stock of the Corporation) between or among any Proponent and any of its affiliates or associates, and any other persons (including their names), including without limitation, any agreements, arrangements or understandings required to be disclosed pursuant to Item 5 or Item 6 of the 1934 Act Schedule 13D, regardless of whether the requirement to file a Schedule 13D is applicable, or otherwise under the agreement, arrangement or understanding, with any of the foregoing&#59; (D) a representation that the stockholder is a holder of record of shares of the Corporation at the time of giving notice, will be entitled to vote at the meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section 5(b)(i)) or to propose the business that is specified in the notice (with respect to a notice under Section 5(b)(ii))&#59; (E) a representation whether any Proponent or any other participant (as defined in Item 4 of Schedule 14A under the 1934 Act) will engage in a solicitation with respect to such nomination or proposal and, if so, the name of each participant in such solicitation and the amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant in such solicitation, and a representation as to whether the Proponents intend, or are a part of a group which intends, (x) to deliver, or make available, a proxy statement and&#47;or form of proxy to holders of at least the percentage of the Corporation&#8217;s voting shares required to approve or adopt the proposal or elect the nominee, (y) to otherwise solicit proxies or votes from stockholders in support of such proposal or nomination and&#47;or (z) to solicit proxies from the required number of the Corporation&#8217;s voting shares  in support of any proposed nominee in accordance with or as required by  Rule 14a-19 promulgated under the 1934 Act&#59; (F) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&#8217;s notice&#59; (G) a description of all Derivative Transactions (as defined below) by each Proponent during the previous 12-month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic or voting terms of, such Derivative Transactions&#59; (H) a certification regarding whether each Proponent has complied with all applicable federal, state and other legal requirements in connection with such Proponent&#8217;s acquisition of shares of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">capital stock or other securities of the Corporation and&#47;or such Proponent&#8217;s acts or omissions as a stockholder or beneficial owner of the Corporation and (I) any other information relating to the Proponents required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and&#47;or for the election of directors in an election contest pursuant to and in accordance with Section 14 of the 1934 Act and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">A stockholder providing the written notice required by Section 5(b)(i) or (ii) shall update and supplement such notice in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i) the record date for the determination of stockholders entitled to notice of the meeting and (ii) the date that is five business days(as defined below) prior to the meeting and, in the event of any adjournment, recess or postponement thereof, five business days prior to such adjourned, recessed or postponed meeting&#59; provided, that no such update or supplement shall cure or affect the accuracy (or inaccuracy) of any representations made by any Proponent, any of its affiliates or associates, or a nominee or the validity (or invalidity) of any nomination or proposal that failed to comply with this Section 5 or is rendered invalid as a result of any inaccuracy therein. In the case of an update and supplement pursuant to clause (i) of this Section 5(c), such update and supplement shall be received by the Secretary of the Corporation at the principal executive offices of the Corporation not later than five business days after the later of the record date for the determination of stockholders entitled to notice of the meeting or the public announcement of such record date. In the case of an update and supplement pursuant to clause (ii) of this Section 5(c), such update and supplement shall be received by the Secretary of the Corporation at the principal executive offices of the Corporation not later than two business days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two business days prior to such adjourned or postponed meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Notwithstanding anything in Section 5(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to the contrary, in the event that the number of directors in an Expiring Class (as defined below) to be elected to the Board of Directors at the next annual meeting is increased effective after the time period for which nominations would otherwise be due under Section 5(b)(iii) and there is no public announcement by the Corporation naming all of the nominees for the additional directorships at least 10 days before the last day a stockholder may deliver a notice of nomination required by this Section&#160;5 and that complies with the requirements in Section 5(b)(i), other than the timing requirements in Section 5(b)(iii), shall also be considered timely, but only with respect to nominees for the additional directorships in such Expiring Class, if it shall be received by the Secretary of the Corporation at the principal executive offices of the Corporation not later than the close of business on the tenth day following the day on which such public announcement is first made by the Corporation. For purposes of this section, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Expiring Class</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a class of directors whose term shall expire at the annual meeting of stockholders. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">To be eligible to be a nominee for election or re-election as a director of the Corporation pursuant to a nomination under clause (iii) of Section 5(a), each Proponent must deliver (in accordance with the time periods prescribed for delivery of notice under Sections 5(b)(iii) or 5(d), as applicable) to the Secretary of the Corporation at the principal executive offices of the Corporation a written questionnaire with respect to the background, qualifications, stock ownership and independence of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being made (in the form provided by the Secretary of the Corporation within 10 days following a written request therefor by a stockholder of record) and a written representation and agreement (in the form provided by the Secretary of the Corporation within 10 days following a written request therefor by a stockholder of record) that such person (i) is not and will not become a party to (A) any agreement, arrangement or understanding (whether oral or in writing) with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Voting Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that has not been disclosed to the Corporation in the questionnaire or (B) any Voting Commitment that could limit or interfere with such person&#8217;s ability to comply, if elected as a director of the Corporation, with such person&#8217;s fiduciary duties under applicable law&#59; (ii) is not and will not become a party to any agreement, arrangement or understanding (whether oral or in writing) with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the Corporation or a nominee that has not been disclosed in such questionnaire&#59;  (iii) would be in compliance, if elected as a director of the Corporation, and will comply </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Corporation and (iv) if elected as director of the Corporation, intends to serve the entire term until the next meeting at which such candidate would face re-election.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">A person shall not be eligible for election or re-election as a director at an annual meeting unless the person is nominated in accordance with Section 5(a) and in accordance with the procedures set forth in Section 5(b), Section 5(c), Section 5(d) and Section 5(e), as applicable, or in the case of a special meeting, in accordance with Section 6(c) and the requirements thereof. Only such business shall be conducted at any annual meeting of the stockholders of the Corporation as shall have been brought before the meeting in accordance with Section 5(a) and in accordance with the procedures set forth in Section 5(b) and Section 5(c), as applicable. Except as otherwise required by applicable law, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures and requirements set forth in these Bylaws (including, without limitation, compliance with Rule 14a-19 promulgated under the 1934 Act) and, if any proposed nomination or business is not in compliance with these Bylaws, or the Proponent does not act in accordance with the representations required in in Section 5, to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded (and such nominee disqualified from standing for election or re-election), or that such business shall not be transacted, notwithstanding such proposal or nomination (as applicable) is set forth in the Corporation&#8217;s proxy statement, notice of meeting or other proxy materials and notwithstanding that proxies or votes in respect of such nomination or such business may have been solicited or received. Notwithstanding the foregoing provisions of this Section 5, unless otherwise required by applicable law, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded (and such nominee disqualified from standing for election or re-election) and such proposed business shall not be transacted, notwithstanding such nomination or proposed business is set forth in the Corporation&#8217;s proxy statement, notice of meeting or other proxy materials and notwithstanding that proxies or votes in respect of such vote may have been received by the Corporation.  For purposes of this Section 5, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at least five business days prior to the meeting of stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding anything to the contrary in these Bylaws, unless otherwise required by applicable law, in the event that any Proponent (i) provides notice pursuant to Rule 14a-19(b) promulgated under the 1934 Act with respect to one or more proposed nominees and (ii) subsequently (x) fails to comply with the requirements of Rule 14a-19 promulgated under the 1934 Act (or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such Proponent has met the requirements of Rule 14a-19(a)(3) promulgated under the 1934 Act in accordance with the next sentence) or (y) fails to inform the Corporation that they no longer plan to solicit proxies in accordance with the requirements of Rule 14a-19 promulgated under the 1934 Act by delivering a written notice to the Secretary at the principal executive offices of the Corporation within two business days after the occurrence of such change, then the nomination of each such proposed nominee shall be disregarded (and such nominee disqualified from standing for election or re-election), notwithstanding that the nominee is included (as applicable) as a nominee in the Corporation&#8217;s proxy statement, notice of meeting or other proxy materials for any stockholder meeting (or any supplement thereto) and notwithstanding that proxies or votes in respect of the election of such proposed nominees may have been received by the Corporation (which proxies and votes shall be disregarded).  If any Proponent provides notice pursuant to Rule 14a-19(b) promulgated under the 1934 Act, such Proponent shall deliver to the Corporation, no later than five business days prior to the applicable meeting, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the 1934 Act. Notwithstanding anything to the contrary set forth herein, and for the avoidance of doubt, the nomination of any person whose name is included (as applicable) as a nominee in the Corporation&#8217;s proxy statement, notice of meeting or other proxy materials for any stockholder meeting (or any supplement thereto) as a result of any notice provided by any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proponent pursuant to Rule 14a-19(b) promulgated under the 1934 Act with respect to such proposed nominee and whose nomination is not made by or at the direction of the Board of Directors or any authorized committee thereof shall not be deemed (for purposes of clause (i) of Section 5(a) or otherwise) to have been made pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto) and any such nominee may only be nominated by a Proponent pursuant to clause (ii) of Section 5(a) and, in the case of a special meeting of stockholders, pursuant to and to the extent permitted under Section 6(c) of these Bylaws. Nothing in these Bylaws shall be deemed to affect any rights of holders of any class or series of preferred stock to nominate and elect directors pursuant to and to the extent provided in any applicable provision of the Certificate of Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">For purposes of Sections&#160;5 and 6, </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">associates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meanings set forth in Rule 405 under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">1933 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">business day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any day other than Saturday, Sunday or a day on which banks are closed in New York City, New York.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">close of business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means 5&#58;00 p.m. local time at the principal executive offices of the Corporation on any calendar day, whether or not the day is a Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Derivative Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the Corporation, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2) &#160;&#160;&#160;&#160;that otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the Corporation, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3) &#160;&#160;&#160;&#160;the effect or intent of which is to mitigate loss, manage risk or benefit from changes in value or price with respect to any securities of the Corporation, or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4) &#160;&#160;&#160;&#160;that provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or associates, directly or indirectly, with respect to any securities of the Corporation, </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation or similar right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the Corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">public announcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press, Business Wire, GlobeNewswire or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&#160;13, 14 or 15(d) of the 1934 Act, or by such other means reasonably designed to inform the public or security holders in general of such information including, without limitation, posting on the Corporation&#8217;s investor relations website.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Special Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Special meetings of the stockholders of the Corporation may be called, for any purpose as is a proper matter for stockholder action under the DGCL, by (i)&#160;the Chairperson of the Board </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of Directors, (ii)&#160;the Chief Executive Officer or the President, if the Chairperson of the Board of Directors is unavailable, or (iii)&#160;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). The Board of Directors or any director or officer to whom the Board of Directors has delegated such authority, at any time before or after notice of such meeting has been given to stockholders may postpone, reschedule or cancel any special meeting of stockholders previously scheduled.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Board of Directors shall determine the date, time and place, if any, of such special meeting. Upon determination of the date, time and place, if any, of the meeting, the Secretary of the Corporation shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&#160;7. No business may be transacted at such special meeting otherwise than specified in the notice of meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Only such business (including the election of specific individuals to fill vacancies or newly created directorships on the Board of Directors) shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting. Nominations of persons for election to the Board of Directors to fill any vacancy or unfilled newly created directorship may be made at a special meeting of stockholders at which any proposal to fill  any vacancy or unfilled newly created directorship is to be presented to the stockholders (i) by or at the direction of the Board of Directors or a duly authorized committee thereof or (ii) provided that the Board of Directors has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record (and with respect to any beneficial owner, if different, on whose behalf such nomination or nominations are made, only if such beneficial owner of shares of the Corporation) at the time of giving notice provided for in this paragraph, who is entitled to vote at the meeting and who delivers written notice to the Secretary of the Corporation setting forth the information required by Section 5(b)(i), 5(b)(iv), 5(c), 5(e), 5(f) and 5(g).  The number of nominees a stockholder may nominate for election at the special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such special meeting. In the event the Corporation calls a special meeting of stockholders for the purpose of submitting a proposal to stockholders for the election of one or more directors to fill any vacancy or newly created directorship on to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation&#8217;s notice of meeting, if written notice setting forth the information required by Section 5(b)(i) and 5(b)(iv) shall be received by the Secretary of the Corporation at the principal executive offices of the Corporation not earlier than 120 days prior to such special meeting and not later than the close of business on the later of the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day prior to such meeting, or the tenth day following the day on which the Corporation first makes a public announcement of the date of the special meeting at which directors are to be elected. The stockholder shall also update and supplement such information as required under Section 5(c). In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">A person shall not be eligible for election or re-election as a director at the special meeting unless the person is nominated either in accordance with clause (i) or clause (ii) of Section 6(c).  Except as otherwise required by applicable law, the chairperson of the meeting shall have the power and duty to determine whether a nomination was made in accordance with the procedures and requirements set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, or if the Proponent does not act in accordance with the representations required in Section 5(b), to declare that such nomination shall not be presented for stockholder action at the meeting and shall be disregarded (and such nominee disqualified from standing for election or re-election), notwithstanding that such nomination is set forth (as applicable) in the Corporation&#8217;s proxy statement, notice of meeting or other proxy materials and notwithstanding that proxies or votes in respect of such nomination may have been solicited or received.  Notwithstanding the foregoing provisions of this Section 6, unless otherwise required by applicable law, if the stockholder (or a qualified representative of the stockholder (meeting the requirements specified in Section 5(e) does not appear at the special meeting of stockholders of the Corporation to present a nomination, such nomination shall be disregarded (and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such nominee disqualified from standing for election or re-election), notwithstanding that the nomination is set forth in (as applicable) the Corporation&#8217;s proxy statement, notice of meeting or other proxy materials  and notwithstanding that proxies or votes in respect of such vote may have been received by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding the foregoing provisions of Section 5 and this Section&#160;6, a stockholder must also comply with all applicable requirements of the 1934 Act with respect to matters set forth in Section 5 and this Section 6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule 14a-8 under the 1934 Act&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, to the fullest extent not prohibited by applicable law, any references in these Bylaws to the 1934 Act are not intended to and shall not limit the requirements applicable to proposals and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">nominations for the election to the Board of Directors to be considered pursuant to Section 6(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Notice of Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Except as otherwise provided by applicable law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of such meeting.  Such notice shall specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, the record date for determining stockholders entitled to vote at the meeting, if such record date is different from the record date for determining stockholders entitled to notice of the meeting,  and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting.   If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the Corporation. If delivered by courier service, the notice is given on the earlier of when the notice is received or left at the stockholder&#8217;s address. If sent via electronic mail, notice is given when directed to such stockholder&#8217;s electronic mail address in accordance with applicable law unless (a) the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or (b) electronic transmission of such notice is prohibited by applicable law. .  Notice of any meeting of stockholders (to the extent required) may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Quorum and Vote Required.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the voting power of the outstanding shares of stock entitled to vote at the meeting shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairperson of the meeting or by vote of the holders of a majority of the voting power of the shares represented thereat and entitled to vote thereon, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the holders of a majority of the voting power of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and voting affirmatively or negatively (excluding abstentions and broker non-votes) on such matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, in which case such different or minimum vote of such applicable statute shall be the applicable vote on the matter, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy duly authorized at the meeting and entitled to in the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by statute, or by the Certificate of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Incorporation or these Bylaws or any applicable stock exchange rules, holders of a majority of the voting power of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where a different or minimum vote is provided or required for such matter by applicable statute or by the Certificate of Incorporation or these Bylaws or any applicable stock exchange rules or otherwise, in which case such minimum or different vote shall be the applicable vote on such matter, the affirmative vote of holders of a majority (plurality, in the case of the election of directors) of the voting power of the shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting and voting affirmatively or negatively (excluding abstention and broker non-votes) on such matter shall be the act of such class or classes or series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.81pt">Adjournment and Notice of Adjourned Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairperson of the meeting or by the vote of the holders of a majority of the voting power of the shares present in person, by remote communication, if applicable, or represented by proxy duly authorized at the meeting. When a meeting is adjourned to another time or place, if any, including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication, notice need not be given of the adjourned meeting if the time and place, if any, thereof and the means of remote communication, if any, by which stockholders and proxyholders may be deemed present in person and may vote at such meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with Section 7. At the adjourned meeting, the Corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.  If after the adjournment a new record date for determination of stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix as the record date for determining stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date so fixed for notice of such adjourned meeting. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Voting Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders or adjournment thereof, except as otherwise provided by applicable law, only persons in whose names shares stand on the stock records of the Corporation on the record date shall be entitled to vote at any meeting of stockholders. Every person entitled to vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with the DGCL. An agent so appointed need not be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the Corporation a revocation of the proxy or a new proxy bearing a later date. Voting at meetings of stockholders need not be by written ballot. Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Joint Owners of Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary of the Corporation is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect&#58; (a)&#160;if only one votes, his or her act binds all&#59; (b)&#160;if more than one votes, the act of the majority so voting binds all&#59; (c)&#160;if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as provided in Section&#160;217(b) of the DGCL. If the instrument filed with the Secretary of the Corporation shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection&#160;(c) shall be a majority or even-split in interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">List of Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Corporation shall prepare, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number and class of shares registered in the name of each stockholder&#59; provided, however, if the record date for determining the stockholders entitled to vote is less than ten days before the meeting date, the list shall reflect all of the stockholders entitled to vote as of the tenth day before the meeting date. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a)&#160;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the principal place of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Action without Meeting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No action shall be taken by the stockholders of the Corporation except at an annual or special meeting of stockholders duly called in accordance with these Bylaws, and no action shall be taken by the stockholders by consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Remote Communication&#59; Delivery to the Corporation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">For the purposes of these Bylaws, if authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders may, by means of remote communication&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">participate in a meeting of stockholders&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote communication, provided that (i) the corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder, (ii) the corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (iii) if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be maintained by the corporation.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whenever this Article III requires one or more persons (including a record or beneficial owner of stock) to deliver a document or information to the corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested and the corporation shall not be required to accept delivery of any document not in such written form or so delivered.  For the avoidance of doubt, with respect to any notice from any stockholder of record or beneficial owner of the corporation&#8217;s capital stock under the Certificate of Incorporation, these Bylaws or the DGCL, to the fullest extent permitted by law, the corporation expressly opts out of Section 116 of the DGCL.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">At every meeting of stockholders, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed, is absent or refuses to act, the Chief Executive Officer, or if no Chief Executive Officer is then serving or the Chief Executive Officer is absent or refuses to act, the President, or, if the President is absent or refuses to act, a chairperson of the meeting designated by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Board of Directors, or, if the Board of Directors does not designate such chairperson, a chairperson of the meeting chosen by a majority of the voting power of the stockholders entitled to vote, present in person or by proxy duly authorized, shall act as chairperson of the meeting of stockholders. The Chairperson of the Board of Directors may appoint the Chief Executive Officer as chairperson of the meeting. The Secretary of the Corporation, or, in his or her absence, an Assistant Secretary of the Corporation or other officer or other person directed to do so by the chairperson of the meeting, shall act as secretary of the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Board of Directors shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairperson of the meeting shall have the right and authority to convene and (for any or no reason) to recess and&#47;or adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairperson, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the Corporation and their duly authorized and constituted proxies and such other persons as the chairperson shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters that are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairperson of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Corporation may and shall, if required by applicable law, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the chairperson of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of the duties of inspector, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#8217;s ability. The inspectors shall&#58; (i) ascertain the number of shares outstanding and the voting power of each&#59; (ii) determine the shares represented at a meeting and the validity of proxies and ballots&#59; (iii) count all votes and ballots&#59; (iv) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors&#59; and (v) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in accordance with Sections 211(e) or 212(c)(2) of the DGCL, or any information provided pursuant to Sections 211(a)(2)b.(i) or (iii) of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast, or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification pursuant to Section 231(b)(5) of the DGCL shall specify the precise information considered by them including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors&#8217; belief that such information is accurate and reliable.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br><br>DIRECTORS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Number and Term of Office.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The authorized number of directors of the Corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">stockholders unless so required by the Certificate of Incorporation. The terms of the directors shall be as set forth in the Certificate of Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Powers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation or the DGCL.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Vacancies&#59; Newly Created Directorships. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vacancies and newly created directorships on the Board of Directors shall be filled as set forth in the Certificate of Incorporation, except as otherwise required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Resignation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Board of Directors or the Secretary of the Corporation.  Such resignation shall take effect at the time of delivery of the notice or at any later time specified therein. Acceptance of such resignation shall not be necessary to make it effective. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his or her successor shall have been duly elected and qualified or until his or her earlier death, resignation or removal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Directors shall be removed from the Board of Directors as set forth in the Certificate of Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Meetings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Regular Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware that has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Special Meetings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware as designated and called by the Chairperson of the Board of Directors, the Chief Executive Officer or a majority of the authorized number of directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Meetings by Electronic Communications Equipment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Notice of Special Meetings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notice of the time and place, if any, of all special meetings of the Board of Directors shall be transmitted orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, or by electronic mail or other electronic means, during normal business hours, at least 24 hours before the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, postage prepaid, at least three days before the date of the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Waiver of Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notice of any meeting of the Board of Directors may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.  The transaction of all business at any meeting of the Board of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Quorum and Voting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification arising under Section 45 for which a quorum shall be 1&#47;3 of the authorized number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation, a quorum of the Board of Directors shall consist of a majority of the total number of directors then serving on the Board of Directors or, if greater, one third of the authorized number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation. At any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time, without notice other than by announcement at the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by applicable law, the Certificate of Incorporation or these Bylaws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Action without Meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission.  After an action is taken, such consent or consents shall be filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Fees and Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Directors shall be entitled to such compensation for their services on the Board of Directors or any committee thereof as may be approved by the Board of Directors, or a committee thereof to which the Board of Directors has delegated such responsibility and authority, including, if so approved, by resolution of the Board of Directors, or a committee thereof to which the Board of Directors has delegated such responsibility and authority, including, without limitation, a fixed sum and reimbursement of expenses, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors, as well as reimbursement for other reasonable expenses incurred with respect to duties as a member of the Board of Directors or any committee thereof. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Committees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Executive Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Board of Directors may appoint an executive committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Executive Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to consist of one or more members of the Board of Directors. The Executive Committee, to the extent permitted by applicable law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it&#59; but no such committee shall have the power or authority in reference to (i)&#160;approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&#160;adopting, amending or repealing any Bylaw of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Other Committees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Board of Directors may, from time to time, appoint such other committees as may be permitted by applicable law. Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Board of Directors, subject to any requirements of any outstanding series of preferred stock and the provisions of subsections&#160;(a) or (b) of this Section&#160;25, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the earliest of the date of his or her death, removal or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&#160;25 shall be held at such times and places, if any, as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Unless the Board of Directors shall otherwise provide, special meetings of any such committee may be held at such place, if any, that has been determined from time to time by such committee, and may be called by any director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">who is a member of such committee, upon notice to the members of such committee of the time and place, if any, of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place, if any, of special meetings of the Board of Directors. Notice of any meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting of the committee at which a quorum is present shall be the act of such committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Duties of Chairperson of the Board of Directors and Lead Independent Director.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Chairperson of the Board of Directors, shall preside at all meetings of the stockholders and the Board of Directors. The Chairperson of the Board of Directors shall perform such other duties commonly incident to the position and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Chairperson of the Board of Directors, or if the Chairperson is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director to serve until replaced by the Board of Directors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Lead Independent Directo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">r&#8221;). The Lead Independent Director will preside over meetings of the independent directors and perform such other duties as may be established or delegated by the Board of Directors and perform such other duties as may be established or delegated by the Chairperson of the Board of Directors. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Organization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> At every meeting of the directors, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director has not been appointed or is absent, the Chief Executive Officer (if a director), or, if a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairperson of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary of the Corporation, or in his or her absence, any Assistant Secretary of the Corporation or other officer, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">director or other person directed to do so by the person presiding over the meeting, shall act as secretary of the meeting.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.7pt"><br><br>OFFICERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Officers Designated.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The officers of the Corporation shall include, if and when designated by the Board of Directors, the Chairperson of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem appropriate or necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the Corporation at any one time unless specifically prohibited therefrom by applicable law, the Certificate of Incorporation or these Bylaws. The salaries and other compensation of the officers of the Corporation shall be fixed by or in the manner designated by the Board of Directors or by a committee thereof to which the Board of Directors has delegated such responsibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Tenure and Duties of Officers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, subject to such officer&#8217;s earlier death, resignation or removal. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors or by a committee thereof to which the Board of Directors has delegated such responsibility or, if so authorized by the Board of Directors, by the Chief Executive Officer or another officer of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Duties of Chief Executive Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Chief Executive Officer shall be the chief executive officer of the Corporation and shall, subject to the supervision, direction and control of the Board of Directors, shall have the general powers and duties of supervision, direction, management, and control of the business and officers of the Corporation as are customarily associated with the position of Chief Executive Officer. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. The Chief Executive Officer shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Duties of President</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless another officer has been appointed Chief Executive Officer of the Corporation, the President shall be the chief executive officer of the Corporation and shall, subject to the supervision, direction and control of the Board of Directors, shall have the general powers and duties of supervision, direction, management and control of the business and officers of the Corporation as are customarily associated with the position of President.  The President shall perform other duties customarily associated with  the office and shall also perform such other duties and have such other powers, as the Board of Directors (or the Chief Executive Officer, if the Chief Executive Officer and President are not the same person) shall designate from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Duties of Vice Presidents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> A Vice President may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant, unless the duties of the President are being filled by the Chief Executive Officer.  A Vice President shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Duties of Secretary and Assistant Secretary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Secretary of the Corporation shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts, votes and proceedings thereof in the minute books of the Corporation. The Secretary of the Corporation shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Board of Directors and any committee thereof requiring notice. The Secretary of the Corporation shall perform all other duties provided for in these Bylaws and other duties customarily associated with the office and shall also perform such other duties and have such other powers, as the Board of Directors or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time. The Chief Executive Officer, or if no Chief Executive Officer is then serving, the President may direct any Assistant Secretary of the Corporation or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary of the Corporation shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Duties of Chief Financial Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Chief Financial Officer shall keep or cause to be kept the books of account of the Corporation in a thorough and proper manner and shall render statements of the financial affairs of the Corporation in such form and as often as required by the Board of Directors, the Chief Executive Officer, or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the Corporation. The Chief Financial Officer shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Duties of Treasurer and Assistant Treasurer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Unless another officer has been appointed Chief Financial Officer of the Corporation, the Treasurer shall be the chief financial officer of the Corporation.  The Treasurer shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time.  The Chief Executive Officer, or if no Chief Executive Officer is then serving, the President, may direct any Assistant Treasurer or other officer to assume and perform the duties of the Treasurer in the absence of disability of the Treasurer, and each Assistant Treasurer shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Delegation of Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Resignations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors, the Chairperson of the Board of Directors, the Chief Executive Officer, the President or the Secretary of the Corporation. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the Corporation under any contract with the resigning officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Removal.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any officer may be removed from office at any time, either with or without cause, by the Board of Directors, or by any duly authorized committee thereof or any superior officer upon whom such power of removal may have been conferred by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br><br>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Execution of Corporate Instruments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">persons, to execute, sign or endorse on behalf of the Corporation any corporate instrument or document, or to sign on behalf of the Corporation the corporate name without limitation, or to enter into contracts on behalf of the Corporation, except where otherwise provided by applicable law or these Bylaws, and such execution or signature shall be binding upon the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All checks and drafts drawn on banks or other depositaries on funds to the credit of the Corporation or in special accounts of the Corporation shall be signed by such person or persons as the Board of Directors shall from time to time authorize so to do.</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise specifically determined by the Board of Directors or otherwise required by applicable law, the execution, signing or endorsement of any corporate instrument or document by or on behalf of the Corporation may be effected manually, by facsimile or (to the extent permitted by applicable law and subject to such policies and procedures as the corporation may have in effect from time to time) by electronic signature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Voting of Securities Owned by the Corporation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> All stock and other securities of or interests in other corporations or entities owned or held by the Corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairperson of the Board of Directors, the Chief Executive Officer, the President, or any Vice President.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:32.38pt"><br><br>SHARES OF STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Form and Execution of Certificates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The shares of the Corporation shall be represented by certificates, or shall be uncertificated if so provided by resolution or resolutions of the Board of Directors. Certificates for the shares of stock, if any, shall be in such form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock in the Corporation represented by certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be entitled to have a certificate signed by or in the name of the Corporation by any two authorized officers of the Corporation (it being understood that each of the Chairperson of the Board of Directors, the Chief Executive Officer, the President, any Vice President, the Treasurer, any Assistant Treasurer, the Secretary and any Assistant Secretary shall be an authorized officer for such purposes), certifying the number, and the class or series, of shares owned by such holder in the Corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Lost Certificates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> A new certificate or certificates or uncertificated shares shall be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The Corporation may require, as a condition precedent to the issuance of a new certificate or certificates or uncertificated shares, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#8217;s legal representative, to agree to indemnify the Corporation in such manner as it shall require or to give the Corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed of the issuance of a new certificate or certificates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Transfers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Transfers of record of shares of stock of the Corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes or series of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes or series owned by such stockholders in any manner not prohibited by the DGCL.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Fixing Record Dates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than 60 nor less than 10 days before the date of such meeting. If the Board of Directors so fixes a record date for determining the stockholders entitled to notice of any meeting of stockholders, such date shall also be the record date for determining the stockholders entitled to vote at such meeting, unless the Board of Directors determines, at the time it fixes the record date for determining the stockholders entitled to notice of such meeting, that a later date on or before the date of the meeting shall be the record date for determining the stockholders entitled to vote at such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day immediately preceding the day on which notice is given, or if notice is waived, at the close of business on the day immediately preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting&#59; provided, however, that the Board of Directors may fix a new record date for determining the stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determining the stockholders entitled to vote in accordance with the provisions of this Section 38(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Registered Stockholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Additional Powers of the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> In addition to, and without limiting, the powers set forth in these Bylaws, the Board of Directors shall have power and authority to make all such rules and regulations as it shall deem expedient concerning the issue, transfer, and registration of certificates for shares of stock of the Corporation, including the use of uncertificated shares of stock, subject to the provisions of the DGCL, other applicable law, the Certificate of Incorporation and these Bylaws. The Board of Directors may appoint and remove transfer agents and registrars of transfers, and may require all stock certificates to bear the signature of any such transfer agent and&#47;or any such registrar of transfers.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.72pt"><br><br>OTHER SECURITIES OF THE CORPORATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Execution of Other Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> All bonds, debentures and other corporate securities of the Corporation, other than stock certificates (covered in Section 35), may be signed by the Chairperson of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or such other person as may be authorized by the Board of Directors&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible electronic signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the Corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the Corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br><br>DIVIDENDS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Declaration of Dividends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Dividends upon the capital stock of the Corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors. Dividends may be paid in cash, in property, or in shares of capital stock or other securities of the Corporation, subject to the provisions of the Certificate of Incorporation and applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Dividend Reserve.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, determines proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose or purposes as the Board of Directors shall determine to be conducive to the interests of the Corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.7pt"><br><br>FISCAL YEAR</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 44.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Fiscal Year.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br><br>INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 45.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Indemnification of Directors, Executive Officers, Other Officers, Employees and Agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Directors and Executive Officers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To the fullest extent and in any manner permitted under the DGCL and any other applicable law, the Corporation shall indemnify any person who </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">is made or threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any Proceeding by reason of the fact that such person is or was a director or executive officer, or while serving as a director or executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, or agent of Another Enterprise, against Expenses (including attorneys&#8217; fees) reasonably incurred by him or her in connection with such Proceeding&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the Corporation shall not be required to indemnify any director or executive officer in connection with any Proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by applicable law, (ii)&#160;the Proceeding was authorized in the specific case by the Board of Directors of the Corporation, (iii)&#160;such indemnification is approved by the Board of Directors of the Corporation, in its sole discretion, pursuant to the powers vested in it under the DGCL or any other applicable law or (iv) such indemnification is required to be made under subsection (d) of this Section 45 (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Covered Indemnitee Initiated Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Other Officers, Employees and Agents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Corporation shall have power to indemnify (including the power to advance expenses in a manner consistent with subsection (c) of this Section 45) its other officers, employees and agents as set forth in the DGCL or any other applicable law.  The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person except executive officers to such officers or other persons as the Board of Directors shall determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Corporation shall, to the fullest extent and in any manner permitted under the DGCL and any other applicable law, advance to any director or executive officer who was or is a party or is threatened to be made a party to any Proceeding prior to the final disposition of the Proceeding, promptly following request therefor, all expenses (including attorneys&#8217; fees) incurred by any director or executive officer in defending any Proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or executive officer in his or her capacity as a director or executive officer (and not in any other capacity in which service was or is rendered by such person, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking (hereinafter, an &#8220;undertaking&#8221;), by or on behalf of such person, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#8220;final adjudication&#8221;) that such person is not entitled to be indemnified for such expenses under this Section 45 or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph&#160;(d) of this Section 45, no advance shall be made by the Corporation to an executive officer of the Corporation (except by reason of the fact that such executive officer is or was a director of the Corporation in which event this paragraph shall not apply) in any Proceeding, if a determination is reasonably made (i)&#160;by a majority vote of directors who were not parties to the Proceeding, even if not a quorum, or (ii)&#160;by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Enforcement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and executive officers under this Section 45 shall be deemed to be contractual rights, shall vest when the person becomes a director or executive officer of the Corporation, shall continue as vested contract rights even if such person ceases to be a director or executive officer of the Corporation, and shall be effective to the same extent and as if provided for in a contract between the Corporation and the director or executive officer. Any right to indemnification or advances granted by this Section 45 to a current or former director or executive officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i)&#160;the claim for indemnification or advances is denied, in whole or in part, or (ii)&#160;no disposition of such claim is made within 90 days of request therefor. To the fullest extent permitted by applicable law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the Corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the Corporation to indemnify the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">claimant for the amount claimed. In connection with any claim by an executive officer of the Corporation (except in any Proceeding, by reason of the fact that such executive officer is or was a director of the Corporation) for advances, the Corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Corporation, or with respect to any criminal Proceeding that such person acted without reasonable cause to believe that his or her conduct was lawful. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a current or former director or executive officer to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the director or executive officer is not entitled to be indemnified, or to such advancement of expenses, under this Section 45 or otherwise shall be on the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Non-Exclusivity of Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The rights conferred on any person by this Section 45 shall not be exclusive of any other right that such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding office. The Corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Survival of Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The rights conferred on any person by this Section 45 shall continue as to a person who has ceased to be a director or executive officer and shall inure to the benefit of the heirs, executors and administrators of such a person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Insurance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To the fullest extent permitted by the DGCL or any other applicable law, the Corporation, upon approval by the Board of Directors, may purchase and maintain insurance on behalf of any person required or permitted to be indemnified pursuant to this Section 45.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Amendments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any repeal or modification of this Section 45 shall only be prospective and shall not affect the rights under this Section 45 in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any Proceeding against any agent of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Saving Clause. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If this Article XI or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify and advance expenses to each director and executive officer to the fullest extent not prohibited by any applicable portion of this Article XI that shall not have been invalidated, or by any other applicable law. If this Article XI shall be invalid due to the application of the indemnification and advancement provisions of another jurisdiction, then the Corporation shall indemnify and advance expenses to each director and executive officer to the fullest extent not prohibited under the  applicable law of such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Certain Definitions and Construction of Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purposes of Article XI of the Bylaws, the following definitions and rules of construction shall apply&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Another Enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">The term the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include, in addition to the resulting Corporation, any constituent Corporation (including any constituent of a constituent) absorbed in a consolidation or merger that, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">officer, employee or agent of such constituent Corporation, or is or was serving at the request of such constituent Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section 45 with respect to the resulting or surviving Corporation as he would have with respect to such constituent Corporation if its separate existence had continued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">References to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of the Corporation shall include, without limitation, situations where such person is serving at the request of the Corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of Another Enterprise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean those persons designated by the Corporation as (a) executive officers for purposes of the disclosures required in the Corporation&#8217;s proxy and periodic reports or (b) officers for purposes of Section 16 of the 1934 Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be broadly construed and shall include, without limitation, court costs, attorneys&#8217; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any Proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">References to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">fines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any excise taxes assessed on a person with respect to an employee benefit plan&#59; The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative, to which a person is made or threatened to be made a party to or is otherwise involved in (as a witness or otherwise) by reason of the fact that such person is or was a director or executive officer of the Corporation, or while serving as a director or executive officer of the Corporation, is or was serving at the request of the corporation as a director, officer, employee or agent of Another Enterprise.  The term Proceeding shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">References to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">serving at the request of the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any service as a director, officer, employee or agent of the Corporation that imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries&#59; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">not opposed to the best interests of the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as referred to in this Section 45. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:32.38pt"><br><br>NOTICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 46.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Notices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Notice to Stockholders. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notice to stockholders of stockholder meetings shall be given as provided in Section 7. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by applicable law, notice to stockholders for purposes other than stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier, or by electronic mail or other electronic means in accordance with Section 232 of the DGCL.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Notice to Directors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any notice required to be given to any director may be given by the method stated in subsection&#160;(a), or otherwise provided in these Bylaws (including by any of the means specified in Section 21(d)), or by overnight delivery services.  Any notice sent by overnight delivery services or by U.S. mail shall be sent to such address as such director shall have filed in writing with the Secretary of the Corporation, or, in the absence of such filing, to the last known post office address of such director.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Affidavit of Mailing. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An affidavit of mailing, executed by a duly authorized and competent employee of the Corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Methods of Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Notice to Person with Whom Communication is Unlawful. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Whenever notice is required to be given, under applicable law or any provision of the Certificate of Incorporation or Bylaws of the Corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting that shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Notice to Stockholders Sharing an Address. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or these Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the Corporation within 60 days of having been given notice by the Corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the Corporation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these Bylaws.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.72pt"><br><br>AMENDMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 47.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Amendments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws. Any adoption, amendment or repeal of the Bylaws by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders also shall have power to adopt, amend or repeal the Bylaws&#59; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least 66-2&#47;3% of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote in the election of directors, voting together as a single class.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE XIV</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LOANS TO OFFICERS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 48.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.31pt">Loans to Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Except as otherwise prohibited by applicable law, the Corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the Corporation or of its subsidiaries, including any officer or employee who is a director of the Corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the Corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the Corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the Corporation at common law or under any statute.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:127%">CERTIFICATION OF AMENDED AND RESTATED BYLAWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:127%">OF</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:127%">LYELL IMMUNOPHARMA, INC.</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">a Delaware Corporation</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:253%">I, Matthew Lang, certify that I am Secretary of Lyell Immunopharma, Inc., a Delaware corporation (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:253%">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:253%">&#8221;), that I am duly authorized to make and deliver this certification, and that the attached Amended and Restated Bylaws are a true and complete copy of the Amended and Restated Bylaws of the Corporation in effect as of the date of this certificate.</font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:253%">Dated&#58;  November&#160;3, 2023</font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:253%;text-decoration:underline">&#47;s&#47; Matthew Lang&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:36pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">Matthew Lang, Secretary</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>lyel-20230930x10qxexx101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i087da506e9404379a27ac48bcdbb9f8d_1"></div><div style="min-height:79.92pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:3.95pt;padding-left:0.77pt;padding-right:205.2pt;text-align:right"><font><br></font></div><div style="padding-left:0.77pt;padding-right:205.2pt;text-align:right;text-indent:-0.36pt"><font><br></font></div><div style="padding-left:102.98pt;padding-right:102.98pt;text-align:center;text-indent:-0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">May 12, 2023</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:355.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Matthew Lang Electronic delivery</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Offer of Employment by Lyell Immunopharma, Inc.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Matt,</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I am very pleased to confirm our offer to you of employment as Chief Business Officer of Lyell Immunopharma, Inc. (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;). The opportunity to work with you to build one of the world&#8217;s great companies whose goal is nothing less than to develop curative therapies for solid tumors is one I am thrilled to have and know that your contributions will help ensure that we will achieve our ambitions.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your proposed start date as Chief Business Officer is July 1, 2023 (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;).</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be based out of our South San Francisco office.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As Lyell&#8217;s Chief Business Officer, you will perform duties as are commensurate and consistent with your position. Your position will be officer level and you will be entitled to defense, indemnity and D&#38;O insurance coverage to the same extent and at the same level as other officers in the Company. In your role as Chief Business Officer you will report to Lynn Seely, President &#38; CEO. The terms of this offer letter (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Offer Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;) and the benefits currently provided by the Company are as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;padding-right:11.3pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.07pt;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As of the Effective Date, your salary will be five hundred thousand dollars ($500,000) annually, less payroll deductions and withholdings. It will be paid on the Company&#8217;s regular payroll schedule, and will be subject to annual review by the Board.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;padding-right:7.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.07pt;text-decoration:underline">Target Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition, you will be eligible to earn an annual incentive bonus of up to fifty percent (50%) of your base salary for the fiscal year of the Company (which runs from January 1st to December 31st during which you commence employment, based on the achievement of performance objectives to be</font></div><div style="margin-top:0.05pt;padding-left:149.05pt;padding-right:11.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determined by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) in the Board&#8217;s sole discretion. Any bonus for the fiscal year in which your employment begins will be prorated, based on the number of days you are employed by the Company during that fiscal year.</font></div><div style="padding-left:149.05pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thereafter, you will be eligible to receive an annual bonus in such amount and upon such terms as shall be determined by the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If your base salary changes during the fiscal year, any bonus earned will be calculated based on the number of days spent</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i087da506e9404379a27ac48bcdbb9f8d_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:149.05pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employed at each salary level. Any bonus for a fiscal year will be paid within 3 months after the close of that fiscal year, and if your employment is terminated either by you without Good Reason or by the Company for Cause (each as defined herein) prior to the bonus being paid, you will not have earned the bonus and no partial or prorated bonus will be paid. The determinations of the Board with respect to your bonus will be final and binding.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.05pt;padding-right:8.65pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.07pt;text-decoration:underline">Sign-on Bonus Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will pay you a signing bonus of four hundred thousand dollars ($400,000), less applicable tax and other withholding within thirty (30) days after your start date (the &#8220;Sign-On Payment&#8221;). You will earn 100% of the Sign-On Payment if you remain continuously employed with the Company through the first anniversary of your Start Date. If you resign your employment with the Company (except for Good Reason) or the Company terminates your employment without Cause, you agree to repay, within thirty (30) days of your last day of employment with the Company, the unearned portion of the Sign- On Payment paid to you by the Company in advance of becoming earned.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:28.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition, you will be eligible to participate in regular health insurance, bonus and other employee benefit plans established by the Company for its senior executives from time to time pursuant to the terms of those plans.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:13.3pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. We will recommend to the Board of Directors of the Company that you be granted an option to purchase up to 2,250,000 shares of Common Stock of the Company (the &#8220;Option&#8221;). The Option will be granted under the Company&#8217;s 2021 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;) and associated form of stock option agreement and will have an exercise price equal to the fair market value of the Company&#8217;s Common Stock, as determined by the Board on the date the Board approves such grant. The Option will be subject to the terms and conditions of the Plan and your grant agreement. The Option will vest at the rate of twenty five percent (25%) of the shares at the end of your first year with the Company, and an additional 1&#47;48 of the total shares subject to the Option per month thereafter, so long as you remain employed by the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event your employment is terminated by the Company without Cause or by you for Good Reason (as defined below) you will receive an additional twelve (12) months of vesting credit for any then outstanding equity awards and the post-termination exercise period of your then outstanding vested stock options shall end on the earliest of the twelve (12) month anniversary of your termination of employment, the expiration date of any such option&#8217;s term or a Change in Control (as defined in the Severance Plan, as defined below). In addition, if either (a) in a Change in Control your then outstanding equity awards are not assumed, substituted or replaced with awards of similar or equal value or (b) your employment is terminated by the Company without Cause or by you for Good Reason during the period beginning on the date that is three</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:20.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3) months prior to the effective date of a Change in Control and ending on the date that is twenty-four (24) months following the effective date of such Change in Control, then 100% of any then outstanding equity awards shall become fully vested.</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.819%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.7pt;padding-left:77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As Chief Business Officer, you will participate in the Lyell</font></div><div style="padding-left:5pt;padding-right:7.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Immunopharma, Inc. Officer Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with its terms as a Tier I Employee (as defined in the Severance Plan), and on or before the Effective Date the Severance Plan will be amended to the extent necessary to provide for such participation. Notwithstanding your participation in the Severance Plan, the terms and definitions in this Offer Letter related to severance and&#47;or accelerated vesting benefits shall supersede (without duplication) the corresponding terms and definitions provided in the Severance Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event your employment is terminated by the Company without Cause or by you for Good Reason (each as defined herein) the Company will pay you a lump-sum payment equal to the sum of (i) twelve (12) months of your base salary and (ii) 1 times your annual bonus paid at target level (the &#8220;Cash Severance Payments&#8221;). In addition, provided that you are eligible for and timely elect group health plan continuation coverage under COBRA, the Company will pay the premiums for you and your dependents to continue group medical, vision and dental coverage under COBRA directly to the insurer or COBRA administrator, as applicable, consistent with terms set forth in the Severance Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Cause&#8221; means (a) you are indicted for, convicted of, or plead guilty or nolo contendre to a felony or crime involving moral turpitude&#59; (b) you engage in conduct that constitutes willful gross negligence or willful misconduct in carrying out your duties&#59; (c) you breach any covenant or any material provision of any agreement with the Company, including, among other things, a willful and material breach of written Company policy&#59; (d) you materially violate a federal law or state law that the Board reasonably determines has had, or is reasonably likely to have, a material detrimental effect on the Company&#8217;s reputation or business&#59; or (e) you commit an act of fraud or dishonesty in the performance of your job duties&#59; provided, however, in the case of (b) or (c) above, if any such conduct or breach is curable, you fail to cure such conduct or breach to the reasonable satisfaction of the Board within fifteen (15) days following the date the Company delivers written notice of such conduct or breach to you.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Good Reason&#8221; means that without your express, written consent, (a) you have incurred a material reduction in authority, duties or responsibilities at the Company or a successor employer (with respect to a termination in connection with a Change in Control, relative to the your authority, title, duties or responsibilities immediately prior to the Change in Control)&#59; (b) you have suffered a material breach of this Agreement or any other material agreement by the Company or a successor employer&#59; (c) you have been required to relocate or travel more than thirty-five (35) miles from your then current place of employment in order to continue to perform the duties and responsibilities of the your position (not including customary travel as may be required by the nature of your position)&#59; or (d) you have been directed by the Board to knowingly and intentionally violate any material state, federal or foreign law, rule or regulation applicable to the Company. Termination of employment by you will not be for Good Reason unless (1) you notify the Company in writing within thirty (30) days of the initial existence of such condition (which notice specifically identifies such condition), (2) the Company fails to remedy such condition within thirty (30) days after the date on which it receives such notice (the &#8220;Remedial Period&#8221;), and (3) you actually terminate employment immediately after the expiration of the Remedial Period and before the Company remedies such condition. If you terminate employment before the expiration of the Remedial Period or after the Company remedies the</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.819%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">condition (even if after the end of the Remedial Period), then the termination will not be considered to be for Good Reason.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In order to receive the Cash Severance Benefits or the equity acceleration described in Section 4, you must first execute a release in favor of the Company in substantially the same form as set forth in the Severance Plan and the Release must become effective and irrevocable within sixty</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(60) days following your termination date (such date the Release becomes effective and irrevocable, the &#8220;Release Effective Date&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6.9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As an employee of the Company, you will have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property of the Company. To protect the interests of the Company, you will need to sign the Company's standard &#34;Employee Invention Assignment and Confidentiality Agreement&#34; as a condition of your employment. We wish to impress upon you that we do not want you to, and we hereby direct you not to, bring with you any additional confidential or proprietary material of any former employer or to violate any other obligations you may have to any former employer. During the period that you render services to the Company, you otherwise agree to not engage in any other employment, business or activity that is in any way competitive with the business or proposed business of the Company. You will disclose to the Company in writing any other gainful employment, business or activity that you are currently associated with or participate in that competes with the Company. You will not assist any other person or organization in competing with the Company or in preparing to engage in competition with the business or proposed business of the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:43.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">No Breach of Obligations to Prior Employers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You represent that your employment with the Company will not violate any agreement currently in place between yourself and current or past employers.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:17.1pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">At Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. While we look forward to a long and profitable relationship, should you decide to accept this offer, you will be an at-will employee of the Company, which means the employment relationship can be terminated by either of us for any reason, at any time, with or without prior notice and with or without cause. Any statements or representations to the contrary (and, indeed, any statements contradicting any provision in this letter) should be regarded by you as ineffective. Further, your participation in any stock option or benefit program is not to be regarded as assuring you of continuing employment for any particular period of time. Any modification or change in your at will employment status may only occur by way of a written employment agreement signed by you and duly-authorized member of the Board (other than yourself).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this letter Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.819%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:6.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JAMS or its successor, under JAMS&#8217; then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;mles-employment-arbitration&#47;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;Excluded Claims&#8221;). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:48.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All questions concerning the construction, validity and interpretation of this Offer Letter will be governed by the laws of the State of California.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:17.5pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.05pt;text-decoration:underline">Background Check</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This offer is contingent upon a satisfactory verification of criminal, education, driving and&#47;or employment background. This offer can be rescinded based upon data received in the verification.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:39.75pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.05pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Offer Letter, once accepted, constitutes the entire agreement between you and the Company with respect to the subject matter hereof and</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.819%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:7.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supersedes all prior offers, negotiations and agreements, if any, whether written or oral, relating to such subject matter as of the Effective Date. You acknowledge that neither the Company nor its agents have made any promise, representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this agreement for the purpose of inducing you to execute the agreement, and you acknowledge that you have executed this agreement in reliance only upon such promises, representations and warranties as are contained herein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6.4pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.05pt;text-decoration:underline">Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you decide to accept the terms of this Offer Letter, and I hope you will, please sign the enclosed copy of this letter in the space indicated and return it to me. Your signature will acknowledge that you have read and understood and agreed to the terms and conditions of this offer letter and the attached documents, if any. Should you have anything else that you wish to discuss, please do not hesitate to call me.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We look forward to the opportunity to welcome you to the Company.</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:257.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Lynn Seely</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:257.05pt;padding-right:123.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lynn Seely President &#38; CEO</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I have read and understood this Offer Letter and hereby acknowledge, accept and agree to the terms as set forth above and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date signed&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">May 12, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Lang</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Matthew Lang</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.819%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>lyel-20230930x10qxexx102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iac125ab6eab64a359de27b207910e8b5_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lyell Immunopharma, Inc.<br>Non-Employee Director Compensation Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adopted and Effective&#58; November 11, 2019</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Last Amended and Restated&#58; September&#160;6, 2023</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each member of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of Lyell Immunopharma, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) who is a non-employee director of the Company (each such member, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) will receive the compensation described in this Non-Employee Director Compensation Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for his or her Board service. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given to such terms in the Company&#8217;s 2021 Equity Incentive Plan or if such plan is no longer in use, the meaning given to such terms or any similar terms in the primary successor to such plan (in either case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Policy is amended and restated effective upon September&#160;6, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Cash Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each Eligible Director will receive the cash compensation described below. The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash retainer fees are vested upon payment. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Annual Board Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:29.07pt">All Eligible Directors other than Lead Director&#47;Chair&#58; $50,000</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Lead Director&#47;Chair&#58; $80,000</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Annual Committee Service Retainer (Chair)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:29.07pt">Chair of the Audit Committee&#58; $15,000</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Chair of the Compensation Committee&#58; $12,000</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:29.07pt">Chair of the Nominating and Corporate Governance Committee&#58; $10,000</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Annual Committee Service Retainer (Non-Chair)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:29.07pt">Audit Committee&#58; $7,500</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Compensation Committee&#58; $6,000 </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:29.07pt">Nominating and Corporate Governance Committee&#58; $5,000 </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each Eligible Director will be eligible to receive the equity compensation set forth below. The equity compensation below will be granted under the Plan and the Company&#8217;s standard form of Option Agreement most recently approved by the Board or the Compensation Committee. All Options granted under this Policy will be Nonstatutory Stock Options, with a maximum term of ten years from the date of grant and an exercise price per share equal to 100% of the Fair Market Value of the underlying Common Stock on the date of grant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Appointment Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;Without any further action of the Board, each person who is elected or appointed for the first time to be an Eligible&#160;Director will automatically, upon the date of his or her initial election or appointment to be an Eligible Director, be granted the lesser of (i)&#160;a Nonstatutory Stock Option to purchase shares of Common Stock calculated to have a Black-Scholes value of $500,000 on the date of grant, rounded to the nearest whole number&#59; and (ii)&#160;a Nonstatutory Stock Option to purchase 260,000 shares of Common Stock (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Appointment Grant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). Each Appointment Grant will vest as to one thirty&#8209;sixth (1&#47;36th) of the shares of Common Stock subject to the Appointment Grant on a monthly basis following the Appointment Grant&#8217;s grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Eligible Director remaining in Continuous Service through the applicable vesting date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;Without any further action of the Board, at the close of business on the date of each annual meeting of stockholders of the Company (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), each person who is then an Eligible Director will automatically be granted the lesser of (i)&#160;a Nonstatutory Stock Option to purchase shares of Common Stock calculated to have a Black-Scholes value of $300,000 on the date of grant, rounded to the nearest whole number&#59; and </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;a Nonstatutory Stock Option to purchase 130,000&#160;shares of Common Stock (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Each Annual Grant will vest as to all of the shares of Common Stock subject to the Annual Grant on the earlier of (a) the date of the next Annual Meeting that occurs following the grant date of the Annual Grant (or the date immediately prior to such date if the Eligible Director&#8217;s service as a director ends at such Annual Meeting due to the director&#8217;s failure to be re-elected or the director not standing for re-election)&#59; or (b) the first anniversary of the grant date of the Annual Grant, subject to the Eligible Director remaining in Continuous Service through the vesting date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Policy, in the event of a Change in Control, each Eligible Director will fully vest in his or her then-outstanding Company equity awards as of immediately prior to the Change in Control, including, without limitation, any equity awards granted under this Policy, provided that the Eligible Director continues to be an Eligible Director through immediately prior to the date of such Change in Control.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligible Director Compensation Limit</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Policy, the cash compensation and equity compensation that each Eligible Director is eligible to receive under this Policy shall be subject to the limits set forth in Section 3(d) of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ability to Decline Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An Eligible Director may decline all or any portion of his or her compensation under this Policy by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company will reimburse Eligible Directors for ordinary, necessary and reasonable&#160;out-of-pocket&#160;travel expenses to cover&#160;in-person&#160;attendance at and participation in Board and committee meetings&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the Eligible Director timely submits to the Company appropriate documentation substantiating such expenses in accordance with the Company&#8217;s travel and expense policy, as in effect from time to time.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Policy may be amended at any time in the sole discretion of the Board or the Compensation Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:97%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:97%">2.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>lyel-20230930x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0342a7b563a04831b1014bf46bce7a70_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lynn Seely, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Lyell Immunopharma, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; LYNN SEELY</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lynn Seely, M.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>lyel-20230930x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9fbdb293bdd143369ae8905fbce5dd45_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles Newton, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Lyell Immunopharma, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; CHARLES NEWTON</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>lyel-20230930x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if5f711ddceec4cd3ae54b01bfe06e72a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in her or his capacity as an officer of Lyell Immunopharma, Inc, Inc. (the&#160;&#8220;Company&#8221;), that, to the best of her or his knowledge&#58;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:6.34pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September&#160;30, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; LYNN SEELY</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lynn Seely, M.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; CHARLES NEWTON</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>lyel-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8759b030-35fe-4fde-9a5a-bde7fe691e10,g:0b784d50-2a9f-447e-ae11-ec2a3c5830c1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lyel="http://lyell.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lyell.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://lyell.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://lyell.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreements" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements">
        <link:definition>0000010 - Disclosure - License, Collaboration, and Success Payment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecurities" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecurities">
        <link:definition>0000011 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherInvestments" roleURI="http://lyell.com/role/OtherInvestments">
        <link:definition>0000012 - Disclosure - Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://lyell.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://lyell.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://lyell.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://lyell.com/role/StockbasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://lyell.com/role/NetLossPerShare">
        <link:definition>0000017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://lyell.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactions" roleURI="http://lyell.com/role/RelatedpartyTransactions">
        <link:definition>0000019 - Disclosure - Related-party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://lyell.com/role/SubsequentEvents">
        <link:definition>0000020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsTables" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables">
        <link:definition>9954472 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesTables" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9954473 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://lyell.com/role/FairValueMeasurementsTables">
        <link:definition>9954474 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://lyell.com/role/LeasesTables">
        <link:definition>9954475 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://lyell.com/role/StockbasedCompensationTables">
        <link:definition>9954476 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsTables" roleURI="http://lyell.com/role/RelatedpartyTransactionsTables">
        <link:definition>9954477 - Disclosure - Related-party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954478 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails">
        <link:definition>9954479 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails">
        <link:definition>9954480 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9954481 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1">
        <link:definition>9954481 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherInvestmentsDetails" roleURI="http://lyell.com/role/OtherInvestmentsDetails">
        <link:definition>9954483 - Disclosure - Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954484 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails">
        <link:definition>9954485 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails">
        <link:definition>9954486 - Disclosure - Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954487 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails">
        <link:definition>9954488 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1">
        <link:definition>9954488 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://lyell.com/role/LeasesNarrativeDetails">
        <link:definition>9954489 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://lyell.com/role/StockholdersEquityDetails">
        <link:definition>9954490 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>9954491 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails">
        <link:definition>9954492 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofRestrictedStockUnitsDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails">
        <link:definition>9954493 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockOptionActivityDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails">
        <link:definition>9954494 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails">
        <link:definition>9954495 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsNarrativeDetails" roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails">
        <link:definition>9954496 - Disclosure - Related-party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails">
        <link:definition>9954497 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://lyell.com/role/SubsequentEventsDetails">
        <link:definition>9954498 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lyel_StanfordMember" abstract="true" name="StanfordMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_StockPurchaseAgreementFairValueOfStockPerShare" abstract="false" name="StockPurchaseAgreementFairValueOfStockPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_FiftyTimesMember" abstract="true" name="FiftyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_FortyTimesMember" abstract="true" name="FortyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_OtherInvestmentMember" abstract="true" name="OtherInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_GSKMember" abstract="true" name="GSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" abstract="true" name="AdjustmentToRevenueRelatedToChangeInEstimateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_PACTPharmaIncMember" abstract="true" name="PACTPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_EquityMultipleAxis" abstract="true" name="EquityMultipleAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_StockPurchaseAgreementSharesSoldPricePerShare" abstract="false" name="StockPurchaseAgreementSharesSoldPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_FredHutchMember" abstract="true" name="FredHutchMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" abstract="false" name="CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_FairValueOfSeriesAConvertiblePreferredStock" abstract="false" name="FairValueOfSeriesAConvertiblePreferredStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityMember" abstract="true" name="SuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ThirtyTimesMember" abstract="true" name="ThirtyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_TwoThousandEighteenEquityIncentivePlanMember" abstract="true" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" abstract="true" name="CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" abstract="false" name="FairValueAdjustmentOfSuccessPaymentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_FredHutchSuccessPaymentLiabilityMember" abstract="true" name="FredHutchSuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_OtherInvestmentsTextBlock" abstract="false" name="OtherInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_LyellImmunopharmaMember" abstract="true" name="LyellImmunopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" abstract="false" name="CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_GoldmanSachsAndBofAMember" abstract="true" name="GoldmanSachsAndBofAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SignificantAccountingPoliciesPolicyTextBlock" abstract="false" name="SignificantAccountingPoliciesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_TwoThousandTwentyOneEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_StanfordSuccessPaymentLiabilityMember" abstract="true" name="StanfordSuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_NonCashLeaseIncomeExpense" abstract="false" name="NonCashLeaseIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" abstract="false" name="RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SouthSanFranciscoCaliforniaMember" abstract="true" name="SouthSanFranciscoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" abstract="false" name="CashReceivedForAmountsRelatedToTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilitiesFairValueDisclosure" abstract="false" name="SuccessPaymentLiabilitiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_StockPurchaseAgreementSharesSold" abstract="false" name="StockPurchaseAgreementSharesSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_PercentageOfCommissionFromEachSaleOfShares" abstract="false" name="PercentageOfCommissionFromEachSaleOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" abstract="true" name="GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_TenTimesMember" abstract="true" name="TenTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SonomaMember" abstract="true" name="SonomaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_SeriesAAConvertiblePreferredStockMember" abstract="true" name="SeriesAAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityMeasurementInput" abstract="false" name="SuccessPaymentLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="lyel_CashEquivalentsFairValueDisclosure" abstract="false" name="CashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_TwentyTimesMember" abstract="true" name="TwentyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" abstract="false" name="VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lyel_EquityMultipleDomain" abstract="true" name="EquityMultipleDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilitiesCurrent" abstract="false" name="SuccessPaymentLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>lyel-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8759b030-35fe-4fde-9a5a-bde7fe691e10,g:0b784d50-2a9f-447e-ae11-ec2a3c5830c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a7b21d98-216d-40e0-9f2e-7f623505ae94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e17c481d-cb5e-4be8-a275-1bca470c9086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a7b21d98-216d-40e0-9f2e-7f623505ae94" xlink:to="loc_us-gaap_Liabilities_e17c481d-cb5e-4be8-a275-1bca470c9086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_79b45abf-b2b9-4267-8e18-d034e0818013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a7b21d98-216d-40e0-9f2e-7f623505ae94" xlink:to="loc_us-gaap_CommitmentsAndContingencies_79b45abf-b2b9-4267-8e18-d034e0818013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0971ada8-3145-4380-8e48-579671ac3b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a7b21d98-216d-40e0-9f2e-7f623505ae94" xlink:to="loc_us-gaap_StockholdersEquity_0971ada8-3145-4380-8e48-579671ac3b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ad11460d-d6bc-40fe-aa61-7979d29f5c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e09d53da-8a5d-4605-a4a5-62baf4f9ef08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ad11460d-d6bc-40fe-aa61-7979d29f5c97" xlink:to="loc_us-gaap_LiabilitiesCurrent_e09d53da-8a5d-4605-a4a5-62baf4f9ef08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ea38162-a668-4c60-ad48-797ff41852a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ad11460d-d6bc-40fe-aa61-7979d29f5c97" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ea38162-a668-4c60-ad48-797ff41852a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5ff306e4-70f0-492e-a6cf-bb8770c4170a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ad11460d-d6bc-40fe-aa61-7979d29f5c97" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5ff306e4-70f0-492e-a6cf-bb8770c4170a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_14e1b2e3-aacd-47b2-be9a-29a29af7d362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2f4ef370-2cec-4949-be56-7a79877ccdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14e1b2e3-aacd-47b2-be9a-29a29af7d362" xlink:to="loc_us-gaap_AccountsPayableCurrent_2f4ef370-2cec-4949-be56-7a79877ccdc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f9d4f1a4-1204-497e-8ca0-cf2ab10a2543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14e1b2e3-aacd-47b2-be9a-29a29af7d362" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f9d4f1a4-1204-497e-8ca0-cf2ab10a2543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent_0160d3be-396d-41f8-897d-cd403a3cc8fd" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14e1b2e3-aacd-47b2-be9a-29a29af7d362" xlink:to="loc_lyel_SuccessPaymentLiabilitiesCurrent_0160d3be-396d-41f8-897d-cd403a3cc8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a36f5796-8e4a-40cd-b63f-9b384368fa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_AssetsCurrent_a36f5796-8e4a-40cd-b63f-9b384368fa7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_e3062e41-4f5d-4ea5-adb7-077c4f73ea9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_e3062e41-4f5d-4ea5-adb7-077c4f73ea9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_7ffbcdc0-1f23-49cd-b57b-ba61c3d0da4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_OtherInvestments_7ffbcdc0-1f23-49cd-b57b-ba61c3d0da4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c54754ec-038a-4cd0-8cfe-ff4f267b3c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c54754ec-038a-4cd0-8cfe-ff4f267b3c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_72ec3d8c-4b82-442f-9554-5264f2ac3465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_72ec3d8c-4b82-442f-9554-5264f2ac3465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5b1a6cd2-3e41-42f7-8d9e-64c310deb017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5b1a6cd2-3e41-42f7-8d9e-64c310deb017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_26ef0fdb-4a18-47cc-8eee-a76222ae1364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07d1adef-7a9d-4ad8-972d-9297435045fa" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_26ef0fdb-4a18-47cc-8eee-a76222ae1364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4d1ca0d-a45c-4ce6-9196-8475a7ba28f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa2a873b-da8a-4308-a15e-857f17327823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4d1ca0d-a45c-4ce6-9196-8475a7ba28f1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa2a873b-da8a-4308-a15e-857f17327823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_acd97bc5-4788-45f3-8d6d-033b1c2ef41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4d1ca0d-a45c-4ce6-9196-8475a7ba28f1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_acd97bc5-4788-45f3-8d6d-033b1c2ef41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_afc8eb21-dab3-47d1-a728-3adf15e77ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4d1ca0d-a45c-4ce6-9196-8475a7ba28f1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_afc8eb21-dab3-47d1-a728-3adf15e77ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0413a08f-69d3-475b-a3fe-5340adfd07f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bbe32122-acbc-4ac4-923f-7165003950ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0413a08f-69d3-475b-a3fe-5340adfd07f2" xlink:to="loc_us-gaap_PreferredStockValue_bbe32122-acbc-4ac4-923f-7165003950ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ef952d7e-32ca-4ca7-951c-4653142e5d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0413a08f-69d3-475b-a3fe-5340adfd07f2" xlink:to="loc_us-gaap_CommonStockValue_ef952d7e-32ca-4ca7-951c-4653142e5d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fa82fe29-fdae-4b43-98e7-914b6b3ab0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0413a08f-69d3-475b-a3fe-5340adfd07f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fa82fe29-fdae-4b43-98e7-914b6b3ab0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_886174de-72b0-44ca-b264-e759130d5d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0413a08f-69d3-475b-a3fe-5340adfd07f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_886174de-72b0-44ca-b264-e759130d5d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_de22c33d-e607-47c7-b5ff-1ca4652296a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0413a08f-69d3-475b-a3fe-5340adfd07f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_de22c33d-e607-47c7-b5ff-1ca4652296a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4ff0f428-a51c-4601-b8fc-62bfb750acc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25a639c1-5857-4978-95c9-a72c0d6ccff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4ff0f428-a51c-4601-b8fc-62bfb750acc7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25a639c1-5857-4978-95c9-a72c0d6ccff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c6da6c1d-7dde-4f5f-8ada-75c2b072d5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4ff0f428-a51c-4601-b8fc-62bfb750acc7" xlink:to="loc_us-gaap_OperatingIncomeLoss_c6da6c1d-7dde-4f5f-8ada-75c2b072d5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1090e4dd-601b-4732-8464-8d8cad07db30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7d4992ca-0c65-4361-82cd-f6420c8f8978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1090e4dd-601b-4732-8464-8d8cad07db30" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7d4992ca-0c65-4361-82cd-f6420c8f8978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_59e85e4b-6ee6-49b7-9d60-7bf4179704e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1090e4dd-601b-4732-8464-8d8cad07db30" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_59e85e4b-6ee6-49b7-9d60-7bf4179704e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_095deb01-10f4-4903-b875-cc768b42053c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1090e4dd-601b-4732-8464-8d8cad07db30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_095deb01-10f4-4903-b875-cc768b42053c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_06579c0e-8e0a-4e58-a035-fb3b691647e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e4da0004-1968-422e-9c73-fe66c29a7b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_06579c0e-8e0a-4e58-a035-fb3b691647e7" xlink:to="loc_us-gaap_OperatingExpenses_e4da0004-1968-422e-9c73-fe66c29a7b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_065d6c61-c711-4f4b-88a1-8e56df35d279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_06579c0e-8e0a-4e58-a035-fb3b691647e7" xlink:to="loc_us-gaap_Revenues_065d6c61-c711-4f4b-88a1-8e56df35d279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c00f7ace-9ce7-43e6-98f6-684de65b0ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81c5bba2-65ec-410e-9d16-4f9a6e67800e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c00f7ace-9ce7-43e6-98f6-684de65b0ac5" xlink:to="loc_us-gaap_NetIncomeLoss_81c5bba2-65ec-410e-9d16-4f9a6e67800e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_429c3668-385b-4936-9bf9-de61f0650a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c00f7ace-9ce7-43e6-98f6-684de65b0ac5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_429c3668-385b-4936-9bf9-de61f0650a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_18b19e32-24d8-4b10-9f46-25a21c07c184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_95f15fbc-412b-422a-9eb6-7ded8a053be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_18b19e32-24d8-4b10-9f46-25a21c07c184" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_95f15fbc-412b-422a-9eb6-7ded8a053be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_10aac85e-f84a-4824-8fbf-9395ca8dcdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_18b19e32-24d8-4b10-9f46-25a21c07c184" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_10aac85e-f84a-4824-8fbf-9395ca8dcdb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_05bc2d33-8e36-43de-94cc-a366a6298023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_18b19e32-24d8-4b10-9f46-25a21c07c184" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_05bc2d33-8e36-43de-94cc-a366a6298023" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9555b7cb-83d3-4507-add7-046bda19a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9db6214-a2e8-4f71-bac5-e7888eeb6a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9555b7cb-83d3-4507-add7-046bda19a7b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9db6214-a2e8-4f71-bac5-e7888eeb6a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27359af7-55a3-4063-afb6-9a7951872f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9555b7cb-83d3-4507-add7-046bda19a7b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27359af7-55a3-4063-afb6-9a7951872f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db356750-6c3f-47fe-83e5-c482a421f4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9555b7cb-83d3-4507-add7-046bda19a7b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db356750-6c3f-47fe-83e5-c482a421f4c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0222769e-fd02-4916-8e2f-d96ab34e7523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0222769e-fd02-4916-8e2f-d96ab34e7523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2591829c-006d-4c18-bb38-1a4b6d188aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2591829c-006d-4c18-bb38-1a4b6d188aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c890bc5-2dad-41f5-ba16-9e96070e31d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_ShareBasedCompensation_6c890bc5-2dad-41f5-ba16-9e96070e31d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f149bc8c-bc02-4048-aded-5489d2c3b8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f149bc8c-bc02-4048-aded-5489d2c3b8c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_09c83084-e555-4dfe-8abb-ff38a42fd5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_09c83084-e555-4dfe-8abb-ff38a42fd5fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_8683f8ca-be10-4d89-bf65-3e2e861cfcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_8683f8ca-be10-4d89-bf65-3e2e861cfcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cea5050f-7350-4fa9-b1f1-ea598c60d9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cea5050f-7350-4fa9-b1f1-ea598c60d9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_d279f96d-2498-4950-a386-6fb5d88461be" xlink:href="lyel-20230930.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_d279f96d-2498-4950-a386-6fb5d88461be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_312ab833-5c14-4e12-9fe8-ccd364887063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_NetIncomeLoss_312ab833-5c14-4e12-9fe8-ccd364887063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_8b21ca6b-6f51-4e85-a258-e660b19eba34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_8b21ca6b-6f51-4e85-a258-e660b19eba34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4d62a5c8-ef0e-4089-9d11-ba11e1f83462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4d62a5c8-ef0e-4089-9d11-ba11e1f83462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_25c59e9f-8ba1-4c7b-b8a1-4509d18675e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_25c59e9f-8ba1-4c7b-b8a1-4509d18675e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense_87a5ef6a-06d5-4b4b-b443-c2ab61cdf41c" xlink:href="lyel-20230930.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_lyel_NonCashLeaseIncomeExpense_87a5ef6a-06d5-4b4b-b443-c2ab61cdf41c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f6105abe-06a9-4b00-8440-07362059bb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f6105abe-06a9-4b00-8440-07362059bb8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_a6df82f7-f581-4e45-b047-5d5aadfc38a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1c84ff6-7784-4394-8924-b7e1252c4c9a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_a6df82f7-f581-4e45-b047-5d5aadfc38a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b63842f3-1dc8-4963-a94f-01edbecdc6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01140e47-524d-4934-af06-4db9912112a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b63842f3-1dc8-4963-a94f-01edbecdc6b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01140e47-524d-4934-af06-4db9912112a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b6781281-e383-47f7-b116-1dd060ed0927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b63842f3-1dc8-4963-a94f-01edbecdc6b6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b6781281-e383-47f7-b116-1dd060ed0927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a2dfe6-b8aa-421d-b14c-ca41f171b153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f414052a-ecc6-4da5-876a-b98741e97e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a2dfe6-b8aa-421d-b14c-ca41f171b153" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f414052a-ecc6-4da5-876a-b98741e97e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b04cbaea-a7be-433a-8800-cc69d5ed00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a2dfe6-b8aa-421d-b14c-ca41f171b153" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b04cbaea-a7be-433a-8800-cc69d5ed00a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_54a3b14d-6504-407d-a044-3efe9c899860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a2dfe6-b8aa-421d-b14c-ca41f171b153" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_54a3b14d-6504-407d-a044-3efe9c899860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d23a186-f7df-450b-9caa-73a3ec25bf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_539c7c09-76d7-499d-8b40-d0416be4ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d23a186-f7df-450b-9caa-73a3ec25bf8a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_539c7c09-76d7-499d-8b40-d0416be4ffec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8720e327-31ed-4b3a-a0b6-60cdb061e53c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d23a186-f7df-450b-9caa-73a3ec25bf8a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8720e327-31ed-4b3a-a0b6-60cdb061e53c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_49cf4758-be48-4431-be0e-ebdacb17e213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d23a186-f7df-450b-9caa-73a3ec25bf8a" xlink:to="loc_us-gaap_ProceedsFromStockPlans_49cf4758-be48-4431-be0e-ebdacb17e213" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_88f21141-0ba4-4463-ab45-249f14acc96d" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d02314a4-fc3d-4ac2-9cb7-fa540161fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_88f21141-0ba4-4463-ab45-249f14acc96d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d02314a4-fc3d-4ac2-9cb7-fa540161fba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19e435c8-721a-4c08-b94a-761351aabdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_88f21141-0ba4-4463-ab45-249f14acc96d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19e435c8-721a-4c08-b94a-761351aabdfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_9cbc97df-7ca4-478c-a7ec-6bb2ed7de6da" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_706107ce-4f97-497c-a5e4-051c5a5b1cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_9cbc97df-7ca4-478c-a7ec-6bb2ed7de6da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_706107ce-4f97-497c-a5e4-051c5a5b1cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e24d0c40-a6ae-4e30-9bf4-d353da7dfe63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_9cbc97df-7ca4-478c-a7ec-6bb2ed7de6da" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e24d0c40-a6ae-4e30-9bf4-d353da7dfe63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b43e455-638d-4a91-a445-332d26308f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7a156fdf-9bf2-4826-9208-1a8d52f188d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b43e455-638d-4a91-a445-332d26308f6f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7a156fdf-9bf2-4826-9208-1a8d52f188d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f7e08b1b-efe4-4fd7-90a7-cde9b5daa590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b43e455-638d-4a91-a445-332d26308f6f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f7e08b1b-efe4-4fd7-90a7-cde9b5daa590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0cb874e-5897-4e9f-90fa-eddfda8638a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4b43e455-638d-4a91-a445-332d26308f6f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0cb874e-5897-4e9f-90fa-eddfda8638a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a518417e-ef67-4399-be81-fa42005a29e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e3dbc11-9e12-4e10-869f-f1b508ebd6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a518417e-ef67-4399-be81-fa42005a29e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e3dbc11-9e12-4e10-869f-f1b508ebd6a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_0da46960-63e4-416c-97c9-0ab70463464f" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_81dcbd65-7edc-4ad8-859f-1271a21b4d46" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_0da46960-63e4-416c-97c9-0ab70463464f" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_81dcbd65-7edc-4ad8-859f-1271a21b4d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50a1ee87-a15a-4ea5-b054-51a1277b0d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_0da46960-63e4-416c-97c9-0ab70463464f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50a1ee87-a15a-4ea5-b054-51a1277b0d52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_264bc300-9a31-40f9-914c-cf2617d285fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_0da46960-63e4-416c-97c9-0ab70463464f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_264bc300-9a31-40f9-914c-cf2617d285fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_81e22c05-a17b-4590-a2d0-37762e90acac" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_427e4ac7-6034-4a36-adc0-55181a4c5b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_81e22c05-a17b-4590-a2d0-37762e90acac" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_427e4ac7-6034-4a36-adc0-55181a4c5b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure_0d9ef9a8-849f-4818-b08c-01c26241ff47" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_81e22c05-a17b-4590-a2d0-37762e90acac" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosure_0d9ef9a8-849f-4818-b08c-01c26241ff47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_91567242-0c94-421a-826b-c79b2c1b5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_81e22c05-a17b-4590-a2d0-37762e90acac" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_91567242-0c94-421a-826b-c79b2c1b5e77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f237ec0f-2db8-4a4f-bc17-c3ed2a11a460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5bf015d-ab8e-44cd-9f09-4338b25289af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f237ec0f-2db8-4a4f-bc17-c3ed2a11a460" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5bf015d-ab8e-44cd-9f09-4338b25289af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d8159707-157f-44ff-9273-777fb5c3ff99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f237ec0f-2db8-4a4f-bc17-c3ed2a11a460" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d8159707-157f-44ff-9273-777fb5c3ff99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5957e73f-d561-49e9-91fe-0d869a838d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_a0473cbd-841b-4076-8d41-a1b3b162d16d" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5957e73f-d561-49e9-91fe-0d869a838d01" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_a0473cbd-841b-4076-8d41-a1b3b162d16d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2af051a8-f461-4341-a09c-c80461bdd70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_31729001-5852-49ba-bcfd-2505e41db14e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2af051a8-f461-4341-a09c-c80461bdd70e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_31729001-5852-49ba-bcfd-2505e41db14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1088a905-9678-40be-973a-a9fef3e3e73f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2af051a8-f461-4341-a09c-c80461bdd70e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1088a905-9678-40be-973a-a9fef3e3e73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6453bb02-1cae-4ae7-aef7-7b368df09ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_faa3f49c-47c2-4880-8cf5-b11aafda9652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6453bb02-1cae-4ae7-aef7-7b368df09ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_faa3f49c-47c2-4880-8cf5-b11aafda9652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5562492a-d2cc-40d1-a61b-5581c91843d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6453bb02-1cae-4ae7-aef7-7b368df09ce9" xlink:to="loc_us-gaap_OperatingLeaseLiability_5562492a-d2cc-40d1-a61b-5581c91843d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1"/>
  <link:calculationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_02b1e4c0-0519-4508-a042-fe9d06efecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_02b1e4c0-0519-4508-a042-fe9d06efecd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_08c602ef-50dd-490e-a272-3406158ad2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_08c602ef-50dd-490e-a272-3406158ad2da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe3e33f4-b52b-47d3-beae-2527623eeea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe3e33f4-b52b-47d3-beae-2527623eeea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2ad47791-ce12-48ac-b8cf-9445ecc493d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2ad47791-ce12-48ac-b8cf-9445ecc493d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_24ac992f-d398-48c0-89c7-d63270ade5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_24ac992f-d398-48c0-89c7-d63270ade5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8aa5a8ea-e64f-4eb8-9981-7f69880a6aa3" xlink:href="lyel-20230930.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e2ce8b1-e3cb-42ca-8a14-3304313f81b9" xlink:to="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8aa5a8ea-e64f-4eb8-9981-7f69880a6aa3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>lyel-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8759b030-35fe-4fde-9a5a-bde7fe691e10,g:0b784d50-2a9f-447e-ae11-ec2a3c5830c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e586b3a2-1a78-416c-8172-79ef09a7043f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6581ee05-07eb-476c-9861-1f94a7902959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e586b3a2-1a78-416c-8172-79ef09a7043f" xlink:to="loc_us-gaap_Revenues_6581ee05-07eb-476c-9861-1f94a7902959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e586b3a2-1a78-416c-8172-79ef09a7043f" xlink:to="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f1e16dce-36e9-474d-8bd7-550bb60c7abf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:to="loc_us-gaap_RelatedPartyDomain_f1e16dce-36e9-474d-8bd7-550bb60c7abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f738415d-670d-43bc-a174-13b8b8ca7905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:to="loc_us-gaap_RelatedPartyDomain_f738415d-670d-43bc-a174-13b8b8ca7905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_bb89a406-80c0-49f5-8d7b-22151555d7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f738415d-670d-43bc-a174-13b8b8ca7905" xlink:to="loc_us-gaap_RelatedPartyMember_bb89a406-80c0-49f5-8d7b-22151555d7c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_173b00d4-2157-49f7-b571-6b9cc4a98a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_173b00d4-2157-49f7-b571-6b9cc4a98a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f78d84e-0598-4541-9e34-30bc346ce858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f78d84e-0598-4541-9e34-30bc346ce858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2938030e-dcf5-459f-94a5-e538bdf4a241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockholdersEquity_2938030e-dcf5-459f-94a5-e538bdf4a241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc703fd6-546a-483d-8cb3-03a4319738b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc703fd6-546a-483d-8cb3-03a4319738b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ab75586-77d4-40ce-9c2a-372d3ca162ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ab75586-77d4-40ce-9c2a-372d3ca162ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_468d31e8-ce3d-4655-af00-a7d9e87115d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_468d31e8-ce3d-4655-af00-a7d9e87115d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bb354b41-66ec-4528-9914-fe77fea3c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bb354b41-66ec-4528-9914-fe77fea3c78a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_863a0714-176a-4813-933e-e711271544de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_863a0714-176a-4813-933e-e711271544de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4cd08bac-7ee8-43a7-a8aa-4fd44d8c25cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4cd08bac-7ee8-43a7-a8aa-4fd44d8c25cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f049b27-1db4-4227-b2bb-2a43e7e59606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f049b27-1db4-4227-b2bb-2a43e7e59606" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1e7494b3-4acb-4357-84d4-a20ae19f36be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1e7494b3-4acb-4357-84d4-a20ae19f36be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8af84410-eddd-4ca5-8cdb-b6473f379c15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8af84410-eddd-4ca5-8cdb-b6473f379c15" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8799029-4bf1-4761-ba23-0db9abd69bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_NetIncomeLoss_a8799029-4bf1-4761-ba23-0db9abd69bb2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8ec5012-f8ed-4010-8b22-bf55b3b62acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_92c2d294-4625-449a-b7fa-8f97ddf339b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_173b00d4-2157-49f7-b571-6b9cc4a98a8f" xlink:to="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5de7edb0-662d-4720-9ef9-126307dd0671_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:to="loc_us-gaap_EquityComponentDomain_5de7edb0-662d-4720-9ef9-126307dd0671_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:to="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d67725f9-76cb-4f2b-ac1e-72f50076751f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_CommonStockMember_d67725f9-76cb-4f2b-ac1e-72f50076751f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9201fbca-b7f0-4732-bb96-b588c4dc7563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9201fbca-b7f0-4732-bb96-b588c4dc7563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d66e6a57-961b-4157-a1bc-ab885441cab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d66e6a57-961b-4157-a1bc-ab885441cab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1e09c11e-fade-46b7-a021-3cc1a406311b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_RetainedEarningsMember_1e09c11e-fade-46b7-a021-3cc1a406311b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e66c6c8a-d28a-42c1-8a2b-39d34cb3829d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_Revenues_e66c6c8a-d28a-42c1-8a2b-39d34cb3829d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2a9375a-683f-4318-b4ae-7cb3efa0782d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_NetIncomeLoss_e2a9375a-683f-4318-b4ae-7cb3efa0782d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_615460c8-974e-47d0-be64-bc94347feff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_EarningsPerShareBasic_615460c8-974e-47d0-be64-bc94347feff8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6b543732-6fc8-4406-9831-6f85805651e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6b543732-6fc8-4406-9831-6f85805651e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d1dd7b-3d1d-43fb-8830-89827e7d0636" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d1dd7b-3d1d-43fb-8830-89827e7d0636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_73d1ab84-3a75-428f-8662-8629bce9d1a3" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d1dd7b-3d1d-43fb-8830-89827e7d0636" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_73d1ab84-3a75-428f-8662-8629bce9d1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93df09b3-1aaf-46af-8027-e2431b6cfd1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93df09b3-1aaf-46af-8027-e2431b6cfd1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7846191c-1139-4e4f-9df6-ae8f6cab6ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7846191c-1139-4e4f-9df6-ae8f6cab6ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5d5176c4-347d-4f1e-9525-908de8173657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7846191c-1139-4e4f-9df6-ae8f6cab6ecb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5d5176c4-347d-4f1e-9525-908de8173657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6b87e793-aa7f-4df7-a0fc-4edfcf96364e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6b87e793-aa7f-4df7-a0fc-4edfcf96364e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c5e3e54e-e244-4514-a8d8-89f70b0c2e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c5e3e54e-e244-4514-a8d8-89f70b0c2e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_59c57679-613b-488f-adfe-57a20807ebb9" xlink:href="lyel-20230930.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c5e3e54e-e244-4514-a8d8-89f70b0c2e03" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_59c57679-613b-488f-adfe-57a20807ebb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_40694c24-d403-42ac-b046-1319d564ef39" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_40694c24-d403-42ac-b046-1319d564ef39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_7e7dfa71-3b06-47c9-8847-0659f89e835d" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_7e7dfa71-3b06-47c9-8847-0659f89e835d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_a2aaea7a-4263-4263-b04d-af9383df5984" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_a2aaea7a-4263-4263-b04d-af9383df5984" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_298613e6-dfae-4177-948b-f2272e3d1be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_298613e6-dfae-4177-948b-f2272e3d1be6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_64e5803f-3d51-4234-9ad2-4bfa638dd339" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_64e5803f-3d51-4234-9ad2-4bfa638dd339" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_21a8eb14-e326-4bcb-b847-1885fb5f1454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_21a8eb14-e326-4bcb-b847-1885fb5f1454" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_0c6f9b8d-cf24-4184-847f-ec4c566a41f5" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_0c6f9b8d-cf24-4184-847f-ec4c566a41f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a4f25b0b-32b8-4315-a742-b8dc31dae623" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a4f25b0b-32b8-4315-a742-b8dc31dae623" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_5bc9c5ce-1be6-4642-b2ad-2b4e3d075553" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_5bc9c5ce-1be6-4642-b2ad-2b4e3d075553" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_d91cd157-1ea7-4b9e-b89e-b03b3626b8d6" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_d91cd157-1ea7-4b9e-b89e-b03b3626b8d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_f4194e30-639b-431e-8d9c-dc24010f1d1c" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_f4194e30-639b-431e-8d9c-dc24010f1d1c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_15abd2a5-18ec-44f1-9d82-b7df6637596c" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_15abd2a5-18ec-44f1-9d82-b7df6637596c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_5f81e8df-6754-472c-be8a-42abbad91be3" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_5f81e8df-6754-472c-be8a-42abbad91be3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_60b13c54-9fa9-40e8-b852-6cadb149920c" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_60b13c54-9fa9-40e8-b852-6cadb149920c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_c17ed3d9-c1d6-4c8f-9039-53d501f0ea14" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_c17ed3d9-c1d6-4c8f-9039-53d501f0ea14" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_ca38b7b4-7960-4e95-b13d-da4631f0d242" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_ca38b7b4-7960-4e95-b13d-da4631f0d242" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_05e2aace-998c-4c5d-8311-fc30047748c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ContractWithCustomerLiability_05e2aace-998c-4c5d-8311-fc30047748c5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSold_8d1efc9d-6e2f-4059-b6c0-50e747169f9e" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementSharesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_StockPurchaseAgreementSharesSold_8d1efc9d-6e2f-4059-b6c0-50e747169f9e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_76c8bf3e-6f05-4ef4-b502-d0cdae7b2401" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementSharesSoldPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_76c8bf3e-6f05-4ef4-b502-d0cdae7b2401" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_0bd7fe96-ca50-40ee-a017-049cadec2ffa" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementFairValueOfStockPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_0bd7fe96-ca50-40ee-a017-049cadec2ffa" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_97010072-469c-4108-82ff-c1bd49d49560" xlink:href="lyel-20230930.xsd#lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_97010072-469c-4108-82ff-c1bd49d49560" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_398cb203-a7fa-4fdc-803f-19a9da654e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_398cb203-a7fa-4fdc-803f-19a9da654e66" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e0b2614-308d-42d9-bef5-a162f6b7ef84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e0b2614-308d-42d9-bef5-a162f6b7ef84" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d655e4b0-01ce-450e-a815-b9c9320bdd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_NetIncomeLoss_d655e4b0-01ce-450e-a815-b9c9320bdd0b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_122113e3-161f-4824-9c8f-e7941b27cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EarningsPerShareBasic_122113e3-161f-4824-9c8f-e7941b27cd01" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9825fd2e-66da-497b-b0f8-c30a7ea15b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9825fd2e-66da-497b-b0f8-c30a7ea15b11" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b49f28da-0e5e-4a8a-8cb9-0f715ca8f5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b49f28da-0e5e-4a8a-8cb9-0f715ca8f5d8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7fd050fc-5a6c-4672-8fec-ffa11b10a329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7fd050fc-5a6c-4672-8fec-ffa11b10a329" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_24306f93-e609-45d7-8508-bb51e9953e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_24306f93-e609-45d7-8508-bb51e9953e5c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3a44059d-b9ad-485e-bf0a-8877265a9c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3a44059d-b9ad-485e-bf0a-8877265a9c8e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_dac8d576-3a86-440e-8e36-f1c72f6212f8" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_FredHutchMember_dac8d576-3a86-440e-8e36-f1c72f6212f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_29d4ef0d-2d08-42e7-9585-3436c81a1f30" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_StanfordMember_29d4ef0d-2d08-42e7-9585-3436c81a1f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_cc36cd32-2938-4aed-af95-ee98e3a329a8" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_cc36cd32-2938-4aed-af95-ee98e3a329a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_f5bbe155-8618-4cc0-88f6-86ceb457ee99" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_PACTPharmaIncMember_f5bbe155-8618-4cc0-88f6-86ceb457ee99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ae8c1834-5d26-4cc6-b2de-2a8a9732d558_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ae8c1834-5d26-4cc6-b2de-2a8a9732d558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf9924cc-a14e-43fc-98b7-7e99c6bfa398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf9924cc-a14e-43fc-98b7-7e99c6bfa398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_897a9bb1-58a8-4efd-968b-ac734643773f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf9924cc-a14e-43fc-98b7-7e99c6bfa398" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_897a9bb1-58a8-4efd-968b-ac734643773f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:to="loc_srt_RangeMember_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:to="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7aa10d1e-6f37-4ec2-b9a5-6e2c714e4a02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:to="loc_srt_MinimumMember_7aa10d1e-6f37-4ec2-b9a5-6e2c714e4a02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cebdcccb-0906-48d1-a99a-4fa0efa7e0a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:to="loc_srt_MaximumMember_cebdcccb-0906-48d1-a99a-4fa0efa7e0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68c1f2d0-ddc2-4e6f-a875-1325be56afc7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:to="loc_srt_ProductsAndServicesDomain_68c1f2d0-ddc2-4e6f-a875-1325be56afc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c496ba08-5f8a-4ea4-9d73-94f80688bdd6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:to="loc_srt_ProductsAndServicesDomain_c496ba08-5f8a-4ea4-9d73-94f80688bdd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2a326b41-80ea-4040-9461-0b19aa1f3804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c496ba08-5f8a-4ea4-9d73-94f80688bdd6" xlink:to="loc_us-gaap_LicenseMember_2a326b41-80ea-4040-9461-0b19aa1f3804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ca3ff53-12c8-4af9-9d46-de24d65df277_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:to="loc_us-gaap_ClassOfStockDomain_5ca3ff53-12c8-4af9-9d46-de24d65df277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:to="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember_5f59ce91-ec5f-4bfd-86f6-231fd2c47103" xlink:href="lyel-20230930.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:to="loc_lyel_SeriesAConvertiblePreferredStockMember_5f59ce91-ec5f-4bfd-86f6-231fd2c47103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAAConvertiblePreferredStockMember_b654c87c-966c-4cc8-94e1-1468a1105c02" xlink:href="lyel-20230930.xsd#lyel_SeriesAAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:to="loc_lyel_SeriesAAConvertiblePreferredStockMember_b654c87c-966c-4cc8-94e1-1468a1105c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f1334ba6-c8e2-44db-98f2-177af131bba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f1334ba6-c8e2-44db-98f2-177af131bba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_83c936a1-9196-4add-bac5-747f6497c874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_83c936a1-9196-4add-bac5-747f6497c874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_d68ae497-da6f-43aa-9763-5bf2d3b1628b" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_83c936a1-9196-4add-bac5-747f6497c874" xlink:to="loc_lyel_OtherInvestmentMember_d68ae497-da6f-43aa-9763-5bf2d3b1628b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_afb4ae13-e1e4-48f2-825a-c232a674a0a0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_afb4ae13-e1e4-48f2-825a-c232a674a0a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_81572837-3ec3-4eec-9105-c7e25474acf0" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:to="loc_lyel_PACTPharmaIncMember_81572837-3ec3-4eec-9105-c7e25474acf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_e20b219e-8159-40d3-9f1c-e580defdcdc8" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:to="loc_lyel_OtherInvestmentMember_e20b219e-8159-40d3-9f1c-e580defdcdc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_efd61545-da5b-42bf-9561-44058d90a3c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_efd61545-da5b-42bf-9561-44058d90a3c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d604ab43-e801-4b65-aacb-a831b6478e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d604ab43-e801-4b65-aacb-a831b6478e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_1e6422cd-9b59-4c57-bfe6-1e7fbf3f319f" xlink:href="lyel-20230930.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d604ab43-e801-4b65-aacb-a831b6478e45" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_1e6422cd-9b59-4c57-bfe6-1e7fbf3f319f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_ea235dc6-d0e4-46d0-ae65-8a84f3c1b7f9" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_ea235dc6-d0e4-46d0-ae65-8a84f3c1b7f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a378de27-beb3-4c63-abf1-9472826ea43f" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a378de27-beb3-4c63-abf1-9472826ea43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_dd5bbc49-e82b-4573-b83e-89f712f0c930" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_dd5bbc49-e82b-4573-b83e-89f712f0c930" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d043da4-58ab-45c1-8adb-281257baa9ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d043da4-58ab-45c1-8adb-281257baa9ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a209d0d-ac3b-47a3-ab99-2389d18df667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a209d0d-ac3b-47a3-ab99-2389d18df667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_390d3cc6-e1df-422d-b54e-fb6c0d83a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a209d0d-ac3b-47a3-ab99-2389d18df667" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_390d3cc6-e1df-422d-b54e-fb6c0d83a69f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_d32efafe-68ec-4f38-a2c4-b42e7c035b14_default" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:to="loc_lyel_EquityMultipleDomain_d32efafe-68ec-4f38-a2c4-b42e7c035b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:to="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember_45fba8a1-3e80-46ae-9548-ea83364c38ab" xlink:href="lyel-20230930.xsd#lyel_TenTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_TenTimesMember_45fba8a1-3e80-46ae-9548-ea83364c38ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember_b9389fc7-f4b5-4d80-9d38-7dae53d6d6db" xlink:href="lyel-20230930.xsd#lyel_TwentyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_TwentyTimesMember_b9389fc7-f4b5-4d80-9d38-7dae53d6d6db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember_b5d9c935-3c9b-48c8-9235-6b88f0785ce1" xlink:href="lyel-20230930.xsd#lyel_ThirtyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_ThirtyTimesMember_b5d9c935-3c9b-48c8-9235-6b88f0785ce1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember_fb8d7b7b-1131-4379-a1b6-ed3de7b0def2" xlink:href="lyel-20230930.xsd#lyel_FortyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_FortyTimesMember_fb8d7b7b-1131-4379-a1b6-ed3de7b0def2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember_f3283d82-4c91-4e70-a641-21f9a724ccba" xlink:href="lyel-20230930.xsd#lyel_FiftyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_FiftyTimesMember_f3283d82-4c91-4e70-a641-21f9a724ccba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_672b5807-891d-4857-8927-fdec9e109884_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_672b5807-891d-4857-8927-fdec9e109884_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_d79ed9bf-92fc-4cb7-a521-9f86273f4110" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:to="loc_lyel_FredHutchMember_d79ed9bf-92fc-4cb7-a521-9f86273f4110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_835fb742-d6c5-40f8-854d-157864413b86" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:to="loc_lyel_StanfordMember_835fb742-d6c5-40f8-854d-157864413b86" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b0aa0d4-3b1d-48b2-acec-19cf5d62098a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b0aa0d4-3b1d-48b2-acec-19cf5d62098a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9a9246-7bfd-4250-878c-e3b373f954b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9a9246-7bfd-4250-878c-e3b373f954b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_f4bf6876-f8d9-42b9-881a-32dce4cb4c1e" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_f4bf6876-f8d9-42b9-881a-32dce4cb4c1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_27a592c9-c81f-4880-82e9-acfdaa474ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_27a592c9-c81f-4880-82e9-acfdaa474ac9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4670a1eb-56b4-4d47-9d5d-56baa0c6191f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4670a1eb-56b4-4d47-9d5d-56baa0c6191f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a5f17bc8-6390-484e-9674-b4d4b06e57a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a5f17bc8-6390-484e-9674-b4d4b06e57a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4415ad95-9137-4f71-a8f3-8da085a862a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4415ad95-9137-4f71-a8f3-8da085a862a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_c37ba1fe-cd0a-4b4e-9d5b-0b4af54ec243" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_c37ba1fe-cd0a-4b4e-9d5b-0b4af54ec243" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure_e4ddefd8-95a6-4730-944d-8df5f96738c5" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosure_e4ddefd8-95a6-4730-944d-8df5f96738c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_86e92484-11e0-46e4-a336-82c42235ba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_86e92484-11e0-46e4-a336-82c42235ba8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7bd995a1-65aa-4547-ac84-eb4bdc98a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7bd995a1-65aa-4547-ac84-eb4bdc98a44d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_b6a9fe95-6aeb-4795-b6fa-66dee99b281e" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c4af05cc-390e-42ad-824b-28934d4853ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c4af05cc-390e-42ad-824b-28934d4853ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35687bd8-5854-4be7-9db8-1dcd74f41359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35687bd8-5854-4be7-9db8-1dcd74f41359" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_04fe3339-8813-444f-8c16-eaedc09c4f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35687bd8-5854-4be7-9db8-1dcd74f41359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_04fe3339-8813-444f-8c16-eaedc09c4f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dbf7416-95e7-40b8-bce8-4efd8de50fc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dbf7416-95e7-40b8-bce8-4efd8de50fc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8393d4a5-6826-4005-a625-caf5e9481b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8393d4a5-6826-4005-a625-caf5e9481b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3dd48867-c677-47f9-90e7-6a575ad69425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3dd48867-c677-47f9-90e7-6a575ad69425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d52880ac-5031-440d-a3e2-e0e49daf56db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d52880ac-5031-440d-a3e2-e0e49daf56db" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_07542bf5-fa90-4d32-aea3-979c9aeabaec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_07542bf5-fa90-4d32-aea3-979c9aeabaec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8070dc48-8c17-4169-89ee-93b5fe947774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8070dc48-8c17-4169-89ee-93b5fe947774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_196f8e3f-19fe-47e8-8660-e007049beb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_196f8e3f-19fe-47e8-8660-e007049beb85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:to="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_860b1b42-3174-44ce-9ce0-0b822ea0df44_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:to="loc_srt_RangeMember_860b1b42-3174-44ce-9ce0-0b822ea0df44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d290186e-6e17-4fd4-b3a4-4addfb16978e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:to="loc_srt_RangeMember_d290186e-6e17-4fd4-b3a4-4addfb16978e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c2dae77-550b-45ab-8ed6-6566121a80fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d290186e-6e17-4fd4-b3a4-4addfb16978e" xlink:to="loc_srt_MaximumMember_2c2dae77-550b-45ab-8ed6-6566121a80fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#OtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_b267fd97-5a89-4a4e-be5a-ddc26fa3d815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_OtherInvestments_b267fd97-5a89-4a4e-be5a-ddc26fa3d815" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a0631959-7ae8-4ab2-bae6-0970853f62c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a0631959-7ae8-4ab2-bae6-0970853f62c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_41a26586-9d97-42d8-91f4-e2191b8c08bd" xlink:href="lyel-20230930.xsd#lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_41a26586-9d97-42d8-91f4-e2191b8c08bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_42208f0b-ce9f-471d-8ca2-b9151f63f575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_42208f0b-ce9f-471d-8ca2-b9151f63f575" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8d7a5400-caf8-4865-8bdc-52ec4b9254d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8d7a5400-caf8-4865-8bdc-52ec4b9254d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_e9af5c80-975a-4359-84e5-c065f1c149e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_e9af5c80-975a-4359-84e5-c065f1c149e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ffa9efc-041f-454d-9799-347b1a5a52f9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ffa9efc-041f-454d-9799-347b1a5a52f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_485412b7-b46e-4f8f-960e-dac82065ec59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_485412b7-b46e-4f8f-960e-dac82065ec59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_79442647-f6c2-4cba-bd75-2287b90ec1aa" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_485412b7-b46e-4f8f-960e-dac82065ec59" xlink:to="loc_lyel_OtherInvestmentMember_79442647-f6c2-4cba-bd75-2287b90ec1aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d145db51-f375-497b-9297-44a047f0c5a4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d145db51-f375-497b-9297-44a047f0c5a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_dc1e7b35-491f-41c2-a4d1-20d3e066faa6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_dc1e7b35-491f-41c2-a4d1-20d3e066faa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6e039136-8d1a-4e50-999b-813f497cba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_dc1e7b35-491f-41c2-a4d1-20d3e066faa6" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6e039136-8d1a-4e50-999b-813f497cba9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dade1ea-fe52-451e-b727-114c8cb7217a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dade1ea-fe52-451e-b727-114c8cb7217a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6337b415-6bee-4865-97ec-77c5108cadcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6337b415-6bee-4865-97ec-77c5108cadcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_84240684-9be8-489a-892b-8d9c53643296" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6337b415-6bee-4865-97ec-77c5108cadcc" xlink:to="loc_lyel_PACTPharmaIncMember_84240684-9be8-489a-892b-8d9c53643296" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9779e151-5d9b-45b2-933d-c8cfc9ad9022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9779e151-5d9b-45b2-933d-c8cfc9ad9022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd9a36b7-defc-4981-ab67-e4efa1d2dd68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd9a36b7-defc-4981-ab67-e4efa1d2dd68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c7e28930-f273-4d2c-a61a-136fba1c6482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c7e28930-f273-4d2c-a61a-136fba1c6482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_37ea646d-ccea-4404-ae28-a6a07d24f3ea" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_37ea646d-ccea-4404-ae28-a6a07d24f3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_68447269-6f4a-4103-8a23-f894a4151f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_68447269-6f4a-4103-8a23-f894a4151f65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_450f7e20-3c59-49c2-af35-1277db73fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_450f7e20-3c59-49c2-af35-1277db73fd56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0e75f081-0f1e-415c-a075-0f28c7b986b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0e75f081-0f1e-415c-a075-0f28c7b986b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_71cec368-a6e2-4629-b023-63844d4f4f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_71cec368-a6e2-4629-b023-63844d4f4f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54cdb5f4-0e8a-4207-9810-a158a72bcbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54cdb5f4-0e8a-4207-9810-a158a72bcbe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_21c2f018-c027-4221-9879-cf8d5b6afac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54cdb5f4-0e8a-4207-9810-a158a72bcbe4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_21c2f018-c027-4221-9879-cf8d5b6afac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02acca51-69ef-4644-a470-eddf21a89219_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02acca51-69ef-4644-a470-eddf21a89219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2724fc25-fc69-4560-a116-b227f51c2b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2724fc25-fc69-4560-a116-b227f51c2b92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_612980ff-34ae-4a3c-8f2b-a901c256e3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_612980ff-34ae-4a3c-8f2b-a901c256e3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_17211a51-6e07-4719-bd4a-8f94d7c025fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_17211a51-6e07-4719-bd4a-8f94d7c025fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_d53617f0-7516-468a-a807-0ca231a3214e" xlink:href="lyel-20230930.xsd#lyel_FairValueOfSeriesAConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:to="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_d53617f0-7516-468a-a807-0ca231a3214e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput_b0343644-4a26-451c-89c6-d0c317e15f01" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:to="loc_lyel_SuccessPaymentLiabilityMeasurementInput_b0343644-4a26-451c-89c6-d0c317e15f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_da338082-f2bd-4d98-8686-54c118c2283b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_da338082-f2bd-4d98-8686-54c118c2283b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember_1b458a9c-e98f-4406-8962-aec4e94bb1c2" xlink:href="lyel-20230930.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:to="loc_lyel_FredHutchSuccessPaymentLiabilityMember_1b458a9c-e98f-4406-8962-aec4e94bb1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember_daf96435-6c00-4a45-a9ee-0b6d36d9d678" xlink:href="lyel-20230930.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:to="loc_lyel_StanfordSuccessPaymentLiabilityMember_daf96435-6c00-4a45-a9ee-0b6d36d9d678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e21963d8-5b55-4889-8ecc-0ee745285bbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e21963d8-5b55-4889-8ecc-0ee745285bbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_73b03824-ba65-4c93-9062-31f1684b286d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_73b03824-ba65-4c93-9062-31f1684b286d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2ea6c39f-c472-4a35-b90b-9247f86153c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2ea6c39f-c472-4a35-b90b-9247f86153c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_a1e0ef72-a3bb-4750-bc85-a4d5a7e23f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_a1e0ef72-a3bb-4750-bc85-a4d5a7e23f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ecbec00e-d857-4385-bb36-bd57e1b4ddf0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:to="loc_srt_RangeMember_ecbec00e-d857-4385-bb36-bd57e1b4ddf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:to="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d57a766f-0792-4b5a-95ec-3202d15c462c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:to="loc_srt_MinimumMember_d57a766f-0792-4b5a-95ec-3202d15c462c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85004171-7cc0-49f8-966a-63e26278c243" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:to="loc_srt_MaximumMember_85004171-7cc0-49f8-966a-63e26278c243" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0e290c0f-8059-49bb-9e7c-afec235dc254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0e290c0f-8059-49bb-9e7c-afec235dc254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b402841b-cb83-4854-a28d-7987ebd30060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b402841b-cb83-4854-a28d-7987ebd30060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_44630a7a-d61e-45bb-8052-0792b1490695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_51a7bac1-ea83-4d11-801e-d6062fd99add" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_51a7bac1-ea83-4d11-801e-d6062fd99add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f4d2f371-3b03-43c7-8532-983582b3ed38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f4d2f371-3b03-43c7-8532-983582b3ed38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a3ce8ba8-b0db-41d6-80fb-058bf31041ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a3ce8ba8-b0db-41d6-80fb-058bf31041ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember_e1a75c12-1769-4ebf-b81a-868ff2444934" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3ce8ba8-b0db-41d6-80fb-058bf31041ed" xlink:to="loc_lyel_SuccessPaymentLiabilityMember_e1a75c12-1769-4ebf-b81a-868ff2444934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d99f3f0b-e665-4dac-a850-648fb0330294_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d99f3f0b-e665-4dac-a850-648fb0330294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2d8d68f-8f55-4c6a-ad43-b1fdaae32fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2d8d68f-8f55-4c6a-ad43-b1fdaae32fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0f1fdb4a-b674-4d07-bf8e-919fe071cc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2d8d68f-8f55-4c6a-ad43-b1fdaae32fbb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0f1fdb4a-b674-4d07-bf8e-919fe071cc3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8e62931-b69d-4f59-a938-3fd19ccc662e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8e62931-b69d-4f59-a938-3fd19ccc662e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_8df7d77b-8031-4d88-816a-0e542bfbe10d" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:to="loc_lyel_FredHutchMember_8df7d77b-8031-4d88-816a-0e542bfbe10d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_b6e0052a-db75-4bcd-9950-1bcaebe2bd38" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:to="loc_lyel_StanfordMember_b6e0052a-db75-4bcd-9950-1bcaebe2bd38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5dd19070-1f68-49ae-95e7-6574a2069567_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5dd19070-1f68-49ae-95e7-6574a2069567_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505183cf-eedd-4f9f-8934-db520ed9ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505183cf-eedd-4f9f-8934-db520ed9ac8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cfc46a25-1455-44e6-8db5-e6c001ecf03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505183cf-eedd-4f9f-8934-db520ed9ac8b" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cfc46a25-1455-44e6-8db5-e6c001ecf03c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_184e362b-4ad7-4138-9e9c-925a224a9a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_184e362b-4ad7-4138-9e9c-925a224a9a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_153661af-dc42-4bdb-ba57-f7d70d941694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_153661af-dc42-4bdb-ba57-f7d70d941694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3fce837e-37ec-4444-911e-4c31e73a6970" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3fce837e-37ec-4444-911e-4c31e73a6970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_ae75a40f-d11e-4fec-b38f-7a3ea40b96a1" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3fce837e-37ec-4444-911e-4c31e73a6970" xlink:to="loc_lyel_OtherInvestmentMember_ae75a40f-d11e-4fec-b38f-7a3ea40b96a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:to="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ddef860-c083-41aa-ae33-d0493110df3e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ddef860-c083-41aa-ae33-d0493110df3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87f38717-630f-4165-ac9d-04944206e0a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87f38717-630f-4165-ac9d-04944206e0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_18260ba1-8bb6-4f60-b089-b93098b789dd" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87f38717-630f-4165-ac9d-04944206e0a0" xlink:to="loc_lyel_PACTPharmaIncMember_18260ba1-8bb6-4f60-b089-b93098b789dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8becec59-cea9-4b57-a407-c41d78d9c851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_OperatingLeaseCost_8becec59-cea9-4b57-a407-c41d78d9c851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_2e191eac-8965-4ed4-8cea-711e8e7f744c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_VariableLeaseCost_2e191eac-8965-4ed4-8cea-711e8e7f744c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1eedd511-1fa9-41f5-ae50-b5700c6cfa27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1eedd511-1fa9-41f5-ae50-b5700c6cfa27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c8148602-74d1-4d5e-b3ec-da017e4104e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c8148602-74d1-4d5e-b3ec-da017e4104e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_8b03769f-3d07-42d1-8516-d13e389ec8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_NetRentableArea_8b03769f-3d07-42d1-8516-d13e389ec8b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_e6b82deb-53b7-4a86-8dc1-4a8bacf9dcef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_SubleaseIncome_e6b82deb-53b7-4a86-8dc1-4a8bacf9dcef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_18a2fb13-9452-4348-b6f0-64f3e29ae2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_TenantImprovements_18a2fb13-9452-4348-b6f0-64f3e29ae2fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_530679ee-f91e-4cf5-8c4c-5109e260927d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:to="loc_us-gaap_RelatedPartyDomain_530679ee-f91e-4cf5-8c4c-5109e260927d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e56ce2dc-1bec-4016-a257-5aeb4c22a0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:to="loc_us-gaap_RelatedPartyDomain_e56ce2dc-1bec-4016-a257-5aeb4c22a0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_70aa0994-6b5e-45c1-aa3b-ba879bccee59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e56ce2dc-1bec-4016-a257-5aeb4c22a0e1" xlink:to="loc_us-gaap_RelatedPartyMember_70aa0994-6b5e-45c1-aa3b-ba879bccee59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e288601c-7d00-4da9-a06a-e7445d4cb98e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:to="loc_srt_SegmentGeographicalDomain_e288601c-7d00-4da9-a06a-e7445d4cb98e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_199d696c-8ac8-41ce-9706-dbddcebfa337" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:to="loc_srt_SegmentGeographicalDomain_199d696c-8ac8-41ce-9706-dbddcebfa337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember_135bd64d-4630-46af-b645-d72243d5ecdf" xlink:href="lyel-20230930.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_199d696c-8ac8-41ce-9706-dbddcebfa337" xlink:to="loc_lyel_SouthSanFranciscoCaliforniaMember_135bd64d-4630-46af-b645-d72243d5ecdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51f882ac-5665-407c-98c8-c3cd7789f9a1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51f882ac-5665-407c-98c8-c3cd7789f9a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fe0a865-373f-4769-87c7-49f41286be49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fe0a865-373f-4769-87c7-49f41286be49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_ea5e3f79-7170-4369-a2a6-59afef8cd003" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fe0a865-373f-4769-87c7-49f41286be49" xlink:to="loc_lyel_SonomaMember_ea5e3f79-7170-4369-a2a6-59afef8cd003" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45959906-8752-4e8f-aca0-813e26164502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_45959906-8752-4e8f-aca0-813e26164502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b9b66341-e1a0-44b8-9ce3-e14029f36b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b9b66341-e1a0-44b8-9ce3-e14029f36b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8e0f9128-0d69-4dc5-b620-a26b93603884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8e0f9128-0d69-4dc5-b620-a26b93603884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e36fe927-f164-4a22-9e1c-be1a18cf892c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e36fe927-f164-4a22-9e1c-be1a18cf892c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4faa8df0-1185-4fd4-8465-7fa83f899af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4faa8df0-1185-4fd4-8465-7fa83f899af3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcd751e9-42e5-44ee-9e92-f24110c3919f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bcd751e9-42e5-44ee-9e92-f24110c3919f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6999fe9-a6c5-45d0-bd2f-5f4fa3133adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6999fe9-a6c5-45d0-bd2f-5f4fa3133adf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_2389d8c7-7039-4dea-ab5e-19688a471282" xlink:href="lyel-20230930.xsd#lyel_PercentageOfCommissionFromEachSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_2389d8c7-7039-4dea-ab5e-19688a471282" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2a76860-727e-4c5f-b392-55f87045c034_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2a76860-727e-4c5f-b392-55f87045c034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc513f30-696a-42ae-8c2c-ca08ada8f8d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc513f30-696a-42ae-8c2c-ca08ada8f8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GoldmanSachsAndBofAMember_b4892a6e-93d8-4abe-acdf-6e3360faa2f2" xlink:href="lyel-20230930.xsd#lyel_GoldmanSachsAndBofAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc513f30-696a-42ae-8c2c-ca08ada8f8d3" xlink:to="loc_lyel_GoldmanSachsAndBofAMember_b4892a6e-93d8-4abe-acdf-6e3360faa2f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3043b850-58db-4dd6-a438-c5a7478483dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3043b850-58db-4dd6-a438-c5a7478483dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_66dceb78-2042-4857-ba90-72d242245aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_66dceb78-2042-4857-ba90-72d242245aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember_faaf8c52-e9fc-4ddf-887d-4b61b524554c" xlink:href="lyel-20230930.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_66dceb78-2042-4857-ba90-72d242245aa8" xlink:to="loc_lyel_AtTheMarketOfferingMember_faaf8c52-e9fc-4ddf-887d-4b61b524554c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87244095-286b-4544-8db6-0c782b6eba3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87244095-286b-4544-8db6-0c782b6eba3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_350e777c-da23-4613-a58c-9e790fc538a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_350e777c-da23-4613-a58c-9e790fc538a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityDistributionAgreementMember_6ad608fd-4538-4130-92dd-2b6b3ff8638b" xlink:href="lyel-20230930.xsd#lyel_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_350e777c-da23-4613-a58c-9e790fc538a7" xlink:to="loc_lyel_EquityDistributionAgreementMember_6ad608fd-4538-4130-92dd-2b6b3ff8638b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3ef206a-2c12-4d01-b556-4a47ec4b87c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3ef206a-2c12-4d01-b556-4a47ec4b87c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_63d210d0-2001-47c8-8b34-ae416c00bb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_63d210d0-2001-47c8-8b34-ae416c00bb8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_13ec8c68-3d1b-4fac-a660-7c6e3227aaeb" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_13ec8c68-3d1b-4fac-a660-7c6e3227aaeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b958910-af8c-42b4-ac76-4227373823f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b958910-af8c-42b4-ac76-4227373823f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_d90f4700-2daf-43fb-be6f-913a5ca07cab" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_d90f4700-2daf-43fb-be6f-913a5ca07cab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea911fae-b33e-4e00-83ba-5e2cb72e5e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea911fae-b33e-4e00-83ba-5e2cb72e5e44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9fc37cda-7e7d-44ef-b1be-03fa4e958966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9fc37cda-7e7d-44ef-b1be-03fa4e958966" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_0794b394-cebd-4bca-9bb3-d49e4476df7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_0794b394-cebd-4bca-9bb3-d49e4476df7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aecf1cd-b1da-4d03-a84f-cba28f31776a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aecf1cd-b1da-4d03-a84f-cba28f31776a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_423e7fcb-5a8a-49f1-9e98-8c31141bd9dd" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_423e7fcb-5a8a-49f1-9e98-8c31141bd9dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_9d01df09-9f8f-45d7-b9c1-f4ccd4bb61bf" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_9d01df09-9f8f-45d7-b9c1-f4ccd4bb61bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_94216a6a-29a6-4932-b6c7-b131dc2bfe25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_94216a6a-29a6-4932-b6c7-b131dc2bfe25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c1f3058e-3634-4562-8315-b5886b093436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c1f3058e-3634-4562-8315-b5886b093436" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a11d979d-75df-4c68-8a83-bea6fc387671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a11d979d-75df-4c68-8a83-bea6fc387671" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c19e707-cf3f-4e74-a821-d3d4e62b0a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c19e707-cf3f-4e74-a821-d3d4e62b0a4f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:to="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5d64b302-99dc-4042-b31b-3b514b22d09b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:to="loc_us-gaap_PlanNameDomain_5d64b302-99dc-4042-b31b-3b514b22d09b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:to="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e7b0950c-5129-4d14-90e7-8e888e44fe9a" xlink:href="lyel-20230930.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:to="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e7b0950c-5129-4d14-90e7-8e888e44fe9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_5fda69a0-57ea-484b-a1a9-61d9b85095f7" xlink:href="lyel-20230930.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:to="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_5fda69a0-57ea-484b-a1a9-61d9b85095f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_970e7ab4-263c-4465-b6d3-e36a851b6496" xlink:href="lyel-20230930.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:to="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_970e7ab4-263c-4465-b6d3-e36a851b6496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:to="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08d8ca68-8428-4fbe-a2fe-a526c0b90367_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:to="loc_srt_RangeMember_08d8ca68-8428-4fbe-a2fe-a526c0b90367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ce2785d-72af-451f-a248-a6d813c1e62e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:to="loc_srt_RangeMember_9ce2785d-72af-451f-a248-a6d813c1e62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9ff6430e-3f77-493c-ab7b-dcdde28863e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9ce2785d-72af-451f-a248-a6d813c1e62e" xlink:to="loc_srt_MaximumMember_9ff6430e-3f77-493c-ab7b-dcdde28863e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab94a858-40b9-4743-9e41-25cd5bac7137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8349fb2b-46d0-42c2-a98e-e434ac19b58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab94a858-40b9-4743-9e41-25cd5bac7137" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8349fb2b-46d0-42c2-a98e-e434ac19b58b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab94a858-40b9-4743-9e41-25cd5bac7137" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cffece33-0f06-4dd0-b3f8-e2828aba6594_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cffece33-0f06-4dd0-b3f8-e2828aba6594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d4906d2-6f37-48b8-83ae-6223556271dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d4906d2-6f37-48b8-83ae-6223556271dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a9a4a26b-e321-4f8a-b913-894291d756b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a9a4a26b-e321-4f8a-b913-894291d756b9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationScheduleofRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e21a76a3-9d0d-407c-aefe-ab8a2e14c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e21a76a3-9d0d-407c-aefe-ab8a2e14c8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9bc3ed7-53e3-4894-811d-f361c405f719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9bc3ed7-53e3-4894-811d-f361c405f719" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6577e8e0-507a-406d-8a84-9c5c80e771c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6577e8e0-507a-406d-8a84-9c5c80e771c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20560f75-21ba-40e5-80f6-cf10d04b3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20560f75-21ba-40e5-80f6-cf10d04b3b9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af73f7c4-4e57-4ab7-a0ab-f62d70b91afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8effc4f-b7a5-4fad-879b-e7b35b5abf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8effc4f-b7a5-4fad-879b-e7b35b5abf4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_35b3ce82-25da-4339-ad0c-a7ccbfdced46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_35b3ce82-25da-4339-ad0c-a7ccbfdced46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1742bac9-1aed-44f2-b423-e62279d006ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1742bac9-1aed-44f2-b423-e62279d006ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d2f74131-6e18-486a-8de1-4d49113b6f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d2f74131-6e18-486a-8de1-4d49113b6f6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4bd99472-5846-4745-8816-db2d49f1a3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:to="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4deebaa2-026d-4f03-a512-9d929ead11b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4deebaa2-026d-4f03-a512-9d929ead11b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21859f7f-c2d2-4fa3-a08c-949414bc90b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21859f7f-c2d2-4fa3-a08c-949414bc90b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ea201ddd-e228-4b2c-8ebe-5bdd1017c006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21859f7f-c2d2-4fa3-a08c-949414bc90b4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ea201ddd-e228-4b2c-8ebe-5bdd1017c006" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#RelatedpartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_b0f4eaed-2f73-4f26-b923-a398b8b99e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_NetRentableArea_b0f4eaed-2f73-4f26-b923-a398b8b99e1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_c49db546-340e-4dc6-aaeb-8e9f7423d223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_TenantImprovements_c49db546-340e-4dc6-aaeb-8e9f7423d223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_dc1b4493-7a8b-4996-a0ae-7b029372b95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_dc1b4493-7a8b-4996-a0ae-7b029372b95a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_22df3143-740c-4656-a527-a8c850bee8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_22df3143-740c-4656-a527-a8c850bee8a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d92bc56c-11dd-43fb-8b37-8af98f7fd28b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d92bc56c-11dd-43fb-8b37-8af98f7fd28b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_81ef6d02-2dde-4403-b804-40a94a311ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_ContractWithCustomerLiability_81ef6d02-2dde-4403-b804-40a94a311ee1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_452da315-eba9-40f3-8442-c76bf583e388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_452da315-eba9-40f3-8442-c76bf583e388" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b4879f51-9635-47c1-976e-cc2916fafdc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:to="loc_us-gaap_RelatedPartyDomain_b4879f51-9635-47c1-976e-cc2916fafdc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eda2a564-8a59-49f2-a6f1-90001230344e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:to="loc_us-gaap_RelatedPartyDomain_eda2a564-8a59-49f2-a6f1-90001230344e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f08224f6-3fe6-41a7-aaca-44fec4eed5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eda2a564-8a59-49f2-a6f1-90001230344e" xlink:to="loc_us-gaap_RelatedPartyMember_f08224f6-3fe6-41a7-aaca-44fec4eed5b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_607f6b08-df8e-432d-ba91-83b15e8423eb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:to="loc_srt_RangeMember_607f6b08-df8e-432d-ba91-83b15e8423eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fec6078f-1768-4db9-9110-cc4a800abe8c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:to="loc_srt_RangeMember_fec6078f-1768-4db9-9110-cc4a800abe8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_402abb00-4e2d-40ae-a0a1-187b299eb5cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fec6078f-1768-4db9-9110-cc4a800abe8c" xlink:to="loc_srt_MinimumMember_402abb00-4e2d-40ae-a0a1-187b299eb5cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:to="loc_srt_OwnershipDomain_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_be910160-1bc6-4f2b-83c9-1f7d7171662c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:to="loc_srt_OwnershipDomain_be910160-1bc6-4f2b-83c9-1f7d7171662c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LyellImmunopharmaMember_b0eceaef-9a9f-4420-9832-773fe475b203" xlink:href="lyel-20230930.xsd#lyel_LyellImmunopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_be910160-1bc6-4f2b-83c9-1f7d7171662c" xlink:to="loc_lyel_LyellImmunopharmaMember_b0eceaef-9a9f-4420-9832-773fe475b203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_624b7c37-7311-46e5-bea1-32a4d126da7d_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:to="loc_dei_EntityDomain_624b7c37-7311-46e5-bea1-32a4d126da7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_75d0167e-90be-4341-98d8-7210247b4435" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:to="loc_dei_EntityDomain_75d0167e-90be-4341-98d8-7210247b4435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_33369945-0bbb-4e90-92e1-3b376ec716e6" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_75d0167e-90be-4341-98d8-7210247b4435" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_33369945-0bbb-4e90-92e1-3b376ec716e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ebc563d-7de7-4b94-8990-8b7588a0d944_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4ebc563d-7de7-4b94-8990-8b7588a0d944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_74073152-d399-4b6d-99a7-ef3b6cb06bfd" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:to="loc_lyel_SonomaMember_74073152-d399-4b6d-99a7-ef3b6cb06bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GSKMember_a33d949c-c3d0-4ef8-8732-a4bf7bdf94fa" xlink:href="lyel-20230930.xsd#lyel_GSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:to="loc_lyel_GSKMember_a33d949c-c3d0-4ef8-8732-a4bf7bdf94fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a865485a-d2c0-4442-8cd0-926bb9f59ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a865485a-d2c0-4442-8cd0-926bb9f59ed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_65f0da3b-aeb6-4f16-876f-36ec29435265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:to="loc_us-gaap_SubleaseIncome_65f0da3b-aeb6-4f16-876f-36ec29435265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f7930537-954e-43f7-8d5c-8342127bb4c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:to="loc_us-gaap_RelatedPartyDomain_f7930537-954e-43f7-8d5c-8342127bb4c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_02058b55-0c20-48aa-8858-6bbd106112eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:to="loc_us-gaap_RelatedPartyDomain_02058b55-0c20-48aa-8858-6bbd106112eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2006e164-9448-4c61-b635-0fced5575dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_02058b55-0c20-48aa-8858-6bbd106112eb" xlink:to="loc_us-gaap_RelatedPartyMember_2006e164-9448-4c61-b635-0fced5575dee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:to="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8dacf4fc-705b-4e6e-992c-ff12e935b2c9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8dacf4fc-705b-4e6e-992c-ff12e935b2c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1166274f-aaa7-4bfc-bb84-0fbc58dd00e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1166274f-aaa7-4bfc-bb84-0fbc58dd00e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_7e766496-738f-4ed3-9974-62b020a5ac37" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1166274f-aaa7-4bfc-bb84-0fbc58dd00e1" xlink:to="loc_lyel_SonomaMember_7e766496-738f-4ed3-9974-62b020a5ac37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3eb3d7fb-ca94-4bcc-98e5-8221ac3b4de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3eb3d7fb-ca94-4bcc-98e5-8221ac3b4de7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_808dd410-2428-4f84-b3c3-217b184d9d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_808dd410-2428-4f84-b3c3-217b184d9d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:to="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9ffc856a-f451-42f4-9f49-24b5e9453bdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9ffc856a-f451-42f4-9f49-24b5e9453bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b4e8af84-1483-48bf-a024-61ea29e52e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b4e8af84-1483-48bf-a024-61ea29e52e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_70d4141d-df8f-4a4e-86b1-927ebc288d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b4e8af84-1483-48bf-a024-61ea29e52e6b" xlink:to="loc_us-gaap_SubsequentEventMember_70d4141d-df8f-4a4e-86b1-927ebc288d2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32b3bba9-0344-40a5-a2b0-17bdc98d057b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:to="loc_srt_RangeMember_32b3bba9-0344-40a5-a2b0-17bdc98d057b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:to="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f1c9b88-d5c2-4548-baa2-91165c95507e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:to="loc_srt_MinimumMember_7f1c9b88-d5c2-4548-baa2-91165c95507e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_384ce796-0900-4e23-bd83-1610b037c93b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:to="loc_srt_MaximumMember_384ce796-0900-4e23-bd83-1610b037c93b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_01619391-3173-4303-9b9e-c27b4b867276" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_01619391-3173-4303-9b9e-c27b4b867276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_47edb95d-5ed9-4d18-82a5-bd12d3c113c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_01619391-3173-4303-9b9e-c27b4b867276" xlink:to="loc_srt_ScenarioForecastMember_47edb95d-5ed9-4d18-82a5-bd12d3c113c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>lyel-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8759b030-35fe-4fde-9a5a-bde7fe691e10,g:0b784d50-2a9f-447e-ae11-ec2a3c5830c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_b47d2457-42bd-4b4a-befe-8a1b08cb5844_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum offering period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_707b4b9f-2126-4484-9e28-5e55636c5940_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6711d61b-704a-4f2c-9f7f-d3a6bbd29137_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_96e64e2d-d3d4-4384-94f3-a6454d48375f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6dda3c7f-faec-4f40-b007-4eceda7c3475_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_01cb4bef-fb79-472b-ab2e-80b07fb20dc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_224ed4e3-c1a8-4dc2-ae6f-b42b76335a17_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_c22939ad-2d81-4336-9ec4-baf408c94670_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_295f121f-f95d-455b-a86c-a43376afec0f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf091e82-5096-4b17-9d26-cbd5f41a7db6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_64e527e3-496a-4da8-b24d-d1ed469de96d_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2004ace9-6e06-4c53-aa69-9fb9753b4f99_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6cc28f20-90fe-4486-897e-2183dcb875d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d14f5b1d-4600-4868-9d39-d3a942479708_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK&#160;Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_22ac551b-825c-4e5f-8ea8-683f05df9658_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_30047bc6-502f-423f-b363-46e16d497a4b_terseLabel_en-US" xlink:label="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities</link:label>
    <link:label id="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lyel-20230930.xsd#lyel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_15699f3b-c548-4321-9249-da3a4d1ca9f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost of Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_335a9ff6-d4d8-4225-8968-b34082ca5aba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9309b0d6-0794-4718-9402-69cff23aeed3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_514bf5f0-d430-490c-a5fd-bad2425a4883_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ce008129-a691-472e-8e58-a91e7737cd4e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1c6bf1a5-8b1d-4a76-889a-ffc7aec52335_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c14f3961-fa95-48da-a70f-b075e97997bd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_650d709d-2847-486c-bda1-9fadafc3d835_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_928daae7-bbf3-419a-bd14-3e56cac20a84_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_691ee1e1-22c8-4e0e-ad6c-0abd49029e09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_e7a8592f-2e0a-4611-8844-de0095cbe61a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_329b6dc2-aa5c-4966-8310-9279535a538c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3245a902-a734-423d-a906-46032f3bd115_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ad3d70b9-adf5-4073-a65b-20fcc44e06c5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_096f2d61-80ac-44ac-a959-d02f9290fc19_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_82ef466b-a46f-442e-b922-bcaa6197c5c9_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:to="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_feea4926-0192-4a5f-8e23-e6f274eb6b39_terseLabel_en-US" xlink:label="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement portion of transaction price</link:label>
    <link:label id="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_label_en-US" xlink:label="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program</link:label>
    <link:label id="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_documentation_en-US" xlink:label="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:href="lyel-20230930.xsd#lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:to="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d059598e-d0bf-4692-a63d-cdc157b9c1cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_9cb75a7f-2e4b-408e-86d9-29812516868b_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e52a62f4-8f25-45bb-94c3-7f0d882e194f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_41def83c-3c88-4b07-be63-dc2056e0df22_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_b05575ad-a152-43e5-b45c-5e5edc1332a6_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f85ac32c-c08b-4eba-98fa-cd63e68de5f5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_d505e4b8-611e-4b4f-bb57-c8ce01f4323e_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of success payment agreement</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_35544e9e-4961-4c19-829b-9b62243967f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_809f714e-d63d-48f3-8fd7-f2932f6decc2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized at September&#160;30, 2023 and December&#160;31, 2022; no shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_428d516b-b1cd-47f5-84d0-5a96d42e41b1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_05777aff-0b1c-4fbc-b261-d399b966a0b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Value at Grant Date Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_553cf20c-8235-4325-9733-32ddfb4c43b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_baad365f-ae06-4134-8697-d23ee2e15b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9f11af03-b633-4e09-853e-a3f2b2a8adb7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_5013b321-7fea-4d59-8dec-d9c31fbe4572_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityMultipleDomain_e23b8c04-bd41-4489-a47b-2ef3c10e1f89_terseLabel_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Domain]</link:label>
    <link:label id="lab_lyel_EquityMultipleDomain_label_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Domain]</link:label>
    <link:label id="lab_lyel_EquityMultipleDomain_documentation_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple Domain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityMultipleDomain" xlink:to="lab_lyel_EquityMultipleDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityMultipleAxis_f92b9aa7-ea9a-46bf-ba10-e6f01f89e324_terseLabel_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Axis]</link:label>
    <link:label id="lab_lyel_EquityMultipleAxis_label_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Axis]</link:label>
    <link:label id="lab_lyel_EquityMultipleAxis_documentation_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple Axis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityMultipleAxis" xlink:to="lab_lyel_EquityMultipleAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4aa30877-2ec0-4a54-87ba-2f8ec7446b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_0576619e-602c-4424-8428-1281614835c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ThirtyTimesMember_569c0210-df65-453b-9e33-6dc38520055c_terseLabel_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty Times</link:label>
    <link:label id="lab_lyel_ThirtyTimesMember_label_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty Times [Member]</link:label>
    <link:label id="lab_lyel_ThirtyTimesMember_documentation_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty Times (30x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember" xlink:href="lyel-20230930.xsd#lyel_ThirtyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ThirtyTimesMember" xlink:to="lab_lyel_ThirtyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51dc4d8e-ad33-4069-a14e-8619c291e0b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fdc3b30b-376d-460a-b3cf-5a953ac3279a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSold_3e1ae15c-66e0-4b02-ae4a-92a08fbd25e7_terseLabel_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sold under stock purchase program (in shares)</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSold_label_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSold_documentation_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSold" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementSharesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StockPurchaseAgreementSharesSold" xlink:to="lab_lyel_StockPurchaseAgreementSharesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_502d678a-5e87-42c1-b784-d7a90a0e1f36_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5782b213-bea8-4bf3-8f50-6f3374f42b4b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cd86ea07-de37-404f-8952-8eadcb559f9a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d1cf11e0-49d7-4d1e-b1cf-4b31b2e2724b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_606ae294-5d4b-43b5-a527-7e6c257cc076_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64c8f0c1-ec2c-4879-b368-5af66ec041d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6dc068b5-dc36-4b3c-9c0f-db9f82d57286_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_807e1407-e4d3-41df-8783-699f4d476724_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2895ae6a-d2b6-4e81-8564-defd829d7cb5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_868c20c5-ef01-4630-bd04-183d5b6a1726_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1148bb06-4ff1-430a-9f0b-8ef2a4a7af3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5a2132b-f95e-4a6d-b778-e80325d142bd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a9ac3a8b-9c0d-4d5d-9932-3e451032eb59_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_08ae87b0-c3b3-46a8-9bb2-7e3ae2ab913e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cef23a7b-beb5-4b08-9676-a4e59ca7ff33_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9425264c-c43d-43b2-b179-d4e290a4dbec_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a44c1c8-30db-487d-abe2-c353a6a017a2_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0ee81318-1047-463f-81c9-076982d3d5a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_GoldmanSachsAndBofAMember_1529f1c0-72d4-4e02-bafb-e6fcd26c3cb7_terseLabel_en-US" xlink:label="lab_lyel_GoldmanSachsAndBofAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs and BofA</link:label>
    <link:label id="lab_lyel_GoldmanSachsAndBofAMember_label_en-US" xlink:label="lab_lyel_GoldmanSachsAndBofAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs and BofA [Member]</link:label>
    <link:label id="lab_lyel_GoldmanSachsAndBofAMember_documentation_en-US" xlink:label="lab_lyel_GoldmanSachsAndBofAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs and BofA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GoldmanSachsAndBofAMember" xlink:href="lyel-20230930.xsd#lyel_GoldmanSachsAndBofAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_GoldmanSachsAndBofAMember" xlink:to="lab_lyel_GoldmanSachsAndBofAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81f726bb-9f64-4120-b0f3-ef12c23f8f33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_aa38cffd-1128-44d1-b1d3-c1710c436029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_16d0fa99-edee-4221-9cd3-22737439ab78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_464683be-e86b-411c-9bd6-40573c7558d1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6ccca8a0-97e0-4430-af41-8e5013c8ea46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_053ed872-937a-431f-a86b-147e79a70abd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ccd7f8c1-b495-4a43-97d4-de99a73e2116_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_b3aae0ce-e37f-4fe6-95d7-6f3ee5173fe3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2dd62eb3-0c0e-4f40-b333-b1c00c58d321_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_10a7b1be-3a3a-4c88-aa3e-eee051091d32_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_d687b79c-3216-47f4-8b6b-22f6d37c5cc9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_12dc836b-70f5-4c49-aefc-18b4fea7200b_terseLabel_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="lyel-20230930.xsd#lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ba24ec33-6073-4c7a-8cef-031fa545e563_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_fff97b52-8827-4c10-b3f6-afe6bdad5b17_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e197062c-8926-4355-bd04-e3174cb5f14f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_de7887eb-ea9d-4686-b7cd-b488b8e2f48d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d0ef473b-768b-4305-a6aa-efc87e10da3a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_a010747e-e614-4b37-bf8f-5a9921d38144_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a75c2728-7960-4783-841d-b478f4e67c4c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_7bf7e867-5116-4a67-ab80-760464627688_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in proportion of common shares reserved for future issuance (as a percent)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_995a7c95-8b78-4d8d-8cb9-9f95270a95af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_515f3fa8-a168-4e74-81f5-46fcb681cb1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa8edb94-1592-4d8e-8ae5-39004a27eccf_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_f78093c3-211d-4412-b9d7-22c728e3f854_terseLabel_en-US" xlink:label="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration and License Agreement estimate</link:label>
    <link:label id="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_label_en-US" xlink:label="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Revenue Related To Change In Estimate [Member]</link:label>
    <link:label id="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_documentation_en-US" xlink:label="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Revenue Related To Change In Estimate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:href="lyel-20230930.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:to="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_24574946-88b0-4f10-acca-c0a51dd139f8_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of stock outstanding (as a percent)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_41662f9f-9c02-4eac-8774-03c749b6bbe9_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liability, measurement input (as a percent)</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability, Measurement Input</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:to="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f34e055e-6078-45f1-8770-265ee4137d98_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_1f65883f-2448-4e5c-9f73-75e5334bcf86_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative impairments of strategic investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_69a57bb0-a9f8-4ca4-88ba-25537d0d8547_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_9b96adcf-8fbe-41e2-9f77-944fb092fdcf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6b3d3204-cde6-413e-9b0f-c83155f807c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4f5992e7-2da2-46ad-ad5b-3178333ba579_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_03d45730-fa8f-4c8d-a45f-b2755ea27ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7cd55edd-4ffa-4630-b58f-171b079a85ca_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b3746847-65cf-4e44-85a7-2a1755b19f92_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e744792-80cf-420d-b5d4-3c3ca821422f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7104b13c-d027-40b0-8e92-4264486176d6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_cbef58f6-4151-4f04-b6f3-12a8eed5cbd8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8989533a-8d64-4bd7-83d6-8a3bfd35e473_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_39a8b820-3732-4232-9357-97648705421f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_787ca0c9-4978-4ef0-a752-37cb1aab5cd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6ca86659-2fde-4187-992c-22e2ac4feffd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6be81741-5f25-44c5-8740-a37354d1be7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eeefab9e-baf7-4de5-b16e-1e8da75ca311_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a3fd8d24-4bc7-417e-927f-5188c4b5d283_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_08a2a202-cffe-461a-a692-c778e63ee505_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5e1432af-5f13-47ab-8662-d579f9ead6af_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b89ef0c6-436f-44aa-a675-618b37c0b55d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2d0a7d97-939f-410b-85d9-9d466ff94684_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_d4d48d20-63e3-4d3e-a7c6-2b18c8a18b1c_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate success payment(s) (in millions)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_b0e42113-0bc3-452e-ba44-17c2caf12de3_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiple of initial equity value at issuance</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_45ccf30f-b594-40b8-95e3-f33f5a01bf87_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare_4955b436-6bc6-40f5-92f8-ac8eb0c0cc70_terseLabel_en-US" xlink:label="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per share of stock sold under stock purchase program (in dollars per share)</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare_label_en-US" xlink:label="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Fair Value Of Stock Per Share</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare_documentation_en-US" xlink:label="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Fair Value Of Stock Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementFairValueOfStockPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:to="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c134f9aa-b7c1-49f3-bd57-199ddbe0bb28_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0dd9b00f-27c3-4a12-ba59-5ed0ffc54cea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b66f3026-e75a-4523-b4ec-a5130ada4bc5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9bbcb049-518f-40b4-a034-b69daeed2083_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34449bd1-66d9-41fc-84b6-d7aada376e79_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FortyTimesMember_0dab34b0-e655-449a-bfbf-3f79d6151f67_terseLabel_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Times</link:label>
    <link:label id="lab_lyel_FortyTimesMember_label_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Times [Member]</link:label>
    <link:label id="lab_lyel_FortyTimesMember_documentation_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Times (40x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember" xlink:href="lyel-20230930.xsd#lyel_FortyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FortyTimesMember" xlink:to="lab_lyel_FortyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1fc67fe4-a10a-4975-b436-385aad02be64_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8438f9d-1ff7-45c1-a370-515f57cac9fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d56f4746-f74a-421e-8635-3bdbd34f81e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8febd919-252a-4429-ad09-8c78ba075976_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f37df329-d0d4-4a3d-b2b6-7267e7f64f0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_d1b1e0cc-49e4-468c-b461-4a12e4f0c3c7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_c52493ec-8526-42b4-b1c7-a86c482bbcea_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_55c0df58-6dfa-4151-92eb-b2b178d31d83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ea3cdd30-4ff2-46af-a217-44b2d0ad9e7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities held in a continuous unrealized loss position for greater than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5bfff48f-d1c8-4f85-b2e2-188f3168377e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_934a32d0-3a61-4119-84fa-41a404871550_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1f53f27b-c1ba-4036-b01a-a6224b02b2c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_015575c3-f1cd-403e-9409-0ab71f9ced71_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_74d07ce7-188f-47ed-ad34-324c4eee444b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aaf9ee72-7be4-472f-842c-72233ec62fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd313911-1d0a-44c6-a1d8-85eaea37e51d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_816ada6e-0917-4652-8e3c-d5b326c25835_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration, and Success Payment Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock_ad35b107-e692-4423-bce6-0992d88e7256_terseLabel_en-US" xlink:label="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock (in dollars per share)</link:label>
    <link:label id="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock_label_en-US" xlink:label="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock_documentation_en-US" xlink:label="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Series A convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:href="lyel-20230930.xsd#lyel_FairValueOfSeriesAConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:to="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6f3f01e1-828a-4495-a00b-ad90213ca279_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a5794f7b-3420-40a0-b690-230f48e77c5a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_17e368ae-5cf1-4253-a989-b4b3ae5e7183_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b5a656ab-2f6a-47df-bf3a-7018049dfba6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation cost related to unvested awards not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c1b5178e-b270-43e9-9d5f-2b3e0890eb6b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7c95f14e-efd7-4bf5-a5ac-e9bbf22ed48b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Income Attributable to Sonoma Sublease</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0e0ef26a-05a3-4806-9f9a-b069a25e52a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address Line</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_e124887b-6147-4b88-a85f-01924a0a9d53_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f8fe66c4-ee11-4fd9-a24e-fab08ecce882_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_9f32049f-d578-4b0e-bd89-ab86bb47b762_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entity maximum loss exposure, amount</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:to="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_34fcaf3d-8953-438e-9f51-b47f8e36a1bb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0a4ac53a-be67-450e-aa58-11361e22d86b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a2fc993b-69d3-4e04-9940-ddee48774ad7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e3fdcd1e-918a-47fd-98a6-328a58cdc2a1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_620a308c-52f2-4041-9ce7-faae5aaa3f02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_61d552ba-c887-4fa0-b890-79d57161d018_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_854dea5e-f489-42b4-aae9-5181e3ad8cf6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_6281696e-de3f-4302-bb4a-7e522a8e60db_terseLabel_en-US" xlink:label="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entity, number of entities company is not primary beneficiary</link:label>
    <link:label id="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_label_en-US" xlink:label="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary</link:label>
    <link:label id="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_documentation_en-US" xlink:label="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:href="lyel-20230930.xsd#lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:to="lab_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ac13ce6b-55f7-4462-9163-e6832dd5e03b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3f05c7bc-3ed8-46a3-9539-303104826713_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock at discount (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_215c6107-6216-4762-8c50-911620e69636_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_582face2-7e73-4a22-943a-2699de37efa0_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share common stock price required for payment (in dollars per share)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_2538051d-2c9c-4a8f-a634-c461916df9bc_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be purchased under ESPP (in shares)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_f4546e95-664a-41dd-add8-e336d122e1fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d45d88c2-0a85-4be5-a311-6e65b8ecaa88_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c57b6c81-1dad-47f4-8baf-584e1c3adb78_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8e1bbdf2-d6f7-48fe-9c38-68344035a807_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_1ff34f20-66d9-4803-b3fc-14f92190869e_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trigger period thereafter</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period After Initial Public Offering</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_b68940aa-6762-453c-9817-096b5c3e5d05_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_bc024522-c214-4870-b101-853a2d200580_verboseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_4befa56d-eb38-4742-9d65-d0e1548b310b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_c8295691-b77a-414d-8cd1-c89e707272a4_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_766f3961-0b59-46cb-ba9a-d99d2afbbe3d_terseLabel_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember" xlink:href="lyel-20230930.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SeriesAConvertiblePreferredStockMember" xlink:to="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_65d4590b-de7d-41fe-abec-237acbd158be_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_114fe237-d38c-4ac8-a220-32a37a65890e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_275d0eb5-8503-44ad-b273-a122e8970d35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3990e5af-1eaa-4735-b304-ca9fd5f0d501_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_4934c8fd-ec8e-4263-913e-d20a2631aa12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4abb19a-f422-4f16-8aea-06868ea34a04_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e0a0239a-0506-4e0b-ba8d-c6fa6906d57b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c6a939c9-a96d-438c-a2a5-ae1eef2ddd68_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_35999eb6-0699-4f2a-9c6e-a5239c762680_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b5478b85-b357-4496-be5a-e2b8f90aab0d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_34189269-0e86-45de-b515-9e47df435708_terseLabel_en-US" xlink:label="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_label_en-US" xlink:label="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited [Member]</link:label>
    <link:label id="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_documentation_en-US" xlink:label="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:to="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_19b8fddd-bc88-47b0-b33c-6cb6198caa03_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_90fc08bc-f94c-47b5-ba02-1728328eda53_terseLabel_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember" xlink:href="lyel-20230930.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AtTheMarketOfferingMember" xlink:to="lab_lyel_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_3ce30540-e0e1-40da-917d-a7df0333fb83_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9075bef7-7e41-47fc-a146-f96104b92178_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4cea195-59e3-42aa-8cd9-9bb0274590b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_44b5ed16-f3e5-4d87-ab5f-e77996592306_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cea7ab1d-2848-4e0b-b6a6-663dfd1d0c88_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_29f79dab-7efa-407c-9a88-53bb2a22224a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_67780e46-0d4d-4ad9-9913-cd3388c4bbbc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8594d5e7-96c3-403e-bc4b-9391e862c790_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b605e29c-4b86-48a3-b937-b6db8cf0fbd3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock at fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9d06d92e-c553-465d-8d04-27d896c329e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_50c0d758-28a0-40c2-b3ce-e6654407838c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7f6a1b6-64c5-404a-a6af-bda6694a24e0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_82929db1-8bf7-45bf-b8fd-eb7cc0ad51c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_PACTPharmaIncMember_89c7d355-1498-4d39-af7d-3a03d74eb0cb_terseLabel_en-US" xlink:label="lab_lyel_PACTPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PACT</link:label>
    <link:label id="lab_lyel_PACTPharmaIncMember_label_en-US" xlink:label="lab_lyel_PACTPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PACT Pharma, Inc. [Member]</link:label>
    <link:label id="lab_lyel_PACTPharmaIncMember_documentation_en-US" xlink:label="lab_lyel_PACTPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PACT Pharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_PACTPharmaIncMember" xlink:to="lab_lyel_PACTPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1a4921a7-1bef-4657-899a-551f67f54f4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f25782f3-7ef6-40bb-b746-6f40afe17fa7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2faf2b72-d994-42e0-ac3e-0bb90358eaf9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_c18924ea-086e-4445-bef3-7b5a3fc63db4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3733c374-f081-4f75-8ba8-959bfe6b0d29_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_caa2027c-ee3e-49ee-8ad8-01ac7ad78c62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_bce9174e-790b-4b89-ade8-a8f53989810e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a3afa87c-7286-4971-9d02-ad577ea0bf81_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_677b3652-0a8b-4033-b0cb-cf0d862187a0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56a4939b-a6be-425d-860d-c1f21be20198_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_149ab913-e621-4359-93ec-1303e5f338a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f49d14f1-96c2-4c28-b37f-1b2bd0b265f5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_9c2bce9a-5ff9-4fce-92d7-95eae7dec6cd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_16565961-dc1b-4ec6-a98a-398e9530685e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_63245384-36af-4312-a956-d47671be576b_negatedTerseLabel_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease income</link:label>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_label_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Income (Expense)</link:label>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_documentation_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense" xlink:href="lyel-20230930.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_NonCashLeaseIncomeExpense" xlink:to="lab_lyel_NonCashLeaseIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3a8d148a-3a90-48aa-b026-0e4365517d1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a68a8e72-6eb2-47cd-9abb-da004d5ded3c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9946dc86-43ce-4968-87ff-58b5035fda75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_668c8615-57b4-453e-abcf-0f67a3081a6e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f10c6ecf-5e87-4ccc-a053-bf5663eaf1ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d1116ca7-ad89-4401-b4cc-445e6d04d014_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future issuance of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_ef42de0f-aa0a-4b6b-a3fe-e3e800caa98a_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:href="lyel-20230930.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_408fc9a3-0d0d-4188-b519-5fc22102851e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_60ebaa10-1297-47b5-b8d9-59b34b31d005_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_48239b49-9eb1-4ca1-b367-89873cb5446e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_19b27b01-4a04-49ee-a207-703b87a4f4d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 500,000 shares authorized at September&#160;30, 2023 and December&#160;31, 2022; 251,869 and 249,567 shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_5eecd0a5-296f-4da7-a422-d17f8b2e61c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities held in a continuous unrealized loss position for less than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_ce14fdde-31dd-4013-8bdc-467abb4cd85e_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_37586178-06a0-4679-a15c-ed47e9c1cc45_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3771511-502e-42d5-8a90-6c2ed366b8d0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_6f2cd5fd-705f-4438-8a59-b61dd55a8552_terseLabel_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of success payment liabilities</link:label>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_label_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment Of Success Payment Liabilities</link:label>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_documentation_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment of success payment liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:href="lyel-20230930.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:to="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ac62b0c7-e278-405a-8292-f2a2314a1155_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_88aee3fa-756d-4c4a-b35e-9c5400994fe8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_a0b09be6-d513-48c2-a958-3be35e86ade7_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaborative arrangement for research</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Term</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_32ef3f5f-de1c-4820-925a-6230cad26a99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ed028f87-c6af-4cfe-b31b-8b2c3a058fef_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c8732501-7091-4c21-8bb6-2b935e94203b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_edbdb589-d337-4df1-a49d-e99993c1a7dc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b21283fa-9965-461e-8247-743b3d9e9522_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_42e6e900-1fc8-4f1a-b099-6a1d3f5f900a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_83a1bfe0-96d9-42eb-b7fe-6b140920b6dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1f5cad98-e32f-4bd6-8206-7112435dcef8_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_0443fcd1-3373-4aae-adfc-d565803313b7_terseLabel_en-US" xlink:label="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances</link:label>
    <link:label id="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_label_en-US" xlink:label="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
    <link:label id="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_documentation_en-US" xlink:label="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:href="lyel-20230930.xsd#lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:to="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_067bd7e7-ef38-4d09-83c7-faf5a007a8e9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_e1a0d44b-5649-467a-ae44-1a5ccfc9163d_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8512cdd6-9ffe-4299-b493-12da606a3a01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_7ea84305-9092-472f-882d-4ec29f34f844_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_708fff0b-04e0-42f5-ae57-7a0cc54f46bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_fc27c908-0090-4a5d-b292-fb0d9b722f5f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_78b17e17-9ee7-44f1-a964-4c9b0261f2a6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26d542f5-7f43-4e01-9450-2c53dc5bd3de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8d94f9a6-becb-4ccc-b60d-e61428e6fe87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_cd1ba1a0-3346-41e1-81af-fd608fee3cf5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrant</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_38518aaa-4fae-4851-ae43-9096aa1c4b5f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_GSKMember_5b67a16e-5b70-4112-95da-f237a771890c_terseLabel_en-US" xlink:label="lab_lyel_GSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_lyel_GSKMember_label_en-US" xlink:label="lab_lyel_GSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_lyel_GSKMember_documentation_en-US" xlink:label="lab_lyel_GSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GSKMember" xlink:href="lyel-20230930.xsd#lyel_GSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_GSKMember" xlink:to="lab_lyel_GSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d860b95d-dde7-4558-9be6-08e5049e831a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_f053ce3a-c2a5-4a79-82b7-a7f3d195162f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma other operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2d5b4bab-3b29-49b9-be4d-ecf895c70305_terseLabel_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="lyel-20230930.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosure_6fe8da38-8f13-4836-ad2d-31fbe9674e39_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosure" xlink:to="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_265eac2a-e89a-48d8-8581-00328bd40a34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7df19c77-20a5-4d14-9f62-a205b79cc21d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_68f7a125-8672-4d3f-83e4-a68bab92c798_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2ad646a0-f9a5-4ff9-853d-9270187210d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_5c7b228c-b450-411f-ac58-255bf978f031_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be002bee-af8f-4bdd-94b5-2e20f0563ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c179ee41-9746-404c-9ed3-f25032967b85_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Success Payment Liability Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b492ba73-ac93-4baf-ad57-299781d8f452_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classified as:</link:label>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_label_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Debt Securities, Available-For-Sale [Abstract]</link:label>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:to="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_3a688361-a48a-48c8-8e0f-ff3eda140d33_terseLabel_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_label_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Policy Text Block]</link:label>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_documentation_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:href="lyel-20230930.xsd#lyel_SignificantAccountingPoliciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_bc264d87-340f-4e81-bab3-edb408ad2c25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_25a2f970-f4f5-4272-bef6-44219f2459e9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_4d4e2064-e6ae-482a-8605-95c3f08547f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_edd133ef-d15a-4134-952a-a8a052d40c99_terseLabel_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_label_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_documentation_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember" xlink:href="lyel-20230930.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SouthSanFranciscoCaliforniaMember" xlink:to="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f8e568a9-6f8a-4650-90ec-7c19853a7095_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b3a492eb-cb8e-4255-8da9-35c8863d1e07_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4981a70c-387f-4d31-a35d-96d5bd88ee94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FiftyTimesMember_5940a817-10e9-454c-9a3c-7521f73a6d32_terseLabel_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifty Times</link:label>
    <link:label id="lab_lyel_FiftyTimesMember_label_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifty Times [Member]</link:label>
    <link:label id="lab_lyel_FiftyTimesMember_documentation_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifty Times (50x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember" xlink:href="lyel-20230930.xsd#lyel_FiftyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FiftyTimesMember" xlink:to="lab_lyel_FiftyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cf2f05a6-ea7f-4ab8-87c5-4bfd0a2a4003_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_13d659b7-c99d-452b-a920-e489676025d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ddd44041-e998-410d-9756-2f2153195f06_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ca2ad1c3-92a5-4332-bf16-35979e7ffce0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_85419f67-ee6f-4f8e-aceb-e85c87285a4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LyellImmunopharmaMember_bd163d38-70b7-4aee-a22a-d10be3a72364_terseLabel_en-US" xlink:label="lab_lyel_LyellImmunopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyell Immunopharma</link:label>
    <link:label id="lab_lyel_LyellImmunopharmaMember_label_en-US" xlink:label="lab_lyel_LyellImmunopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyell Immunopharma [Member]</link:label>
    <link:label id="lab_lyel_LyellImmunopharmaMember_documentation_en-US" xlink:label="lab_lyel_LyellImmunopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyell Immunopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LyellImmunopharmaMember" xlink:href="lyel-20230930.xsd#lyel_LyellImmunopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LyellImmunopharmaMember" xlink:to="lab_lyel_LyellImmunopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_4fdb5706-a45a-4d61-9363-1e8d907edc69_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0743cb24-bac0-4083-9f08-f726fde875c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5f86a0ad-72bf-41d2-b929-f3c24b6e8c7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91031e9a-d548-4797-a0a6-9ca4c28c5a85_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2170187d-0132-4782-94b2-02106e03ca50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7b50f799-a9a6-4d03-a8b6-bb9f89b15b09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3c9275a9-9cac-47dc-89a1-ff6ace18dfc0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ceb41f08-889d-457b-831d-43b532d8d918_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_8a7dd111-34a9-4279-b9de-1249e352dd74_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a2b576ad-985d-4943-b745-1911f8cbe8d1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_97e68d04-a60e-4e3d-8505-7576565c349f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_167780d6-937f-4775-8852-47596443ddd0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b1644632-aedf-4c4b-add5-74bfce5ddac3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0375d13c-5244-42c7-9749-08c489557a14_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_d6024313-6eb9-4222-94e5-49fecab5e2d6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_db2cf2c1-9276-4774-90a6-c8de1c5cfae6_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of potential success payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_93ded781-3d86-4a52-9070-a07ba304bb42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Potential Success Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_303bf2bd-2034-45b5-8bbd-26e0029da8a7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_934119d4-b6d1-4441-8b12-983037a5a609_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a8265092-97f0-4f54-a4ae-cd2d2c8ad0eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StanfordMember_50a43238-678c-4d08-b4e4-be9026ace8d6_terseLabel_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford</link:label>
    <link:label id="lab_lyel_StanfordMember_label_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford [Member]</link:label>
    <link:label id="lab_lyel_StanfordMember_documentation_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StanfordMember" xlink:to="lab_lyel_StanfordMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7e31864d-438c-4385-84f4-734ebf99129c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_b976fbba-77cc-48f5-825b-aa12a3bd0550_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trigger period from IPO date</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_bfcd7f81-5ee1-4dd2-930d-373c27019d09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_1826f03f-444d-43fa-ba43-73afa20b0a9b_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:href="lyel-20230930.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0632cb5b-6207-4be9-8e75-908fee40633f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9b693b4b-e566-4ac9-afcf-d39edd0834e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b44492c7-b92f-4a67-960a-23df2a842585_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_56be87ba-8c1b-441e-b9b8-c0238b677b55_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e758c613-5f44-42c5-b5cd-a4b9d38fa9dd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_433d1d68-47e1-4466-bafb-d89a67b07374_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_200c48b3-6111-48f4-a918-fc2a150f4bcc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cc43c3aa-331b-4eef-acfe-c66148b515a7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7d49537b-3dca-4dcd-a61a-607cdde1b9d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense by Classification</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ca1a37f8-d4b8-412b-a797-b5eeec44d817_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization and accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d50b056f-526e-4543-9af1-4f634c583ced_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_331e24ba-a73a-4176-875f-9f7a625e49cb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c7ac0cc0-eb8f-4da6-859f-a4f7c57bf1dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_36d3e9c0-2e6c-424f-97cf-9f3fb8c8316f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e6a744b5-48f3-47f6-bf6a-f4d66db0b199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4d6b7697-7723-4dc6-a17f-3cced74b35e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9f631bff-2e65-4710-85d3-1753a4293b7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0950663a-9295-4891-afa3-dec34067ef8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2740a198-d14e-4646-bc23-b832aa2a5d61_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_7c8635d3-1802-4e7a-a909-0cff6c86d861_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in workforce (as a percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_062868a6-337e-4756-a132-9920e6e12c92_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_03a2813d-9ec3-4d22-90aa-4fd9d7dc09e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SonomaMember_4de0311e-eac3-42ff-9a85-df23dab12208_terseLabel_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma</link:label>
    <link:label id="lab_lyel_SonomaMember_label_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma [Member]</link:label>
    <link:label id="lab_lyel_SonomaMember_documentation_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SonomaMember" xlink:to="lab_lyel_SonomaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_fc2b29e6-3a80-438b-bc37-4627ff6fe44a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of workforce reduction charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ef8a0d10-bd9a-4938-8912-eee267048807_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_682e052d-51e0-4a12-87a4-25c8d60a223f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_39b5a808-1d64-4a8d-8e8e-2d04385ad79e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidations</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_4c9d4544-0e1b-4d2a-9bf2-7e62a419a2b0_terseLabel_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_dc0f2027-beae-4a6a-8b8f-2b529fb817d9_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b61926db-59a1-401b-ab39-6a1718754c5a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_231b971f-3ad7-4ccb-bc90-390fe2598a8d_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Current</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilitiesCurrent" xlink:to="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2206c638-f0b0-46cf-9ce9-8e7f6e53ef11_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e0f0d728-cdc7-4b13-bf4d-3efa29f40967_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_23df282e-55ac-4ed9-b933-0b20a44be7aa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1674e870-7eab-4df8-9f2c-2ebaa365ff30_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityDistributionAgreementMember_624c266f-01cf-44e1-8d99-2443f35551af_terseLabel_en-US" xlink:label="lab_lyel_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_lyel_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_lyel_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_lyel_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_lyel_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityDistributionAgreementMember" xlink:href="lyel-20230930.xsd#lyel_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityDistributionAgreementMember" xlink:to="lab_lyel_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_29ff6b71-aa0c-4bff-9ae9-6e576d98e78e_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment expense (gain)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9b4cae32-3856-450e-8d71-f94b3a0326aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d05c5080-8d36-4d72-b8a7-5f0397514b96_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cc354384-1e44-42f7-a01f-e56b3fbc8fea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_48cfa281-8645-4d5d-bf68-d3f15489534c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FredHutchMember_0701a1c3-951b-45eb-ad6f-6be48e6a82b1_terseLabel_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch</link:label>
    <link:label id="lab_lyel_FredHutchMember_label_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch [Member]</link:label>
    <link:label id="lab_lyel_FredHutchMember_documentation_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FredHutchMember" xlink:to="lab_lyel_FredHutchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_9ace2db5-1514-48ce-872e-1f23a8aaa6c8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_316bb1e7-a3a8-400d-9619-47b8e26f895f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_cfd1c861-4c24-4b29-9e82-2d220838f0c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SeriesAAConvertiblePreferredStockMember_9ea437ba-7adf-48af-9f1e-16936957dfc4_terseLabel_en-US" xlink:label="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series AA Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_SeriesAAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_lyel_SeriesAAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series AA Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAAConvertiblePreferredStockMember" xlink:href="lyel-20230930.xsd#lyel_SeriesAAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SeriesAAConvertiblePreferredStockMember" xlink:to="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_715e376b-eec0-4c70-8f6b-44c984e74a9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited or canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6a3a8707-2739-45cd-a3a7-e49ee40df587_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8835ad18-5201-4843-9f99-00d08ab095b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e140da6d-ef43-4473-86af-72006041e811_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_d459f371-a13d-4e62-8de7-f024556e998c_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on property and equipment disposals, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b532dece-cfd8-4857-9198-ea49b3dd952d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_699dd2a7-8da2-4820-a85c-486703426937_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2449c43b-8d78-4bfc-9289-af0b9358f8bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_c3b1e7cb-19e3-4c79-b407-d73aa07a7504_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4c0ba976-54fd-4262-9890-e8271468527d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c331c086-8c5b-435c-a59b-ed313ea77566_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_PercentageOfCommissionFromEachSaleOfShares_5c0f23aa-b17b-4de3-8283-b4a185c29837_terseLabel_en-US" xlink:label="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission from each sale of shares</link:label>
    <link:label id="lab_lyel_PercentageOfCommissionFromEachSaleOfShares_label_en-US" xlink:label="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Commission From Each Sale Of Shares</link:label>
    <link:label id="lab_lyel_PercentageOfCommissionFromEachSaleOfShares_documentation_en-US" xlink:label="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Commission From Each Sale Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:href="lyel-20230930.xsd#lyel_PercentageOfCommissionFromEachSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:to="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c393ddd8-780e-4af5-9809-e52a4d626504_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c1a836ee-9d1e-454d-8b79-e31b0c8bb58e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_627cb6b2-f8f5-4a5b-9199-843a00aa4ac1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_36e4f75f-cbbc-4a3e-8885-486629e54fb5_terseLabel_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represented by:</link:label>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represented By Cash And Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represented by Cash and Cash Equivalents and Restricted Cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:href="lyel-20230930.xsd#lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b4e191e2-3e26-429f-9964-4459b6672ae4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3e2d7b2e-4825-4e0b-9987-1762dbe537ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ecc17a3e-c78e-4201-b96f-7e6700c93e0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bdf480f2-f07a-420e-b05e-fe54006d66bb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2290536c-c659-4f35-8d87-c636c3954dc3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0b23315c-f9e2-4556-9ba2-0c84a801e001_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_dcfbff86-c7fc-4035-8244-0a27d71d1b5a_totalLabel_en-US" xlink:label="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost</link:label>
    <link:label id="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_OtherInvestmentMember_0cc63125-398d-4a46-88cb-99db182cbbcf_terseLabel_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment</link:label>
    <link:label id="lab_lyel_OtherInvestmentMember_label_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment [Member]</link:label>
    <link:label id="lab_lyel_OtherInvestmentMember_documentation_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_OtherInvestmentMember" xlink:to="lab_lyel_OtherInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_86477cd4-160b-47ed-accb-02dae2c7cb9e_verboseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityMember" xlink:to="lab_lyel_SuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fae5d0dc-3b18-4d9f-ba44-4152e6b39084_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_ec8ca806-d85b-4036-a56d-6ccf9bbf853b_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_7c78bdef-2b64-464d-92e9-c1168f002dc1_totalLabel_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:to="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_db9c95a5-97e6-4641-84b5-902c6fdeb5f8_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on other investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_288582c7-2320-4e5c-bcba-90e484e946aa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bd3ae54a-7ad7-4290-8802-f21053b2198f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_695085e5-f620-4e60-a090-516139193694_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_d7774983-09fc-4498-9d53-ffd909543470_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_1cb1ce62-ff05-41fc-bbe9-01d9b8cc2b13_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentable area</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_15aa4025-28bb-4f85-ab37-7295047f1b4b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_5a56ea63-2ee4-4d48-b631-bed9db50ceb3_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0c1fa9e8-7d6a-4716-a68a-8e57fc623363_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_8a88eff4-06a9-4009-a238-5eb7f57e10ea_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_c6437a64-bb53-4d94-8d40-05f79bef65ec_terseLabel_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_label_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Text Block]</link:label>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_documentation_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentsTextBlock" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_OtherInvestmentsTextBlock" xlink:to="lab_lyel_OtherInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_43557e16-d40e-49e7-b7db-292772bc4bbe_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fdc88d67-2f86-4b58-9128-d898c11d9311_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_670a387b-dbdd-457d-9607-3b4f59dbeed5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_92500cd4-62a2-4d9e-84a8-c807862ca0cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3d4e9cf9-5de7-4bcb-be10-e5d07be76f3d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare_a3c0d9d8-ff1b-49f1-99c8-34e1ea3a1d7e_terseLabel_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share of stock sold under stock purchase program (in dollars per share)</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare_label_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold, Price Per Share</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare_documentation_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementSharesSoldPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:to="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21cb1768-551b-429e-960f-589eb4455a63_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_71336d61-6855-4406-a2f2-9e2036095aa6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_26d3a191-2e47-47f1-aeb6-a31fc815afe8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6a72be06-7dc1-4264-929e-c660ecd43a17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40bdcffb-7c36-4eb3-9dee-9eb7fb9db9fd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_39ec0e6a-35e2-4978-ae53-d7b4c6306acd_terseLabel_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford</link:label>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember" xlink:href="lyel-20230930.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StanfordSuccessPaymentLiabilityMember" xlink:to="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7cfa8ae8-1aae-4b96-8d2d-ed1dc6c6bebb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0bd6122c-1bf3-46ec-b4e4-fea71a701ff8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_fb34c078-5827-40a4-af37-cb42f41fca89_terseLabel_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch</link:label>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:href="lyel-20230930.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:to="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_dbf1ce19-e0e9-4b68-9d85-b6ecbc7728fe_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TenTimesMember_bb7638a1-f380-492d-a1b3-154fc7e09415_terseLabel_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten Times</link:label>
    <link:label id="lab_lyel_TenTimesMember_label_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten Times [Member]</link:label>
    <link:label id="lab_lyel_TenTimesMember_documentation_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten Times (10x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember" xlink:href="lyel-20230930.xsd#lyel_TenTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TenTimesMember" xlink:to="lab_lyel_TenTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0c92663d-d043-4bc7-b326-d0364d0e9a2a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6e541b0-0912-45f9-81ca-c7bb84c60abe_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7541d470-2ecd-45b7-b70d-8e78f820d72e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_39c3d19a-4b96-4969-bc9c-4a1c0ec75f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bb250b12-6db3-4b3f-8f19-233588f94b06_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_40706ca6-9ba1-4a65-afb5-a57f4c9f09c4_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_a4bbefa5-4b23-49d6-80f3-01d574720802_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_c3c6aee1-c179-457e-9ac4-f842617674a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_edd303cd-8e55-4e55-ae2a-ed21dd7d1ee0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_840465e6-b3d7-4300-9147-b29043850d7a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5b66e01a-f540-45f4-8dd4-bf29132e5f46_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_9d05d274-e920-4a30-96a4-84daa9618740_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:href="lyel-20230930.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_32392edb-2b5d-4a99-99a7-9915938b4b21_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_93de6991-b4cf-4667-8b61-64a68d10762c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee purchase of shares, proportion of fair value (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_0632b995-1e35-46eb-ae4e-5e1eda92d211_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwentyTimesMember_901c7792-694c-4ea3-90a7-2736f2da7662_terseLabel_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Times</link:label>
    <link:label id="lab_lyel_TwentyTimesMember_label_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Times [Member]</link:label>
    <link:label id="lab_lyel_TwentyTimesMember_documentation_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Times (20x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember" xlink:href="lyel-20230930.xsd#lyel_TwentyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwentyTimesMember" xlink:to="lab_lyel_TwentyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_9f350d91-8cdd-4c27-bc77-4d3f3f5081fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cd3944cb-38bf-4d1b-9ebf-754c3c61ead4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3ec87345-733c-4fb6-8965-65c3f3bb671b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a81e82fe-f571-4f84-89d0-7319ca0fb017_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_8b8adaed-7dcc-4902-82f5-8300acabc039_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_341b70ab-0849-4c17-93e4-9d033eb36485_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_602363be-acd7-49ba-a0ff-61b075ecd4b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_da3cb576-bb0e-4629-86ea-1cf6b4263588_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b157cad1-298e-43a3-9ac7-6312bc095e5e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_87e6181b-3ce2-4823-bb22-d5260fa47a47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ea1fd058-a705-4074-b962-1e944e4eafad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_444ae58b-850c-4f54-a9f1-7d6ffca1ee27_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate research payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7a67fc85-6dfe-4bcf-9611-8badf4810687_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>lyel-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8759b030-35fe-4fde-9a5a-bde7fe691e10,g:0b784d50-2a9f-447e-ae11-ec2a3c5830c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyell.com/role/Cover" xlink:type="simple" xlink:href="lyel-20230930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6ebefad7-4856-4b56-8f09-8dc92d8fe4a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_DocumentType_6ebefad7-4856-4b56-8f09-8dc92d8fe4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7b27a5b2-c7d9-49fc-80a7-7ac78953408c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_DocumentQuarterlyReport_7b27a5b2-c7d9-49fc-80a7-7ac78953408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_90f73e19-97bb-42ea-8cb7-05e29699a379" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_DocumentPeriodEndDate_90f73e19-97bb-42ea-8cb7-05e29699a379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0131b1b2-f9d9-4dbf-923d-bd7e48dc4986" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_DocumentTransitionReport_0131b1b2-f9d9-4dbf-923d-bd7e48dc4986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b2123498-c280-4358-8395-29932c517595" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityFileNumber_b2123498-c280-4358-8395-29932c517595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_45baeaa9-fd90-48d7-9bca-cf511ac25668" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityRegistrantName_45baeaa9-fd90-48d7-9bca-cf511ac25668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d820b710-f7e9-45d4-b7a7-4bc01b5d015a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d820b710-f7e9-45d4-b7a7-4bc01b5d015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6fe65683-6815-4ca4-95db-0e63b685c1e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityTaxIdentificationNumber_6fe65683-6815-4ca4-95db-0e63b685c1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9314e9ac-f3b5-4df5-a6a2-b516dd8791a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityAddressAddressLine1_9314e9ac-f3b5-4df5-a6a2-b516dd8791a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fcc59c5b-0ea4-4018-96ef-f5ab543c01c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityAddressCityOrTown_fcc59c5b-0ea4-4018-96ef-f5ab543c01c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f4c440c4-9bfc-4aba-b291-bba898d5afad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityAddressStateOrProvince_f4c440c4-9bfc-4aba-b291-bba898d5afad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6d58a519-ccbd-41cb-b814-6400182f3582" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityAddressPostalZipCode_6d58a519-ccbd-41cb-b814-6400182f3582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b2299234-8abe-4a4b-b418-e61b7e5316e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_CityAreaCode_b2299234-8abe-4a4b-b418-e61b7e5316e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6b6f855f-c1be-453f-a32d-9c7e12bedd8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_LocalPhoneNumber_6b6f855f-c1be-453f-a32d-9c7e12bedd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_40e3e1a2-3678-4d0c-8ab9-4e37ffe738cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_Security12bTitle_40e3e1a2-3678-4d0c-8ab9-4e37ffe738cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e00ecbe6-c8bc-4c8b-a769-4c5e0ba88dae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_TradingSymbol_e00ecbe6-c8bc-4c8b-a769-4c5e0ba88dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b5a693bd-9096-4efc-8f13-ed771dadbadb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_SecurityExchangeName_b5a693bd-9096-4efc-8f13-ed771dadbadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8cce2943-229d-486c-89f2-8f8eb3095503" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityCurrentReportingStatus_8cce2943-229d-486c-89f2-8f8eb3095503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_faa7f5d7-bf6c-44a9-b160-221f010f3d6f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityInteractiveDataCurrent_faa7f5d7-bf6c-44a9-b160-221f010f3d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_30c5c389-1f0d-44dc-8bfd-b0101f3480b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityFilerCategory_30c5c389-1f0d-44dc-8bfd-b0101f3480b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_38fdc174-7ce1-4df3-a5d3-24ef222f418a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntitySmallBusiness_38fdc174-7ce1-4df3-a5d3-24ef222f418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fb310977-1071-4d5f-8b9b-d10c540adcff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityEmergingGrowthCompany_fb310977-1071-4d5f-8b9b-d10c540adcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_94d0f964-263c-4aa7-8976-f24fea598368" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityShellCompany_94d0f964-263c-4aa7-8976-f24fea598368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_68d5b7d3-30ce-419c-a9f0-a20587c38772" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_68d5b7d3-30ce-419c-a9f0-a20587c38772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_56db7e8b-5717-41c7-9e51-c60e92232ff1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_EntityCentralIndexKey_56db7e8b-5717-41c7-9e51-c60e92232ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1a4e8bca-9929-44ee-aba7-b7c445f23e69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_CurrentFiscalYearEndDate_1a4e8bca-9929-44ee-aba7-b7c445f23e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6b813bbd-c261-4584-b92d-bea54f502e05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_DocumentFiscalYearFocus_6b813bbd-c261-4584-b92d-bea54f502e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fceeb9db-682e-49a9-a666-b6365334d3b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fceeb9db-682e-49a9-a666-b6365334d3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_128ba252-fce8-4c97-9560-9aa9bb15f92c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ae148cff-af50-4615-b239-81287cd16c33" xlink:to="loc_dei_AmendmentFlag_128ba252-fce8-4c97-9560-9aa9bb15f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6a0ad432-9b34-4230-bf88-5944b91b2a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6a0ad432-9b34-4230-bf88-5944b91b2a1f" xlink:to="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ac4d551c-67f1-40d1-b410-a629fc25e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ac4d551c-67f1-40d1-b410-a629fc25e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_412e9e1b-d208-4d3c-98f8-61a6ed0a6f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ac4d551c-67f1-40d1-b410-a629fc25e6fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_412e9e1b-d208-4d3c-98f8-61a6ed0a6f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_0a9c5c5b-3a7b-46f8-bb76-0d36f8532123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ac4d551c-67f1-40d1-b410-a629fc25e6fc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_0a9c5c5b-3a7b-46f8-bb76-0d36f8532123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0643b0d4-ec09-4b55-985d-361c991c252b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ac4d551c-67f1-40d1-b410-a629fc25e6fc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0643b0d4-ec09-4b55-985d-361c991c252b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d27b35ac-7a4c-4136-9f46-be90ae02eff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ac4d551c-67f1-40d1-b410-a629fc25e6fc" xlink:to="loc_us-gaap_AssetsCurrent_d27b35ac-7a4c-4136-9f46-be90ae02eff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2498cdf0-f809-4b60-b49e-8ca697e2e474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2498cdf0-f809-4b60-b49e-8ca697e2e474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_e0a2dc58-8529-424a-a720-1020e2baca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_e0a2dc58-8529-424a-a720-1020e2baca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_d4d4f38e-34a8-4b73-9128-cd0692e0ff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_OtherInvestments_d4d4f38e-34a8-4b73-9128-cd0692e0ff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff254ef4-6a90-47e7-8b2c-0a08f62e812e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff254ef4-6a90-47e7-8b2c-0a08f62e812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2988be2c-1e07-4265-8201-b3a3b449f987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2988be2c-1e07-4265-8201-b3a3b449f987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f1c2f42f-cdff-4c34-8ca9-28240d011563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f1c2f42f-cdff-4c34-8ca9-28240d011563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_80e5e987-0878-496f-8bf3-6d413cc9b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78d619cb-0021-4e00-97c9-2c7273334c59" xlink:to="loc_us-gaap_Assets_80e5e987-0878-496f-8bf3-6d413cc9b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6a0ad432-9b34-4230-bf88-5944b91b2a1f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0555e67e-1a3e-4548-b035-49e385337eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0555e67e-1a3e-4548-b035-49e385337eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cebbe401-05da-472b-80c0-4730f8ec42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0555e67e-1a3e-4548-b035-49e385337eb2" xlink:to="loc_us-gaap_AccountsPayableCurrent_cebbe401-05da-472b-80c0-4730f8ec42ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_243df100-b07d-4bc8-9746-5dafc5882c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0555e67e-1a3e-4548-b035-49e385337eb2" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_243df100-b07d-4bc8-9746-5dafc5882c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent_a946f807-fd23-44de-8cdf-2dc438bc46a1" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0555e67e-1a3e-4548-b035-49e385337eb2" xlink:to="loc_lyel_SuccessPaymentLiabilitiesCurrent_a946f807-fd23-44de-8cdf-2dc438bc46a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_69e85ecd-026c-414d-aa17-59a7e37e92f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0555e67e-1a3e-4548-b035-49e385337eb2" xlink:to="loc_us-gaap_LiabilitiesCurrent_69e85ecd-026c-414d-aa17-59a7e37e92f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_229348e6-df69-4c56-b3c6-348a2a95d246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_229348e6-df69-4c56-b3c6-348a2a95d246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3f6504c6-e2bf-4ac9-bfb1-26248b8ce21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3f6504c6-e2bf-4ac9-bfb1-26248b8ce21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_11fe063c-62dc-47ab-9cd2-53979367d181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_Liabilities_11fe063c-62dc-47ab-9cd2-53979367d181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2abf9c48-80a9-4c29-b862-496ec3b06ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2abf9c48-80a9-4c29-b862-496ec3b06ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7a303bf8-9406-4a33-8fca-9bf58fd039fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:to="loc_us-gaap_PreferredStockValue_7a303bf8-9406-4a33-8fca-9bf58fd039fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_10806c0b-6d2b-4698-b57f-0f64478ffac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:to="loc_us-gaap_CommonStockValue_10806c0b-6d2b-4698-b57f-0f64478ffac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9c68441f-e4ce-42e0-88be-3948b1d10328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9c68441f-e4ce-42e0-88be-3948b1d10328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_188d51db-b7b5-4a4f-9e2f-7fb040a5e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_188d51db-b7b5-4a4f-9e2f-7fb040a5e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_970dfc94-62f1-4331-a1c3-1398d3bc52da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_970dfc94-62f1-4331-a1c3-1398d3bc52da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51307a58-2877-46ed-a204-de01d6bcd018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e0cfde92-0d60-40b6-b42b-b067a5522ac9" xlink:to="loc_us-gaap_StockholdersEquity_51307a58-2877-46ed-a204-de01d6bcd018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c31b9aa0-c25c-4016-a6de-c0a7c3f3f6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9d9a890-f77d-4366-bbda-613e067f98c4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c31b9aa0-c25c-4016-a6de-c0a7c3f3f6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_76cffb45-5007-4c93-ab18-e698b5f02522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_76cffb45-5007-4c93-ab18-e698b5f02522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b177594b-fd10-4bfd-9c78-f89a48a104bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b177594b-fd10-4bfd-9c78-f89a48a104bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bf652366-4104-4f1b-8ec2-93b61a50d635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bf652366-4104-4f1b-8ec2-93b61a50d635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6ee7c7b5-7b34-43f8-9ad0-30bb35166a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6ee7c7b5-7b34-43f8-9ad0-30bb35166a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6df1a402-9dc3-4b58-8fdb-b6a1656293bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6df1a402-9dc3-4b58-8fdb-b6a1656293bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_93dd0ded-afe8-4870-b66b-91828e36ce99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_93dd0ded-afe8-4870-b66b-91828e36ce99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c5426a8e-d547-475d-855a-9d69565c7e02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_CommonStockSharesIssued_c5426a8e-d547-475d-855a-9d69565c7e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4af042c9-45a0-4c62-8eb2-a0a3dacad73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c656a4e7-c682-484f-aa5b-08f42c971b1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4af042c9-45a0-4c62-8eb2-a0a3dacad73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0282fd4b-0d04-400e-93ac-baf7eba01c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_Revenues_0282fd4b-0d04-400e-93ac-baf7eba01c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_21c32290-c50a-4cd1-acb8-c7aaecc4cc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_21c32290-c50a-4cd1-acb8-c7aaecc4cc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1ffee136-daa2-4a6d-9f66-86376ea77918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21c32290-c50a-4cd1-acb8-c7aaecc4cc53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1ffee136-daa2-4a6d-9f66-86376ea77918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_344f6c4f-e1d4-4782-bdf7-f4550ae44770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21c32290-c50a-4cd1-acb8-c7aaecc4cc53" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_344f6c4f-e1d4-4782-bdf7-f4550ae44770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9150adfc-f7f5-4576-8f96-17ce3692d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21c32290-c50a-4cd1-acb8-c7aaecc4cc53" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9150adfc-f7f5-4576-8f96-17ce3692d3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8c3dd26b-521b-476a-ad11-ffe6c4c8c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21c32290-c50a-4cd1-acb8-c7aaecc4cc53" xlink:to="loc_us-gaap_OperatingExpenses_8c3dd26b-521b-476a-ad11-ffe6c4c8c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_65712504-68fb-48a4-9b7a-4024c1bf5e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_OperatingIncomeLoss_65712504-68fb-48a4-9b7a-4024c1bf5e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c798bb5a-b76b-4b99-b5c9-825ade028e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c798bb5a-b76b-4b99-b5c9-825ade028e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cd6e65eb-d8cb-4116-aea3-f2b8b0a65759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cd6e65eb-d8cb-4116-aea3-f2b8b0a65759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_c59f36ed-50ce-4a44-9c6a-70498b39b452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_c59f36ed-50ce-4a44-9c6a-70498b39b452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ec598627-fa29-4d6c-999d-b527441ae4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ec598627-fa29-4d6c-999d-b527441ae4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cee97edc-a634-46b3-a0c4-53bfe4d57828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_NetIncomeLoss_cee97edc-a634-46b3-a0c4-53bfe4d57828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10737982-f307-4ce9-8e54-e7e2983dab08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10737982-f307-4ce9-8e54-e7e2983dab08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_45c3aa3c-17c8-4016-b759-15e9f7b7d96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10737982-f307-4ce9-8e54-e7e2983dab08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_45c3aa3c-17c8-4016-b759-15e9f7b7d96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_23657006-1e6e-43d0-a5d4-cc9a9cf10196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10737982-f307-4ce9-8e54-e7e2983dab08" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_23657006-1e6e-43d0-a5d4-cc9a9cf10196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2b120ade-b597-41da-a511-a9d27c165e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_EarningsPerShareBasic_2b120ade-b597-41da-a511-a9d27c165e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_14be93d9-2e52-48f5-8384-90b31768eec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_14be93d9-2e52-48f5-8384-90b31768eec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34fb9013-01d6-462f-99e5-b5c403d44059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34fb9013-01d6-462f-99e5-b5c403d44059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b5b43da-e9d0-4180-858c-a0d28f79b1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d642c5cb-cf3a-48d3-893b-8af7cb0d4d7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b5b43da-e9d0-4180-858c-a0d28f79b1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ce24c685-2ebc-4101-b3e7-a9b032db0fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ce24c685-2ebc-4101-b3e7-a9b032db0fcd" xlink:to="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f738415d-670d-43bc-a174-13b8b8ca7905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f1e16dce-36e9-474d-8bd7-550bb60c7abf" xlink:to="loc_us-gaap_RelatedPartyDomain_f738415d-670d-43bc-a174-13b8b8ca7905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_bb89a406-80c0-49f5-8d7b-22151555d7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f738415d-670d-43bc-a174-13b8b8ca7905" xlink:to="loc_us-gaap_RelatedPartyMember_bb89a406-80c0-49f5-8d7b-22151555d7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e586b3a2-1a78-416c-8172-79ef09a7043f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1d9a408f-5f60-497d-8d20-11e7fa280508" xlink:to="loc_us-gaap_StatementLineItems_e586b3a2-1a78-416c-8172-79ef09a7043f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6581ee05-07eb-476c-9861-1f94a7902959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e586b3a2-1a78-416c-8172-79ef09a7043f" xlink:to="loc_us-gaap_Revenues_6581ee05-07eb-476c-9861-1f94a7902959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9440e707-9cb9-43d1-bf56-e9a9b9885d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9440e707-9cb9-43d1-bf56-e9a9b9885d9d" xlink:to="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5de7edb0-662d-4720-9ef9-126307dd0671" xlink:to="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d67725f9-76cb-4f2b-ac1e-72f50076751f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_CommonStockMember_d67725f9-76cb-4f2b-ac1e-72f50076751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9201fbca-b7f0-4732-bb96-b588c4dc7563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9201fbca-b7f0-4732-bb96-b588c4dc7563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d66e6a57-961b-4157-a1bc-ab885441cab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d66e6a57-961b-4157-a1bc-ab885441cab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1e09c11e-fade-46b7-a021-3cc1a406311b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_69645dae-1979-4491-b5e9-86ea432eeee1" xlink:to="loc_us-gaap_RetainedEarningsMember_1e09c11e-fade-46b7-a021-3cc1a406311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_173b00d4-2157-49f7-b571-6b9cc4a98a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67fa3ebc-98e9-4974-a9ff-92ed337fe6b0" xlink:to="loc_us-gaap_StatementLineItems_173b00d4-2157-49f7-b571-6b9cc4a98a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_173b00d4-2157-49f7-b571-6b9cc4a98a8f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f78d84e-0598-4541-9e34-30bc346ce858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f78d84e-0598-4541-9e34-30bc346ce858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2938030e-dcf5-459f-94a5-e538bdf4a241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockholdersEquity_2938030e-dcf5-459f-94a5-e538bdf4a241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc703fd6-546a-483d-8cb3-03a4319738b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc703fd6-546a-483d-8cb3-03a4319738b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ab75586-77d4-40ce-9c2a-372d3ca162ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ab75586-77d4-40ce-9c2a-372d3ca162ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_468d31e8-ce3d-4655-af00-a7d9e87115d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_468d31e8-ce3d-4655-af00-a7d9e87115d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bb354b41-66ec-4528-9914-fe77fea3c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bb354b41-66ec-4528-9914-fe77fea3c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_863a0714-176a-4813-933e-e711271544de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_863a0714-176a-4813-933e-e711271544de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4cd08bac-7ee8-43a7-a8aa-4fd44d8c25cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_4cd08bac-7ee8-43a7-a8aa-4fd44d8c25cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f049b27-1db4-4227-b2bb-2a43e7e59606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f049b27-1db4-4227-b2bb-2a43e7e59606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1e7494b3-4acb-4357-84d4-a20ae19f36be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1e7494b3-4acb-4357-84d4-a20ae19f36be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8af84410-eddd-4ca5-8cdb-b6473f379c15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8af84410-eddd-4ca5-8cdb-b6473f379c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8799029-4bf1-4761-ba23-0db9abd69bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_NetIncomeLoss_a8799029-4bf1-4761-ba23-0db9abd69bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8ec5012-f8ed-4010-8b22-bf55b3b62acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e8ec5012-f8ed-4010-8b22-bf55b3b62acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_92c2d294-4625-449a-b7fa-8f97ddf339b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_16565057-0b35-428a-8613-8f369f10e0ca" xlink:to="loc_us-gaap_StockholdersEquity_92c2d294-4625-449a-b7fa-8f97ddf339b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lyel-20230930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_141eedc8-f7bd-4ffd-b48a-49af223e9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_141eedc8-f7bd-4ffd-b48a-49af223e9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e96b8e8-0a25-401a-bb42-7188e6392d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_141eedc8-f7bd-4ffd-b48a-49af223e9e17" xlink:to="loc_us-gaap_NetIncomeLoss_4e96b8e8-0a25-401a-bb42-7188e6392d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_141eedc8-f7bd-4ffd-b48a-49af223e9e17" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c080d26b-3c45-4962-94e0-7fc115d7a922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_ShareBasedCompensation_c080d26b-3c45-4962-94e0-7fc115d7a922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fc081a59-b4e4-4ce7-8d55-6ce283de9572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fc081a59-b4e4-4ce7-8d55-6ce283de9572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_923709f2-7128-42ec-b2e8-c5ca18db14e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_923709f2-7128-42ec-b2e8-c5ca18db14e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_eb08c051-b038-4741-95ff-790dc606f093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_eb08c051-b038-4741-95ff-790dc606f093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_4baf9580-871f-4b70-8bc9-2d3f66658a1a" xlink:href="lyel-20230930.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_4baf9580-871f-4b70-8bc9-2d3f66658a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense_8e3d7dd8-b3e2-4a75-b61c-0e435f6c5af4" xlink:href="lyel-20230930.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_lyel_NonCashLeaseIncomeExpense_8e3d7dd8-b3e2-4a75-b61c-0e435f6c5af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_834d6d8c-0925-4a34-b488-deb3402d2a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_834d6d8c-0925-4a34-b488-deb3402d2a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_e9c2b3a2-746d-4342-8c78-c69088db087a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_e9c2b3a2-746d-4342-8c78-c69088db087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_46af3a6b-5012-4420-8a37-6ad4067dbad3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d113a7a6-ca69-4b22-b81b-45bf1dfa26d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d113a7a6-ca69-4b22-b81b-45bf1dfa26d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6e5bca10-5cf6-49ad-83e3-a3fe5da3af61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6e5bca10-5cf6-49ad-83e3-a3fe5da3af61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_119a1b2f-74cb-4c9b-8a47-6b3e42867567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_119a1b2f-74cb-4c9b-8a47-6b3e42867567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5f32f42a-d101-49c9-b01e-0874da6b87d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5f32f42a-d101-49c9-b01e-0874da6b87d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a5db82c0-a005-4147-bec4-0a0efec13e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a5db82c0-a005-4147-bec4-0a0efec13e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_651ff01a-c958-4430-8c23-19040b962d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b582aee5-16b2-4d65-aa97-5c5b963dc023" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_651ff01a-c958-4430-8c23-19040b962d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8465515-6790-498d-9101-f7cceb8b4324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_141eedc8-f7bd-4ffd-b48a-49af223e9e17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8465515-6790-498d-9101-f7cceb8b4324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da5f7040-1ecb-4d7a-b919-cf06537cad81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da5f7040-1ecb-4d7a-b919-cf06537cad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_758c5eea-a9c4-4d93-bece-c8230f99bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da5f7040-1ecb-4d7a-b919-cf06537cad81" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_758c5eea-a9c4-4d93-bece-c8230f99bfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8722ac7c-bdf2-4a3a-b4b8-8dad6676f171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da5f7040-1ecb-4d7a-b919-cf06537cad81" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8722ac7c-bdf2-4a3a-b4b8-8dad6676f171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_41431004-d062-4607-8dc7-371cc053d1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da5f7040-1ecb-4d7a-b919-cf06537cad81" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_41431004-d062-4607-8dc7-371cc053d1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd65bb7a-0dd2-4460-9b90-21aa48c29577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da5f7040-1ecb-4d7a-b919-cf06537cad81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd65bb7a-0dd2-4460-9b90-21aa48c29577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51f4556d-c109-4d1d-a52b-f49425cf0e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51f4556d-c109-4d1d-a52b-f49425cf0e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_10a2d171-b0db-4738-a594-9b45d3a768ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51f4556d-c109-4d1d-a52b-f49425cf0e94" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_10a2d171-b0db-4738-a594-9b45d3a768ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_78e35837-009e-48ef-b849-9941b3d7be8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51f4556d-c109-4d1d-a52b-f49425cf0e94" xlink:to="loc_us-gaap_ProceedsFromStockPlans_78e35837-009e-48ef-b849-9941b3d7be8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_778f5cb5-e852-49c9-8144-9930a91f7355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51f4556d-c109-4d1d-a52b-f49425cf0e94" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_778f5cb5-e852-49c9-8144-9930a91f7355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_193aad06-8251-4c46-8da1-841b07a51532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_51f4556d-c109-4d1d-a52b-f49425cf0e94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_193aad06-8251-4c46-8da1-841b07a51532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_28062898-13a2-4399-a859-71c23d1ac6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_28062898-13a2-4399-a859-71c23d1ac6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e351ae48-51ec-4b7b-94a4-97dce539debf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e351ae48-51ec-4b7b-94a4-97dce539debf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8052ef7a-a8c8-4c58-84ab-ce6cc0ee5117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8052ef7a-a8c8-4c58-84ab-ce6cc0ee5117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_088c37b3-a4f7-4e13-9c18-9bc057ea9fc1" xlink:href="lyel-20230930.xsd#lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_088c37b3-a4f7-4e13-9c18-9bc057ea9fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97a7c6e1-af06-446e-8a98-b48259952532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_088c37b3-a4f7-4e13-9c18-9bc057ea9fc1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97a7c6e1-af06-446e-8a98-b48259952532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d6a57c08-b523-461d-a4af-0e60985ba8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_088c37b3-a4f7-4e13-9c18-9bc057ea9fc1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d6a57c08-b523-461d-a4af-0e60985ba8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d7464d4-a7e2-494d-93f3-fb4145a3a8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_088c37b3-a4f7-4e13-9c18-9bc057ea9fc1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d7464d4-a7e2-494d-93f3-fb4145a3a8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbfb61f8-271e-42d4-bad2-1645d13b3fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33ea3ca3-e75a-4302-bc75-d276f2281098" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbfb61f8-271e-42d4-bad2-1645d13b3fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_dd5ba4d7-daf6-4e0e-9212-d2fe84f06f53" xlink:href="lyel-20230930.xsd#lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbfb61f8-271e-42d4-bad2-1645d13b3fd6" xlink:to="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_dd5ba4d7-daf6-4e0e-9212-d2fe84f06f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_16f2c323-c160-4095-968c-edf3c4dea383" xlink:href="lyel-20230930.xsd#lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbfb61f8-271e-42d4-bad2-1645d13b3fd6" xlink:to="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_16f2c323-c160-4095-968c-edf3c4dea383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a66d4bbe-8f20-4c1a-aec2-9e5a28e8b6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbfb61f8-271e-42d4-bad2-1645d13b3fd6" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a66d4bbe-8f20-4c1a-aec2-9e5a28e8b6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4b0a2eee-6f7b-45b4-9db9-cbd0d6778210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a66d4bbe-8f20-4c1a-aec2-9e5a28e8b6ee" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4b0a2eee-6f7b-45b4-9db9-cbd0d6778210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/Organization" xlink:type="simple" xlink:href="lyel-20230930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d726df58-a2c9-4d95-872b-95c89e14abb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_50193c25-493d-4891-9df1-24c504d2e0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d726df58-a2c9-4d95-872b-95c89e14abb2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_50193c25-493d-4891-9df1-24c504d2e0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lyel-20230930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8af35274-f969-4afb-96b5-377b1ae804ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_95a5879c-b5c7-4cd6-89c2-d8a2b825ec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8af35274-f969-4afb-96b5-377b1ae804ee" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_95a5879c-b5c7-4cd6-89c2-d8a2b825ec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements" xlink:type="simple" xlink:href="lyel-20230930.xsd#LicenseCollaborationandSuccessPaymentAgreements"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e86d0c1-207b-46a3-87fc-e4c338c1cf45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5352076a-4592-41d3-b9e1-f8fbda35432d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e86d0c1-207b-46a3-87fc-e4c338c1cf45" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5352076a-4592-41d3-b9e1-f8fbda35432d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7b8eacb3-288a-4259-854a-5b7ecb1d49df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1a062683-3332-45a9-95c6-653bcbed365b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7b8eacb3-288a-4259-854a-5b7ecb1d49df" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1a062683-3332-45a9-95c6-653bcbed365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestments" xlink:type="simple" xlink:href="lyel-20230930.xsd#OtherInvestments"/>
  <link:presentationLink xlink:role="http://lyell.com/role/OtherInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0187dad3-bfa3-4bbe-b77e-9fc5c61deb08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentsTextBlock_de62feab-7f24-4470-9164-535cd1ffcd3c" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0187dad3-bfa3-4bbe-b77e-9fc5c61deb08" xlink:to="loc_lyel_OtherInvestmentsTextBlock_de62feab-7f24-4470-9164-535cd1ffcd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_362483bf-0778-47a1-9d4e-33b4ae50112e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_747f9128-0ad1-438c-8ac5-6560a6251b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_362483bf-0778-47a1-9d4e-33b4ae50112e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_747f9128-0ad1-438c-8ac5-6560a6251b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/Leases" xlink:type="simple" xlink:href="lyel-20230930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a4d867e3-aaeb-48ef-bc97-350a8d611ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c7180357-f22f-4823-a390-fae150a0dcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d867e3-aaeb-48ef-bc97-350a8d611ff3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c7180357-f22f-4823-a390-fae150a0dcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_e9413143-05f7-4b46-8a02-15cefafe1f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d867e3-aaeb-48ef-bc97-350a8d611ff3" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_e9413143-05f7-4b46-8a02-15cefafe1f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b73df802-9192-4381-9863-2400801d6180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_914aac5a-ec85-44bf-aa1d-2acd5b778542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b73df802-9192-4381-9863-2400801d6180" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_914aac5a-ec85-44bf-aa1d-2acd5b778542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bba4a60-229a-4053-b24a-743689f19a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251d8ad6-81a2-4c63-a8c6-0782adb66630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bba4a60-229a-4053-b24a-743689f19a0d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251d8ad6-81a2-4c63-a8c6-0782adb66630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/NetLossPerShare" xlink:type="simple" xlink:href="lyel-20230930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://lyell.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f7feb8d4-86bf-4ab5-9cdd-05fe7bf7d240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_05355f36-8de2-4afb-9014-4b32f639b989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7feb8d4-86bf-4ab5-9cdd-05fe7bf7d240" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_05355f36-8de2-4afb-9014-4b32f639b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lyel-20230930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_125eb0d0-ba66-4510-9af7-a85ade33424a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0f15d07-63b4-4f90-9eac-71f88e0b849e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_125eb0d0-ba66-4510-9af7-a85ade33424a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0f15d07-63b4-4f90-9eac-71f88e0b849e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactions" xlink:type="simple" xlink:href="lyel-20230930.xsd#RelatedpartyTransactions"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_393b308f-e215-496c-b719-60cbea3d3cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5f6203e5-b325-4bfc-b0ea-c0518ee35dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_393b308f-e215-496c-b719-60cbea3d3cec" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5f6203e5-b325-4bfc-b0ea-c0518ee35dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SubsequentEvents" xlink:type="simple" xlink:href="lyel-20230930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_7a73a3fd-8323-4ec9-8608-8c7c2462e8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f34c494c-229e-4592-8e6c-409a03ba40a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_7a73a3fd-8323-4ec9-8608-8c7c2462e8a9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f34c494c-229e-4592-8e6c-409a03ba40a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lyel-20230930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55450d45-7574-433b-967a-a524f5a5c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55450d45-7574-433b-967a-a524f5a5c36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_fc6c8e94-448d-489b-a052-0eca97f98bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_fc6c8e94-448d-489b-a052-0eca97f98bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_916707fb-fb35-4f46-9de4-a15d4888c865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_us-gaap_UseOfEstimates_916707fb-fb35-4f46-9de4-a15d4888c865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b0e7e5d2-76fa-49ba-93e6-a7d9ffedb0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b0e7e5d2-76fa-49ba-93e6-a7d9ffedb0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_33991d71-6de8-4bec-a1e7-a3f386f6d3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_33991d71-6de8-4bec-a1e7-a3f386f6d3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock_c9d53f00-a4db-4f03-86f0-3f5eb4bdc618" xlink:href="lyel-20230930.xsd#lyel_SignificantAccountingPoliciesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock_c9d53f00-a4db-4f03-86f0-3f5eb4bdc618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c0e52d35-03a3-4979-9f04-0888e1f1a4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_604e16b3-048e-4328-aa32-976e8965da6e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c0e52d35-03a3-4979-9f04-0888e1f1a4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables" xlink:type="simple" xlink:href="lyel-20230930.xsd#LicenseCollaborationandSuccessPaymentAgreementsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5217db9f-8822-4280-b4c5-253a2ae2f43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_04b751e8-fc48-423c-8327-a559278c9e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5217db9f-8822-4280-b4c5-253a2ae2f43c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_04b751e8-fc48-423c-8327-a559278c9e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_88492419-d28e-4efe-a6dc-3a3154708904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2495b66e-54e2-4302-8f2a-c6b0c5d15d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_88492419-d28e-4efe-a6dc-3a3154708904" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2495b66e-54e2-4302-8f2a-c6b0c5d15d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_54050824-9be0-4c93-8177-2bac6192f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_88492419-d28e-4efe-a6dc-3a3154708904" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_54050824-9be0-4c93-8177-2bac6192f4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_11fa5897-3864-4a7e-813f-4a11b557e196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3f17d8be-0b12-4c56-8366-f2808b13378b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_11fa5897-3864-4a7e-813f-4a11b557e196" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3f17d8be-0b12-4c56-8366-f2808b13378b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_64abbf56-a7e1-4607-a466-637f045c7333" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_11fa5897-3864-4a7e-813f-4a11b557e196" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_64abbf56-a7e1-4607-a466-637f045c7333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c876d162-ea4c-4107-8fee-e939fe48b5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_11fa5897-3864-4a7e-813f-4a11b557e196" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c876d162-ea4c-4107-8fee-e939fe48b5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesTables" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8200c855-8889-4989-9ff0-6cba26852d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5d0dff2d-3d25-47e3-b5f1-7c15c4e6f365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8200c855-8889-4989-9ff0-6cba26852d1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5d0dff2d-3d25-47e3-b5f1-7c15c4e6f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_df9c4c97-dcd1-4857-bb7f-feb29de046c9" xlink:href="lyel-20230930.xsd#lyel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8200c855-8889-4989-9ff0-6cba26852d1f" xlink:to="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_df9c4c97-dcd1-4857-bb7f-feb29de046c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b99a2a1-1bcf-4b9f-bff9-e9b8cc871b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_85fc80c9-2c4e-4a35-870a-f6c95779adfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b99a2a1-1bcf-4b9f-bff9-e9b8cc871b76" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_85fc80c9-2c4e-4a35-870a-f6c95779adfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_fd680eb3-94ee-411e-930b-03efac3536c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b99a2a1-1bcf-4b9f-bff9-e9b8cc871b76" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_fd680eb3-94ee-411e-930b-03efac3536c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_988dfa5c-eab4-413a-a39f-4255fcd7db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b99a2a1-1bcf-4b9f-bff9-e9b8cc871b76" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_988dfa5c-eab4-413a-a39f-4255fcd7db3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5d5f310f-9311-4c50-be15-5509d0275c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b99a2a1-1bcf-4b9f-bff9-e9b8cc871b76" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5d5f310f-9311-4c50-be15-5509d0275c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsTables" xlink:type="simple" xlink:href="lyel-20230930.xsd#RelatedpartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e25daf9b-5018-4365-a297-21bee2e8b890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_abb43165-d321-4622-8614-dbdcfabcaa23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e25daf9b-5018-4365-a297-21bee2e8b890" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_abb43165-d321-4622-8614-dbdcfabcaa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_719bb4e4-ed56-4296-99d9-862644000edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_719bb4e4-ed56-4296-99d9-862644000edb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d1dd7b-3d1d-43fb-8830-89827e7d0636" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e7ea2fe8-c433-4ea0-ad47-651aa5948a2c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d1dd7b-3d1d-43fb-8830-89827e7d0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_73d1ab84-3a75-428f-8662-8629bce9d1a3" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d1dd7b-3d1d-43fb-8830-89827e7d0636" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_73d1ab84-3a75-428f-8662-8629bce9d1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7846191c-1139-4e4f-9df6-ae8f6cab6ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93df09b3-1aaf-46af-8027-e2431b6cfd1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7846191c-1139-4e4f-9df6-ae8f6cab6ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5d5176c4-347d-4f1e-9525-908de8173657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7846191c-1139-4e4f-9df6-ae8f6cab6ecb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5d5176c4-347d-4f1e-9525-908de8173657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c5e3e54e-e244-4514-a8d8-89f70b0c2e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6b87e793-aa7f-4df7-a0fc-4edfcf96364e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c5e3e54e-e244-4514-a8d8-89f70b0c2e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_59c57679-613b-488f-adfe-57a20807ebb9" xlink:href="lyel-20230930.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c5e3e54e-e244-4514-a8d8-89f70b0c2e03" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_59c57679-613b-488f-adfe-57a20807ebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6503b5c-2e34-4465-a7a6-fd3756d37a14" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e66c6c8a-d28a-42c1-8a2b-39d34cb3829d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_Revenues_e66c6c8a-d28a-42c1-8a2b-39d34cb3829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2a9375a-683f-4318-b4ae-7cb3efa0782d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_NetIncomeLoss_e2a9375a-683f-4318-b4ae-7cb3efa0782d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_615460c8-974e-47d0-be64-bc94347feff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_EarningsPerShareBasic_615460c8-974e-47d0-be64-bc94347feff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6b543732-6fc8-4406-9831-6f85805651e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_50d14fe3-3c47-444b-b744-56ad83391123" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6b543732-6fc8-4406-9831-6f85805651e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76a66495-fcb8-45ea-ab91-f05dc221cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76a66495-fcb8-45ea-ab91-f05dc221cf30" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9fd0cdb3-237a-4101-9445-4e6fae9ebbf3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_dac8d576-3a86-440e-8e36-f1c72f6212f8" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_FredHutchMember_dac8d576-3a86-440e-8e36-f1c72f6212f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_29d4ef0d-2d08-42e7-9585-3436c81a1f30" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_StanfordMember_29d4ef0d-2d08-42e7-9585-3436c81a1f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_cc36cd32-2938-4aed-af95-ee98e3a329a8" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_cc36cd32-2938-4aed-af95-ee98e3a329a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_f5bbe155-8618-4cc0-88f6-86ceb457ee99" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61e807b2-1115-410e-8fc0-6d8ef486f23a" xlink:to="loc_lyel_PACTPharmaIncMember_f5bbe155-8618-4cc0-88f6-86ceb457ee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf9924cc-a14e-43fc-98b7-7e99c6bfa398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ae8c1834-5d26-4cc6-b2de-2a8a9732d558" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf9924cc-a14e-43fc-98b7-7e99c6bfa398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_897a9bb1-58a8-4efd-968b-ac734643773f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf9924cc-a14e-43fc-98b7-7e99c6bfa398" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_897a9bb1-58a8-4efd-968b-ac734643773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f49fd0f5-dea2-4cb5-9973-d57b7eace4e9" xlink:to="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7aa10d1e-6f37-4ec2-b9a5-6e2c714e4a02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:to="loc_srt_MinimumMember_7aa10d1e-6f37-4ec2-b9a5-6e2c714e4a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cebdcccb-0906-48d1-a99a-4fa0efa7e0a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b4eb6fed-4f4c-477e-a488-f19bfca51a54" xlink:to="loc_srt_MaximumMember_cebdcccb-0906-48d1-a99a-4fa0efa7e0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c496ba08-5f8a-4ea4-9d73-94f80688bdd6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_68c1f2d0-ddc2-4e6f-a875-1325be56afc7" xlink:to="loc_srt_ProductsAndServicesDomain_c496ba08-5f8a-4ea4-9d73-94f80688bdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2a326b41-80ea-4040-9461-0b19aa1f3804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c496ba08-5f8a-4ea4-9d73-94f80688bdd6" xlink:to="loc_us-gaap_LicenseMember_2a326b41-80ea-4040-9461-0b19aa1f3804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5ca3ff53-12c8-4af9-9d46-de24d65df277" xlink:to="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember_5f59ce91-ec5f-4bfd-86f6-231fd2c47103" xlink:href="lyel-20230930.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:to="loc_lyel_SeriesAConvertiblePreferredStockMember_5f59ce91-ec5f-4bfd-86f6-231fd2c47103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAAConvertiblePreferredStockMember_b654c87c-966c-4cc8-94e1-1468a1105c02" xlink:href="lyel-20230930.xsd#lyel_SeriesAAConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2c2a2277-b25c-4c97-bd33-19e9ea3f4ed7" xlink:to="loc_lyel_SeriesAAConvertiblePreferredStockMember_b654c87c-966c-4cc8-94e1-1468a1105c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_83c936a1-9196-4add-bac5-747f6497c874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f1334ba6-c8e2-44db-98f2-177af131bba9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_83c936a1-9196-4add-bac5-747f6497c874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_d68ae497-da6f-43aa-9763-5bf2d3b1628b" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_83c936a1-9196-4add-bac5-747f6497c874" xlink:to="loc_lyel_OtherInvestmentMember_d68ae497-da6f-43aa-9763-5bf2d3b1628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_afb4ae13-e1e4-48f2-825a-c232a674a0a0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_81572837-3ec3-4eec-9105-c7e25474acf0" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:to="loc_lyel_PACTPharmaIncMember_81572837-3ec3-4eec-9105-c7e25474acf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_e20b219e-8159-40d3-9f1c-e580defdcdc8" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8e284542-dace-45b3-a871-4f3923873e8e" xlink:to="loc_lyel_OtherInvestmentMember_e20b219e-8159-40d3-9f1c-e580defdcdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d604ab43-e801-4b65-aacb-a831b6478e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efd61545-da5b-42bf-9561-44058d90a3c3" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d604ab43-e801-4b65-aacb-a831b6478e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_1e6422cd-9b59-4c57-bfe6-1e7fbf3f319f" xlink:href="lyel-20230930.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d604ab43-e801-4b65-aacb-a831b6478e45" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_1e6422cd-9b59-4c57-bfe6-1e7fbf3f319f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f3fae843-2fe4-48ae-b78c-aa710480051e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_40694c24-d403-42ac-b046-1319d564ef39" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_40694c24-d403-42ac-b046-1319d564ef39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_7e7dfa71-3b06-47c9-8847-0659f89e835d" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_7e7dfa71-3b06-47c9-8847-0659f89e835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_a2aaea7a-4263-4263-b04d-af9383df5984" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_a2aaea7a-4263-4263-b04d-af9383df5984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_298613e6-dfae-4177-948b-f2272e3d1be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_298613e6-dfae-4177-948b-f2272e3d1be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_64e5803f-3d51-4234-9ad2-4bfa638dd339" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_64e5803f-3d51-4234-9ad2-4bfa638dd339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_21a8eb14-e326-4bcb-b847-1885fb5f1454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_21a8eb14-e326-4bcb-b847-1885fb5f1454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_0c6f9b8d-cf24-4184-847f-ec4c566a41f5" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_0c6f9b8d-cf24-4184-847f-ec4c566a41f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a4f25b0b-32b8-4315-a742-b8dc31dae623" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a4f25b0b-32b8-4315-a742-b8dc31dae623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_5bc9c5ce-1be6-4642-b2ad-2b4e3d075553" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_5bc9c5ce-1be6-4642-b2ad-2b4e3d075553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_d91cd157-1ea7-4b9e-b89e-b03b3626b8d6" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_d91cd157-1ea7-4b9e-b89e-b03b3626b8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_f4194e30-639b-431e-8d9c-dc24010f1d1c" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_f4194e30-639b-431e-8d9c-dc24010f1d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_15abd2a5-18ec-44f1-9d82-b7df6637596c" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_15abd2a5-18ec-44f1-9d82-b7df6637596c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_5f81e8df-6754-472c-be8a-42abbad91be3" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_5f81e8df-6754-472c-be8a-42abbad91be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_60b13c54-9fa9-40e8-b852-6cadb149920c" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_60b13c54-9fa9-40e8-b852-6cadb149920c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_c17ed3d9-c1d6-4c8f-9039-53d501f0ea14" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_c17ed3d9-c1d6-4c8f-9039-53d501f0ea14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_ca38b7b4-7960-4e95-b13d-da4631f0d242" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_ca38b7b4-7960-4e95-b13d-da4631f0d242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_05e2aace-998c-4c5d-8311-fc30047748c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ContractWithCustomerLiability_05e2aace-998c-4c5d-8311-fc30047748c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSold_8d1efc9d-6e2f-4059-b6c0-50e747169f9e" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementSharesSold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_StockPurchaseAgreementSharesSold_8d1efc9d-6e2f-4059-b6c0-50e747169f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_76c8bf3e-6f05-4ef4-b502-d0cdae7b2401" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementSharesSoldPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_76c8bf3e-6f05-4ef4-b502-d0cdae7b2401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_0bd7fe96-ca50-40ee-a017-049cadec2ffa" xlink:href="lyel-20230930.xsd#lyel_StockPurchaseAgreementFairValueOfStockPerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_0bd7fe96-ca50-40ee-a017-049cadec2ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_97010072-469c-4108-82ff-c1bd49d49560" xlink:href="lyel-20230930.xsd#lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_97010072-469c-4108-82ff-c1bd49d49560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_398cb203-a7fa-4fdc-803f-19a9da654e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_398cb203-a7fa-4fdc-803f-19a9da654e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e0b2614-308d-42d9-bef5-a162f6b7ef84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e0b2614-308d-42d9-bef5-a162f6b7ef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d655e4b0-01ce-450e-a815-b9c9320bdd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_NetIncomeLoss_d655e4b0-01ce-450e-a815-b9c9320bdd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_122113e3-161f-4824-9c8f-e7941b27cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EarningsPerShareBasic_122113e3-161f-4824-9c8f-e7941b27cd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9825fd2e-66da-497b-b0f8-c30a7ea15b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9825fd2e-66da-497b-b0f8-c30a7ea15b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b49f28da-0e5e-4a8a-8cb9-0f715ca8f5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b49f28da-0e5e-4a8a-8cb9-0f715ca8f5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7fd050fc-5a6c-4672-8fec-ffa11b10a329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7fd050fc-5a6c-4672-8fec-ffa11b10a329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_24306f93-e609-45d7-8508-bb51e9953e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_24306f93-e609-45d7-8508-bb51e9953e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3a44059d-b9ad-485e-bf0a-8877265a9c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_71b4fe97-b66a-451b-a903-f14db76b9257" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3a44059d-b9ad-485e-bf0a-8877265a9c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_57f019b2-987f-46fc-9d97-6d1e0e37f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_57f019b2-987f-46fc-9d97-6d1e0e37f21f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a209d0d-ac3b-47a3-ab99-2389d18df667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d043da4-58ab-45c1-8adb-281257baa9ad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a209d0d-ac3b-47a3-ab99-2389d18df667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_390d3cc6-e1df-422d-b54e-fb6c0d83a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a209d0d-ac3b-47a3-ab99-2389d18df667" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_390d3cc6-e1df-422d-b54e-fb6c0d83a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:href="lyel-20230930.xsd#lyel_EquityMultipleDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleAxis_d32efafe-68ec-4f38-a2c4-b42e7c035b14" xlink:to="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember_45fba8a1-3e80-46ae-9548-ea83364c38ab" xlink:href="lyel-20230930.xsd#lyel_TenTimesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_TenTimesMember_45fba8a1-3e80-46ae-9548-ea83364c38ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember_b9389fc7-f4b5-4d80-9d38-7dae53d6d6db" xlink:href="lyel-20230930.xsd#lyel_TwentyTimesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_TwentyTimesMember_b9389fc7-f4b5-4d80-9d38-7dae53d6d6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember_b5d9c935-3c9b-48c8-9235-6b88f0785ce1" xlink:href="lyel-20230930.xsd#lyel_ThirtyTimesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_ThirtyTimesMember_b5d9c935-3c9b-48c8-9235-6b88f0785ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember_fb8d7b7b-1131-4379-a1b6-ed3de7b0def2" xlink:href="lyel-20230930.xsd#lyel_FortyTimesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_FortyTimesMember_fb8d7b7b-1131-4379-a1b6-ed3de7b0def2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember_f3283d82-4c91-4e70-a641-21f9a724ccba" xlink:href="lyel-20230930.xsd#lyel_FiftyTimesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_179af07e-a2d8-4f3d-b632-2cf5fd2f04d0" xlink:to="loc_lyel_FiftyTimesMember_f3283d82-4c91-4e70-a641-21f9a724ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_672b5807-891d-4857-8927-fdec9e109884" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_d79ed9bf-92fc-4cb7-a521-9f86273f4110" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:to="loc_lyel_FredHutchMember_d79ed9bf-92fc-4cb7-a521-9f86273f4110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_835fb742-d6c5-40f8-854d-157864413b86" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7367f799-13c3-42f5-850f-f31792fe5068" xlink:to="loc_lyel_StanfordMember_835fb742-d6c5-40f8-854d-157864413b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76f34eb8-9ffd-438e-80cf-daea96163df0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_ea235dc6-d0e4-46d0-ae65-8a84f3c1b7f9" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_ea235dc6-d0e4-46d0-ae65-8a84f3c1b7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a378de27-beb3-4c63-abf1-9472826ea43f" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_a378de27-beb3-4c63-abf1-9472826ea43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_dd5bbc49-e82b-4573-b83e-89f712f0c930" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6842119-3bbf-438b-bb2a-e69ffd41210d" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_dd5bbc49-e82b-4573-b83e-89f712f0c930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_ccdf2703-67ce-4768-94be-b678beed1e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ccdf2703-67ce-4768-94be-b678beed1e87" xlink:to="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35687bd8-5854-4be7-9db8-1dcd74f41359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c4af05cc-390e-42ad-824b-28934d4853ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35687bd8-5854-4be7-9db8-1dcd74f41359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_04fe3339-8813-444f-8c16-eaedc09c4f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35687bd8-5854-4be7-9db8-1dcd74f41359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_04fe3339-8813-444f-8c16-eaedc09c4f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3dbf7416-95e7-40b8-bce8-4efd8de50fc4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8393d4a5-6826-4005-a625-caf5e9481b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8393d4a5-6826-4005-a625-caf5e9481b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3dd48867-c677-47f9-90e7-6a575ad69425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3dd48867-c677-47f9-90e7-6a575ad69425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d52880ac-5031-440d-a3e2-e0e49daf56db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5e5e6d5-5ff0-439d-893e-5d8a18e79148" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d52880ac-5031-440d-a3e2-e0e49daf56db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_888cd5ee-49cd-4fc8-9bb2-47ac5a2755f8" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b0aa0d4-3b1d-48b2-acec-19cf5d62098a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b0aa0d4-3b1d-48b2-acec-19cf5d62098a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9a9246-7bfd-4250-878c-e3b373f954b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4d9a9246-7bfd-4250-878c-e3b373f954b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_f4bf6876-f8d9-42b9-881a-32dce4cb4c1e" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_f4bf6876-f8d9-42b9-881a-32dce4cb4c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_27a592c9-c81f-4880-82e9-acfdaa474ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_27a592c9-c81f-4880-82e9-acfdaa474ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4670a1eb-56b4-4d47-9d5d-56baa0c6191f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4670a1eb-56b4-4d47-9d5d-56baa0c6191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a5f17bc8-6390-484e-9674-b4d4b06e57a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a5f17bc8-6390-484e-9674-b4d4b06e57a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4415ad95-9137-4f71-a8f3-8da085a862a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4415ad95-9137-4f71-a8f3-8da085a862a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_c37ba1fe-cd0a-4b4e-9d5b-0b4af54ec243" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_c37ba1fe-cd0a-4b4e-9d5b-0b4af54ec243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_7dbabd8e-4409-4c04-9229-12c7ed219f2b" xlink:to="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure_e4ddefd8-95a6-4730-944d-8df5f96738c5" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosure_e4ddefd8-95a6-4730-944d-8df5f96738c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_86e92484-11e0-46e4-a336-82c42235ba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_86e92484-11e0-46e4-a336-82c42235ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7bd995a1-65aa-4547-ac84-eb4bdc98a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7bd995a1-65aa-4547-ac84-eb4bdc98a44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_b6a9fe95-6aeb-4795-b6fa-66dee99b281e" xlink:href="lyel-20230930.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_b3c5729b-fd48-483c-a983-ade78b7d67ef" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_b6a9fe95-6aeb-4795-b6fa-66dee99b281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_b57737d1-454f-46b4-af5c-8188b0233eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b57737d1-454f-46b4-af5c-8188b0233eb7" xlink:to="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:to="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d290186e-6e17-4fd4-b3a4-4addfb16978e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_860b1b42-3174-44ce-9ce0-0b822ea0df44" xlink:to="loc_srt_RangeMember_d290186e-6e17-4fd4-b3a4-4addfb16978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c2dae77-550b-45ab-8ed6-6566121a80fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d290186e-6e17-4fd4-b3a4-4addfb16978e" xlink:to="loc_srt_MaximumMember_2c2dae77-550b-45ab-8ed6-6566121a80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_2960a985-da98-471f-932d-645da5222da5" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_07542bf5-fa90-4d32-aea3-979c9aeabaec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_07542bf5-fa90-4d32-aea3-979c9aeabaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8070dc48-8c17-4169-89ee-93b5fe947774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8070dc48-8c17-4169-89ee-93b5fe947774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_196f8e3f-19fe-47e8-8660-e007049beb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_c0943ce1-c0d0-4951-b563-a89ef2484b15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_196f8e3f-19fe-47e8-8660-e007049beb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#OtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_112c1d0b-2f35-4985-8a49-e757352112a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_112c1d0b-2f35-4985-8a49-e757352112a0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_485412b7-b46e-4f8f-960e-dac82065ec59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ffa9efc-041f-454d-9799-347b1a5a52f9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_485412b7-b46e-4f8f-960e-dac82065ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_79442647-f6c2-4cba-bd75-2287b90ec1aa" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_485412b7-b46e-4f8f-960e-dac82065ec59" xlink:to="loc_lyel_OtherInvestmentMember_79442647-f6c2-4cba-bd75-2287b90ec1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_dc1e7b35-491f-41c2-a4d1-20d3e066faa6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d145db51-f375-497b-9297-44a047f0c5a4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_dc1e7b35-491f-41c2-a4d1-20d3e066faa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6e039136-8d1a-4e50-999b-813f497cba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_dc1e7b35-491f-41c2-a4d1-20d3e066faa6" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6e039136-8d1a-4e50-999b-813f497cba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6337b415-6bee-4865-97ec-77c5108cadcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5dade1ea-fe52-451e-b727-114c8cb7217a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6337b415-6bee-4865-97ec-77c5108cadcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_84240684-9be8-489a-892b-8d9c53643296" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6337b415-6bee-4865-97ec-77c5108cadcc" xlink:to="loc_lyel_PACTPharmaIncMember_84240684-9be8-489a-892b-8d9c53643296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_70906398-f8e4-4a37-9380-133e6cd0e9b8" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_b267fd97-5a89-4a4e-be5a-ddc26fa3d815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_OtherInvestments_b267fd97-5a89-4a4e-be5a-ddc26fa3d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a0631959-7ae8-4ab2-bae6-0970853f62c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a0631959-7ae8-4ab2-bae6-0970853f62c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_41a26586-9d97-42d8-91f4-e2191b8c08bd" xlink:href="lyel-20230930.xsd#lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary_41a26586-9d97-42d8-91f4-e2191b8c08bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_42208f0b-ce9f-471d-8ca2-b9151f63f575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_42208f0b-ce9f-471d-8ca2-b9151f63f575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8d7a5400-caf8-4865-8bdc-52ec4b9254d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8d7a5400-caf8-4865-8bdc-52ec4b9254d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_e9af5c80-975a-4359-84e5-c065f1c149e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_00b7d869-7367-421f-bcea-5a09e2305089" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_e9af5c80-975a-4359-84e5-c065f1c149e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b8723ad9-c0be-4d3d-abf8-07969cb2dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b8723ad9-c0be-4d3d-abf8-07969cb2dd7d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361ba0b5-70c1-4c80-9c1c-02e2b59cec0a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_450f7e20-3c59-49c2-af35-1277db73fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_450f7e20-3c59-49c2-af35-1277db73fd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0e75f081-0f1e-415c-a075-0f28c7b986b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0e75f081-0f1e-415c-a075-0f28c7b986b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_71cec368-a6e2-4629-b023-63844d4f4f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9e6416a-6138-4109-9221-8ec1566f69f4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_71cec368-a6e2-4629-b023-63844d4f4f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54cdb5f4-0e8a-4207-9810-a158a72bcbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a25a7f9b-9d71-40ff-8c47-8f9a850f3c3d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54cdb5f4-0e8a-4207-9810-a158a72bcbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_21c2f018-c027-4221-9879-cf8d5b6afac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54cdb5f4-0e8a-4207-9810-a158a72bcbe4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_21c2f018-c027-4221-9879-cf8d5b6afac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_02acca51-69ef-4644-a470-eddf21a89219" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2724fc25-fc69-4560-a116-b227f51c2b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2724fc25-fc69-4560-a116-b227f51c2b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_612980ff-34ae-4a3c-8f2b-a901c256e3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_612980ff-34ae-4a3c-8f2b-a901c256e3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_17211a51-6e07-4719-bd4a-8f94d7c025fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39cc0af7-1c82-49c3-8552-6d7b819038b4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_17211a51-6e07-4719-bd4a-8f94d7c025fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_242791f2-bbad-46c5-b01b-746c80739051" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9779e151-5d9b-45b2-933d-c8cfc9ad9022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9779e151-5d9b-45b2-933d-c8cfc9ad9022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd9a36b7-defc-4981-ab67-e4efa1d2dd68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd9a36b7-defc-4981-ab67-e4efa1d2dd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c7e28930-f273-4d2c-a61a-136fba1c6482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_da86e3a9-5cc2-45cc-abc2-0ddbc82f0654" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c7e28930-f273-4d2c-a61a-136fba1c6482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf11a676-a1fd-4a58-befd-b48bc15b1544" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_37ea646d-ccea-4404-ae28-a6a07d24f3ea" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_37ea646d-ccea-4404-ae28-a6a07d24f3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_68447269-6f4a-4103-8a23-f894a4151f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_679b5cdc-28ea-4000-a943-fcb28add2065" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_68447269-6f4a-4103-8a23-f894a4151f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ae9b7b18-aa5d-4a07-aec7-0905a1c67277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ae9b7b18-aa5d-4a07-aec7-0905a1c67277" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_da338082-f2bd-4d98-8686-54c118c2283b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember_1b458a9c-e98f-4406-8962-aec4e94bb1c2" xlink:href="lyel-20230930.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:to="loc_lyel_FredHutchSuccessPaymentLiabilityMember_1b458a9c-e98f-4406-8962-aec4e94bb1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember_daf96435-6c00-4a45-a9ee-0b6d36d9d678" xlink:href="lyel-20230930.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8a48bfaa-7ca4-403a-b52d-bfea9f6c4036" xlink:to="loc_lyel_StanfordSuccessPaymentLiabilityMember_daf96435-6c00-4a45-a9ee-0b6d36d9d678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e21963d8-5b55-4889-8ecc-0ee745285bbb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_73b03824-ba65-4c93-9062-31f1684b286d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_73b03824-ba65-4c93-9062-31f1684b286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2ea6c39f-c472-4a35-b90b-9247f86153c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2ea6c39f-c472-4a35-b90b-9247f86153c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_a1e0ef72-a3bb-4750-bc85-a4d5a7e23f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7cc22f81-3317-4079-b00f-6d4a20e9f965" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_a1e0ef72-a3bb-4750-bc85-a4d5a7e23f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ecbec00e-d857-4385-bb36-bd57e1b4ddf0" xlink:to="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d57a766f-0792-4b5a-95ec-3202d15c462c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:to="loc_srt_MinimumMember_d57a766f-0792-4b5a-95ec-3202d15c462c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85004171-7cc0-49f8-966a-63e26278c243" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8d33fd6-78c6-4d8d-b3bd-ce596cae009b" xlink:to="loc_srt_MaximumMember_85004171-7cc0-49f8-966a-63e26278c243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10908f7d-6d44-40c7-8bb2-92202c2dbd13" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_d53617f0-7516-468a-a807-0ca231a3214e" xlink:href="lyel-20230930.xsd#lyel_FairValueOfSeriesAConvertiblePreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:to="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_d53617f0-7516-468a-a807-0ca231a3214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput_b0343644-4a26-451c-89c6-d0c317e15f01" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7d1ae7fe-0045-4350-8d83-dd3454a81788" xlink:to="loc_lyel_SuccessPaymentLiabilityMeasurementInput_b0343644-4a26-451c-89c6-d0c317e15f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5bf369f3-2da8-429a-8c6b-2652e89aec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5bf369f3-2da8-429a-8c6b-2652e89aec4c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a3ce8ba8-b0db-41d6-80fb-058bf31041ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f4d2f371-3b03-43c7-8532-983582b3ed38" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a3ce8ba8-b0db-41d6-80fb-058bf31041ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember_e1a75c12-1769-4ebf-b81a-868ff2444934" xlink:href="lyel-20230930.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3ce8ba8-b0db-41d6-80fb-058bf31041ed" xlink:to="loc_lyel_SuccessPaymentLiabilityMember_e1a75c12-1769-4ebf-b81a-868ff2444934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2d8d68f-8f55-4c6a-ad43-b1fdaae32fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d99f3f0b-e665-4dac-a850-648fb0330294" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2d8d68f-8f55-4c6a-ad43-b1fdaae32fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0f1fdb4a-b674-4d07-bf8e-919fe071cc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2d8d68f-8f55-4c6a-ad43-b1fdaae32fbb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0f1fdb4a-b674-4d07-bf8e-919fe071cc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c8e62931-b69d-4f59-a938-3fd19ccc662e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_8df7d77b-8031-4d88-816a-0e542bfbe10d" xlink:href="lyel-20230930.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:to="loc_lyel_FredHutchMember_8df7d77b-8031-4d88-816a-0e542bfbe10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_b6e0052a-db75-4bcd-9950-1bcaebe2bd38" xlink:href="lyel-20230930.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ba15685-1b11-4fc7-8ca1-1674bfbf1959" xlink:to="loc_lyel_StanfordMember_b6e0052a-db75-4bcd-9950-1bcaebe2bd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505183cf-eedd-4f9f-8934-db520ed9ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5dd19070-1f68-49ae-95e7-6574a2069567" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505183cf-eedd-4f9f-8934-db520ed9ac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cfc46a25-1455-44e6-8db5-e6c001ecf03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505183cf-eedd-4f9f-8934-db520ed9ac8b" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cfc46a25-1455-44e6-8db5-e6c001ecf03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11b67b0c-1554-4fa9-b4a6-30395e8ae794" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0e290c0f-8059-49bb-9e7c-afec235dc254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0e290c0f-8059-49bb-9e7c-afec235dc254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b402841b-cb83-4854-a28d-7987ebd30060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b402841b-cb83-4854-a28d-7987ebd30060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_44630a7a-d61e-45bb-8052-0792b1490695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2028db92-101f-4920-bb30-6a933f2455f5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_44630a7a-d61e-45bb-8052-0792b1490695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_51a7bac1-ea83-4d11-801e-d6062fd99add" xlink:href="lyel-20230930.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f434236-bacb-4010-926f-ce07536186e5" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_51a7bac1-ea83-4d11-801e-d6062fd99add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a2c7834a-82c4-4317-a7af-b77bf34c10e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a2c7834a-82c4-4317-a7af-b77bf34c10e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3fce837e-37ec-4444-911e-4c31e73a6970" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a5c11e23-ceb1-4ad2-8af7-a042f0cbf776" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3fce837e-37ec-4444-911e-4c31e73a6970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_ae75a40f-d11e-4fec-b38f-7a3ea40b96a1" xlink:href="lyel-20230930.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3fce837e-37ec-4444-911e-4c31e73a6970" xlink:to="loc_lyel_OtherInvestmentMember_ae75a40f-d11e-4fec-b38f-7a3ea40b96a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:to="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87f38717-630f-4165-ac9d-04944206e0a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5ddef860-c083-41aa-ae33-d0493110df3e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87f38717-630f-4165-ac9d-04944206e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_18260ba1-8bb6-4f60-b089-b93098b789dd" xlink:href="lyel-20230930.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87f38717-630f-4165-ac9d-04944206e0a0" xlink:to="loc_lyel_PACTPharmaIncMember_18260ba1-8bb6-4f60-b089-b93098b789dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1e3bf830-dace-4051-adde-17fc6358af73" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_184e362b-4ad7-4138-9e9c-925a224a9a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_184e362b-4ad7-4138-9e9c-925a224a9a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_153661af-dc42-4bdb-ba57-f7d70d941694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacf4ecc-c8f5-434d-93ca-2482ee9cdcfa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_153661af-dc42-4bdb-ba57-f7d70d941694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3519c56c-6fd5-415b-8937-51ecaabff93c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3519c56c-6fd5-415b-8937-51ecaabff93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f66a7fb7-0c43-4d74-8360-4dc003062fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f66a7fb7-0c43-4d74-8360-4dc003062fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ae28db55-355b-4e1b-bc8a-a8148dd83ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ae28db55-355b-4e1b-bc8a-a8148dd83ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17424f61-897a-438d-b9ae-51dec3a7d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17424f61-897a-438d-b9ae-51dec3a7d1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d7541692-c615-4e7a-a592-77620dc50f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d7541692-c615-4e7a-a592-77620dc50f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7bd1bdcd-58ab-4add-9e72-df01e4e29729" xlink:href="lyel-20230930.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7bd1bdcd-58ab-4add-9e72-df01e4e29729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2e37296f-8604-4888-a5f7-bc41e5662c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2e37296f-8604-4888-a5f7-bc41e5662c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5bd27552-0982-4591-b059-a22a3bffbbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5bd27552-0982-4591-b059-a22a3bffbbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_15db82cc-39d5-4405-9055-61497db36969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_OperatingLeaseLiability_15db82cc-39d5-4405-9055-61497db36969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_a4682a59-fe0f-4b4c-97b0-a0cde272aaac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_015689d2-654e-4528-8b48-b09995c0f3f6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_a4682a59-fe0f-4b4c-97b0-a0cde272aaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5bb7cb8c-45f4-40a8-9032-260a0e249f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a4682a59-fe0f-4b4c-97b0-a0cde272aaac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5bb7cb8c-45f4-40a8-9032-260a0e249f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ac8061b-366a-4cb3-b057-ea5355259963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a4682a59-fe0f-4b4c-97b0-a0cde272aaac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ac8061b-366a-4cb3-b057-ea5355259963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a838f6a1-b410-4952-bfa4-22ce9318e5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a4682a59-fe0f-4b4c-97b0-a0cde272aaac" xlink:to="loc_us-gaap_OperatingLeaseLiability_a838f6a1-b410-4952-bfa4-22ce9318e5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ff4a9ea3-b17e-40f2-beb3-c8ff409e6091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a9ea3-b17e-40f2-beb3-c8ff409e6091" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e56ce2dc-1bec-4016-a257-5aeb4c22a0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530679ee-f91e-4cf5-8c4c-5109e260927d" xlink:to="loc_us-gaap_RelatedPartyDomain_e56ce2dc-1bec-4016-a257-5aeb4c22a0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_70aa0994-6b5e-45c1-aa3b-ba879bccee59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e56ce2dc-1bec-4016-a257-5aeb4c22a0e1" xlink:to="loc_us-gaap_RelatedPartyMember_70aa0994-6b5e-45c1-aa3b-ba879bccee59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_199d696c-8ac8-41ce-9706-dbddcebfa337" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e288601c-7d00-4da9-a06a-e7445d4cb98e" xlink:to="loc_srt_SegmentGeographicalDomain_199d696c-8ac8-41ce-9706-dbddcebfa337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember_135bd64d-4630-46af-b645-d72243d5ecdf" xlink:href="lyel-20230930.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_199d696c-8ac8-41ce-9706-dbddcebfa337" xlink:to="loc_lyel_SouthSanFranciscoCaliforniaMember_135bd64d-4630-46af-b645-d72243d5ecdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fe0a865-373f-4769-87c7-49f41286be49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_51f882ac-5665-407c-98c8-c3cd7789f9a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fe0a865-373f-4769-87c7-49f41286be49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_ea5e3f79-7170-4369-a2a6-59afef8cd003" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fe0a865-373f-4769-87c7-49f41286be49" xlink:to="loc_lyel_SonomaMember_ea5e3f79-7170-4369-a2a6-59afef8cd003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a477ebfe-15c0-402d-8e76-f293d0286e7f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8becec59-cea9-4b57-a407-c41d78d9c851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_OperatingLeaseCost_8becec59-cea9-4b57-a407-c41d78d9c851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_2e191eac-8965-4ed4-8cea-711e8e7f744c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_VariableLeaseCost_2e191eac-8965-4ed4-8cea-711e8e7f744c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1eedd511-1fa9-41f5-ae50-b5700c6cfa27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1eedd511-1fa9-41f5-ae50-b5700c6cfa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c8148602-74d1-4d5e-b3ec-da017e4104e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c8148602-74d1-4d5e-b3ec-da017e4104e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_8b03769f-3d07-42d1-8516-d13e389ec8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_NetRentableArea_8b03769f-3d07-42d1-8516-d13e389ec8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_e6b82deb-53b7-4a86-8dc1-4a8bacf9dcef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_SubleaseIncome_e6b82deb-53b7-4a86-8dc1-4a8bacf9dcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_18a2fb13-9452-4348-b6f0-64f3e29ae2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ca691292-0ca6-4ade-8862-ed348e98cf38" xlink:to="loc_us-gaap_TenantImprovements_18a2fb13-9452-4348-b6f0-64f3e29ae2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_484899b4-19b1-4026-84c1-e290b69753aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_484899b4-19b1-4026-84c1-e290b69753aa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc513f30-696a-42ae-8c2c-ca08ada8f8d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a2a76860-727e-4c5f-b392-55f87045c034" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc513f30-696a-42ae-8c2c-ca08ada8f8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GoldmanSachsAndBofAMember_b4892a6e-93d8-4abe-acdf-6e3360faa2f2" xlink:href="lyel-20230930.xsd#lyel_GoldmanSachsAndBofAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc513f30-696a-42ae-8c2c-ca08ada8f8d3" xlink:to="loc_lyel_GoldmanSachsAndBofAMember_b4892a6e-93d8-4abe-acdf-6e3360faa2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_66dceb78-2042-4857-ba90-72d242245aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3043b850-58db-4dd6-a438-c5a7478483dd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_66dceb78-2042-4857-ba90-72d242245aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember_faaf8c52-e9fc-4ddf-887d-4b61b524554c" xlink:href="lyel-20230930.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_66dceb78-2042-4857-ba90-72d242245aa8" xlink:to="loc_lyel_AtTheMarketOfferingMember_faaf8c52-e9fc-4ddf-887d-4b61b524554c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_350e777c-da23-4613-a58c-9e790fc538a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87244095-286b-4544-8db6-0c782b6eba3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_350e777c-da23-4613-a58c-9e790fc538a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityDistributionAgreementMember_6ad608fd-4538-4130-92dd-2b6b3ff8638b" xlink:href="lyel-20230930.xsd#lyel_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_350e777c-da23-4613-a58c-9e790fc538a7" xlink:to="loc_lyel_EquityDistributionAgreementMember_6ad608fd-4538-4130-92dd-2b6b3ff8638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c88da60-7f81-408f-bc17-fa65c3b0505d" xlink:to="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45959906-8752-4e8f-aca0-813e26164502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_45959906-8752-4e8f-aca0-813e26164502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b9b66341-e1a0-44b8-9ce3-e14029f36b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b9b66341-e1a0-44b8-9ce3-e14029f36b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8e0f9128-0d69-4dc5-b620-a26b93603884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8e0f9128-0d69-4dc5-b620-a26b93603884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e36fe927-f164-4a22-9e1c-be1a18cf892c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e36fe927-f164-4a22-9e1c-be1a18cf892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4faa8df0-1185-4fd4-8465-7fa83f899af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4faa8df0-1185-4fd4-8465-7fa83f899af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcd751e9-42e5-44ee-9e92-f24110c3919f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bcd751e9-42e5-44ee-9e92-f24110c3919f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6999fe9-a6c5-45d0-bd2f-5f4fa3133adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6999fe9-a6c5-45d0-bd2f-5f4fa3133adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_2389d8c7-7039-4dea-ab5e-19688a471282" xlink:href="lyel-20230930.xsd#lyel_PercentageOfCommissionFromEachSaleOfShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_132507a6-e52e-4ab3-bbe7-09dc45d66d4a" xlink:to="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_2389d8c7-7039-4dea-ab5e-19688a471282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_091819f9-acbd-40be-8caa-1e1baac04de5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_091819f9-acbd-40be-8caa-1e1baac04de5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:to="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5d64b302-99dc-4042-b31b-3b514b22d09b" xlink:to="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e7b0950c-5129-4d14-90e7-8e888e44fe9a" xlink:href="lyel-20230930.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:to="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e7b0950c-5129-4d14-90e7-8e888e44fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_5fda69a0-57ea-484b-a1a9-61d9b85095f7" xlink:href="lyel-20230930.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:to="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_5fda69a0-57ea-484b-a1a9-61d9b85095f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_970e7ab4-263c-4465-b6d3-e36a851b6496" xlink:href="lyel-20230930.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e09eee65-4e17-4832-8922-dec750ece2de" xlink:to="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_970e7ab4-263c-4465-b6d3-e36a851b6496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:to="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ce2785d-72af-451f-a248-a6d813c1e62e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_08d8ca68-8428-4fbe-a2fe-a526c0b90367" xlink:to="loc_srt_RangeMember_9ce2785d-72af-451f-a248-a6d813c1e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9ff6430e-3f77-493c-ab7b-dcdde28863e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9ce2785d-72af-451f-a248-a6d813c1e62e" xlink:to="loc_srt_MaximumMember_9ff6430e-3f77-493c-ab7b-dcdde28863e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5d54857-28a5-40ea-bf40-76aa5ca30795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3ef206a-2c12-4d01-b556-4a47ec4b87c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3ef206a-2c12-4d01-b556-4a47ec4b87c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_63d210d0-2001-47c8-8b34-ae416c00bb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_63d210d0-2001-47c8-8b34-ae416c00bb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_13ec8c68-3d1b-4fac-a660-7c6e3227aaeb" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_13ec8c68-3d1b-4fac-a660-7c6e3227aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b958910-af8c-42b4-ac76-4227373823f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6b958910-af8c-42b4-ac76-4227373823f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_d90f4700-2daf-43fb-be6f-913a5ca07cab" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_d90f4700-2daf-43fb-be6f-913a5ca07cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea911fae-b33e-4e00-83ba-5e2cb72e5e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea911fae-b33e-4e00-83ba-5e2cb72e5e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9fc37cda-7e7d-44ef-b1be-03fa4e958966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9fc37cda-7e7d-44ef-b1be-03fa4e958966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_0794b394-cebd-4bca-9bb3-d49e4476df7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_0794b394-cebd-4bca-9bb3-d49e4476df7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aecf1cd-b1da-4d03-a84f-cba28f31776a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aecf1cd-b1da-4d03-a84f-cba28f31776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_423e7fcb-5a8a-49f1-9e98-8c31141bd9dd" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_423e7fcb-5a8a-49f1-9e98-8c31141bd9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_9d01df09-9f8f-45d7-b9c1-f4ccd4bb61bf" xlink:href="lyel-20230930.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_9d01df09-9f8f-45d7-b9c1-f4ccd4bb61bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_94216a6a-29a6-4932-b6c7-b131dc2bfe25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_94216a6a-29a6-4932-b6c7-b131dc2bfe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c1f3058e-3634-4562-8315-b5886b093436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c1f3058e-3634-4562-8315-b5886b093436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a11d979d-75df-4c68-8a83-bea6fc387671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a11d979d-75df-4c68-8a83-bea6fc387671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c19e707-cf3f-4e74-a821-d3d4e62b0a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35b0d5a2-8b36-4fef-be08-6808840b902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c19e707-cf3f-4e74-a821-d3d4e62b0a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_061c049b-dac9-4ca8-a703-45528c05ec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_061c049b-dac9-4ca8-a703-45528c05ec1a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cffece33-0f06-4dd0-b3f8-e2828aba6594" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d4906d2-6f37-48b8-83ae-6223556271dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d4906d2-6f37-48b8-83ae-6223556271dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a9a4a26b-e321-4f8a-b913-894291d756b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fe22f0c-5bbb-4eda-8802-39ef7168f901" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a9a4a26b-e321-4f8a-b913-894291d756b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab94a858-40b9-4743-9e41-25cd5bac7137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01af3309-beeb-40b8-b1bc-53c52dce4996" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab94a858-40b9-4743-9e41-25cd5bac7137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8349fb2b-46d0-42c2-a98e-e434ac19b58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab94a858-40b9-4743-9e41-25cd5bac7137" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8349fb2b-46d0-42c2-a98e-e434ac19b58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationScheduleofRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_080c081b-7924-4ab7-971d-414463532cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_080c081b-7924-4ab7-971d-414463532cff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:to="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21859f7f-c2d2-4fa3-a08c-949414bc90b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4deebaa2-026d-4f03-a512-9d929ead11b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21859f7f-c2d2-4fa3-a08c-949414bc90b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ea201ddd-e228-4b2c-8ebe-5bdd1017c006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21859f7f-c2d2-4fa3-a08c-949414bc90b4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ea201ddd-e228-4b2c-8ebe-5bdd1017c006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba7d8ec2-3082-44a8-b4f3-fb60e410a661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e21a76a3-9d0d-407c-aefe-ab8a2e14c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e21a76a3-9d0d-407c-aefe-ab8a2e14c8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9bc3ed7-53e3-4894-811d-f361c405f719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9bc3ed7-53e3-4894-811d-f361c405f719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6577e8e0-507a-406d-8a84-9c5c80e771c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6577e8e0-507a-406d-8a84-9c5c80e771c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20560f75-21ba-40e5-80f6-cf10d04b3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20560f75-21ba-40e5-80f6-cf10d04b3b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af73f7c4-4e57-4ab7-a0ab-f62d70b91afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03569c72-0238-43f4-83c5-4f5240e493f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af73f7c4-4e57-4ab7-a0ab-f62d70b91afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d8d29c0-1d92-469c-94f9-90bd2f7ff8e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8effc4f-b7a5-4fad-879b-e7b35b5abf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8effc4f-b7a5-4fad-879b-e7b35b5abf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_35b3ce82-25da-4339-ad0c-a7ccbfdced46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_35b3ce82-25da-4339-ad0c-a7ccbfdced46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1742bac9-1aed-44f2-b423-e62279d006ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1742bac9-1aed-44f2-b423-e62279d006ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d2f74131-6e18-486a-8de1-4d49113b6f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d2f74131-6e18-486a-8de1-4d49113b6f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4bd99472-5846-4745-8816-db2d49f1a3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_efd675a8-349b-4034-8048-62ddc4aac0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4bd99472-5846-4745-8816-db2d49f1a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_95edabc3-5301-46e5-bc36-a28807052852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_95edabc3-5301-46e5-bc36-a28807052852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0008d6d3-2c16-4d1d-aa42-bb9d7875bd72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0008d6d3-2c16-4d1d-aa42-bb9d7875bd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b3e4626-3daa-4d9a-b2d4-acca23a619cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b3e4626-3daa-4d9a-b2d4-acca23a619cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6eb71525-81a7-4ca8-a2c7-8dc3e6ddeb82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6eb71525-81a7-4ca8-a2c7-8dc3e6ddeb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6aaeac7f-da24-4af5-9be8-ca321fc10694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_589cd91d-ef5a-4dc4-b2a7-151453cbe226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6aaeac7f-da24-4af5-9be8-ca321fc10694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d9cd3d4b-d08a-4e20-a6c2-35a14e38fcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d9cd3d4b-d08a-4e20-a6c2-35a14e38fcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dde72a45-96e8-4bb1-88fe-e61874aa26ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dde72a45-96e8-4bb1-88fe-e61874aa26ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d2a2ecbc-87c2-4abf-8354-47efa419ca2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d2a2ecbc-87c2-4abf-8354-47efa419ca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9f8a58d-5c94-4f16-88c9-7e033a51e1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9f8a58d-5c94-4f16-88c9-7e033a51e1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_49f01416-0cd1-4074-9a95-de9e02842abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_49f01416-0cd1-4074-9a95-de9e02842abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_475650ba-d626-4f26-9249-6530f63a9177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_254b74f4-d2c7-406c-b78e-2a4faa378579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_475650ba-d626-4f26-9249-6530f63a9177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8c95f69a-96f5-43b6-8118-134b5f5a1682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8c95f69a-96f5-43b6-8118-134b5f5a1682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7afd070-5594-43a3-8153-4790933457f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7afd070-5594-43a3-8153-4790933457f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18fc89b3-8efc-436f-9759-16eca2d5934f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7afd070-5594-43a3-8153-4790933457f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18fc89b3-8efc-436f-9759-16eca2d5934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c381dee-40a3-484c-862a-4bb98e24f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7afd070-5594-43a3-8153-4790933457f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c381dee-40a3-484c-862a-4bb98e24f85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cf9185e9-a4ee-48e0-8276-d61d39664fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee7c220e-5dbe-40c5-924f-6b71a3cab320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cf9185e9-a4ee-48e0-8276-d61d39664fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8dca86a2-2381-49d7-b75c-b5f7b2dd707f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cf9185e9-a4ee-48e0-8276-d61d39664fe8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8dca86a2-2381-49d7-b75c-b5f7b2dd707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4f34a829-cb2d-4cdf-80de-bf822e1806fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cf9185e9-a4ee-48e0-8276-d61d39664fe8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4f34a829-cb2d-4cdf-80de-bf822e1806fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c7833e-9a36-4e50-83a9-8ce8742706b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394f547d-60ef-4012-aafc-3f9994bf3822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c7833e-9a36-4e50-83a9-8ce8742706b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394f547d-60ef-4012-aafc-3f9994bf3822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7d2cf811-32c1-4be9-be42-8fbc1f87d374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c7833e-9a36-4e50-83a9-8ce8742706b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7d2cf811-32c1-4be9-be42-8fbc1f87d374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4d83cd7e-8d3e-453e-aef3-405c15013b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c7833e-9a36-4e50-83a9-8ce8742706b2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4d83cd7e-8d3e-453e-aef3-405c15013b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ea346c6e-6230-4be5-9931-90b7bdaac4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c7833e-9a36-4e50-83a9-8ce8742706b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ea346c6e-6230-4be5-9931-90b7bdaac4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#RelatedpartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bd32d014-bcb1-408a-95f3-5bb7642d5682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bd32d014-bcb1-408a-95f3-5bb7642d5682" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eda2a564-8a59-49f2-a6f1-90001230344e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b4879f51-9635-47c1-976e-cc2916fafdc0" xlink:to="loc_us-gaap_RelatedPartyDomain_eda2a564-8a59-49f2-a6f1-90001230344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f08224f6-3fe6-41a7-aaca-44fec4eed5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eda2a564-8a59-49f2-a6f1-90001230344e" xlink:to="loc_us-gaap_RelatedPartyMember_f08224f6-3fe6-41a7-aaca-44fec4eed5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fec6078f-1768-4db9-9110-cc4a800abe8c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_607f6b08-df8e-432d-ba91-83b15e8423eb" xlink:to="loc_srt_RangeMember_fec6078f-1768-4db9-9110-cc4a800abe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_402abb00-4e2d-40ae-a0a1-187b299eb5cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fec6078f-1768-4db9-9110-cc4a800abe8c" xlink:to="loc_srt_MinimumMember_402abb00-4e2d-40ae-a0a1-187b299eb5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_be910160-1bc6-4f2b-83c9-1f7d7171662c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0ac2cfd0-d1ce-430f-b3ab-bb070defc88d" xlink:to="loc_srt_OwnershipDomain_be910160-1bc6-4f2b-83c9-1f7d7171662c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LyellImmunopharmaMember_b0eceaef-9a9f-4420-9832-773fe475b203" xlink:href="lyel-20230930.xsd#lyel_LyellImmunopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_be910160-1bc6-4f2b-83c9-1f7d7171662c" xlink:to="loc_lyel_LyellImmunopharmaMember_b0eceaef-9a9f-4420-9832-773fe475b203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_75d0167e-90be-4341-98d8-7210247b4435" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_624b7c37-7311-46e5-bea1-32a4d126da7d" xlink:to="loc_dei_EntityDomain_75d0167e-90be-4341-98d8-7210247b4435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_33369945-0bbb-4e90-92e1-3b376ec716e6" xlink:href="lyel-20230930.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_75d0167e-90be-4341-98d8-7210247b4435" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_33369945-0bbb-4e90-92e1-3b376ec716e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4ebc563d-7de7-4b94-8990-8b7588a0d944" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_74073152-d399-4b6d-99a7-ef3b6cb06bfd" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:to="loc_lyel_SonomaMember_74073152-d399-4b6d-99a7-ef3b6cb06bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GSKMember_a33d949c-c3d0-4ef8-8732-a4bf7bdf94fa" xlink:href="lyel-20230930.xsd#lyel_GSKMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7ba39ee-0045-4395-8792-dcfe720e005f" xlink:to="loc_lyel_GSKMember_a33d949c-c3d0-4ef8-8732-a4bf7bdf94fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e82168fc-2ad9-46a8-92d8-ead85dc3baf9" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_b0f4eaed-2f73-4f26-b923-a398b8b99e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_NetRentableArea_b0f4eaed-2f73-4f26-b923-a398b8b99e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_c49db546-340e-4dc6-aaeb-8e9f7423d223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_TenantImprovements_c49db546-340e-4dc6-aaeb-8e9f7423d223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_dc1b4493-7a8b-4996-a0ae-7b029372b95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_dc1b4493-7a8b-4996-a0ae-7b029372b95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_22df3143-740c-4656-a527-a8c850bee8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_22df3143-740c-4656-a527-a8c850bee8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d92bc56c-11dd-43fb-8b37-8af98f7fd28b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d92bc56c-11dd-43fb-8b37-8af98f7fd28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_81ef6d02-2dde-4403-b804-40a94a311ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_ContractWithCustomerLiability_81ef6d02-2dde-4403-b804-40a94a311ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_452da315-eba9-40f3-8442-c76bf583e388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2fa8ef89-6516-4bd9-93e3-7592e25b3878" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_452da315-eba9-40f3-8442-c76bf583e388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ec11ea8a-1685-42bf-ab78-8831a0efe6de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ec11ea8a-1685-42bf-ab78-8831a0efe6de" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_02058b55-0c20-48aa-8858-6bbd106112eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7930537-954e-43f7-8d5c-8342127bb4c1" xlink:to="loc_us-gaap_RelatedPartyDomain_02058b55-0c20-48aa-8858-6bbd106112eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2006e164-9448-4c61-b635-0fced5575dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_02058b55-0c20-48aa-8858-6bbd106112eb" xlink:to="loc_us-gaap_RelatedPartyMember_2006e164-9448-4c61-b635-0fced5575dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:to="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1166274f-aaa7-4bfc-bb84-0fbc58dd00e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8dacf4fc-705b-4e6e-992c-ff12e935b2c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1166274f-aaa7-4bfc-bb84-0fbc58dd00e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_7e766496-738f-4ed3-9974-62b020a5ac37" xlink:href="lyel-20230930.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1166274f-aaa7-4bfc-bb84-0fbc58dd00e1" xlink:to="loc_lyel_SonomaMember_7e766496-738f-4ed3-9974-62b020a5ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3a5ea359-afda-4e4a-aef2-9786ae773e9e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a865485a-d2c0-4442-8cd0-926bb9f59ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a865485a-d2c0-4442-8cd0-926bb9f59ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_65f0da3b-aeb6-4f16-876f-36ec29435265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a3e0209b-c22a-4360-8365-ac064ca40538" xlink:to="loc_us-gaap_SubleaseIncome_65f0da3b-aeb6-4f16-876f-36ec29435265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="lyel-20230930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_28ac1ced-8c53-4e91-9ece-bd655c63e42a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_28ac1ced-8c53-4e91-9ece-bd655c63e42a" xlink:to="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b4e8af84-1483-48bf-a024-61ea29e52e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9ffc856a-f451-42f4-9f49-24b5e9453bdb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b4e8af84-1483-48bf-a024-61ea29e52e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_70d4141d-df8f-4a4e-86b1-927ebc288d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b4e8af84-1483-48bf-a024-61ea29e52e6b" xlink:to="loc_us-gaap_SubsequentEventMember_70d4141d-df8f-4a4e-86b1-927ebc288d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_32b3bba9-0344-40a5-a2b0-17bdc98d057b" xlink:to="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f1c9b88-d5c2-4548-baa2-91165c95507e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:to="loc_srt_MinimumMember_7f1c9b88-d5c2-4548-baa2-91165c95507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_384ce796-0900-4e23-bd83-1610b037c93b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ec2e32a6-494c-4370-847f-dd3afc497db0" xlink:to="loc_srt_MaximumMember_384ce796-0900-4e23-bd83-1610b037c93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_01619391-3173-4303-9b9e-c27b4b867276" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_84d5a542-f1cd-4ff8-a7ba-aad3c5c89cc8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_01619391-3173-4303-9b9e-c27b4b867276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_47edb95d-5ed9-4d18-82a5-bd12d3c113c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_01619391-3173-4303-9b9e-c27b4b867276" xlink:to="loc_srt_ScenarioForecastMember_47edb95d-5ed9-4d18-82a5-bd12d3c113c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82fcafa4-eb31-4f12-97ba-4e04e0d5b72e" xlink:to="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3eb3d7fb-ca94-4bcc-98e5-8221ac3b4de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3eb3d7fb-ca94-4bcc-98e5-8221ac3b4de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_808dd410-2428-4f84-b3c3-217b184d9d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_856b7966-89a4-4e57-8ad5-699ac5bb1234" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_808dd410-2428-4f84-b3c3-217b184d9d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>lyel-20230930_g1.jpg
<TEXT>
begin 644 lyel-20230930_g1.jpg
M_]C_X  02D9)1@ ! 0 !2@%*  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        %*     0   4H    !  .@ 0 #     0 !  "@
M @ $     0  #X&@ P $     0  !U<     _^T .%!H;W1O<VAO<" S+C
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MW0 $ /G_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]#]_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y/3O'W@7
M5]7?P_I/B/3;W5(BP>T@O(9+A2GWLQ*Q<8QSQQ0!UE%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4454O[^QTNSFU'4[
MF.SM+=2\DTSK'&BCJ69B ![DT 6Z*Y[P]XN\)^+8I;CPKK5EK,4!"R/97,5R
MJ$] QC9@#QWKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKD]7\>
M^!O#^I1Z-KWB/3=-U"8 I;W-Y##,P;IMC=@QSVP*ZP'/(H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__T?W\HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX13XN^(=2U?3;. Q/<3VFLR27-H92%0SB*4L 6(4D%@"<$C-?IU_P3U_:_\
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M_'OP<O-8N/A?J'AJ2\U%M.N9(;.2";]\SW<2.N]&MV7AU(QN'J*_(7X0Z?\
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M\:>(M>T'P_J=A/KL=UKDSP)8/*?,\R&>?]ZK(CC"JW..A(HY N?T@T5^6_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2V@N)EFM;R0\>7!/M3]X3T1U4G("ECQ0XL+GZ#4445(PHHHH **** "BBB@
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MK$[+P0"1^5 $E%8WAZZGO=&M;FY??*ZG<V ,X)':MF@ HHHH **** "BBB@
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M^]U9;:.T$D.B2VZ^5$S,H*QQ*"07/)YQ@= *Z/\ 9+_;G\5?LNZ5J/@N_P!
M7Q-X<O+AKH6S7!M;BUN6"H[1R%) 58*-T93[PR&&6S]+>-O^"NWB^\M_(^'7
M@"RTN;_GMJ=W)>@CVBA6WP?JY^E&H'W)J7ASQ-X1_P""=.H^&/&5NUIK.F>
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M ()[?![X\_ GP_\ %#Q9KFO66J:L]ZLL5E/:I HMKJ6!=JRVTC<J@)RQYSC
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M'(YK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBLS69Y;;2KNX@;9)'&S*?0@4 :=%5;"5YK&WFE
M.7DC1F/J2 35J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **PO$=W<6.EM<6K^7('C&< \%@#UK=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HK"UF[N+6?34@?8)[E4?@'*D'(YK=H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK"TR[N)]4U2WE?=';O&$&
M!\H9<F@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _,C_@J__P FVZ-_V,]E_P"DEY7Y"?L4_#KP;\5_VE/"?@/Q_IPU
M;0M174#<6QDEA#F&QGEC^>%D<8=%/##.,'CBOU[_ ."K_P#R;;HW_8SV7_I)
M>5^3W[!'B;PWX/\ VJO!OB'Q;JMIHFE6J:D);N^GCMK>/S-/N$7?+*51=S,%
M&3R2 .36L=B7N?K)\;?^"9OP&U[P1JDWPFTN?PKXFM8))K,QW=Q=6\\J#<(I
M8[B24A7QM!0J5)#8;&T_SPV5[>:;>0:CI\SVUU:R++%+&Q5XY$.Y65AR"" 0
M1T-?TX_'C]N_X#_#'P1JMYX4\6:?XK\2M#)'I]GI<Z7BM<LI\MI9(2T:1JV"
MY+9QPH)XK^8RTM+J_NX;"QA>XN;EUCBCC4L[NYVJJ@<DDG  ZT0OU$S^M?P5
M\9],7]FO0?CIXXG9+;_A';75M2DBC+-YGV=7GV1KU^?< !Q]!7COPG_X*"?L
M^?&#QI#X%T";4M.OKB&YG274;9+>V\NTA>XE+2K*X0+%&S$O@8'7-1_%7P5<
M_#G_ ()^ZQX$OL?:]"\&):7&,8\^*W42XQVWYQ7\QMO=7-F[2VDSPNR/&61B
MI*2*4=21V9258=""0>*2BF-L_HC\7?\ !5+]GKPYXDFT32--UGQ#:6TAC>_L
MX85@?!P3")IHW<>A*J#VR.:_0WP;XKTCQWX1T3QMH#.^F:_96]_;&1=C^3<Q
MK*FY><-M89&>#Q7\Y?PV_P"";'[0WQ)^']MX]@;3-#74(UFM+'4IIHKJ:%AE
M9"J12+&''*AR"1R0HQG[;_;0^*?BK]FC]ECX<?L_:+?BV\4:OI%MIM_=6K$>
M5::?;Q17/DM\I'G2$(K8!*!^ 2"$XK9#N?4'Q=_X*#_LW?"+5+C0+G5KCQ-J
MUHQ2:WT6);D1.#@JTSO'!N!X91(64\$ \5X78_\ !6KX$S70BO\ PKXBMH"P
M'F+%:2$#U*_:!^A-?CA^SG^SWXP_:3^(D7@+PG)'9I%$;J^O9@3%:6J,JLY4
M8+L2P"(""Q/)"AF'W[\7/^"4GB#P?X%OO%'P\\9'Q-J>EP-/)I\]B+5KA8QN
M?R)%FD ?:#M1A\QXW XI\J%=GZ[?!C]HKX0?'[3IK_X8Z_'J,UJH:YLY%:&\
MMP3@&2%P&VYX#C*$\!C7MU?QS?"GXG>*?@[X_P!'^(G@ZY:WU'2)ED !(2:+
MI)#(!U21<JP]#D<@&OZ<?V@OC_#X#_98U3XX^%&_?:CI5K-I)8!B)=4$:V[D
M<@^7YHD(Z':12E$:9@?'7]NKX!_ /5Y?#'B"_N=<\06^/.T_28TGE@)Z"9W>
M.)&[E"^\#G;@C/CW@/\ X*E?L[>+-:AT;7[35O"BW#!4N[Z&*2U4DX'F-!)(
MZ9]2FT=20.:_GQT31O$_Q$\76>AZ5'-K'B#Q#>+%$K-NEN+JY?&6=SU9FRS,
M?4D]37Z7>,/^"47Q<\/^ G\1Z!XEL/$'B&WC\V;2(H7AW@#)2WN';$C^@9(P
M?7.!5<JZBNSXH_:GO['5?VCOB/J>F7$=W9W>N7LL,T+B2.2-Y"5=&4D,K Y!
M!P17]%?["G_)I?PX_P"O&;_TIFK^5ZZM;JQNIK*]A>WN+=VCDCD4HZ.APRLI
MP001@@\@U_5#^PI_R:7\./\ KQF_]*9J)[ CBOBC_P %#OV??A-XZU7X>>(A
MJ]UJFBR^1=&TLU>)), E0TDL9.,\D#'H37U5\+OB7X6^,/@+2?B1X*EDFT;6
MDD>!IHS%)^ZD:%U9#T*NC#N#C()&#7\P/[:7_)U'Q+_["TG_ *"M?O=_P3U_
MY,]^'O\ N:E_Z<KJIE&R&F>F_M ?M,?#/]FO2M*U7XCM>%=:EEBM8K*#SY',
M(5G)RR*  R]6YSQWKG/V?_VP/A#^TGJNIZ'\/3J$-_I,"W,T-];"$F%F";E9
M'D4X8@$9!YZ=:^$O^"OW_(M?#/\ Z^]3_P#1=O7C7_!([_DK_C7_ + 2_P#I
M5%1RZ7"^I^]M]?66F64^HZE<1VEI:QM+--*X2..-!EG=F("JH&22< 5^>GQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_#_P7I6AWA!7[3;VJ"XVG@KYQ!DP?3=BO6J*=P"BBBD 4444 %%%% !1110
M4444 %%%% !1110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %8_B#_D!WW_7%_Y5L5C^(/\ D!WW_7%_Y4 6M,_Y!MI_UQC_
M /015ZJ.F?\ (-M/^N,?_H(J]0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <SXN_P"0*_\ UTB_]#%=
M-7,^+O\ D"O_ -=(O_0Q734 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!S/B'_ (^=(_Z^T_D:Z:N9\0_\?.D?]?:?
MR-=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7,Z-_R&M:_ZZ1?^@5TU<SHW_(:UK_KI%_Z!0!TU%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__U/W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\R/^"K__ ";;
MHW_8SV7_ *27E?@G\./AOXS^+?C&Q\ ?#[3_ .U->U(2FWM_-B@WB")II/WD
MSI&,(C'EAG&!S@5^]G_!5_\ Y-MT;_L9[+_TDO*_+G_@G+_R>%X&_P!S5?\
MTVW-:QV)>YKZ+_P33_:VU2Y2"^\-V>CHQP9;K4[5D7W(MY)F_)37Z:?LI?\
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MOQEXBU/Q9XENFOM5UBXEN[J=\!I)IF+NV!@#)/0  = ,5_49^PI_R:7\./\
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M_42?[I_E0!A^%/\ D7[/_=/_ *$:Z&N>\*?\B_9_[I_]"-=#0 4444 %%%%
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M\/A)?^B3+_X/?_N&C_A\)+_T29?_  >__<-/E8KG[945^)O_  ^$E_Z),O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8
MKIJYGQ=_R!7_ .ND7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2PXS&2CRR >Z(#V8CFFD%S]5Z*_!:W_X*Z_$U;[S+OP'I$EG_P \TN+A)?\
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M$/VKH/%*S>%O^$9N?"YL]P6\^UI.MYYVT@F*(J5,)R,'.1SVHLPN?;-%%%(
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M HHHH **** /_]7]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTRY@,UFDCDEC Z,'B3/2/:X'\)50%'FOP^_X)&7R:O#<_%+QS"^FQ,#);:1
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M8KAX+"UD:6=8G#>7OE9!'NQ@MM;'H:_;.BGS,5@HHHJ1A1110 4444 %%%%
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MQ(QLE?3-0C>R5L'Y&>W"1!L$?*64X(R.:YWX+_\ )QG@3_L:]+_]+HZ_?O\
MX*(_ RT^+?P"U+Q)86BR>(_ ZOJ=I(JYD:V09NX<]=K1 R #J\:ULWJ0D?-7
M_!+[X ?#5-(?X^Q:]'X@\3H);%;-(S&NCNX'F!P_S/+(AP'&$V,P&XDD0_\
M!7/Q[J=CX>\!?#>QNFCL]6FO-1O8E./,^RB*.WW>J@R2''3(!Z@8^-O^";_Q
MK;X5_M 6GA?4[CRM#\>*NESACA%N\DV<GU\PF(>@E)KZY_X*\>#+^>Q^'?Q
MM;9GL[1[_3KN8#*QO-Y4MNI/;=LFQ]*G[0^A\U_L6_'7]DOX(^$M2N_BUX>N
MM9\9:C=.//.G0WL4-DJJ(XXC+(-I9MQ<A03P#D 5\P_M2>*O@QXW^+M]XL^!
M.FS:1X=U.&*66UEMTM5BO.1-Y42,RJC85L @;BV !BOKS]AK0_V)/'7A"^\,
M?'ZQTZS\8VMV\D-SJ>HW%C#=VDBKL".)XH0Z-N!3AB,,,_-C[ \;?#W_ ()4
M_#ZW^T>(3H3M_P \K'5;_49L^\5I<3./J0!3O9BL5/VBO%-]XT_X)@:-XEU2
M9[B^O--\/?:)9#EY9H[B".21B>I=E+$^]?GC^P'^SAX0_:)^*NH6OCV2230O
M#5HM[-9QL4-X[R!$C:12&2/J6VD,<  C.1^L'[>^G>'-(_8;U33/!]O':Z%;
M+HJ6,4*E8TMA=0>4%!YQMQUY]>:_)_\ 8#_:/\(_L[_%6_N?'D;QZ%XFM4L9
M[V,%S9,D@=)6C4%G3/#;?F .0#C!%L-[GU#_ ,%)OV4_A;\+O _A_P"*?POT
M6+P\3J"Z9?6ML6$$JS12212A&)"LIB*DKC=N&02,UW/_  2$\5ZA<Z#\1_!%
MQ,S65A<:?J%O&?NK)=+-%.1Z9$,7Y5Y]_P %)OVK?AA\5/"'A_X5?"[5XO$"
M17ZZI?WEN&,$9BBDBAA5V #,WFLS;>%PHSDD#T__ ()$^"]0L/"7Q \?7=N4
MM-8N[&PM9&XWFR25YMOJ,SH,],@CJ#2?PZAU/R1^+NEW.N?M"^--%LMHN-0\
M4ZE;Q[SA=\M](BY/.!D\U^__ ,+/^"=/[._@#2?#=SK.E2ZYXJT.>WO9-5>Z
MN(O-NX6$G$"2"(1!Q\J%"<#YB3DG\(O%W_)V6M?]CM<_^G)J_K4IS8(_D\_:
M5\5Z[\:/VH/%UQ+=&ZDO-=ETK3]Q^1+:"<VUJH Z#:%)P.22>I-?T%^&_P!A
MW]F?0OA[!X O/ ^G:H1;B&?4KB!6U&:0KAY1=?ZV-B22 C +P%  %?SQ?M >
M']:^$'[3/C"SDMC:W&D>(;B^LUD'#0/<&YM7X_A>-D;CUQUK^AG0?VZ/V9-7
M^'T/CZ[\;V&G9MQ--ILTH&I12!<M"+4?O'8$%044JW!!P0:4O($?SE>-=+U;
M]GGX_P"KZ7X<O76]\":[(+*Y!P["SGS"[8&,LH&X8QR1TK]2O^"N5SJ>H>'O
MA3J-GN;1+A]3=B <>=(ELT6[MDIOVC_>K\P=<EUS]IG]HN_G\.63B_\ '^O2
MO;6XY:*.ZF)7<>F(H^7;H I/2OTS_P""M/C/6]+M/A_\)]/C-OX=DCFU%\*-
MLL]OB"% W4>2C,2!P?,!/08I[H1N?L6^,/V+M&_9;:Q^)EQX=@US-[_;T.K+
M ;ZYS*YB$*2#S95\C8$$(.&S@;\FOSI_8^\(:%\0/VK/"/AJ32(=6T&[O;MY
M+2^B6>)K..WFD(E1MRDA%X)SA\$'.*F^'OPK_92\4>&=)U/QI\;;GP?K4B?Z
M?ILWAVZO D@8_P"JN(',>TC&"1GU Z5^OW[$7@[]C+X?WD\7P8\;VWBWQGJ4
M!CFN;R3R;UX 0S1V]K(L;)'D L%5F.!N8@ !/09PG_!6&RL],^ G@G3M.@2U
MM+77HHH88E"1QQI93JJ(HP%50  !P!7Q7_P3V_9)\'?M":QKGC'XE%KOPYX:
M>* :='(\37=S,I8>9)&5=8D49PK LQ'( (;[>_X*W?\ )$?"'_8Q)_Z27%<]
M_P $B/\ DGGQ _["MK_Z(-*_N@]S[P\.?LK_  5\&?#'Q9\)/">D2Z5X;\9"
M?[?&ES++(#/$(28Y)VD9=BJ"N<@'D@\U\/Z5XC_X)?\ [.;2>&XO[,\3:K;$
MK-<S64FO3,ZG!_T@Q/;H>Q$14>HKZ0_X*&^+/$?A']E3Q5=^&99;:>^DL[*:
M>%BCQ6UQ.BR\CG$B_NC[.:_&#]A?X2? #XL>.M:L_CUKD5A;:=;126%C->BP
M2^D=F$F9MR,?*4 [$8,=V<X4T+:[&SC?VQ/&/P \>_$ZV\4?L]:=_9.DW-BB
MWUNMH+*'[:DCYDCA'RJ&C*9V@ D$XR23^ZG[$^HW&J?L3^#+FZ.733=1@'^Y
M;W5S"G_CJ"OP_P#VUM*_9N\/_$^S\.?LUQP_V3IMD(]0EM;F>\MY+TR,3Y<\
M\LN_;'M!*-MSQDD&OVQ_85_Y,?\ !_\ UYZQ_P"E]W3EL);G\[7P4^'*_%SX
ML>%OAJ]Z=.3Q#?16KW 3S#$C<LP7(R=H. 2!GK7["?MM?L7_  +^&/[,-YXO
M^'FA_P!E:QX0>Q)N_-DDFO(KBXCMI!<%F*L290^0HP5PN%.*_,G]BW_DZCX:
M?]A:/_T%J_>O_@H=_P F=_$'_=TS_P!.=K1)Z@MC\2_V$OV=O"_[1GQAFT/Q
MK/(NA:!9'4KFVB)1[P+*D2P>8I!127R[+\VT$*03N7WK_@I=^SC\,?@Q=^"O
M%/PPTE-"M]=%Y:W=I"S&$R6HB:.10[-M9ED8-C@[0<9R3=_X)(?\EJ\8_P#8
MOG_TK@KW'_@K[_R*OPU_Z_=2_P#1<%%]0Z'KO_!*75+K4/V:M3M+ABR:9XDO
M;>($Y"HUM:S$#T&^5C]3FOP_^*ND2:_^T9XPT**01/J7BO4+9789"F:_= 2!
MV&<U^UW_  27_P"3=/$?_8UW?_I#8U^-WB[_ ).RUK_L=KG_ -.34X[L'L?L
M/\7_ /@G_P# ;P+^RSXH31]+,WBCPQH]UJBZY([BZGN;*$SON7=Y8CD"%!&!
MA0<\L-Q_';]E?X,:?\??CCX>^&>KWTFG:??F::YEB ,IAM8FF=(\\!G"[0Q!
M"YS@XP?Z;_VC_P#DWGXH_P#8K:W_ .D,U?S^?\$U_P#D[CPO_P!>FI_^D<M3
M%Z T?5W_  44_9.^#7PG^#N@^//A?H2>'[RPU*'3KA8I)'6YMYXI"&D\QV)D
M5XQANI#-NSQC?_X(_P"J74ND?%+1'8FWM9](N$7/ >X6[1R!ZD1+GZ>U>]_\
M%3_^388O^P]8?^BYZ^<O^"/77XM_]P'_ -OZ+^Z'4^$OV^/^3NOB+_U\VG_I
M%!7[Q?&+_DQWQ)_V([_^D K\'?V^/^3NOB+_ -?-I_Z105^\7QB_Y,=\2?\
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MQ)R:EO2P(]@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-VW<%.<9QVK^BWQ?^W3^S5X<^'=SX[TSQKI^LS?9C+:Z;;3!K^:8KF.)K?\
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M# P!^SO[ &J76L?LA?#R[NV+R1P7MN"3GY+:_N(4'/8(@ ].E?F9_P %<?\
MDL?@O_L G_TJEK](?^"=?_)G/@#_ +BO_ITNZ); MS\ _%W_ "=EK7_8[7/_
M *<FK]>_^"MW_)$?"'_8Q)_Z27%?D)XN_P"3LM:_[':Y_P#3DU?KW_P5N_Y(
MCX0_[&)/_22XJGN@[GQY_P $Y?V4_A[\=+[7_'OQ+0ZIIGAJ:*VATO+)%//*
MI?S)G4ABB <(.&)^8[1M;@_^"B_P'\"_ [XOZ3'\.;$:5H_B+31=FS5F:.&X
MCE>.3R]Q)", K;<X!)QQ@#[>_P""1'_)//B!_P!A6U_]$&O$?^"NO_)3/ ?_
M &"+C_TH-*^H6T/KC]G#4_$6M?\ !,^Y_L@O+J]OX=\2VUL>6<M%)=K"$[Y"
M[54>H':ORP_8 U;X):-\>TO/CB]A#IPT^==.EU0)]BBU O'L:4R_NU_=>9M9
M_E#8Z-M-?I5^S;XXU[X;?\$R[GQSX70MJVD66MS6K!0_ERF]G592IX(BSO(/
M&%YK\6?A)X<^$GC'6M1L_C%XWN? \#1>9;7\6FR:G&TY;YEEBA82 $<@J.O4
MCN);@SZ5_P""A^N? W7OC;:77P1?3KB%--C75)])$?V*6\\QR"K1?NW<1[0[
M)D= 26!Q^WO[&7@#1/!/[._@B[LM$L])U77-'L+O4)+:W2&6Z=X0T;SE0"\F
MQADMDY)[DU^4?P.^"W_!//2_%%EJ?C+XTIXP:V='2TN[&XT6Q>0$$>=YZDLG
MJIE4'^+*Y!_?C3KS3]0L+>]TF>*YLIXU>&2!E>)XR/E*,N5*D=".*F3TL-%V
MBBBH&%%%% !1110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?%_[2_[$?P[_:=\4Z5XO\4Z
MSJ6D7^EV?V$?8C#LDA$C2KN$L;'*L[<@\Y]J^T**:8'X=?M!_P#!-CX7?"#X
M,>*_B7HOBG6;V^T"T^T10W'V?RG;>J8;9$K8PW8BOR5\ >';?Q?X[\.>$[N5
MH(-;U*SL9)$P71+F98F9<\9 ;(S7]0O[;_\ R:C\2?\ L&C_ -'1U_,Y\$O^
M2S> O^P_I7_I7'6L62T?M9_PZ/\ @U_T.>O_ /DK_P#&:^N_A]X>^"?[$_PF
ML_!FL^+H=,TJ.>>X%SJ]Q%'/<RS-N;8BA=Y48 5%)P,GN:^IJ_GJ_:;_ &7?
MVFOCC^UGXS_L7PU?7FG27$0L]2O,P:;'9")/+$=Q)A"%&0R1[F#;OESFH6NX
M['Z7:A_P4?\ V1;&X-O'XOGN]I(+PZ;>E!CW:%<CW&:]E^%_[5'[/WQEOUT?
MX>>-+/4=2D!*6<HDM+I\#)V0W*1N^ ,G8#@<]*_)&#_@D9\56TAI[GQQHT>I
M[,K;I%</"7Q]TS%58#/&?*/KBOS$\3>'O%?PL\=:AX;U;S-+\0^&;YX7:)RK
MPW%L_#QR+@\$!D<=1@BGRI["NS^RNOF'4_VS_P!E_1O$EQX1U/X@V$&J6MPU
MK*A6<QI,C;&5IA&8AAA@G=@>M=7^S/\ $/4?BM\!/ _C_6)!-J.JZ=&;N11@
M/<PDPS-@<#=(C'';.*_E<^+I*_%OQJPZC7-2/_DS)2C$;9_41\8?VL_@)\"=
M3CT+XB^)X[35I%$GV*WBENKA4;D-(D*MY8(Y&\KD<C-=_P#"7XR?#GXY>%3X
MS^&.K#5]*2=[61_*DA>.>-5=HW2548,%=3TP0002*_EZ^'GP2^/_ .U1XCUW
MQ%X1TJX\37[3-<:EJ%Q-'#&9YCN(::9D0R-U"*<@<X"U^P_[*/A[XB?L=_LA
M?$KQ-\3M!_LS6-+OK_5+:REECD\[9:6\4&YH790CS(5X.<<^E#B"9]Z?$[XZ
M_"'X-0P2_$[Q59:"UT"88IG+SR*.K)#&&E91T+!<9XSFO [#_@H=^R%J%[]A
M3QV(6)PKS:??Q1M[[VMP /\ >Q7\\'A_2/B3^U'\;+;26O/[3\6^-;YR]Q<L
M0BDAI)'; .V*&-6.U1\J+A5X K['_:(_X)L>+O@=\,+OXFZ1XN@\4V^CJDFH
MVWV-K.2*)V"&2(F:42!2PW ["%R1GI3Y5U%<_8'_ (;@_90_Z*3IW_?,W_QN
MOIC1-;TGQ)H]CXAT"[CO]-U*&.XMKB%@\<L,JAD=&'!# @BOY#O@E\(==^.W
MQ(TSX7^&=0LM-U75EG-O)J#2I QMXFF92T4<K!BB,1\N#C&<XS^WG[4?Q7U_
M]C/]D_P-\)/#.I*?&FH6$6D17L.5\B*SA07ES#D @[F5(R0"-^[JM)Q&F?87
MQ2_:O_9[^#5^^D?$#QG:66IQXWV<"R7ERA/0216R2-'D<_.%XKRW0?\ @H?^
MR1K]ZFGIXU-A+(=JM>6-W!&?K(T6Q1[LPK\!OV=?V=_'O[4?Q"G\,>'+E+=8
M4-YJ6I799T@C9L%FQ\TDCL?E7.6.22 &8?1G[3?_  3L\:?L]^ W^)&D^)8?
M%VC6+1KJ&VT:SGMA*RHD@3S9@\>]@K'<"N0=I&2KY5L*[/Z--(UC2/$&F6VM
M:#>P:EI]X@D@N;:19H94/1D="58'U!K\WO\ @H?\=OA%<? 7Q_\ !RW\46DO
MC,-IBG3$+-,&2^M;A@2%V K$"Q&[C&.O%?!W_!,W]H#Q%X)^+]I\&]1NY)_"
M_C'S4B@=BR6M_'&TD<L8)^7S0IC< ?,2I/W:N_MW_L@?%/P_XR^(G[14DMA/
MX/GO(;O<L[?:E%Y)%;A3$4QE99 .&QMY]J%'4+Z'R#^R=XL\.^!?VB_ OBWQ
M;?)IFCZ9?^;<W,F=D2>6ZY.T$]2.@K^F+X>_M+_ CXJ^(/\ A%?A[XSLM:U8
MQ/.+:+>LC1QXW$!U7.,\@<XYZ U_*;\-OA_X@^*GCG1_A[X5\HZMKDWD6_GO
MY<>_:6^9L' P#VK]DOV+_P!A#XU_!#XZ:?\ $GQ_+ID.F:;:7<>VUN6GEDDN
M(S$JA?+4 #<6))[>].:0(_9.BBBLB@HHHH **** "BBB@ HHHH **** "BBB
M@ K'\0?\@.^_ZXO_ "K8K'\0?\@.^_ZXO_*@"UIG_(-M/^N,?_H(J]5'3/\
MD&VG_7&/_P!!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#F?%W_(%?\ ZZ1?^ABNFKF?%W_(%?\
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M9OPK]Z/^"F7_ ":=KG_80TW_ -*%H>Z!;'XU_P#!/QE3]K[X>NY 59-0))X
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MM)_ [XV2-;?#3Q?9ZO>(I<VAWV]V%'5OL\ZQRE1W8*0/7I7XT_"7_@E?X_\
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MI\0/%5Y8Z[?B\8Q*/+SY5FSA6*F&)R<$$>:7YP00<JZBN?FA^VUXX\*?$?\
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M9@I(7?MS@9Q7N58LL^,_^"@__)GWQ"_ZYZ?_ .G&VK^;GX->#=,^(GQ;\&>
MM:EF@T_Q%K%CI]Q);LJS+%=3I$YC+JZA@&."5(SU!Z5_2-_P4'_Y,^^(7_7/
M3_\ TXVU?S7?"GQK%\-_B=X3^(,]JU]'X;U6SU%K=7$;2BUF64H&((4MMQG!
MQZ5K#8EG[M_\.E_V<_\ H8_%?_@98?\ R#7HGPF_X)Q? OX/?$/1OB5X?U;Q
M!?ZEH4K36\5]<VKVYD*,@+K%:Q.=N[(PXY SD<'YM_X>^^&/^B9WG_@SC_\
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M&<X '%4XV%<]]HHHJ1A1110 45#)<V\3K'+*B.W0%@"?H*FH **** "BBB@
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MT^"V>!?M$8E1=TUS$Q;8RD_+CGKUII ?=%%?ES_P]I_9X_Z%KQ3_ . MC_\
M)M'_  ]I_9X_Z%KQ3_X"V/\ \FT^5A<_4:BORZ7_ (*T?L[E@#X;\4J">IM;
M'C\KVOT.^&WQ T#XJ> ]$^(GA?S1I>OVR74 G4)*JMP5=06 92"#AB,C@D<T
MF@.WHHHI %%%% !1110 4444 %%%% !1110 444C,J@LQP!U)H 6BHHIX)U+
M02+(!QE2"/TJ6@ HHHH **** "BBB@ HHHH **** "HI_P#42?[I_E4M13_Z
MB3_=/\J ,/PI_P B_9_[I_\ 0C70USWA3_D7[/\ W3_Z$:Z&@ HHHH ****
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M?Q-NO'0\0&"TN+5+5-.^RY-P -[2&XEZ ?="\^O'/Z6444-A8^!?VH/^"?\
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MH **** "BBB@ HHHH **** "BBB@ K'\0?\ (#OO^N+_ ,JV*Q_$'_(#OO\
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M %%%?S9?%+_@H!^UAI7Q.\4:9HOC1;#3]-U6]MK>VCTZP9(XH9V1%S);N[<
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MN<[#BW#8[9W;O?/-?T[VLK3VL,[@!I$5CCIDC--QL),GHHHJ1A1110 4444
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M44 %%%% !1110 4444 %?S"_\%'/^3P?&W_7/2O_ $W6]?T]5_,+_P %'/\
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M33=?U+]IGX:CP[;27$UOKUA/-Y:EMEK',IN';'15BW9)K^EB;]J']F^WT_\
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M(^.=EHGPR^%%W)J/A_3+DW][?&.2!+BY5&BBCC254<K&KN2Q #%AC[N3R/\
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M.&&-06(&U54$GN:A1N4V?TZZ=^U%^SAJMZ-/L/B;X=DN&8*JG4[==S'H%+.
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M<-JK;>N#*R@XSS7":1^T5\ =?F-MHWQ(\.W<RY/EQZK:E\#J0OF9(]Z_E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCK]FKQPO@WQH8KJ.[B^T6-];9,%U#G!*[@&5D;Y70C(/(RI5C_0?_P $]?\
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M ((']'W[%?[0EU^T9\%;3Q1KH1?$>D3MINJ[ %62XB56695   EC96( P&W
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MN8XIHUDC+13Q,K%6VLP^A%?I=_P5S_Y)-X(_[#<G_I,]-*S$]CY#_P""4/\
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MR\#22PWFMW,KWFJW< ;RYKJ3 PA<*QCC0*BY S@M@%B*^FJ*3D%C\@/VP/\
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M)XF^TW1E6U6;>H\LVY^<)QC>1GC=CFOWTHHYV%@HHHJ1A1110 4444 %%%%
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MS#\6;;X'_';PE\2]15WT_2[EDO!&NY_LMS&]O,57NRI(64=R!7](_C?]L/\
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M[]F"_L5U.Q^&W@ZXLW7>LT>CZ>\17KD.(L$>^:\ZTVX_88\/?$71_"?A_3O
M]OXSN9PEC%IVGV+723@$@"2WB/E/QQN92>W44E+L@:/K^OYSO^"HGQ7_ .$W
M^/D'@*QF\S3O MFMN0#E?MMV%FN&'T3RD/HR&OZ!_'/B_2O '@S7/'&N-LT_
M0+*XOI^<$I;QERH_VFQ@#N2!7\?FO:QXB^)WCR_UV[5KW7/%.HR3LB<F2YO)
M2VU1[NV /PH@NH2/VZ_X)-_"C^QOA_XF^,&H0XN/$=R-.LF8<BTLN964^DDS
M;3[Q5^N=>8_!?X<67PB^%/A7X;6.TKH%A#;R.O DGQNGD_[:2EG_ !KTZH;N
MRD%%%%( HHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@V
MT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@#
M\ZO^"HG_ ":U/_V&=/\ _:E?CE^P=_R=O\.?^ORX_P#22:OV-_X*B?\ )K4_
M_89T_P#]J5^.7[!W_)V_PY_Z_+C_ -))JUCL2]S^J*OSU^/?_!1SX+?!?7KW
MP=HEK<^,_$%@[1W,=DZ16D$R<-%)<MN^=3PPC1]I!#$,"*^O/C;K.L>'/@UX
M\\0^'2RZKIF@ZI<VA3[PGAM9'C(]PP!K^0WP]:6&K^)-,L-<O?L5E>W<,5S=
M-SY,4D@624Y_NJ2QSZ5,(W&V?KA??\%?/%LDK'3?AM8P19X674996 ]V6&,'
M\J_([Q+K/_"1^(]5\0_9UM?[4NY[KR4)*Q^?(7V*3R0N<"OZ=(?V9?V+_@Q\
M/V\1Z[X2T(:#IEL)IM3U>-+]I%(&',D_F;VD/W50<D@(O(%?S+^-[S1-1\9Z
M_J'AJ(0:1=:A=2V4:IY82V>5FB4(/N@(0-O;I5QMT)9_6;^S?(\O[._PNED8
ML[^%M$))Y))L8<DU_*A\7_\ DK/C;_L-ZE_Z4R5_5;^S7_R;I\+/^Q4T/_TA
MAK^5+XO_ /)6?&W_ &&]2_\ 2F2E#J.1_3!^Q!\,_"7PY_9M\%S>&K0177B;
M3;35]0N& ,MQ<WD2RG<P RL8;8@[*/4DGGO^"A/@+6/'W[+/BBVT&W>[O=&>
MVU00Q_>>*UD!G..^R%G?'4[>.<5[#^RY_P FV?"W_L6=(_\ 22.OF3_@IO\
M$3Q5X#_9R6R\+326@\4ZI#I5[/'D$6DD$TLD88<CS?+"'U0L.]0MQL_&K]B[
M]H71_P!FOXS+XW\26,M]HVHV$VF7GV<*T\,4TD4HEC5BH8J\*Y&X94G'.!7U
MM^W7^W3\-?CI\-;3X7_"ZVO+B*>]BO+V\O(?(54M]VR.)-Q9F9B&+$  # R3
M\OPI^S[X/^!'C;7M3T;XY^,KOP3;M;*VG7D$'GPM<[P&2<!'(&S)4_*,]6'
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MT35+BX6ZM2%D"6LTB@D!N&52#P>U>J44TUU$SQ3_ (:!^&O_ #\W?_@%<?\
MQ%'_  T#\-?^?F[_ / *X_\ B*]KHJ[Q[!J>*?\ #0/PU_Y^;O\ \ KC_P"(
MH_X:!^&O_/S=_P#@%<?_ !%>UT47CV#4\4_X:!^&O_/S=_\ @%<?_$4?\- _
M#7_GYN__  "N/_B*]KHHO'L&IXI_PT#\-?\ GYN__ *X_P#B*/\ AH'X:_\
M/S=_^ 5Q_P#$5[711>/8-3Q3_AH'X:_\_-W_ . 5Q_\ $4?\- _#7_GYN_\
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M4_X:!^&O_/S=_P#@%<?_ !%>@>$?&N@>-[*:_P##\DDD5O)Y3^;$\)#8#='
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M (!7'_Q%>UT47CV#4\4_X:!^&O\ S\W?_@%<?_$4?\- _#7_ )^;O_P"N/\
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M?_@%<?\ Q%'_  T#\-?^?F[_ / *X_\ B*]KHHO'L&IXI_PT#\-?^?F[_P#
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M>O\ #F]\)3>%M6DMI;FV87@O89A!@NA;R861MI+#Y2" >0< NS"Y^B%%%%(
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\JV*
MQ_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H ***
M* "BBB@ HHHH *_D:_:B_P"3DOBE_P!C/J__ *5R5_7+7\C7[47_ "<E\4O^
MQGU?_P!*Y*TIBD<OHGQ?^,^CZ!!X.\.>-=?L=%A#+%I]IJ-U%:J'8NP6&.0(
M-S,6.!R23U-==\./V:OC[\9M62+PCX0U*\%V^Z2_NHGM[1=Q^9Y+F;:A/.2
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M.R0@MG9&6. =Q4X!^<_^"N?_ "2;P1_V&Y/_ $F>IBM1L^0_^"4/_)R>L?\
M8LWO_I79U]>?\%<_^23>"/\ L-R?^DSU\A_\$H?^3D]8_P"Q9O?_ $KLZ^O/
M^"N?_))O!'_8;D_])GJOM"Z'R'_P2A_Y.3UC_L6;W_TKLZ^O/^"N?_))O!'_
M &&Y/_29Z^0_^"4/_)R>L?\ 8LWO_I79U]>?\%<_^23>"/\ L-R?^DST?:#H
M?#__  3!\(^&_%?[3!F\16$5^="T:ZU&S$HW+%=QSV\22A>A9%D;;D'!PP^8
M C]]?CGHNG^(O@MX[T75(EFMKO0]11E89&?L[E2/=2 0>Q -?A=_P2A_Y.3U
MC_L6;W_TKLZ_>?XK_P#)+?&/_8&U#_TG>IEN-'\>>CR/%J]C+&<,D\3 ^X8$
M5_5Q^V'_ ,FO?$W_ + EU_Z#7\HFE_\ (3M/^NT?_H0K^KO]L/\ Y->^)O\
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M(/\ D!WW_7%_Y4 6M,_Y!MI_UQC_ /015ZJ.F?\ (-M/^N,?_H(J]0 4444
M%%%% !1110 4444 %%%% 'QI^W?\(O'GQK^ -UX-^'%@NIZRNH6ETMNTT<!D
MCA+;]KRLB9&[."PSVYP#^9O['O[%O[2?P_\ VB?"'COQOX0.C:'HD\\MS<2W
MEH^ UO+&H5(IG=B68#A<>I K]_:*I2%8J:A86>JV%SIFH1">UO(GAFC;H\<B
ME64^Q!(K^=CX^?\ !-7XU>!_%%[>?"73?^$P\*W$KO:B"9!>VT1.5BGCE*%V
M4<!X]P;&2%)Q7]&5%)2L#1_+EX3_ &)/VO?'MU:^&Y?"6H:981.!YFKS?9;2
MW'W=^V1MQ !Z1HS8Z UV'Q#_ .";G[2_A?Q9/HG@WP^?%FE)';F+4H;FTMXY
M9'A1I@(YIU= DI= 6 R &[U_2[15<[#E/,_@KX:U?P9\&_ ?@_Q!$(-4T+0-
M+L+N-6#JEQ:VL<4BAE)# ,I&0<'J*_GT^*7[!7[5VJ?$[Q3J6D>!FOK+4=5O
M;BWN([ZQ$<D4T[NC?/.I7*D<, 1W%?TKT4E*P-'E7P+\*ZSX&^"W@3P9XBB6
M'5=#T/3K*[C1Q(J3P6Z)(H9<AL,",@X/;BOC+_@IK\5_!?@WX&KX U_2(M;U
MCQE(Z:?'*2HLS:[2]Z"I#;XBZA!G#%L-E RG](J_(W_@JG\$O&?C?0/"GQ.\
M(:=/JL'AE;NVU**!3))%!.8WCG$:@DHI1Q(PZ94GY02".X,_*+]G#]F'XB_M
M.>(]0T/P.;:SMM(A6:]OKQG6W@\S(B0[%=B\A5MH"]%8G %?1?Q)_P""9'Q^
M^'?A#5/&::EHFNVFCV\MU<0V=Q.MSY,*EY&59H(T;:H)(WY., $\5\]?LX_M
M3_$S]F+5]3U#P&+2\L]:6);VROHVD@E,!;RW!1D='4.P!5L'/S!L#'OWQ>_X
M*6?'7XJ^#]0\#VMCIGABPU:%[>[EL4E:ZDAD7;)&))9&"*X)!VJ&QP&%:.]R
M=#YD_9U^.'BWX"_%#1_&/AR_DM[,7$2:C;;F\B[LV;;*DL8.&PI)0D95L,.1
M7](W[5/[+_A3]I_P+'X>U:?^S-<TIGFTK4E3>UO(X ='7(+1287>H(.55@<K
M7X*_L??LF^.OCY\0='U2[TJ>S\#:=<1W&H:C-&R0S10L&-O QP))),;3MR$!
MW-V!_J*J9O4:/Y>?'?\ P3W_ &J? ^H2VT7A$^(K16(CN])FCN8Y .XC)6=?
M^!QK7':9^Q;^U;KDT=M;?#?5E;[J_:52V4?\"G=% _'%?U;T4N<?*?EW_P $
M^OV/?B=^SUK/B'QO\3I+2TNM:LH[*"PMYOM$L8$@D=IG4>6#E0%",^><D<9^
MUOVB?@MI7[0'PBUWX9:E,+26_19+.Y(+?9[R$[X9"!@E=PPX[J6 YKVZBI;Z
MCL?RT>,/V!_VJO!^JSZ<W@>XUF&.0I'=:9)'=0S*.CJ%;S%4_P#31%/J!7Z0
M?\$U_P!F3XQ?!WQ1XI\<?$[0V\/VVI:?'96L$\D;3RL91(SE(V8HJA /GVDD
M\ @9K]=Z*IS%8****@84444 %%%% !1110 4444 %13_ .HD_P!T_P JEJ*?
M_42?[I_E0!A^%/\ D7[/_=/_ *$:Z&N>\*?\B_9_[I_]"-=#0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^\O^"2G_ "0+Q3_V,T__ *16E7+82W/U.HHHK(H**** "BBB@ HHHH ****
M"N9T;_D-:U_UTB_] KIJYG1O^0UK7_72+_T"@#IJ*** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#F?$/_'SI'_7VG\C735S/B'_CYTC_ *^T_D:Z:@ HHHH
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MH_O,Q8GJ223R:SO'_P 1O _PM\-W/B[X@ZU;:'I5J"6FN'V[CC(2-1EI'/\
M"B L>P-?)'QY_:1TWQ)^Q+XN^.'P=O+@17EO]BM9VC:">%IKU+"5\=49 [,C
M9XX-9I%%/QM^V+^Q[^S%<7O@OP[%;_;K>5C=:;X7T^$*DV<-YCKY-OY@.0P\
MPLIX(%?-?C?_ (*I_![Q5X7UOPK_ ,(+K$]KK%G<V;^>]LH*7$;1G<H=QC#<
MC-?D)\#_ (<1_%_XN>%OAK<:@-,B\0WT=M)<D!C&ARS%02 7(!"@]6(%?NWX
MI_X)^?L<?#'X<ZQXC\3V%P\>DV,LC:AJ6J3Q8D53L9A"\,>YGP H3DD  DXK
M2R1-V?SKVES-9W4-W;,4E@=71AU#*<@_@:_KG_:7_P"3<OBI_P!BKK?_ *0S
M5_(B.HK^O+]I*&2X_9W^*,$*EY)/"VM*JCJ2;&7 HGT")_*5\*O^2H>#_P#L
M,Z?_ .E"5_8]7\:'@#4[31?'?AO6;]_+M;#4K.XE;^['%,KL?P K^R2/4+"6
M.VFBN8GCO # RNI$H*[@4.?FRO(QGCFE4")^4/\ P5S_ .23>"/^PW)_Z3/7
MR'_P2A_Y.3UC_L6;W_TKLZ^O/^"N?_))O!'_ &&Y/_29Z^0_^"4/_)R>L?\
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MVG_7&/\ ]!%7JHZ9_P @VT_ZXQ_^@BKU !1110 4444 %%%% !1110 4444
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M^!O[1_PG_:'T.76/AMJWVB:U"_:[&X7R;VU+=/-B)/RGH'0LA.0&)! _)O\
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M*_\ %_\ Y*SXV_[#>I?^E,E?U0?LN?\ )MGPM_[%G2/_ $DCJZ@HGY/>*/\
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MFU[Q1J5OI.FVY427-U*L,*%V"+N=R%&6( R>2<5-AFU17FF@?&;X2>*]7M]
M\,^,](U74[K=Y5M:WT,TTFQ2[;41BQPJEC@< $UT/BOQUX+\"VL%[XTUVRT*
MWN7,<4E[<1VZ.X&2JF0@$XYP*+,#JJ*X?PQ\3/AUXU%XWA#Q-INM#3T62Y-G
M=Q3B%&SAI"C':#M."<=#7FFJ_M6?L[:+?MIE]X\TXSHVT^2SW" C_II"KI_X
M]1RL#Z#HKF_"OC'PIXXTM=;\':O:ZU8,=OG6DRS(&ZE6*D[6'=3@CN*Z2D 4
M444 %%%% 'R+^T[^U2/V<+WP_9GPQ_PD/]NQW,F[[;]D\K[.8QC'D2[MV_VQ
MCO7'?L^?MQ>'_C?XY_X0+4_#O_",7MS"TED[7HNDN9(_F>+_ %,.UMF67KD
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M'PG^T/\ MK+\!/B%_P (&?!QUS_1(;K[1_:'V;_7%AMV?9Y>FWKNYSTKW/\
M9T^.$?Q_\ 2>.4T8Z$8KV:R:W-Q]IYB5'W"3RX^H<<;>,5\P_M0_ GX'_$3X
MG#Q#X_\ BG:>#]5^PP0FQGEME?RT+[9,2R(V&R>V..M?0G[+'@'P+\.?AK/H
M'P]\60^,M+?49YVO8&B=%F>.)6BS$SKE0JGKGFM))<HD?2=%%%9#/F_]I?\
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MPWH"V?B/4M8B>XNQ<7#EVNFD>8['D:,;FYX48[8J.1*5F.Y[_P#\-Z?LS_\
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M !UX]^%'A.+P/X?O_$,NGZPTMQ'I]M)=21QM;NH=DB5F"YXW8P#C/45\K?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .9\7?\@5_P#KI%_Z&*Z:N9\7?\@5
M_P#KI%_Z&*Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%"O@?J_QJ^ <P\)Z=)J?B3PQ=Q:C96\";YYT.8KB*-1RQ,;[]HY8Q@#)P*_
MKPG^R]\?O%GB?3O#$'@#7K)[^XC@:>YTNZA@MP[!3)+(\:JB(#EBQ P*_K?H
MH4[ T<YX/\+Z5X(\*:-X-T*/RM.T.S@LK=>XBMXQ&N??"\GN:_!7_@H]\'/B
MUXG_ &D;SQ+X8\&:QK.E7>G6*175C83W4+/&A5UWQ(P# ]5)!Z'&"*_H-HI)
MV!H_/C_@FGX&\9> ?V>+K2O'&AWF@7UUKMY<QV]_ ]M,86AMT5_+D"L 61L9
M SC(XKX+_P""E?P@^*WBK]H>/Q'X5\':QK6E3:/9Q+=6-C/=0^9&TNY"\2,
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MH __U/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q<_X+!?\
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M -*#7JG_  24^%'V31O%_P :=0AQ)?R+HM@Q&#Y46V:Z8>JNYB7/JC"O+/\
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M'7\K_P 7_P#DK/C;_L-ZE_Z4R5_5!^RY_P FV?"W_L6=(_\ 22.BH$3^>_\
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M1?'K5?C+\.KK2?%<YN?$?A9XX)YV^_<V\H)@F?U?Y&1CW*AB<M7@G_!3C2K
MZ-X$UO:JWJW%[;[L?.T3)&^">X5AQZ;CZFO+?^":%U<)\4O%5DI/D2Z,)&';
M?'<1!<^^';%1+WH7!;G#?\%#_P#DX7_N$6?_ *%)7W%_P3E_Y(%>_P#8<N__
M $3;U\._\%#_ /DX7_N$6?\ Z%)7W%_P3E_Y(%>_]AR[_P#1-O1/X$"W/OBB
MOY[/BA^TA\=])^)?BW2]-\<ZK;6EGJ]_##$EPP6...X=451V   %<-_PT_\
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M>_<=TK(O&1QG-?1WAF7P]/X>TV?PE]G_ +%DMXVLOL@5;?[.R@Q^6$PH7;C
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M=^UGX1_9]\'ZQX;\1:+?:G-J5_\ :T>U,055\I(\'>RG.5S3/^"BO_)P,/\
MV!;/_P!&350_9=_9'TC]H?P;K/B.]\1SZ)<:;??9$2.W6=&'E))N.70]6Q@&
MM-.7474^L+S_ (*9^ $B9K#P;J<TH'RK+-!$I/NR[R/R-?F!\9/BSXA^-GC^
M_P#'OB**.WGNPD45O#GRX((AM2-2>3ZDGJQ)P!P.F^/G[/?C/]G[Q-%HWB1D
MO=/OP[V.H0J1%<(APP(.2DBY&Y"3C(P2"#7T!^PWXN^!]EXWM/#/Q#\,6A\1
MW<P&E:Q<,\J"?.4B:*5C%')GB*1%!)PIYP2))*Z$?H!^PQ\*M9^&'P52;Q)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /_U?W\HHHH **** "BBB@
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M;WMJ7[!XWC< _4.<>N#Z5^M]M;6UE;16=G$D$$"+'''&H5$11A551P !P .
M*\Y^+?PE\'_&GP;<>"O&<#/:R,)89HB%FMYU!"RQ,00& )'((()!!!K%3]ZX
M['X\?L/_ +1?@WX(ZQXAT3X@2/::1X@6WD2\2-YA!/;%QATC5G*NLAY ."HX
MP<CTC]M/]K;P)\3O",/PQ^&4SZG:37,=S?7[1/#$5AR4BB60*['?AF8J -H
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M$T_1O,\[[!;Q6^_&W?Y2!-V,G&<9QDX]:*LT]@2/YT_VK?\ DXKQ[_V$I/\
MT%:_:S]D>*.;]FCP/#*NY)+&16!Z$&:0$5\Z_%C_ ()]#XG_ !&U_P ?KX]_
MLS^W+DW'V;^R_/\ *R -OF?:H]W3KM%?:_P@^'O_  JGX;:%\/?M_P#:G]B0
MF'[3Y7D>;EV?/E[WV_>QC<:)S3BD@2."_P"&4/V<_P#H0M-_[X?_ .*J]I?[
M,7P"T;4K36-+\$:?;WEC-'/!*J-N26)@R,,MC(8 U[O167,QV/PL_P""BO\
MR<##_P!@6S_]&35]8_\ !-#_ ))9XJ_[#/\ [;15W7[1?[%@^/WQ C\=#QC_
M &#LLH;,V_\ 9_VK/E,[;]_VB+&=^,;>W7GCU?\ 9G_9[_X9V\+:KX9_M_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X@_Y =]_UQ?\
ME6Q6/X@_Y =]_P!<7_E0!:TS_D&VG_7&/_T$5>JCIG_(-M/^N,?_ *"*O4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% ',^+O^0*_P#UTB_]#%=-7,^+O^0*_P#UTB_]#%=-0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',^(
M?^/G2/\ K[3^1KIJYGQ#_P ?.D?]?:?R-=-0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,Z-_P AK6O^ND7_ *!7
M35S.C?\ (:UK_KI%_P"@4 =-1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?_UOW\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KYB^,O['_P !_CUXE@\8?$;19KO5X+=+
M03P7D]N6AC9F565'"'!=N<9YP3P,?3M%-,#Q3X,_L\?"'X 6-_9?"O05TDZH
MT;7<S32W$TYBR$#23.Y"KN.%7"@DG&22?:Z**0!1110 4444 %%%% !1110
M4444 %8_B#_D!WW_ %Q?^5;%8_B#_D!WW_7%_P"5 %K3/^0;:?\ 7&/_ -!%
M7JHZ9_R#;3_KC'_Z"*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5%/_ *B3_=/\JEJ*?_42?[I_E0!A^%/^1?L_]T_^A&NAKGO"G_(O
MV?\ NG_T(UT- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?SA>+_V?/CK<^+-:N+?P!KDL4M[<LCII\[*RM*Q!
M!"8((Y!%?T(^ K6YL? OARRO(F@N+?3;..2-P59'2%0RL#R"",$5UE%:3J7%
M8****S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!S/B'_CYTC_ *^T_D:Z:N9\0_\ 'SI'_7VG\C734 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !6/X@_P"0'??]<7_E6Q6/X@_Y =]_UQ?^5 %K3/\ D&VG_7&/_P!!%7JH
MZ9_R#;3_ *XQ_P#H(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 <SXN_Y K_]=(O_ $,5TU<SXN_Y
M K_]=(O_ $,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_P#'SI'_ %]I_(UTU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<SHW_(:UK_ *Z1?^@5TU<SHW_(:UK_ *Z1?^@4 =-1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_7_?RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"U
MIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G
M_(OV?^Z?_0C70USWA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#
M_P ?.D?]?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_K
MB_\ *MBL?Q!_R [[_KB_\J +6F?\@VT_ZXQ_^@BKU4=,_P"0;:?]<8__ $$5
M>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .9\7?\@5_P#KI%_Z&*Z:N9\7?\@5_P#KI%_Z&*Z:@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.9\0_P#'SI'_ %]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_\
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M ,<H ]@HKQ__ (5=JO\ T-5[_P"/?_'*/^%7:K_T-5[_ ./?_'* /8**\?\
M^%7:K_T-5[_X]_\ '*/^%7:K_P!#5>_^/?\ QR@#V"BO'_\ A5VJ_P#0U7O_
M (]_\<H_X5=JO_0U7O\ X]_\<H ]@HKQ_P#X5=JO_0U7O_CW_P <H_X5=JO_
M $-5[_X]_P#'* /8**\?_P"%7:K_ -#5>_\ CW_QRC_A5VJ_]#5>_P#CW_QR
M@#V"BO'_ /A5VJ_]#5>_^/?_ !RC_A5VJ_\ 0U7O_CW_ ,<H ]@HKQ__ (5=
MJO\ T-5[_P"/?_'*/^%7:K_T-5[_ ./?_'* /8**\?\ ^%7:K_T-5[_X]_\
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M *&J]_\ 'O\ XY0![!17C_\ PJ[5?^AJO?\ Q[_XY1_PJ[5?^AJO?_'O_CE
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M5VJ_]#5>_P#CW_QRC_A5VJ_]#5>_^/?_ !R@#V"BO'_^%7:K_P!#5>_^/?\
MQRC_ (5=JO\ T-5[_P"/?_'* /8**\?_ .%7:K_T-5[_ ./?_'*/^%7:K_T-
M5[_X]_\ '* /8**\?_X5=JO_ $-5[_X]_P#'*/\ A5VJ_P#0U7O_ (]_\<H
M]@HKQ_\ X5=JO_0U7O\ X]_\<H_X5=JO_0U7O_CW_P <H ]@HKQ__A5VJ_\
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M_'* /8**\?\ ^%7:K_T-5[_X]_\ '*/^%7:K_P!#5>_^/?\ QR@#V"BO'_\
MA5VJ_P#0U7O_ (]_\<H_X5=JO_0U7O\ X]_\<H ]@HKQ_P#X5=JO_0U7O_CW
M_P <H_X5=JO_ $-5[_X]_P#'* /8**\?_P"%7:K_ -#5>_\ CW_QRC_A5VJ_
M]#5>_P#CW_QR@#V"BO'_ /A5VJ_]#5>_^/?_ !RC_A5VJ_\ 0U7O_CW_ ,<H
M ]@HKQ__ (5=JO\ T-5[_P"/?_'*/^%7:K_T-5[_ ./?_'* /8**\?\ ^%7:
MK_T-5[_X]_\ '*/^%7:K_P!#5>_^/?\ QR@#V"BO'_\ A5VJ_P#0U7O_ (]_
M\<H_X5=JO_0U7O\ X]_\<H ]@HKQ_P#X5=JO_0U7O_CW_P <H_X5=JO_ $-5
M[_X]_P#'* /8**\?_P"%7:K_ -#5>_\ CW_QRC_A5VJ_]#5>_P#CW_QR@#V"
MBO'_ /A5VJ_]#5>_^/?_ !RC_A5VJ_\ 0U7O_CW_ ,<H ]@HKQ__ (5=JO\
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M\*NU7_H:KW_Q[_XY0![!17C_ /PJ[5?^AJO?_'O_ (Y1_P *NU7_ *&J]_\
M'O\ XY0![!17C_\ PJ[5?^AJO?\ Q[_XY1_PJ[5?^AJO?_'O_CE 'L%%>/\
M_"KM5_Z&J]_\>_\ CE'_  J[5?\ H:KW_P >_P#CE 'L%%>/_P#"KM5_Z&J]
M_P#'O_CE'_"KM5_Z&J]_\>_^.4 >P45X_P#\*NU7_H:KW_Q[_P".4?\ "KM5
M_P"AJO?_ ![_ ..4 >P45X__ ,*NU7_H:KW_ ,>_^.4?\*NU7_H:KW_Q[_XY
M0![!17C_ /PJ[5?^AJO?_'O_ (Y1_P *NU7_ *&J]_\ 'O\ XY0![!17C_\
MPJ[5?^AJO?\ Q[_XY1_PJ[5?^AJO?_'O_CE 'L%%>/\ _"KM5_Z&J]_\>_\
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M7_H:KW_Q[_XY0![!17C_ /PJ[5?^AJO?_'O_ (Y1_P *NU7_ *&J]_\ 'O\
MXY0![!17C_\ PJ[5?^AJO?\ Q[_XY1_PJ[5?^AJO?_'O_CE 'L%%>/\ _"KM
M5_Z&J]_\>_\ CE'_  J[5?\ H:KW_P >_P#CE 'L%%>/_P#"KM5_Z&J]_P#'
MO_CE7]+^'>HZ=J-M?2^([NY2WD5S$^[:^TYP?G/!^E 'J-%%% '_T?W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H
MM:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/P
MI_R+]G_NG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\
M0_\ 'SI'_7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.^_
MZXO_ "K8K'\0?\@.^_ZXO_*@"UIG_(-M/^N,?_H(J]5'3/\ D&VG_7&/_P!!
M%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#F?%W_(%?\ ZZ1?^ABNFKF?%W_(%?\ ZZ1?^ABNFH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#F?$/\ Q\Z1_P!?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF=&_Y#6M?]=(O_
M $"NFKF=&_Y#6M?]=(O_ $"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#__2_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*
MO51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?_0C70USW
MA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]?:?R-=-7
M,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\ *MBL?Q!_R [[
M_KB_\J +6F?\@VT_ZXQ_^@BKU4=,_P"0;:?]<8__ $$5>H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.9\7?\@5_P#KI%_Z&*Z:N9\7?\@5_P#KI%_Z&*Z:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\0_P#'SI'_ %]I
M_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_\ 0*Z:N9T;_D-:U_UT
MB_\ 0* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[
M_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T
M$5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*?_ %$G
M^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z
M&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ',^+O\ D"O_ -=(O_0Q735S
M/B[_ ) K_P#72+_T,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <SXA_P"/G2/^OM/Y&NFKF?$/_'SI'_7VG\C7
M34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5S.C?\AK6O^ND7_H%=-7,Z-_R&M:_ZZ1?^@4 =-1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]3]_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J
M +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##
M\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4_8S_@H-XI\,^'/V5?&-EXAFC6;7$@LK&%L;YKHS)(NP=R@0R$]@OTK\_/\
M@D1H.L2>-_'_ (H1772H-.MK-VZ(UQ-,9$'N52-NG0-SU%?"WQ]\!_M76DL/
MBK]H;3O$-PD?[F*]U-I+FWBW'_5K*&>*/<>=H(R><5^LO_!-_P#:5^$NN^';
M?X":1X=C\'>(;1)+I%CD::+5F"@S3>8_S^> ,F-B0$4;#M7:I:R#J?2G[>WQ
M.O/A;^S%XIU'2IOL^I:X(]'MGS@@WIVS%3U#" 2E2.00#VK\K?\ @EQ\$M+^
M('Q8U;XF>(K9;JQ\"10O:QR %3J-T6$,F#P?)2-V'HY1NH%?9'_!6R>=?@/X
M4MU'[F3Q)$S'_:6SN@H_)C6=_P $CH;9?@[XTN%QY[Z\$?UV+:Q%?U9J%\(=
M3]8Z" 1@T45F44-,TK2]%LUT_1K.&PM4+,L5O&L489V+,0J #+,23QR22:OT
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X@_Y =]_UQ?\ E6Q6
M/X@_Y =]_P!<7_E0!:TS_D&VG_7&/_T$5>JCIG_(-M/^N,?_ *"*O4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% ',^+O^0*_P#UTB_]#%=-7,^+O^0*_P#UTB_]#%=-0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',^(?^/G
M2/\ K[3^1KIJYGQ#_P ?.D?]?:?R-=-0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7,Z-_P AK6O^ND7_ *!735S.
MC?\ (:UK_KI%_P"@4 =-1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?_U?W\HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@BKU4=,_Y
M!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<]X4_Y%^S
M_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .9\0_\ 'SI'_7VG\C735S/B'_CY
MTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMLHR/Q%7+82/DC_@L'_QZ_"C_?UO^5E7VA_P3M_Y,Y^'W_<5_P#3I=U\9?\
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M_P @VT_ZXQ_^@BKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!S/B[_ ) K_P#72+_T,5TU<SXN_P"0
M*_\ UTB_]#%=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% ',^(?\ CYTC_K[3^1KIJYGQ#_Q\Z1_U]I_(UTU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<SHW_(:UK_KI%_Z!735S.C?\AK6O^ND7_H% '34444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__6_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(
M-M/^N,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV
M?^Z?_0C70USWA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYZ]Z[_P5\(/A5\-V:3P#X0TGP_*XPTME90P2L/\ :D10Q_$FO1J*=P"BBBD
M4444 %%%% !1110 4444 %%%% !1110 4444 %8_B#_D!WW_ %Q?^5;%8_B#
M_D!WW_7%_P"5 %K3/^0;:?\ 7&/_ -!%7JHZ9_R#;3_KC'_Z"*O4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ',^+O^0*__ %TB_P#0Q735S/B[_D"O_P!=(O\ T,5TU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <SXA_X^
M=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7,Z-_R&M:_ZZ1?^@5TU<SHW_(:
MUK_KI%_Z!0!TU%%% !1110 4444 %%%% !7P1/\ \%#/A#!\=/\ A0S:)K9U
M4:X/#YNQ%;_9OMAN/LN[_7[_ "O,_BVYQSM[5][U_+[J/_*19_\ LJ"_^GH5
M45<3/Z@J**Q;3Q)X=O\ 4)=(L=4M;B^@W>9;QSH\J;3@[D!+#!X.1Q4C-JBN
M0\4?$+P#X(\O_A-/$NF:!YPRG]H7D-KO&<97S77//I6GH'B?PWXKL?[3\+:M
M::Q9YV^=9SQW$6?3?&S#/XT ;E?F3^T7_P %(])^ WQ>U+X4VW@:7Q"=%%N+
MN[.H"T&^XA2?;%'Y$N[:DBY)9<MD8QR?TVKX<^-_['/[+OQ5^)+^._B3<R:?
MXAU-81/''J2VHN_)00QEHWRV=B*F4*YQZY-.-NHF?8OA7Q#9^+O"^C^*].1X
M[76K.WO85D&'6.YC610P'0@,,^];U9%E::-X5T.UTVU$>GZ7I<$=O$K-MCBA
MB4(B[F/    R:_G8_P""H.M0ZE^TK;2Z;?K=6\&AV0C:*4.B-YDQ.TJ2 >YQ
M32N#9_1]7COQ]^,.F? 3X3:]\5=6L9-4AT58=MK$XC::6XF2"-=Y!"C<X+-@
MX4$@$\'4\!>,O#+^!O#K7.N6;3-IUH7+W,98L85SG+9SGKFKGQ3^'W@OXJ_#
M[6/ GQ!B$_A[5(E^T_O3#M$3K,D@D!&THZ*P/3CG(R*0SY._9$_;BL/VI_$6
MN>%9/",GAB_TBU6]4B\%[%+"9%C;+>3"48,RX&"",G(QBOO.ODW]FW]F;X ?
M V\U?7/@_</J=[J,:6US=2WR7C)$&WB(>6%106 )XR<#GBOK*A@%%<=XE^(?
M@#P8P3QAXFTS0F8;@+^]@M21ZCS77BE\-?$+P#XTS_PAWB73-=P"3]@O(;K
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M;*34;9+D/_=,1D#Y]L5F,]"HHJEJ.I:=H]E+J.K745E:0#=)-.ZQQH/5F8@
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M %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\
MZ$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_
MD:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#
M;3_KC'_Z"*O51TS_ )!MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND
M7_H8KIJYGQ=_R!7_ .ND7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'_CYT
MC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *YG1O^0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:BBB@
M HHHH **** "BBB@ K^7W4?^4BS_ /94%_\ 3T*_J"K^7W4?^4BS_P#94%_]
M/0K2F)G]05?R2Z5\6/%_P7^.WB7QWX%>.+6XKO5[:"65/,\HW;2PF15/!=0V
M5W KN R".*_K:K^87]F/2]-UC]O+0K'5K6.\M_\ A(M3E\N50Z;X5N)8VP<C
M*.JL/0@&B F>T>!O^"<'[0_QPTJ;XF_%'Q+'H.K:V/M"1ZJ)KO4)M_(:YY!B
MR,84EG X*+C%?,^GZI\;OV$/CU+I[3FRU32Y(OM<$4F^RU2P8[@#D8>.1<[2
M5#QM_==2!_557X)?\%=-/MHOBCX%U1$ N+G1YH7;')2&X+(#]#(WYT1E<&C]
MS_"WB/3/&/AC2/%VB.9-.URSM[ZV8C!:&YC66,D=B585_.9_P4\)_P"&JM0]
MM*T[_P!%FOW)_9)E>;]F/X8/(<D>'[!?P6(*/T%?AM_P4\_Y.KU'_L%:=_Z+
M-$-P9^V_Q^^#6H_M ?LYW/PNTK5$TB\U6WTZ2.XE5GB!MI8IBKJO)#!,<=#@
M\XQ7\W'[1WP"UW]F_P"(O_"NO$.IVVK7+6<-ZL]JKJFR8LH4AP"""A]1T_#^
MLCPY_P B]I?_ %ZP?^@"OYWO^"IW_)ST7_8!L/\ T9/1!ZC:.[T'_@D_\2M>
MT33M<B\<:1%'J-O#<*C07!95F0. <#&0#7Z=?M4:$WA7]BGQ?X9-P;HZ1X=A
MLS,1@R>0(H]Y&3][;GK7TI\._P#DG_AG_L%V7_HA*\-_;7_Y-4^)7_8*;_T8
ME*]V%C\V_P#@D 3_ ,)#\3AV^RZ5_P"AW-??W[<LGQZ;X,0:;^SS#?R:_J>J
MV]K=MIO%W'8/%,79'&&C'FB(-(I!4$\@9(^ ?^"0/_(P_$[_ *]=+_\ 0[BO
MVB\8>,?"W@#PY?>+O&FIP:/H^G)YD]S<-M1!T ]2Q. J@%F)  )(%$MP6Q^&
MO@?_ ()2?%SQ?;'7?BKXTM/#E_>GS9(4B?5KH,W+><_FPQ[\]=LCC_:KYU_:
M8_8[^)G[(-QHWC:Q\0C5=)N+D16VK6*R65Q;7BJ7570,QC+*K%&61L[6S@@9
M_2?QG_P5C^"NC7TEGX.\-ZOXCCCX%P_EV4,A]4#EY,?[T:GVKXB_:G_X*"Z?
M^TE\+)OAK'X"?0F:]M[N.\?4A<[3 6X\H6T?+!B,[^/>J5Q.Q^M_[#?QQUCX
M]_ #3/$WB9O.UW1[B72-0G./](FMD1UF('1GBD0O_M[B!C%?(O\ P5W_ .2>
M?#__ +"MU_Z(%;O_  20=S\%?&,98[%\0$@=@3:09/XX%87_  5W_P"2>?#_
M /["MU_Z(%)+WAO8^BO^";'_ ":-X6_Z^M3_ /2R6OO"O@__ ()L?\FC>%O^
MOK4__2R6OO"IEN-!7\[O[?O[4_C3XK_%/4O@?X"N[B/PKH=T=-DMK,MOU74$
M?9)Y@3F1%E&R*/D$C?@DC;_0S>W<5A9SWUP<16T;2/C^Z@R?T%?S#_L)Z/;?
M$/\ ;'\)7NO1B=4NK[5W5N]Q;P2W$3#W68(WX4X=Q,]\\._\$G?B]J_@F'7=
M5\4:9H^OW$(E72I8Y9%C++D1S7*9"N.C;(W4'HQZU\2?&23XY^ [>V_9_P#C
M!)=1P>$[A[BQM+H^:L*S*$W6TW.ZW<*"H4E 0< '<*_K@K\;O^"O6G6'_",_
M#K5OLT?V[[9?0>?M'F>5Y<;;-W7;NYQTSS3C+431]3_\$W?^30_"'_7QJG_I
M=/7B'[>O@/\ :R^+WQ*\/?#+X.PWP\$7FEK+>R03"TLFNVGE647<V5W*L0B(
MB.[.255FZ>W_ /!-W_DT/PA_U\:I_P"ET]?0GQH^/_PJ^ &@Q:_\3=973UNB
M5MK9%,UU<LO410IEB!D;F.%7(W,,BD]Q]#\E]#_X)!^*KC2EF\1_$FSL-2*Y
M,%KILEU"&]/.>>!B/?R_PKXK\1Z'\:_V"?CS;VT.H^3J-EY-Y%+:R.+/5+!G
M/RR*0I:-]K(ZL,JP.TY"M7Z4Z]_P5V^'=M-*OACP!JFHQJ2$:[NH+0L.Q(1;
MC&?J:_-G]K[]J6U_:G\3Z!XF@\+GPS)HMG):,IO!>&8-)YBG=Y,.W;D\8/6J
M5^HG8_??XU^ I/VM_P!F$:'X8U!=#_X32RTO5+66<&1$1GAO%20)R05&,CH<
M'G&*_G&_:.^ 6N_LW_$7_A77B'4[;5KEK.&]6>U5U39,64*0X!!!0^HZ?A_2
MW^R6[R?LR?#!G8L1X?T\9/HL*@#\!Q7XE_\ !4[_ ).>B_[ -A_Z,GI0WL-H
M[O0?^"3_ ,2M>T33M<B\<:1%'J-O#<*C07!95F0. <#&0#7ZO?':P^*W@3]E
MG4M#^"QN=2\9Z/IFGV%E);1B2YD$<D$$\L:'=^\\GS&'4@\CD"O</AW_ ,D_
M\,_]@NR_]$)71ZIJFFZ)IUSK&LW45C864;33SSNL<44:#+.[L0%4 9))P*ER
M"Q^!7@7_ ()E?M!_%=G\8_&;Q3'X;O-0Q(_VUI-6U-B>\P$BH"1V,Q;L0#7F
MG[3?_!/OQ[^S=X3'Q+T;Q)%XIT*QFB6ZFBMWLKJT:1PL4AC\R4%-Y"[A)D,5
MXP<C]%_B%_P51^ ?A749-,\'Z;J?B\PEE-S B6MJQ''R/,1(WU\L#N":^0?C
MM_P4UTKXQ_"OQ/\ "^+X<R6$?B"V^SI=R:HLAB8,KJYB%LN[!4'&\?6K5Q:'
MVK_P35_: \3?&3X5:MX5\;7<NI:UX(G@A^VS/OEN+.[#M!YK'EG0Q.A8\E0N
M26R:_2"OPV_X) NX\1_$V,,=C6FEDCL2)+C!_#)K]R:B2U&@K^>[]M']AOQ9
M\/4^('[15QXGL[[2;W69;Y;/RI5N@NJ7ORJS'*$H9>3GD#.!G%?T(U\*_P#!
M2+_DT/Q?_P!?&E_^ET%$7J#/Q7_9=_8S\6?M2:1KVK^'/$%EHJ:#/#!(MW'*
MYD,RLP*^6#P-O.:_;'X%?L]ZQ^S1^R]XR^'^MZS%K5W<1ZOJ!E@1DBC$UHL8
MC0/SP(MQ.!RQ^I^7/^"0O_(D_$7_ +"-C_Z)DK]3/B=_R3;Q9_V";_\ ])WJ
MI/6P)'\FWPK^+?Q ^%Z>(=/^'%Q)9ZGXOLTTIY[?=]J2)YD<K;E>1)(5"!A\
MP!.W#$$?:&C?\$M/VC=:\(6WB6XO='T[5+M1*=+N[B9;F-6YQ(Z1/&).Y7<0
M.[ \5S?_  3+\)^'_%/[4%I-KUFEX=#TR[U&T#\K'=1/%'')CH2@D8KGHV&'
M(!K^E6G*5A)'B/CSX@Z3^SQ\"9_&GC B>/PII=O&\<3<W%RJ)#'%&S<_O)2%
M!/0')Z&OYYK5_P!I+_@H/\77L&NVNPC&=D=WBTC1[5C@$(-P7^Z,!I9".=Q!
M(_3+_@K3K]U8_!'PMX?@<I%JFNK)+C^);:WE(4^VYP?J!5[_ ()/^$M.TKX#
M:[XN2%1J.NZW+%),/O-;V<,:Q(?97>5A_O4EHK@SYE\2?\$B_'EAX=FOO#'C
MVQU?6(HRZV4UD]I'(X&=BW'G2<GH"R*,]2!S7S_^RY^U#\4/V4/BE'\//B%+
M=IX3CO/L.KZ1>%B=/8MM:>W5C^[:,G<P7Y9%SG)VLO\ 3#7\XW_!4WPOIN@?
MM-0ZKI\0BD\1:%97UR1_'.DL]KN/OY<""B+OHP:/W_\ B3*DOPS\4S0N'1](
MOF5E.00;=R""*_E'^"WQ;^*/POU#6-.^$<DD&N^,;5-(66VC:2\423(X6U"\
MB5RH0, 6&3MPV"/Z4/AYJ]UKO[&>@ZO?.9+FZ\#0M*YZL_\ 9P#,?J1FOQ@_
MX)<:7IVH_M/^=?VT=Q)8:)?7%NTBAC%-OAC\Q,_=;8[+D<X)]:([,&=G8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"HI_]1)_NG^52U%/_J)/]T_RH P_"G_(OV?^Z?\ T(UT-<]X4_Y%^S_W3_Z$
M:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#F?$/_'SI'_7VG\C735S/B'_ (^=(_Z^T_D:
MZ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XWXC>+/^$"^'WB?Q
MR+?[7_PCNEWNH^3NV^;]D@>;9NYQNVXSVH [*BOY_-'_ ."MGQNBUN";7_"G
MAZYT@2@S06T5W#<&+/(29[F10V.YC(SVK]U_ GC;P]\1_!NC>._"EQ]JTG7+
M:.ZMWZ'9(,[6'.'4Y5EZA@0>13<;"N=9117Y!?!C]O[XO_$3]JRU^"VM:1HL
M/AV\U34; -!#<+=I':I,T;>8T[(6S&-WR8.3@#C E<=S]?:**_)3]IW_ (*<
M6/PX\3ZC\/\ X+:1;:_J>E3&"ZU2^9FL%E3B2.&*%T>7:<J7+HH8' <8-"5P
MN?K717\Y\G_!23]L.UV>([FTL%TN0@J'TEUM&'H)-P8@_P#72OT;_8N_;KF_
M::UZ_P# 'BKP['HOB33[%M0\^SD9[.XBCDCB<!),O$P,JX!9P1D[AC!;BQ)G
MZ*T45^=_[4/_  4-^'GP&U6Y\#^$[+_A,/%UJ=MQ$DHBLK)^Z3S ,6D'>-!Q
MT9E/%)(9^B%%?SE:C_P5'_:BU.ZDNM,M]%L+>,EC%!8/(JIV#-+*Y_'(KV#X
M6_\ !6OQ?::A#9_&/PG::AI[':]WHY>WN8US][R9GDCD(] \?U]:Y&+F/W5H
MKFO!OB[0/'WA32?&OA6Y^V:1K=M'=6LN"NZ*5=RY5L%3V((R#P>:_(S]EK_@
MH-\:?C3^T5H'PO\ %>F:+!HFN/?*WV2WG2>(6]K-<)L=YW!^:( [E.03C!QB
M4AW/V8HHHI %%<_XJ\5^'/ _AV_\6>+M0ATK1]+B,US<SMMCC0>O<DG@ 9+$
M@ $D"OQD^,/_  5GU0:E<:9\#?"]O]AB.U=1UH.[RXZLEK$Z;!_=+R,2.J@\
M4TKB;/V[HK^<:T_X*B_M2V%TEY>Q:+=02'<L4VGND;*.H5HY48CWW5^AW[*_
M_!1?PQ\=O%%C\-O&VAGPSXIU'<MI)!(9K&ZD12Y0%@'A<J#M5MRG&-^XA2W%
MA<_2NBBBI&%%%% !1110 4444 %%%% !1110 4444 %8_B#_ ) =]_UQ?^5;
M%8_B#_D!WW_7%_Y4 6M,_P"0;:?]<8__ $$5>JCIG_(-M/\ KC'_ .@BKU !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!S/B[_D"O_UTB_\ 0Q735S/B[_D"O_UTB_\ 0Q734 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/B
M'_CYTC_K[3^1KIJYGQ#_ ,?.D?\ 7VG\C734 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5S.C?\AK6O\ KI%_Z!73
M5S.C?\AK6O\ KI%_Z!0!TU%%% !1110 4444 %%%% !7\ONH_P#*19_^RH+_
M .GH5_4%7X-7O[&_[1TO[;9^)T?A(GPL?'2ZY]O^V6GE_8/[2%T9-GG>9GR^
M=FW=GC&:N#$S]Y:_F4_91_Y/\T+_ +#^K_\ HJZK^FNOPK_9Z_8__:(\%?MC
MZ=\1_$WA-K+PU9:OJ=U)?&[M'3R9HYUC9429I#N+K@!<C/(&#@@]P9^ZE?A!
M_P %>/\ DH'P^_[!=W_Z/6OW?K\DO^"D7[-OQI^-_BOP9K/PL\.-KUMIEE<V
M]R4N+>%HI'E5E!6>2,D$9Y&0,<XXRH;@S[A_9$_Y-A^&/_8!LO\ T6*_#K_@
MIY_R=7J/_8*T[_T6:_>K]G3PCK_@+X$^!/!GBFV%GK&C:1:6UW"'23RYHT 9
M-Z%E;!XRI(]":_*/]O/]DC]H/XO?M"3^,OASX3;6=&N]/LH$N%N[2$"2)2KJ
MRS3(PQZD8QT/6JB]09^U7AS_ )%[2_\ KU@_] %?SR_\%4[>:']IJTDD7"W'
MAZQ=#ZJ)KA,_FI%?T0Z-;2V6D6-G. )(((HV .1N50#S]:_.C_@H#^QSXF_:
M&MM'\>_#00R^*] MY+22TFD$/VZT+F2-(Y'(19(W9R-Y56#G+# RHO4&?<_P
MDU2SUOX5^#=8T^02VU[HVGS1LIR"KVZ,.?QKQ[]M?_DU3XE?]@IO_1B5^+'A
MKX&?\%']*TJ/X8>';7Q-I&C1DQK;QZHMM9QJ[;F"R"<($)R2%;!R>.3G]K/C
M=\.?'/BW]E#7/AEIB?VQXKN= @LPIF5?M-W$D>\^;,5&7920SD9[FBUF!^:W
M_!('_D8?B=_UZZ7_ .AW%;O_  5Y\5:]"GP[\%0R/%HUU]OOI4!(2:XA,4<>
M[U,2NV/3?7I__!-C]G3XR? [5/'>H?%3PZV@Q:Q#816F^XMYFE:!IC)Q!)(0
M%#KRV,YXS@X^EOVSOV5X/VH?A_9Z;IEY'IOBCP_+)/I=Q/N\@^<%$T,NT,0D
M@13N"DJRJ<$9!;>HK:'A'_!/W]F;X)#X#^'?B?JN@6'B7Q'XA$\T]U?0I="W
MV3/$(84D#+'L"?,0-Q8MD[< 4/\ @INOPO\ "G[/D?AVVM=,TS7]5U"U:QMX
M8(H[B2.!B9F4(H8(JG#-P,D+G) KX8\%_"+_ (*1?L\_:O#/PYTW5["PNI6)
MCLI+2_LW?IYJ*YE2,L ,MM1B,;N0 .EOO^"?W[5OQ2\.>)/BM\7;^6]\9&W4
MZ=ID]Y%<7UW)O7Y9)F?R((DC+%4#YR-N$[OK>X'U=_P2/_Y(SXR_[#__ +:0
MUB?\%=_^2>?#_P#["MU_Z(%>W_\ !.7X)_$WX(?"SQ)HGQ1T4Z'?ZEK!NH(6
MFAF9H1;Q)O)@>0#+*1@D'C.,8SE?\%(/@7\4_CCX&\(V'PLT,Z[=:3J$\US$
MD\$+)')%M5AY[QAAD8(!)]L4K^\/H=A_P38_Y-&\+?\ 7UJ?_I9+7WA7R5^Q
M!\,_&OPC_9Q\.^!_B#IW]E:Y:S7TLUL98YBBSW,DB9:)G3)4@X#'&<'!R*^M
M:B6XT1RQ1SQ/#,H=)%*L#T((P17\L/[.GB0?LV?M?:'-XTQ80>'=8NM)U)IN
M%@CF$EE)*Y_NQ[_,)'9<\U_5%7Y'?MR?L >)/BQXLN?C#\&##+KE^B#4]*FD
M6 7,D2!%FMY'(C#E54.CE0<;MVXD&HL3/UMAFBN(DN+=UEBE4,CJ0RLK#(((
MX((Z&OP>_P""J/QP\">-M;\-_"GPI=C4M1\*3W,^I30L&@AEF54%N&'WI%VD
MR <)PI.[<%\D\/\ PH_X*5VVAQ_"_1H/%%AHRH+=(#?I!;Q0GY?+6=I@%C X
MVJ^W'&,5W'C'_@F#\4O#7P7MM9T9!XJ^(UWJ<!N+&TGBBMK/3O)F\P"2X:,3
M2F4Q;B,8&0H(RQ:23$S]'O\ @F[_ ,FA^$/^OC5/_2Z>OQV_;YU_6?&G[8/B
M31?$-VUM9Z7-8Z9:^:3Y=M:F&-RP'96:1I3Z[J_</]B/X;>-/A+^S?X9\#?$
M#3_[*URSDOI)K8RQS&,3W<LJ9>)G3)1@<!CC.#@Y%?)W[=W[!WB?XT>*&^,/
MP@,$WB&:!(M2TV>40F\,"B.&6"1\1B01@(RNRJ0JD$'.X3U!K0^X/AA^R_\
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MXR2[T[2=&N=2M#9Z:J6T,<DMT[ HD(1=VX %B1]T L< $U^6'A[]G+_@H/\
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M:BG_ -1)_NG^5 &'X4_Y%^S_ -T_^A&NAKGO"G_(OV?^Z?\ T(UT- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJMW*G8O&+:.(_@'D'XU])_\ !+[PY:Z+^RW:ZM"@$VOZM?W<K8Y)B9;51GT
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M>%?LM?\ 0QW7_@NNO_C=?SJ44?ZL8?N_O7^0?V!0[L_HK_X>%?LM?]#'=?\
M@NNO_C='_#PK]EK_ *&.Z_\ !==?_&Z_G4HH_P!6,/W?WK_(/[ H=V?T5_\
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MT,=U_P""ZZ_^-U_.I11_JQA^[^]?Y!_8%#NS^BO_ (>%?LM?]#'=?^"ZZ_\
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M"NFKF=&_Y#6M?]=(O_0* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF/&?C/PQ\/?"^H^-/&>H1Z5HNE1^;<W,NXK&F0HX4%B2Q  4$DD  DU\E_\
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MOPC\)OA3H+ZAHFMWZ6=SJUZ6@9A)D;K> #< .#NEP3R-@^]4<K*N?IW1112
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YG1O\ D-:U_P!=(O\ T"NF
MKF=&_P"0UK7_ %TB_P#0* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_!2;]H#P/\:OB9H.A_#V]CU?2_"%M/"]_"=T,]S=.C2+"W\:((U&\<%BVW(
M)(MB:/W-_9N^*TOQN^!_A+XG742P7>LVI^U(GW!<V\CV\^T=E,D;%1V! YZU
MX?\ MT_M13_LW?#*!/##(?&7BAI+?3-ZAUMTB"F>Z93PWEAE" \%V4D%0PKN
M/V*?AYK'PO\ V8_ _A7Q% UKJAMYKVXB;[T;7T\ERJ,.S*DBJP[$$=:_%O\
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M-^'7[44GC=/'^HZKIX\-#33;?V9-!%O^V?:=_F>?!-G'DKMV[>ISGC'["?\
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M#2?"GA;0=0U'5M#T>RTZ^UB3SKVXMK>.&6ZE_OS.BAI&]V)-0G8IG\E_QX^
M_C+]GGQ3IG@SQY+;/J^H:9#J<D=LYE6 3R2QB)GP SKY66*Y7)P"1R?ZEO@'
M_P D*^'/_8MZ1_Z1Q5^%_P#P5<_Y.5TK_L6K+_TINZ_=#X!_\D*^'/\ V+>D
M?^D<57/82/6:***S&%%%% !1110 4444 %%%% !1110 5%/_ *B3_=/\JEJ*
M?_42?[I_E0!A^%/^1?L_]T_^A&NAKGO"G_(OV?\ NG_T(UT- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'O/[+G_)Q?PX_[#MC_ .C17]1=?RZ?LN?\G%_#C_L.V/\ Z-%?
MU%U\1Q3_ !8>GZGRG$/\2/H%%%%?+'SP4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!S/B'_CYTC_K[3^1KIJYGQ#_Q\Z1_U]I_(UTU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<SHW_(:UK_KI%_Z!735S.C?\AK6O^ND7_H% '34444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YGQ#_Q\Z1_U]I_(UTU<SXA_X^=(_P"OM/Y&NFH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L?Q!_R [[_ *XO_*MBL?Q!_P @.^_ZXO\ RH _FN_;'_Y.
M3\9_]=+/_P!(X*^9*^F_VQ_^3D_&?_72S_\ 2."OF2OU; ?P*?HOR/T3"?PH
M>B_(****ZCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#WG]ES_DXOX<?]AVQ_\ 1HK^HNOY=/V7
M/^3B_AQ_V';'_P!&BOZBZ^(XI_BP]/U/E.(?XD?0****^6/G@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/_'SI'_7VG\C735S/B'_
M (^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N9T;_ )#6M?\ 72+_ - KIJYG1O\ D-:U_P!=(O\
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M@1HGQ5_8A\&?!GQC/<65GJ_A[2)9I+8JL\,@\J\7;O5ER' # @Y&1[U\Y_\
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M+;PSXF\.64U_:26(,2W M4,CP3)DJ_F(I"M@,'VG=C<#W/\ P38_Y-&\+?\
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M)\ _]@FY_P#2BOWFK\&?^"NW_)2? /\ V";G_P!**J&XF?K#^R9_R;+\+_\
ML7M/_P#1*U^&?_!3LD?M6:@0<$:7IW_HLU^YG[)G_)LOPO\ ^Q>T_P#]$K7X
M9_\ !3S_ ).KU'_L%:=_Z+-..XGL?>?[)7_!.;P%X>\*V7CCX\Z='XD\2ZK$
MLZ:=,Q>RL(Y!E5=5.)IB#\Y;**>%!(WGP+_@H]^R)\.OA;X6TGXO_"K2UT*V
MDO%T_4K& G[/F9&>&>-&SL.4*. =IRI"@AB?W"\.?\B]I?\ UZP?^@"O@_\
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M< J$ER[,=7S-^UA\=M4_9Y^%:^.=$TZ#4[^XO[>QABN2PB!E5Y&9MA#'"QD
M CDCZ5],UXA^T%\#="_:$^'Y\ Z]?3:;&EU#>17$"JSI+"&7[K<$%78?CFO-
MPCIJK%U?AOJ<.&<%4BZFW4_*;_AZ5\6_^A2T/_R9_P#CU'_#TKXM_P#0I:'_
M .3/_P >KW+_ (=7>!O^A[U+_P !8?\ &OS _:,^%%C\$?C#KOPSTV_DU.VT
M@6I2XF14=_M%M%.<JN1P9"!["OM,)2R^O+DIQN]^I]1AJ>"JRY81U^9]F_\
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M6W_)8O%?_8!;_P!*H*+?\)?R_4/^8#Y?J?N;1117PI\B%%%% !1110 4444
M%8_B#_D!WW_7%_Y5L5C^(/\ D!WW_7%_Y4 6M,_Y!MI_UQC_ /015ZJ.F?\
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M*X&T\8&,5Z-114#"BBB@ HHHH **** "BBB@ HHHH *BG_U$G^Z?Y5+44_\
MJ)/]T_RH P_"G_(OV?\ NG_T(UT-<]X4_P"1?L_]T_\ H1KH: "BBB@ HHHH
M **** "BBB@ HHHH **** "BOD']J/\ :RLOV=&T;P]I_A34?%OBKQ.DATNT
MM4*P2-$0K!I5#N6!93Y<:,Q!&=H(-?F3KG[7O[77PM_: \$^+OVBK:X\->&=
M2'G-H4*+%:G3;AC#*YB5GD::'[X69O,5@.%5L&E%BN?OI7R3^W7XG_X1/]D_
MXAWZOMDO+*/3U'=OM\\=LP'_  "1B?8&OJZTNK:_M8;ZRE6>WN$62.1"&1T<
M95E(X((.0:_-?_@J1JMT_P $?#/@733F]\5^([2W5/[R1QRM_P"C3%2CN#/J
M/]D/PQ_PA_[,GPUT4IY;'1;:[=>A#WP^U.#[[I3GWKZ-K,T72K70M&L-#LAB
MWTZWBMXAZ)"@1?T%:=#&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ6I7T>EZ==:E-'
M)+':1/,R1(9)&$:EB$1>68XX Y)XK\>OB!^VW^TI\<-'UQ_V3_ %]IWAK28)
MYKK7[J%'N#% I:3R1(?LZ2;0<1J9I3QM ;BFE<#]DJ*_.7_@G%^T?JGQI^&%
M_P"$/&^IRZGXM\)3?O;BYD,D]W97+,T,K,W+,C;HV/8!,G+5^C5#0'Y>:!_Q
M7O\ P5+\079_>0_#WPPD4;]0KS11 J/?-[)^1K]0Z_+S]AC_ (K/]H?]H[XK
M/\\5SKBZ=9R=<PQSW!QG_KFD-?J'3D)!1114C"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]?:?R-=-7,^(?^/G2/^OM/Y&N
MFH **** "BBB@ HHHH **** "BJ6HZEIVCV$^J:M=165E:H9)IYW6.*-%&2S
MNQ"J .I)Q7Q?XN_X*(_LH>$;U]/_ .$M?6IXL[O[,M9KF//M-M6)OJKD4T@/
MMVBO@OP]_P %*/V3]>NX[2Y\0WFCM*<![VPG6,'MN:)9 OU/'J:^T_"WBWPO
MXXT2W\2>#M6M=:TJ[&8KFTE6:)O4!D)&1T(Z@\'FAH#H:***0!117/>+=8F\
M/>%-:U^W199=,LKFZ1'SM9H8V< XYP2.: .AHK\G?V)OVZ?BU^T7\8+SX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** />?V7/\ DXOX<?\ 8=L?_1HK^HNOY=/V7/\ DXOX<?\
M8=L?_1HK^HNOB.*?XL/3]3Y3B'^)'T"BBBOECYX**** "BBB@ HHHH ****
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MGM/BKX*^(^D1:OIDUMI3J'RLD,H>Y"RPR+AHW&3AE/3(.02#I'8E[GZ7R?\
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M+2(4445X!XX5_.'^WY_R=?XT_P!S3/\ TWV]?T>5_.'^WY_R=?XT_P!S3/\
MTWV]?2<+_P"\2]/U1[O#_P#&?I^J/K/_ ()1_P#'U\3O]S1_YWE?L37X[?\
M!*/_ (^OB=_N:/\ SO*_8FN3/_\ >Y_+\D<V<_[S+Y?D@HHHKQCRS\_/^"E'
MBR?P_P#L[KH=N2#XEU:TLY,''[J(/='_ ,?A0?C7X#6EK-?7<-E;KNEN'6-!
MZLYP!^9K]M_^"IL<Y^%_@V53^Y76'##_ &C;OM_0-7X[?#26T@^(WA6:_P ?
M9H]5L6EW<#RQ.A;/MBOT'AY*.$YEYGV>2JV'NO,_J@\ ^#-(^'?@K1/ VA1B
M.QT.TBM8\#&[RU 9SC^)VRS'N22:ZZBBOS^4FW=GQLI-N["O$?VAOC3I7P$^
M%NJ?$#4(Q<W,>VWL+8G N+R4'RD)_NC!=\<[%;'.!7MU?CC_ ,%4_$]TU_X!
M\&QL5MTBO;^1<\.[,D49(_V0KX_WC7?E>%5:O&G+8[,OPZJUHP>Q^:7CGX@?
M$?XW^-#K7BJ]N=?UO4I1%;P(&<*9&PD%M"N0JY("H@Y/J22?H"\_8'_:=LO#
M+^)9/#$<GEQF5K*.ZADO @&[B)6.YL?P*2^>-N>*\Y_9A^)_@GX-_%S3_B)X
MZTNYU:UTJ&<V\5JL;2+=2+L23$CHN%5F(YR#@CD9'ZF?\/2/@U_T*NO_ /?%
MK_\ )%?:XZOB:<HPPU.Z_K0^JQE:O3:C0A='X\_#3XH^/_@MXOA\4^"=0ETS
M4;1]LT1SY4ZJ?FAN(C@.IY!!Y!Y!# $?TW?!SXG:3\8_AIH/Q'T9/)AUB#>\
M.[<89T)2:(GOLD5E!P,@ XYK^9GXU^,/#7Q!^*_B?QOX0L)=,TK7+Q[N*WF"
MK(C2@-)N",R@M(6;@GK7[+?\$P]5N+WX!ZQI\[%ET_7[E(L]%CDMK>3 _P"!
MLQ_&N'B+#J5"-9JTE;\>AQYW14J2JVLS\Z_^"@O_ "=1XI_ZX:;_ .D4-?8O
M_!*?_D!_$?\ Z^=,_P#0+BOCK_@H+_R=1XI_ZX:;_P"D4-?8O_!*?_D!_$?_
M *^=,_\ 0+BKQW_(L7I']"\7_N"](_H>-_\ !4C_ )+-X6_[ "?^E=Q3_P#@
MEM_R6+Q7_P!@%O\ TJ@IG_!4C_DLWA;_ + "?^E=Q3_^"6W_ "6+Q7_V 6_]
M*H*/^99\OU#_ )@/E^I^YM%%%?"GR(4444 %%%% !1110 5C^(/^0'??]<7_
M )5L5C^(/^0'??\ 7%_Y4 6M,_Y!MI_UQC_]!%7JHZ9_R#;3_KC'_P"@BKU
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M\%23=VTBW-M\/_":M'(A#)BYA!!4C@Y_M'C%7;6Y)^I%%%%9E!1110 4444
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MCPU%\6+:Y<1:@#/:7&L:E*EW>*?^6L>[>^&_A:0H&'S E2"11"Y^IG_!4?\
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M5\L?/!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',^(?\
MCYTC_K[3^1KIJYGQ#_Q\Z1_U]I_(UTU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<SHW_(:UK_KI%_Z!735S.C?\
MAK6O^ND7_H% '34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!X%^U+X.\1_$#]GOQUX-\(V9U#6=4TYXK:W#*AED#*V
MT,Y502 <9(KX7_X)G_ #XP?!C5/'NH?$_P -S>'X=6AT^*U,\D3-*T+3F3"Q
MNQ 4,O) !SQGFOUEHIJ6EA6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_QI_N:9_P"F^WK^CROYP_V_/^3K_&G^YIG_ *;[>OI.%_\ >)>GZH]WA_\
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MV/<E #GOUKYW-:&+A23KSNF]CQ,QI8F--.M*Z;V/Q+_X*"_\G4>*?^N&F_\
MI%#7V+_P2G_Y ?Q'_P"OG3/_ $"XKXZ_X*"_\G4>*?\ KAIO_I%#7V+_ ,$I
M_P#D!_$?_KYTS_T"XKV<=_R+%Z1_0]/%_P"X+TC^AXW_ ,%2/^2S>%O^P G_
M *5W%/\ ^"6W_)8O%?\ V 6_]*H*9_P5(_Y+-X6_[ "?^E=Q3_\ @EM_R6+Q
M7_V 6_\ 2J"C_F6?+]0_Y@/E^I^YM%%%?"GR(4444 %%%% !1110 5C^(/\
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M^'5'A_\ Z*+=?^"U/_C]='^L&$_F_!_Y&W]LX?\ F_!GXR45^S?_  ZH\/\
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M%?LW_P .J/#_ /T46Z_\%J?_ !^C_AU1X?\ ^BBW7_@M3_X_1_K!A/YOP?\
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MP83^;\'_ )!_;.'_ )OP9^,E%?LW_P .J/#_ /T46Z_\%J?_ !^C_AU1X?\
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M_P"'5'A__HHMU_X+4_\ C]'^L&$_F_!_Y!_;.'_F_!GXR45^S?\ PZH\/_\
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M_P"/T?ZP83^;\'_D']LX?^;\&?C)17[-_P##JCP__P!%%NO_  6I_P#'Z/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS0 445XSXX_:)^!?PWO'TWQOXZTC2;Z/.^VDNXVN%Q_>A0M(/Q6@#V:BO#?
MW[2_P!^).IQ:)X)\>:3J>I3G$5J+A8KB4^D<4NQW/LH->Y4 %%%% !17D'BG
M]H'X&>"-9F\.^+O'VAZ1JEO@2VMSJ$$<\189 ="^Y"001N XYKT7P]XC\/>+
M='MO$/A74[;6-*O 6@N[.9+B"4*2I*21EE;!!!P>"".M &U1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_0_?RBBB@ HHHH
M **** "BBB@ HHHH *Y'QIX!\%_$71VT#QUHEIKFGL=PBNHED"M_>0GE&_VE
M(/O7744XR:=T.,FG='PMK?\ P3I_9EU:XDGL],U#2!(<[+2^D*+]!.)3^M:7
MAO\ X)]?LQ>'KE+N?0+G67CY47U[,Z9]2D9C5OHP(]J^UZ*[7F>(M;VC^\ZG
MCZ]K<[^\PM)\+^&] T-?#.A:7;:=I*(8UM+:%(8 C#! 1 % (Z\5\GO_ ,$_
M_P!E5[@S_P#"(RA2<^6-1O@GT_UV<?C7V;16%+%587Y)-7\S*GB*D+\LFKF+
MX<\.Z)X2T&P\,>&[1+#2]+A2WMH(\[8XHQA5&22>.I)))Y))K:HHK%MMW9DW
M?5A7QSJ7[ _[+.IW\VH2>$7@>X=I&2&_O(X]S')VH)<*,] N .@ %?8U%:T<
M14I_PY->AI2KSA\$FCSWX=?"OP'\*/"2^!_ FEKIVBAY)&@,DDV]YOOL[RL[
M,6Z<GIP.*^>+G]@/]E6YNVNCX/>/>Q8QIJ%ZL>3Z 3<#V! ':OLFBJABZL6Y
M1FTWOJ5'$U(MN,GKYG.^$O"?AWP+X;L/"/A*R33M(TN/RK:W0LRQIDG&6)8D
MDDDDDDG).:Z!T25&CD4.C@A@1D$'J"*=16#DV[LQ;;=V?&U]^P)^RO?7DMX?
M"+P&5BY2*_O$C!/)VJ)L*/0# '0<5](?#KX;>"_A/X6M_!?@'3AI>CVSO(D(
MDDE.^0[G8O*SN23ZGV'%=S16]7%U9KEG-M>;-JF)J35I2;7J%%%%<Y@%?-_Q
M-_9)^ ?Q=\2S>,?'/ALW6M7*QI+<Q75S;M(L2A$WK%(J$JH"@[<X &>!7TA1
M6M*M.F^:#L_(TIU90=X.S/(?A-\!_A5\#[6_M?AEH:Z0-4,;73F::>28P[O+
MW/,[D!=[8 P.3Q7KU%%34J2F^:3NR9S<G>3NPHHHJ"0JGJ&G:?JUE/IFJVT5
M[9W*E)89D62.1#U5D8$,#W!%7**$P/C;Q9^P1^S'XJNFO1X9?1IGR6_LVYE@
M0Y](B6C7'^RHKE]*_P""<?[,^GS++=V.IZFJG.RXOW52/0^0L1Q^.:^\:*[E
MF>(2LJC^\ZUCZR5N=_>>?^ /A5\.?A9IS:7\/?#UGH4$F/,-O&!)+CH9)3F2
M0CL68UZ!117'.;D[R=V<TI-N[9X3\4?V:/@A\8YS?^/?"UO=ZB1C[;"7M;HX
M&!NEA*,^.P?<!Z5\X2?\$T_V<GG$JRZW&G_/-;V/;^9A+?K7Z"T5U4LPKP7+
M";2]3HIXVK!6C)V/D3P?^PM^S)X.N([V+PDNKW,9R'U.>6[7\86;R3^,9KZT
MM;6VLK:*SLHD@MX$6...-0B(BC"JJC@ #@ <"IZ*QK8BI4=ZDF_4RJUISUF[
MGSA\3OV3/@+\7_$LGC#QUX<-WK,R)')<Q7=S;M(L2[4W+%(J$A0!G;G  SP*
M[;X3_ [X8?!#3KW2_AGHPTF'4I$DN29IIWE:,$*6>9W.%!. " ,GC)->LT4Y
M8JJX>S<G;M?0;Q%1QY')V['A?Q:_9L^#7QPOK/5?B3H/]I7VGQ&""=+B>WD6
M(L6V'R9$##<21N!QDXQDTOPE_9M^#?P/O;S5/AMH/]FWVH1"">=[B>XD:(,&
MV#SI'"C< 3M R0,]!7N=%'UJKR>SYGR]KZ!]8J<O)S.W8****P,0HHHH ***
M* "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*
MO51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?_0C70USW
MA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?%W_(
M%?\ ZZ1?^ABNFKF?%W_(%?\ ZZ1?^ABNFH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\
M=/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MQ_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_ )!M
MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_ .ND
M7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H
MM:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!
M7_ZZ1?\ H8KIJYGQ=_R!7_ZZ1?\ H8KIJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_)5?1W[)G_!0/XY_&[X]>'/AEXMTG1CI&L"[\^2RM;B.:(06TLRN&:>10-R
M'*XP<9!P:_9VBAR78+!1114#/QV_X*]HY\'_  WD"G:+_4 3C@$Q18&??!KZ
ME_X)Q(Z?L@^#-ZE=TNJ$9&,@ZA/S7V]/;V]U'Y5S$LR==KJ&&?H:D1$C4)&H
M55&  ,  >E5S:6%8=1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% ',^+O^0*__ %TB_P#0Q735S/B[_D"O_P!=(O\
MT,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,Z-_R&M:_
MZZ1?^@5TU<SHW_(:UK_KI%_Z!0!TU%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!__]3]_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\
MH(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#
M7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGP7;>&?&GA.RM-#\7ZU>2QW5I:!8EN[549FN7A7 #))M4N "^\[B2HQ]H?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ZZ1?\ H8KIJYGQ
M=_R!7_ZZ1?\ H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YGQ#_Q\Z1_U]I_(UTU<SXA_X^=(_P"OM/Y&NFH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KF=&_Y#6M?]=(O_0*Z:N9T;_D-:U_UTB_] H Z:BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]7]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F
M?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\
MB_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/_
M !\Z1_U]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+
M_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_ )!MI_UQC_\ 015Z
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_ .ND7_H8KIJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MGQ#_ ,?.D?\ 7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YG1O^0UK7_72+_P!
MKIJYG1O^0UK7_72+_P! H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH __UOW\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@BKU4
M=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<]X4_
MY%^S_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .9\0_\ 'SI'_7VG\C735S/B
M'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_ "K8K'\0?\@.^_ZX
MO_*@"UIG_(-M/^N,?_H(J]5'3/\ D&VG_7&/_P!!%7J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?
M%W_(%?\ ZZ1?^ABNFKF?%W_(%?\ ZZ1?^ABNFH **** "BBB@ HHHH ****
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M  -B_P :_FPHH^K+N'M6?TG_ /#2?P!_Z*#HO_@;%_C1_P -)_ '_HH.B_\
M@;%_C7\V%%'U9=P]JS^D_P#X:3^ /_10=%_\#8O\:/\ AI/X _\ 10=%_P#
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M!_Z*#HO_ (&Q?XT?\-)_ '_HH.B_^!L7^-?S844?5EW#VK/Z3_\ AI/X _\
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M1R>/]%5EB0$&]BX(49[U<_X:3^ /_10=%_\  V+_ !K^;"BCZLNX>U9_2?\
M\-)_ '_HH.B_^!L7^-'_  TG\ ?^B@Z+_P"!L7^-?S844?5EW#VK/Z3_ /AI
M/X _]%!T7_P-B_QH_P"&D_@#_P!%!T7_ ,#8O\:_FPHH^K+N'M6?TG_\-)_
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M_P"&D_@#_P!%!T7_ ,#8O\:/^&D_@#_T4'1?_ V+_&OYL**/JR[A[5G])_\
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M  -B_P :/^&D_@#_ -%!T7_P-B_QK^;"BCZLNX>U9_2?_P -)_ '_HH.B_\
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M_P"&D_@#_P!%!T7_ ,#8O\:/^&D_@#_T4'1?_ V+_&OYL**/JR[A[5G])_\
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M  -B_P :/^&D_@#_ -%!T7_P-B_QK^;"BCZLNX>U9_2?_P -)_ '_HH.B_\
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M_P"&D_@#_P!%!T7_ ,#8O\:/^&D_@#_T4'1?_ V+_&OYL**/JR[A[5G])_\
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M?P!_Z*#HO_@;%_C7\V%%'U9=P]JS^D__ (:3^ /_ $4'1?\ P-B_QH_X:3^
M/_10=%_\#8O\:_FPHH^K+N'M6?TG_P##2?P!_P"B@Z+_ .!L7^-'_#2?P!_Z
M*#HO_@;%_C7\V%%'U9=P]JS^D_\ X:3^ /\ T4'1?_ V+_&C_AI/X _]%!T7
M_P #8O\ &OYL**/JR[A[5G])_P#PTG\ ?^B@Z+_X&Q?XT?\ #2?P!_Z*#HO_
M (&Q?XU_-A11]67</:L_I/\ ^&D_@#_T4'1?_ V+_&C_ (:3^ /_ $4'1?\
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M?P!_Z*#HO_@;%_C7\V%%'U9=P]JS^D__ (:3^ /_ $4'1?\ P-B_QH_X:3^
M/_10=%_\#8O\:_FPHH^K+N'M6?TG_P##2?P!_P"B@Z+_ .!L7^-'_#2?P!_Z
M*#HO_@;%_C7\V%%'U9=P]JS^D_\ X:3^ /\ T4'1?_ V+_&C_AI/X _]%!T7
M_P #8O\ &OYL**/JR[A[5G])_P#PTG\ ?^B@Z+_X&Q?XT?\ #2?P!_Z*#HO_
M (&Q?XU_-A11]67</:L_I/\ ^&D_@#_T4'1?_ V+_&C_ (:3^ /_ $4'1?\
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M_P!%!T7_ ,#8O\:/^&D_@#_T4'1?_ V+_&OYL**/JR[A[5G])_\ PTG\ ?\
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MT7\[G_XU1_P[4^*W_0T:+^=S_P#&J_9^BCV\@]FC\8/^':GQ6_Z&C1?SN?\
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MBM_T-&B_G<__ !JC_AVI\5O^AHT7\[G_ .-5^S]%'MY![-'XP?\ #M3XK?\
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MT7\[G_XU7[/T4>WD'LT?C!_P[4^*W_0T:+^=S_\ &J/^':GQ6_Z&C1?SN?\
MXU7[/T4>WD'LT?C!_P .U/BM_P!#1HOYW/\ \:H_X=J?%;_H:-%_.Y_^-5^S
M]%'MY![-'XP?\.U/BM_T-&B_G<__ !JC_AVI\5O^AHT7\[G_ .-5^S]%'MY!
M[-'XP?\ #M3XK?\ 0T:+^=S_ /&J/^':GQ6_Z&C1?SN?_C5?L_11[>0>S1^,
M'_#M3XK?]#1HOYW/_P :H_X=J?%;_H:-%_.Y_P#C5?L_11[>0>S1^*&I_P#!
M.3XHZ9:&[E\3:,Z@JN%-QG+''>*M#_AVI\5O^AHT7\[G_P"-5^O/B[_D"O\
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MBM_T-&B_G<__ !JC_AVI\5O^AHT7\[G_ .-5^S]%'MY![-'XP?\ #M3XK?\
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M1?SN?_C5'_#M3XK?]#1HOYW/_P :K]GZ*/;R#V:/Q@_X=J?%;_H:-%_.Y_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^
MN,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?
M_0C70USWA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]
M?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\ *MBL
M?Q!_R [[_KB_\J +6F?\@VT_ZXQ_^@BKU4=,_P"0;:?]<8__ $$5>H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .9\7?\@5_P#KI%_Z&*Z:N9\7?\@5_P#KI%_Z&*Z:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\0_P#'
MSI'_ %]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_\ 0*Z:N9T;
M_D-:U_UTB_\ 0* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /_]+]_**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:
M?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\
M=/\ Z$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_
MZ^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:
M9_R#;3_KC'_Z"*O51TS_ )!MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_
M .ND7_H8KIJYGQ=_R!7_ .ND7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'
M_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *YG1O^0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH __T_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'
M\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI_\ 42?[I_E4M13_
M .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .9\0_\ 'SI'_7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__4_?RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"U
MIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G
M_(OV?^Z?_0C70USWA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#
M_P ?.D?]?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_K
MB_\ *MBL?Q!_R [[_KB_\J +6F?\@VT_ZXQ_^@BKU4=,_P"0;:?]<8__ $$5
M>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .9\7?\@5_P#KI%_Z&*Z:N9\7?\@5_P#KI%_Z&*Z:@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.9\0_P#'SI'_ %]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_\
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MHHH **** "BBB@ HHHH **** "L?Q!_R [[_ *XO_*MBL?Q!_P @.^_ZXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML(SVTS1O$6".T;920*P(=6'([<<8-.P':T444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_
MR#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ZZ
M1?\ H8KIJYGQ=_R!7_ZZ1?\ H8KIJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_Q\Z1_U]I_(UTU<SXA_X^=(
M_P"OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KF=&_Y#6M?]=(O_0*Z:N9T;_D-:U_UTB_] H Z:BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$R%CT+[L5^)__!1OPW:^'?VL_%<EF@BCU>&QOBHZ;Y;9$D/U9T9C[DU]A_\
M!('7;CSOB;X9<Y@VZ7>1C^Z^;B-S_P "&S\J):H%N?MG1116104444 %%%%
M!1110 4444 %%%% !1110 5C^(/^0'??]<7_ )5L5C^(/^0'??\ 7%_Y4 6M
M,_Y!MI_UQC_]!%7JHZ9_R#;3_KC'_P"@BKU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %13_ZB3_=/\JEJ*?_ %$G^Z?Y4 8?A3_D7[/_
M '3_ .A&NAKGO"G_ "+]G_NG_P!"-=#0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/B'_CY
MTC_K[3^1KIJYGQ#_ ,?.D?\ 7VG\C734 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HHHH **** "L?Q!_R [[_ *XO_*MBL?Q!_P @.^_ZXO\
MRH BMM5TNQL;.&]O(;=S!&P6214)&,9P2..*E_X2+P__ -!.U_[_ "?XU_-C
M^V7))+^TIXS:5BY#V2Y)R<+90 #Z   >U?,-?68?AA3IQG[3=)[?\$^CHY I
MP4N?==O^"?UV?\)%X?\ ^@G:_P#?Y/\ &C_A(O#_ /T$[7_O\G^-?R)T5M_J
MHO\ GY^'_!-?]75_/^'_  3^NS_A(O#_ /T$[7_O\G^-'_"1>'_^@G:_]_D_
MQK^1.BC_ %47_/S\/^"'^KJ_G_#_ ()_79_PD7A__H)VO_?Y/\:/^$B\/_\
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M%>%FN6_5IJ/->YY&8X#V$E&][A1117E'G!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <SXN_P"0*_\ UTB_]#%=-7,^+O\ D"O_ -=(O_0Q734
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MA^?59EMX+G4[>W2U\V0[45WAN)63<Q #%=H_B('-?H=7\8T7A77)O"<_C>"
MOI-I>Q6$TJ_\L[B:-Y8E;TWK&^T_[)]L_P!+W[!G[0__  OOX*6D>MW/G>*_
M"?EZ=JFXYDF 7_1[D]_WR+\Q[R*_;%.403/LO5M3MM%TJ\UB]S]GL89)Y-HR
MVR)2S8'<X%?'?[/?[=7PH_:0\=7/@#P;I.LZ=J%O9RWROJ$-ND3Q1.B, 89Y
M2&RX(!&,9YSP?J/XB?\ )/\ Q-_V"[W_ -$/7\_O_!*O_DYJ[_[%Z^_]'6])
M+0&S^ACQ+XATOPEX<U7Q7KDIATW1;2>]N9 "Q2"VC,DC8')PJDX%?FM)_P %
M9_V=D=E3PYXI=02 PM;( CUYO<\^]?</[17_ ";[\3O^Q7UK_P!(I:_GS_X)
M[?!GX;_'/XUZMX1^*.D?VSI-KH-S>QPBXGMMMQ'=6L:OOMY(W.%D<8)QSG&0
M,.*0,_3.S_X*Q?LX7,PBN-#\3VBG^-[.T91]=EXS?D*^J?A%^US^S]\;[J/2
MO GBR!]6D&1I]XKV=V3Z(DP42D=_*+XKQW6O^":G[).J6LEO8^&KS1Y'&!+:
MZG=LZ'U N))DS]5(]J_*/]KK]A3Q5^S/%'\0O!FIS:]X-$Z*;EE$=[ITK,!%
MY^S"LK-@+*@4;L JI*[BR8:G]*-%?F3_ ,$Z?VL]9^-GAV^^&'Q%O#>^+?#,
M*SPWDA!EO[ L$W2?WI86*J[=7#*3EMQ/Z;5+5AA7QC^U_P#MA:=^RC9^&P_A
MI_$VH>)6NO*A%T+..*.T\O>SR>5,2295"J%YP<D8&?LZOFG]I+]GOX*?'?2-
M('QCE:Q31))?L=W'=K9O&;@+YB;GRC!_+4X()^7C'-" T/V8OV@=._:5^%T7
MQ'L-(DT)Q=S64]I)*)PDT(5CLE"IO4JZD'8ISD8XKZ&KR+X'_"CX<?!KX?VG
M@WX6)_Q(_,DN1*9_M+3RRGYY&EZ,3M XP   !7HNK>(O#^@^5_;FIVNG>?D1
M_:9DAWXZ[=Y&<9[4,#8HJC?ZIIFE6$FJZG=PV=E"N]YYI%CB1?[S.Q"@>Y-<
M?H'Q6^%WBR__ +*\+>,=&UF]Y'D66H6]Q+QU^2-V;COQ2 [ZBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#__7_?RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^=OVN/^38OB?_V +[_T4:_DLK^M/]KC_DV+XG_]@"^_]%&O
MY+*UAL3(_L-^"/\ R1?P#_V+^E?^DD=>GUYA\$?^2+^ ?^Q?TK_TDCKT^LV4
M?DW_ ,%3?@)_PEG@+3OCEH%MNU3PGBUU+8/FDTV9_D<]SY$S?@LCD\+7X$!F
M (!(##!]QUK^T'Q)H>E>)O#VI^'-=MEO-.U2VFM;F%QE9(9D*.I]BI(K^+VM
M(,F1^E/_  3-^ G_  LSXQM\2]<MO,T'P%LN$W#Y)=3DS]F49Z^5@S''1E3/
M#5_1G7PM_P $W]$TK2OV1?"-]I]NL-QK$^I75VZCF:9;Z:W#M[B*)$^BBONF
MHD]1H^"O^"E?_)I/B7_K\TS_ -*XZ_FT\,?\C+I/_7W!_P"C%K^DO_@I7_R:
M3XE_Z_-,_P#2N.OYM/#'_(RZ3_U]P?\ HQ:TAL*1_:!1116)05XU^T9_R;W\
M3_\ L5]:_P#2&:O9:\:_:,_Y-[^)_P#V*^M?^D,U- ?R$5_7C^S5_P FY_"O
M_L5-#_\ 2"&OY#J_KQ_9J_Y-S^%?_8J:'_Z00UI4)B>UT445D4?BQ_P6$_X]
MOA/_ +^N?RL:^(?^"=G_ ">-\/\ _N+?^FJ[K[>_X+"?\>WPG_W]<_E8U\0_
M\$[/^3QOA_\ ]Q;_ --5W6J^$E[G]0M?GO\ \%)?@UKOQ6^ 0U;PM;/>:GX-
MO!J9@C&Z26T\MH[@(.I90PDP.H0@ G%?H116:=BC^+G0==U?POK=AXD\/W;V
M.IZ7/'=6MQ$</%-"P='4^JL :_1=?^"JO[2RZ)'I9L?#[7:(%:^-E-Y[D#&\
MH+@0[B>3B,+Z**_5WXI?L ?LS?%;5I_$&H>'Y=!U2Z8O-/H\WV02L>2S0E7@
MW$G)81@D\DFO-=!_X):_LO:1-YNH?VYK:YSY=Y?JBX]/]%B@;'XYK3F1-C^?
M;XA_$CQO\5_%5UXU^(6K2ZUK-YM#SR[1A5^ZB(@5$1>RJ !Z5^I__!(6%V\:
M_$:X'W$T^P4_5I9"/_037Q#^VA#\.-,_:&\1^%_A3IEKI7A[PV(-+2*T0(AG
MM8PMR6/+.XF+JSL2S;>2>*_3;_@D5X.DLO ?CWQY-$5&KZA:Z?$Y&,K8Q-(V
MWVS< ''<>U.6PEN?K]1116)84444 %%%% !1110 4444 %%%% !1110 5C^(
M/^0'??\ 7%_Y5L5C^(/^0'??]<7_ )4 6M,_Y!MI_P!<8_\ T$5>JCIG_(-M
M/^N,?_H(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M4_\ J)/]T_RJ6HI_]1)_NG^5 &'X4_Y%^S_W3_Z$:Z&N>\*?\B_9_P"Z?_0C
M70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110!S/B[_D"O_UTB_\ 0Q735S/B[_D"O_UTB_\
M0Q734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!S/B'_CYTC_K[3^1KIJYGQ#_ ,?.D?\ 7VG\C734 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S.C?\AK
M6O\ KI%_Z!735S.C?\AK6O\ KI%_Z!0!TU%%% !1110 4444 %%%% !1110
M4444 ?(G[</P5UGXZ_L^:QX6\,1B?7-,FBU6PA(YFFM0P:)?1Y(G=4[%B <
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M04445(PHHHH **** "BBB@ HHHH **** /_0_?RBBB@ HHHH **** "BBB@
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M_&6^_P""/]P;Z0Z9\456S+$H)M(+2JO8,5N@K$=R N?0=*F#0VC[@_X)W_\
M)G7P^^FJ?^G2[K[4KQWX ?"&U^ _PA\/?">SU)]8CT%)Q]KDC$+2O<7$EPY\
ML,VT!I" -QX R2>:]BJ6-'P5_P %*_\ DTGQ+_U^:9_Z5QU_-+IMXVG:C:Z@
MJ[S:RI*%)P"48-C/OBOZ[?CW\&M%^/WPLUCX7:]>3:=;ZKY+K<P!6DAEMY5E
M1@K<,-RX8<9!(!!Y'Y:'_@CT,\?%OC_L _\ W?5QDK$M'-?\/>_%_P#T3>Q_
M\&$O_P :KH?"7_!6?Q#KGBK1]%U/X=VL-IJ%Y;V\TD-_(TB)+(J,RJ8L$@'(
M!Z],CK3_ /ASS_U5O_R@?_?"M_PI_P $D+/0/$^D:[J/Q0:_M=.NX+F6W31?
M):9(9 YC$AO7V;@,;MC8ZX-%XAJ?H+^U!^T-I?[,WPS7XB:EI$FN&:^@L(;6
M.80;Y9E=\F0J^T*D;'[IR<#OFORW^)/_  54TSQ_\.O%/@2/X;363>(]*OM-
M%P=5600F\@>$2%/LJ[MN_.,C.,9%?J%^U-^SO9_M-_#!?AU=:TWA^2"_@U""
M[6W%T$DA5T(:+S(MP9)&'WQ@X/.,'\X?^'//_56__*!_]\*4;=1NY^*-?L/\
M,O\ @JCIGP\^&WA/P!)\-YKYO#.DV&F&X&JK&)C96Z0&0)]E;;NV9QDXSC)Z
MUT__  YY_P"JM_\ E _^^%'_  YY_P"JM_\ E _^^%4VA69^JWP-^*^G?''X
M4>'OBII5D^G6^O0R/]FD<2-$\,KPR)O  8!XVP<#(P<#I7QE^TC_ ,%%]#_9
M\^*VH?"P>"9_$%QI<-M)/<B^6U4/<Q+,$5##*2 CJ<Y')(QQD_97P)^$]I\#
MOA+X<^%5EJ#:K'H$,D9NGC\HS/+*\TC>7N?8"[G"[FP,#)ZU\4?M+_\ !.6S
M_:$^+6H_%6V\>-X;EU2&VCGM6TP7H\RVB6$.LGVJ# *(OR[3R"<\X$*UQGY<
M?ME?MAVG[5T?A&.U\*OX:_X1@WY)>\%WYWVSR,8Q#%MV^3[YSVQSX9^SA\8(
M?@)\9_#WQ9GTIM:30OM>;19A;F7[5:36W^L*/MV^;N^Z<XQQG-?I]_PYY_ZJ
MW_Y0/_OA1_PYY_ZJW_Y0/_OA5W1-F>J?"7_@J1H'Q-^)?AKX=W/P_N-('B2^
M@T]+H:BMQY4MRPCC)C^SQY!<@'YA@'/.,'[6_:D^-&H?L_\ P3UWXH:1I\6J
M7VFO:QPV\[,L3-<W$<)+E?FPJL3@=2 *^&_A#_P2TM/AA\3_  Q\1;WXDMK$
M?AN_@U 6B:1]E,TENP>-3+]LEVC> 3\AR,CC.1^C'QF^$WAKXX_#76OAAXM>
M:+3=92,-+;L%FBDAD66-T+!AE713@@@C(/!J':^A1^8_@[_@KMX-GM53X@^
M;^QN%&&?2[F*Z1SZA)_(*_3<WUKA/CC_ ,%7)-=\,W7A_P"!GAZ[T2_O5*'5
M=3:+S;=3P3#;QF5/,(Z.SD+_ '2<$9OBC_@D1XT@NG/@OX@:?>VQ)*C4+66V
M=1V!,1G#?7 ^@J'PW_P2(\=SW2#Q=\0--L;;JYL;6:Z<^P$I@ SZ]O0U?NBU
M/RG\-^'/%7Q'\767AOP]:SZSK^NW(CBC7+RS32G)9B?Q9V8X RS' )K^LW]G
MSX267P,^#OAGX8VC)++I%L/M4R#"S7DI,EQ(,\X:1FVYY"X':N"_9Y_9"^#O
M[-UN]SX.L9+_ %ZX3RY]7ORLMVRG[R1D*JQ1D]50 GC<6P#7U'4RE<:04445
M PHHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_ "K8K'\0?\@.
M^_ZXO_*@"UIG_(-M/^N,?_H(J]5'3/\ D&VG_7&/_P!!%7J "BBB@ HHHH *
M*** "BBB@ HHHH *\K\1?'3X)^$-6GT#Q7\0/#^C:G;8\VUO-4M;>>/(R-\<
MDBLN1SR*]4K^4OXM>$V^(?[:GBKP(]X;(^)/'=UIGVDIYWD"[U)H!)LW+NV!
ML[=RYQC(ZU48W$V?TD1_M+?LYRL$C^*7A8L>@_MNQY_\C5ZOHVNZ)XCT^/5O
M#VH6^J6,WW+BUE2>)_\ =="5/X&OQ9O_ /@C[J$=L[:9\58KBX ^5)M%:%"?
M0NMY(0/?:?I7P?KNF?M"?L'_ !A2PAU$Z/J\2)<1RVLAET_4K1B0"R,%$L9*
ME2KJ&5AD;2 :?*GL%S^JNBO*_@C\4;#XT_"?PS\4--@-M%K]H)7A)SY4Z,8I
MHP>X25&4'N!G Z5Y9^US^TMI?[,OPOD\3B*.^\1:HYM=(LI"0LL^,O))M^;R
MH5.Y\8R2J9!8$389]!>*?&7A#P/IK:QXSUNRT&Q7.9[ZXCMH^.VZ1E!/M7@D
MO[:7[*T-R+1_B7I)<]UD=D_[[52OZU^!WP[^%O[1G[>7Q%OM9O-3DU(VQ!OM
M6U&1ELK%)"66*)%! SSLAB7'<[1EJ^]8/^"0&D?V<%N?B?/]O*C+II2^2&QS
M\AN=Q&?]H57*EN*Y^L/@GXH?#CXDVS7?P_\ $^F^(8T&7^PW44[(.GSJC%D_
MX$!7=U_+C\=/V8_CG^QEXDTWQ=;ZF_V!YMNGZ_I,DD.V;!/E2 $/#(5!.TDJ
MPSAFPP'[/_L)?M83_M(^!+O2O%YC3QMX8\M+XQJ$2[@DR(KI5' 8E2LBKP&
M( #JH3CU!,^X-4U33-$T^XU?6KN&PL;1#)-<7$BQ11(O)9W<A54=R3BO'_\
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M"Y_0[117XR_M=_\ !0CQQIWC36/@3\ =-EM=7L;N33+K5#'Y]V]RC>6\5C
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M *Z1?^ABNFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP!)!!%&P!R-RJ >?K7Y*_M^?L->/OBWXV7XR?!VVBU/4KNWAM]3TUID@FE>
M>7'<1/*RQG]T%1D+*?D!7<20%%ZC9^O2LKJ'0AE89!'((/<4ZOYY/AU\&O\
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M]HC5]$N0TLVD&YL)P/D34-+O8RNX=L21,LBYSM<#/*U]!_\ !*O_ ).:N_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&
MVG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH *_E]U'_ )2+/_V5!?\
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M44_^HD_W3_*I:BG_ -1)_NG^5 &'X4_Y%^S_ -T_^A&NAKGO"G_(OV?^Z?\
MT(UT- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?&O[.G[0_
MC7XT_&/XP^#]0LM/@\,_#S4ETZPGMXY5N9W\ZXB)E=Y71N("?D1>HK[*IM %
M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M^-?VGOVA_&OP@^(7PB^'O@2RT^]O/B+K'V&Y-]'+)Y-N)K>(O'Y4L6UOWY.6
MW#Y3Q7V53L 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKY _;5_:'\4?LW?"K
M3_%_@JRLM0UO5-6M]-@@OXY98BLD4LKMMADB<D", ?-C)'!KZTL#>FQMCJ6P
M79C3SO+!">9@;]H))VYSC)/'>G8"W1112 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BOC7]I[]H?QK\(/B%\(OA[X$LM/O;SXB
MZQ]AN3?1RR>3;B:WB+Q^5+%M;]^3EMP^4\5]E4[ %%%%( HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .9\0_P#'SI'_ %]I_(UTU<SXA_X^=(_Z
M^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *Q_$'_ " [[_KB_P#*MBL?Q!_R [[_ *XO_*@#
M^:[]L?\ Y.3\9_\ 72S_ /2."OF2OIO]L?\ Y.3\9_\ 72S_ /2."OF2OU;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_
MD:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N9T;_D-:U_UTB_] KIJYG1O^0UK7_72+_T"@#IJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF=_]D8C^3\4?K/17Y,?\/5O#O_1.[O\ \&,?_P 8H_X>K>'/^B=W?_@QC_\
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MK-;"_P#$&E6=_/ @8)')<0K(RJ'^;;D\9).,<GK7HU9%!1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUQ?^5;%8_B#_ ) =]_UQ?^5 '\UW[8__ "<GXS_ZZ6?_ *1P5\R5]-_MC_\
M)R?C/_KI9_\ I'!7S)7ZM@/X%/T7Y'Z)A/X4/1?D%%%%=1T!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >\_LN?\G%_#C_L.V/_ *-%?U%U_+I^RY_R<7\./^P[8_\ HT5_477Q'%/\
M6'I^I\IQ#_$CZ!1117RQ\\%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!S/B[_D"O_UTB_\ 0Q735S/B[_D"O_UTB_\ 0Q734 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/B'_CYTC_K
M[3^1KIJYGQ#_ ,?.D?\ 7VG\C734 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S.C?\AK6O\ KI%_Z!735S.C?\AK
M6O\ KI%_Z!0!TU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\9M!MO&&J7<'A+0;U0]K+=1M+<W$9^[)';J5_=GLSNN1@J"I!KTSQS_P2_\
MBGH>GS7W@?Q)8>)Y8AD6TD;6$T@]$+M)'N]FD4>]?N5'''#&L,*A$0!551@
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M\JN;]F[(_FX\$_ WXM?!S]IKX;^'_&>A3V%T_B+3'AGC'FVT\:7*,[13)E&
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MM,_Y!MI_UQC_ /015ZJ.F?\ (-M/^N,?_H(J]0 4444 %%%% !1110 4444
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MS]"_AEX9'@KX;^%/!P79_86DV-CCT-M D1_]!KN***D84444 %%%% !1110
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MK=1,^N_A)\2]!^,7PW\/_$OPV<6.O6J3B,L&:&3[LL+$8!:*0,C>ZG%>B$@
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MR[EF,=A;S+PT:[ 7G93D/@HJG@,Q! 25QGZBU_-)_P %-/\ D[#6O^P=IO\
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MC_L.V/\ Z-%?U%U\1Q3_ !8>GZGRG$/\2/H%%%%?+'SP4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ',^+O^0*__ %TB_P#0Q735S/B[_D"O_P!=
M(O\ T,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^$/COQ]I?Q-\9>&+76?$>BVXM;2XNMTJ11*[2J/)9O)9E=V969"RD\$5ZV
M  , 52DD(_G*^"__  4J^/7PW\0I8?%6=O&NA!_*N8+J.."_M\-AFBF1%)=>
MZ2A@<8!3K7]"_A7Q1H7C;PUIGB[PQ=I?:3K%O'=6LZ='BE4,I]0<'D'D'(/(
MK\#O^"KG@CPUX<^-'A[Q1HMO':WWB73&EOUC&WS9;>7RUF8#^)D(4GOL'?)K
M]+O^"<MYJ%Y^R'X,^W<K#)J44)[F);Z?&?H<@>P%.2TN)'OOQY^.'@_]GSX<
M7_Q%\9.7AMR(;6UC($UY=2 F."//<X))_A4,QX%?AA??MF_MN_M&^*[G3?A
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MZ_QI_N:9_P"F^WK^CROYP_V_/^3K_&G^YIG_ *;[>OI.%_\ >)>GZH]WA_\
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MS\K/&%A@/_ 0TOYU^MMUJ&GV,D$5[<Q6[W3B*%9'5#)(>0J D;F]AS7XL_\
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M?\@VT_ZXQ_\ H(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^-/\ P50^"EU
MGA[]I'PFC07FER1:?JDL.5= &W65SD8P4DS&6ZY:,#I7T]8?M*6OQ-_8.\2_
M&)9E36+?P]?V5^JX'E:LD!@/ ^Z'=TD4?W'7O7V+\1/ NA?$WP-KOP_\2Q^;
MIFOVDMI-C[RB1<!UST=&PRGLP!K^7/4_%OQ _9\T3XN_LOZZA,.MSVUM<#)
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M^)'C*U^'?P^\2^/;U1)#X=TV[U!D)QO^S1-($SZL5P/<U_-!^R_\+-2_:_\
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M_DY/QG_UTL__ $C@KYDK]3?VC_V*/CY\1_C!KOCSP;I=I?Z3K)MI(6^VQ1.
MEK"AW+*4(.Y2.,]/IGPS_AWK^U+_ -"Y:_\ @QM?_CE?I."S&@J,$YJ]EU\C
M[K"XVBJ44YK9=3XEHK[:_P"'>O[4O_0N6O\ X,;7_P".4?\ #O7]J7_H7+7_
M ,&-K_\ '*ZO[2P__/Q?>CH^O4?YU]Y\2T5]M?\ #O7]J7_H7+7_ ,&-K_\
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MOO/B6BOMK_AWK^U+_P!"Y:_^#&U_^.4?\.]?VI?^A<M?_!C:_P#QRC^TL/\
M\_%]Z#Z]1_G7WGQ+17VU_P .]?VI?^A<M?\ P8VO_P <H_X=Z_M2_P#0N6O_
M (,;7_XY1_:6'_Y^+[T'UZC_ #K[SXEHK[:_X=Z_M2_]"Y:_^#&U_P#CE'_#
MO7]J7_H7+7_P8VO_ ,<H_M+#_P#/Q?>@^O4?YU]Y\2T5]M?\.]?VI?\ H7+7
M_P &-K_\<H_X=Z_M2_\ 0N6O_@QM?_CE']I8?_GXOO0?7J/\Z^\^):*^VO\
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M%% !1110 4444 %%%% !1110!S/B[_D"O_UTB_\ 0Q735S/B[_D"O_UTB_\
M0Q734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!S/B'_CYTC_K[3^1KIJYGQ#_ ,?.D?\ 7VG\C734 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S.C?\AK
M6O\ KI%_Z!735S.C?\AK6O\ KI%_Z!0!TU%%% !1110 4444 %%%% !1110
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MW^'.I_##QAI&@VNE:JT#RR6-M=1W -O,DR;6DNI%&60 Y4\9Q@\U]M_\$?\
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MV\4K\:_BU#)/X/M+IYT6Z+-)K5Z'W-N+<M KY,KG[[?(,_/M_H;5550JC '
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MY1116104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[/QU5_A5H;:3)K?DB[=[JXN6D$&_RQ^_D?:%WM]W&<\YP,',K6"Q\R_\%/\
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M#I@?U7UYK\3/@]\,?C'HZZ%\3?#EIK]I&28O/4B6$GJ8ID*RQD]RC#/>B,K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YGQ=_R!7_ZZ1?\ H8KIJYGQ=_R!7_ZZ1?\ H8KI
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH YGQ#_Q\Z1_U]I_(UTU<SXA_X^=(_P"OM/Y&NFH **** "BBB@ HHHH
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M+$8BBCQ_KFW9SGC&,<_4]$G=@CX9_P""D'_)H/C+_KMI?_IP@KY-_P""/_\
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MG( "C QU/-5S:"L>K4445 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_D:Z:
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Q_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_K
MC'_Z"*O51TS_ )!MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8
MKIJYGQ=_R!7_ .ND7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'_CYTC_K[
M3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *YG1O^0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
MU_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_
MZXO_ "H M:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HI_\ 42?[I_E4M13_ .HD_P!T
M_P J ,/PI_R+]G_NG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .9\0_\ 'SI'_7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'
M\0?\@.^_ZXO_ "K8K'\0?\@.^_ZXO_*@"UIG_(-M/^N,?_H(J]5'3/\ D&VG
M_7&/_P!!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#F?%W_(%?\ ZZ1?^ABNFKF?%W_(%?\ ZZ1?
M^ABNFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#F?$/\ Q\Z1_P!?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF=&_Y#
M6M?]=(O_ $"NFKF=&_Y#6M?]=(O_ $"@#IJ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__0_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^
MN,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?
M_0C70USWA3_D7[/_ '3_ .A&NAH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]
M?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\ *MBL
M?Q!_R [[_KB_\J +6F?\@VT_ZXQ_^@BKU4=,_P"0;:?]<8__ $$5>H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .9\7?\@5_P#KI%_Z&*Z:N9\7?\@5_P#KI%_Z&*Z:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\0_P#'
MSI'_ %]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_\ 0*Z:N9T;
M_D-:U_UTB_\ 0* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /_]']_**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:
M?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\
M=/\ Z$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_
MZ^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:
M9_R#;3_KC'_Z"*O51TS_ )!MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_
M .ND7_H8KIJYGQ=_R!7_ .ND7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'
M_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *YG1O^0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH __TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'
M\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI_\ 42?[I_E4M13_
M .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .9\0_\ 'SI'_7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__3_?RBBB@
MHJCJ=S)9:;=WD0!>"*210W0E5)&<=J_$+_AXG\?O^??1?_ 27_X_5PIN6Q,I
M);G[ET5^&G_#Q/X_?\^^B_\ @)+_ /'Z/^'B?Q^_Y]]%_P# 27_X_6GU>1/M
M4?N717X:?\/$_C]_S[Z+_P" DO\ \?H_X>)_'[_GWT7_ ,!)?_C]'U>0>U1^
MY=%?AI_P\3^/W_/OHO\ X"2__'Z/^'B?Q^_Y]]%_\!)?_C]'U>0>U1^Y=%?A
MI_P\3^/W_/OHO_@)+_\ 'Z/^'B?Q^_Y]]%_\!)?_ (_1]7D'M4?N717X:?\
M#Q/X_?\ /OHO_@)+_P#'Z/\ AXG\?O\ GWT7_P !)?\ X_1]7D'M4?N717X:
M?\/$_C]_S[Z+_P" DO\ \?H_X>)_'[_GWT7_ ,!)?_C]'U>0>U1^Y=%?AI_P
M\3^/W_/OHO\ X"2__'Z/^'B?Q^_Y]]%_\!)?_C]'U>0>U1^Y=%?AI_P\3^/W
M_/OHO_@)+_\ 'Z/^'B?Q^_Y]]%_\!)?_ (_1]7D'M4?N717X:?\ #Q/X_?\
M/OHO_@)+_P#'Z/\ AXG\?O\ GWT7_P !)?\ X_1]7D'M4?N717X:?\/$_C]_
MS[Z+_P" DO\ \?H_X>)_'[_GWT7_ ,!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/O
MHO\ X"2__'Z/^'B?Q^_Y]]%_\!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_@)
M+_\ 'Z/^'B?Q^_Y]]%_\!)?_ (_1]7D'M4?N717X:?\ #Q/X_?\ /OHO_@)+
M_P#'Z/\ AXG\?O\ GWT7_P !)?\ X_1]7D'M4?N717X:?\/$_C]_S[Z+_P"
MDO\ \?H_X>)_'[_GWT7_ ,!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO\ X"2_
M_'Z/^'B?Q^_Y]]%_\!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_@)+_\ 'Z/^
M'B?Q^_Y]]%_\!)?_ (_1]7D'M4?N717X:?\ #Q/X_?\ /OHO_@)+_P#'Z/\
MAXG\?O\ GWT7_P !)?\ X_1]7D'M4?N717X:?\/$_C]_S[Z+_P" DO\ \?H_
MX>)_'[_GWT7_ ,!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO\ X"2__'Z/^'B?
MQ^_Y]]%_\!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_@)+_\ 'Z/^'B?Q^_Y]
M]%_\!)?_ (_1]7D'M4?N717X:?\ #Q/X_?\ /OHO_@)+_P#'Z/\ AXG\?O\
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M_P" DO\ \?H_X>)_'[_GWT7_ ,!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO\
MX"2__'Z/^'B?Q^_Y]]%_\!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_@)+_\
M'Z/^'B?Q^_Y]]%_\!)?_ (_1]7D'M4?N717X:?\ #Q/X_?\ /OHO_@)+_P#'
MZ/\ AXG\?O\ GWT7_P !)?\ X_1]7D'M4?N717X:?\/$_C]_S[Z+_P" DO\
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M  $E_P#C]'_#Q/X_?\^^B_\ @)+_ /'Z/J\@]JC]RZ*_#3_AXG\?O^??1?\
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M2_\ Q^CZO(/:H_<NBOPT_P"'B?Q^_P"??1?_  $E_P#C]'_#Q/X_?\^^B_\
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M$E_^/T?\/$_C]_S[Z+_X"2__ !^CZO(/:H_<NBOPT_X>)_'[_GWT7_P$E_\
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M !^CZO(/:H_<NBOPT_X>)_'[_GWT7_P$E_\ C]'_  \3^/W_ #[Z+_X"2_\
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M2_\ Q^C_ (>)_'[_ )]]%_\  27_ ./T?5Y![5'[ET5^&G_#Q/X_?\^^B_\
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M$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\
MC]'U>0>U1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E
M_P#C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_
M^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^/T?5
MY![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U>0>U
M1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C]'U>
M0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?5Y![
M5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^/T?5Y![5'[ET
M5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=%?AI
M_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1^Y=%
M?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[ET5^&
MG_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^/T?5Y![5'[ET5^&G_#Q/
MX_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=%?AI_P /$_C]
M_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1^Y=%?AI_P\3^
M/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[ET5^&G_#Q/X_?
M\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_
M^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=%?AI_P /$_C]_P ^^B_^
M DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_
M ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_P#@
M)+_\?H_X>)_'[_GWT7_P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?
MH_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H
M_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q
M^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X
M>)_'[_GWT7_P$E_^/T?5Y![5'[2^+O\ D"O_ -=(O_0Q735^$^H?\%!?COJ5
ML;6XM]&V$JWRVD@.5.1_RVJ[_P /$_C]_P ^^B_^ DO_ ,?H^KR#VJ/W+HK\
M-/\ AXG\?O\ GWT7_P !)?\ X_1_P\3^/W_/OHO_ ("2_P#Q^CZO(/:H_<NB
MOPT_X>)_'[_GWT7_ ,!)?_C]'_#Q/X_?\^^B_P#@)+_\?H^KR#VJ/W+HK\-/
M^'B?Q^_Y]]%_\!)?_C]'_#Q/X_?\^^B_^ DO_P ?H^KR#VJ/W+HK\-/^'B?Q
M^_Y]]%_\!)?_ (_1_P /$_C]_P ^^B_^ DO_ ,?H^KR#VJ/W+HK\-/\ AXG\
M?O\ GWT7_P !)?\ X_1_P\3^/W_/OHO_ ("2_P#Q^CZO(/:H_<NBOPT_X>)_
M'[_GWT7_ ,!)?_C]'_#Q/X_?\^^B_P#@)+_\?H^KR#VJ/W+HK\-/^'B?Q^_Y
M]]%_\!)?_C]'_#Q/X_?\^^B_^ DO_P ?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\
M!)?_ (_1_P /$_C]_P ^^B_^ DO_ ,?H^KR#VJ/W+HK\-/\ AXG\?O\ GWT7
M_P !)?\ X_1_P\3^/W_/OHO_ ("2_P#Q^CZO(/:H_<NBOPT_X>)_'[_GWT7_
M ,!)?_C]'_#Q/X_?\^^B_P#@)+_\?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?
M_C]'_#Q/X_?\^^B_^ DO_P ?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?_ (_1
M_P /$_C]_P ^^B_^ DO_ ,?H^KR#VJ/W+HK\-/\ AXG\?O\ GWT7_P !)?\
MX_1_P\3^/W_/OHO_ ("2_P#Q^CZO(/:H_<NBOPT_X>)_'[_GWT7_ ,!)?_C]
M'_#Q/X_?\^^B_P#@)+_\?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?_C]'_#Q/
MX_?\^^B_^ DO_P ?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?_ (_1_P /$_C]
M_P ^^B_^ DO_ ,?H^KR#VJ/W+HK\-/\ AXG\?O\ GWT7_P !)?\ X_1_P\3^
M/W_/OHO_ ("2_P#Q^CZO(/:H_<NBOPT_X>)_'[_GWT7_ ,!)?_C]'_#Q/X_?
M\^^B_P#@)+_\?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?_C]'_#Q/X_?\^^B_
M^ DO_P ?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?_ (_1_P /$_C]_P ^^B_^
M DO_ ,?H^KR#VJ/W+HK\-/\ AXG\?O\ GWT7_P !)?\ X_1_P\3^/W_/OHO_
M ("2_P#Q^CZO(/:H_<NBOPT_X>)_'[_GWT7_ ,!)?_C]'_#Q/X_?\^^B_P#@
M)+_\?H^KR#VJ/W+HK\-/^'B?Q^_Y]]%_\!)?_C]'_#Q/X_?\^^B_^ DO_P ?
MH^KR#VJ/VE\0_P#'SI'_ %]I_(UTU?A/=_\ !07X[WKV\DUOHV;:02+BTD'S
M#U_?5=_X>)_'[_GWT7_P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?
MH_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H
M_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q
M^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X
M>)_'[_GWT7_P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[
M_GWT7_P$E_\ C]'U>0>U1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^
M_P"??1?_  $E_P#C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?
MO^??1?\ P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GW
MT7_P$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$
ME_\ C]'U>0>U1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_
M  $E_P#C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\
MP$E_^/T?5Y![5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^
M/T?5Y![5'[ET5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U
M>0>U1^Y=%?AI_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C
M]'U>0>U1^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?
M5Y![5'[ET5^&G_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^/T?5Y![5
M'[ET5^&G_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=
M%?AI_P /$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1
M^Y=%?AI_P\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[E
MT5^&G_#Q/X_?\^^B_P#@)+_\?H_X>)_'[_GWT7_P$E_^/T?5Y![5'[ET5^&G
M_#Q/X_?\^^B_^ DO_P ?H_X>)_'[_GWT7_P$E_\ C]'U>0>U1^Y=%?AI_P /
M$_C]_P ^^B_^ DO_ ,?H_P"'B?Q^_P"??1?_  $E_P#C]'U>0>U1^Y=%?AI_
MP\3^/W_/OHO_ ("2_P#Q^C_AXG\?O^??1?\ P$E_^/T?5Y![5'[EUS.C?\AK
M6O\ KI%_Z!7XM?\ #Q/X_?\ /OHO_@)+_P#'ZI6W_!07X[VMS<W4=OHV^Z*L
M^;23&5&!C]]1]7D'M4?NQ17X:?\ #Q/X_?\ /OHO_@)+_P#'Z/\ AXG\?O\
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M_P" DO\ \?H_X>)_'[_GWT7_ ,!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO\
MX"2__'Z/^'B?Q^_Y]]%_\!)?_C]'U>0>U1^Y=%?AI_P\3^/W_/OHO_@)+_\
M'Z/^'B?Q^_Y]]%_\!)?_ (_1]7D'M4?N717X:?\ #Q/X_?\ /OHO_@)+_P#'
MZ/\ AXG\?O\ GWT7_P !)?\ X_1]7D'M4?N717X:?\/$_C]_S[Z+_P" DO\
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MTW_H!K^5FOZN9(XY8VBE4.C@JRL,@@\$$'L:X'_A4GPI_P"A,T7_ ,%UM_\
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M+K;_ .-T?65V#V1_,)17]/?_  J3X4_]"9HO_@NMO_C='_"I/A3_ -"9HO\
MX+K;_P"-T?65V#V1_,)17]/?_"I/A3_T)FB_^"ZV_P#C='_"I/A3_P!"9HO_
M (+K;_XW1]978/9'\PE%?T]_\*D^%/\ T)FB_P#@NMO_ (W1_P *D^%/_0F:
M+_X+K;_XW1]978/9'\PE%?T]_P#"I/A3_P!"9HO_ (+K;_XW1_PJ3X4_]"9H
MO_@NMO\ XW1]978/9'\PE%?T]_\ "I/A3_T)FB_^"ZV_^-T?\*D^%/\ T)FB
M_P#@NMO_ (W1]978/9'\PE%?T]_\*D^%/_0F:+_X+K;_ .-T?\*D^%/_ $)F
MB_\ @NMO_C='UE=@]D?S"45_3W_PJ3X4_P#0F:+_ ."ZV_\ C='_  J3X4_]
M"9HO_@NMO_C='UE=@]D?S"45_3W_ ,*D^%/_ $)FB_\ @NMO_C='_"I/A3_T
M)FB_^"ZV_P#C='UE=@]D?S"45_3W_P *D^%/_0F:+_X+K;_XW1_PJ3X4_P#0
MF:+_ ."ZV_\ C='UE=@]D?S"45_3W_PJ3X4_]"9HO_@NMO\ XW1_PJ3X4_\
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MI/A3_P!"9HO_ (+K;_XW1_PJ3X4_]"9HO_@NMO\ XW1]978/9'\PE%?T]_\
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MF:+_ ."ZV_\ C='UE=@]D?S"45_3W_PJ3X4_]"9HO_@NMO\ XW1_PJ3X4_\
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MV_\ C='_  J3X4_]"9HO_@NMO_C='UE=@]D?S"45_3W_ ,*D^%/_ $)FB_\
M@NMO_C='_"I/A3_T)FB_^"ZV_P#C='UE=@]D?S"45_3W_P *D^%/_0F:+_X+
MK;_XW1_PJ3X4_P#0F:+_ ."ZV_\ C='UE=@]D?S"45_3W_PJ3X4_]"9HO_@N
MMO\ XW1_PJ3X4_\ 0F:+_P""ZV_^-T?65V#V1_,)17]/?_"I/A3_ -"9HO\
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MI/A3_P!"9HO_ (+K;_XW1_PJ3X4_]"9HO_@NMO\ XW1]978/9'\PE%?T]_\
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M_P#&Z/\ A4GPI_Z$S1?_  76W_QNCZRNP>R/YA**_I[_ .%2?"G_ *$S1?\
MP76W_P ;H_X5)\*?^A,T7_P76W_QNCZRNP>R/YA**_I[_P"%2?"G_H3-%_\
M!=;?_&Z/^%2?"G_H3-%_\%UM_P#&Z/K*[![(_F$HK^GO_A4GPI_Z$S1?_!=;
M?_&Z/^%2?"G_ *$S1?\ P76W_P ;H^LKL'LC^82BOZ>_^%2?"G_H3-%_\%UM
M_P#&Z/\ A4GPI_Z$S1?_  76W_QNCZRNP>R/YA**_I[_ .%2?"G_ *$S1?\
MP76W_P ;H_X5)\*?^A,T7_P76W_QNCZRNP>R/YA**_I[_P"%2?"G_H3-%_\
M!=;?_&Z/^%2?"G_H3-%_\%UM_P#&Z/K*[![(_F$HK^GO_A4GPI_Z$S1?_!=;
M?_&Z/^%2?"G_ *$S1?\ P76W_P ;H^LKL'LC^82BOZ>_^%2?"G_H3-%_\%UM
M_P#&Z/\ A4GPI_Z$S1?_  76W_QNCZRNP>R/YA**_I[_ .%2?"G_ *$S1?\
MP76W_P ;H_X5)\*?^A,T7_P76W_QNCZRNP>R/YA**_I[_P"%2?"G_H3-%_\
M!=;?_&Z/^%2?"G_H3-%_\%UM_P#&Z/K*[![(_F$HK^GO_A4GPI_Z$S1?_!=;
M?_&Z/^%2?"G_ *$S1?\ P76W_P ;H^LKL'LC^82BOZ>_^%2?"G_H3-%_\%UM
M_P#&Z/\ A4GPI_Z$S1?_  76W_QNCZRNP>R/YA**_I[_ .%2?"G_ *$S1?\
MP76W_P ;H_X5)\*?^A,T7_P76W_QNCZRNP>R/YA**_I[_P"%2?"G_H3-%_\
M!=;?_&Z/^%2?"G_H3-%_\%UM_P#&Z/K*[![(_F$HK^GO_A4GPI_Z$S1?_!=;
M?_&Z/^%2?"G_ *$S1?\ P76W_P ;H^LKL'LC^82BOZ>_^%2?"G_H3-%_\%UM
M_P#&Z/\ A4GPI_Z$S1?_  76W_QNCZRNP>R/YA**_I[_ .%2?"G_ *$S1?\
MP76W_P ;H_X5)\*?^A,T7_P76W_QNCZRNP>R/YA**_I[_P"%2?"G_H3-%_\
M!=;?_&Z/^%2?"G_H3-%_\%UM_P#&Z/K*[![(_F$HK^GO_A4GPI_Z$S1?_!=;
M?_&Z/^%2?"G_ *$S1?\ P76W_P ;H^LKL'LC^82BOZ>_^%2?"G_H3-%_\%UM
M_P#&Z/\ A4GPI_Z$S1?_  76W_QNCZRNP>R/YA**_I[_ .%2?"G_ *$S1?\
MP76W_P ;H_X5)\*?^A,T7_P76W_QNCZRNP>R/YA**_I[_P"%2?"G_H3-%_\
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MW1]978/9'\PE%?T]_P#"I/A3_P!"9HO_ (+K;_XW1_PJ3X4_]"9HO_@NMO\
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M4_\ 0F:+_P""ZV_^-T?65V#V1_,)17]/?_"I/A3_ -"9HO\ X+K;_P"-T?\
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M?\*D^%/_ $)FB_\ @NMO_C='UE=@]D?S"45_3W_PJ3X4_P#0F:+_ ."ZV_\
MC='_  J3X4_]"9HO_@NMO_C='UE=@]D?S"45_3W_ ,*D^%/_ $)FB_\ @NMO
M_C='_"I/A3_T)FB_^"ZV_P#C='UE=@]D?S"45_3W_P *D^%/_0F:+_X+K;_X
MW1_PJ3X4_P#0F:+_ ."ZV_\ C='UE=@]D?S"45_3W_PJ3X4_]"9HO_@NMO\
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MHO\ X+K;_P"-T?\ "I/A3_T)FB_^"ZV_^-T?65V#V1_,)17]/?\ PJ3X4_\
M0F:+_P""ZV_^-T?\*D^%/_0F:+_X+K;_ .-T?65V#V1_,)17]/?_  J3X4_]
M"9HO_@NMO_C='_"I/A3_ -"9HO\ X+K;_P"-T?65V#V1_,)17]/?_"I/A3_T
M)FB_^"ZV_P#C='_"I/A3_P!"9HO_ (+K;_XW1]978/9'XD_L'?\ )RWA_P#Z
M]K__ -)9*_?>N1TCX?\ @+P_?+J>@^&],TV\0$+-;6<,,H##! =$! (X/-==
M6%6?,[FD(V04445F4?_5_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.
M^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\
M]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG_P!1
M)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?_0C70USWA3_D7[/_ '3_ .A&
MNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]?:?R-=-7,^(?^/G2/^OM/Y&N
MFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\
M=/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MQ_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_ )!M
MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_ .ND
M7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YG1O^
M0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __U_W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3
M_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_N
MG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY-NT/_L:+/\ ]([ROP4N_ ^LV'P_TCXEC)TW5-2O=-5E!S'<6,5O,03VW+<
MK_NMZ5I&*:$V?V2T5\X_LF_&!?CC\ _"OCFXF$NJ?9Q9ZES\POK3]W,S#MYF
M!*!_=<5]'5FQD4\\-M#)<W$BQ11*7=V(5551DDD\  =37YJZ]_P56_9MT?6+
MK2[/3?$.L0VTC1B[M+2V$$P4XW1^==1R%3VW(I]J[O\ X*+?&;_A5/[.^HZ-
MIL_E:UXW8Z1;!3AUMY%S=R?019CR.C2*:_G3UOP!J^@_#_PQ\0-0'EVOBNXU
M**S0CEHM.,"/*#W#22NGUC-7&(FS^NSX=>/O#OQ2\#Z+\0O"<CR:3KMNMS;F
M5=D@5N"KKDX96!5@"1D<$CFNTKY._88_Y--^''_7A)_Z42U]8U+&%%<9XF^(
M_P //!4BQ>,O%&EZ"[C<JW][!:DKZ@2NO%7?#?C7P;XRA>X\(:]8:Y%%C>]C
M=17*KGIDQ,P%(#IJ_)#_ (*/?M,?&SX'>,O!^A_"OQ&=!M-2L)[FY"VMM.TD
MBR[%):>*0@ =EP.><\5^M]?@S_P5V_Y*3X!_[!-S_P"E%5#<3/V%_9\\6Z[X
M\^!W@3QGXGG%UJ^M:-975W,$6,232Q*SML0!5R><* !V %>PU\]?LF?\FR_"
M_P#[%[3_ /T2M?0;ND:-)(P55!)).  .I-)[C0ZBO+[SXW_!;3KS^S]0\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ',^+O^0*__ %TB_P#0Q735S/B[_D"O_P!=
M(O\ T,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,Z-_R
M&M:_ZZ1?^@5TU<SHW_(:UK_KI%_Z!0!TU%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!__]#]_**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZX
MQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]
M"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ!?S3^%_$@GCM+:7+"RU!5,JM'GE%D",C(."[!B <D_NQ\3[OQ98?#;Q9?>
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M %%%% !1110 4444 %%%% ',^+O^0*__ %TB_P#0Q735S/B[_D"O_P!=(O\
MT,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <SXA_X^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,Z-_R&M:_
MZZ1?^@5TU<SHW_(:UK_KI%_Z!0!TU%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!__]']_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\
MH(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#
M7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,R8R/DV;L\8K]DOBW\,O#_QD^&^O?#+Q1O73M>M_)=X_OQ.K"2*5>VZ.15<
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ZZ1?\
MH8KIJYGQ=_R!7_ZZ1?\ H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH YGQ#_Q\Z1_U]I_(UTU<SXA_X^=(_P"O
MM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KF=&_Y#6M?]=(O_0*Z:N9T;_D-:U_UTB_] H Z:BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]+]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+
M_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\
M*@##\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'
M_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_ )!MI_UQ
MC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_ .ND7_H8
MKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YG1O^0UK7
M_72+_P! KIJYG1O^0UK7_72+_P! H Z:BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH __T_W\HHHH **** "BBB@
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MHAL_HG_X)^_M!_$7]H7X8Z[K?Q+FM[K4M'U3[)'/!"L!DB,,<@WHF$W L>5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI9P /=WDH&2D,9*YP.69B%7C<1D9D9[717\_WCS_ (*Q?&/6-1DC^'7AK2M
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MLW?@WX0Z9'XQU:R=HI[^64IIL4B\%8S'\]P0>&*E$_NNU-*X7/U0HK^<.?\
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M:H^/_P#T.$__ 'YM_P#XU1_PU1\?_P#H<)_^_-O_ /&J/]2L3_/'\?\ (/\
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M/_WYM_\ XU1_J5B?YX_C_D'_ !,!E/\ SYJ?='_Y(_<ZBOPQ_P"&J/C_ /\
M0X3_ /?FW_\ C5'_  U1\?\ _H<)_P#OS;__ !JC_4K$_P \?Q_R#_B8#*?^
M?-3[H_\ R1^YU%?AC_PU1\?_ /H<)_\ OS;_ /QJC_AJCX__ /0X3_\ ?FW_
M /C5'^I6)_GC^/\ D'_$P&4_\^:GW1_^2/W.HK\,?^&J/C__ -#A/_WYM_\
MXU1_PU1\?_\ H<)_^_-O_P#&J/\ 4K$_SQ_'_(/^)@,I_P"?-3[H_P#R1^YU
M%?AC_P -4?'_ /Z'"?\ [\V__P :H_X:H^/_ /T.$_\ WYM__C5'^I6)_GC^
M/^0?\3 93_SYJ?='_P"2/W.HK\,?^&J/C_\ ]#A/_P!^;?\ ^-4?\-4?'_\
MZ'"?_OS;_P#QJC_4K$_SQ_'_ "#_ (F RG_GS4^Z/_R1^YU%?AC_ ,-4?'__
M *'"?_OS;_\ QJC_ (:H^/\ _P!#A/\ ]^;?_P"-4?ZE8G^>/X_Y!_Q,!E/_
M #YJ?='_ .2/W.HK\,?^&J/C_P#]#A/_ -^;?_XU1_PU1\?_ /H<)_\ OS;_
M /QJC_4K$_SQ_'_(/^)@,I_Y\U/NC_\ )'[G45^&/_#5'Q__ .APG_[\V_\
M\:H_X:H^/_\ T.$__?FW_P#C5'^I6)_GC^/^0?\ $P&4_P#/FI]T?_DC]J/%
MW_(%?_KI%_Z&*Z:OPHNOVG?CM>PF"Z\6SR1D@X,-OU!R.D=6?^&J/C__ -#A
M/_WYM_\ XU1_J5B?YX_C_D'_ !,!E/\ SYJ?='_Y(_<ZBOPQ_P"&J/C_ /\
M0X3_ /?FW_\ C5'_  U1\?\ _H<)_P#OS;__ !JC_4K$_P \?Q_R#_B8#*?^
M?-3[H_\ R1^YU%?AC_PU1\?_ /H<)_\ OS;_ /QJC_AJCX__ /0X3_\ ?FW_
M /C5'^I6)_GC^/\ D'_$P&4_\^:GW1_^2/W.HK\,?^&J/C__ -#A/_WYM_\
MXU1_PU1\?_\ H<)_^_-O_P#&J/\ 4K$_SQ_'_(/^)@,I_P"?-3[H_P#R1^YU
M%?AC_P -4?'_ /Z'"?\ [\V__P :H_X:H^/_ /T.$_\ WYM__C5'^I6)_GC^
M/^0?\3 93_SYJ?='_P"2/W.HK\,?^&J/C_\ ]#A/_P!^;?\ ^-4?\-4?'_\
MZ'"?_OS;_P#QJC_4K$_SQ_'_ "#_ (F RG_GS4^Z/_R1^YU%?AC_ ,-4?'__
M *'"?_OS;_\ QJC_ (:H^/\ _P!#A/\ ]^;?_P"-4?ZE8G^>/X_Y!_Q,!E/_
M #YJ?='_ .2/W.HK\,?^&J/C_P#]#A/_ -^;?_XU1_PU1\?_ /H<)_\ OS;_
M /QJC_4K$_SQ_'_(/^)@,I_Y\U/NC_\ )'[G45^&/_#5'Q__ .APG_[\V_\
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ML69DN6CC\I9&25XUD"# 'F*H? &.>.,4[:7%<][HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH __]3]_**** "BBB@ HHHH **** "BBB@
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M23/A52*&$9+'CD[G8_,S,Q).L-B6?>WQF_X*=?$'XG_"8_#_ $'0(?#&JZM
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M%M$"5="5(R".#51=V#6A^J/_  2._P"2/^-?^PZO_I+%7WE^T[_R;?\ %/\
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MBKCN#V/TN^"/C?3/AK^Q3X0^(.M12SV/AWPA;7\T<(!E=+>V#E4#$#<V,#)
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MKY21S@?3S*_-/]DC]F37OVH/'S^&8KTZ9X<T94NM5NU(9XXY"51(4/!EE*D
MD;5 +'. K?OK:_L)_LJVOA$^#AX!LY86B\MKR0NU^6(YD^U%O,5L\_*0HZ!<
M<4VDA:C?V;OVT?A'^TK)+HWAQY]%\2VT9EDTN_"K*\:XW/ Z$I*BYYQAQU*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#N)G[?\ [.W[*_PM_9U\,6>G^'--AO?$'EC[;K,T2M=W$I'SE6.3%'GA8T(
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M2U^"/^PM:?\ HP5^^=?G'&W\:'I^I_6'T?/^1?B/\:_])04445\4?T %%%%
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M+X6?#4RM=>) L5TBR-';_9HG65I+HKQY,3*KG(/S!=H+[17[E>%/^"5O[/\
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M+1(7$5UICO@9VK]LB&3[9(K^95'>-UDC8HZ$$$'!!'0@UI#8F1_:U17\=?\
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M)VH%7)Q3F]+ CV>BBBLB@HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\
M(#OO^N+_ ,JV*Q_$'_(#OO\ KB_\J +6F?\ (-M/^N,?_H(J]5'3/^0;:?\
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M63_QVAM@C\FKO_@F%^U1XM\1IJWC?Q5H]Y/=/&+F^N=1N[NY\M %SF2#<Y5
M H+#H!D#I_00BE$5"2VT 9/4X[U\)VW_  42_9ZUSXF>'/AAX*FU#Q'=^(K^
M#3TO+>V,-G#+<.(T+-<&*1AN(R4C(QR">A^[JB3?4:"BBBI&%%%% !1110 5
M%/\ ZB3_ '3_ "J6HI_]1)_NG^5 &'X4_P"1?L_]T_\ H1KH:Y[PI_R+]G_N
MG_T(UT- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *YG1O^0UK7_72+_T"NFKF=&_Y#6M?]=(O_0* .FHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _E]_X)^_\GG>!/\ KKJO_IMNZ_I*
M^)W_ "3;Q9_V";__ -)WK^;7_@G[_P GG>!/^NNJ_P#IMNZ_I*^)W_)-O%G_
M &";_P#])WK2>XHGX"?\$J_^3FKO_L7K[_T=;U_1G7\YG_!*O_DYJ[_[%Z^_
M]'6]?T9TI[A$_FR_X*?HJ?M47K*,%])T\GW.UA_(5_1;X3)/A71B>2;*W_\
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M&-Q;_M"V-U;^#9;JW:0RV%A;HLX8F$%X$$HY]3CL:^[?^"1__)&?&7_8?_\
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M'T(KR _LU_LYDY/PK\*$G_J!V/\ \9KVNB@#Q3_AFK]G/_HE?A3_ ,$=A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!_]#]_**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY6_;"\9^*/ _P )8]3\)7\N
MF7ESJ5O;M/ VR18V21R PY&2@!QVXKZIKG?%'A+PWXUTB30?%>GQ:GI\C*[0
MS#*[D.5([@CU%=>!KPIUHU)JZ3V/%XCR^MB\#6PV'GR3E%I/71_+7[C\+_\
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MX84R-TCG@#( &68A02/Q+\1?\%'OVJ/BYXGFT;X#>&5TZ$9:&UL;!M8U QY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !4<TT-O"]Q<.L442EG=B%5549))/
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M;^W?J?[0W[/5S\,OB%HT=CXIM]1L[J*\L05M;F*'>'#QNS-%(-P/#,K<\)@
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M5_\ )S5W_P!B]??^CK>OW[^)W_)-O%G_ &";_P#])WK\!/\ @E7_ ,G-7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML^&/^$._9R^&^@,GER1:'932K_=FN8A/*/P=VKWRI>XT%%%%( HHHH ****
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M=8_Y\9_^_3_X4<R#V$_Y69E%:?\ 8NL?\^,__?I_\*/[%UC_ )\9_P#OT_\
MA1S(/83_ )69E%:?]BZQ_P ^,_\ WZ?_  H_L76/^?&?_OT_^%',@]A/^5F9
M16G_ &+K'_/C/_WZ?_"C^Q=8_P"?&?\ []/_ (4<R#V$_P"5F916G_8NL?\
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M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2^^,/^OB+_T1'7[H5^'_ .UGI.IZ=\=_$US?6TD,-[)#+!(RD)*GD1C*-T8
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M3\1+RTU#Q[X/TGQ%<V">7!)?V4-R\<><[%,BL0N>=O3/:O1$1(T6.-0J*
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M[X1-%(V.B*\)4D]&=?6OF7]F_P#X*37'P.^#VG_"_7?!K>(I=#\Y+&YCO1;
MPR.TJQRJ8I.49B R_P .!C(R?Z"[JUMKVVEL[V)+BWG1HY(Y%#HZ,,,K*<@@
MC@@\&OGF?]D+]F&XU(:K)\,="$X.=JV:)#_WY4"/_P =IJ2M9BL5_"?Q-N/C
M)^RO+\3KO3UTJ;Q!X?OYVME<R+&1'*F Q520=N1QW_&OQA_X)5_\G-7?_8O7
MW_HZWK^B*UT?2++2H]!LK&"WTR&$6Z6L<2I L(7:(UC "A-O&T#&.,5PG@WX
M+_"'X=ZI-K?@+P7H_A[4)XS$]Q86,%M*8F(8IOC4':2 2N<$@<<"DI!8^*_^
M"GW@7PWXH_9\A\1ZQKEOHE]X9OUN+);C<1?/+&R-:1A,GS'&'4X(&P[MJ;G7
M\FOV>OC]^VAX2\,R>&_@6NKZ[X>TIL-:V^DG5H+1IF9\!A#(T6X[FVA@"<G&
M:^NO^"O=WK__  DWPXL)68:(;._EB7/RM="2)921W*IY>/3)QU.?M/\ 8+^)
M'P)_X9Z\*>$_!FM:=8ZQ96P.K6,LT<-X=0;_ %\KQN5=U=ON. 5V[5!^7 I;
M"ZGYUWW[>_[=W@",:GXW\,);VB$!CJV@W%I$23@ LIAZGCAA7Z"?L>?MXZ)^
MTEJ,O@3Q3I4?AWQE! 9XXX9&>UOHT_UC0[OFC9!R8V9CM^8,<-CZ3^,'QW^!
M_P -?"&J7OQ(U_39+,P2H^G&6*XGO 5.8$MLDR%Q\N"-O/S$#)K\#/\ @G?X
M?UCQ+^U]X>UGPY;O;V&C+J-]=%>5@M'MY855CC&&>5(_QS1N@/U$_P""C7[+
M^O?''P-IGCGP!9F^\4^$!*#:1C,M[8RX9TC'\4D3+O1>K N!EBH/YO?LK_M]
M^,OV:M"?X9>+] ;Q%X;LI93;P&0VMY82.Y:5%9E8,A<L3&R@AB2& XK^D6O(
MO'7P"^"GQ,NSJ/CSP1I.M7K8S<SVD9N2 , &8 2$ =BV*2ET8VC\U_$'_!7C
MP3#I['PK\/M1N[XKPM[=PV\2L>Y:-9F('I@9]17T=^PM^TQ\4?VF--\:>(?'
M^CVFF:=IEU:Q::UE#+'$XD64S1EY7?S&CVQDD8QNY R /:]$_9$_9C\/7"76
MF_#31#*ARIGM%NL'U GWC([>E?0=G96>G6L5CI\$=K;0*%CBB4(B*.@55  '
ML*3:Z ?D=_P5W_Y)Y\/_ /L*W7_H@5]%?\$V/^31O"W_ %]:G_Z62U]>^-?A
MSX!^)%A#I?Q \.:?XCM+:3S8HM0MH[E8Y,8W()%.UL'&1SCBM7PSX5\,^"M%
MM_#?@_2;71-)M-WDVEE"EO!'O8LVV.,!068DDXY))/-'-I8+&9\1/^2?^)O^
MP7>_^B'K^?;_ ()8_P#)STO_ & ;_P#]&05_1M-#%<1/!<(LD4BE71@&5E(P
M00>"".HKS;P=\%OA!\/-5EUSP'X*T?P]J,\;1/<6%C!;RF-B&9-\: A20"5!
MP<#C@4*6@SY+_;Y_:"^+W[.V@>"_%OPQB@>RN+^>+4_M-MY\#@(IAB=AAHPY
MW\JRL2O!Z@_/OAO_ (*[>!Y=(5O%_@'4;;5%7YEL;B&>W=QW#2^4Z@]<;6QT
MR>M?KO?Z?8:K93:;JEM%>6ERI26&9%DCD4]59&!!!]"*^>+_ /8\_9>U*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_.)^WY^S=<^"
M?VE+*\\-6_E:-\4;E)K7:OR1ZA-*L=U$/K(ZR@=,28'2OZ.Z\P^)WPE\*?%9
M/#1\2QDS>%-:L=<L9$ W+<64@<*<]4D7*N.^0>H%5%V$T>B6%E;:98V^G6:>
M7;VL:11K_=1 %4?@!5NBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M^\=9>MZ'HOB72KG0O$>GV^JZ;>IY<]K=1)/!*A_A>-P58>Q%3%V&S\,OAO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',^+O^0*_P#U
MTB_]#%=-7,^+O^0*_P#UTB_]#%=-0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ',^(?^/G2/\ K[3^1KIJYGQ#_P ?
M.D?]?:?R-=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7,Z-_P AK6O^ND7_ *!735S.C?\ (:UK_KI%_P"@4 =-
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\G?M9_M6>%/V8_!)OI_+U+Q7JB.NDZ9NYD8<&:;'*P1GJ>"Q^5
M><E?HOQKXA/A'P;KWBM8/M1T6PNKT1 X\S[-$TFS/;=MQ7\B7Q&^*7BGXO\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q!_R
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M!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#F?%W_(%?_KI%_P"ABNFKF?%W_(%?_KI%_P"ABNFH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/_'SI
M'_7VG\C735S/B'_CYTC_ *^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_] KIJYG1O^0U
MK7_72+_T"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &2Q1S1O#,@DCD!5E89# \$$'J#7C#?LV?LZ,Q9O
MA9X5)/))T.QR3_WYKVJB@#Q3_AFK]G/_ *)7X4_\$=A_\9H_X9J_9S_Z)7X4
M_P#!'8?_ !FO:Z*=P*MC8V6F65OINFV\=I:6D:10PQ((XXHXP%1$10 JJ
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M "BBB@ HHHH **** "BBB@#_U/W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_
M$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@BKU4=,_Y!MI_
MUQC_ /015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
MI_\ 42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<]X4_Y%^S_P!T
M_P#H1KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% ',^(?^/G2/^OM/Y&NFKF?$/\ Q\Z1_P!?:?R-=-0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7,Z-_R&M:_P"ND7_H%=-7,Z-_R&M:_P"ND7_H% '34444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_U?W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H
MM:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/P
MI_R+]G_NG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\
M0_\ 'SI'_7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K^7W]J/_D^KQ+_ -C'8_R@K^H*OY??VH_^3ZO$O_8QV/\
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M#__6_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R
M[[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG_P!1)_NG^52U%/\ ZB3_
M '3_ "H P_"G_(OV?^Z?_0C70USWA3_D7[/_ '3_ .A&NAH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWPNVB:3_ &+=6:SM=6LP>>2>!E55AED8Y5&.<8XZY(S^EG[4'@KQ)\1?V?\
MQSX)\'VGV[6=7TYX;6#>D7FR;E8+OD*H"<<%B![T2>H^A^67_!('_D8?B=_U
MZZ7_ .AW%?N/7Y2?\$V/V=/C)\#M4\=ZA\5/#K:#%K$-A%:;[BWF:5H&F,G$
M$DA 4.O+8SGC.#C]6ZF>X(_F4^#_ /RD3M?^QWU'_P!*9Z_IKK\*_AM^Q_\
MM$:%^VS%\3=5\)F#PM#XHOM3-^;RT:,VDLTLB.$68R$L&'R[-PSR!SC]U*<V
M"/YY_P#@K1_R<7X<_P"Q4M/_ $NOJ_;+X/:=#K'[/7@C2;@D17OA;38'(ZA9
M+&-3^AK\S?\ @HM^RW\=OC5\9M!\7?"_PNVNZ7;Z#!822I<VT)2XCN[J5E*S
M2QMC9*A#8QU&<@U^K7PHT+4_"_PN\'>&=:B$.H:1HVGV=S&&#A)K>W2.10RD
M@X92,@X/:AO0#^9/]F;QD?V;?VKM"OO'"_8XM!U.ZTC5=^0(%F$EG-(WM"S;
MS[+7]45I=VFH6D-_83)<VURBR12Q,'CD1QE65ER"I!R"."*_+?\ ;3_X)\3?
M&CQ!<?%;X0W%O8>*;I1_:%A<GRK>^9!A98Y "(YB  VX;'X)*G<6^%/#?PV_
MX*7?"73QX+\)VGB6PTV E(K>UN8KJVB!Y/E,))$C4GGY"!GGK3=F+8^]_P#@
MJ5\8M!\-_!5/A#!<QS:[XNN;:22V5P9(;&TE$YF=1R TL:(F0 WS$'Y37(?\
M$D? -_I'P[\:_$6\B:.'Q'?6UG;%OXX].20NZ_[)><KGU0CM7S%\-?\ @G/^
MT=\8_&/_  EG[0-_+H%G=2++>W-[=K?:M=*,#:@5Y K%1M#2L-HP0C 8K]YO
M _@KPU\.?".E>!O!]FMAHVBP+;VT*\[47J6)Y9F.69CRS$D\FD]%89^(?_!7
M;_DI/@'_ +!-S_Z45^L/[)G_ ";+\+_^Q>T__P!$K7PE_P %(?V:_C7\;O&?
M@[6_A9X;;7K33K">VN&2XMX3'(TH=05GEC)!'<9''..*_1#]GOPGKO@3X&>
M_!OBBW%IJ^C:-96MW"'63RYHHE5TWH65MIXRI(/8D4-Z!U/4M5U;2M"TZ?5]
M;O(=/L+52\UQ<2+%#&@_B=W(51[DU0U32/"_C?06T_6K*SU[1M00,8IXX[JV
MGC89!VL&1@1R#S7G/[0GPNNOC3\&/%?PPL+U-/NM>M1%#/("8TECD65-^WG:
M60!B 2 20#T/X>Z/\#_^"D/[.SR:%\/EU;^RT8F-=*NX;^Q;GETMY&;9N/7=
M$C'N*25P.I_X*/?LI?"KX*:?H/Q(^&<8T1==OGLKC25<O#N\MI?/@#DLBC;M
M=0=HW)M"\@_H;_P3<\2Z_P")/V5=!_M^22?^R[N\L;620EF:UADS& 3_  Q[
MC&H[*H X&*_-&/\ 8W_;D_:7\6VFJ?&RXGTZVB7:+[6[J-Q!&2-RP6<#,RL<
M9VA(U)'S,.M?NQ\(_A=X9^"_PYT3X9^$4<:9HD)C5Y#F261V,DLKG^])(S.<
M<#.   !52>E@1Z/11168PHHHH **** "BBB@ HHHH **** "L?Q!_P @.^_Z
MXO\ RK8K'\0?\@.^_P"N+_RH M:9_P @VT_ZXQ_^@BKU4=,_Y!MI_P!<8_\
MT$5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** .9\7?\@5_^ND7_H8KIJYGQ=_R!7_ZZ1?^ABNFH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#F?$/_'SI'_7VG\C735S/B'_ (^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9T;_ )#6M?\ 72+_
M - KIJYG1O\ D-:U_P!=(O\ T"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]?]_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\
MH(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\ =/\ *@##\*?\B_9_[I_]"-=#
M7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]I_(U
MTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'_(#OO^N+_P JV*Q_$'_(
M#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_ )!MI_UQC_\ 015Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_ .ND7_H8KIJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_ ,?.D?\
M7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *YG1O^0UK7_72+_P! KIJYG1O^0UK7
M_72+_P! H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH __T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$'_(
M#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@BKU4=,_Y!MI_UQC_
M /015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI_\
M42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<]X4_Y%^S_P!T_P#H
M1KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .9\0_\ 'SI'_7VG\C735S/B'_CYTC_K[3^1
MKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K'\0?\@.^_ZXO_ "K8K'\0?\@.^_ZXO_*@"UIG_(-M
M/^N,?_H(J]5'3/\ D&VG_7&/_P!!%7J "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?%W_(%?\ ZZ1?
M^ABNFKF?%W_(%?\ ZZ1?^ABNFH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#F?$/\ Q\Z1_P!?:?R-=-7,^(?^/G2/
M^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KF=&_Y#6M?]=(O_ $"NFKF=&_Y#6M?]=(O_ $"@#IJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#__1_?RBBB@"O=W,=E:37DH)2!&D8+U(49.,]Z_.O_AY7\*?^A7UK\K;_P".
MU^@VO?\ ("U'_KVF_P#0#7\K-;T::E>YG4DUL?M!_P /*_A3_P!"OK7Y6W_Q
MVC_AY7\*?^A7UK\K;_X[7XOT5O[")G[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7
M\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H
M5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_
M ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+
M]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A
M[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+]%'L(A[1G[0?
M\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX
M4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?
ME;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_
M\=H_X>5_"G_H5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7
M\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H
M5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_
M ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+
M]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A
M[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+]%'L(A[1G[0?
M\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX
M4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?
ME;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_
M\=H_X>5_"G_H5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7
M\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H
M5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_
M ..U^+]%'L(A[1G[0?\ #ROX4_\ 0KZU^5M_\=H_X>5_"G_H5]:_*V_^.U^+
M]%'L(A[1G[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A
M[1G[0?\ #ROX4_\ 0KZU^5M_\=JAJ?\ P4A^%E]I]Q9Q^&-95ID902+? S_V
MUK\;J*/81#VC/V7M/^"DOPKM[2&W;PQK1,2*I(%MSM&/^>M6?^'E?PI_Z%?6
MORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W_P =H_X>5_"G_H5]:_*V_P#C
MM?B_11["(>T9^T'_  \K^%/_ $*^M?E;?_':/^'E?PI_Z%?6ORMO_CM?B_11
M["(>T9^T'_#ROX4_]"OK7Y6W_P =H_X>5_"G_H5]:_*V_P#CM?B_11["(>T9
M^T'_  \K^%/_ $*^M?E;?_':/^'E?PI_Z%?6ORMO_CM?B_11["(>T9^T'_#R
MOX4_]"OK7Y6W_P =H_X>5_"G_H5]:_*V_P#CM?B_11["(>T9^T'_  \K^%/_
M $*^M?E;?_':/^'E?PI_Z%?6ORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W
M_P =H_X>5_"G_H5]:_*V_P#CM?B_11["(>T9^T'_  \K^%/_ $*^M?E;?_':
M/^'E?PI_Z%?6ORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W_P =H_X>5_"G
M_H5]:_*V_P#CM?B_11["(>T9^T'_  \K^%/_ $*^M?E;?_':/^'E?PI_Z%?6
MORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W_P =H_X>5_"G_H5]:_*V_P#C
MM?B_11["(>T9^T'_  \K^%/_ $*^M?E;?_':/^'E?PI_Z%?6ORMO_CM?B_11
M["(>T9^T'_#ROX4_]"OK7Y6W_P =H_X>5_"G_H5]:_*V_P#CM?B_11["(>T9
M^T'_  \K^%/_ $*^M?E;?_':/^'E?PI_Z%?6ORMO_CM?B_11["(>T9^T'_#R
MOX4_]"OK7Y6W_P =H_X>5_"G_H5]:_*V_P#CM?B_11["(>T9^T'_  \K^%/_
M $*^M?E;?_':/^'E?PI_Z%?6ORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W
M_P =H_X>5_"G_H5]:_*V_P#CM?B_11["(>T9^T'_  \K^%/_ $*^M?E;?_':
M/^'E?PI_Z%?6ORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W_P =H_X>5_"G
M_H5]:_*V_P#CM?B_11["(>T9^T'_  \K^%/_ $*^M?E;?_':/^'E?PI_Z%?6
MORMO_CM?B_11["(>T9^T'_#ROX4_]"OK7Y6W_P =J.3_ (*4_"IXV0>%]:RP
M(Z6W?_MK7XQT4>PB'M&?L9HW_!1WX6Z;ID%C+X9UEWB!!(%OCDD_\]?>M3_A
MY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\ ':/^'E?PI_Z%
M?6ORMO\ X[7XOT4>PB'M&?M!_P /*_A3_P!"OK7Y6W_QVC_AY7\*?^A7UK\K
M;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\ ':/^'E?PI_Z%?6ORMO\ X[7X
MOT4>PB'M&?M!_P /*_A3_P!"OK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB
M'M&?M!_P\K^%/_0KZU^5M_\ ':/^'E?PI_Z%?6ORMO\ X[7XOT4>PB'M&?M!
M_P /*_A3_P!"OK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%
M/_0KZU^5M_\ ':/^'E?PI_Z%?6ORMO\ X[7XOT4>PB'M&?M!_P /*_A3_P!"
MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
M':/^'E?PI_Z%?6ORMO\ X[7XOT4>PB'M&?M!_P /*_A3_P!"OK7Y6W_QVC_A
MY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\ ':/^'E?PI_Z%
M?6ORMO\ X[7XOT4>PB'M&?M!_P /*_A3_P!"OK7Y6W_QVC_AY7\*?^A7UK\K
M;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\ ':/^'E?PI_Z%?6ORMO\ X[7X
MOT4>PB'M&?M!_P /*_A3_P!"OK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB
M'M&?M!_P\K^%/_0KZU^5M_\ ':/^'E?PI_Z%?6ORMO\ X[7XOT4>PB'M&?M!
M_P /*_A3_P!"OK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%
M/_0KZU^5M_\ ':/^'E?PI_Z%?6ORMO\ X[7XOT4>PB'M&?M!_P /*_A3_P!"
MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MV@_X>5_"G_H5]:_*V_\ CM'_  \K^%/_ $*^M?E;?_':_%^BCV$0]HS]H/\
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M^5M_\=K\7Z*/81#VC/V@_P"'E?PI_P"A7UK\K;_X[1_P\K^%/_0KZU^5M_\
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MG_H5]:_*V_\ CM'_  \K^%/_ $*^M?E;?_':_%^BCV$0]HS]H/\ AY7\*?\
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MX4_]"OK7Y6W_ ,=H_P"'E?PI_P"A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/\
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MK7Y6W_QVC_AY7\*?^A7UK\K;_P".U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?\
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MX4_]"OK7Y6W_ ,=H_P"'E?PI_P"A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/\
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MT:-BO4!A@XSWKX7_ .'=GP!_Y^-:_P# N+_XQ7WA151DUL)I/<^#_P#AW9\
M?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**KVDNXN1'P?_P[L^ /_/QK
M7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7
M%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\
M&*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^
M'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP
M!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^
M-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\
M"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_
M (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7
MWA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11
M[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<
M.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P
M?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[
ML^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /
M_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK
M7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7
M%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\
M&*/^'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^
M'=GP!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP
M!_Y^-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^
M-:_\"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\
M"XO_ (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_
M (Q7WA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7
MWA11[27<.1'P?_P[L^ /_/QK7_@7%_\ &*/^'=GP!_Y^-:_\"XO_ (Q7WA11
M[27<.1'P?_P[L^ /_/QK7_@7%_\ &*S]5_X)Z_ 6RTVYNX;C6=\4;,N;N/&0
M/^N-?H!6/X@_Y =]_P!<7_E1[27<.1'P[9?\$\?@'/9P3R7&M;I(U8XNXNI&
M3_RQJU_P[L^ /_/QK7_@7%_\8K[BTS_D&VG_ %QC_P#015ZCVDNX<B/@_P#X
M=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V?
M'_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GX
MUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P
M+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^
M,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\
M.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@
M#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\
M:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X
M%Q?_ !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_
M !BOO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BO
MO"BCVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BC
MVDNX<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX
M<B/@_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@
M_P#X=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X
M=V? '_GXUK_P+B_^,4?\.[/@#_S\:U_X%Q?_ !BOO"BCVDNX<B/@_P#X=V?
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MQK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "XO\ XQ1_P[L^ /\
MS\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\  N+_ .,4?\.[/@#_
M ,_&M?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_  +B_P#C%'_#NSX
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M%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "XO\
MXQ1_P[L^ /\ S\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\  N+_
M .,4?\.[/@#_ ,_&M?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_  +B
M_P#C%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "
MXO\ XQ1_P[L^ /\ S\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\
M N+_ .,4?\.[/@#_ ,_&M?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_
M  +B_P#C%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK
M_P "XO\ XQ1_P[L^ /\ S\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-
M:_\  N+_ .,4?\.[/@#_ ,_&M?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?
MC6O_  +B_P#C%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\
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M=GP!_P"?C6O_  +B_P#C%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\
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M<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\  N+_ .,4?\.[/@#_ ,_&M?\
M@7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_  +B_P#C%'_#NSX _P#/QK7_
M (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "XO\ XQ1_P[L^ /\ S\:U
M_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\  N+_ .,4?\.[/@#_ ,_&
MM?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_  +B_P#C%'_#NSX _P#/
MQK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "XO\ XQ1_P[L^ /\
MS\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\  N+_ .,4?\.[/@#_
M ,_&M?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_  +B_P#C%'_#NSX
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M%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "XO\
MXQ1_P[L^ /\ S\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\  N+_
M .,4?\.[/@#_ ,_&M?\ @7%_\8K[PHH]I+N'(CX/_P"'=GP!_P"?C6O_  +B
M_P#C%'_#NSX _P#/QK7_ (%Q?_&*^\**/:2[AR(^#_\ AW9\ ?\ GXUK_P "
MXO\ XQ1_P[L^ /\ S\:U_P"!<7_QBOO"BCVDNX<B/@__ (=V? '_ )^-:_\
M N+_ .,4?\.[/@#_ ,_&M?\ @7%_\8K[PHH]I+N'(C\]M6_X)]? BRFL(X;C
M6<7,ZQMF[C/RD'I^YK9_X=V? '_GXUK_ ,"XO_C%?97B'_CYTC_K[3^1KIJ/
M:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[A
MR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#
M_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#A
MW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\
M?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C
M6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\
MP+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_
M^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?
M\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/
M@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S
M\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_
MX%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?
M_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^
M\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/
M:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[A
MR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#
M_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#A
MW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\
M?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C
M6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\
MP+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_
M^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?
M\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/
M@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,5GZK_P3U^
MMEIMS=PW&L[XHV9<W<>,@?\ 7&OT K'\0?\ (#OO^N+_ ,J/:2[AR(^';+_@
MGC\ Y[.">2XUK=)&K'%W%U(R?^6-6O\ AW9\ ?\ GXUK_P "XO\ XQ7W%IG_
M "#;3_KC'_Z"*O4>TEW#D1\'_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:
M_P# N+_XQ7WA11[27<.1'P?_ ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_
M ,"XO_C%?>%%'M)=PY$?!_\ P[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\
MP+B_^,5]X44>TEW#D1\'_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P#
MN+_XQ7WA11[27<.1'P?_ ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"X
MO_C%?>%%'M)=PY$?!_\ P[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_
M^,5]X44>TEW#D1\'_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P# N+_X
MQ7WA11[27<.1'P?_ ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"XO_C%
M?>%%'M)=PY$?!_\ P[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_^,5]
MX44>TEW#D1\'_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P# N+_XQ7WA
M11[27<.1'P?_ ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"XO_C%?>%%
M'M)=PY$?!_\ P[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_^,5]X44>
MTEW#D1\'_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P# N+_XQ7WA11[2
M7<.1'P?_ ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"XO_C%?>%%'M)=
MPY$?!_\ P[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_^,5]X44>TEW#
MD1\'_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P# N+_XQ7WA11[27<.1
M'P?_ ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"XO_C%?>%%'M)=PY$?
M!_\ P[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_^,5]X44>TEW#D1\'
M_P##NSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P# N+_XQ7WA11[27<.1'P?_
M ,.[/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"XO_C%?>%%'M)=PY$?!_\
MP[L^ /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_^,5]X44>TEW#D1\'_P##
MNSX _P#/QK7_ (%Q?_&*/^'=GP!_Y^-:_P# N+_XQ7WA11[27<.1'P?_ ,.[
M/@#_ ,_&M?\ @7%_\8H_X=V? '_GXUK_ ,"XO_C%?>%%'M)=PY$?!_\ P[L^
M /\ S\:U_P"!<7_QBC_AW9\ ?^?C6O\ P+B_^,5]X44>TEW#D1\'_P##NSX
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M1\'_ /#NSX _\_&M?^!<7_QBC_AW9\ ?^?C6O_ N+_XQ7WA11[27<.1'P?\
M\.[/@#_S\:U_X%Q?_&*/^'=GP!_Y^-:_\"XO_C%?>%%'M)=PY$?!_P#P[L^
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MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
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MW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\
M?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C
M6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\
MP+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_
M^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?
M\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/
M@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S
M\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_
MX%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?
M_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^
M\**/:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/
M:2[AR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[A
MR(^#_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#
M_P#AW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#A
MW9\ ?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\
M?^?C6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C
M6O\ P+B_^,4?\.[/@#_S\:U_X%Q?_&*^\**/:2[AR(^#_P#AW9\ ?^?C6O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3_KC'_P"@
MBKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_NG_T(UT-<
M]X4_Y%^S_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\0_\ 'SI'_7VG\C73
M5S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_ "K8K'\0?\@.
M^_ZXO_*@"UIG_(-M/^N,?_H(J]5'3/\ D&VG_7&/_P!!%7J "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#F?%W_(%?\ ZZ1?^ABNFKF?%W_(%?\ ZZ1?^ABNFH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/\ Q\Z1_P!?
M:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KF=&_Y#6M?]=(O_ $"NFKF=&_Y#6M?]
M=(O_ $"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#__4_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.
M^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\
M]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG_P!1
M)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?_0C70USWA3_D7[/_ '3_ .A&
MNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]?:?R-=-7,^(?^/G2/^OM/Y&N
MFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110 4444 %%%% !6/X@_Y =]_P!<7_E6Q6/X@_Y
M=]_UQ?\ E0!:TS_D&VG_ %QC_P#015ZJ.F?\@VT_ZXQ_^@BKU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %13_P"HD_W3_*I:BG_U$G^Z
M?Y4 8?A3_D7[/_=/_H1KH:Y[PI_R+]G_ +I_]"-=#0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!S/B'_ (^=(_Z^T_D:Z:N9\0_\?.D?]?:?R-=-0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B#
M_D!WW_7%_P"5;%8_B#_D!WW_ %Q?^5 %K3/^0;:?]<8__015ZJ.F?\@VT_ZX
MQ_\ H(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <SXN_Y K_ /72+_T,5TU<SXN_Y K_ /72+_T,
M5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <SXA_X^=(_P"OM/Y&NFKF?$/_ !\Z1_U]I_(UTU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SHW_ "&M
M:_ZZ1?\ H%=-7,Z-_P AK6O^ND7_ *!0!TU%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!__6_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _&[]MG_ (*#?$'X
M9_$/5_@S\(;:#3+G1A$EYJ]Q&MQ-YTT22[;:)\QJ$#@%I%?+9PJ@ M^2_B?]
MH?X[^,KJ2[\2_$#7+UI>J'4)TB'LL2,L:CV50*_:'XK_ /!-VY^-'[2?B3XH
M^*?%,>G>#]:>WG%M9*S:DSI!'%(A:1/)C!9"RO\ O#@X* \U]#Z9_P $]_V1
M]-TC^R6\"I>;D"O<7%[>/<.1_%O$PVD_[ 4>U:*21-F?SL^$_P!HCX[>![V.
M_P#"WC[6K*2,@[/MTTD+8Z!X9&:-Q[,I%?NE^PI^V]=_M"_:?AS\1XX;;QKI
ML!N(KB%1'#J-NA"NPCZ),F065?E8$LH4 @?C+^U[\"]._9Y^.&K?#_0[F2ZT
M=HH;VP:8AIEM[@$A)"  2CAESCD 'J36S^PI?:A8?M9?#J736(DDO987P<9B
MEMY4D!]MA-4U="1_5-117YI:E_P54_9OT[6I]'.E>))TMYFA-S'9VWDG:VTN
M UTLFWOR@/M6219^EM%?+7QI_;'^!?P+TFROO%NKO=ZAJ=O'=6NF6*":^DAE
M7>CM&658E8'@RLF><9P<?&=M_P %=/A>^H".\\":Q%9;A^]2:W>7;W/EDJN?
M;?\ C0HL5S]<:*\<^"OQ[^&/[0'AEO%'PTU47T4#*EU;R*8KJUD89"31'E<X
M.&&5;!VL<&O8Z0PHKYA^/W[7GP6_9R$=GXYU*2ZUN=/,BTK3T6>\*'H[J61(
MU)Z&1UW<[<X./BVU_P""NGPN?45BO? NL0V)(!F2:WDE [GRB54_3S*:BQ7*
M'_!7G_D0OAY_V$[S_P!$I7Y_?\$Z/^3Q/ ?^[JO_ *;+JOJ3_@HK\<_AE\>O
M@Y\//%/PTUA-2MX]4NTN(&!CN;61H%(2>%OF0]<'E6P2K$<U\M_\$Z/^3Q/
M?^[JO_ILNJT6Q/4_J HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Q_$'_(#OO\ KB_\JV*Q_$'_ " [[_KB_P#*@"UIG_(-M/\
MKC'_ .@BKU4=,_Y!MI_UQC_]!%7J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *BG_ -1)_NG^52U%/_J)/]T_RH P_"G_ "+]G_NG_P!"
M-=#7"V$CQV-ND;%5"+P#@=*M^?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS
M?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS
M?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS
M?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS
M?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS
M?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS
M?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<AY\W_ #T;\S1Y\W_/1OS-
M '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]&_,T>?-_ST;\S0!U]%<A
MY\W_ #T;\S1Y\W_/1OS- '7T5R'GS?\ /1OS-'GS?\]&_,T =?17(>?-_P ]
M&_,T>?-_ST;\S0!9\0_\?.D?]?:?R-=-7$RN\DUKYC%ML\1&3G'S"NVH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L?Q!_R [[_KB_\JV*Q_$'_(#OO^N+_P J +6F?\@VT_ZXQ_\
MH(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .9\7?\@5_^ND7_ *&*Z:N9
M\7?\@5_^ND7_ *&*Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .9\0_\?.D?]?:?R-=-7,^(?^/G2/\ K[3^1KIJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *YG1O^0UK7_72+_T"NFKF=&_Y#6M?]=(O_0* .FHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_7_?RBBB@
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MW_7%_P"5;%8_B#_D!WW_ %Q?^5 %K3/^0;:?]<8__015ZJ.F?\@VT_ZXQ_\
MH(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44_^HD_
MW3_*I:BG_P!1)_NG^5 '#V?_ !YP?]<U_E5FJUG_ ,><'_7-?Y59H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH C;_76W_7>+_P!"%=Q7#M_KK;_KO%_Z$*[B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Q_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_
M )!MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_
M .ND7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
MG1O^0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __T/W\HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R(_X*%?MM
M7'@=;[X"_":\,7B">,)K.I1-AK**5<_9H&'29U(WN/\ 5J<+\Y)3\4?AU\/?
M%/Q4\8Z=X&\'6PNM4U.38F]@D4:CEY)7/"1H.68]NF3@'O\ ]I_3=;TO]HKX
ME0>((98+J3Q#JDP\U2I>*6YD>)USU1D*E3T*D8KPFMTM"&?U4_LM_L]_#']F
M3P.NAZ/J%I?^(-05'U75&=!)<R@<(G)*0H20B?5CEB37U FM:/*ZQQW\#NQ
M $JDDGH ,U_%M4]L+EKF);,.;@NOEB/._?GY=N.<YZ8YS4N ^8_M5K^+?7/^
M0UJ'_7Q+_P"AFO[,M!^V_P!AZ=_:6[[9]FA\[=][S-@WY]\YS7\:GB6VN+/Q
M%JEI>1/!/#=3(\;J5=&5R"&!Y!!Z@TH!(_J"_8(_Y-&^'7_7K=?^EL]>??\
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MZY7+'L-S 9/<@=Z.@=3^GNBBBL2PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^
MN,?_ *"*O51TS_D&VG_7&/\ ]!%7J "BBB@ HHHH **** "BD9E498@#WH!#
M#(.10 M%%% !1130Z%MH89],\T .HHHH **** "BBOD?]I+]LOX:_LPZOHVA
M^-M+U74KK6X)+B(:=% ZI'&VP[S--%R3T !Z<X[B0'UQ17(?#_QKI'Q(\$:%
MX_T!)8]-\0V4%];K.H298YT#J'568!@#@@,1GH3UKKZ "BBHY98H(GGG=8XX
MU+,S$!54#)))X  ZF@"2BO/_  I\6?A9X[U&?2/!'C'1O$-]:J7EM]/U"WNI
M8U!P69(G9@ 3C)&,\5Z!0 4444 %%%% !17PO\/?^"@'P>^)/QGA^".B:1K<
M&K7-W=6<5S<06ZVK2VBR,Q)2X:0*PC.T[,],@<X^Z*;0!1112 **** "BBB@
M HHHH **** "HI_]1)_NG^52U%/_ *B3_=/\J .'L_\ CS@_ZYK_ "JS5:S_
M ./.#_KFO\JLT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45XC\:?VA_A3\ M)CU+XC:N+:>Y5FM;&!?.O+G;U\N(=L\;
MW*H#P6!K\T/%G_!6*[-VT7@7X?H+9<[9=2O"9&],Q0H O_?QJ:BV*Y^SM%?A
MKIO_  5?^(T4X;6/ NE74.>5@N)X&QZ;F\T9]]OX5]K? 3_@H+\)?C7K]EX+
MU&RNO"?B/47$5M!<LL]M/*WW8X[A OSGH Z)DX )) IN+"Y]Z4445(PHHHH
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ME'X6D\2ZEJEI]N<&[%G%% 9'B3YO*F+,S(W&!@#KS0D,^YJ*_&?_ (>VR_\
M1*U_\'?_ -Q4?\/;9?\ HE:_^#O_ .XJKD8KG[,45\K?LI?M.VO[3WA76?$,
M?A]O#L^C7:6LD!N1=*X>,.KA_+BQSN&-O;.><#ZIJ&AA1110 445^>__  4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*YG1O^0UK7_72+_T"NFKF=&_Y#6M?]=(O_0* .FHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_1_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJE-ING7$WVB>UBDE'\;(I;\R,U=HH *0@,"K#(/44M% %.WT[3[1S):6L4+M
MU*(JD_B!5RBB@"M>6=GJ%K+97\$=S;S*5DBE4.CJ>H96R"/8UQ>F_"KX7Z-J
M U?1_!^C6-\K!A<0:?;Q2AAT.]4#9'KFN]HH 1E5U*. 588(/((-5;:PL;,L
M;.WC@+]?+0+GZX JW10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8_B#_D!WW_ %Q?^5;%8_B#_D!WW_7%_P"5 %K3/^0;:?\
M7&/_ -!%7JHZ9_R#;3_KC'_Z"*O4 %%%% !1110 4444 ?S_ '_!6W5M3D^-
MGA/0GNI#IT'AZ*Y2WW'RUFEN[E'D"]-S+&H)] *\(_81^.>N?!+X^:#HNKWL
M]KX8\42IIVH6LK,L*M=@"VN"C?*I20H2^,^66YP:]G_X*U?\G!>&/^Q7MO\
MTMO*\>_;)^$3>#M%^#_Q7TJ+R['QIX0T59V48"ZA8V,$;'CIOA,1'<LKGUK9
M;$L_IRHKYQ_9,^,"_''X!^%?'-Q,)=4^SBSU+GYA?6G[N9F';S,"4#^ZXKZ.
MK%E'YE?\%.?CUJ'PS^%.G?#GPK?O9:YXUE=9I(7*2Q:;;X,V&4@KYKLB?[2^
M8/6OP5\!76M^&_B-X9U&VDFT_4(+^QN(I%+1R+YCI)&X/!PRL&![@^AKZ^^.
MFNZG^V=^VNGA;PY.TNF7.H1:%ITB?,L>GV;-Y]RO7*G$UQ_NG%<S^U7HFF>&
MOVTM6\.:) MKIVE7^AVMM$OW8X8+.T2-1[*H K:*Z$,_J'HHK\7_ !-^W?\
M'/2?VQO^%,6G]E_\(POBNVT3RFM"93:RW*0,WF>9GS-K$@],]L<5DE<L_:"B
MBOSZ_P""@/[2GQ)_9Q\*^$M1^&QLTN=<O+B&=[N#S\)#&K (-P R6Y)!Z<8H
M2 _06OP9_P""NW_)2? /_8)N?_2BOU+_ &/OBWXJ^.'P \._$?QJ+<:QJ#WD
M<QMHS%$WV>YDA4A"S8)5!GG&>@'2ORT_X*[?\E)\ _\ 8)N?_2BJBM1/8_6'
M]DS_ )-E^%__ &+VG_\ HE:^:/V[?VP_B)^S!JGA'2_ 6DZ5J!U^&[FG?4XY
MY=OD-&JA!#-#C.\Y))[<"O4?A7XD\2^#_P!A#P]XK\&V0U'7='\$QW=E;E&E
M$EQ#9[T4QH0S\C[JD%N@Y-?@/^TI\?OC'\=]3T.Z^,.G0Z=<Z/#,EHL5G)9[
MHYV4N2)&8MR@P134;L5]#^F;X"?$/4_BQ\&_"/Q'UFVAL[_Q!81W4\5ON\E)
M&R&";RS!<C(!)(]3UK9^+WA'4?B!\*?&7@71[A;2^\0Z/?Z?!*Y(1);J!XD+
MD D+EANP"<9Q7\_/PN_;;_:T^'_P^T+P7X*\/VUUH6D6RP6<K:3<3L\2DX)D
M5PK?4"OW$^%OQ)\=>(OV:M.^*7C33H]/\42Z+<:A/;&%X8Q+$LC1DQ,V]5=5
M5B,]#Q2<;#3/SA_8E_8<^._P8^/-E\1?B%;V6G:3I5K>1?NKM9WN'N(C$H58
M\X4;MQ+XZ=,]/VDK\A?V%_VU_C5\?_C->> _B&VG2:8-*N;U/LUJ8)$EAEB5
M0&#G*D.<@@GISZ_H=^T=\0->^%?P-\9?$+PP(3JNAV#SVWGH7B\S<J@LH(SC
M.<9I2O<$>V45^(/PO_X*FZUI7PS\1:I\5[2WUWQ<MU'%HUE8PFT1XVC)DDN9
M,LJQHP &T;V)P!C++X;J_P"WY^W'KUI-X[T:W_LKPVC%C)9Z&LNGHH.,&XGC
MF. >I,G7\J?(PYC^C"BOR5_8Y_X*,7_Q7\76/PI^,]G:V6M:H?*TW4[-6BAN
M9\<0SQ$L$D?G8ZD*S87:"03^M52U8:9_,I^RC_R?YH7_ &']7_\ 15U7]-=?
MS*?LH_\ )_FA?]A_5_\ T5=5_375U!1"BOQ]_:?_ ."G#^#?$][\/O@'IUKJ
M]UI\K6]SK%X&EM_.4E72UA0KYFUN/-9MI(.U&7#'YHOOVN_^"COAS33XTU_2
MM2MM!0>8TMWX96&S5!U+2_9T*J?4N/8U/(PN?T,T5^;O[&G[?5C^T-K ^&_C
M_38-"\9F)Y;9[4M]COUB!:01JY9XY%4%MA9@RAB&&-M?I%2:L,****0!1110
M 4444 %13_ZB3_=/\JEJ*?\ U$G^Z?Y4 </9_P#'G!_US7^56:K6?_'G!_US
M7^56: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4^<PHR2)%L0D.1M0!B#DG:,?#O\ P5D_Y'#X>?\ 7A??^C8ZV?\ @DI_Q_\
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M_AOWX;_]"[JWY6__ ,<H_P"&_?AO_P!"[JWY6_\ \<K\GZ*/]4\%_*_O8?\
M$;<__P"?D?\ P%'ZP?\ #?OPW_Z%W5ORM_\ XY1_PW[\-_\ H7=6_*W_ /CE
M?D_11_JG@OY7][#_ (C;G_\ S\C_ . H_6#_ (;]^&__ $+NK?E;_P#QRC_A
MOWX;_P#0NZM^5O\ _'*_)^BC_5/!?RO[V'_$;<__ .?D?_ 4?K!_PW[\-_\
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MXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N9T;_D-:U_UTB_] KIJYG1O^0UK7_72+_T"@#IJ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_X*[?\ )2? /_8)N?\ THK[\_X)N_\ )H?A#_KXU3_TNGKX#_X*[?\ )2?
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M\;8YO#>NP(J37MO ]Q8W!''F!80\L3'NNQE'9L<#22ZH29\E?&O_ ()RZO\
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MQ'^-?^DH****^*/Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MYGQ=_P @5_\ KI%_Z&*Z:N9\7?\ (%?_ *Z1?^ABNFH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]
MI_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_] KIJYG1O^0UK7_72
M+_T"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#__T_W\HHHH **** "BBB@ HHHH X3XE_$KP?\ "/P5J7Q
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M5W =3B7..@)K];? 7C_P?\3_  I8>-O FJ1:OHVI)OAGB)QQPRLIPR.IX9&
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M8B>-X (. RJ2,CBPN?45%%%2,**** "BBB@ K'\0?\@.^_ZXO_*MBL?Q!_R
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M>(/#]_.ULKF18R(Y4P&*J2#MR.._XU8G_9"_9AN-2&JR?#'0A.#G:MFB0_\
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M110!&W^NMO\ KO%_Z$*[BN';_76W_7>+_P!"%=Q0 4444 %%%% !7PW^UO\
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MW8!UR?P4"B,KL&C[@_X)+?$75->^&?B_X;ZA*9;?PG>V]S:;NL<.IB4M&/\
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M]HLLZIYMS=3DI:V< X\R9P&('90 68\*#VV?VK?^3E_BC_V,>I_^E#U^S_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_T+.D_^DD=#V0(XK]N/_DT_XD?]@Y?_ $?'7YU_\$?_ /D,_%'_ *]](_\
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M  K\C_/'B[_D;8O_ *^3_P#2F%%%%=I\Z%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z[\ _P#DM?@C
M_L+6G_HP5^^=?@9\ _\ DM?@C_L+6G_HP5^^=?G'&W\:'I^I_6'T?/\ D7XC
M_&O_ $E!1117Q1_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M,^+O^0*__72+_P!#%=-7,^+O^0*__72+_P!#%=-0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',^(?^/G2/^OM/Y&N
MFKF?$/\ Q\Z1_P!?:?R-=-0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7,Z-_R&M:_P"ND7_H%=-7,Z-_R&M:_P"N
MD7_H% '34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-Q$<-'=V4\##ZAT%;W@[X&_&3X@7J6'@WP5J^JR.1\T5G+Y2YZ%Y641H/=F
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MHH **** "BBB@ HHHH **** "HI_]1)_NG^52U%/_J)/]T_RH X>S_X\X/\
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M1:1XNT,(;VTB<M%-$_ N( WS!"V5926*'&6.X&OLNH:&%%%%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#B_%GQ(^'?@-H4\<>*-+\.M< M$-1O8+0R
M'!*B9UR,^E;F@^(O#_BG38]:\,:G:ZOI\V0ES9S)<0OC@[9(RRG'L:_GY_X*
M->#O'G_#2FK^(+O3+R;1K^TL!I]P(G> QQVZ)(BN 5!$P<E<Y&[..03]P?\
M!+KPIXS\.?##Q7>>)+"ZT[3M3U.*2Q2Y1HA(4AVS2QHX!*GY%WC@E<9^4U;C
MI<5S]/J***@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'P)K/@O4_@3\)KN#Q%+JX6+5=3A(DM((4</Y-NX.V61BHW.N45> 2Q^3G/\
M@C__ ,AGXH_]>^D?^AW5?1WPR_X)D_"_P)X*\1Z?K&K/K_B[7M+O-.AU6>V
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M[Z=_Z4P5_377YB^,?^"=4OBO]I1_CX/':VUM+K=KK+:?_9Q>0&WDCD,0F^T
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M^1MB_P#KY/\ ]*84445VGSH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'KOP#_Y+7X(_P"PM:?^C!7[
MYU^!GP#_ .2U^"/^PM:?^C!7[YU^<<;?QH>GZG]8?1\_Y%^(_P :_P#24%%%
M%?%'] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <SXN_Y K_\
M72+_ -#%=-7,^+O^0*__ %TB_P#0Q734 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!S/B'_CYTC_K[3^1KIJYGQ#_Q
M\Z1_U]I_(UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<SHW_(:UK_KI%_Z!735S.C?\AK6O^ND7_H% '34444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '__UOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!DO]N/P_\ M$7S^"?$NGIX=\8Q1--'#&Y>UO8T&7,!;YE=!DM&VX[?F#,
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M6&ZW%K<*NWN%;[26!]R3]*_63]E_]J'PC^TQX4N-2TFW;2]=TCREU/3I#O\
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M_KK;_KO%_P"A"NXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ KF=&_P"0UK7_ %TB_P#0*Z:N9T;_ )#6M?\
M72+_ - H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH __7_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***HZEJFF:-9OJ&KW<-C:QXW2SR+%&N3@99B ,G
M@<TTF]$3.:BG*3LB]17$_P#"R_AS_P!#5I/_ ('0?_%T?\++^'/_ $-6D_\
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M  5 \4_"W3/@3;>&/'%K+?\ B#5KLRZ#'!)Y3PW-NA62Y=B&!A1)=KH0=Y<
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M?_Y-8UO_ *_]._\ 1ZU^0G[!7_)VG@#_ *ZW_P#Z;[BOU[_X*/\ _)K&M_\
M7_IW_H]:_(3]@K_D[3P!_P!=;_\ ]-]Q1'8'N?TTU^#O[<O[9/Q&U+XDZW\)
M?ASK$_A[P_X<F:RNI;*1H;F\NHOEGWRH0ZQH^8PBD!L$MG("_O%7\O/[9?P^
MUGX>_M'^-K?5;:2&#6]0N-7LY'^[-;W\C3;D;N%=F0^A4@]*F"&S:^$?[%_[
M07QZT0>.=#LH+;2;YF,5_JMR8A<LK%79 !)*P!!&\KM)S@D@UY)\<?@CXN^
M'C?_ (0'QK<6=SJ/V6*[WV,CRP^7,6"C=)'&V?E.1M_&ONOX&_\ !24_"CX2
M:3\.M:\%'6+SP_;FVM+F&\%O'+$I)B$J&)RI4'#,I.[&< U\#_&/XM^-/CAX
MYO/B-XX='O+W$4:1)L@@AB^Y#&/[J!NY+'.6))S6BN2?M-_P2N_Y-[\0?]C1
M=_\ I%95\(?\%-?^3F#_ -@6Q_\ 0I:^[_\ @E=_R;WX@_[&B[_](K*OA#_@
MIK_R<P?^P+8_^A2U*W&]C[C_ ."57_)"O$__ &,DW_I':TG_  55_P"2%>&/
M^QDA_P#2.ZI?^"57_)"O$_\ V,DW_I':T?\ !57_ )(5X8_[&2'_ -([JE]H
M?0^'_P#@F/\ \G+-_P!@2^_]#AK]POCS_P D-^(O_8N:O_Z1RU^'O_!,?_DY
M9O\ L"7W_H<-?N'\>?\ DAOQ%_[%S5__ $CEHGN$3^5CP+_R._A[_L(VG_HY
M:_IU_:W_ .39_B1_V!;K_P!!K^8KP+_R._A[_L(VG_HY:_IU_:W_ .39_B1_
MV!;K_P!!IRW0D?S=? /_ )+K\.?^QDTC_P!+(J_K.K^3'X!_\EU^'/\ V,FD
M?^ED5?UG4J@XG\F'Q\_Y+K\1O^QDU?\ ]+):_I)_9,_Y-I^&W_8$M/\ T"OY
MM_CY_P EU^(W_8R:O_Z62U_21^R9_P FT_#;_L"6G_H%.>PEN?DS_P %5O\
MDN7A?_L7(?\ TLNJ^@O^"3O_ ")'Q _["-G_ .B7KY^_X*K?\ER\+_\ 8N0_
M^EEU7T#_ ,$G?^1(^('_ &$;/_T2]#^$.I\F?\%-?^3F#_V!;'_T*6ON/_@E
M5_R0KQ/_ -C)-_Z1VM?#G_!37_DY@_\ 8%L?_0I:^X_^"57_ "0KQ/\ ]C)-
M_P"D=K0_A!;GPY_P4U_Y.8/_ &!;'_T*6ON/_@E5_P D*\3_ /8R3?\ I':U
M\.?\%-?^3F#_ -@6Q_\ 0I:^X_\ @E5_R0KQ/_V,DW_I':T/X06YVO\ P4Q_
MY-EF_P"PQ8?^U*_+3_@GE_R=GX/_ .N6I_\ I!/7ZE_\%,?^39)O^PQ8?^U*
M_+3_ ()Y?\G9^#_^N6I_^D$]$=@>Y]J?\%6]9\ /HG@OP]=>9)XT@FFNK;8<
M)%ITHV3&4=_,EC3R\<Y1^0,@_EK\./$OQS^&MK-XQ^&,^M:+9:ANMY+RRCF%
MM.8NJ,P4QNR;N^2N>,9K] O^"JGP[U&T\=^%_BHL\3:?J-@NDF)I5\Y)[:26
M;<L1(8QE).64$*PPQ!9<_&WP<_:]^.?P+\/OX4\":Q"NC-*\ZVEU;13I'+)C
M>R,P#KNQRN[;G)QDDTX[">Y'H7P6_:9_:.\9-J4FB:QK6I:B0TVJ:HLD5NJ#
M !>YG 0*H^ZBDG PJGI7]#_[.GP3TK]G_P"%.E?#O3IOM5Q#NN+ZYQ@7%[-@
MRN!V48"H.NQ5SDY-?C)I/_!4#]HRPG5]0L]"U.+NDMG*A_ Q3I@_F/:OT[_9
M0_;,\*_M*QW>@W-A_P (_P"+=-A$TUD91+%<19VM+;N0K$*Q&Y6&5W#EADU,
M[C1]I4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% $;?ZZV_Z[Q?^A"NXKAV_UUM_
MUWB_]"%=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8_B#_D!WW_7%_Y5L5C^(/\ D!WW_7%_Y4 ?
MAW^TI_R6SQ+_ +UK_P"DL5>%U^U/BO\ 9.^%'Q&U9O%^N"_AU#4(X6F-O<!4
M8K$B [71\<*.G?-<W_PPM\%/^>^K?^!4?_QJOTK!<586%&$)7NDEMV1_)7$'
M@OG.(Q^(Q%+DY9SE)>]T;;70_'JBOV%_X86^"G_/?5O_  *C_P#C5'_#"WP4
M_P">^K?^!4?_ ,:KJ_UOP?G]QY'_ ! O/?[G_@7_  #\>J*_87_AA;X*?\]]
M6_\  J/_ .-4?\,+?!3_ )[ZM_X%1_\ QJC_ %OP?G]P?\0+SW^Y_P"!?\ _
M'JBOV%_X86^"G_/?5O\ P*C_ /C5'_#"WP4_Y[ZM_P"!4?\ \:H_UOP?G]P?
M\0+SW^Y_X%_P#\>J*_87_AA;X*?\]]6_\"H__C5'_#"WP4_Y[ZM_X%1__&J/
M];\'Y_<'_$"\]_N?^!?\ _'JBOV%_P"&%O@I_P ]]6_\"H__ (U1_P ,+?!3
M_GOJW_@5'_\ &J/];\'Y_<'_ ! O/?[G_@7_  #\>J*_87_AA;X*?\]]6_\
M J/_ .-4?\,+?!3_ )[ZM_X%1_\ QJC_ %OP?G]P?\0+SW^Y_P"!?\ _'JBO
MV%_X86^"G_/?5O\ P*C_ /C5'_#"WP4_Y[ZM_P"!4?\ \:H_UOP?G]P?\0+S
MW^Y_X%_P#\>J*_87_AA;X*?\]]6_\"H__C5'_#"WP4_Y[ZM_X%1__&J/];\'
MY_<'_$"\]_N?^!?\ _'JBOV%_P"&%O@I_P ]]6_\"H__ (U1_P ,+?!3_GOJ
MW_@5'_\ &J/];\'Y_<'_ ! O/?[G_@7_  #\>J*_87_AA;X*?\]]6_\  J/_
M .-4?\,+?!3_ )[ZM_X%1_\ QJC_ %OP?G]P?\0+SW^Y_P"!?\ _'JBOV%_X
M86^"G_/?5O\ P*C_ /C5'_#"WP4_Y[ZM_P"!4?\ \:H_UOP?G]P?\0+SW^Y_
MX%_P#\>J*_87_AA;X*?\]]6_\"H__C5'_#"WP4_Y[ZM_X%1__&J/];\'Y_<'
M_$"\]_N?^!?\ _'JBOV%_P"&%O@I_P ]]6_\"H__ (U1_P ,+?!3_GOJW_@5
M'_\ &J/];\'Y_<'_ ! O/?[G_@7_  #\>J*_87_AA;X*?\]]6_\  J/_ .-4
M?\,+?!3_ )[ZM_X%1_\ QJC_ %OP?G]P?\0+SW^Y_P"!?\ _'JBOV%_X86^"
MG_/?5O\ P*C_ /C5'_#"WP4_Y[ZM_P"!4?\ \:H_UOP?G]P?\0+SW^Y_X%_P
M#\U_@'_R6OP1_P!A:T_]&"OWSKY;\%_L@_"/P-XIT[Q=I7]H7%YI<OG0K<7"
MO%Y@!"L56-2=I.X<]0,Y'%?4E?'<29I2Q52,J5[)=3]W\)^#<9DV$JT<9;FE
M*ZL[Z62[(****^</U4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#F?%W_(%?_KI%_Z&*Z:N9\7?\@5_^ND7_H8KIJ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ#_Q\Z1_U]I_(UTU
M<SXA_P"/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KF=&_P"0UK7_ %TB_P#0*Z:N9T;_ )#6M?\
M72+_ - H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#1]#LH-.L+50D-O;1K##&HZ*B( JCV HYET"QHT445 PHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %13_ .HD_P!T_P JEJ*?_42?[I_E0!P]G_QYP?\ 7-?Y
M59JM9_\ 'G!_US7^56: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** (V_UUM_UWB_]"%=Q7#M_
MKK;_ *[Q?^A"NXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "L?Q!_R [[_ *XO_*MBL?Q!_P @.^_Z
MXO\ RH M:9_R#;3_ *XQ_P#H(J]5'3/^0;:?]<8__015Z@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MYGQ=_P @5_\ KI%_Z&*Z:N9\7?\ (%?_ *Z1?^ABNFH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/_ !\Z1_U]
MI_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N9T;_D-:U_UTB_] KIJYG1O^0UK7_72
M+_T"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_='YBNEHH YK^S;O^Z/S%']FW?]T?F*Z6B@#C+N&2TGLA,,>;<1JO?D'/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YG1O^0UK7_72+_T"NFKF=&_Y#6M
M?]=(O_0* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /_3_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.
M^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&VG_7&/\
M]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG_P!1
M)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?_0C70USWA3_D7[/_ '3_ .A&
MNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]?:?R-=-7,^(?^/G2/^OM/Y&N
MFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^N+_P J +6F?\@VT_ZXQ_\ H(J]5'3/^0;:?]<8_P#T$5>H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*?_ %$G^Z?Y5+44_P#J)/\
M=/\ *@##\*?\B_9_[I_]"-=#7/>%/^1?L_\ =/\ Z$:Z&@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#F?$/_ !\Z1_U]I_(UTU<SXA_X^=(_Z^T_D:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MQ_$'_(#OO^N+_P JV*Q_$'_(#OO^N+_RH M:9_R#;3_KC'_Z"*O51TS_ )!M
MI_UQC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGQ=_R!7_ .ND7_H8KIJYGQ=_R!7_ .ND
M7_H8KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH YGQ#_ ,?.D?\ 7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YG1O^
M0UK7_72+_P! KIJYG1O^0UK7_72+_P! H Z:BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __U?W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q_$'_(#OO^N+_RK8K'\0?\@.^_ZXO_ "H M:9_R#;3
M_KC'_P"@BKU4=,_Y!MI_UQC_ /015Z@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HI_\ 42?[I_E4M13_ .HD_P!T_P J ,/PI_R+]G_N
MG_T(UT-<]X4_Y%^S_P!T_P#H1KH: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\0_\ 'SI'
M_7VG\C735S/B'_CYTC_K[3^1KIJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0?\@.^_ZXO_ "K8
MK'\0?\@.^_ZXO_*@"UIG_(-M/^N,?_H(J]5'3/\ D&VG_7&/_P!!%7J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#F?%W_(%?\ ZZ1?^ABNFKF?%W_(%?\ ZZ1?^ABNFH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$/\
MQ\Z1_P!?:?R-=-7,^(?^/G2/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF=&_Y#6M?]=(O_ $"NFKF=
M&_Y#6M?]=(O_ $"@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#__6_?RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK'\0?\@.^_ZXO_*MBL?Q!_R [[_KB_\ *@"UIG_(-M/^N,?_ *"*O51TS_D&
MVG_7&/\ ]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *BG_P!1)_NG^52U%/\ ZB3_ '3_ "H P_"G_(OV?^Z?_0C70USWA3_D7[/_
M '3_ .A&NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH YGQ#_P ?.D?]?:?R-=-7,^(?^/G2
M/^OM/Y&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "L?Q!_R [[_KB_\ *MBL?Q!_R [[_KB_\J +
M6F?\@VT_ZXQ_^@BKU4=,_P"0;:?]<8__ $$5>H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\7?\@5
M_P#KI%_Z&*Z:N9\7?\@5_P#KI%_Z&*Z:@ HHHH **** "BBB@ HHHH ****
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MM?E;?_':/^'E?PI_Z%?6ORMO_CM?B_16_L(F?M&?M!_P\K^%/_0KZU^5M_\
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MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MOK7Y6W_QVC_AY7\*?^A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_\
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MG[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\
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MG[0?\/*_A3_T*^M?E;?_ !VC_AY7\*?^A7UK\K;_ ..U^+]%'L(A[1G[0?\
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M^.T?\/*_A3_T*^M?E;?_ !VOQ?HH]A$/:,_:#_AY7\*?^A7UK\K;_P".T?\
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MG_H5]:_*V_\ CM'_  \K^%/_ $*^M?E;?_':_%^BCV$0]HS]H/\ AY7\*?\
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MA3_T*^M?E;?_ !VOQ?HH]A$/:,_:#_AY7\*?^A7UK\K;_P".T?\ #ROX4_\
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M6ORMO_CM'_#ROX4_]"OK7Y6W_P =K\7Z*/81#VC/V@_X>5_"G_H5]:_*V_\
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M_':/^'E?PI_Z%?6ORMO_ ([7XOT4>PB'M&?M!_P\K^%/_0KZU^5M_P#':/\
MAY7\*?\ H5]:_*V_^.U^+]%'L(A[1G[0?\/*_A3_ -"OK7Y6W_QVC_AY7\*?
M^A7UK\K;_P".U^+]%'L(A[1G[0?\/*_A3_T*^M?E;?\ QVC_ (>5_"G_ *%?
M6ORMO_CM?B_11["(>T9^T'_#ROX4_P#0KZU^5M_\=H_X>5_"G_H5]:_*V_\
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MX4_]"OK7Y6W_ ,=H_P"'E?PI_P"A7UK\K;_X[7XOT4>PB'M&?M!_P\K^%/\
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MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8
MH_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=
MV? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '
M_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXU
MK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+
MB_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\
MC%?>%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>
M%%'M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M
M)=PY$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY
M$?!__#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!_
M_#NSX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NS
MX _\_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\
M_&M?^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?
M^!<7_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?!__#NSX _\_&M?^!<7
M_P 8H_X=V? '_GXUK_P+B_\ C%?>%%'M)=PY$?*?PL_8Z^$GP@\9VOCOPI+J
M;ZE9I+'&+FX22+$R&-LJL2DG!..:^K***AR;W&E8****0S__T?W\HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M_]+]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH __3_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA17E^B_&WX/>(]570]!\;:-?W[ML2"&^@=Y&]$ ;Y_\ @.:]0IM %%>::_\
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M;9);S7L*RQMZ.F[<G_ @*Z^W\7>%+O0&\5VNM64VB(C2-?)<QM:A%ZL9@VP
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M Y!!Y!!]*Y;PUX^\"^-)+B+P=XCTW77L]OGK87D-T8MV0N\1,VW.#C/7!I6
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M6/[Z KL9,$'EL=?J?]H;XQ6GP.^%^I>-Y(UN+_*VNGP.?EENY@=@;H2J@,[
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M%BYP)[.=)X\CMNC)&?;K3L%S<HK'USQ#H'ABP.J>)-3M=)LE.TSW<R01 GD
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M:LX[F6.%K?RT9^H7=$3CZDUM[.-KW(YG>Q^I:>(= ETDZ_'J=J^F $FZ$R&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_U?W\HHHH **** "B
MBB@ K\?O^"F?_(W>!_\ KQN__1J5^P-?C]_P4S_Y&[P/_P!>-W_Z-2MJ'Q$5
M-CJ/$'_!3.!M-FC\*^!W2_=2(Y+R\#11MV9HXXPSCV#K]:V_V'?@AXJN_$EY
M^TKX\NHI9]?2YDL5CD21YI+Q]T]Q)Y>50YW*$SN!+;E7 !^X/C)\&/!WQE\&
M:AX8\06,'VJ:)OLEYY:^=:S@?NY$?&X -]X X9<@\&OSO_X)^_$/5O!_CSQ+
M^S_XK=H7=YYK:&0_ZJ^LR4NHE'JZ+N/;]V3U)JDTXOE%U5SE?^"BL\^J_'#P
MAX9DDVVXTB!EST5KJ[FC=ORC7\J_8ZRLK73;.WTZPB6"VM8UBBC485$0!54#
MT &!7Y(_\%*_"E_:^*?!OQ"@1OL\UK)IS2#HDMO(9XP?=A*Y'^Z:_2SX0?$S
M1/BY\/M'\;Z+/%(;V"/[3%&P8VUT%'FPN.H9&/?J,$<$&E/X4..[/2R P*L,
M@\$&OQH_8L6+PQ^USXP\-Z>H6T\C5[-57[H2"[C9,#V$>!]:_5OXF_$7PY\*
MO!6I^-O$]RD%K81,T:,P5IYMI,<,8[O(1@ ?4\ FOR\_X)W^&M6\3_%'QC\6
M]2C_ ',-O);E\$*UW?S+,^WUVHAR.V]?44J?PMA+='+?MC^)HO!7[8GA[QE<
M0-=1:"NC7[PJ0K2+:SF4H"<@%@N :[3Q_P#\%)M0U7P]>:5X"\)MI6H7<;1I
M?75T)?(W@@ND21J"XSE26P#U5AQ5+]I  _M[_#\'_G^\-_\ I8*^W_VI/@%X
M>^,/PUU9K/3(1XITV%[K3KF.-5G:6(;O(+ 9990-N#P&(;J*TO'W;HFSUL>4
M?L,_L[ZS\*- O_'OBR2+^U?%$$(MX8)4G2&S'[P$R1ED9I20WRL0% YR2!]]
M5^:W_!.CXM3:]X2U?X3:Q<&2Z\.L+NP#G+?8YVQ(@]HI3G_MH!T''Z4UC5OS
M.Y<+6T/Q^_:5_P"3\_A__P!?GAS_ -+17[ U^/W[2O\ R?G\/_\ K\\.?^EH
MK]@:JKLA1ZA165>:[H>G7D&G:AJ%O;7=U@0PRS(DDF3@;%8@MSQP*U:Q+"OY
MX/@#\'_%?QU\>ZG\/M-U"73?#AG6^UB5>5"6[.L6%Z-(3*RQ@\#+,00IK^A^
MOR,_X)P?\E"^(?\ U[0?^CWK>E*T6R)*[1]C_#']G?X<?LNQ^*?'OAR^U&ZM
MFTUGN8[R2&3;':!IF*%(X^6QT/']/@3X(?#^3]LOXD>)?B9\9]9F31M.D5(K
M-)PG,Q9H[>(M_JX85'.T L2#G)8U^K?QITNYUKX/>.-(LMWVB\T/48HPO4N]
MLX4?B>*_'#]D+]G+X8?M!6?B*W\7:QJ-AJVCR0M'#920H'MI01O(EAD)PZX)
M!XR,CD55-Z-MBDM4CT[]JG]F[P=\"]%TOXN?!+5KC2;C3[R**6%+LR/&9 VR
M:&3/F AAM8%B""",8.?N)?VA)K7]DZ+X]W<$;ZA_9:N8Q_JVOS)]E' Z(9^2
M.H7CWKQW_AVS\%?^A@\0?]_[3_Y%KI/VCOA1I/P[_8MUKX>>$&N);#P^EM+&
M9V$DKK]O2>9G*JHZNS<* ,= *3DG97"S5V?*7[+_ .S+!^TE;:Q\8?C1JU_?
MQW5V\$*K+MEN94"F2624AB$7.Q54#D'D  'ZN^'W[%MC\(OC7HGQ'^'7B*XA
MT*V2Y2]T^Z)>619871561 JNF\JQ5UR"H().,2?\$^?$.F:K^S_#HUK(IN]%
MU"[BN$'W@9G\Y&(]&5\ ^Q'8U]IW6KZ38WMGIM[>P6]WJ!=;:&214DG:-=[B
M-"07*J"3M!P.3Q2J5'=H(Q5KGY&_&W5_$'[4/[4Z_ R/5WT?PEX?FD@F <!-
MUHI:YG*$[6E+9BCSG:,' RU>K_%G]AGX(VWPXU2]^']W-8:_I5K+<PR2WGG)
M<M"A<QRJW W@8!0+@X.",@_(]M\*/"GC[]LSQ9\-?B+J%WIUMJNL:J\,UNZ1
MRO-)(]Q I:5'7YT/'')( /(S]K_\.V?@K_T,'B#_ +_VG_R+6DFE;4E*]S;_
M & ?BOKWQ!^&&H^&_$MT]]>>%+F.&*>5R\K6MPI:)7+9)*%74$G[H4=J^"+W
MP)XV^*'[6WQ"^'?@K4VTC^WM4U2'49PQ51IZ77FRAU!!<;D3Y ?F. 2%R1^M
M7P'_ &<O _[/=KK%OX.N[Z]?7'@:XDOI(W;%N'$:J(HXP /,8G@DYZ\"OSS^
M"^O:-H/[?_C$ZS>1V:W^HZU:0-*=JO/+.2D8)XW-@A<]3@#D@&8R5Y-#:T29
MZ9\5?^"?'P_T7X7ZEJO@/4-1?Q)HUI)<@W$B21WAA4NZ&-47:S $)M. <;L\
MFKG[%7B,_'?X'>+O@K\0+BXO;721#;++YF)A8WBMY<:N<G,3PMM)R I5<8&*
M^_?B3XCTSPC\/_$?B;6)!%::;87,SEL<[8SA1GJ6.%4=R0*_-G_@F/I-R$^(
M&N.K"W<Z=;(<?*SKY[N,^J@K_P!]4E)N#;':ST/G;5_V?O EG^V5%\!H)+P>
M&GFMT+&53<[9+!;IOWFS;]\D?=Z<=>:_6OX*_LY?#OX"R:O-X&-X\FM"%9VN
MYA*0(-Y4+M1 /OG/7M7P'XF=8/\ @IC:R3'8KW5D 3W+:2BC\SQ7ZX7,33V\
ML"N8S(K*&'521C(]Q2JR=D$$M3\6+6T\2_MT_M%ZGIVI:K<6'@K0C++'&AR(
M+.-Q$@B4Y03W!^9G(;'/WE4+7O?Q?_X)\_#NU\!:EJWPQN+^VU[2[=[B**XF
M$\5WY2EFC(VJ5=P,*RD*#U7!R/)?^"<VJVGASXI^,O!.KD6^J7EHHB1^"7L9
M6$L8S_%A]V.N%)[5^LWC3Q+I?@WPCK'BO6Y%BL=)M)KF4MTVQH3C'<MT ZDD
M <U52;4K(48IJ[/B#_@GY\8]?^(/@;6?!7BFZDO[WPG)!Y%S,Y>1[2Z#[(V9
MLD^4T; $G[K*.U?!6O>!?&?Q/_:R\>_#KP9=-9OX@UC4;>^E!(C6Q2Z\Z5I<
M8RBF-6VY^9@J]Z^DO^"9.BW9OO'GB)E9;58[&U5L?*\A,LC 'N4 7/IN'K53
MX _\I /'O_7SKO\ Z/%5M*5A;I7/KKX-_L;_  [^"?C*T\<^&M5U.[U""TEM
MI%NGA:&0R@!G"I$K+T.!N/\ C]<T45RRDWN:I6/P^_;I^!'@7X/:GX=UOP?]
MJ$WBNXU2>[6XE$B*T;0.HC 52HS,W4GMSZ_?/P>_8V^$/PYUWP_\2-"?4I=7
ML81+']HN4>+?/"48E%C7/#G'/6OF[_@IXK>3\-VQP&U<$^Y%I7Z>>%Y8Y_#.
MD31,&22SMV4CH08U(-;RF^1$)*[/Q^\0J?V8OVZ(-7_X]O#_ (ANA<$]$^Q:
ML2DV?]F&?<P'I&/I7Z-_M2_$3_A67P+\4>(()?*O[FW-A9D'#?:+S]TK+[QJ
M6D_X#7S3_P %&?AK_;_PXTGXDV,6ZZ\,7'DW+ <_8[PA<GUV3! /3>QKY%^-
MOQLU+]H/P/\ ![X7Z'+]JUJ=(QJ,><EM2+_88-^.C,%>7_=E!JE'FLQ7M='T
M!^RA\.#X;_9+^)7C^\CVW7BS3-3$1(_Y=+*VFC0^VZ4R_4!37RY^RK^SWKG[
M0UU-I6MZG<Z?X%\/3M<7 A8;GO+E$4I"&!4.R1+O<AMJJ!C+"OV&\8>%=.\#
M?LX^(/!NDC%GHOA>]M(SC!80V3KN/NQ&3ZDFOD7_ ()H?\D\\7_]A6+_ -$+
M24W:4D'+JD>TV/@+P=^Q9\'?'?BKPG/=ZG" +Q([YXV(G(6""/=&D?R&1ADX
MS@\<]?B?]FK]G"X_:BDUCXQ_&O6K^^MIKIK>)4D"S7,J!2[&1@VR% P140#G
M(!4+@_=_[;&F76J?LS^,8K3<7@6SN&5?XDANX7?/L%!;\*X'_@GMXCTO5?@&
MFAVDB_;-$U"ZBN8_XAY[>=&Y'HP; /JI':DI/E<NHVE>Q\I?M1_LJV?[/FE:
M?\8/@YJM_916%W''.C39FM7DR(YH9D",%W80JV3EAS@D#[^^'/Q>UWX@?LP#
MXJV40/B!=&OI"B@$-?V*RQY"XP!))'N"\X# 5P/[??B72]&_9WU/1;R11=Z_
M=V=M:H?O,T,Z7+D#T"1$$].0.XK;_8:T6[T?]FSPV;U61M0DO+I4<8(CDN'"
M''HRJ&'J&S2;O!-@E9V1^?O['OPM^#'QTU/Q'/\ &+4I=3\533AX+.6[>!YT
MD!:2<,K*\K[\A@&.T<D?,"/TL^"7[,W@[X"^(O$.L>#+^\DL]?C@3[)<LKB#
MR2YRK@ L#OP-PR!W.:\(^,7_  3^\"^,;ZZ\2_#34'\):O,QF^S[?,L&ESG*
MJ,/#D]U+*O\ "@KAOV*/C#\45^)GB'X ?$N_DU=M#BNA%+/(9YK>>QF6&6(2
MGYGC.3MW$[=H"\'%5-\R;3%%6T9QGP!_Y2 >/?\ KYUW_P!'BND_X*<_\@SX
M>?\ 7;4__0;:N;^ /_*0#Q[_ -?.N_\ H\5TG_!3G_D&?#S_ *[:G_Z#;57V
MT'V6;'PP_81TGQOX;/CGX[ZWJ&I>*/$B"[<6]PH^SB8!EWR,K^9)@C/\"_=
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M\$X/^2A?$/\ Z]H/_1[TXVY96![H/&W_ "DHTO\ Z^;#_P!-RU[W_P %&?\
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MRA1[ #M7S+\7/V&/!7P^^%GB+Q]J_C/4]2U31[)YT:<PQ0RS@81"&#OAV(
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MPEJWH<?_ ,$]/B1XF>Z\4_!7Q+=-=IX?7[39;I#)Y"QR>1/$A/\ RSW%&4#
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MZ_!KQ3\=O&NN>!+'6)-'\,++'>:RT;<R+"[K JQYP[Y=]I;Y5R6.2 #]_?\
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MQ<MIV7X5IQ^\L9P.QE1@H'_309Z"OV1O+VSTZUDO=0GCM;>$9>65@B*/4LV
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M@WX-?#ZV^)'PVO;Z)M,N8(KN.YE$A*RG:DT;JJ%763:".ASD;=N#^AW[-'Q
MO?'?P \)^-/$MT&NWM)(KJXE;&Y[.5[=I)&8_>?R]S$]R37"?MT_\FR>*O\
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MGAF#4?$UQHVC:*\[W5I!'O-R9=FUE+,$1T"D!F1\!C@=<^*^/?\ @G]\%X?
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M'GAS6] O([ZQN+"WV2Q'*DJ@5@>X96!# X((((S3<FH*PK)MW/R-^&47B/\
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M=7D]AH?B2XTQ7N8F5)(XIK6* ,K.K* )%QDJ0 #GIFOK;_AVS\%?^A@\0?\
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M !C.23CV;_@H_IEQ=_!+1]0AR4L-<@:0#H$DMYT#'Z,0/QKWC]DKQ#IGB/\
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M >1DIRNVV$ET1]<?%G]AGX(VWPXU2]^']W-8:_I5K+<PR2WGG)<M"A<QRJW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;+CSK^XN$<(?E;R_*#2,O4>:1CU%?HU\&/A#X;^"/@.T\"^&F>>.)FFN+B4
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MNKKKGB[6HC#++%O,,,;N))%5Y,/*TCJK,[*IX  ')/V713E5;T!01\*_"_\
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M]OIU)7>@HJP4445F4?"OB+]F;QYJW[7MC\>;:]T]?#MO);2/$TLHN_W%H("
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MVY8\"OJJBDZCM8.76Y\*_"_]F;QYX+_:C\4?&C5;W3Y-"UB349((X996NO\
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M_93OOA!XJ\00:SXTU!"9+^YGFDA9OMHN55IF0R$+& @.S P !M&:[?\ 9?\
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M76BK]M(GV:/&OV@OA[K7Q5^#WB3P!X=F@@U'5HX5A>Y9DA!BGCE.YD5V&0A
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M:YL;O4]8%O#!]B>218H(MS/N:2.,Y=F7@ C"CFO/_P!K#]C;QK\9OB3#X]\
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MB?3%?1?[-7[+OC3X9>-=2^*_Q3\5?\)#XHU.U>T*QO).BI(Z.S//, [M\@4
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M[UZK^T;^QY=_%3QI%\5?AUXB_P"$;\61K#O,GF"*62W 6*59HCYD,BJ ,JK
M@#@$$GS*3X$?M[:Q9OH6K_%.Q@L"NQI(KJ9964\'$D=HDI./5P:V4]%9D<NN
MJ,?]B7XH?$NT^+OBCX$>,]9D\16.CQ7GESR2-<>3/8W"P,8I7^;R9-QP#QG;
M@#)SZ-\>OV*M4\7^/6^+/P9\0)X9\2W$PN)XYFDAB\\#!GAF@5GC=B,N-K!B
M2<CD'U_]FG]EKP]^SW:7NH-?'6_$FJHL=Q>F/RE2($-Y,298A2P!8DY8@' P
M!7U342J6E>)48Z:GY>O\$_V__$$']A:Q\2+:RL?N--'>-'(4[D/;VZRG/NP]
MZ^\/@M\/=0^%GPTT?P-JVL2:]>:<)C+>2!@9'GF>8@!F<X7?M&3R!GCH/4J*
MB4V]!J-CX5_9*_9F\>? GQ5XMUOQ?>Z?<P:U''';BREED;Y)&<EQ)%& ,$8P
M37NO[2?PRU[XP?!S7/ 'AF:WM]2U%K5HGNF9(?W%Q'*P9D5V&50@?*><9P.:
M]UHH<VW<=M+'A7[-GPSU[X0?!O0OA_XFFM[C4M.:Z:5[5F>']_<23*%9U1CA
M7 /RCG.,CFO=:**EN[N-(^%?VCOV9O'GQ=^-'@SXA>&KW3[?3-!CM8[E+J65
M)OW%V\[%%2)U;*M@98<]<#FONJBBFY-JPDCY2_:<_9;T/]H73K2^AO?['\2Z
M3&\=K=%-\4D;'=Y,ZCYBH;)5E.4)8X;)%?,6G? []OWPU9Q^&-%^(5F^FQ((
MXY#>-)L1>%4/-;&9<#H!T[5^I5%4JC2L)Q1\M?LT_!+XA_"<>(=8^)OC&3Q7
MK/B(VQ?,DTT<'V;S/NRSG<Q;S/[B@!1U[>:?M/?L;-\8O$<?Q&^'^JQ:'XJ"
MQ+.)RZ6]QY(Q'+YD2M)'*H 7< P(5> 1D_>%%)5'>X<JM8_)^Y_93_;$^(T,
M?A;XG?$6-?#J,!*&O)[HR*IX/E*D8E(ZCS7'UK[H\2_L^>#/%GP3L/@AK,DT
MFFZ9:6MO;78V_:8I;1 L<Z\;0QP=PQ@JS+T->\44W4;!11^4NB?LL_MB?" 3
MZ3\(_']FVBO*S1Q&9XQ\W\;6\\,D2,1UV,W/<U[+\&?V>?VAM/\ B?I7Q/\
MC9\0O[6_LD3F/3H)YIXW,\+PX8,L448&_=\B-D@#CJ/O6BAU6P4$?EA_P4Y_
MY!GP\_Z[:G_Z#;5B:9^R=^TSX"LD'P(\>_9_#VO0Q7#PR74EI+$TJ*26549-
MPSCS(RK$#H.!7TI^V3^SMXY^/]CX5@\$W-C;OHDMVTXO99(@1<"(*4,<<F<>
M6<YQU&,U]@:#82Z5H>G:7.RO)9VT,+%<[2T:!21G!QD<5?M+15A<MV?%/[,/
M['+_  =\13?$;X@:K'KGBQQ*L/D%W@@\X8ED\R55DDE<$C<0H )X).1]!?M
M?!VS^.?PSO\ P'/=_8+F1X[BTN2I=8KB$Y4LH(RK LA] V1R!7M5%9N;;N4H
MJUC\N?A+^S1^U[X#UOP]X>F\<6]EX,T?48+J:WM;Z<I) DPDEBC3RD8K)\P*
M,50DG/4U]D?M#?L_>&OV@O",.A:O</IVHZ<[36%[&H=H9'7:RNIQNC? W*"I
M)4$$8KWZBAU&W<2BMC\FM+_9C_;=\"Z8OA#P9\0+:/1 "L:PZA/&L*DYP@DA
MWQY))Q&:^B?V9?V/;+X+ZM)X^\9ZFNO^,9UD421[C;VPF_UC(T@#R2.,AI&
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M]CCQ;\:?'UIX\^']WIUI--:);W\=[)+$7DA)$<JF.*3.4(0YQ@*N,Y./K/X
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M570/%T"11L\@86]R(3^[9VC!D25!@!P&X &W@$?;M%/VCO<.56L?EY'\&?\
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M9OO&/BZ]&GZ/IJJ]Q.4>38KL$7Y(U9SEF P%/6ORS_X*;_\ (;\ ?]>^H_\
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M&F-=6T;R%93/?S0R$LS%AN10O!'3CFM5;G=R'?E1^J7P\_:)^#7Q7UR3PWX
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M-\2/BW\._A'I]IJGQ$UA='MK^4PP,T4LQ>15W$!84=N!W(Q7Y(?MH^#OV?\
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MCFGZ!+^RQ^VWH_AOPS/)_86K7=I;HDCD[K#52(BDA_B\F0DJ3R3&I/)KV/\
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MBMXKJ"!4P&"'$;%<E2<'Z5Q7['O[.?P5^(/P-TGQ9XS\+0:IJUQ<WBR3R2S
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M!^=OQ9\0>'?CI^V%<^&/BEK\.A>"?"UQ/8$S7 @C$=EGS45V(423S @MU"X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M16X9/8,M=W_P4PC\,GP9X-ENCCQ +^<6H&.;0Q#[1GO@/Y./J:^COV-/AO\
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M^/OB5XPN?%.H:7/%<P0HC1)YT#!XS++)))(ZJPSM&SIR2,@_3'[07P%\._M
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M0P[Q]_RNF_C/4XYIS6FH*+U/)?V _P#DW'3/^OZ^_P#1M?-/_!3K_C_^'?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;82,#K@"OLR*..&-(85"1H JJHP !P !Z"GT53DVK"2"BBBI&%%%% !1110
M5X]\0?@5\.OBCXIT'Q;XVLY=1NO#9S:0M,PMLEP^7B'ROEE&0>&  ((XKV&B
MFG;8+!1112 **** "BBB@ HHHH **** "O'/$OP'^'/C#XEZ3\5_$EG+?:WH
M<<<=HLDS&VC\IF=&\G[I97<L#ZX.,BO8Z*:=@L%%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#_]/]_**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH __4_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006754800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyell Immunopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1300510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Line</a></td>
<td class="text">201 Haskins Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">695-0677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,868,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005822608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 286,214<span></span>
</td>
<td class="nump">$ 123,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">289,217<span></span>
</td>
<td class="nump">516,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,423<span></span>
</td>
<td class="nump">11,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">586,854<span></span>
</td>
<td class="nump">651,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">22,729<span></span>
</td>
<td class="nump">70,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">32,001<span></span>
</td>
<td class="nump">44,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">108,096<span></span>
</td>
<td class="nump">123,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">40,603<span></span>
</td>
<td class="nump">43,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4,423<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">794,989<span></span>
</td>
<td class="nump">937,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,365<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">29,652<span></span>
</td>
<td class="nump">28,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesCurrent', window );">Success payment liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,064<span></span>
</td>
<td class="nump">37,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">58,576<span></span>
</td>
<td class="nump">63,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,776<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">97,416<span></span>
</td>
<td class="nump">104,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized at September&#160;30, 2023 and December&#160;31, 2022; no shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000 shares authorized at September&#160;30, 2023 and December&#160;31, 2022; 251,869 and 249,567 shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,647,911<span></span>
</td>
<td class="nump">1,608,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,181)<span></span>
</td>
<td class="num">(7,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(949,182)<span></span>
</td>
<td class="num">(767,480)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">697,573<span></span>
</td>
<td class="nump">833,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 794,989<span></span>
</td>
<td class="nump">$ 937,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006734368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">251,869,000<span></span>
</td>
<td class="nump">249,567,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">251,868,968<span></span>
</td>
<td class="nump">249,567,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005798080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 36,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,849<span></span>
</td>
<td class="nump">41,607<span></span>
</td>
<td class="nump">135,950<span></span>
</td>
<td class="nump">121,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,507<span></span>
</td>
<td class="nump">26,084<span></span>
</td>
<td class="nump">53,816<span></span>
</td>
<td class="nump">90,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
<td class="num">(2,149)<span></span>
</td>
<td class="num">(3,544)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,064<span></span>
</td>
<td class="nump">66,440<span></span>
</td>
<td class="nump">187,617<span></span>
</td>
<td class="nump">208,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59,039)<span></span>
</td>
<td class="num">(66,437)<span></span>
</td>
<td class="num">(187,500)<span></span>
</td>
<td class="num">(172,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,608<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
<td class="nump">16,369<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,578<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
<td class="num">(1,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(12,923)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,186<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
<td class="nump">5,798<span></span>
</td>
<td class="num">(2,447)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,853)<span></span>
</td>
<td class="num">(70,254)<span></span>
</td>
<td class="num">(181,702)<span></span>
</td>
<td class="num">(174,721)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,198<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
<td class="nump">6,418<span></span>
</td>
<td class="num">(8,373)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (49,655)<span></span>
</td>
<td class="num">$ (71,899)<span></span>
</td>
<td class="num">$ (175,284)<span></span>
</td>
<td class="num">$ (183,094)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per common share, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">251,318<span></span>
</td>
<td class="nump">248,320<span></span>
</td>
<td class="nump">250,377<span></span>
</td>
<td class="nump">246,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per common share, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">251,318<span></span>
</td>
<td class="nump">248,320<span></span>
</td>
<td class="nump">250,377<span></span>
</td>
<td class="nump">246,285<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)&#160;&#160;&#160;&#160;Including related-party revenue of zero for both the three months ended September&#160;30, 2023 and 2022, and zero and $36,299 for the nine months ended September&#160;30, 2023 and 2022, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006693168">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 36,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,299<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)&#160;&#160;&#160;&#160;Including related-party revenue of zero for both the three months ended September&#160;30, 2023 and 2022, and zero and $36,299 for the nine months ended September&#160;30, 2023 and 2022, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005305728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 929,787<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 1,515,748<span></span>
</td>
<td class="num">$ (1,623)<span></span>
</td>
<td class="num">$ (584,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">9,252<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">63,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(8,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(174,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,721)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">820,026<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,589,080<span></span>
</td>
<td class="num">(9,996)<span></span>
</td>
<td class="num">(759,083)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">868,042<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,565,197<span></span>
</td>
<td class="num">(8,351)<span></span>
</td>
<td class="num">(688,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(70,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 820,026<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,589,080<span></span>
</td>
<td class="num">(9,996)<span></span>
</td>
<td class="num">(759,083)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">249,567,343<span></span>
</td>
<td class="nump">249,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 833,252<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,608,306<span></span>
</td>
<td class="num">(7,599)<span></span>
</td>
<td class="num">(767,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">1,478,537<span></span>
</td>
<td class="nump">1,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">38,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">6,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (181,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,702)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">251,868,968<span></span>
</td>
<td class="nump">251,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 697,573<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,647,911<span></span>
</td>
<td class="num">(1,181)<span></span>
</td>
<td class="num">(949,182)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="nump">736,855<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,637,538<span></span>
</td>
<td class="num">(2,379)<span></span>
</td>
<td class="num">(898,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,853)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">251,868,968<span></span>
</td>
<td class="nump">251,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 697,573<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 1,647,911<span></span>
</td>
<td class="num">$ (1,181)<span></span>
</td>
<td class="num">$ (949,182)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005982480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (181,702)<span></span>
</td>
<td class="num">$ (174,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">38,621<span></span>
</td>
<td class="nump">63,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">15,193<span></span>
</td>
<td class="nump">12,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization and accretion on marketable securities</a></td>
<td class="num">(6,212)<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities', window );">Change in fair value of success payment liabilities</a></td>
<td class="num">(3,309)<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_NonCashLeaseIncomeExpense', window );">Non-cash lease income</a></td>
<td class="num">(1,344)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on property and equipment disposals, net</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of equity warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="num">(5,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(337)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(123,059)<span></span>
</td>
<td class="num">(129,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,661)<span></span>
</td>
<td class="num">(19,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(220,095)<span></span>
</td>
<td class="num">(346,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">507,494<span></span>
</td>
<td class="nump">308,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">284,738<span></span>
</td>
<td class="num">(58,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">9,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(334)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">9,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">162,663<span></span>
</td>
<td class="num">(177,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">123,834<span></span>
</td>
<td class="nump">294,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">286,497<span></span>
</td>
<td class="nump">116,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Represented by:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">286,214<span></span>
</td>
<td class="nump">116,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">286,497<span></span>
</td>
<td class="nump">116,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">8,030<span></span>
</td>
<td class="nump">8,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances', window );">Cash received for amounts related to tenant improvement allowances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for amounts related to tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of success payment liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_FairValueAdjustmentOfSuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_NonCashLeaseIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_NonCashLeaseIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represented by Cash and Cash Equivalents and Restricted Cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294094610000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in June 2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex&#160;vivo</span> genetic and epigenetic T&#8209;cell reprogramming technologies. The Company&#8217;s primary activities since incorporation have been to develop T&#8209;cell therapies, perform research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions, execute clinical trials, raise capital and provide general and administrative support for these activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294011265792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s audited financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of September&#160;30, 2023 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#8220;GSK&#160;Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#8220;GSK&#8221;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#8217;s basic and diluted net loss per common share for the nine months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007264048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Success Payment Agreements</a></td>
<td class="text">License, Collaboration and Success Payment Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fred Hutch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#8220;CARs&#8221;) and/or T-cell receptors (&#8220;TCRs&#8221;), subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay Fred Hutch annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#8220;Fred Hutch Collaboration Agreement&#8221;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $12.0&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a six-year term. The Company incurred $0.3&#160;million and $0.4&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended September&#160;30, 2023 and 2022, respectively, and $0.7&#160;million and $1.4&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $1.83 per share issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The aggregate success payments to Fred Hutch are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#8217;s IPO and each two-year anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of September&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payment liability was estimated at fair value at inception and at each subsequent reporting period and the associated expense was accreted over the service period of the success payment obligations as research and development expense through 2022. As of December&#160;31, 2022, the Company&#8217;s associated success payment liability was fully accreted to fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and nine months ended September&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other income (expense), net, as the requisite service obligation had been met. The success payment liability was $0.4&#160;million and $2.5&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized a gain of $1.5&#160;million and expense of $1.4&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and a gain of $2.1&#160;million and expense of $0.8&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments to Stanford of up to a maximum of $3.7&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $2.5&#160;million collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#8209;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#8220;Stanford Collaboration Agreement&#8221;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a four-year term. The Company is committed to fund aggregate research performed by Stanford of $12.0&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $0.8&#160;million in expense in connection with the Stanford Collaboration Agreement for both the three months ended September&#160;30, 2023 and 2022, respectively, and $2.3&#160;million for both the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $1.83 issuance price of the Company&#8217;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s IPO. The aggregate success payments to Stanford are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#8217;s IPO and each two-year anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of September&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the success payments to Stanford as of September&#160;30, 2023 and December&#160;31, 2022 were $0.8&#160;million and $3.3&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $0.6&#160;million and $1.9&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized a gain of $1.2&#160;million and expense of $1.0&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and a gain of $1.2&#160;million and expense of $1.4&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into the GSK Agreement with GSK for potential T&#8209;cell therapies that apply the Company&#8217;s platform technologies and cell therapy innovations with TCRs or CARs under distinct collaboration programs. The GSK Agreement defined two initial collaboration targets, LYL331 and LYL132, and allowed GSK to nominate seven additional targets through July 2024, though no additional targets were nominated over the life of the GSK Agreement. The Company was expected to perform research and development services for each selected target up until a defined point (the &#8220;GSK Option Point&#8221;), at which time GSK would decide whether or not to exercise an option to obtain a license from the Company (&#8220;License Option&#8221;) and take over the future development and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, GSK exercised the License Option on LYL331 (NY-ESO-1 TCR with c-Jun) and assumed sole responsibility for future development and commercialization of the program at its own cost and expense. The investigational new drug (&#8220;IND&#8221;) application for LYL132 was cleared in January 2022, though no patients were treated, and the IND for LYL331 was not submitted to the U.S. Food and Drug Administration. GSK terminated the GSK Agreement effective December&#160;24, 2022, and Lyell has also discontinued any further work on these programs. There are no future performance obligations associated with the GSK Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a non-refundable upfront payment of $45.0&#160;million under the GSK Agreement. In connection with the GSK Agreement, in May 2019, the Company also entered into a stock purchase agreement with GSK, pursuant to which the Company agreed to sell 30,253,189 shares of Series&#160;AA convertible preferred stock at a price of $6.78 per share, which was above the issuance date estimated fair value of $4.84 per share. The difference between the per share values resulted in $58.6&#160;million additional deemed consideration, bringing the total upfront consideration of the GSK Agreement to $103.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GSK Agreement was deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;)&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, because GSK engaged the Company to initially provide research and development services, which were outputs of its ongoing activities, in exchange for consideration. In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the GSK Agreement due to GSK and the Company mutually agreeing to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#8217;s basic and diluted net loss per common share for the nine months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no revenue related to the research and development services related to the two initial targets for both the three months ended September&#160;30, 2023 and 2022, and zero and $36.3&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. As of September&#160;30, 2023 and December&#160;31, 2022, there were no contract assets or contract liabilities related to the license contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PACT</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a commitment agreement (&#8220;PACT Commitment Agreement&#8221;) with PACT Pharma, Inc. (&#8220;PACT&#8221;) to jointly develop and test an anti-cancer T-cell therapy against solid tumors, in connection with which it also purchased PACT Series&#160;C-1 convertible preferred stock, which was recorded in other investments at $36.4&#160;million in the Company&#8217;s Condensed Consolidated Balance Sheet. In December 2021, the Company recorded a $36.4&#160;million impairment expense for its investment in PACT. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company filed a demand for arbitration seeking, among other things, rescission of the PACT Commitment Agreement. On October&#160;1, 2022, the Company entered into a settlement agreement to resolve its </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding legal dispute with PACT, pursuant to which PACT issued shares of PACT&#8217;s Series&#160;D convertible preferred stock to the Company in exchange for the Company&#8217;s tender of its PACT Series&#160;C-1 convertible preferred stock. The settlement agreement also included the termination of the commitment agreement with PACT. The Company recorded a gain of $2.9&#160;million in October 2022 for the estimated fair value of the PACT Series&#160;D convertible preferred stock, which was included in other investments in the Company&#8217;s Condensed Consolidated Balance Sheet as of December&#160;31, 2022. In connection with the preparation of the financial statements for the nine months ended September&#160;30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment of the PACT Series&#160;D convertible preferred stock investment, resulting in $2.9&#160;million impairment expense for the nine months ended September&#160;30, 2023. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294008557920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash Equivalents and Marketable Securities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">69,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">577,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,187)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">264,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">289,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">277,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">221,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">702,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">107,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">516,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">70,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of securities held by the Company in an unrealized loss position for less than 12&#160;months were $247.6&#160;million and $287.8&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The fair values of securities held by the Company in an unrealized loss position for greater than 12&#160;months were $104.9&#160;million and $278.7&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. As of September&#160;30, 2023 and December&#160;31, 2022, all of the Company&#8217;s marketable securities had a maturity date of two years or less, were available for use and were classified as available&#8209;for&#8209;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both September&#160;30, 2023 and </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September&#160;30, 2023 and 2022 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three and nine months ended September&#160;30, 2023 and 2022 were also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note&#160;6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding cash equivalents and marketable securities.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294008557920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_OtherInvestmentsTextBlock', window );">Other Investments</a></td>
<td class="text">Other Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company makes minority ownership strategic investments. As of September&#160;30, 2023 and December&#160;31, 2022, the aggregate carrying amounts of the Company&#8217;s strategic investments in non-publicly traded companies were $32.0&#160;million and $44.9&#160;million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of September&#160;30, 2023 and December&#160;31, 2022 were $17.9&#160;million and $5.0&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the acquisition of each of the Company&#8217;s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of September&#160;30, 2023 and December&#160;31, 2022, the Company held an interest in two entities that were concluded to be variable interests for which the Company was not the primary beneficiary. As of September&#160;30, 2023 and December&#160;31, 2022, the carrying value and maximum exposure to loss of the Company&#8217;s variable interests were $13.0&#160;million and $15.9&#160;million, respectively, which is recorded in other investments in the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received shares of PACT&#8217;s Series&#160;D non-voting convertible preferred stock (See Note&#160;3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company recognized its investment in PACT preferred stock at its estimated fair value of $2.9&#160;million on October&#160;1, 2022, which was included in the Company&#8217;s Condensed Consolidated Balance Sheet within other investments as of December&#160;31, 2022. </span></div>For the nine months ended September&#160;30, 2023 and the three and nine months ended September&#160;30, 2022, the Company performed qualitative assessments of potential indicators of impairment and determined that indicators existed for certain of its other investments. The Company did not identify any impairments for the three months ended September&#160;30, 2023. The Company did identify impairments for the nine months ended September&#160;30, 2023 and for the three and nine months ended September&#160;30, 2022. While there was no single event or factor in each instance, the Company considered the underlying companies&#8217; operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies&#8217; inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded a $2.9&#160;million impairment expense for the PACT Series&#160;D convertible preferred stock investment and a $10.0&#160;million impairment expense for one investment for the nine months ended September&#160;30, 2023 and $5.0&#160;million impairment expense for one investment for the three and nine months ended September&#160;30, 2022, which were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as reductions to the investment balances within other investments on the Condensed Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_OtherInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_OtherInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294010421264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">407,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">626,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Level&#160;3 financial instruments fair values are estimated using valuation models, including Monte Carlo simulations for the Company&#8217;s success payment liabilities. Monte Carlo simulations model the future movement of stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the estimated fair value of the success payment liabilities: fair value of the Company&#8217;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.26% - 5.42%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.71 - 4.22</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 4.97</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.21% - 5.42%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.71 - 6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 6.75</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#8217;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at September&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in the fair value associated with the Fred Hutch success payment liabilities of approximately $(2.1)&#160;million is recorded in other income (expense), net. The change in the fair value of approximately $(1.2)&#160;million associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received non-voting PACT Series&#160;D convertible preferred stock with a fair value of $2.9&#160;million (See Note&#160;3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In connection with the preparation of the financial statements for the nine months ended September&#160;30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment of the PACT Series&#160;D convertible preferred stock investment, resulting in $2.9&#160;million impairment expense for the nine months ended September&#160;30, 2023. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006656224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining three months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">86,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(21,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of September&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">58,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were $2.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $6.7&#160;million and $7.0&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $4.1&#160;million and $3.8&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.0&#160;and 7.8&#160;years as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted&#8209;average discount rates for operating leases were 8.5% as of both September&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $0.6 million for both the nine months ended September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $1.4 million for both the nine months ended September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining three months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">86,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(21,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of September&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">58,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were $2.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $6.7&#160;million and $7.0&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $4.1&#160;million and $3.8&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.0&#160;and 7.8&#160;years as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted&#8209;average discount rates for operating leases were 8.5% as of both September&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $0.6 million for both the nine months ended September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $1.4 million for both the nine months ended September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007036688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 10.0&#160;million shares of preferred stock with a par value of $0.0001 per share. As of September&#160;30, 2023 and December&#160;31, 2022, no shares of preferred stock were outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 500.0&#160;million shares of common stock with a par value of $0.0001 per share. As of September&#160;30, 2023 and December&#160;31, 2022, there were 251,868,968 shares and 249,567,343 shares of the Company&#8217;s common stock outstanding, respectively.</span></div>On August&#160;4, 2022, the Company entered into an Equity Distribution Agreement with Goldman Sachs &amp; Co. LLC (&#8220;Goldman Sachs&#8221;) and BofA Securities, Inc. (&#8220;BofA&#8221;, and together with Goldman Sachs, the &#8220;Agents&#8221;) with respect to an at-the-market offering program (the &#8220;Equity Distribution Agreement&#8221;). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agents shares of the Company&#8217;s common stock having an aggregate offering amount of up to $200.0&#160;million (the &#8220;Placement Shares&#8221;). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 of the Securities Act of 1933, as amended. The Company will pay commissions to the Agents of up to 3.0% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither the Company nor the Agents are obligated to sell any shares and, to date, the Company has not made any sales under the Equity Distribution Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007192256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;), which on the date of the underwriting agreement related to the Company&#8217;s IPO became effective with an initial reserve of 26,662,087 shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;5% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#8217;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2023, the Company reserved an additional 12,478,367 shares of common stock for issuance under the 2021 Plan representing 5% of the total common shares outstanding as of December&#160;31, 2022. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#8217;s board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years but may be granted with different vesting terms. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, 22,478,430 shares were available for future issuance pursuant to the 2021 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s IPO with an initial reserve of 2,470,000 shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;1% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;4,940,000 shares; provided, however, that the Company&#8217;s board of directors may act to provide a lesser increase in number of shares. The Company&#8217;s board of directors elected to reserve no additional shares under the 2021 ESPP for the year beginning January&#160;1, 2023. The Company may specify offerings with durations not more than 27&#160;months and may specify shorter purchase periods within each offering. Under the 2021 ESPP, no shares were issued for both the three months ended September&#160;30, 2023 and 2022, and 542,921 and 283,574 shares were issued for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, 3,905,099 shares were available for future issuance pursuant to the 2021 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#8209;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While no shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">24,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">51,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">63,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2023, total stock-based compensation cost related to unvested awards not yet recognized was $76.5&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.79 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">872,077&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,559,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(414,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(240,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of September&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,777,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">53,849,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.09&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">24,887&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,276,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,478,537)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(4,196,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">60,449,815</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">32,422,027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">88.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div>The weighted-average grant date fair value of options granted for the nine months ended September&#160;30, 2023 and 2022 were $1.69 per share and $4.33 per share, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006961920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include unvested RSAs, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSAs and unvested RSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007047776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#8217;s obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both September&#160;30, 2023 and December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007044048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party Transactions</a></td>
<td class="text">Related-party Transactions<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma (&#8220;Sonoma Sublease&#8221;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#8217;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both September&#160;30, 2023 and December&#160;31, 2022, there were accrued liabilities and other current liabilities of $0.5&#160;million, and as of September&#160;30, 2023 and December&#160;31, 2022, other non-current liabilities of $3.1&#160;million and $3.5&#160;million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was party to the GSK Agreement with GSK, which is a holder of more than 10% of the Company&#8217;s outstanding common stock. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. GSK terminated the </span></div>GSK Agreement effective December&#160;24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both September&#160;30, 2023 and December&#160;31, 2022. Revenue recognized in connection with the GSK agreement was zero for both the three months ended September&#160;30, 2023 and 2022, and zero and $36.3&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006961920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn November 6, 2023, the Company committed to and commenced a reduction in its workforce of approximately 25% to reduce operating costs and improve operating efficiency. The reduction in workforce is expected to be completed in the fourth quarter of 2023. In connection with this reduction in workforce, the Company estimates that it will incur charges of approximately $6 million to $7 million for severance payments, employee benefits and related costs, primarily in the fourth quarter of 2023. Substantially all of the estimated charges are expected to result in future cash expenditures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006683280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,853)<span></span>
</td>
<td class="num">$ (70,254)<span></span>
</td>
<td class="num">$ (181,702)<span></span>
</td>
<td class="num">$ (174,721)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007667072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006007904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidations</a></td>
<td class="text">All significant intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#8220;GSK&#160;Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#8220;GSK&#8221;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Concentrations of Credit Risk and Off-balance Sheet RiskThe Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-balance Sheet Risk</a></td>
<td class="text">The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007036688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Aggregate Potential Success Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007030640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Fair Value and Amortized Cost of Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">69,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">577,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,187)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">264,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">289,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">277,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">221,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">702,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">107,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">516,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">70,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value and Amortized Cost of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">69,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">577,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,187)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">264,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">289,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">277,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">221,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">702,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">107,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">516,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">70,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007317344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">249,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">68,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">168,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">407,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">576,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">626,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Estimated Fair Value of Success Payment Liability Assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.26% - 5.42%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.71 - 4.22</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 4.97</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.21% - 5.42%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.71 - 6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 6.75</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at September&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The change in the fair value associated with the Fred Hutch success payment liabilities of approximately $(2.1)&#160;million is recorded in other income (expense), net. The change in the fair value of approximately $(1.2)&#160;million associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294094488288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining three months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">86,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(21,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of September&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">58,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining three months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">86,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(21,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of September&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">58,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005294368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense by Classification</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">24,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">51,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">63,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">872,077&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,559,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(414,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(240,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of September&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,777,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">53,849,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.09&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">24,887&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,276,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,478,537)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(4,196,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">60,449,815</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">32,422,027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">88.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294011237952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Total Income Attributable to Sonoma Sublease</a></td>
<td class="text">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006871600">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 36,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (50,853)<span></span>
</td>
<td class="num">$ (70,254)<span></span>
</td>
<td class="num">$ (181,702)<span></span>
</td>
<td class="num">$ (174,721)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | GSK&#160;Agreement | Change in Collaboration and License Agreement estimate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)&#160;&#160;&#160;&#160;Including related-party revenue of zero for both the three months ended September&#160;30, 2023 and 2022, and zero and $36,299 for the nine months ended September&#160;30, 2023 and 2022, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140293996925024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,849,000<span></span>
</td>
<td class="nump">$ 41,607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,950,000<span></span>
</td>
<td class="nump">$ 121,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,853,000)<span></span>
</td>
<td class="num">$ (70,254,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (181,702,000)<span></span>
</td>
<td class="num">$ (174,721,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,923,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | GSK&#160;Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments', window );">Annual license maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments', window );">Aggregate research payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm', window );">Term of collaborative arrangement for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm', window );">Term of success payment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate', window );">Trigger period from IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering', window );">Trigger period thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability', window );">Fair value of potential success payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | GSK&#160;Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | GSK&#160;Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | GSK&#160;Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments', window );">Annual license maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments', window );">Aggregate research payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm', window );">Term of collaborative arrangement for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm', window );">Term of success payment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate', window );">Trigger period from IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering', window );">Trigger period thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability', window );">Fair value of potential success payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability', window );">Success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | GSK&#160;Agreement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments', window );">Potential milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | GSK&#160;Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | GSK&#160;Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | GSK&#160;Agreement | Maximum | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments', window );">Potential milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | GSK&#160;Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | GSK&#160;Agreement | Change in Collaboration and License Agreement estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | GSK&#160;Agreement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram', window );">Stock purchase agreement portion of transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | GSK&#160;Agreement | License | Series AA Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_StockPurchaseAgreementSharesSold', window );">Stock sold under stock purchase program (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,253,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_StockPurchaseAgreementSharesSoldPricePerShare', window );">Price per share of stock sold under stock purchase program (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_StockPurchaseAgreementFairValueOfStockPerShare', window );">Fair value per share of stock sold under stock purchase program (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other investments</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT | Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT | GSK&#160;Agreement | Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Strategic equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsResearchPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_StockPurchaseAgreementFairValueOfStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Fair Value Of Stock Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_StockPurchaseAgreementFairValueOfStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_StockPurchaseAgreementSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Shares Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_StockPurchaseAgreementSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_StockPurchaseAgreementSharesSoldPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Shares Sold, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_StockPurchaseAgreementSharesSoldPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyel_SeriesAAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140293995289552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details) - GSK&#160;Agreement<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Ten Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Ten Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Twenty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Twenty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Thirty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Thirty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Forty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Forty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fifty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fifty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_TenTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_TenTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_TwentyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_TwentyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_ThirtyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_ThirtyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_FortyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_FortyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_FiftyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_FiftyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294004092192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 286,214<span></span>
</td>
<td class="nump">$ 123,554<span></span>
</td>
<td class="nump">$ 116,311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">577,654<span></span>
</td>
<td class="nump">702,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,187)<span></span>
</td>
<td class="num">(7,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale', window );">Fair Value</a></td>
<td class="nump">576,473<span></span>
</td>
<td class="nump">694,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">264,527<span></span>
</td>
<td class="nump">107,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">289,217<span></span>
</td>
<td class="nump">516,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">22,729<span></span>
</td>
<td class="nump">70,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">576,473<span></span>
</td>
<td class="nump">694,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">249,643<span></span>
</td>
<td class="nump">277,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(492)<span></span>
</td>
<td class="num">(5,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">249,157<span></span>
</td>
<td class="nump">271,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">69,497<span></span>
</td>
<td class="nump">135,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(544)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">68,953<span></span>
</td>
<td class="nump">134,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">89,714<span></span>
</td>
<td class="nump">221,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">89,563<span></span>
</td>
<td class="nump">220,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">168,800<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 168,800<span></span>
</td>
<td class="nump">$ 67,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005850672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value of securities held in a continuous unrealized loss position for less than twelve months</a></td>
<td class="nump">$ 247.6<span></span>
</td>
<td class="nump">$ 287.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value of securities held in a continuous unrealized loss position for greater than twelve months</a></td>
<td class="nump">$ 104.9<span></span>
</td>
<td class="nump">$ 278.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maturity of marketable securities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294001892048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>entity</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>entity</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>entity</div>
</th>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">$ 32,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary', window );">Variable interest entity, number of entities company is not primary beneficiary | entity</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Variable interest entity maximum loss exposure, amount</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount', window );">Cumulative impairments of strategic investments</a></td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment | PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph b<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140293995223872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 576,473<span></span>
</td>
<td class="nump">$ 694,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">249,157<span></span>
</td>
<td class="nump">271,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">68,953<span></span>
</td>
<td class="nump">134,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,563<span></span>
</td>
<td class="nump">220,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">168,800<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">168,800<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">168,800<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">407,673<span></span>
</td>
<td class="nump">626,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">249,157<span></span>
</td>
<td class="nump">271,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">68,953<span></span>
</td>
<td class="nump">134,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,563<span></span>
</td>
<td class="nump">220,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294006061568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueOfSeriesAConvertiblePreferredStock', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">4.26<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.42<span></span>
</td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.800<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.71<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">4.22<span></span>
</td>
<td class="nump">4.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueOfSeriesAConvertiblePreferredStock', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.42<span></span>
</td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.800<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.71<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">6.00<span></span>
</td>
<td class="nump">6.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_FairValueOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the Series A convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_FairValueOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007613760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | GSK&#160;Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="num">$ (1,500)<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="num">$ (2,100)<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | GSK&#160;Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=lyel_SuccessPaymentLiabilityMember', window );">Success Payment Liabilities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=lyel_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=lyel_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294000234272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 12,923<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment | PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005866288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining three months)</a></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">11,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">12,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">12,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">35,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">86,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(21,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">64,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</a></td>
<td class="nump">6,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">58,576<span></span>
</td>
<td class="nump">$ 63,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 64,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294003973936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term of operating leases</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294008162016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,868,968<span></span>
</td>
<td class="nump">249,567,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GoldmanSachsAndBofAMember', window );">Goldman Sachs and BofA | At The Market Offering | Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering amount</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_PercentageOfCommissionFromEachSaleOfShares', window );">Percentage of commission from each sale of shares</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_PercentageOfCommissionFromEachSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission From Each Sale Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_PercentageOfCommissionFromEachSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GoldmanSachsAndBofAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GoldmanSachsAndBofAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lyel_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lyel_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyel_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyel_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005056592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total stock-based compensation cost related to unvested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period compensation cost to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 4.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,662,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Proportion of stock outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">12,478,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Increase in proportion of common shares reserved for future issuance (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,478,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,478,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">542,921<span></span>
</td>
<td class="nump">283,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Proportion of stock outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,905,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,905,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Purchase of common stock at discount (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee purchase of shares, proportion of fair value (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable', window );">Maximum number of shares to be purchased under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod', window );">Maximum offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005867008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,516<span></span>
</td>
<td class="nump">$ 19,123<span></span>
</td>
<td class="nump">$ 38,621<span></span>
</td>
<td class="nump">$ 63,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,548<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
<td class="nump">14,439<span></span>
</td>
<td class="nump">12,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,968<span></span>
</td>
<td class="nump">$ 14,681<span></span>
</td>
<td class="nump">$ 24,182<span></span>
</td>
<td class="nump">$ 51,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007585904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Restricted Stock Units (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at beginning of period (in shares) | shares</a></td>
<td class="nump">872,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares) | shares</a></td>
<td class="nump">2,559,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares) | shares</a></td>
<td class="num">(414,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited or canceled (in shares) | shares</a></td>
<td class="num">(240,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at end of period (in shares) | shares</a></td>
<td class="nump">2,777,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Value at Grant Date Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs forfeited or canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">3.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007611088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">53,849,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">12,276,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(1,478,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled or forfeited (in shares) | shares</a></td>
<td class="num">(4,196,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">60,449,815<span></span>
</td>
<td class="nump">53,849,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">32,422,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">4.63<span></span>
</td>
<td class="nump">$ 5.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding</a></td>
<td class="text">7 years 6 months 29 days<span></span>
</td>
<td class="text">7 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable</a></td>
<td class="text">6 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding | $</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 24,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable | $</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294007530096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.13%<span></span>
</td>
<td class="nump">2.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.20%<span></span>
</td>
<td class="nump">85.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005018672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">$ 29,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Minimum | Lyell Immunopharma | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lyel_LyellImmunopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lyel_LyellImmunopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294005136976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Sonoma other operating income, net</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="nump">$ 2,149<span></span>
</td>
<td class="nump">$ 3,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Sonoma other operating income, net</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sonoma sublease income</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="nump">$ 1,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140294008487712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 06, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimate of workforce reduction charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimate of workforce reduction charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>lyel-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lyel="http://lyell.com/20230930"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lyel-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">lyel:AdjustmentToRevenueRelatedToChangeInEstimateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GoldmanSachsAndBofAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyel:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyel:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lyel:LyellImmunopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-06</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="entity">
        <measure>lyel:entity</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001806952</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40502</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Lyell Immunopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">83-1300510</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">201 Haskins Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">695-0677</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">LYEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">251868968</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">286214000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">123554000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">289217000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">516598000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">11423000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">11143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">586854000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">651295000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">283000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">280000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">22729000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">70117000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherInvestments contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">32001000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">44924000</us-gaap:OtherInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">108096000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">123023000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">40603000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">43242000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">4423000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">4680000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">794989000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">937561000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">4365000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">3917000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">29652000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">28755000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <lyel:SuccessPaymentLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">1047000</lyel:SuccessPaymentLiabilitiesCurrent>
    <lyel:SuccessPaymentLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">4356000</lyel:SuccessPaymentLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">35064000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">37028000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">58576000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">63168000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">3776000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">4113000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">97416000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">104309000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-68"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-70" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-71" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="-3" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-80" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-81" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-82" unitRef="shares">251869000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-83" unitRef="shares">251869000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-84" unitRef="shares">249567000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">249567000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">1647911000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">1608306000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">-1181000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-7599000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">-949182000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">-767480000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">697573000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">833252000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">794989000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">937561000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">25000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">3000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">117000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-3" id="f-101" unitRef="usd">36297000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">43849000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">41607000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">135950000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-105" unitRef="usd">121156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">15507000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">26084000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">53816000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-109" unitRef="usd">90959000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">292000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">1251000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">2149000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">3544000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">59064000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">66440000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">187617000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">208571000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">-59039000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">-66437000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-187500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-121" unitRef="usd">-172274000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">6608000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">2251000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">16369000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">3600000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">1578000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">-1068000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">2352000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">-1047000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">12923000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">8186000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">-3817000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">5798000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">-2447000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">-50853000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">-70254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-181702000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-141" unitRef="usd">-174721000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-142" unitRef="usd">1198000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">-1645000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">6418000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="-3" id="f-145" unitRef="usd">-8373000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-49655000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">-71899000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-175284000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-149" unitRef="usd">-183094000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-158" unitRef="shares">251318000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-159" unitRef="shares">251318000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-160" unitRef="shares">248320000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-161" unitRef="shares">248320000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-162" unitRef="shares">250377000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-163" unitRef="shares">250377000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-164" unitRef="shares">246285000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-165" unitRef="shares">246285000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-167" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-3" id="f-168" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-169" unitRef="usd">36299000</us-gaap:Revenues>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-12" decimals="-3" id="f-170" unitRef="shares">251027000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-171" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-172" unitRef="usd">1637538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-173" unitRef="usd">-2379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-174" unitRef="usd">-898329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-175" unitRef="usd">736855000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-17" decimals="-3" id="f-176" unitRef="shares">646000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-18" decimals="-3" id="f-177" unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-17" decimals="-3" id="f-179" unitRef="shares">196000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-18" decimals="-3" id="f-180" unitRef="usd">-215000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">-215000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-18" decimals="-3" id="f-182" unitRef="usd">10516000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">10516000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-3" id="f-184" unitRef="usd">1198000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">1198000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-186" unitRef="usd">-50853000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">-50853000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-21" decimals="-3" id="f-188" unitRef="shares">251869000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-189" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-190" unitRef="usd">1647911000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-191" unitRef="usd">-1181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-192" unitRef="usd">-949182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-193" unitRef="usd">697573000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="-3" id="f-194" unitRef="shares">249567000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-195" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-196" unitRef="usd">1608306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-197" unitRef="usd">-7599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-198" unitRef="usd">-767480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-199" unitRef="usd">833252000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-29" decimals="-3" id="f-200" unitRef="shares">1479000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-201" unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-29" decimals="-3" id="f-203" unitRef="shares">543000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-30" decimals="-3" id="f-204" unitRef="usd">1163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">1163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-29" decimals="-3" id="f-206" unitRef="shares">280000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-30" decimals="-3" id="f-207" unitRef="usd">-334000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">-334000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-209" unitRef="usd">38621000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">38621000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-31" decimals="-3" id="f-211" unitRef="usd">6418000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">6418000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-213" unitRef="usd">-181702000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">-181702000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-21" decimals="-3" id="f-215" unitRef="shares">251869000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-216" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-217" unitRef="usd">1647911000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-218" unitRef="usd">-1181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-219" unitRef="usd">-949182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-220" unitRef="usd">697573000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-33" decimals="-3" id="f-221" unitRef="shares">247110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-222" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-223" unitRef="usd">1565197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-224" unitRef="usd">-8351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-225" unitRef="usd">-688829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-226" unitRef="usd">868042000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-38" decimals="-3" id="f-227" unitRef="shares">1375000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-39" decimals="-3" id="f-228" unitRef="usd">5127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-229" unitRef="usd">5127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-38" decimals="-3" id="f-230" unitRef="shares">105000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-39" decimals="-3" id="f-231" unitRef="usd">-367000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-6" decimals="-3" id="f-232" unitRef="usd">-367000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-38" decimals="-3" id="f-233" unitRef="shares">650000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-3" id="f-234" unitRef="usd">19123000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">19123000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-40" decimals="-3" id="f-236" unitRef="usd">-1645000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-237" unitRef="usd">-1645000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-41" decimals="-3" id="f-238" unitRef="usd">-70254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-239" unitRef="usd">-70254000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-240" unitRef="shares">249240000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-241" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-242" unitRef="usd">1589080000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-243" unitRef="usd">-9996000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-244" unitRef="usd">-759083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-245" unitRef="usd">820026000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-47" decimals="-3" id="f-246" unitRef="shares">242738000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-247" unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-248" unitRef="usd">1515748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-249" unitRef="usd">-1623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-250" unitRef="usd">-584362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-251" unitRef="usd">929787000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-52" decimals="-3" id="f-252" unitRef="shares">3513000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-52" decimals="-3" id="f-253" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-53" decimals="-3" id="f-254" unitRef="usd">9251000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-255" unitRef="usd">9252000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-52" decimals="-3" id="f-256" unitRef="shares">284000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-53" decimals="-3" id="f-257" unitRef="usd">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-52" decimals="-3" id="f-259" unitRef="shares">105000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-53" decimals="-3" id="f-260" unitRef="usd">-367000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-7" decimals="-3" id="f-261" unitRef="usd">-367000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-52" decimals="-3" id="f-262" unitRef="shares">2600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-53" decimals="-3" id="f-263" unitRef="usd">63561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">63561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-54" decimals="-3" id="f-265" unitRef="usd">-8373000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">-8373000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-55" decimals="-3" id="f-267" unitRef="usd">-174721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">-174721000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-269" unitRef="shares">249240000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-270" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-271" unitRef="usd">1589080000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-272" unitRef="usd">-9996000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-273" unitRef="usd">-759083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-274" unitRef="usd">820026000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">-181702000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-276" unitRef="usd">-174721000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">38621000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">63561000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">15193000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">12979000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">12923000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">6212000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">-278000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <lyel:FairValueAdjustmentOfSuccessPaymentLiabilities contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">-3309000</lyel:FairValueAdjustmentOfSuccessPaymentLiabilities>
    <lyel:FairValueAdjustmentOfSuccessPaymentLiabilities contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">2177000</lyel:FairValueAdjustmentOfSuccessPaymentLiabilities>
    <lyel:NonCashLeaseIncomeExpense contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">1344000</lyel:NonCashLeaseIncomeExpense>
    <lyel:NonCashLeaseIncomeExpense contextRef="c-7" decimals="-3" id="f-288" unitRef="usd">1104000</lyel:NonCashLeaseIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">-1072000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">-97000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">1067000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">23000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">672000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">1039000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">1193000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">1020000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">-5836000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-300" unitRef="usd">-36299000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-302" unitRef="usd">3331000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">-337000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">-339000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">-123059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-306" unitRef="usd">-129288000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">2661000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-308" unitRef="usd">19694000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">220095000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-7" decimals="-3" id="f-310" unitRef="usd">346647000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">507494000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-7" decimals="-3" id="f-312" unitRef="usd">308153000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">284738000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-314" unitRef="usd">-58188000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">155000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-316" unitRef="usd">9252000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">1163000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-7" decimals="-3" id="f-318" unitRef="usd">887000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">334000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-320" unitRef="usd">367000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-322" unitRef="usd">9772000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">162663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-324" unitRef="usd">-177704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-325" unitRef="usd">123834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-51" decimals="-3" id="f-326" unitRef="usd">294294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">286497000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-46" decimals="-3" id="f-328" unitRef="usd">116590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">286214000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-46" decimals="-3" id="f-330" unitRef="usd">116311000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">283000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-46" decimals="-3" id="f-332" unitRef="usd">279000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-333" unitRef="usd">286497000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-46" decimals="-3" id="f-334" unitRef="usd">116590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">8030000</lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-7" decimals="-3" id="f-336" unitRef="usd">8136000</lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">0</lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
    <lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances contextRef="c-7" decimals="-3" id="f-338" unitRef="usd">3238000</lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">2000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-340" unitRef="usd">3563000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-341">Organization&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lyell Immunopharma, Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware in June 2018. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ex&#160;vivo&lt;/span&gt; genetic and epigenetic T&#x2011;cell reprogramming technologies. The Company&#x2019;s primary activities since incorporation have been to develop T&#x2011;cell therapies, perform research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions, execute clinical trials, raise capital and provide general and administrative support for these activities.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-342">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#x2019;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#x2019;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of September&#160;30, 2023 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#x201c;GSK&#160;Agreement&#x201d;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#x201c;GSK&#x201d;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#x2019;s basic and diluted net loss per common share for the nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#x2019;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#x2011;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-343">Basis of PresentationThe accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-344">All significant intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-345">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#x201c;GSK&#160;Agreement&#x201d;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#x201c;GSK&#x201d;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:Revenues contextRef="c-56" decimals="-5" id="f-346" unitRef="usd">35300000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-5" id="f-347" unitRef="usd">35300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-56"
      decimals="2"
      id="f-348"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-56"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-350">Concentrations of Credit Risk and Off-balance Sheet RiskThe Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in a bank account and is used as collateral associated with the Company&#x2019;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#x2011;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock contextRef="c-1" id="f-351">The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <lyel:SignificantAccountingPoliciesPolicyTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</lyel:SignificantAccountingPoliciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-354">License, Collaboration and Success Payment Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fred Hutch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#x201c;Fred Hutch&#x201d;) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#x201c;CARs&#x201d;) and/or T-cell receptors (&#x201c;TCRs&#x201d;), subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay Fred Hutch annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#x201c;Fred Hutch Collaboration Agreement&#x201d;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $12.0&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a six-year term. The Company incurred $0.3&#160;million and $0.4&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended September&#160;30, 2023 and 2022, respectively, and $0.7&#160;million and $1.4&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Success Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#x2019;s common stock relative to the original $1.83 per share issuance price of the Company&#x2019;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#x2019;s common stock in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). The aggregate success payments to Fred Hutch are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payments will be owed if the per share fair value of the Company&#x2019;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#x2019;s IPO and each two-year anniversary of the Company&#x2019;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of September&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#x2019;s common stock was below the price required for payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payment liability was estimated at fair value at inception and at each subsequent reporting period and the associated expense was accreted over the service period of the success payment obligations as research and development expense through 2022. As of December&#160;31, 2022, the Company&#x2019;s associated success payment liability was fully accreted to fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and nine months ended September&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other income (expense), net, as the requisite service obligation had been met. The success payment liability was $0.4&#160;million and $2.5&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized a gain of $1.5&#160;million and expense of $1.4&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and a gain of $2.1&#160;million and expense of $0.8&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stanford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#x201c;Stanford&#x201d;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments to Stanford of up to a maximum of $3.7&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $2.5&#160;million collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#x2011;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#x201c;Stanford Collaboration Agreement&#x201d;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a four-year term. The Company is committed to fund aggregate research performed by Stanford of $12.0&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $0.8&#160;million in expense in connection with the Stanford Collaboration Agreement for both the three months ended September&#160;30, 2023 and 2022, respectively, and $2.3&#160;million for both the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Success Payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#x2019;s common stock relative to the original $1.83 issuance price of the Company&#x2019;s Series&#160;A convertible preferred stock, which converted into an equal number of shares of the Company&#x2019;s common stock in connection with the Company&#x2019;s IPO. The aggregate success payments to Stanford are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payments will be owed if the per share fair value of the Company&#x2019;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#x2019;s IPO and each two-year anniversary of the Company&#x2019;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of September&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#x2019;s common stock was below the price required for payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of the success payments to Stanford as of September&#160;30, 2023 and December&#160;31, 2022 were $0.8&#160;million and $3.3&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $0.6&#160;million and $1.9&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized a gain of $1.2&#160;million and expense of $1.0&#160;million for the three months ended September&#160;30, 2023 and 2022, respectively, and a gain of $1.2&#160;million and expense of $1.4&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into the GSK Agreement with GSK for potential T&#x2011;cell therapies that apply the Company&#x2019;s platform technologies and cell therapy innovations with TCRs or CARs under distinct collaboration programs. The GSK Agreement defined two initial collaboration targets, LYL331 and LYL132, and allowed GSK to nominate seven additional targets through July 2024, though no additional targets were nominated over the life of the GSK Agreement. The Company was expected to perform research and development services for each selected target up until a defined point (the &#x201c;GSK Option Point&#x201d;), at which time GSK would decide whether or not to exercise an option to obtain a license from the Company (&#x201c;License Option&#x201d;) and take over the future development and commercialization. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, GSK exercised the License Option on LYL331 (NY-ESO-1 TCR with c-Jun) and assumed sole responsibility for future development and commercialization of the program at its own cost and expense. The investigational new drug (&#x201c;IND&#x201d;) application for LYL132 was cleared in January 2022, though no patients were treated, and the IND for LYL331 was not submitted to the U.S. Food and Drug Administration. GSK terminated the GSK Agreement effective December&#160;24, 2022, and Lyell has also discontinued any further work on these programs. There are no future performance obligations associated with the GSK Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a non-refundable upfront payment of $45.0&#160;million under the GSK Agreement. In connection with the GSK Agreement, in May 2019, the Company also entered into a stock purchase agreement with GSK, pursuant to which the Company agreed to sell 30,253,189 shares of Series&#160;AA convertible preferred stock at a price of $6.78 per share, which was above the issuance date estimated fair value of $4.84 per share. The difference between the per share values resulted in $58.6&#160;million additional deemed consideration, bringing the total upfront consideration of the GSK Agreement to $103.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The GSK Agreement was deemed to be within the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;)&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, because GSK engaged the Company to initially provide research and development services, which were outputs of its ongoing activities, in exchange for consideration. In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the GSK Agreement due to GSK and the Company mutually agreeing to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#x2019;s basic and diluted net loss per common share for the nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no revenue related to the research and development services related to the two initial targets for both the three months ended September&#160;30, 2023 and 2022, and zero and $36.3&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. As of September&#160;30, 2023 and December&#160;31, 2022, there were no contract assets or contract liabilities related to the license contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PACT&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a commitment agreement (&#x201c;PACT Commitment Agreement&#x201d;) with PACT Pharma, Inc. (&#x201c;PACT&#x201d;) to jointly develop and test an anti-cancer T-cell therapy against solid tumors, in connection with which it also purchased PACT Series&#160;C-1 convertible preferred stock, which was recorded in other investments at $36.4&#160;million in the Company&#x2019;s Condensed Consolidated Balance Sheet. In December 2021, the Company recorded a $36.4&#160;million impairment expense for its investment in PACT. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company filed a demand for arbitration seeking, among other things, rescission of the PACT Commitment Agreement. On October&#160;1, 2022, the Company entered into a settlement agreement to resolve its &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding legal dispute with PACT, pursuant to which PACT issued shares of PACT&#x2019;s Series&#160;D convertible preferred stock to the Company in exchange for the Company&#x2019;s tender of its PACT Series&#160;C-1 convertible preferred stock. The settlement agreement also included the termination of the commitment agreement with PACT. The Company recorded a gain of $2.9&#160;million in October 2022 for the estimated fair value of the PACT Series&#160;D convertible preferred stock, which was included in other investments in the Company&#x2019;s Condensed Consolidated Balance Sheet as of December&#160;31, 2022. In connection with the preparation of the financial statements for the nine months ended September&#160;30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment of the PACT Series&#160;D convertible preferred stock investment, resulting in $2.9&#160;million impairment expense for the nine months ended September&#160;30, 2023. See Note&#160;5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details regarding the PACT investment impairment.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments contextRef="c-57" decimals="-3" id="f-355" unitRef="usd">50000</lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchPayments contextRef="c-57" decimals="-5" id="f-356" unitRef="usd">12000000</lyel:CollaborativeArrangementRightsAndObligationsResearchPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchTerm contextRef="c-57" id="f-357">P6Y</lyel:CollaborativeArrangementRightsAndObligationsResearchTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-58" decimals="-5" id="f-358" unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-59" decimals="-5" id="f-359" unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-60" decimals="-5" id="f-360" unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-61" decimals="-5" id="f-361" unitRef="usd">1400000</us-gaap:ResearchAndDevelopmentExpense>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-62" decimals="0" id="f-362" unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-63" decimals="0" id="f-363" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-64"
      decimals="2"
      id="f-364"
      unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-63" decimals="-5" id="f-365" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-63" decimals="0" id="f-366" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-62" decimals="-5" id="f-367" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-62"
      decimals="2"
      id="f-368"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-63" decimals="-5" id="f-369" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-63"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm contextRef="c-57" id="f-371">P9Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-65"
      decimals="INF"
      id="f-373"
      unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-66"
      decimals="INF"
      id="f-374"
      unitRef="number">20</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-67"
      decimals="INF"
      id="f-375"
      unitRef="number">30</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-68"
      decimals="INF"
      id="f-376"
      unitRef="number">40</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-69"
      decimals="INF"
      id="f-377"
      unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-65"
      decimals="2"
      id="f-378"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-66"
      decimals="2"
      id="f-379"
      unitRef="usdPerShare">36.58</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-67"
      decimals="2"
      id="f-380"
      unitRef="usdPerShare">54.86</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-68"
      decimals="2"
      id="f-381"
      unitRef="usdPerShare">73.15</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-69"
      decimals="2"
      id="f-382"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-65" decimals="-6" id="f-383" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-66" decimals="-6" id="f-384" unitRef="usd">40000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-67" decimals="-6" id="f-385" unitRef="usd">90000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-68" decimals="-6" id="f-386" unitRef="usd">140000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-69" decimals="-6" id="f-387" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate contextRef="c-57" id="f-388">P1Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering contextRef="c-57" id="f-389">P2Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-70" decimals="INF" id="f-390" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-70" decimals="-5" id="f-391" unitRef="usd">400000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-71" decimals="-5" id="f-392" unitRef="usd">2500000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-58" decimals="-5" id="f-393" unitRef="usd">-1500000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-59" decimals="-5" id="f-394" unitRef="usd">1400000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-60" decimals="-5" id="f-395" unitRef="usd">-2100000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-61" decimals="-5" id="f-396" unitRef="usd">800000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments contextRef="c-72" decimals="-3" id="f-397" unitRef="usd">50000</lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments contextRef="c-73" decimals="-5" id="f-398" unitRef="usd">3700000</lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments contextRef="c-74" decimals="-5" id="f-399" unitRef="usd">2500000</lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchTerm contextRef="c-75" id="f-400">P4Y</lyel:CollaborativeArrangementRightsAndObligationsResearchTerm>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchPayments contextRef="c-75" decimals="-5" id="f-401" unitRef="usd">12000000</lyel:CollaborativeArrangementRightsAndObligationsResearchPayments>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-76" decimals="-5" id="f-402" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-77" decimals="-5" id="f-403" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-78" decimals="-5" id="f-404" unitRef="usd">2300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-79" decimals="-5" id="f-405" unitRef="usd">2300000</us-gaap:ResearchAndDevelopmentExpense>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-80" decimals="0" id="f-406" unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-81" decimals="0" id="f-407" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-82"
      decimals="2"
      id="f-408"
      unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-81" decimals="-5" id="f-409" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-81" decimals="0" id="f-410" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-80" decimals="-5" id="f-411" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-80"
      decimals="2"
      id="f-412"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-81" decimals="-5" id="f-413" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-81"
      decimals="2"
      id="f-414"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm contextRef="c-75" id="f-415">P9Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-83"
      decimals="INF"
      id="f-416"
      unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-84"
      decimals="INF"
      id="f-417"
      unitRef="number">20</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-85"
      decimals="INF"
      id="f-418"
      unitRef="number">30</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-86"
      decimals="INF"
      id="f-419"
      unitRef="number">40</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-87"
      decimals="INF"
      id="f-420"
      unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-83"
      decimals="2"
      id="f-421"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-84"
      decimals="2"
      id="f-422"
      unitRef="usdPerShare">36.58</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-85"
      decimals="2"
      id="f-423"
      unitRef="usdPerShare">54.86</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-86"
      decimals="2"
      id="f-424"
      unitRef="usdPerShare">73.15</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-87"
      decimals="2"
      id="f-425"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-83" decimals="-6" id="f-426" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-84" decimals="-6" id="f-427" unitRef="usd">40000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-85" decimals="-6" id="f-428" unitRef="usd">90000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-86" decimals="-6" id="f-429" unitRef="usd">140000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-87" decimals="-6" id="f-430" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate contextRef="c-75" id="f-431">P1Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering contextRef="c-75" id="f-432">P2Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-88" decimals="INF" id="f-433" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-88" decimals="-5" id="f-434" unitRef="usd">800000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-89" decimals="-5" id="f-435" unitRef="usd">3300000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability contextRef="c-88" decimals="-5" id="f-436" unitRef="usd">600000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability contextRef="c-89" decimals="-5" id="f-437" unitRef="usd">1900000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-77" decimals="-5" id="f-438" unitRef="usd">-1200000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-76" decimals="-5" id="f-439" unitRef="usd">1000000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-78" decimals="-5" id="f-440" unitRef="usd">-1200000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-79" decimals="-5" id="f-441" unitRef="usd">1400000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <us-gaap:ContractWithCustomerLiability contextRef="c-90" decimals="-5" id="f-442" unitRef="usd">45000000</us-gaap:ContractWithCustomerLiability>
    <lyel:StockPurchaseAgreementSharesSold
      contextRef="c-91"
      decimals="INF"
      id="f-443"
      unitRef="shares">30253189</lyel:StockPurchaseAgreementSharesSold>
    <lyel:StockPurchaseAgreementSharesSoldPricePerShare
      contextRef="c-91"
      decimals="2"
      id="f-444"
      unitRef="usdPerShare">6.78</lyel:StockPurchaseAgreementSharesSoldPricePerShare>
    <lyel:StockPurchaseAgreementFairValueOfStockPerShare
      contextRef="c-92"
      decimals="2"
      id="f-445"
      unitRef="usdPerShare">4.84</lyel:StockPurchaseAgreementFairValueOfStockPerShare>
    <lyel:RevenueRemainingPerformanceObligationAmountStockPurchaseProgram contextRef="c-90" decimals="-5" id="f-446" unitRef="usd">58600000</lyel:RevenueRemainingPerformanceObligationAmountStockPurchaseProgram>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-90" decimals="-5" id="f-447" unitRef="usd">103600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-5" id="f-448" unitRef="usd">35300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-5" id="f-449" unitRef="usd">35300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-56"
      decimals="2"
      id="f-450"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-56"
      decimals="2"
      id="f-451"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-5" id="f-452" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-5" id="f-453" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-5" id="f-454" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-5" id="f-455" unitRef="usd">36300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-97" decimals="-5" id="f-456" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-97" decimals="-5" id="f-457" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-98" decimals="-5" id="f-458" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-98" decimals="-5" id="f-459" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-99" decimals="-5" id="f-460" unitRef="usd">36400000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-100" decimals="-5" id="f-461" unitRef="usd">36400000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-101" decimals="-5" id="f-462" unitRef="usd">2900000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-102" decimals="-5" id="f-463" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-464">Cash Equivalents and Marketable Securities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;69,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;577,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;264,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;289,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;277,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(5,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;135,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;221,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;702,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;107,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;516,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;70,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of securities held by the Company in an unrealized loss position for less than 12&#160;months were $247.6&#160;million and $287.8&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The fair values of securities held by the Company in an unrealized loss position for greater than 12&#160;months were $104.9&#160;million and $278.7&#160;million as of September&#160;30, 2023 and December&#160;31, 2022, respectively. As of September&#160;30, 2023 and December&#160;31, 2022, all of the Company&#x2019;s marketable securities had a maturity date of two years or less, were available for use and were classified as available&#x2011;for&#x2011;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both September&#160;30, 2023 and &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three and nine months ended September&#160;30, 2023 and 2022 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three and nine months ended September&#160;30, 2023 and 2022 were also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See Note&#160;6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information regarding cash equivalents and marketable securities.&lt;/span&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;69,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;577,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;264,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;289,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;277,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(5,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;135,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;221,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;702,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;107,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;516,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;70,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;69,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;577,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;264,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;289,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;277,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(5,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;135,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;221,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;702,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;107,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;516,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;70,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-103" decimals="-3" id="f-467" unitRef="usd">168800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-468" unitRef="usd">168800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-104" decimals="-3" id="f-469" unitRef="usd">249643000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-104" decimals="-3" id="f-470" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-104" decimals="-3" id="f-471" unitRef="usd">492000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-104" decimals="-3" id="f-472" unitRef="usd">249157000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-105" decimals="-3" id="f-473" unitRef="usd">69497000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-105" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-105" decimals="-3" id="f-475" unitRef="usd">544000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="-3" id="f-476" unitRef="usd">68953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-106" decimals="-3" id="f-477" unitRef="usd">89714000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-106" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-106" decimals="-3" id="f-479" unitRef="usd">151000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-3" id="f-480" unitRef="usd">89563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost contextRef="c-3" decimals="-3" id="f-481" unitRef="usd">577654000</lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-482" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-483" unitRef="usd">1187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-3" decimals="-3" id="f-484" unitRef="usd">576473000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <lyel:CashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-485" unitRef="usd">264527000</lyel:CashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-486" unitRef="usd">289217000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">22729000</us-gaap:MarketableSecuritiesNoncurrent>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-3" decimals="-3" id="f-488" unitRef="usd">576473000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-107" decimals="-3" id="f-489" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-490" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-108" decimals="-3" id="f-491" unitRef="usd">277056000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-108" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-108" decimals="-3" id="f-493" unitRef="usd">5257000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="-3" id="f-494" unitRef="usd">271799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-109" decimals="-3" id="f-495" unitRef="usd">135460000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-109" decimals="-3" id="f-496" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-109" decimals="-3" id="f-497" unitRef="usd">1416000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-3" id="f-498" unitRef="usd">134045000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-110" decimals="-3" id="f-499" unitRef="usd">221608000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-110" decimals="-3" id="f-500" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-110" decimals="-3" id="f-501" unitRef="usd">930000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-502" unitRef="usd">220681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost contextRef="c-4" decimals="-3" id="f-503" unitRef="usd">702094000</lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-504" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-505" unitRef="usd">7603000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-4" decimals="-3" id="f-506" unitRef="usd">694495000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <lyel:CashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-507" unitRef="usd">107780000</lyel:CashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-508" unitRef="usd">516598000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-509" unitRef="usd">70117000</us-gaap:MarketableSecuritiesNoncurrent>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-4" decimals="-3" id="f-510" unitRef="usd">694495000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-5" id="f-511" unitRef="usd">247600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-5" id="f-512" unitRef="usd">287800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-5" id="f-513" unitRef="usd">104900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-5" id="f-514" unitRef="usd">278700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-111" id="f-515">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-112" id="f-516">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <lyel:OtherInvestmentsTextBlock contextRef="c-1" id="f-517">Other Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company makes minority ownership strategic investments. As of September&#160;30, 2023 and December&#160;31, 2022, the aggregate carrying amounts of the Company&#x2019;s strategic investments in non-publicly traded companies were $32.0&#160;million and $44.9&#160;million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of September&#160;30, 2023 and December&#160;31, 2022 were $17.9&#160;million and $5.0&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a part of the acquisition of each of the Company&#x2019;s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of September&#160;30, 2023 and December&#160;31, 2022, the Company held an interest in two entities that were concluded to be variable interests for which the Company was not the primary beneficiary. As of September&#160;30, 2023 and December&#160;31, 2022, the carrying value and maximum exposure to loss of the Company&#x2019;s variable interests were $13.0&#160;million and $15.9&#160;million, respectively, which is recorded in other investments in the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company received shares of PACT&#x2019;s Series&#160;D non-voting convertible preferred stock (See Note&#160;3, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company recognized its investment in PACT preferred stock at its estimated fair value of $2.9&#160;million on October&#160;1, 2022, which was included in the Company&#x2019;s Condensed Consolidated Balance Sheet within other investments as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;For the nine months ended September&#160;30, 2023 and the three and nine months ended September&#160;30, 2022, the Company performed qualitative assessments of potential indicators of impairment and determined that indicators existed for certain of its other investments. The Company did not identify any impairments for the three months ended September&#160;30, 2023. The Company did identify impairments for the nine months ended September&#160;30, 2023 and for the three and nine months ended September&#160;30, 2022. While there was no single event or factor in each instance, the Company considered the underlying companies&#x2019; operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies&#x2019; inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded a $2.9&#160;million impairment expense for the PACT Series&#160;D convertible preferred stock investment and a $10.0&#160;million impairment expense for one investment for the nine months ended September&#160;30, 2023 and $5.0&#160;million impairment expense for one investment for the three and nine months ended September&#160;30, 2022, which were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as reductions to the investment balances within other investments on the Condensed Consolidated Balance Sheets.</lyel:OtherInvestmentsTextBlock>
    <us-gaap:OtherInvestments contextRef="c-3" decimals="-5" id="f-518" unitRef="usd">32000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-5" id="f-519" unitRef="usd">44900000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-113" decimals="-5" id="f-520" unitRef="usd">17900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-114" decimals="-5" id="f-521" unitRef="usd">5000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary contextRef="c-3" decimals="INF" id="f-522" unitRef="entity">2</lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary>
    <lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary contextRef="c-4" decimals="INF" id="f-523" unitRef="entity">2</lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary>
    <us-gaap:OtherInvestments contextRef="c-115" decimals="-5" id="f-524" unitRef="usd">13000000</us-gaap:OtherInvestments>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-3" decimals="-5" id="f-525" unitRef="usd">13000000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-4" decimals="-5" id="f-526" unitRef="usd">15900000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:OtherInvestments contextRef="c-116" decimals="-5" id="f-527" unitRef="usd">15900000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-117" decimals="-5" id="f-528" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-102" decimals="-5" id="f-529" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-118" decimals="-5" id="f-530" unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-119" decimals="-5" id="f-531" unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-120" decimals="-5" id="f-532" unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-533">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;407,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;626,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level&#160;3 financial instruments fair values are estimated using valuation models, including Monte Carlo simulations for the Company&#x2019;s success payment liabilities. Monte Carlo simulations model the future movement of stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the estimated fair value of the success payment liabilities: fair value of the Company&#x2019;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.26% - 5.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.71 - 4.22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 4.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.21% - 5.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.71 - 6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 6.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#x2019;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(3,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The change in the fair value associated with the Fred Hutch success payment liabilities of approximately $(2.1)&#160;million is recorded in other income (expense), net. The change in the fair value of approximately $(1.2)&#160;million associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company received non-voting PACT Series&#160;D convertible preferred stock with a fair value of $2.9&#160;million (See Note&#160;3, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In connection with the preparation of the financial statements for the nine months ended September&#160;30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment of the PACT Series&#160;D convertible preferred stock investment, resulting in $2.9&#160;million impairment expense for the nine months ended September&#160;30, 2023. See Note&#160;5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details regarding the PACT investment impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-534">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;249,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;68,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;168,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;407,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;576,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;626,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-535" unitRef="usd">168800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-537" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-538" unitRef="usd">168800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="-3" id="f-539" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-3" id="f-540" unitRef="usd">249157000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-3" id="f-541" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-104" decimals="-3" id="f-542" unitRef="usd">249157000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-127" decimals="-3" id="f-543" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-128" decimals="-3" id="f-544" unitRef="usd">68953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-129" decimals="-3" id="f-545" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="-3" id="f-546" unitRef="usd">68953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-130" decimals="-3" id="f-547" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-131" decimals="-3" id="f-548" unitRef="usd">89563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-132" decimals="-3" id="f-549" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-3" id="f-550" unitRef="usd">89563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-551" unitRef="usd">168800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-134" decimals="-3" id="f-552" unitRef="usd">407673000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-553" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-554" unitRef="usd">576473000</us-gaap:AssetsFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-133" decimals="-3" id="f-555" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-134" decimals="-3" id="f-556" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-135" decimals="-3" id="f-557" unitRef="usd">1047000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-558" unitRef="usd">1047000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-133" decimals="-3" id="f-559" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-134" decimals="-3" id="f-560" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-135" decimals="-3" id="f-561" unitRef="usd">1047000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-562" unitRef="usd">1047000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-563" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-137" decimals="-3" id="f-564" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-138" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-566" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-3" id="f-568" unitRef="usd">271799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="-3" id="f-570" unitRef="usd">271799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-3" id="f-571" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="-3" id="f-572" unitRef="usd">134045000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-144" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-3" id="f-574" unitRef="usd">134045000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-3" id="f-575" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-146" decimals="-3" id="f-576" unitRef="usd">220681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-147" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-578" unitRef="usd">220681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-148" decimals="-3" id="f-579" unitRef="usd">67970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-149" decimals="-3" id="f-580" unitRef="usd">626525000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">694495000</us-gaap:AssetsFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-148" decimals="-3" id="f-583" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-149" decimals="-3" id="f-584" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-150" decimals="-3" id="f-585" unitRef="usd">4356000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-586" unitRef="usd">4356000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-148" decimals="-3" id="f-587" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-149" decimals="-3" id="f-588" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-150" decimals="-3" id="f-589" unitRef="usd">4356000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-590" unitRef="usd">4356000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-591">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.26% - 5.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.71 - 4.22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 4.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.21% - 5.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.71 - 6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 6.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-151"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">1.47</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-152"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">3.47</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-153" decimals="4" id="f-594" unitRef="number">4.26</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-154" decimals="4" id="f-595" unitRef="number">5.42</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-155" decimals="4" id="f-596" unitRef="number">3.58</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-156" decimals="4" id="f-597" unitRef="number">4.65</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-157" decimals="3" id="f-598" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-158" decimals="3" id="f-599" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-159" decimals="2" id="f-600" unitRef="number">0.71</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-160" decimals="2" id="f-601" unitRef="number">4.22</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-161" decimals="2" id="f-602" unitRef="number">0.46</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-162" decimals="2" id="f-603" unitRef="number">4.97</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-163"
      decimals="2"
      id="f-604"
      unitRef="usdPerShare">1.47</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-164"
      decimals="2"
      id="f-605"
      unitRef="usdPerShare">3.47</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-165" decimals="4" id="f-606" unitRef="number">4.21</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-166" decimals="4" id="f-607" unitRef="number">5.42</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-167" decimals="4" id="f-608" unitRef="number">3.58</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-168" decimals="4" id="f-609" unitRef="number">4.65</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-169" decimals="3" id="f-610" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-170" decimals="3" id="f-611" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-171" decimals="2" id="f-612" unitRef="number">0.71</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-172" decimals="2" id="f-613" unitRef="number">6.00</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-173" decimals="2" id="f-614" unitRef="number">0.46</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-174" decimals="2" id="f-615" unitRef="number">6.75</lyel:SuccessPaymentLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-616">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(3,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The change in the fair value associated with the Fred Hutch success payment liabilities of approximately $(2.1)&#160;million is recorded in other income (expense), net. The change in the fair value of approximately $(1.2)&#160;million associated with the Stanford success payment liabilities is recorded as research and development expenses. (See Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-175" decimals="-3" id="f-617" unitRef="usd">4356000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-176" decimals="-3" id="f-618" unitRef="usd">-3309000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-177" decimals="-3" id="f-619" unitRef="usd">1047000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-60" decimals="-5" id="f-620" unitRef="usd">-2100000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-78" decimals="-5" id="f-621" unitRef="usd">-1200000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-178" decimals="-5" id="f-622" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-102" decimals="-5" id="f-623" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-624">LeasesThe Company&#x2019;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;86,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(21,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;58,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for all operating leases were $2.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $6.7&#160;million and $7.0&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and nine months ended September&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $4.1&#160;million and $3.8&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.0&#160;and 7.8&#160;years as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted&#x2011;average discount rates for operating leases were 8.5% as of both September&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $0.6 million for both the nine months ended September&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#x201c;Sonoma&#x201d;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $1.4 million for both the nine months ended September&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c-1" id="f-625">LeasesThe Company&#x2019;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;86,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(21,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;58,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for all operating leases were $2.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $6.7&#160;million and $7.0&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and nine months ended September&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.3&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $4.1&#160;million and $3.8&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.0&#160;and 7.8&#160;years as of September&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted&#x2011;average discount rates for operating leases were 8.5% as of both September&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $0.6 million for both the nine months ended September&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#x201c;Sonoma&#x201d;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended September&#160;30, 2023 and 2022, and $1.4 million for both the nine months ended September&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-626">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;86,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(21,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;58,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <lyel:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-627">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of September&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;86,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(21,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;58,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;64,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lyel:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-628" unitRef="usd">2815000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-629" unitRef="usd">11347000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-630" unitRef="usd">11859000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-631" unitRef="usd">12209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-632" unitRef="usd">12569000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-633" unitRef="usd">35525000</lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-634" unitRef="usd">86324000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-635" unitRef="usd">21687000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-636" unitRef="usd">64637000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-637" unitRef="usd">6061000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-638" unitRef="usd">58576000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-639" unitRef="usd">64637000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-5" id="f-640" unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-5" id="f-641" unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-642" unitRef="usd">6700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-5" id="f-643" unitRef="usd">7000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-5" id="f-644" unitRef="usd">1300000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-5" id="f-645" unitRef="usd">1300000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-5" id="f-646" unitRef="usd">4100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-5" id="f-647" unitRef="usd">3800000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-648">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-649">P7Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-650" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-651" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:NetRentableArea contextRef="c-179" decimals="-3" id="f-652" unitRef="sqft">11000</us-gaap:NetRentableArea>
    <us-gaap:SubleaseIncome contextRef="c-180" decimals="-5" id="f-653" unitRef="usd">200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-181" decimals="-5" id="f-654" unitRef="usd">200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-182" decimals="-5" id="f-655" unitRef="usd">600000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-183" decimals="-5" id="f-656" unitRef="usd">600000</us-gaap:SubleaseIncome>
    <us-gaap:NetRentableArea contextRef="c-184" decimals="-3" id="f-657" unitRef="sqft">18000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements contextRef="c-185" decimals="-5" id="f-658" unitRef="usd">4600000</us-gaap:TenantImprovements>
    <us-gaap:SubleaseIncome contextRef="c-186" decimals="-5" id="f-659" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-187" decimals="-5" id="f-660" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-188" decimals="-5" id="f-661" unitRef="usd">1400000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-189" decimals="-5" id="f-662" unitRef="usd">1400000</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-663">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 10.0&#160;million shares of preferred stock with a par value of $0.0001 per share. As of September&#160;30, 2023 and December&#160;31, 2022, no shares of preferred stock were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 500.0&#160;million shares of common stock with a par value of $0.0001 per share. As of September&#160;30, 2023 and December&#160;31, 2022, there were 251,868,968 shares and 249,567,343 shares of the Company&#x2019;s common stock outstanding, respectively.&lt;/span&gt;&lt;/div&gt;On August&#160;4, 2022, the Company entered into an Equity Distribution Agreement with Goldman Sachs &amp;amp; Co. LLC (&#x201c;Goldman Sachs&#x201d;) and BofA Securities, Inc. (&#x201c;BofA&#x201d;, and together with Goldman Sachs, the &#x201c;Agents&#x201d;) with respect to an at-the-market offering program (the &#x201c;Equity Distribution Agreement&#x201d;). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agents shares of the Company&#x2019;s common stock having an aggregate offering amount of up to $200.0&#160;million (the &#x201c;Placement Shares&#x201d;). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule&#160;415 of the Securities Act of 1933, as amended. The Company will pay commissions to the Agents of up to 3.0% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither the Company nor the Agents are obligated to sell any shares and, to date, the Company has not made any sales under the Equity Distribution Agreement.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-664" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-665"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-666" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-667" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-668" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-669"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-670" unitRef="shares">251868968</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-671" unitRef="shares">249567343</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-190" decimals="INF" id="f-672" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <lyel:PercentageOfCommissionFromEachSaleOfShares
      contextRef="c-190"
      decimals="INF"
      id="f-673"
      unitRef="number">0.030</lyel:PercentageOfCommissionFromEachSaleOfShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-674">Stock-based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;), which on the date of the underwriting agreement related to the Company&#x2019;s IPO became effective with an initial reserve of 26,662,087 shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#x201c;2018 Plan&#x201d;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;5% of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#x2019;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2023, the Company reserved an additional 12,478,367 shares of common stock for issuance under the 2021 Plan representing 5% of the total common shares outstanding as of December&#160;31, 2022. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#x2019;s board of directors or by a committee authorized by the Company&#x2019;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years but may be granted with different vesting terms. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, 22,478,430 shares were available for future issuance pursuant to the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#x201c;2021 ESPP&#x201d;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#x2019;s IPO with an initial reserve of 2,470,000 shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;1% of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;4,940,000 shares; provided, however, that the Company&#x2019;s board of directors may act to provide a lesser increase in number of shares. The Company&#x2019;s board of directors elected to reserve no additional shares under the 2021 ESPP for the year beginning January&#160;1, 2023. The Company may specify offerings with durations not more than 27&#160;months and may specify shorter purchase periods within each offering. Under the 2021 ESPP, no shares were issued for both the three months ended September&#160;30, 2023 and 2022, and 542,921 and 283,574 shares were issued for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, 3,905,099 shares were available for future issuance pursuant to the 2021 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#x2011;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#x2019;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While no shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;14,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;14,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;24,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;51,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;19,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;63,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2023, total stock-based compensation cost related to unvested awards not yet recognized was $76.5&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.79 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;872,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,559,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(414,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(240,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,777,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;53,849,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;24,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,276,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,478,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(4,196,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;60,449,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options exercisable as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;32,422,027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;88.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;85.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted-average grant date fair value of options granted for the nine months ended September&#160;30, 2023 and 2022 were $1.69 per share and $4.33 per share, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-191"
      decimals="INF"
      id="f-675"
      unitRef="shares">26662087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-192" id="f-676">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-192"
      decimals="INF"
      id="f-677"
      unitRef="number">0.05</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-193"
      decimals="INF"
      id="f-678"
      unitRef="shares">12478367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="c-193"
      decimals="INF"
      id="f-679"
      unitRef="number">0.05</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-194" id="f-680">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-192" id="f-681">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-195"
      decimals="INF"
      id="f-682"
      unitRef="shares">22478430</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-196"
      decimals="INF"
      id="f-683"
      unitRef="shares">2470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-196" decimals="2" id="f-684" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-197" decimals="2" id="f-685" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-197" id="f-686">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-197"
      decimals="INF"
      id="f-687"
      unitRef="number">0.01</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable
      contextRef="c-197"
      decimals="INF"
      id="f-688"
      unitRef="shares">4940000</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-198"
      decimals="INF"
      id="f-689"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod contextRef="c-197" id="f-690">P27M</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-199"
      decimals="INF"
      id="f-691"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-200"
      decimals="INF"
      id="f-692"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-201"
      decimals="INF"
      id="f-693"
      unitRef="shares">542921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-202"
      decimals="INF"
      id="f-694"
      unitRef="shares">283574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-203"
      decimals="INF"
      id="f-695"
      unitRef="shares">3905099</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-204" id="f-696">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-204" id="f-697">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-205"
      decimals="INF"
      id="f-698"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-699">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;14,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;14,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;24,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;51,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;19,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;38,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;63,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-206" decimals="-3" id="f-700" unitRef="usd">4548000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-207" decimals="-3" id="f-701" unitRef="usd">4442000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-208" decimals="-3" id="f-702" unitRef="usd">14439000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-209" decimals="-3" id="f-703" unitRef="usd">12401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-210" decimals="-3" id="f-704" unitRef="usd">5968000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-211" decimals="-3" id="f-705" unitRef="usd">14681000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-3" id="f-706" unitRef="usd">24182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-3" id="f-707" unitRef="usd">51160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-708" unitRef="usd">10516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-709" unitRef="usd">19123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-710" unitRef="usd">38621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-711" unitRef="usd">63561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-712" unitRef="usd">76500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-713">P2Y9M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c-1" id="f-714">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;872,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,559,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(414,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(240,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,777,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-214"
      decimals="INF"
      id="f-715"
      unitRef="shares">872077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-214"
      decimals="2"
      id="f-716"
      unitRef="usdPerShare">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-717"
      unitRef="shares">2559677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-718"
      unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-719"
      unitRef="shares">414018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-720"
      unitRef="usdPerShare">3.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-721"
      unitRef="shares">240673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-722"
      unitRef="usdPerShare">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-216"
      decimals="INF"
      id="f-723"
      unitRef="shares">2777063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-216"
      decimals="2"
      id="f-724"
      unitRef="usdPerShare">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-725">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;53,849,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;24,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,276,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,478,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(4,196,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;60,449,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options exercisable as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;32,422,027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-726" unitRef="shares">53849045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-217" id="f-728">P7Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-729" unitRef="usd">24887000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-730" unitRef="shares">12276063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">2.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-732" unitRef="shares">1478537</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">0.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-734" unitRef="shares">4196756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-735"
      unitRef="usdPerShare">5.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-736" unitRef="shares">60449815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-737"
      unitRef="usdPerShare">4.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-738">P7Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-739" unitRef="usd">7517000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-740" unitRef="shares">32422027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-741"
      unitRef="usdPerShare">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-742">P6Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-743" unitRef="usd">7517000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-744">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;88.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;85.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-745" unitRef="number">0.0413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-7" decimals="4" id="f-746" unitRef="number">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="3" id="f-747" unitRef="number">0.882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-7" decimals="3" id="f-748" unitRef="number">0.856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-749">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-7" id="f-750">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-751" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-7" decimals="2" id="f-752" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-753"
      unitRef="usdPerShare">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-7"
      decimals="2"
      id="f-754"
      unitRef="usdPerShare">4.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-755">Net Loss Per ShareBasic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#x2019;s potentially dilutive shares, which include unvested RSAs, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSAs and unvested RSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-756">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#x2019;s obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both September&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-757">Related-party Transactions&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma (&#x201c;Sonoma Sublease&#x201d;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#x2019;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both September&#160;30, 2023 and December&#160;31, 2022, there were accrued liabilities and other current liabilities of $0.5&#160;million, and as of September&#160;30, 2023 and December&#160;31, 2022, other non-current liabilities of $3.1&#160;million and $3.5&#160;million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#x201c;other operating income, net&#x201d; such as common area maintenance charges. See Note&#160;7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more detail on the Sonoma Sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma other operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was party to the GSK Agreement with GSK, which is a holder of more than 10% of the Company&#x2019;s outstanding common stock. See Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. GSK terminated the &lt;/span&gt;&lt;/div&gt;GSK Agreement effective December&#160;24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both September&#160;30, 2023 and December&#160;31, 2022. Revenue recognized in connection with the GSK agreement was zero for both the three months ended September&#160;30, 2023 and 2022, and zero and $36.3&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NetRentableArea contextRef="c-185" decimals="-3" id="f-758" unitRef="sqft">18000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements contextRef="c-185" decimals="-5" id="f-759" unitRef="usd">4600000</us-gaap:TenantImprovements>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-218" decimals="-5" id="f-760" unitRef="usd">500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-219" decimals="-5" id="f-761" unitRef="usd">500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-219" decimals="-5" id="f-762" unitRef="usd">3100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-218" decimals="-5" id="f-763" unitRef="usd">3500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-764">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#x201c;other operating income, net&#x201d; such as common area maintenance charges. See Note&#160;7, &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more detail on the Sonoma Sublease.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma other operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-186" decimals="-3" id="f-765" unitRef="usd">638000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-187" decimals="-3" id="f-766" unitRef="usd">659000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-188" decimals="-3" id="f-767" unitRef="usd">1955000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-189" decimals="-3" id="f-768" unitRef="usd">1976000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:SubleaseIncome contextRef="c-186" decimals="-3" id="f-769" unitRef="usd">466000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-187" decimals="-3" id="f-770" unitRef="usd">465000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-188" decimals="-3" id="f-771" unitRef="usd">1396000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-189" decimals="-3" id="f-772" unitRef="usd">1396000</us-gaap:SubleaseIncome>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-220" decimals="2" id="f-773" unitRef="number">0.10</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ContractWithCustomerLiability contextRef="c-221" decimals="-5" id="f-774" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-222" decimals="-5" id="f-775" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-223" decimals="-5" id="f-776" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-224" decimals="-5" id="f-777" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-225" decimals="-5" id="f-778" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-226" decimals="-5" id="f-779" unitRef="usd">36300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-780">Subsequent EventsOn November 6, 2023, the Company committed to and commenced a reduction in its workforce of approximately 25% to reduce operating costs and improve operating efficiency. The reduction in workforce is expected to be completed in the fourth quarter of 2023. In connection with this reduction in workforce, the Company estimates that it will incur charges of approximately $6 million to $7 million for severance payments, employee benefits and related costs, primarily in the fourth quarter of 2023. Substantially all of the estimated charges are expected to result in future cash expenditures.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-227" decimals="2" id="f-781" unitRef="number">0.25</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-228" decimals="-6" id="f-782" unitRef="usd">6000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-229" decimals="-6" id="f-783" unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-784">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-785">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-786">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-787">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-101"
          xlink:label="f-101"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-100"
          xlink:label="f-100"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-98" xlink:label="f-98" xlink:type="locator"/>
        <link:loc xlink:href="#f-99" xlink:label="f-99" xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1)&#160;&#160;&#160;&#160;Including related-party revenue of zero for both the three months ended September&#160;30, 2023 and 2022, and zero and $36,299 for the nine months ended September&#160;30, 2023 and 2022, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-101"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-100"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-98"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-99"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,V!9U<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #-@6=7LL*4#.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:05Q=#E9<,G!<&!XEM(;EM8TX;DI-VW-ZU;A^@'\#%W__SN
M=W"-"=+T$5]B'S"2PW0S^K9+TH05.Q %"9#, ;U.94YTN;GKH]>4GW$/09NC
MWB-4G-^!1])6DX8)6(2%R%1CC301-?7QC+=FP8?/V,XP:P!;]-A1 E$*8&J:
M&$YCV\ 5,,$(HT_?!;0+<:[^B9T[P,[),;DE-0Q#.=1S+N\@X/WYZ75>MW!=
M(MT9S+^2DW0*N&*7R6_U>K-]9*KB55T(4?#[;26DN)7\X6-R_>%W%?:]=3OW
MCXTO@JJ!7W>AO@!02P,$%     @ S8%G5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M=JMVW?\%<UYM#^H1K]@UE2C0"Y'E3F%UM=J9G13[D4[]>+FM^YGJ 5.BF"U
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MN__UDO6+&^!7\G88^\#<V-]9ZIYM0W45%4":+!R!-_ $:IVK-UP!=#O<TC.
MX)%^!.26",,@K=IRP?[10X@":]HH6EU3L</T>)#1K:)/-!^_Z@\ISG3I/OIB
M4AJ"ZDBI55+I"[,E_91?YU39C2Z<UI3/Y#"I@S+ ?F5@RHG7GHQ&\)53BB-T
ME,999X/#["B*D_\CQT= >VQH=])8/C@S;DL9/)4[?IO#G ]B!S\A=HJ"F7-0
MO=F:0XAC5NL^N6%Z\W7"M.4*BL,D0],&SVD(TP#.J 4\*!OL5S9:G;556W:G
MB[TBXY6N\:TY$K[3C,REFRML\7*,4&H!=Y@E439'%8/(P7Z1,X9=T W+F5,C
M8%NW'.N6!*53X>@R3.(DG.N:\"!QL%_B[)A7SF[N3M@.S9(E43)M]!QV:1#@
M:*8G#09Q$_C%C247NFI\61#])\:'D,YVT&'G; >7H]-T\U/&9R)N6"VU<MSH
M@? DT6D0NU\'=C>*-]T!^S57BE?=Y982#=X8Z/<;K@5%?V/.[/>_T:S^!5!+
M P04    " #-@6=7-N6JY0,#   Y"@  &    'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;*V676_:,!2&_XJ535,K=>0+ G00J:6JMHM)J&C;Q;0+DQR(52?.
M; /=?OV.$YH1"!"T<0&V<][7SW&.L4<;(9]5 J#)2\HS-;82K?-;VU91 BE5
M'9%#AD\60J948U<N;95+H'$A2KGM.4Y@IY1E5C@JQJ8R'(F5YBR#J21JE:94
M_KH'+C9CR[5>!Y[8,M%FP Y'.5W"#/27?"JQ9U<N,4LA4TQD1,)B;-VYMQ/7
M,8(BXBN#C=II$Y/*7(AGT_D4CRW'$ &'2!L+BC]KF #GQ@DY?FY-K6I.(]QM
MO[H_%LEC,G.J8"+X-Q;K9&P-+!+#@JZX?A*;C[!-J&?\(L%5\4TV96S0MTBT
M4EJD6S$2I"PK?^G+=B%V!&[WB,#;"KRV G\K\(M$2[(BK0>J:3B28D.DB48W
MTRC6IE!C-BPSKW&F)3YEJ-/A1&0QOA2(";:4X"RF&COWE-,L C(SQHI<3:F$
M3">@643Y-7E/WA*;J 1'U<C6R&'<[&@[YWTYIW=DSAGD'>([-\1S/+]!/CDM
M?X (Y6XA]^IR&[.OEL"KEL K_/QC.!I3QLK41"S((\LP<48YF0K%BDK[?C=7
M6F*]_6A*M?3N-GN;37BK<AK!V,)=ID"NP0K?O7$#YT-3XO_)K+8,?K4,_BGW
M<(K[!Z3$EX]%%SW?D)Q*LJ9\!>2*9206G%.I2 ZR?/'73:M13M$OIC#_(.O0
MZ3B.XX[L]6Z>9\-J&72K#+J79$#H2B="LM\X8#(HR[41N_3M[?"X3OG9 V\1
M6$/O5>B]B]"94JOSV+T#FGW>4Q$UT* "#2X"Q9-!:9K%+%N>HPW.TIZ*J-'V
M*]K^2=J)2%/<P?]0T/UV!7TVK(8_J/ 'K?$OJ.;!P3+VG.9R;A-9(Q]6Y,/V
MY.V*>7C XO7<03 \I&Z([ Y[0?\HM>O\/0V=]MP7U/;6]H!^, P&>_1-H06^
MW_7W\.V=<]U<JCY3N629(AP6J'4Z?321Y3VE[&B1%T?]7&B\.!3-!.]V($T
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M5:7E<L,$Q-HC:\+3A#8TX<!#M+K4S'$<,]BH!1N]FM(]GU9.CF/!JCOX![W
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M@U08CN0_Z>B=V.G]COYBJBM-5=N452?'S<%9N:%");^4&7LYW&C&)@ISD_G
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M^C;HK4=59\^DK& 778\@ J1%?J_<*Y5[4)&;3'5JO=%%<VVA?->O.#<M[H[
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MA)=U*:#*DAR_-&] DZY8@78+ZJ[%,.P#+=$644ET22J.]^OW'"DKRIN7%L&
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M5N.M!)\]?2>@DCGN6\BB)_VTX3OS?,D#?"_9>U79W+"?JTQD-_G[P- "239
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M:MYW];[@)\>M.5B#<[)2ZM$%W[))$#E!*#"UCH'1XQEO4 A'1#*>&LZ@;>F
MA^L]^Q?OG;RLF,$;)7[QS.:38!1 AFM6"?N@ME^Q\3-P?*D2QO_"MJY-J&-:
M&:N*!DQQP67]9"_-_W  &$7O )(&D'C==2.O\I99-AUKM07MJHG-+;Q5CR9Q
M7+I#65I-NYQP=KJT*GW,E<A0F\]P]U1QNQN'EIC=?I@V+/.:)7F'Y1+NE;2Y
M@3N98?86'Y*B5E:RES5/3A(NL>Q"+^I $B6]$WR]UF;/\_7>X:N-P>_9REA-
M-^'/,8\U1?\XA7L[KDS)4IP$=/T-ZF<,IN=G\3"Z/B&PWPKLGV+_\#E\G.7\
M;)3$%]<-%RSHMJ/6F($O@N\YPHTJ2B9WP VPRN9*\[^T;Q4E3(401]V([IP0
M[O4Q.2/7H-90MDS&,VVYS8%!R30\,T$XJOE$T"B*H41=([LP\V Z6(O%BM+[
MTP4F,[C%M,G&/IMT0*I3/5%3G\H:2V@N-UWGI2"9'S8WB(Z[2VN>_VK-YDZ^
M]Y ,XLYH..I<#D=[$0Z4]"\[@^%%I]?O'6BSK[::TS5O]1[\(QT:F:9$/_3$
MKGOLBH8'8Z- O?'#T3%6TM83I,VV\W=6CYW7\GIXWS.]X=* P#5!H^[%( !=
M#\0ZL*KT0VBE+(TTO\SI&X+:%=#^6BF[#UR#]JLT_0=02P,$%     @ S8%G
M5VJ)0X@1"P  O2   !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULS5IK
MC]LV%OTKA)L6,X"BD619LO,88)*FW13;9I!IMA\6^X&6:(N-)+HD-1[OK]][
M+RF-[/$XCZ+H LU8#_+R/L\]I/IBJ_1'4PEAV5U3M^;EI+)V\^SBPA25:+@)
MU4:T\&:E=,,MW.KUA=EHP4N:U-07211E%PV7[>3R!3V[UI<O5&=KV8IKS4S7
M-%SO7HE:;5].XDG_X+U<5Q8?7%R^V/"UN!'VP^9:P]W%(*64C6B-5"W38O5R
M<A4_>Y7B>!KP+RFV9G3-T)*E4A_QYFWY<A*A0J(6A44)''YNQ6M1UR@(U/C#
MRYP,2^+$\74O_0>R'6Q9<B->J_HW6=KJY60^8:58\:ZV[]7V'\+;,T-YA:H-
M_65;-S:=3EC1&:L:/QDT:&3K?OF=]\-HPCQZ9$+B)R2DMUN(M/R>6W[Y0JLM
MTS@:I.$%F4JS03G98E!NK(:W$N;9RQNKBH]/T:Z2O58-Q-IP=->+"PO2<<Q%
MX26]<I*21R0MV,^JM95A;]I2E/OS+T"K0;6D5^U5<E+@C=B$;!H%+(F2Z0EY
MT\'4*<F;/B:OXEH\?46F7O,=9)9E5UKS=BWH^M]72V,UI,E_CAGO9*?'96/I
M/#,;7HB7$Z@-(_2MF%Q^]TV<1<]/:)X.FJ>GI']1D+Y.$OHX9F_^Z*3=L;=M
M ?Z 8F'7-6_AEOW4M8*&!,Q6@F;R=L=XJ386).&S$P+.OOMFGB31<QJ"3^@^
M?GX>L&TEBXK!^BBBY%8PM:+K#I)(;[6TLETSOM;"Q4B+FM.*:JP(RHOSYX:]
MO7['EJ+@C6!BM1)4\5!0MF*@AFQ!&J^9CP^NE&1!EB5!-,^9P>PP =O4G6%H
MG'L :+7\'03ABH!IQO*V))6V7)>&K2%]4!]2U_LAGG_2#S!D[ >8R&V ;E":
M\97UH@836F%,[YC!B1 *H0$1R&F:B;N-U *L!Z"&J7="%]+0&R.LK<E] 0.3
M6*LLD\9TH#;ZJH-1*)@L@A=^/%RVK."F<I- ZDI(.YKC]5EQ67<P /QS*PQ:
MH6D"=(@"O*!A!CS!&%2B+MD9W-PK<([3, /-"K*)67[G1JJ:G*R6M5R[_%3.
M)9M.%Q4WWF)OXT;+0H28I[PL)0YW:=IVS1)<"8KZ6/K(EV@-:< A0'NQ\[YE
MO /@A94+7M<[\$0!YAB0 )K\Q-L.VA>+43 86;&=X)I$<K816JJ2?"-:>@$I
MM11KV;9DT&@ZX5H"J5:R H!3MAV.L)56W;K:'S:%OQ -U*M1'92!^*.#1 ;?
MG<7G;/9M'PNK+#Q^8+9_>U@LA6H:4,@@).SE-CS\7A2"I$SC?KIL&E%*R#9P
M"&!<(6@LFD@Q/TO.P?X:,A5F/5"A%"Y9,7]V1[59*DP_F%%"SA16:0-YPK#:
M,3;\"U4*V;M#5T_WL6O(!7Z?-N"\. G2?!Y,LWSDO3U/?3)WM* 6T!)T'0:G
M%^5ECQ&%EAI9Z1(D9!\>KK%O2L-W#H@P43W@^*ANT"Q(P5:U3V$E"VD-#CEX
M"9I8*"$L;O?&@UN/5^]OKLP]9#\8W0&NC@=_& WV\C88'>DJ62-/0J 5FC@E
MNM$OB+6@P#+MYOD^Y5Z&[%?((/+16$DLC*+NR(.(/_BK!0$/(IYQZ/55Z0=Q
M7B(J8<BDM4(@*E1*R_]^B9A@W$$V6MU*Y+,/X1SLPR0!-?$5-:!1E(XVFC[A
M"MXBI(J[0F!K[($G9#]"Y]"(8,%AO]I7GSS'U*U &.NTF\Z6G:746HIA&K72
M4D)?TMB->X>CUH8 &)#L]ZYUA-OU7:0(#M@>S=]2&H^  Y?P#=+)@(S;> >V
M0/.%:ZY]6ER1+X$L6E\X45_NB:OE=!KU];8%O1F_A9;%ES4U-;;J++:OH:*A
MP^"5[2G&*$".XC2;6NT@&8A*L>N^(7TQ53HE9X\QO;FYOCYD3 ](SCX42FR7
M3G_HDD7G6NB?95:GB!1X.@JBJ/>TR^9!?09)J+:&">CG$CTOO/6&JJ*W_0OZ
M%;=0F90XV _[KKGA.ZWJ&NJ]["@)25BWP57B 8HE< >NL2$?5">ZOI90[(14
M!J&W)NJ%F+1%JO$U0!*,K$4PHM0[8C:8-+]O%^ OUT$]R=)0B_HC[-)O>=V)
MS^OICE:OI(;J[LDUQT2 ^J5&K_LQ@RXXS 7OJVC$9S$LEQ'_=PS+!]13&%@
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MQ#T]81U#S>@&FKZBYN@=:Z60VA:=5*#5OXD-5O1FDMO!'XJ.V%,PH 4=D(O
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M8DTS+2X;^HA QPIT7EE*P;!A!^-GR?8_4$L#!!0    ( ,V!9U<Q"E%HT00
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M01B<7OK&(?S,E,.XL@Y^">U!GU/D"<&XC2);*#]J\:(.=(]NH$:<T[7X=QF
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MR=/IVAPO 8F>)":4%V@I)>8%F&/7*O:UV<'&^5E'6[6T\ HM0H^"ZU*A+YP
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M0O@^)?^%F+>%0JYDKJRDW9(_:BOK7$>5BQN'Z-F0G@+<E$L:_DY;:3,MC5A
MA$+.QB *^:#$4BDK8'\E/=9IRX)]CM4*.(^%>#=:C,1:6>6E,5N:5A6)E%TX
M*J\AO#*$P*^_.IW-)N??S^>W_#@]?SH2I/"_TQ&"39TK$1N3:QJ$.^C])CE
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M>H%/79]NTM)+=!7?7BU=C*[DQP)-L_*T /,KY^+NA0YH[S.O_@102P,$%
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MP;S\%/IB3=>Z[ 0ZZLN*(EH1:5@I2[R]$2^#;H[Q/ZGA./]/-<*64DSMN*S
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MQF<3ZA+=#47=QJK&#R)K96FL\<N*YDC4SH#N-TK9_<8%&";3Y7]02P,$%
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MO$J/ JZP&L(X&4":I.,C>..^ZG' &Q^O&J[_K_K;Y=J19>O[H;H;V,EA6/^
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M#>*F?5CT@9'&%K&2J))TO"GVXTM2BGP)+=BIT#Y8YF7F<'A&FB%GN*;L"T\
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MJ!8=> YKEX)M*A\-S:&:I#2U\MMXW< <K^NZZ*V9ZUST:* .U3Q4\U%-H%J
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M1#5):6JYMWG%D3'3](,7$\UXYV(G-1?5/%3S44V@6H!J(:I%C6:^J4M3\^3
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M5VMM_L^\:^>"1O-_J.:AFH]J M6"1AL=4=!HM@_58E1+4$U2FEK0;01P;(X
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MV"?6EU59KA:;+V^S]"HKZ@VJ?[]>K<K';^H!OJV*/S8/Y_S_ %!+ P04
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M\ PO%>@B39FZ/T4A5R.GZSQT7/%%8FR'&PYSML IFNO\4E'+;5QBGF*FN<Q
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MLUP3CA[B+1%259@4Z+U#)*:A^(#>(1JCKVN6"!POQ+@C5;XTJA/D[/L]V[[
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M]_Y-D6ZKIZ$?TJ)(-]7+M0J7*BL-].>K-"U>WY0/6!\>J)_]!U!+ P04
M" #.@6=7/NV7.&,%   ]*   &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6S-6EUOVS84_2N$-@PID%H2Z:]DCH$F;=$"S1 D6/<P[(&1Z)B()&HD92=
M?_PH618E1Z*M@2[\DNCC\I#WD$<ZOM1LS?BS6!(BP4L<)>+*64J97KJN")8D
MQF+ 4I*H.PO&8RS5*7]R1<H)#HM&<>1"SQN[,::),Y\5U^[X?,8R&=&$W'$@
MLCC&_/6:1&Q]Y?C.]L(]?5K*_(([GZ7XB3P0^6=ZQ]696Z&$-":)H"P!G"RN
MG _^Y0V:Y V*B.^4K$7M&.2I/#+VG)]\#:\<+Q\1B4@@<PBL_JW(#8FB'$F-
MX]\2U*GZS!O6C[?HGXOD53*/6) ;%OU%0[F\<J8.",D"9Y&\9^LOI$QHE.,%
M+!+%7[ N8ST'!)F0+"X;JQ'$--G\QR\E$;4&<-31 )8-X*$-4-D %8EN1E:D
M]1%+/)]QM@8\CU9H^4'!3=%:94.3?!H?)%=WJ6HGYY\QY> [CC(";@D6&2=J
MCJ0 [\&#6C%A%A' %N"3D%111D)0BU?7'[(@($* ._R:-P/?*'ZD$96OX(-0
M"R/-9TJ LX]$8AJ)=S-7JB'G';M!.;SKS?!@Q_ >2#H R#L'T(,(_ I<():8
M$]&"=&-&^D@"A>072+ 3R57T51S"BD-80 ^[..2*F"^9#)9M"1K;YBJ]%"D.
MR)6C9"@(7Q%G_MLO_MC[O2U'2V"--%&5)BK0T=ZE<IY/+U&K!"=A->>4B.T2
M"H$2Z#T),LYI\E1$_<$27EVXQH(*\/<WU0'X*DDL_FDC#MDDSA)8@[AA1=S0
MO#YRXE9;S00LCA4]2MG!,SBC"0A9%&$N0$KX9DVVZF33Q;3H(G\VK^;^8#B9
MN:MZEF^#4#VH,?I1-?K1@:L;_ #W5#R_7W!" $TD451)P-5S0=VYI0F-L[AM
MZ$;\OA-I":Q!Q;BB8GQ2"AC;),X26(.X247<Q+B&MN^)M'Q/1-OWQ#F(]5M'
MK:DTD^ ,*UIS-03J6JL6-IWY7FV=#P=PO".&EB@T&$W;U3"M,IE:40-^Z5*#
M$;_OI%H":U!Q45%Q<5)JN+!)G"6P!G&^ITV7]S/U4/;66.JCP1#N"*(M;#@8
MC]H5X=<LI'^X)CZ]I,JAJPLK%F%9)-4Z9"-DW]FTA=8D0/L_'YZ4$GRKGM(6
M6I,\[2I]H_>RKH5-;[Y?6^3>8+HKA3U1S5RTT?/W.+U6):A70UPXO5>B?-X[
MLUDR]]![;BVA-?G0UM$?G98PK%I-6VA-\K39](V6S+HPQF^?_MY@XN\JHS5L
M..Z0AG: OMD"'BR-;N=D[J'W[%I":_*A?:0_/2UI6/6=MM":Y&GGZ1O]F75I
M7+3^H'CCGUK#+CI^7T/M!N$>-RAQLF \;*T>&9OV+A]90FLFJHTB]$]JS4.K
M)M,66I.\6I%Q3Y711A6I[&-/&:DEJKN.!+73@WN<7KG._V\=R0S?>SJ/41*$
MVBK"X6EIP:JOM(76)$_[2FBN25I^_I>][3[_=ZU16UAW10EJHP?W&+V#=-'M
MB\SPO:?V&(5"J'TBG)R6+JR:2EMH3?*TJ83FZJ1M74P/JBNUA777E:!V>7"/
MR].Z.+"J9 ;L/9G'*!(B;0N1=U)*0%:MIBVT)GG::B)S3=*R$LK>]E25]D4U
M<]'.#YF=7YL.>M64S/B]9_8HF]"U7>@3VX:VNP]]#->)M.M$Y@*E;5D,#ZHI
MM8=UU920MH%HCPT\3!C=SLF,WWMNCU$O1-I&HM/:G496;:<MM"9YVG:BG[I#
M7?8VJBWXW>UIU+(_/1Y,=EV36_NV*_^P[A;S)YH($)&%:J;$IOK@FV_5-B>2
MI<7G7H],2A87ATN"0\+S '5_P9C<GN1?D%5?#,[_ U!+ P04    " #.@6=7
MB:18Y?$#   %%0  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RMF&UO
MVS80Q[\*H15# JS1HQ^2V09B2VF'-D!0M]UK1CK;1"72(RD[!?;A1TJR(MF*
M9F]\8TLT[W>\^Y].)B=[QG^(#8!$+UE*Q=3:2+F]LVT1;R##XH9M@:I?5HQG
M6*I;OK;%E@-."J,LM3W'&=H9)M2:38JQ)SZ;L%RFA,(31R+/,LQ_SB%E^ZGE
M6H>!+V2]D7K GDVV> U+D-^V3US=V34E(1E001A%'%93Z]Z]BUQ?&Q0SOA/8
MB\8UTJ$\,_9#W_R13"U'KPA2B*5&8/6U@P6DJ2:I=?Q50:W:IS9L7A_H#T7P
M*IAG+&#!TC])(C=3:VRA!%8X3^47MO\(54 #S8M9*HI/M*_F.A:*<R%95AFK
M%62$EM_XI4I$PT!QN@V\RL [-@C>,/ K _]<#T%E$)SK85 9%*';9>Q%XD(L
M\6S"V1YQ/5O1]$61_<):Y8M072A+R=6O1-G)V0,F''W':0[H$;#(.:@JD *]
M1TM5DTF> F(KM-A@N@:!"$61D$3I PEJF*HI#X1B&A.<HL\$/Y.42*(,KD*0
MF*3B6@&_+4-T]>X:O=.8KQN6"TP3,;&E"D,OQHZK)<_+)7MO+-E'CXS*C4 1
M32#IL _[[6][[&V5OCJ'WB&'<Z\7N(3M#?*=WY#G>'['>A;GFWM=X?P_[]%_
M]MY*AE\7E%_P@K<*BJO2^)C+>(/^1A^6GW[]Q1TZO]^O.125U25W+U!WRCNQ
MQ3%,+=4*!? =6+.2VI5KD[#0)"PR!&NI$M2J! 7=?TOE/(Y!"/2$?VH5FL]H
MER*!245,PD*3L,@0K*7(H%9DT/N<'!395HK BWKW"T!7:_5VO^X2I>0-"YY^
M_^]F[]V!XTSL73/;I[/<X'A2V('RW.-9T>FL<6-.*^IA'?6P/VJ)J?IWDYS=
M&WIQEU:B25AH$A89@K4T&=6:C$SVAI%)14S"0I.PR!"LI<BX5F1LN#>4O$&K
M-W@GO6%\VAN<D]YP%BKJ0 5O-8?;.NS;L\+N*$35+S[##E+4]0]GWHN]M"1-
MPD*3L,@0K*6-Z[QN%!R3;:*B&1+%*"TT2HM,T=JZ-#9P;N]3,X<UH930-9KC
M5&W!H%.-7L;%:IBDA16MV7$"?S \:CBF?+:S[+UFV>O-<KD#UCO7E=[V[O2V
MMS/1O9B+$VV2%E:T5FOW?>?V.-.&G+8S_;I_=/LWD&I7_F_%['>\QX+1T<NN
MW\W%N3O'9V3*9YDZNW&LDP%?%^=I L4LI[+<D->C]9G=?7%2=30^=^\6;L=X
MJ,_XBF.D5WQY0/B(N>HJ J6P4JZ<FY$J&EZ>N94WDFV+0Z5G)B7+BLL-X 2X
MGJ!^7S$F#S?:07WR.?L'4$L#!!0    ( ,Z!9U??.=J+(00  +0;   9
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M>CCR?,=P?B+9)MM_^L"D9'%VN*9D07EJH+Y?,B:?3](&RGW;T_\!4$L#!!0
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MLN;%;UA4.1R?9\WL\71T8 *@KE%MZ,8&,,_T <C_R!?Z'"6[I+-=H98 E.9
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M;"]W;W)K<VAE971S+W-H965T-#8N>&ULM9AK;^(X%(;_BI4=K5II2F+G!EU
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M(1O8_#&4EQA@"B#?+R@5FX%:H+H6>;\ 4$L#!!0    ( ,Z!9U=3<E *_ (
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
M1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2
M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;
MZ/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #.@6=7&X"%N#D$  !R
M(0  #P   'AL+W=O<FMB;V]K+GAM;,6:36_;.!! _PJAR[9 L[8^G+9!7:#;
MM+L!TB2H@EP+6J(M(A3IDI2SSJ_?H52C5!,/]C+5R19%T4\D-6](^=V#L?<K
M8^[9OZW2;IDTWF_/9C-7-:+E[D^S%1K.K(UMN8=#NYFYK16\=HT0OE6S;#X_
MG;5<ZN3]NT-;-W86'Q@O*B^-AL)0<"?%@_MY/ARRG71R)97T^V72?U<B8:W4
MLI6/HEXF\X2YQCS\8ZQ\--IS55;6*+5,TN'$G;!>5D^*RP!YRU>N+_%\]94#
MR#(YG4.#:VF=[VOT[7-@W FH/!QUWGR6R@M[SKWXVYIN*_4F- -W,8MNH^^'
MP^?0B6?V_W2C6:]E)<Y-U;5"^Z$?K5 !4+M&;EW"-&_%,OEH=L*&^X$?N*B'
M>_, %?64/9-PPE[4/1XEBJZ%=J)F\,T9)6O@J-E?7'%="19!9@AD-B'DMRR"
MS!'(?!+(,N# I1%D@4 6$T*.>G*!0"ZFA,PCR%,$\G1*R"*"?(U OJ:%O+8;
MKN5C?R(B>H,0O:$E*KNVY7;/S)J5<J,E7,:U9Q^JRG3:RPCR+0+YEA;R$JK!
MT+Z"H56*KXSMJ[QB7,, =U4<N>=8Z)X33T'N&O;I>R=W7$%-U_-]X?9>@!<#
MR4],U##$BKGVC;#L0N^$\Z&JB\$PJZ3$6OG,I65W7'6"?1'<=58\P<-\DA(+
MY1*8Q(@&$T=*;([2F^J^,:H6UOW1SSJ_C]DP7Z3$PNC93E9\B,8MM.1^#7DI
MIHJ4V!57T.ZE<8[=P(-0-MR.GDW,#RFQ(*"W6CD\E7WT )=YR(J%KN1XZF'*
M2(F=\344BOIDRZW?LUO+87C[Y<>($/-%2BR,LELY\;V#2NS3[I<8DF&*R(@5
M<</W;-?/N_[RD-*?2U<I$Z)=#(D)(B,6Q(5V$L)*&-D:)A_[8&&(-T^"<8:N
M0(A=@>8MH\0YPYR143L#RUS&F)A,,NIE"):YC#$QKV3$7CF2(+ 7MR&_&LU-
M3"\9L5Z&1.% ]3+&PMR2$;OEF)5_@,:8F%VRR>S2@\:8F&(R<L5@ 2A>%.>8
M<')BX> !:(2)*2<G5@Z.&:_><\PZ.?7&%QHG1[V)[GQ1;WVAF*/>Q*R3$UOG
MR4*4O3@'0JE&,3/'C)-/9)P35D+K=8R)&2<G-@Z*.=Z0Q0R4$QL(QQP]/IB!
M<F(#'<>\XI *QYB8@7+J7;$AS?@Q%3LE@HNNMR+$3LC:XPUNS$ %M8$.F'WG
MA3= SS[F!::?@E@_SVVF/$^)V:>@7O,<2^"&OHTQ,?L4Q/9!,,-,C3'1-R^_
M8P/M&.8H9A:8@8J)]M(&S#AF%IB!"F(#X9AQRE%@!BJ(#80L+L)#%&-B!BJF
M6P.%_HPQ,0,5OWN;[=F8N<#LL^CM,SN\XZ_%6FI17T'S#LHKKJH;R\+'\':B
M6(1]Q76GU$<HN]:7AM>'OPP<_N[P_C]02P,$%     @ SH%G5SB#;R;$ 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( ,V!9U>RPI0,[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " #-@6=7-N6JY0,#   Y"@  &
M    @(%B%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MS8%G5Y@9/&*B!@  1!T  !@              ("!FQ<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,V!9U=Z;'_&10,  'L*   8
M          " @7,>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " #-@6=7"P$F,&<*  !47P  &               @('N(0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ S8%G5]RRXSA""   =20
M !@              ("!BRP  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+
M 0(4 Q0    ( ,V!9U<Y$]M,K@(  ,(%   8              " @0,U  !X
M;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #-@6=7T?@)/>T)
M  !I&0  &               @('G-P  >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL4$L! A0#%     @ S8%G5U/XRS!T$0  :D,  !D              ("!
M"D(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #-@6=7
M] !@H*8%  !V#P  &0              @(&U4P  >&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,V!9U=<,?(%R 0  .D+   9
M      " @9)9  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ S8%G5S_,=H G"   ;A@  !D              ("!D5X  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #-@6=7EMV+4[H&  !((
M&0              @('O9@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( ,V!9U<V8"A9M@(  *$&   9              " @>!M  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ S8%G5VJ)0X@1
M"P  O2   !D              ("!S7   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " #-@6=7A;>(DR0#  !H!P  &0
M@($5?   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,V!
M9U?^#(5*P ,  *((   9              " @7!_  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ S8%G5S$*46C1!   @ L  !D
M         ("!9X,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " #-@6=7^W<L/@<#  #L!@  &0              @(%OB   >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,V!9U<Z\):2? (  +P'
M   9              " @:V+  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ S8%G5T@U17Y# @  B@8  !D              ("!8(X
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #-@6=7OGX6
M%0,(  #;%   &0              @(':D   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( ,V!9U?9MR',5 ,  +<(   9
M  " @129  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MS8%G5ZQM]Y;X P  I0\  !D              ("!GYP  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " #-@6=7P7,5'60%  "-$   &0
M            @('.H   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( ,V!9U?V1]*\@0,  *4*   9              " @6FF  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ S8%G5R]RQW9=!0
M1 T  !D              ("!(:H  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " #-@6=75?[>M \#   <!P  &0              @(&U
MKP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,V!9U?F
MAME KP0  %(6   9              " @?NR  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ SH%G5R^,T\4?%P  2H$! !D
M     ("!X;<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Z!9U<=U(^9;P<  %P_   9              "
M@<WE  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ SH%G
M5S[MESAC!0  /2@  !D              ("!<^T  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " #.@6=7B:18Y?$#   %%0  &0
M        @($-\P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( ,Z!9U??.=J+(00  +0;   9              " @37W  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ SH%G5Q"0HEW< P  ,P\
M !D              ("!C?L  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " #.@6=7V\H9 K,%  ##+0  &0              @(&@_P
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,Z!9U=1N*7]
MN@,  %D0   9              " @8H% 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ SH%G5QM#^A+1"   4E@  !D
M ("!>PD! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #.
M@6=7M^7$K;D#   E$0  &0              @(&#$@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,Z!9U<I%3,@6 ,  #4+   9
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M970T.2YX;6Q02P$"% ,4    " #.@6=74W)0"OP"   P#   &0
M    @(%S*P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M ,Z!9U?B$$!61@,  - 4   -              "  :8N 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ SH%G5Y>*NQS     $P(   L              ( !
M%S(! %]R96QS+RYR96QS4$L! A0#%     @ SH%G5QN A;@Y!   <B$   \
M             ( ! #,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,Z!
M9U<X@V\FQ $   T>   :              "  68W 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,Z!9U> A/B=P $    >   3
M          "  6(Y 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z #H
*S0\  %,[ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>229</ContextCount>
  <ElementCount>264</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - License, Collaboration, and Success Payment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/OtherInvestments</Role>
      <ShortName>Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related-party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactions</Role>
      <ShortName>Related-party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lyell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/CashEquivalentsandMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/StockbasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Related-party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsTables</Role>
      <ShortName>Related-party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/RelatedpartyTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/OtherInvestmentsDetails</Role>
      <ShortName>Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/OtherInvestments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/StockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Related-party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails</Role>
      <ShortName>Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lyel-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/SubsequentEvents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="lyel-20230930.htm">lyel-20230930.htm</File>
    <File>lyel-20230930.xsd</File>
    <File>lyel-20230930_cal.xml</File>
    <File>lyel-20230930_def.xml</File>
    <File>lyel-20230930_lab.xml</File>
    <File>lyel-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lyel-20230930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="610">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lyel-20230930.htm": {
   "nsprefix": "lyel",
   "nsuri": "http://lyell.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "lyel-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "lyel-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lyel-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lyel-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lyel-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyel-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 225,
   "keyCustom": 39,
   "axisStandard": 25,
   "axisCustom": 1,
   "memberStandard": 25,
   "memberCustom": 26,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 229,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 519,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 610,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://lyell.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://lyell.com/role/Organization",
     "longName": "0000008 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements",
     "longName": "0000010 - Disclosure - License, Collaboration, and Success Payment Agreements",
     "shortName": "License, Collaboration, and Success Payment Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecurities",
     "longName": "0000011 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lyell.com/role/OtherInvestments",
     "longName": "0000012 - Disclosure - Other Investments",
     "shortName": "Other Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lyel:OtherInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lyel:OtherInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lyell.com/role/FairValueMeasurements",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lyell.com/role/Leases",
     "longName": "0000014 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lyell.com/role/StockholdersEquity",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lyell.com/role/StockbasedCompensation",
     "longName": "0000016 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lyell.com/role/NetLossPerShare",
     "longName": "0000017 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lyell.com/role/CommitmentsandContingencies",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://lyell.com/role/RelatedpartyTransactions",
     "longName": "0000019 - Disclosure - Related-party Transactions",
     "shortName": "Related-party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://lyell.com/role/SubsequentEvents",
     "longName": "0000020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables",
     "longName": "9954472 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)",
     "shortName": "License, Collaboration, and Success Payment Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables",
     "longName": "9954473 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lyell.com/role/FairValueMeasurementsTables",
     "longName": "9954474 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lyell.com/role/LeasesTables",
     "longName": "9954475 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://lyell.com/role/StockbasedCompensationTables",
     "longName": "9954476 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://lyell.com/role/RelatedpartyTransactionsTables",
     "longName": "9954477 - Disclosure - Related-party Transactions (Tables)",
     "shortName": "Related-party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954478 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
     "longName": "9954479 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)",
     "shortName": "License, Collaboration, and Success Payment Agreements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
     "longName": "9954480 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)",
     "shortName": "License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-65",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9954481 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "longName": "9954482 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://lyell.com/role/OtherInvestmentsDetails",
     "longName": "9954483 - Disclosure - Other Investments (Details)",
     "shortName": "Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "lyel:VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954484 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
     "longName": "9954485 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)",
     "shortName": "Fair Value Measurements - Schedule of Estimated Fair Value of Success Payment Liability Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-151",
      "name": "lyel:FairValueOfSeriesAConvertiblePreferredStock",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-151",
      "name": "lyel:FairValueOfSeriesAConvertiblePreferredStock",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
     "longName": "9954486 - Disclosure - Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-58",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954487 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails",
     "longName": "9954488 - Disclosure - Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)",
     "shortName": "Leases - Schedule of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lyel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lyel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://lyell.com/role/LeasesNarrativeDetails",
     "longName": "9954489 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:OperatingLeaseCost",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:OperatingLeaseCost",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://lyell.com/role/StockholdersEquityDetails",
     "longName": "9954490 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
     "longName": "9954491 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails",
     "longName": "9954492 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
     "longName": "9954493 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (Details)",
     "shortName": "Stock-based Compensation - Schedule of Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-214",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-214",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails",
     "longName": "9954494 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails",
     "longName": "9954495 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
     "longName": "9954496 - Disclosure - Related-party Transactions - Narrative (Details)",
     "shortName": "Related-party Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-218",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
     "longName": "9954497 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)",
     "shortName": "Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-186",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://lyell.com/role/SubsequentEventsDetails",
     "longName": "9954498 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyel-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liability",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "lyel_StockPurchaseAgreementSharesSoldPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "StockPurchaseAgreementSharesSoldPricePerShare",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share of stock sold under stock purchase program (in dollars per share)",
        "label": "Stock Purchase Agreement, Shares Sold, Price Per Share",
        "documentation": "Stock Purchase Agreement, Shares Sold, Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r393"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r264"
     ]
    },
    "lyel_FairValueOfSeriesAConvertiblePreferredStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "FairValueOfSeriesAConvertiblePreferredStock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock (in dollars per share)",
        "label": "Fair Value Of Series A Convertible Preferred Stock",
        "documentation": "Fair value of the Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r515"
     ]
    },
    "lyel_FredHutchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "FredHutchMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fred Hutch",
        "label": "Fred Hutch [Member]",
        "documentation": "Fred Hutch"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r798",
      "r799",
      "r864",
      "r883",
      "r885"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r393"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r515",
      "r533",
      "r885",
      "r886"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total cash equivalents and marketable securities",
        "label": "Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale",
        "documentation": "Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r88",
      "r454",
      "r685",
      "r797",
      "r821",
      "r867"
     ]
    },
    "lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 ESPP",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand twenty one employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in proportion of common shares reserved for future issuance (as a percent)",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r393"
     ]
    },
    "lyel_SuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SuccessPaymentLiabilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Success Payment Liabilities",
        "label": "Success Payment Liability [Member]",
        "documentation": "Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ThirtyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "ThirtyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thirty Times",
        "label": "Thirty Times [Member]",
        "documentation": "Thirty Times (30x)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r264"
     ]
    },
    "lyel_TwoThousandEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Equity Incentive Plan",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Eighteen Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_FairValueAdjustmentOfSuccessPaymentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "FairValueAdjustmentOfSuccessPaymentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of success payment liabilities",
        "label": "Fair Value Adjustment Of Success Payment Liabilities",
        "documentation": "Fair value adjustment of success payment liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r14",
      "r118",
      "r121",
      "r126",
      "r363",
      "r364",
      "r369",
      "r441",
      "r457",
      "r790",
      "r791"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r805"
     ]
    },
    "lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classified as:",
        "label": "Cash Equivalents And Debt Securities, Available-For-Sale [Abstract]",
        "documentation": "Cash Equivalents And Debt Securities, Available-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trigger period from IPO date",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of stock outstanding (as a percent)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_FredHutchSuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "FredHutchSuccessPaymentLiabilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fred Hutch",
        "label": "Fred Hutch Success Payment Liability [Member]",
        "documentation": "Fred Hutch Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate success payment(s) (in millions)",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_OtherInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "OtherInvestmentsTextBlock",
     "presentation": [
      "http://lyell.com/role/OtherInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investments",
        "label": "Other Investments [Text Block]",
        "documentation": "The entire disclosure for other investments."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_LyellImmunopharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "LyellImmunopharmaMember",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lyell Immunopharma",
        "label": "Lyell Immunopharma [Member]",
        "documentation": "Lyell Immunopharma"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier": {
     "xbrltype": "pureItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of initial equity value at issuance",
        "label": "Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_GoldmanSachsAndBofAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "GoldmanSachsAndBofAMember",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goldman Sachs and BofA",
        "label": "Goldman Sachs and BofA [Member]",
        "documentation": "Goldman Sachs and BofA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://lyell.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r166"
     ]
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum offering period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SignificantAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SignificantAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Policy Text Block]",
        "documentation": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty one equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "lyel_NonCashLeaseIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "NonCashLeaseIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash lease income",
        "label": "Non-Cash Lease Income (Expense)",
        "documentation": "Non-Cash Lease Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsResearchTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsResearchTerm",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of collaborative arrangement for research",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Term",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Term"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_StanfordSuccessPaymentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "StanfordSuccessPaymentLiabilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stanford",
        "label": "Stanford Success Payment Liability [Member]",
        "documentation": "Stanford Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r499",
      "r500",
      "r502",
      "r504",
      "r566",
      "r575",
      "r589",
      "r597",
      "r610",
      "r614",
      "r615",
      "r631",
      "r635",
      "r636",
      "r637",
      "r638",
      "r690"
     ]
    },
    "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost",
        "documentation": "Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of success payment agreement",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trigger period thereafter",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period After Initial Public Offering",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r801"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 500,000 shares authorized at September\u00a030, 2023 and December\u00a031, 2022; 251,869 and 249,567 shares issued and outstanding at September\u00a030, 2023 and December\u00a031, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r451",
      "r685"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r110",
      "r111",
      "r112",
      "r135",
      "r158",
      "r159",
      "r161",
      "r163",
      "r169",
      "r170",
      "r225",
      "r251",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r264",
      "r265",
      "r268",
      "r271",
      "r278",
      "r362",
      "r477",
      "r478",
      "r479",
      "r480",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r515",
      "r536",
      "r558",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r774",
      "r796",
      "r802"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock at fair value",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r361",
      "r446"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest (as a percent)",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r295",
      "r775",
      "r776",
      "r801"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r336",
      "r878"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of workforce reduction charges",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r243",
      "r244"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r295",
      "r775",
      "r801"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r174"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized at September\u00a030, 2023 and December\u00a031, 2022; no shares issued and outstanding at September\u00a030, 2023 and December\u00a031, 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r450",
      "r685"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on property and equipment disposals, net",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r822",
      "r823"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of securities held in a continuous unrealized loss position for less than twelve months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r236",
      "r671"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r677",
      "r879"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of securities held in a continuous unrealized loss position for greater than twelve months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r236",
      "r671"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used to compute net loss per common share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r163"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense by Classification",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used to compute net loss per common share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r285"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r386",
      "r387",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r532",
      "r534",
      "r565",
      "r869"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term of operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of marketable securities",
        "label": "Debt Securities, Available-for-Sale, Term",
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r234",
      "r447"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r129",
      "r187"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r793"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success Payment Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in workforce (as a percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r110",
      "r111",
      "r112",
      "r135",
      "r158",
      "r159",
      "r161",
      "r163",
      "r169",
      "r170",
      "r225",
      "r251",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r264",
      "r265",
      "r268",
      "r271",
      "r278",
      "r362",
      "r477",
      "r478",
      "r479",
      "r480",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r515",
      "r536",
      "r558",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r774",
      "r796",
      "r802"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r245",
      "r246",
      "r646",
      "r825"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r119",
      "r121",
      "r127",
      "r442",
      "r459"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r727",
      "r752"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r86"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs forfeited or canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Line Items]",
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Value at Grant Date Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r721",
      "r731",
      "r748",
      "r756",
      "r760",
      "r768"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r357",
      "r398",
      "r399",
      "r400",
      "r672",
      "r673",
      "r677",
      "r678",
      "r679"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r82"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherInvestments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on other investments",
        "label": "Gain (Loss) on Sale of Other Investments",
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Table]",
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r340",
      "r341",
      "r342",
      "r343",
      "r391",
      "r656",
      "r828",
      "r831",
      "r832"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with restricted stock units, net of tax",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r340",
      "r341",
      "r342",
      "r343",
      "r391",
      "r656",
      "r828",
      "r831",
      "r832"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r82"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r393"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r751"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r427",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r659",
      "r675",
      "r686",
      "r778",
      "r826",
      "r827",
      "r834",
      "r881"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r287",
      "r292",
      "r357",
      "r398",
      "r677",
      "r678",
      "r679"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r750"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses, other current assets and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r427",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r659",
      "r675",
      "r686",
      "r778",
      "r826",
      "r827",
      "r834",
      "r881"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r180",
      "r182",
      "r669"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r515"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate offering amount",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Potential Success Payments",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59",
      "r515",
      "r533",
      "r885",
      "r886"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r287",
      "r292",
      "r357",
      "r399",
      "r672",
      "r673",
      "r677",
      "r678",
      "r679"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r102",
      "r122",
      "r123",
      "r124",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r168",
      "r226",
      "r227",
      "r279",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r382",
      "r468",
      "r469",
      "r470",
      "r485",
      "r558"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r172",
      "r173",
      "r175",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r225",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r362",
      "r444",
      "r829"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r168",
      "r427",
      "r476",
      "r496",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r537",
      "r538",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r691"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r498",
      "r501",
      "r503",
      "r575",
      "r589",
      "r610",
      "r631",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r660",
      "r676",
      "r690",
      "r834",
      "r881"
     ]
    },
    "us-gaap_OtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Other Investments",
        "documentation": "Amount of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rentable area",
        "label": "Net Rentable Area",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r748",
      "r756"
     ]
    },
    "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityEntityMaximumLossExposureAmount",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest entity maximum loss exposure, amount",
        "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount",
        "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r85",
      "r474",
      "r475"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "verboseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r135",
      "r225",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r340",
      "r342",
      "r362",
      "r685",
      "r829",
      "r830",
      "r870"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r498",
      "r501",
      "r503",
      "r575",
      "r589",
      "r610",
      "r631",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r660",
      "r676",
      "r690",
      "r834",
      "r881"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r105",
      "r135",
      "r225",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r341",
      "r342",
      "r343",
      "r362",
      "r685",
      "r829",
      "r870",
      "r871"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r175",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r283",
      "r284",
      "r427"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r168",
      "r427",
      "r476",
      "r496",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r537",
      "r538",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r691"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r679",
      "r882"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r262",
      "r276",
      "r350",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r458",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate by Type [Axis]",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "documentation": "Information by type of change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r149"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate, Type [Domain]",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r149"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r538"
     ]
    },
    "lyel_CollaborativeArrangementRightsAndObligationsResearchPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsResearchPayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate research payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/OtherInvestmentsDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r260",
      "r266",
      "r389",
      "r662",
      "r664"
     ]
    },
    "lyel_SouthSanFranciscoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SouthSanFranciscoCaliforniaMember",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South San Francisco, California",
        "label": "South San Francisco, California [Member]",
        "documentation": "South San Francisco, California"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "RevenueRemainingPerformanceObligationAmountStockPurchaseProgram",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase agreement portion of transaction price",
        "label": "Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program",
        "documentation": "Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CashReceivedForAmountsRelatedToTenantImprovementAllowances",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for amounts related to tenant improvement allowances",
        "label": "Cash Received For Amounts Related To Tenant Improvement Allowances",
        "documentation": "Cash received for amounts related to tenant improvement allowances."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SuccessPaymentLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liabilities",
        "label": "Success Payment Liabilities, Fair Value Disclosure",
        "documentation": "Success Payment Liabilities, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share common stock price required for payment (in dollars per share)",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r445",
      "r455",
      "r685"
     ]
    },
    "lyel_StockPurchaseAgreementSharesSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "StockPurchaseAgreementSharesSold",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sold under stock purchase program (in shares)",
        "label": "Stock Purchase Agreement, Shares Sold",
        "documentation": "Stock Purchase Agreement, Shares Sold"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Represented by:",
        "label": "Represented By Cash And Cash Equivalents And Restricted Cash [Abstract]",
        "documentation": "Represented by Cash and Cash Equivalents and Restricted Cash."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment expense (gain)",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r65",
      "r113",
      "r452",
      "r472",
      "r473"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address Line",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares to be purchased under ESPP (in shares)",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_PercentageOfCommissionFromEachSaleOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "PercentageOfCommissionFromEachSaleOfShares",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission from each sale of shares",
        "label": "Percentage of Commission From Each Sale Of Shares",
        "documentation": "Percentage of Commission From Each Sale Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r787",
      "r795"
     ]
    },
    "lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited [Member]",
        "documentation": "Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_TenTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "TenTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ten Times",
        "label": "Ten Times [Member]",
        "documentation": "Ten Times (10x)."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SonomaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SonomaMember",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sonoma",
        "label": "Sonoma [Member]",
        "documentation": "Sonoma"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SuccessPaymentLiabilityMeasurementInput",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liability, measurement input (as a percent)",
        "label": "Success Payment Liability, Measurement Input",
        "documentation": "Success Payment Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SeriesAAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SeriesAAConvertiblePreferredStockMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series AA Convertible Preferred Stock",
        "label": "Series A A Convertible Preferred Stock [Member]",
        "documentation": "Series AA Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r82",
      "r453",
      "r471",
      "r473",
      "r481",
      "r516",
      "r685"
     ]
    },
    "lyel_CashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, Fair Value Disclosure",
        "documentation": "Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Distribution Agreement",
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address City Or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://lyell.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Assets and Liabilities",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634"
     ]
    },
    "lyel_TwentyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "TwentyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Twenty Times",
        "label": "Twenty Times [Member]",
        "documentation": "Twenty Times (20x)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Line Items]",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address State Or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r72"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r72",
      "r133"
     ]
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of potential success payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_EquityMultipleDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "EquityMultipleDomain",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Multiple [Domain]",
        "label": "Equity Multiple [Domain]",
        "documentation": "Equity Multiple Domain."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "lyel_VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "VariableInterestEntityNumberOfInvestmentsThatCompanyIsNotThePrimaryBeneficiary",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest entity, number of entities company is not primary beneficiary",
        "label": "Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary",
        "documentation": "Variable Interest Entity, Number of Investments that Company is Not the Primary Beneficiary"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_SuccessPaymentLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "SuccessPaymentLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment liabilities",
        "label": "Success Payment Liabilities, Current",
        "documentation": "Success Payment Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance Sheet Risk",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "RSUs forfeited or canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation cost related to unvested awards not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future issuance of common shares (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r386",
      "r387",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r532",
      "r534",
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liability",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in dollars per share)",
        "periodEndLabel": "Balance at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r241",
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSUs vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r543"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "verboseLabel": "Sonoma sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r684"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r77",
      "r517",
      "r533",
      "r559",
      "r560",
      "r685",
      "r697",
      "r797",
      "r821",
      "r867",
      "r885"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r393"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r298"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Amortized Cost",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r106",
      "r661"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r237",
      "r238",
      "r262",
      "r276",
      "r350",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r458",
      "r671",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r80",
      "r81",
      "r82",
      "r110",
      "r111",
      "r112",
      "r169",
      "r264",
      "r265",
      "r266",
      "r268",
      "r271",
      "r276",
      "r278",
      "r477",
      "r478",
      "r479",
      "r480",
      "r674",
      "r774",
      "r796"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r282",
      "r285"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r169",
      "r264",
      "r265",
      "r266",
      "r268",
      "r271",
      "r276",
      "r278",
      "r477",
      "r478",
      "r479",
      "r480",
      "r674",
      "r774",
      "r796"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity warrant",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r5"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected weighted-average period compensation cost to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_StanfordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "StanfordMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stanford",
        "label": "Stanford [Member]",
        "documentation": "Stanford."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r156",
      "r158",
      "r161",
      "r162",
      "r163",
      "r167",
      "r353",
      "r354",
      "r443",
      "r460",
      "r667"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r721",
      "r731",
      "r748",
      "r756",
      "r760",
      "r768"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r793"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r386",
      "r387",
      "r388",
      "r389",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r532",
      "r534",
      "r565"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r714",
      "r724",
      "r749"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r539",
      "r540",
      "r543"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvements",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r387",
      "r390",
      "r482",
      "r483",
      "r484",
      "r541",
      "r542",
      "r543",
      "r562",
      "r564"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r714",
      "r724",
      "r749"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r135",
      "r225",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r341",
      "r342",
      "r343",
      "r362",
      "r513",
      "r668",
      "r697",
      "r829",
      "r870",
      "r871"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r54",
      "r449",
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r543"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r685",
      "r884"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r82"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r82"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with restricted stock units, net of tax (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value and Amortized Cost of Cash Equivalents",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r82",
      "r309"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/OtherInvestmentsDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r260",
      "r266",
      "r389",
      "r663",
      "r664"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled or forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled or forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r685"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidations",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r665"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (loss), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r727",
      "r752"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r728",
      "r753"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic equity investment",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "lyel_StockPurchaseAgreementFairValueOfStockPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "StockPurchaseAgreementFairValueOfStockPerShare",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share of stock sold under stock purchase program (in dollars per share)",
        "label": "Stock Purchase Agreement, Fair Value Of Stock Per Share",
        "documentation": "Stock Purchase Agreement, Fair Value Of Stock Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "lyel_FiftyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "FiftyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fifty Times",
        "label": "Fifty Times [Member]",
        "documentation": "Fifty Times (50x)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee purchase of shares, proportion of fair value (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments due",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r74",
      "r89",
      "r103",
      "r117",
      "r120",
      "r124",
      "r135",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r160",
      "r171",
      "r176",
      "r180",
      "r182",
      "r225",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r354",
      "r362",
      "r456",
      "r535",
      "r556",
      "r557",
      "r669",
      "r696",
      "r829"
     ]
    },
    "lyel_FortyTimesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "FortyTimesMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forty Times",
        "label": "Forty Times [Member]",
        "documentation": "Forty Times (40x)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, Collaboration, and Success Payment Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r94",
      "r100"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r294",
      "r425",
      "r467",
      "r505",
      "r506",
      "r569",
      "r588",
      "r593",
      "r594",
      "r625",
      "r657",
      "r658",
      "r670",
      "r674",
      "r680",
      "r687",
      "r833",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "lyel_OtherInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "OtherInvestmentMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investment",
        "label": "Other Investment [Member]",
        "documentation": "Other Investment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r723",
      "r733",
      "r758"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r158",
      "r161",
      "r162",
      "r163",
      "r167",
      "r353",
      "r354",
      "r443",
      "r460",
      "r667"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r286",
      "r294",
      "r323",
      "r324",
      "r325",
      "r401",
      "r425",
      "r467",
      "r505",
      "r506",
      "r569",
      "r588",
      "r593",
      "r594",
      "r625",
      "r657",
      "r658",
      "r670",
      "r674",
      "r680",
      "r687",
      "r690",
      "r824",
      "r833",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "lyel_GSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "GSKMember",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "GSK [Member]",
        "documentation": "GSK"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lyell.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r134",
      "r263",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r279",
      "r351",
      "r561",
      "r563",
      "r644"
     ]
    },
    "lyel_PACTPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "PACTPharmaIncMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PACT",
        "label": "PACT Pharma, Inc. [Member]",
        "documentation": "PACT Pharma, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "AdjustmentToRevenueRelatedToChangeInEstimateMember",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Collaboration and License Agreement estimate",
        "label": "Adjustment To Revenue Related To Change In Estimate [Member]",
        "documentation": "Adjustment To Revenue Related To Change In Estimate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r108",
      "r135",
      "r171",
      "r177",
      "r181",
      "r225",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r340",
      "r342",
      "r362",
      "r448",
      "r527",
      "r685",
      "r697",
      "r829",
      "r830",
      "r870"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r294",
      "r425",
      "r467",
      "r505",
      "r506",
      "r569",
      "r588",
      "r593",
      "r594",
      "r625",
      "r657",
      "r658",
      "r670",
      "r674",
      "r680",
      "r687",
      "r833",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://lyell.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r394"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r286",
      "r294",
      "r323",
      "r324",
      "r325",
      "r401",
      "r425",
      "r467",
      "r505",
      "r506",
      "r569",
      "r588",
      "r593",
      "r594",
      "r625",
      "r657",
      "r658",
      "r670",
      "r674",
      "r680",
      "r687",
      "r690",
      "r824",
      "r833",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "lyel_EquityMultipleAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyell.com/20230930",
     "localname": "EquityMultipleAxis",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Multiple [Axis]",
        "label": "Equity Multiple [Axis]",
        "documentation": "Equity Multiple Axis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r677",
      "r679",
      "r879"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment of other investments",
        "terseLabel": "Impairment of other investments",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r226",
      "r227",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r344",
      "r346",
      "r347",
      "r349",
      "r352",
      "r468",
      "r470",
      "r485",
      "r885"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r485",
      "r798",
      "r799",
      "r800",
      "r864",
      "r885"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r357",
      "r400",
      "r672",
      "r673",
      "r677",
      "r678",
      "r679"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Income Attributable to Sonoma Sublease",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative impairments of strategic investments",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount",
        "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r93",
      "r95",
      "r97",
      "r98"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating income, net",
        "terseLabel": "Sonoma other operating income, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r360"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r102",
      "r122",
      "r123",
      "r124",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r168",
      "r226",
      "r227",
      "r279",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r382",
      "r468",
      "r469",
      "r470",
      "r485",
      "r558"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r43"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r7",
      "r23",
      "r345",
      "r348",
      "r382",
      "r468",
      "r469",
      "r790",
      "r791",
      "r792",
      "r798",
      "r799",
      "r800"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Value of Success Payment Liability Assumptions",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net amortization and accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r398",
      "r399",
      "r400",
      "r672",
      "r673",
      "r677",
      "r678",
      "r679"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average discount rate (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r684"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r772"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://lyell.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value and Amortized Cost of Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r360"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, non-current",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r499",
      "r500",
      "r502",
      "r504",
      "r566",
      "r575",
      "r589",
      "r597",
      "r610",
      "r614",
      "r615",
      "r631",
      "r635",
      "r636",
      "r637",
      "r638",
      "r690"
     ]
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsScheduleofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK\u00a0Agreement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r772"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock at discount (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r772"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r300",
      "r328",
      "r329",
      "r331",
      "r681"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r234",
      "r440",
      "r804"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r75",
      "r76",
      "r85"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lyell.com/role/LeasesScheduleofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 (remaining three months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r335"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://lyell.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r96"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "b",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-30/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001628280-23-037360-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-037360-xbrl.zip
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M4;QGKV2?LX><S[SW<C)H') A4:%1\F9@0BB3@=(K^=XL]ISDM<(^ >Z/WVQ
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MT@QV%_&-ZB^F*8GO?:"A^_\[P\1(2>FGU;IF0VGO:A4])/56+)0I.=#U&08
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M#ER6S97]P'9;QJ3"GLCZF"NXQ?6/Z^^"X+N3A.M4F20[B_,A#E0U<]$-//T
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MJX%\6 Y8=.$OM9O;;TOV9-BN.=LT?V1#W,414T>@EV;9X,6#NNVSZFLX("S
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M\DEB9PXC?D\N5R6(=CGP8R\JR?/9_ZVGF3'_E5K3"?,J"Y!I:];._.GE)YE
MON:\?)D)Y&:CUM4:IMPT6I5H:;K?[?-3WB _F2WP=>*6*\W;;):?YBU$B!,T
M"1%:)T([;[UM&BP96VG+NE)6_R8A9D+,#O[2Q1(N%WJF[2[A$AO<RDUS\5SA
MINF60LXX@9R0L[5R5J@[V79RAGU+C9;<:"M"TH2D'8&D%1&TA0,$I8N76>NV
M=5W6FEOW!MZ+C)54(S 1#F6)=+#/CF=3+^K4S<4$82[["<=#^).FW9_Q:O*U
MG[2%7ADQ/LK2-46#B6M*[W[89G=%\^U"(J@I[!QMH[5UA0I1)&F_2!,ET:K
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M$3"0RKG1$@.KDR<9:5<YCX9S4^6\<B(Y#T\_@MIGSN :;?^6NWH!8[[!>CK
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M"I]D/Y?D@R$S$I8&4'#GH8O>5G^U)%X9 XP[3!U0E!P*A5$\S7YV\&^^\5<
M\YPG30D_53%>"CS#5V4N;0Y8A^Z"V!]BT-X$8%"Q"7._R##38^>2X3#^6^$6
M 0)#7*93<LLN&0Q'R(D8(]A+=//[!^J!MXG@,7$VSOH^"C"OSS89Y%AI'BP
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M&HIW[Y3V 5 8T[7 XW?%[&?M62B@H<#U(V/7HMEV+VAW;30((QZ/&J43^,N
MC[0EY=Y^=O!^$<M?3!Q))O-Y6")\C4IUBKA)$P'3@T4J>MH3[1JDX (W^1?
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ME"Y&K^6D&_A QO#!"Z.? _UZOJ/_"$DTPB(/CNW".7\ ;;]HKHE7Z\&U+Z8
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M_\[=.(+WS*ZG+M-^7&LSV.P'S7K55M[5+^E8N6E?)P&8/7OI"6>S@X4O.'\
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MU*_2J\QC,#@G][N3'(_)>>PJTO!93%QN@D(39;\*C:9+&DU_+XVFN'MT-]U
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M#--.>057>3[,]ND+U9K9OGG]ZW$.T+VF;J((9U&>DA,OF&_$FR%@<JBFZVZ
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MEE;@)3FS%TS_)937A&4N:;@W#T211KT$8W:L='OCC=<-CR2O&WZH@1**;3M
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M<G]8*M)RD9&-S,]E2X2F32I&9;HL ^!^=%D.M0R=>EGCT[&W(\_)%N09PE$
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M:+@,97>QOP(3&"XFX76DIX*Q>DL',_1,S;)6_(! 1V(+\)*YJ<\ET]:MP&#
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MK>ES$W9 \(1= =._AM^!66EZ<V3]\>XT"Y7A9Y0ECKO"97\1Z@#?7_S*$EW
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MGFO<H\#=]K@T^M,U/P6I\""V\T)*_YHS8\L?%\.QK\B27QEG_"_\@GG74S2
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MTX\O7QW]Y_^Z..F_8+' \8+S">HMGW%S,I@R"/,,]R#*E/U]1MU.9Q3\H79
M^COZ'L)F9NIP/,5?T5PI*%9$5^3X'93C-]?/0*46R;7N<@K/_# 8@C,[&B45
M H?S<4J7'H9:1WF\8%?-P/]9%D:@"R5,AWF9 /'#R81"^2@;TWJ&SP59,^M!
MN4TG.E**XL+.-B(-)FWO9:CLC*NBSL:T]-B(3AK'\:M>__SF0W" _WT@S7=\
M=G?5-^@=K]-\,,&G5'W/,#LG/>Y %C]K34,*27(END,@O&$^I;,Z2O,<+V X
MAQ4<QVJF4RB8!*"]!OU #Z9$?!F!NED$,SBXB&VP46DG,L+[.595C<';$6B
M"<5]56R$*"F=6!,"+U;F-9V[T(E_<1 ._G;XH1&T0CV88ZT\A9>*I%3>X\!H
M075@91&35Y]1_>+'-0B8%@ [@H"7-4G0:"%51-$=&UBC\#&)KWUI[6A>G,K2
MX+#P<T^M%1OE=H*:LJ&Z:L'*$(@ 68>\J*#M4;W3NI$2!U%(*C2R:WHR67(Z
MG(2&(BHAO)!*A-@STL=/_TDQ,-\ YB*B=[IW#KWUX/\[[?_',_MR^,4Q_"(D
M?T- JJC^%)P"?(!(G%9G"$A9D>" 1X8Z\AL:T PI9-Q^S(O335V."Z4RD0&T
MGFU3;LX>2P>]J.*&87@?V\1 :I8*[EWJL8EB-*G3$#,0LVCAI3(8(.4OOEXF
MN;[2_$;A1,;8_Y81^#1,J\#=-72[E4_S I9='1K3Q+S"N\WM%6TA6WY^?M,S
M(%0!AT@]08? .Q6' S)'G^A@$"SG],73:7U_=? K/_SC=89%^&Y#V';?F<+?
M-H:,<I=G5SGEKCX1A*..30/XLG'Z\%Z<HZZC%/JD("#5@D\;_(J/>+?%#[3%
M;UD3V[TDE!Z:FJF.@(%"BL0PK*A]9!4,^W83VR2C*1 >2%]C_Y.BQ.!X.A'<
M_W&WRP^URY_T!@5+IQ8ALCJ>@G89^A,J"](('+L07 GL[HQ%(FW&BCPA6W&B
M?VP>YYMISMF0290@B-'($UZ>. ^!X3*DB9)GMSZ8;^&53\;^W!J$( _N!9?H
M2^LG*U)R\!WZ/M_+Y+N WBOMG81F"5UL#?<8UV&T$$32-$%&D2DXBF"_+ESE
M1X5._"H[N,&),PQ,?&VB$.DS/&LY28[U2'LL9@B]N#M3#W6F+MT@Y9)QGD\.
MX7_!*D/;II%*IQU\"5\#M5A253S;PQ4?0=W]-F)/.%IZO*3HR:T>U4D:<Q67
M(/2I6A +KGK![YC-(5GP!A#*KS!GCK$M3E!RCV0\X\OCM^X2WPV(SQ8/Q-CK
MCA=&FG\!$S2H3KD'G!63PQ@&-5G%>CGD&_3OX..TKJI4=9'++>EWNC/_P-:2
MYYWYDK["1]-^:2PP!WMY:(<)E+GOUX;!R=%_! >__?WLC!W.(_[GX/S94M_7
MLMT!Q+;I(T7@R-5N(%U2RP,N/=RO!JCXD]4%+C@Z76[I8V(Z67PH67R/"*",
M[@RM7C]I>XR2O@2#RC&7@!8'[OK1.0C&)4$<@U^5TH!J[EDZ3C <A]K\+=DR
MV@S#K+[$S#^^_?3R&;6;AP5XE:BK'.\+4\D_.#SA6OY--WV7<I;GQR>4LV3,
MT;I,96L>]X&3DON(/FYF)=OCKUYF;46*7,/+OB:9%M45O@_^3F_1TDTM?%M6
MOS1Q83/F;RDZ_/VARH8=JFP'QO+(J+)=48>H<<C+ JOO.B$=)7WIC;DDO!G+
MT12&0,%IG\'QI,84[7%P)_4ZJRL=O!O5!4R^%[RO"0.-2L.$\ZII4L2'3!-+
M.I$L-AH86ZF4@J'["90:%M)BM8X>1:.$"KX_)IR!IM_0C#)>R8BMD<*Z>_HQ
MX-0O%K8Y>GEI&7C"9C&\F>MR9DSPAP%M*M8F<S!3D@FT_&0+S_#3G+8@CELN
M]LU'L+?74J/47/)>\%.1R_U$%#O1>&&-:ZK?XQIDRORKK(![2J>N_.I$DS_5
MU=#TC7_74:IQ$?II6$8#\S89$WP6YV84U2QAI)4>U0O>1$F*MC>64&'--Z;Z
MYWFZX+0]/AB^BV./S?6@R7HPXT.Y62Y"A!$EA5O*![O!CHL&2/#HKQ*LS</Q
M)]F4+)U@"GM=$#H$[]@LTH$ _U(52\O+^J\S#CPOAH^,5X7H& R<RYM&&#"#
M8XJU9:5^@'_TZ&%-V(8I<2I<P7235Q%G]@I,>@M;,:6G==&BM[>ZIC*83\$J
M(0 +@<(YV((K'JL9O*8JK%>8FTRT#JZD;..84E6-B7,,2MIQE462?&N(FR\&
M(!=9GAF=@V94D7!=^)Y:F*LRR2AD5/G5/,JAQ$Z95,QH"@T+>OGAY3,X[<3A
MD'.EA>1(-4(A+Y5KFIN\J2Y::%-;[AD(O22HE:XI&L XJDR-/X,6PV)VV*10
M*S .AV=CTLEC&?#])3\?@\YE/[SK8XXT;)?\1%G3NNU.V4_8WA_]@+]SZ<(?
MTEQPM.L$&J3WW@(NG4 T!&(I5>I:4FL2H"@3S03HO:8[NYUJ[-2G6P[K ^8\
M[^\<WRUYV/)83<37DE/D-\+OX(4;91.[Z^:A9/:]6_^!BB7G[6![\/VP/<+C
MQ^BG&./G0A/_TQ6,GN0CKRLT=-$XU+7X3(3*YH4V5;E_B TP5P&&?GMV,,LQ
MN$:5L[0=T: #<VHZQ?? 0N3F!/#F69D36+'%>QBZQZ*KP^ R<TEZ**764D7D
MA>F-6^7RSNP;I/8R^*P6P3S!_+DNJ3<( 6:]T5RG['#0&BF7^8,+TNGBX/P'
M.QV?JVF1UU?31B4,,6X(T1&^VI(9Y0Z>U.>OHD)G+Q!@7&%]844!L@/=4MV]
M@%ORP_'E4? YR\>?09N%4AZ W[V].!R^_A%T85<2=3=1"RW="K4/:#);H.AE
M<"IN80S@(TL&#I* -2OWP58:?Q9NI5C"B.B&85H%A;FMN,VP';CWX03)A55A
M:+*INL#0-:U(RF&D+)"XFN@6JG*B )"655.L0-12""AW7/JQCIH2?]45_@L&
MH>.[R[1L/KSZ8:#-W4W9N"GIMO"YZ5"%Q$5]%1R\_>W5,^:L&@MY_9*Y0XP@
M1% OGC\)RH,C6[M]7-[':%12EPVF \3/LX'<6D\M/CGN5KL!M&_V3X.][,\:
ME X+K:M8GS_.OK4/\4DIZ?Y0-E\F4,<X']<SWG7*8) _1(C+*TJG9W[5K>:/
MU/B#D;I*,B9I(A&#%V"N.)C7(V02$HND8E0"7@94@HD$3_ XQ9<E)2_X:YA%
M.#WI!;_FQ2B)=19HAE6T="%1@$E7ITK%9$%]Z=GAOR((5\V!:+P"L?F")BL4
MHRYB.(^ 6U891WR[3V!UD&DRSWQQ(D2JOCS-%2EA>"?X'F' 8YK'7C;*6U"L
M%*IP:DP%29!576+HV'"27B&L*K^,")V=\28&@69;"AA>)&)1M7:F3AE) A3,
MY;K4O( -^DKAU@7?.0NP[Z@F]6V,;XR-7IC24'OC&-H1$ =5[[H+&!H'? Q>
MQY5^K[LR!E=G5BC"YB9(BIR/QT1=U23#A)NA1HMDGH*G+[25F'JB,1SJLEZ]
M77OFVKS"G;)I,EXR$%&=9S/+JTTR'YWH2 HSJ>D,GPUQC2,X^_K,Z8,5-^"9
MHP2F4GQ&_=%,&HJ1JY-]<O;QE*HOTP3+IQWF1&-Y,N<8\6,B"+O03\-Z=7=.
M\G3IALK<:=PDB.+0N,.?DY39U\HR6I .*)1_JZ' 4+_53!LZ+M;O(\H*@:T_
MZ(-S\/;C1^2^I(Y03;2@T-<-CID5^Z>\K%"T?[WL;-7'MW&:^ID!%.RS(ZR#
MH<JNLM]1FV<]KS<HOE^]<.9+.+6DKI.-B9EV1:7]84FA$RK0'1>)1IE:[@R)
MV<"A%Q^8XC<,7@!MF&"U+-:%1 0"+]UKTH1<VN/%>"DGY/287@$NIR[>7]D5
M\R3-L+V&#Q<)"0>./NZ4V"<TD:FNE^+?$R@"V]W%K%<UND6FU LNB>Y4; 85
M+U'42DX]1E9TRT>)/8M*Z:7$OAN.D@I@- H2X2'^O.$G<Z_K)>6DOCN/6?2%
M8)JV?Y9057HA# <V@P%UB^ZD<AMWJGP/<$&9;UL@7V?,>7\=.L$6%44])^]?
M##;;#P.=4AW6)"#PR]RTQNY( RV\\ZB#=^[ 6+XUTL!V'=[@MB5K#UEPJ:N!
ML,R#.JL\0+BCJIF^=77C!+@CL(]%"ZZ[4DCW0)0J]@84.A6'Z0*M2K#7K$8A
M5VC/;DJ\]G]9O'D-1MGQ^?!%8R58VU V78+//Z&+FZ9A\$=$7+\5Q^U\ZN^S
M(V+^+K'CG HF2E6:STFC^&/<H4:]99T0OY]44.:%[JF3XVV!.X;CE(<(3["F
M2G?"T2-E8+$)>>5D\POM>!R\KM$M@'7^/4N<WD$_(ZF.;_Z\IZY\8R2Q'__\
MZ_MGZ.IF<53$I5P[Q.65JB^)#J+/X.(B-BD:CN5LMG'Z$(U'^,]+$[@G,8/'
M@RPBN\^U&E=YX=V!OI$2JT,T*!JUH+1^Y+.,>2BV^P]_\,^<Z9MAR3)[/-SK
MN1>\N\G<&][<Z3A3/GG89R*:I>2#^[35XR(O2Q,5")W$N8T),HS2,QM@5&AJ
M'VK;A<XKQBGD*@?3N3%)+,'=MS,FT1L;1)%)NMS6LA6ZQ=,RS*G$Q< 3 (9=
M%4QJ\H>%G%OK*F[H<:-!4+INASI_Y%[IL']>3^"P)MFD)NIMQ-T&"T5R3.T<
MV2%=KL6:)5] BU)PR6G"0BV7C,.?(&Q<K+W*K7 DVBC-GFJ8_PG1,$^N\\J4
M-C)C3S(Q=,ZA,'13K]H"^S(E?^G0C]1#T5UQ':6UCF98!+XO3GFS59=F^I-8
MEZX7]S-M&U>=A_=::+[;_N.OJ .0C36?@1?QVG:'V;/#^LYIL,;7CVW!AP!D
M/%"3"2>I1@L, Z?Q#7:K,',WS?Q*'<O&[^GVU);!,=+/N$KS4812X:Z@XR6Z
MPJGHW<87%0AL<*7R>9ZRCXNOFJ3)F%EC?O]<@';'%L$JX_.-OX3K\/ EW-\1
M=\43RGU!XZ%&*; &TSZ([I2ZF.5)JL.COR9Q#%+Z.BJK4*J=L2%4POV1W4&^
M?/=_W[XZ'%P$5%8!DT-O>"+,-\6"0B7(3D=>,M81@IM'+IO38PC_A"T&$HVP
MQP>/HHQB\!B>12H0WB]SR(K/8'A<Y_@B_%8O>)/@#%FY80-V4QZRE$L\XA ?
M/8/VR#7\Y,FV^]\B='(0*^>F1UO/IRJZ1LRYOG\Y\IIH;W1Y(0W\=6DID68%
MX]U(!9G/="B_5($A[61)*VV(5&)7&"/GN9M%">6[,L%XD<$)&Y>^_&HF"MHF
M6:U0KV3):JL$\P,M(3"+56$?:$\&/5(/D8,RE!URNQONF>)X@]$B@X9P&F+B
MEL#%'[<VC.2,D31'Y+@[]V=T5L0V'A=&!) <I;Q^A93(>(1NB;M]!WUPNZ/_
MH;NC[YD<O7-J_4]#.5XWBKV>2K 1@MF9*0%U>7WAB</==*%?ZO0^/+F/CO=.
M7W1LKI-C@)5;(V',4!=T$$^VL7&IEFON]@ 8YX633)R#WL3^.KJVJT!O@PJV
M[26LW^_,U\YU&4&BZR,M(=J*9NAOT6G,,CE/ CTB:L>V-[&5+6W2^=C>*$:0
MPTV DY;&Z4NK_[=3KUO]V3?5\YWV9OE)>GVL6\*+Q%VUJ.,M";5&2>.BN8UT
M*=WGM[G%^V-E"UM5VE%PI,<48,J+;8L!EGKL(&/],[SK<-DYD<TVFS3/I:G@
MTSA5[#>[Q?9)%KS7R&*&<FNVB5-;6F^S3K&#?O^65K'8T?")]/%++^+0V@+\
MR2^4+8% 'U .ZGV[4S0\(S/=.EK:(]EL2H9JR,%R8%NE@B?.1TP' _!K>V>H
M+6-5]-RL%C4&M]"OZ]PO_JJ>PU^QKR"KZ* V_&\OEWJY_2*]W"YU+S=I!*>K
M-ZA60W<S@;_'RFU>-^S3'UZI,9L#\)M!</#SQ_^VSWO&5]7/:?0E_PCVP?2_
M*:+RUNV^]EYW7SOX+>\%)\]@5%S\C@^G;P8_@TLP-[\_T+WFPP!>]JR'_P7_
M$1O?11K/Y8U"'!5T-]S!#D.A7M%-NN0"T$:R)U-+!'K<FAM[;K.1"F;0 V,&
M5NJ"=D&2S0U;]OVC5#._%QDQ*U4^+;)<K(-H++W\T'J#C6%F"!+N+*IC$H*7
M.9[4DG\BO#3M_9L$B^ 1\V#;G=ONB;Z/X;D8FW@8@M+Z5RA5Y>:6CA5X381%
MTLW7M3@Z!],3R;TKM7\KAAO95J;>W7 P.(OA'1MV(+V#@_ZAR>>#741Y$,RL
MD+Q2>,=I+>GI<K)@(K2:1_[BEFNB[M]?'ORXRX/OP%B^F3SXEC;H.^.6OT;G
M"V'$NZ?KMKQ+/[B-5E_9K.'N36P]!97366)%XUB]94(E2C N\D')-2TXW%Q;
MQE^,)&),>['T*,GB.@!</X#2UL>: ;A$H=)X:[(< %G1I;@,Y;M5;IH5N\5_
M()XE/BD];$0I+ 8.";P_'XX(!DPXBJSDVT:6)[3I9XHLVRDV'NFMLX$.+,PR
M4PKNAC+MI=R5]D_"=&C6(T,'E1+3R@O/TKMZP>^^X<^? "%2B,XESI$D9CLJ
M*6*&A@J^K1E8:MLQRZ&$EC)2"R&/F,6L8 1M@BF&D5T7O_<M-@IG /*UMB.0
MP= $<C+I"J2W?-\<MP^WGBD=XI&^QMFA#5'AG[7LB*U+%0+*,#*8L-4D2HH
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MZOZ7 =B22:G9#GP3E\@ M$T:NE:B-?&0:["@V*1K=S:2H_LFHROU"-%6BGH
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MH%$0U0'3&.'D8K@D*CQ"UV 3X=ME.0G^4:(Y]5M4QM&_\5.T>CAM>#Z>IS!
MC52RK723(! %ERZV:ZV7@M!*BV &>YW'B/6:)14J)_A]&MV CH)A4JICA'=6
M@*;;L/^B?8/ICX,7^&+4;1E;BA_J5,SVX\&)7@ K><'EF%9T<'$$6@F^&LW8
MTSA8_MPS4J6T1. NT\8E!'TRABU/R^[04:__'_J=#?4EO]7W:MNV(*X\=GSP
M]6<5I;!0R6Q4%Z5R1X/7@X90F8P.J)J$SE==PL53N)_'<(;$#22CA;*-VR2"
M"V\*\?=X@]EK$J\O%AO\)(G;AD/?5+WNC#GYIB;XUQN8'YZ,#VAE%,KG-MN/
MF^(/Y9@<9.BX#I&71&Q://I^!/%2I5)D4TUX82+,".-53.8)?KD%=KD,99W
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M@*FMAYV:RA8]LY%R#H<^A_J447#1D#%H>''K^B(6MT[0\@_FR5Q1#-09J'-
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M=:G)IUL/W.Q\!K:Z[4=%*I(1-HJ[>VD^$F1T4/^N%8>(LML)!)BAA%N_(@%
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M?&Z6C[3PG9*:*[F6!Q;OK!?\,[]1AAE.KE7]12_1%7$S>P&M.\ZV-R][K=&
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M[,.&"7_\N,\(()._GM(H'N<[PP!:/BFW].5,4WW)%92>FL)C2><29?E\G[3
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M_<%("3-*\,O%(&E16N9!3Y@.[F40'LA0G2'?Z2O:EE"I]EC8Y=2@1ZB[S(<
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MWEXYP";XPNU-?4/E6!\A^?>DI(AXE+Z4Z+Q+=%!J:87 ! $ZMNF%C*.#BH6
M!R"AA+:BP(5F+O4IX<YQ,+G?W= 'E8^<9SDV.(:(3>% ]+Y?O%@!GEV&&E,F
M[-+:!"\-PC!?M4(:&J<"1B%PR%FV1QKFT]KB;G%R]P3ED 0M&GHF' "6F<"(
M4U_CS$S++&'GTAT3<S5G3.Q]J0G<>L#CM"@CL?6##ZXAG >P)V4*W&1$;E-H
M J?6E%G#E6,ASMNNT@M#@!4]-^M751U01H[B'A#)773U%Q<>@S$6&M-/[/J%
MRL]"Q@J5+8B+= %>X(AUN/B$4%=%T&;]N)('Y[%<#%BU.<TD-DBW6Y0K7"J
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M\X=ATD0;O%GG[UN8<^Q]E@9O=\+$L/8&>X%MHI77R4_;[,2)3ZFXFB1BE*A
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MUY]%K3=E0A$8#A6A\;0(4!AO13\PKUX+7V;>_E'J]0*.CKZBY:(&M"(LTS8
M&!'52[2@VN.W")0#C6H#0;IJH@%)K\\M$_PXSU8OM.XE^L4__IW;.#F[U708
M $NT3[L+'+6R HVL?NIJ^:*&!?7,3>!^*F# B085_[5-*KT@L<@R@$@5HX@Y
MD&:VI4E(+MO/\@YFIN,*6M.^#23FV2V<'Z3!K7["]=$CY\I:I+G)]^3HR7&8
M$>(\T&,$YUR^SJ @WR?V1ZDZQ1(QXQY4ZAOJ0\L/LH=4K^>VJMG\YS\]#*UY
M_KO?_M,_7E2I?"R\P738&^NA>:,:G3A<?PXW<4>\1'E5: L[PV//07,)_GE
M[',B]_*8!5@IBQ5O/3[3(&@R)2)N2'&=E+GC]21^Q@=T0)J.*9KNMK--F82D
MSN*"/5+EDI]JOIZM/@]P8@R";<?U_-]__O??_DZ\';Z5@.%+UZ?3@8G"',EJ
M"3O;^Y>'JD$?2I?$_KA\$?%K:/<YR7XX:?MDB65^.)<L2BMKN9.ID!? ?A7H
M?:Z4-U*FK(+[7/"MBF_]]PN^]0-XEE^'\F$2/&6N2FLQ5IG31;,3DHKXLB:Q
M5;8*W'+>ENI= CFE)KFR>2P8G8H-$CAD:=L9]LI&CQMT9=>H*R85&M#IK:+Y
M:W94M$L<\OZF;K5GO$^#25 U!& G-:1D'>95$N]29DL/8N^0&JV[=%BRVQ@-
MHJ8RP&GD= :%:TG: YM[N>F#]<[R, 1!J8\Y Q&1"<@DC\F48"H+NZ7IW3/M
MGJ7?0'W1Q3 Q6]-P:OVU!3SVZMN1%RI((([L,=CR6SH2?1E9""%77WWQXK.X
M*N+K ?-#Q70;CWHHT=;DE%;YX1YX+'@,[$?O!;D= !"R%%Q]SAF64Q>U0SY;
M:9)W+"N0U!)6FFM M /3,";$$UB"]5LLW''X2NF,5O-L0[S*L*5^<QFE.-[X
MD=-O6EFU8OZTX";5V[AQ#A,#OBESR8G=P.\/W\_?B-ON^-)Y>^R:^04JR8]J
M<Q0JSI*W5V^B:=1Q<!Q\"*V?/^W(C"Z!"4GQL<4,XH.OSX[/^"V)9 8Y)C8>
M0R-KFV'Q,N&/7N4POU,;_>@X:63@KN,^,B7@L7Z'!"MQ)1]#C1+F0J(P3Q5#
MJJ8U1!M61DI-'Y(*)Z@T"MMJ>F^.DA:.(MT"3OA-*8L>D1ZQ?'RW@W;S08]6
MX0##"OGQP%T*^VZBETI$2^.I 8L5(I0X#3?))& + V:D5AM:YC1&4T_A54&/
MB&M00SGT$LJN.[A=?*!XQ>_CA0>8+$H["M47:OOBF@CE %BX@0IJ2YBU08W4
M5!ZU=1VGRDQ21@:<9AU")P</V^4XZMDJ:3+)9S6OI<#K4%ZPJ#G%:F=OK]:0
M_%UHPVQA?SL>9/LTTR$S313Z?LPB)29JB'N1PE!*IVI^%&T>5,$\3\!6N)LJ
MT*< ;BG2CNU(J@V_B7S-5$O,4MR="X_//'OQ)9,*E92YD),\9\K)[9QW)=[/
MTA$;JNU5;->&PP:N[SU5;$1CH^"X;R;DC@,U(D=U!^<18=F P>HF6K #-!35
M/?@+>+1!HYP:&%+13D@>63L@Y:VXGOHX4]1#!.5.?6I8(5@^1#"08V/CLX$U
M4%\5"(@>2F'87B^[A#X02HQ0)09 K\>C.BP-ZQ+#$C]B0;[.2S06$MJ$BA)N
M^7Y6&X5N/)*1DELEW] 7!:7OH:LX#EG,(LZ+!$4Z8"PKL$VN9):%U./\.(&0
MO2$:2)!58,Q",4L'#/=A0#:7^"@)3P.,8PR.@TJXI=43NEW(CK!XV,=OM\>J
MQ(F1::78)S@KU[0NBR><3L6(ND">%K="?<1M"\6CFQ,;Y-SL\#=_5Y)=MD&Z
M&(AOC/?>3G/Y"9E@J>CEY3H@Z-+.8D=UX!85*3W*4I+HQZI_R&T )&A))7V>
M;<T+ZPN63ZPR85AJUQ,L1!AAR/@>C7\,(Y&%",BBGFE@!&?7MF%MZAJ%,2YN
M.'2OCDV XITWGI0+0J(TB0V[OI0Q*09XT8N*&XPR>KW2B>["N2UU%P/@&0-]
MJ'CV9R'3]=%7]+&?&?DDK[NZCU'*1Z_>?#Y\S#CXFRD&X434$0=F/^UN:M>;
M_!<!=KWBZQ%P[$_8C+OZZ"^O_O1QA=M$)W5&428.+%'1POG,)18JJS ./U[W
M+:X0+-!#@9DR>\.QC5<&B_ORQ1O:B/&MW4?65_]O@HBH9ST.YWKP6\N7=*CJ
M-AN>ZZ9CT0\2=!Q#B(/T^<N/ 4^TZZCYWW_!/L8B1W"CP>X4B"R+P!7Q2[PO
MHP=%0L5DX>W=VFF]"W"JK)L8)76[$"U(8#8 %&31FU,]*#X;) =HSU'&9!NL
M+S%AA(,<RPB.W4!!DV(!"83="1B$&JPE=@SM7=-W+96@OKMM=N2LQ GW*P9&
M'>S#'LA8<$=.+8(LDJ>(]B!&& -1)0XS/B!2QP6BEZ'K0[YZ!V;@08&;>'<5
MB-Z^YW Z#;P]J2=Y-D>*2I+[8AP*O[X',3ZWKF0@_F@#<=?M8H1=]W'/<UH!
MZ3#!"8-TWLVM[L]-6&.=\3X^*MS2^&@P8K/SAV<>22]5@0?)B@*Q!:#8 EA>
M++CA@.-Z3S%Z3@.'"H=$LHD?)58#S&Q ?-CL#V$3U/?@>E\CU,0%U>3*4ZOB
MZX&R/5V<]8T(HV@@0M8ULNN>FQ%^H?*<UBC$VP]9KU,JODUWD,'+7$B,HBCN
M]\YD9^=_E2EH->UV-X6644!P5,9;M%P0YO5)PIWHA" )6Z&= H.<]\7G5-CM
M>7L<"(-,P>UU]&>;:Q5\IY<Q]V4?((,4WY2,%BP/(WY^Z(;T[M%"N=AT32&D
MU5]\J%@Q(8>2%*1ZJ_ SKG?M#Q.JV4R*E\0:HC]U@^3.8"HP9<D<4!V&B%"@
M+:9^SFPQO]89K93]1(C)FWYS16)J&#K 0,6C@[PL-' =+6]<V#)Z5:(#QISG
MAF:#G/Y:C)L*GMN<30<D6&&>,/HV52R>K>Q9?<#-VP#3&N#0W'3Z%7M"),R[
M !(4D/"'"R#A WB67P<@@4\%"@\JAM:"#T3N 8<-H'?0=9J:UITKY5#?MJG[
M&P_04=LH.%:42L/ZMH.( SZ!EZ/FP-#[^\8@7?0 *4HW7U"K-ZE=9%N8O 8'
MQ6GK<7PC._&/4NR/CXPQ+OX\C3ARZ!"AQ3N[1-I;\O.%-]I<[%+U#$H$=0_T
MY_,B&@<24I$"/YHK>5")B)?F% _?C B42XEW:G%:!](K*'5X*.9B6]]U/;L@
M] K168(D>8$NLE<BT%_ J?^MY,G:!V8,$3>H;)$/R*8+ U.66F:H/':XWC6-
MS9 )'7+=<!AEP7C"GM)B.=8I,P4+C$]%L!/!.1K]8FB?MJ3Q(GFV^G/S+MPC
M<BA)?6D8R%B1!YLRXOQ-4#L)6647C T1!"#[=6\L<EEO.172@'T7ER&DN5#;
MR)<8AC!>U^MWNB2O2%ADYLIC_$7NZ! ")^/VS4#>L:YJV7<+V[+ -CL-:7 W
M$W*F"&Z7)AO\]9'>F55Q#P=0UQ,:UXH:>G#]0/50@V$(*:@:>>*EI>(B?(K4
M'>X53F3QE!8)L<IJC\.\,&+- ,4:\]GEQRV?"\S_4G>3Z72>-)2"X8!DNG:B
MX&OVZ1>P((?[?&%R>%IIW HVMLKQR"<J&5KI7Z[F<2G*!<G,KOAL]:6)&HGR
MEO3W$.0NMS%"1$BTT3N!_FR[8JB7+903K0!C'OR>B'AA[%!-1]V87'9 EKV+
MFAY-+?R!>A$O2R4P3GV!E@&4)L9; X 2/$'R7+A8P:"*7 PX5M&LGUUZ_R?L
M/_G ^QDP]0Q.'0O:GZC6#ZO;.$3TM1+T*JU$G1")ZH/*IF5?HLM(3BE+!V6E
M-N[PJWP^6'$OU++3W'0(_W+E!P-G0;)- 6*^5=/CV$J@54SEMR(K 'BNOJ$T
M,@&/P5HS@C*Z/^Z=3JR0GP 3>L+LE3"@XVV/V7#>T56"1;*M[=T(>!W5O\L6
M -K$Y0DGREXX^.GZVFDO@$_1:9SA/1%O9[7<*A&86[A94GFRQK@!W$=(AZW-
M&1U,G*D-A,E)1XDBRN-R2=._PHBB9[-W&!B^/X^29M,")YZ<AK@WX32=!E4!
M.) V'-R,DO>PUL*F0$ J&-WT<_%!S\T8I_:&UR"=P=KDRQC613PB2?I0&@)3
M$!R9#AG(#HHO"+1SX%3')2&PQD$.-J)>@9V/UE8//B\9=C/5?0PDI$0YYXVP
M;F57BAN4$]K($B@],JQOPV:"M@.PAR/TUCY;?<7V&UZ@6X..J,^8>^#HC!9Z
MC5J;XJ,]5FNK5OAB^K@96,&+I?'V$(<77UH\/5<Z30Q$Z[KLEIOA=-,AYL'Z
MXECG#6X@2*_-XOE=1G^#($81ND8A]J 4+J4$AZAG#+=4AF1-STWVJA0:03)M
M!+P,)+F":$DB6 7*RQLUV4EH-[?%Y[:_$SRU!+HX&6ZIY<U4M.[\8LNVF7/U
M'P"K,S<+\CN$,0FQD>@A!E*L<XST9J(PQ&)L:GNL\R@>/R ,<V+)&C[98D*]
MYQIX@TSAD2,AB748-.G!DID::HPMY01!B,5BI'/T-RC%5;)OZ0K^EM$+I$HC
M>ERC#;E+03IJ.$DJ)I AKE4^;I*V;BMC^=O<1!<A*@;T.FUL($GD)*WCA 6,
M0T6@H[DVD].,<,&><0FY)W,,3[^X-O$XYP3NOW<- K0EE30P.:U*9UUR6"L/
MY.EQ6K%<^UR^$>7M"<  -#>)>B-/F>#P'G&J:2=?*26V<&C?$"Z4N5FT^ ]U
MC#CV5>I;$B,)4@9K#"-I%](GB9]SS/^]]$*8A_"0)_"-1A$.M8=I-RG=C],>
MAIXP$BNLCH0-3P@,% :B__+/SW__R6?/Y_GW[3R0A5G8 U/3 ?2XNEVSX7LD
M+O W.7*6D=EX])>?#3>]O80VSV1O,&N7160 C@<;:F/(@F!XVLPXL<(/83TQ
M)X\RA\W]I4%4<A?%OIU).]U%<"F"2Q'\=Y]<BN ?P+/\.HK@,\\/<^133EH\
M/)A6 0.LW[GM=AM-%TXDI_TRNR";##1%8/QC6'^@H!QL&8,#)8A]0%AV#NR^
MR+X\%=]G<F99]=3I"UL\!J[B#\T:RY.5E1GB=-TU=QWQ=,8?Q[Z;U3KF&,\+
M(^_/-,/F2]JL[HZNTZ."O@R S,4[_LV\RU&<S;K<AA$O1^T-M*<IZ31S.B_S
M^O3SVD-R&6<**GI[K:P^MB!H#+ZB]]%#?7.'ETI(SB^3^S--;KE:0G/V-Z5,
M5J[;'#!_F9BGFAC;:ZW;;E"0<)FMZ.X,19U"$M>DYC DYH#4_,LWWW#UGKX8
M]QHE;=BG*I8 VW#3R6F:<!ZX--!.&!" 6QJS^,7GN2R6I]_%K]Y\CGF4\18Z
M,JRO2]-#,;BF$J'.RV5:GFX/HY(+99'8A_'DZEE?R\6X_EP3(U4AF0O-5>53
M0$#9Z(\2; K;=:S_@SKCKJ;#9::>+FRDXXN[_9:..1.J?6SW%]-_[B71E[4#
M0BKB,JM/*_XA$UBA9V+1 [9JD7$,2*-.=0DFF$ETF+&YL^\.1,D_<57K8CV?
M=/8$Y08G6.BA$1%/K_6ZZS>8PB<$8W$3IAV.*9%8#"&5<^N/+U]GG^V6FBS]
MQPJ0LLLZ>*IU$'\CK 4"G%+: 8#PM,IC :T0"[1KW'=M*P%Q-[T0_S,0&A$-
MXUR[L$R,J.P9TK?=I;U)5EV6%J?+(GG"1<+,%R[5:]TJES#Q9YR+G(]8)^1_
M)N!OQ.,6P!=%7E0&9^:9N6B7+_/U1/-%M:U!.3 ]]45T<X'V1B!""=,'@#HQ
ML9/COS*JDDIH<;Z *LJW9+N_[EK0%8$/?@[\.@P:TI1!_)>CYWDHY;N90D[.
M5*01!4CI)A#_PF957W=W9X>P99+,:AY$*HM@N509AW/BQ!Q.J6D3N#F-6^^1
M<ZH3ZF;RI2:"YK/YTTZE<PX%[%4 S!;\Q26/3G29Y +B^N-=)3B<*8?SVUE8
MJ!JI<,:\SPHF+!Z7BQ^,&:O5!-0<80BA36E45E2\0F_&BSE5?L@2$+O"U3'P
MF9A!JL 2ZZ26K 4#6QD3#EVO)PM([;7^95>OWY&WQ9#')7+'='S/;8<:FIQ[
ML:77ZB@(ZSA; E0#N-AM0*TV(235)-$-8*IGW$$./D8LGW.@7;QH'& L@QOL
MBEQBW"O20"(DA\[DOZ]:8I7" NM$A4SK L,R9EO1<M! #(9%: -+A7SYMK)Z
MXII]X,(,XLC)H-NCIY/D\1#X80D^^&22D#^)^B-P$#(&9OPY%!__,6*/'\H>
M_V:YKY8ZG@"J-30$*,Q%]1".:_V!@3)0CA#5(R#O"+)-S1@%UE)DU<U[S:3S
MB'K[E;)J5U\'3C9++[>'6;?AAFRVTENO@^=[7R#%+6G]%7D^4_)-QN2[<B ^
MGC2MR6GI^)9==YZ0Z,((U";HD5XOND'UCGH#T5!*AP<N[N.#_H"SJQ.PY7$-
M!55<XK1*3=2W/9[;,O[KTBK%18P^XTFI0%[KS/11=&SB>&._1C\=QLI6]FV<
MF6)G:DX)7%,KARZ$N#QU&9/!X2N>MCPE5^QQS.''N+ZAG9H?"<E4B3BC)P"9
M.V:]$J9;/DU;.E42$NQ3Y-:MXU%Y-.&"M$K0>%X S I@?GX!,'\ S_+K ##+
M^3VQIXH2&"(XX;0TU)^%^ E;3/BO2+F,[N"SU5=X)M7@F*&NP%T#W?"Y#37>
M7*#^?4NM(401+"R9J]L0/3?JKJ;VC($Y=6[!DT4V(')U-\HYL#Z.W;OX?B"(
M@$[P<&PW/7358I?M?C^U<GIT1%I]Y;+H;9@@GF9C*5\%QR')NZN2./1U%7+P
MN^/^<-MM@@M=7OWYZE.PVG'66GYW^<:<G3SW5-Y\\^8Y]Q5SVR; CUSFH04J
MS)TTKR0' 7_;GX-=7&[8V0JTG]LK;GSAMWY&G,MP.WQ%+_\.?<#MND-&:#L#
MZ:)$,'Q<N2F,"Y++87@(@$T%]PT_\6SUQKKZX-!)>B!AG6&4!AZ-(+R.R!6Q
M&F!QBE*2$TG>9GF$+E>)YIJ'E%T\G]M2B]BKE@FN6YKZ:OZHRYDL(Z1X5.^.
M=T;HTET/%-[$Y[[&Q;REI-I<3*!]3/!BA#L]MC&5VIN)BB,9.',09,9K_(N6
MN1C8(T^#@3;'AO%9M(O/<]@F[5 .6R+>E-6DY#5VC5QSO:N;_=FYL*\H@)4X
MJ7Z 5T@<J:'H)7(H(1[BP(WC3 9^3*(Z*%:T#B:YX#_[Y,20DJAY$_!P'.8=
M8Y<*O?22/!VN;I%O2L)/3*E@ &[4+UFF:V J&Z*C(J.#K!68ZI'(7*5KMENF
MV@'7_E*C_ ?,K3&'&<<R3*IF)P:@%F*XB/;"FN)3/1-YPI9Y4N?8A9Y!F4;+
MC#W.1)\HH#'T-RQ*C<Z5TF2PM!(\B-S3(EHI!3@.[_H: $L.P7!95/_ 156O
M]D&7!4I"@/^T8^)MYO@R&Y*<*>!E;*"P C)6W#(AV%*&&E+V09M=P%D%_YW5
M0A1<WPC1YXJ*0#?'U4=OOOSZVX^QUQZ1^6VJ7).2]%H^.@&\X+-?EM=3+:\R
M70;+36+:",K;["C>LQ*%3!2$'<KE3 G8AP@1T;6VJZO]2Y? 9;Z??KY]CMQI
M$\;]"UQ%_#E@L(T.)>D)"@(G7*;J9X'08%DNLXU,=DXUPZ2/Z3(1/_.>T?.N
MZQ<#W\_@;+Q,S%/UCDV0ACA,W( +DT0,WN>6;WBA-7;+6U)H[I*]C":R;(NH
MA-;]V$)>@;3;-=.+-KM1QUX*.Y1<X"P<QB/H"OIXL>>;.WEL9))ELS/7M#2-
M&&)3M$H10 &@!6FA!BTY;)>^3CFZ,(5M^KR>[_1]ZZ,?#,?R*V+S!JJ( _R5
M!P1.X1;:4Y$80LG=BT2K(*[0MMV$T]B3;MQPR^,$A(^0$(#_._'P>J"JIV0"
M\3;7 5DLC? ,THW,Z_XN*#P+8>A]F>2 L2,9[VH];1J"IT &>"OA"7YG$Y?M
M@E@KH#\PP^B 843!#,XD//*Y[>VO\CG1$BVI_0'/1#.L=]T0A.?]D2MC229B
M7A)6ENGK6@L2_KIU'-SCT(BWT5[9>H!;6G+<2T6(BO6V0<"=5-HAATBXWVQ%
M\#)TT _30._#+3=M,U4SVR9\82>7C:Z0<@&O5+B:,'W $H=U$%R[P,NU/[ T
M-+#&[D4G.H[-6M&%LZ<>\ Z2[:6A(4?,QL(5V;'(Q0G@#:$0:*PZI'696H9=
M$4T><<SV@4GS6'$3,_RXN%<*Q=UW&]TV ]--0%YO+RVXIS8D40B)X TE"V2+
MN3V-"!\E-AE$"N\Z0)=IU^?.9]:FDI2IRHEQUV>E#?8\"ER7R#@CD>6\O>D0
M&)PSKR65,BQ&\#:1"XAMC$X!,.J@LXRWI4V3"M?(VPUUW)N\?S#EX:@ W+H@
MQA=(G@@N%RZ/D,@M9^1-5P$))RP(QF6,"^4:P+6Z6I"A.5D)&R#6I)?"+^%R
M[L.>%,S?U[JF$Y_:449?B\'='=U[ZWD[,S[W0:O$NZ.<._#4Z=SX5QANI?;&
M/4U42"4!^]44W8M=_F@H(2LFZ)=C\'$RU=C[L45>*-+X^%$V'CB*'[A:B;\Y
M4U(E&5HD?*6S!^USCD]GYFM:_V[YF)LA'H;CL10HTF!$NB?]$"OCRZJ$<M5U
M&.]A YT:.MQ3MI38DTT8/R OCJ-[#<AT0,PJICBOYO-LL3+"J?MB*P2WF!"8
M=W\(8X. V=S+N>O@]"$L-4L=]<U:Q1? P<8\:K=^M[SZ?WTHJT\O**L/X%E^
M9I35!V/6Q3&C*KYO'/(UFAC)4L5-)80PX,:X"L6$%-];\D]#YIU6N0MB[FB/
M=S#:<FCZP*J)-/KT&N6C?7+^5PKC))DF_!HX(6KPG9^-'/3U/NG+$-!(7\@'
M%*^0N9#2DD&J;V@(*0M /2C41?:(<,C</>_JU20-;1X9ZBR?GCI/LA'MOILN
M;G/1B4"&*RAX9*T53&CL1;.JK'TEKK@J09/,P#-S22WI8O&S-CO#*FD9,[FY
MRLZUBNK%;5P2&%UW+9UR9Y<\><L0K1+21OI?8B"KJC;@@%V!XS[MI0L@T>O@
M=BKR.:CW2<CJA0">9U4+9._5A%*ECH;T#Z6I-9K@<W-TOQ/*<MP?)"[;UN-I
M%2E(!* H(_B+.Y@F2O*<U#[*<*H"TP.%>ZQ=A433D>(+:US)D.]OKP#4: !.
M#);78"O[Z/UA:V=\#+"2%)L6UED]WD(M5/C2EW>NZL&HO%*5"<[H0DTZN9P6
M 0W,^:V.URK2KC/K^PP2BTB-<_UT4S@GBA)<<!)>]UV]*6M;X0IP6RR&UXP\
MQ</A'I#$0M^Z) + ,9$J5KAS[81BA1[_&$8M*,H\H"5%C5E>L<DA</$%'AD5
M"CNB.@D('W5Q/CC&"^J,J?)7Y_+0%%(N+WUX.54^K6@,\#MN43L"AY+&B6NL
M\6U;I:.:,+#P28VP4UQ< 9/P..G54^\8&NZTDS7>L_*K]="!QT$9F,ZX*7?2
M"99QQ7H3Q<[6V8%F%]H7R5V1-KD3TLTXWGOJ!YSQG6."2#+'%WCJ4U54?Q0
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M')OHHL\Z7JP8K#SE 9@H=JNW/1R)6$2FD_ZCK]Z^_'A%^W^G_KWN7WIBW$/
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MW<;Q&#'(.4P 'HX_Z,B@3XYLJ0B";EF&$!M5K\-X'T*")>-. G'T3+3=<<B
M.^??2]H[BHZ0]\:+CXMY(?_ <=8&E=6"VT+-<6+FP7C/87OT<]:7!MMG,7:-
M]EK5QR04*+RPE<3H;;G'A]IHR=Z(SB6_*U7\O?([1X>SL>!MYIF/N3YR@CO
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M/B,DFH80O(/[>46H+TFZ7/&)TT;C6'Q4O!0>E=4&%K5E<%$U<X">9Y>28;*
MJ!X@5##S'?P3$U@S$;Q/ %F<&Y5/@[2VUE@]GZ,U1CYA6J:S23Q*6PE03[[,
MR%4J?S6>)=^N$XLKQ,P+ =T]T&Z%Y;%N=N!3&'I!\=0?I8HI7V5?9*3+900+
MW>J-)!_+G"A63 1S2TITRKI*<-R=8X&TM',.=%-$9:,6ZDSP(0#@1RRRV!QC
MLL5 K/P6B@)#IAY&G7N_!6%WM2C<VW+U*K [$OP+WMD/C<EN]LL^(G*V :4+
M;M8'A!+,=00B%1<MRE,91.7CNSE)/HIG= C>0J/LT3BD;WMG57*HB.,C_\CP
M-8P;[.4(_)6P$6Z<@NCC1!@,T4J0J$4E>@A34$]P.UFD$*1M2<H'SC(QJ1?;
MNJDZN5"O3Z65$OQ<Z%?<HDXI71A$XV6%4_ ![!,A?D01?1V.)[A5+^!/^"KH
MLMHP::#6ZQ?+2:F4=WYB#HDD$DIL\6ZDG1.3Y=$*EL$W$E$?4VT6EG%9<1A;
M"XWC(4R-;@\^@.GB1ASXX4_Q_&+K=>'.Z6/"9 Q?'NVR&$_K8L"CJHM+V^Q-
MU,\[79@\N\\A%&7M*^O5J/@6MYT"^*M;,'GEUBSU5*!(3$%J-LA0> 4$ H92
M!.56_:,A[ZOS@D+!H*8$<%$/:6#?JRNB.Y(L%(^%$*B,LG+43%D,-"(0F,7Z
M4,>Q>2V6OT$>1=DZ[CF#EP\(9@(_SKP=<J4&D/PQ,E2)6 0MHA\&3[-G)+<B
MBGINDZ2SRA/ND89L_%FY<%L%%;WG*W<MN9CEI_&"Y'IT0;]BFM:"<[Q(@2$7
M*=GB<5J3B^0<3/</[I(]U]R @10,--R @1[!LWPS8*"EY]FRK1PX%-B^1WL;
MC"[9QC[_Y2D'^"#-SE) '6>&CP+V:5BJJ6V-\3J!2<;3#'CY4'/*"]I8KM(Q
MIVF(]F&4S9 ,$D):BNV TUGP0X&8$_[,W[TH_8]8\BB0.D*[3YH,2ZKR3'_#
M:8Z4<?UXE&#8VO<;?_1S@7JQ3ZE2V99<8:EC&'5T\JQ8K3W')%PVD&0- 58X
M2U5CBYH=\[GOUDRG9T4R%U1(WTE72'C3[_\L^AE$?=ZY#)X=4=R##O40K+RL
MZO.3/8L$N^U7,2+BF:Y!5CY2M3'Z0@5,R>ECDDWNUD"".7!/*DA I)HA6 #2
M!4L 516\L,G30,-SDYN$N'0C>]<1B7R[S'5%[J58(-F#V7$%QO'7--ND;>F4
MTT0V M\A>?/ :ANMK]$'CI.+M9T5JX%CWUR7:[=!<]K8O7R&0L2K3=5M0A&)
MH8.01&1$:;&V,S7]30[K%LYJMA-:B"2)CCEKSU1I>-?+@$YT087 EJF0[Y])
MPZ,^CK=@#<,_,!E!C^HBI@"9#^V.=:W'$CUV&4\6B3F'[7N:1P8^:J:(73(7
MDBQ$)&<O*X?J__&\)MK)$::>#0\YMEUYO 8I(R0#E38/;M#D$]$LH(9ET^T.
ML!M?(^Z*M]<@+%3D9'4L<N0B#0D=N-L[?##M-Y*H>P$IIK:,"/$J<QK/%M#H
M!HI#K0M*.]%RHIF6D,&":[3Z/4M*2'.$AR\F0O1>>'X%IN#MP7$^;_>B=K@:
MB'Y'EH)O Y-5ZO&*X'1X!ET!;;<8= E?>2.1;I>"I_T%R^*0W< )* ?/C=S)
MALX!%XU*<FC_7-_!%O$ZB//."\I;N.,E9+C@N[".V4[('4%G%"E]3J=%CH4&
MW0FLW)L+_]@Y@JH942PDMC8G@)(K-/[+GJ/O&8R8#WGDW&+J#L3)I+A"]#7N
M$;J^T,)T;M/D=!&^;OO]NS?.P&!8(JO![RT(=KCN6T+!2.O@:8@6ZYLJ>!H8
M[85FFMKUH-6+^#4]3T\4\-.[<:_2B>F'8]*%&#9F24VW38ZT/JJ=8T5SWL+H
M^K4C3;I"%%U@X2P<7BPH+A_,OL5D*%4PU $4L'.B:L'E(T-=>1'/*N[P#Q2=
MK?I"OK#2<(I9ZK9PL_GM<DUEWV^ZSL?Y6\-5&%FF0K!?RD\8'"EL,_O@!494
ML&LC,;=LOE$K;R&G/-O4A4Q)5FO\$L3WX8FBLLTAO NSV77-\H;T05%ZD)+9
MGRWOI<?G6,B6SM6VCB-*=?. UD9*(V5*V^Z&P8Y"3D@B@8QZ>"&U2N\VXY9J
M>2&_DWZUI]-:QS^KJU!PAIH*JD!P8/%Y5"S+($ASNNPY^QSMAGE*ELN@()?8
M-,T[$Y2)<KJ+:>=J&6$)H6XD(B\O&;D[ZPI3A123N3,_J-M &3 ^,=IHA+ZG
MUF1#>U680KHAQ*%B2 @8;G>H+NI2)S<*UO)T5ML:KH<^N9C1$P.032;.-^QA
M?V_!/AKB #0"%NNX]U<NQ$TIGBU<+%/V.CXK4[(P?;]^/ZOHJN"Y=UEK.IH!
M#P7-Z#Q)*W/$0P=Y[(3+!;4SI^<$L3+'B>96&"0:T*WV1#A993JA\6UIUA+<
MWDEJ*N,X[09K[%X:S5MCJ_V1186$%9-14Y:2,:2VF/7O'CQ>2'$1[&32S]-(
MOX?0G;;.@EA'J</3RL>1]@:>\B'L]DQ(E[&=B.I!=A3>"5/B&O:R1@I+S/MB
MCA%H<QZ/1@4VP0&4+''G7<9Q]X(WTM:I!5'GZ@I@ADP"??T^;OZ;0IR6"$X@
M'4;Z3;5(IWG=DHYNO#MPB08C]B<?.!IOO@UNNL <P;$5DD'X9X^4@H[HU$9$
M9@^A9D\#L:?^74P9B 3/Q80!ANR>4R9^W%"!6Y6%V$&)M=':'X[V4*REXS,7
MN"J&BYY&D9^+Z1'[,BCP*'\TD)SU<MK]E!;MY^KE5T$?0?S^D"33A-I^F*VV
MS^)Q728;%!&X,QCL15)"ZV:8@W;&,T%%CSE)VB?:X/L\%0Q)M+@Y'ZUXV*W*
M9X0P/!QY7%)";4M>P@(6,\-O-767=F:,SG&NQ34^8$956V#?#M4F;I!PORVS
MDM IJ=O?QZ94!"T!&[(2@T_8V^ 3'L&S?#/XA+N6KGH4!487D(3U$CA!SJ)]
M@BR7F%FW@^%W<:M,\:-_D-!P@W4&5B[DN4]3Q 5(!(0!8]"XH*ZI5.G08J:5
MD@F8W,\RV9ZXHA_3K% HM25_;;')6\:W8!Z9/**BKGP)WXA: KUB0U"!9,$Y
MG &Q?3QP?PLI &C&R;)?+4AWO/,>2W]:#4M$OI9&W'NRT'I6J7TSH<L9LW"@
M5^H$9PE3-I[)_)[8WWR2S8 53?LGYE(4C--4BV"MDB'.-26T/"'LR[U+6TW"
M("/I<' &@[2,6K)7VA(B,\\724/;"C:8S$ZVS=H5_ON8@B7FJUM4M)P1QD;]
MH"KI!\)VJAF7+Y*"C2>/M*5C\=RZ@GH=U;YVLFW=S'*+IK%*T\]R.)GL5@QI
M \YNJ3[R%4;0<PSES/ 'O\,<:#ACILG8S*V=*&W9MGP)4F6B4$D*L50EA\_1
MRA#U9=@\&PKI8/5+*>Q- =ULGHGWT<.5$2TAI?$W94%LZOOL>Z]HT.90]FO/
MOK*!]O#C4Y7<Q"60.>_1G^G(-_6%0 OV!J_H5+KQ?&K5W<P%:*//T$/:4"Z3
M1:W+60QU-CM8V'1C**6J%A,]7E\Y;TU76SMOKNG*JI5-4[18P3E/;1I:HBT.
M.[]QAX?[H)T]#N0ZV4\A@J!UV]2? FO(6=!@U?.VPZ(7[/DV^,.LC2A<-8LH
M40RQ&LYN3;(ZR,:TQ 10L[K 7 E\R!JS70JXP!OT7I,5;S3)-F>],TCI1P,C
M3,O+R[B2T@UB'PK%S! 'F2P9&;MK4-7@ H&@5X0#-142P4"V+M4B*%_\AL$;
ML##]PM=UU@"\GRSGK"3N%<PNX7%64V^]XHR[IV<1VHEHH:&H"VL>6DF0CN*-
MPL/.L=*C99K>!X ]!/!>?E@V#>'^AVR1.\)3HL?5I\+\+"S2#)*$A&OPQ(XK
M64#!/J#LT14EEZE")9K?/4^7J@J(O+C!.7!KB_=,);-.#J'^)$R=Q@&;(=ZX
M9_13*0>UF3BX+[K/OJV;17N#IS21_!)!,&O4!.U&$ZR<V,E"\U+Q@)IE$"ZX
MK.JI$5EV>\GY:_FX PCJX,VQ:F%H%(/Z.U8X.,7=YP%Q94-"G?!I;6F3H8>4
MG]=_96$N;DV0)]'"R"]M=P$S_Z(1ER;6P>@=KPX?DI)DQUG967.^A3<X5-D2
M+V07]+K8BR6P>Q2SUR[B698OTK+(@I,OM$7!.4=X>R2V34D-5*P%]_95A7N^
M+.0!Y6K*55GDYV3VFHKE4?B\"/WYT)%M"S:OF8V1UMDR951I\*9Q2Z7:OGF7
M$Z,K:$<S"-.5769)$T\HQX-'#1P&0 <+AQI--*(F*!P)U5$!]!.*HYI.Z1N7
MDJ_ZWG%!A4Y$@/J^[5IK0[2X>T&'1]55$?O(S\ONSVU7)<K!A %1N?"&8>H1
M')O7:3Q1V(5)X>"BR-/SHLX,+L.P.<.W8M)O79[?69C>Z:DG^^3.0@F3E7-_
MDHJZ4<NMF\H*+X"CLB2A)0(]E,PB[ V&T+=XW:X]R9+_>G)S?6%XN/ODX?L;
M^ZW_QZSZ7 T^>@'4]Y;+#K I)XBZ'IS6Q>CSNIUMK]U[(>#8_4<LJ(M2" '%
MO%.L*,HL-S4I] "^>,P)!H!VCHIRQB4FVBIS0H6@.XU)F09$C2.2\:+^/'*P
M8TAGY^1\H#DK)CX6(#D="'CP._I0X1+DBNZ8*'I3=^6*/"OPBAB>/3)E9IRO
M"N9KW8[ #W_R],3S[N1$X>PX4WL.)(*&=R?R99KNW%%9'P87Z.,%MZ1<-0KU
M#*5VW)@(GDI5R^=%PPO('V)\]A,UR31KIIA"G,-(5.[8M9DT,\N<03"+6X'#
M\J(8VC4L&LI STK @L'K8.,N-EF0\LZTN$Q;BY(5G&E!UNU[+_"I&4B]8*$.
MCMV?SWU-C33L$4AV[KP+HL@!&IUBU&"29,,H?5^,ILJ/Y-W_LR(N$P++N!6*
M[AA*L1+D%'-L@";%XYB2<2?P!R*Q>!O^[2WNT.!?W#?0<T$5#+R$"_7*2Z*6
MBL_/A4 H3;?FJ?3G+J8G_OX0)_L;Q,DC>):OC#C96+;;6C8&R7N[YLV9\B'"
M<9=0>RT<O0@@W#"A?Y49N8Q'D$TC+H8%QP[/TQARK3Q-F/6>QO_2%BW_;6R5
M!D\22D\IBX!RF61"7C2T@P[^:(JRF6ZF^=Y<"B"=0)D8Y[TU=! /+HN:*G34
MQ#Z1IDHS@9L9N:\9T6S[HHT&+5^(E/=QQTQ)B]!G9PA"JU$R@#)0:Q:FP*#6
M1Y>RD9%G*Z%T#*\)P5J!5U@T0;PUP-+!93S9K(U[,\HPHW4G*D1F*8EBT?)B
M!2QI)M!5C_8XSG.6V41&)_='(,H23A-L[IFC&'(VA6;]*V>QG>^#T7.Z$1RY
MUV/V(CMKSRDA0]W,45VS/65NV]JO;V;GOF;'D^ZW4TOG6K\<(3,E6-<:RK9\
MFGISC?6$,]BV4"0J*JCOC E)@8DISHV%II1G>C.U#W;,1BWOU9U_*3+A8-Y3
MB_<FN\:%=,IP;J1]OLZ^1 V]#$MZY+@2S9[PAAP>#O9V]O]B>_$8K0%%-G1T
MO!=ETYY^IJ>>#L#.=I)6HS([@Z/US 6FZY;/#^J#I^3@4])O;W=?7O=OR.<X
M&9R8)/Z[^$H^1EHA^(L6<YZ^_MO)NV<#.=2@XXYZW";S+>QLU&_:N@">=FE^
M'G-?@?N5 5%/SX0N S.1IH5#W%VRF8)QRBKFH<3&7VZLY<_JXIRDW:AS$![0
MK9Y)1KQ_5SG5D)GZDA R6,^$!"KD-RMD]82N@B0:# _^(@ES=H[Q:8C3!V^<
M%0F-E?\]YO?PT@D/'I>+I SAJQ"XX.CIH5URFBY[=Z8M0P/4-W;0_8CN.36,
M8!5#%C"!@M9M!1\3,2?M1YF(6Q>EHOZ?D!''U1!4*IGKG 9:.C_&5+YB'G.N
MZS BK5.EHAH,43VB*9H!V6F3PQDCBD[=JD]?[8D8Q5K%IW@&)5@3!AK6LTZY
MQS?" M"V(A0LR*=DY'ERL[0\UEWJEX^FX/S^3B5+SH)5RC7C;"'TT4-V^ )\
MOW*^V!JBM-(9G5*^)VD,"2T<TQ"TZO['-XCUB!S;11'B.3UOJ/V.4E5X\@GE
M4O&T-_]RT3[&%OZQ]"&$2X2GW[A&E+4CY_;6'46/Q8#\"2M"[>Y5*J$RVF_G
M,?+^0>2ES:!!5G/B;'A.'@L.>_1GKRQLI%3J.VA+1PNA*8* G8J);O7B, J-
MF^>Y$,84R*VZ*>O>6R@"G3M,P78IB9QPDI1 3?+OZ44\&6^BP_N<$IX'YC0T
M '-@[D!((_%.CK.D<284FE<;*'-<,=[?8\H76,Y61V9$)%+AT>_-[R;C\^ 3
M#VW;F!LW&C5QVPT%VPMAD,S;E^"D-EF$!YMK$@3PM/D8> '.R7G1<59"D\:H
M+MU=ULWM"7AX3+_117S)/@N#=07""Q[-% 229^@ONCT S2W::8'Q*Q+6R4K.
M*Q"7(&@;X<2A<:69H+.![#G(_T?4M,@Y%AN(69 79:C9'?:0T#Q[[_U/=-5$
M0P$QRME(7D1[:0(]@0I($V[RUH#X;=+X.Y-0YP0T@L/%*;1)LG#9)'FQ@M-T
MU)1($0:*6=N#O[L#Z1)2!!TX(#6@0>T'" CG!+6'I(@X&[8)F@\W($24B +E
ML?T.>7/-T>XQ$>_C >C9(TS+M1U"'CGL(?"#8Y<9M39S)L297G>7BF-M#\\D
M53/^9S@EI:W+\GTLBY4!-0==G@BU#KL].+V/\Y+(XJ$ODJ-=IN<%LR;SV KP
M<W11\$]INEM 4(K<8GNV<]A6V;CMK+26"2.X5MQ&S>$UM#TE%:4Z?8RW**C3
M[MD>_R1J>R<XH^=*E=*(^](7EH;H7NX $'4&PZ:.''CP(5,RX!171HQ.*=>\
M1C*UXY'(;5 R48*"]GCY&V(KKNQGX$4$:E)FQI/.3AA!8O-:.'?0ZT*,G41#
M$74(\HC2EAI8D'DDI(-#2^.%=9:'9RW>03,43/]15<4HPXTHC3/%A!":#<X%
M\2 K+W%@P<-$PM?IMOO^0*#/-R#01_ LWROMF*%F0E8@=R)RY7+&5-DJ0^Z]
M7$Y75R2NZ_>WU^:"AD"6];9&2?F1KMQ*SHGW).OHFO0PRL8C9][<CZE[$/JL
MD4P:;H=VJ,?&4!M$CU&R!Y%1S9[,NYK@ZL,&G#]!JONO:^;A'_NZFW0R1=*[
M9V7%=2FT9WWQI.-@%3(MX%\MF&]5G++7W0XKC<]WGVN*,R[/8O?KK??7DW2.
M'N33]G>?M939H'46F<'JM ?PIFLZ-^I+*[\HJ8BXF,7=C")!X3["NG%<"C/M
MM*EP%4]39*:S_6$L)\/T-[<88Q)4<='6-0<\5.RV\N_2;".<5<!YR]/CSD=4
M'0/$M/,@F(/D?1/V[XH"("CR,0OI" D(X#)04%>!/KMBP)>H5-;D3QAB\-QQ
MC(A>1=3H16@7ZZ0!Y<#ME]QQ]_O$!9ND;C S%,&C1+<62[&BQQ\RP_?JTX>/
M$8JVQ);RA>:'?7NBJM 'G&85!K>DXZB\)- DC?S YH;ZO8JJ 6Q-.9KG)NBT
M)FXRE&AADWKFHB?J")?*DET7L8LK?%.W:3]G6P\.:]PWHOGM9I\:B[W@C5L%
M,,/0>2>;6U]+CQER8&\\8=8Z(V,.1^JK-^,^Z3U>(YU(X?/7PQM)R$%BQ3VH
M_J.,KW#G!')Z*KQL&)I-"ZRG*:?<#IW#.OUZJ-K8O,5%OWC.X4F9_K-OCG4]
MF+CP2[<.TUJ@?^$<)"9.0PU9I'0BTVB<'D]3T-6#N$KM]6YG;4->0_?@8@"-
M'MAJ]@<H:XP_%WA>4N974H21?H7<KY&JD[CCIPX,^PIV:#$[8AAG?KE+-OC9
MSQ:><_/^D^$.=HD45S(8 )'354>)<R(ZO'*U:NYF=UKYLQ(P^=8!RXA.0Z$8
MD)'"Q"&N/%KSH3Z)9*>($N=+* [V'RW%@>#+@.K S2BFH-815V)<E,#T8A8G
M:<K4JE1HUS>=SFC5T[)DJ' \HEAF7+J3>-T.LM^%'T0I9AC#EA5)8$8#?6X.
M 6SZ6+T#=*]U^ZTPSI:<3YVNN1PU3,!I^=SH%DIZI_+36"A ^6P/X/9)]B#7
MG:&V$+5/<9$"C%638VTBZ>'B+2$_D8!9%);$!(A2IFY:D6:+O@./P5D]-M+(
M/D;C69D,HJB68+B"^;A"NWM<;/7F!-V]LW0"E)O^K%UA.(NNZ6Q_)P+V.LHR
M#H":]2J=3$!%AY/GZ)O,2!8\0L9)Z2S$1A7O&$=4B>"D7D13AO!ZQ5X5N*[<
M9?7=0@.,J\]%8A):9/D%U9DPSR[Z2B:V*(&^A[0_X1[_:I)S6I/(:S/";._6
M-,:\,I-ECF/G>\R%^,W]"%-V"8!'\2L%G*/6>ZKP**$MSI2LT*_3X@P/>U[Q
M$Y3^ 88'@0PPEUI M"1I'5W ,3I[E$YUKXMT,2 06<:J<@F/AC4CDHC7Q! T
M$?DC3(3+B$'/(E1M1&:30);?B%G-J3!'%1CG!VJ::#*/_'KBD265;8Y>M.HJ
M)$QJ&1&OJ*6"LSER=C9:?;\J--,^2XL9[5^$8X1,=N  E+@,@Y54M;S5EE#)
M@A4E#I)9BU'@D3K#U*"SHLL #3SQ7^**T3:L5,.VM<-8?O(4?@OY1! ]"VKO
MM(68HL6="@T3:T:#2Q")SI!)WSB-_119(./)=,Z*85V[A-V?/&[ZA?&D 6[[
MCMI83"D)'$^$,%V"DAFU:(^%2U;Z'EBJ%S49YH5$FIK08QD=C#)BZ>V.26F*
MMDZ]RMN!(=*G1;1UAB!W=V@55Z9O5>[AVR_P\'-',$),=E]97Q+_:?@*V"FQ
M%K!!TMP3DH9]$TE!FIQ\#I%LEB,?854W2<8>BOYC#?%:I1CS+B_W!NMV7[,F
M&0^F2R1K$EL,B@C/\*185GN>YS0N2=KUO(R7,?]LYNK+=QCS+L*LI-=9)54X
M2NX9)N?.%@J4!++-EKK/QD2U?&T+A[7*<X@1 5HO7 F6-DY8T3?3<U_3@^H1
MK+1'FZ*<FJ*/D=(%O[Y])FW,WP/N*]TY $%$&5PK<B@ID!!Y:?2KA%M],T7W
M>4*5Z:ALLGJJ&4Y('G#E]G,Z]^6CS33<US0$N\("/PWI*5+^8(J.< T],N01
M<0PE7M1)&U:Z<@0;PD>/]3O88/T>P;-L"!\?N9DB$>W\G+2@J**J6?V3]__W
M[>NMX4MG?-P 3K-16UV13O9\<#XIS@ 3[FQ9,<5BJR 2-@?,?<T<>LB4,"A%
M:J%L9H2".$^+60$E%0A\L-()"@ %UMB;'*H T> J+BW17)DZKV#45 &)SA3P
M47# :"%!.N(_PC=C7 "_?2Y!RP?@;[E2DX..S=;)A?/J?1$D&J25>Z"8X753
M5H6 ZS+8H"FG!4F7PMU_R9+$680W,3QNC2G[K)I& _]JT%# #1J15B:XXG^9
M%1,(,J+!63$?N:/,W=^=N'7&I2;L>K!#8OS4BS2>@% $K_O-,KY7=W4"OA*E
M4["II-*B%S=V<FS>"?00_23Q?4OK<1,)WN_!06J]V%_F]F(VHU[ 4*4!X+!3
M"@%52<Z"?3A)4P9SA_A(.%XVDW=?DW=U0?1+O?.!Q$GI*!9-X]ZY(6P>=5)"
M>Y57RZY\WV.<QY-Y):)%7!7<S.K]^7)YT9BLFID9+"3XYA"><_+X &2SF93[
MFI0JGO1KDB#1*_=59]1J;:/[#<W$5TE$^_/*GU58(: 4=<)VS<U5CUVCQE7H
MZL%2.ZI!>XZ0S:S=UZPQBB'$O<-91&[[",&/".':S,%]S0%S.VK,#Z%D O))
M<X:]M*>HBUJ)5#XU<T$@Z1>5<V1$K C12#%N=>&.J/A<0K8&21+<SB4D*L>\
M@$&+\\_2/F"+#M-X5!::FQ@;F6G3LZV? X30Q:'YAO/EOL.^+T<2K1LP^VV.
M;!;./4,6TH@] >XM@!?G;>4%C7DC00TTU!G5A@:1=0?I>$CI,(4'P),A_1&T
M>1C]@<MBTDQ317OA'F5:302[ NW\&7(?YA*-<QD#Z+-+W*TU=<GX0Y28-+']
M%^H9:8D0[WQDX)WRU%<D>""D'_K OC*R]%FW!S^51:R&AE3JV0"-K2"JM+XH
M&@_FCGKI#!'G3< X8%TXC\MD8CIQ) 3N>U^ %0OOGP#%(3@"@\?X0&@\#/66
M]>ZQ] LK"XGW/B+KB9 4&..!C;@GTN/Z*10B&:\,BNX*WL(-9(BM]>AA\Z#\
MRC1=^)S:(L<]:X@]<[LNK5M1H'FLL#W04N0L$29M*[&*+"F KPV@WQ.VU/C\
M3. %-!Q-">H92&]LL]=KA^M]&XPK*0'+D<N1MDB6-Z1/IQDS]&FIG\*=J4V;
M4@2NA;,_UY_FZ3GQ+2&TJ:GQL*<^;PGU=45$7>U"6BDTETD*2;JUZP?]9 1$
MC1GN!'(E-'2H&89Z"#-)T=#[)I)*&E]XUL"WZ<F6R S01'GF05VW [<0>JAL
M] (8B" JS=9JLCP#%>24/@9"("+RUMG%QYE,!FS-P-H[7^@<A>6)Y/@+Y[__
MN2O[Y&E<<>=E$$M1NRJQ[,+1  1 9WTF-*!N5BKR'"H+8EG8V(76C/27;[5,
M'XU9.)440QS8RKR9GL$8CI<(HXJ^J>(8 ]Y+.UY+Q4GMZ*T;Z/^8FK @L^F.
MUB\82EZ(7'W2  B&$%M+J*45N0A&VJ$+SL$HG=G3D7^IW58R&_A4$SAA>Y^G
M]2QU2A0AN*-%5DKZT-$-H09(.6V39K1:B\#VX!CO=^J>.H7'(&*0_=UHL+>[
MMX\[%1VOO8-A='1X%+T\/%KTF$;_P7D#'1INH>A:/.960 *#0_HJ8V::&=OB
M]-J-<L9]8/3#&5LQ<P%J*\3M\$=#I@5\=<3R3N(<-=2UH](PCUE?)[[2GF(*
M2EF.3SK*W1^K8I+T+I;MP9IMG5^<$2^0TU!D6,Q:73)K1.N'D*5@3'VV(**^
M42)<X?ZX#+E4SE&.'O=+0+U17TB3I3_^0F;^LL5HXC_"9M/^"PM) [;Q9$SB
MYU[(;:O+M.I/U^(YY]5*X'SSJ7>^)::HW-?%]<JP?16- ;9KRNZ?*\<X?;MO
MW42KM?;<R1=[-(?<QY@(-BWOGK;F2XM3DC%W)]<:>X^U*.SZ-Q1ZZ"3;-0>>
M70ZJYQ>\7.7"%L4O[AG#D]>.?__WE,/B]'/?Z-87&#Q23&JI>81! [N0@30]
M%;M9 *\L<28FZ5GMRTV8\8 6Y'/W0W"6<S<?%]F,LW&321:KT*&[-L!)$"FB
M3;-(F!-)M(]]NM =VJ/+0+LF+CGK4%$+K#L7]*@ _6S,-AC[S0<'4)K(,6FE
MZ4VL#'W"W)GLE2#Q;0L]/^R%\\7&_?L#9QYNP)F/X%F^&2+&I>;-L!F)72+K
M0+1 $*YWBQ7=1M>^\H6G4)HY!SHCNF6I(U)(/H6&ATB:,B&5$M>&0JWU8$1F
M=-R< Q>&\Z;W\!ZX5=$J(1QJ\(:LRVLDO3ZC ^_XO$RI\&])\2G\9?<%;\*F
M;^*>'O-AR&0!!"$8_C0S^/-_[.WN;N^26S\%"2**318[=-N#3\Q$=XT =G&:
MRC@+G9_VF8+>?4SK2LZ.DJRH37@:-5SS<LC_L6PH(J"T*E$F#$\9ST$M/A7Z
M"\"'H03J*,?+++_H*$XR=XLD%II+@=Y[45ZB\6@S]N*=V6? -F]S/!&I(=((
MXS6(G '>.DTP4W/5RH"ZKP(_!_(]76,OP)PP'IX%RVA,9?EE,4'>;(Y#+BGE
MX\Y@\K>IYF:9$QC6:ZBN.R3'\'C1#3\B\F\(HW&!(4GY"%FB8>0G0.D."7-B
M/*WG.CZZV7PJW091DJX.J9&SZ2QF%\X\ NSAIL68W":\,!NOU6DFFXVV&@<5
M64GD&QG3!PEOBBQF=LES=#;<^G'WK8T6E"'CB)T?.98^>B0@:EK48!@Z].V<
M<9,CU27MFWXG*C(>E(Y]VX'J>2O-Y&-<%KJ]F/!#%LN5_5^<^/,R1G:.$>$Y
MP4G"K=7DG@\=956V!R<<.PI[@=*X6\^+B<BM<\XJ6GW*UU%H^5H,M_3#M8N
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M]LWC%@VRTCGG,]::1W7N^>"<!;\S2Z<]F+BG:N 0!MW!&-4YW5&+PO0T$H]
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MOKE)%/#4(O_3.LAG._K;7]\=]$[^B<(.]Q"G<%QB?WKML.<M^/Z4E1;0DW4
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ME1I9ZNVR+FYO5'S-C*09%RW@N4."<L";'7N&QXOI'(P>0_8FZD:F /#&LYQ
MOA#PZF5&+)@(J@%<E2DS&3>R$8'UF\#?MG%.<9>=:VTD=Q@1';4N^H!$IO#V
M0DUD(A:*Y8H:I9(AP="(H%BXO8UM&6:#?,N.N]_;6;WLK/HA6#&9%M?\V5:,
M:[.7E/Q3+\:GS:64.C!.\V6[!8_--!>.7"5,Y5EBR$8+5+YFMZRT9C^/BC2>
MKF/J_L7R?;E">#X9S2\=[/NJH$)>W@SF#3O5&D4N>[S"*+*+9MCL(M\L$@B-
MYFA1I+TE%8#Z"+$-IY9Z30JT_ (=FU<(;<!;:Q>Y1+6A7:2=AA1(=;O'OFQ"
MWZMD6-\"7UMUN5Z/M1;Y7/*YBD= 8:<H[G4/? $ZF23H%VA$O0L'6U_A/C#Q
M0P4^P!R"7<<=LXDS9CS*@<&5;/XW!=G_Q+$GS+?_WUY"K1D6/XVM-\-LAEG*
M+E.(2OIV)'YDHNUH $B- ,$04#J&Y7QVQK1]%(VDD:9=5D)<.:@U9J0UE%R&
M>455<M,#VS*MIS-_R 1V;CS B?2CCTW(H@'!!LQC+AX$\ .FX*8PK]VAUARJ
M%*DO>@XE"0I%05E99(8GE ;%XC32>I8?Z34O92^FTV)94+2^]$3PGQV']YW%
MSQ&$OQ<^62 _6!!]]$6A))7_VT!@H.#V'7%'\I7E> 1A.9C]>4OP@+34)Q9D
MH++8RJ.RF%>^33ULI3Z<<S8CG#)[J%Z2;@=AI6\+^0"%H"*0OSYQ%LS.6V%S
M*HC;0N$[U=,OZ9S9,'VH=P,W):?T^PL%HL-B^Q!P:PKS+*D=3J**^S"J2%^)
MD0YMC!T_,[9J;/1C#[^:(JH/?19U8C#X:SH&1TE=64^R"KE\NUI@EZD&?R)]
M6&F]B6KQ*+\_Y?<]^W[DT(F2PK^CCDSL>R0N]2Z%<D.N%9 -;XW"=X6?MRP.
ML:\IX.$5%[H6F,]-L&;<#.M<NUI@O50#MWH,)8UK,9!/@Y]7"Y]IL#N!S>7M
MV_\+0C4.V2.!93 @48PS9&'=Q$U2Q[%Z8.MPJ@5D#_W+X0.X5!=#N+9ZC(5-
M:S&(\&3D+G $G3FD_T+]LC$4M=S"$&QQ9H-;\>2W!V]RGDSF\;S)EIU^R4-+
M28'85M8 ?2=U71)DZ?8#IC:X_+XKG\.,3L:)?>-EBF?NQ^K ,U/W5*ZW]3E6
ML;!7U5)Q:*="+'_ '%MF=LB: 6(IEUVZC"H!(FCVWX&PIIJ88;E9+3S>TB,0
M23">[O%@(G\D(Y$^HM!_@MV=%!P,> !D*PU]8][K^P6;C'88*69V+2 +2'[)
M();B@H*L#YR,">?1*4^I?BKQJ,=F2+7+G7AFG/_%/&T2>_MGS.V^;:N]-G;"
MZ=P/Q)1Q^0S4YT!.!U!!>%V^*5'6\> )J$76_3 OO',?"#D^6?E3[D!J(MZ.
M/9,4P 2LXFIT30)B-5$MG-;PF0VG+)"/>PR?X<[\WB-7[LQA<T(6UI '< 6K
MA[L6JWHH84K--JL%#>LQ@%3U5S)D),0+H^JDD*\2? 8\:C'LI551NP3VHX&7
MJ6!]?EM71\5=2K+^I9O>^Y)':%;%TU79;!!$[S2DV,)^:LCI9$+X@QK+-6?N
MC<QP8^<A %+K?@P1!4#S$8L50=OK2K'ML":\$@.X9:WW/2^0S]RH%VW<P707
M1#[PLMUTJ;Z3NFZ5UXZ^P%GSL+I\*=K*N"YUQ)\-OEXA*MR67/4(!Y,-Z%IQ
MH2EU/=;8*O--]TJ>[<QJ?2]UG=;+3]8/R8NX<%9M;%=0[-(\1-R-P:!NY7GX
MC>L&'INI5/1JZR]M_MV9>V)_D>%%*6RZ./:U[7P5^]VL];-@MYF+._Q"W<"-
MPY8PJMG^6E/2S8YB] H!TB?FV"[V!MB:2JPOV+BO.9LK)ZC%;-&_;WVN=W'5
MF-3%ZQ5F.S;8<YLPJ0?FFORJ)B=F2%V+H5;QUH_$)YA;TR'A[E;<_R+#[VIS
M)Y.Y$$O#TK6;,IB5_.L:^\7E:.NEDLV(ZS%KEK)HXA)S/@_32MJ,6O8]=*:G
M89OT4-,SL6VDCK;EB%;R_Z[\DDF2K3\6<L-5D&5[M3S?*A&^N;X_,T].O_@5
M!LPET3.1I>I905';(HQU%NJM+G%YIG5=UY+2.KD\A-LM6*E<V74ZGK Z9_$4
MD+,)Q^4N:F.^=578@ 5B.L#>-9=O>/(M=HD="D/SJ"9S8D!8FP @?F%(6IF5
MU%X.91)>W+@SSIX49=]QV+/4_.I"KW59UO60JO1<K:"ZIWSS7(E)7:?$5M._
M*BFDZMM>)]V<[:\FI46:XK^UJP9W=]"MNC!:;:*GFXA],9=> <#*']NGS^FK
M)IIC_\UX?NNC__6CSR@,^P1>?0>Q[0+WVOK@#7/,X=2X\?U CFYGJ>SE;K[U
M+%RNW*.^K+*7]0E7V)K*;79\>%NJDBHLZG'H>PNV3<CB6]Z2#,R071!9B:[V
M;O^%T/V:!>7'0.NPJNO:_<G!+VS@4C']V:$>[/ $<1QBB0 VKYR!?&+^F1W?
M4FA!;' 8JKWJ/KJF.0+9%OM:A,80J)J4&2ZUJH7HX3/BNAU*MDT='B>+SALV
M/*[X3LXK2K/#R9,P-]XL*,^K&M/O* M%+.IB9RN/6FSP)$5MD\+1JPNI'[Z\
M0480<8B^VHH-"&MAO^&+_?L+7QX(ETKUO47]4;(Y@_H<(\MC7Y,U(=^P'IB)
MX92$WU^)L]2:QW++"6HQH"UD\S-/([W*LY_%_=4U8/P%<RKEDJ$<A/?BRH,^
MYG%9:+;6;8J%W"]A;W[C?V;2;AXXE=_UO" >&5.+PI^E>MUV-[M9\V1-\H3P
MR@]4?U3F;/9(==RV%M.K-&%Y&4!0Y54-3K*$W]S@U?MK?&M*7/SAS?\!4$L#
M!!0    ( ,Z!9U<!OAI@OQ@  &WS   5    ;'EE;"TR,#(S,#DS,%]C86PN
M>&ULY7U9<ULYLN9[_PJ/YW6RC'VIZ.H;+KO<4Q&NLJ.6Z3M/C 20*'.:(CTD
MY>7^^DE0DDW)DD61.-21)\)A6Q)%?LC\3FY()/[^'Q].9H_>T7(U7<Q_>"R_
M$X\?T3PORG3^UP^/__SC!83'__&/O_WM[_\-X#]__.WEH^>+?'I"\_6C9TO"
M-95'[Z?K-X_6;^C1OQ;+?T_?X:/7,US7Q?($X!^;7WNV>/MQ.?WKS?J1$DI?
MO.SBI\OO@[<Q"2U VTI@:B&(:!%2(5_)14E2_(^_OA?)!U.L (6Q@C&> $E*
MH*Q09QNTR'+SIK/I_-_?M[\2KN@1+V^^VGSYP^,WZ_7;[Y\\>?_^_7<?TG+V
MW6+YUQ,EA'YR\>K'YR__\,7KW^O-JV6,\<GFIY]>NII>]T)^6_GD/W]Y^7M^
M0R<(T_EJC?/</F U_7ZU^>;+1<;U1NJWXGITXRO:5W#Q,FC? JE R^\^K,KC
M?_SMT:,S<2P7,_J-ZJ/V[Y^__?SI(V<?:3;[+B].GK2?/'FVF!>:KZCP?U:+
MV;0T#?^(LP;]]S=$ZQ4O8/.&ZX]OZ8?'J^G)VQE=?._-DNH/C]M;0M.TB%HT
M&/]]AW=]\AEJQED^G6TD\Y*_/G_O!J\7:OJP)OZ-,_E<?.QLD2^]:-:TLUA>
M_.8,$\TVWYV<KN OQ+>3EU-,T]ET/:75TWGY?;W(_WZSF!5^E'[ZOZ?3]<<)
M^J1DB0&4= 6,( &Q*@)?G=)66*1H+LNNK6_%"]SHN.(J;11]_H%/FE"?T&R]
MNOC.1LP;$>^*Z4S07=8\(>FS";) 3I:?VT0!4'D+,F4T7N0H@AMN>9=7LD6:
MI\O\:+'D);,U>_SH/37+<V[8SK#@,E]BTY</U?DKGJQ.3TXV[PG3-9U<_'Y=
M+DX&9,)ZT4?D9RKEI1RJ\V>+DY/INMG\MCI^QM;L&]A'-$ ^)F,Q54@J13#*
M>0@D Q2A#8D@@Y"Z,P>^ F<73JAO@1.]5-*-(]>L3T0OL6!@9V0L&!T$XS !
MK(^.?Y)U,KDS-6ZS=]<S0G\+C#A0 =V(L&VML$AIG"A07,J\'H[N$)T$'WTL
M*E:;HS^6@SAH)<].ETM^UB8D8K&Z( 2TK" G+*!!"TXEK*9&JB(,MZ!S%"-U
M?'?2]E=\W#ZR[L;>5V]IB<V6OB0.IR]0??QU,<_GL 2A#M(I0.<"F.P$8.&'
MBE=9JY'!*NP=T]T*:J1N[R!&]-5$/X)PHKO<6N,6'ENK%HX,>%$%F,B&&UUF
M-YR"Y]#,2"^P-S-N1#-2OW<8)?K(?@A7=V&TI"&9%&E>5&:CQ?X<$D4$%9'_
M5%^T4T=V$'=?U].<%Z<<6;[&CYAF=+$V50U5[06H3*RZ:"*OS3KPZ"-+.>>2
M8^>U78]DI YP'PY<I7@'T7>C-V-9GE*Y'+5>?08G-193)1J02AB&Y@E"1@&Y
M*DQ2H+*F=P*X$["1^L1.).FLF(,YTPIRD]]/<Z95XVY+3*]9M)!L^74BT+'E
M-[(&"-$7R,4(C3KG4,MMM<2=/FFDWN\0Y?>7<#]#L5K1>C41OG"Z296M4N3/
MQA(@>E4@JN@-IZ_&UM[QS]DG]\%_(4+4KK8,N>7*R!$*:R@Y72$F'8QVH:+O
M7;:X!&!,WFT/S7YAK/86;C=^_H++?].Z^=/?B0/&J[$C<>2HR$@PM26:Q#DF
MEN1!L&,UU6O"2)T5_G5$8W)='1C04?Q]T[B?Y^]H=59$G7#*F#B*$B"KTNPM
M&S&M3Y X.<FZB()FD.1M"\.8G%8'M1\DXFZ*?KU<O*7E^N/K&<[7'":UTNC;
MAN=76D^R-=X:CJB%#FR-<A$<(G%&6JNIROFDLRB=E?XU/+L0P#P< G03_4#5
MO=^:&%_5/U>T6>S$*V(:!LZO4E!@C&*W9*T!JQQCPJR-LX-6]JX VH4.]N'0
MH9_P^WJ!LZ5MUY*21)>+ KWQ2JIZ""42.).U%(62D+UW+:X%LHO^W0/2_\'"
M[J;WW]@G+:=Y3>49KMYLH5&.JJ@E\=)DX,0L9PY4B0"]4THA2>UZ%_=OPK*+
M]OW#T7X7D7?.6"^2DFR*S"@*H+%L@#(YB++E*.RBT"=4H<KC97Q[]&>P1%L7
M /_3?.P[G&WZ M;/<+G\R ;W?^'LE":("H/7"0HVCZM% )26(%A?I=?*!]6]
M4V,78./+=_?AQ1<-&MUU,F@Z_"D_SR7ZE"T_B(&?1ELUFV-7.$K3269%U<C>
M:=!7X(PO$>Y!C5[R[Y@CT5N<EI\^O&U-E!>UY"N%FYH#)269J8F3-_8$;*%5
M (VE,F.]+Z5_JG0KK/&ES#T(TEL?@S9Y&:E1A HNEH;#)D#->9S51C"4(GSM
MO>'9OZF5!5Z)Y7K6DW5FFE,BK:12@+EM5&,V'.=HCGVDLTR/: 7UMH37P!B3
M<SQ0^]>P_""A=VUO7<RW4%"-5A5/H%5NM0GTG(M*QN.LED:1+;IW%G 5PY@\
M7V>]'R3NGIO;IR=-IG1F71G5VR6]88,[?4<_S_/BA%XN5JM?:?VJ_H$?)A6#
MJJ0BU(*M\=IHB($8J33))8U)E &:'^X"<4R^L#-EAE16QZ+"&J=S*C_A<LX!
M_FH+]'.JTSQ=3T)PTIM"X%428)CJD)0S0-Y&J46QQ?<O+]R&:DQ5Y\Z\Z:R2
M?L:GE&F3!LY><YSW\_P9OIVN<38II%36N@ YX5LMQ$.RM0)'DFP,E8H.16\C
M<SV4,=6>>QN3#L*_PH2_/[DJII?\=9_#=[^O^>_-!MJBGI?0^:?8#GUL&<%F
M_BZ#.^!DWAT^LO^QO7W7V^E,'_N0SPYE8FH5U7!:A6<!B9"00LVM![TF;P7F
MW'LKX!* 0PW-KXOYXF+;Y>Q=SY/*B;+H=,P2;+"^=8<%#KIR;$ED%L7E7&MO
M5W0CF#$E.?OK_ZJ=Z2/[_GN?6\O+KJ#+LH OI1V\MA4"%@1O,WM#KXI-@YUE
MN(GD]YOK]%/_H?+NIOB;>2A%%&1* 5Y88H^G%03#L4\H(2/[T))T[W!C1QNP
MYU;NS4OUQ<38TDN173L*YR0$E0M49Y3(H09^"(?8TWT8-J\+0Z[=[^VCD6[/
MPL_S-2UIM;X$91MC:TVQD8(ED\ 1.3;/B1/'X@3X5(WTT0M#O3?*=L$U*C,Y
M"&.Z:Z<;;\[2CL_;-2_>_3K]<[XDG$W_B\K&MHMH-]T*(-EE,"ZAV5=X"^PB
M7$C,::M[MPW?CNJ.-2%X@*3IK)I!XRWAK(]9$ 02"(8L1Q9"6ZA))Q>E,YZZ
M=Q;=%F\=L+)S]:TFK#L40AB0L9W$5(H@9J^ADG-91?3)]6Z@^ +$'1WJL%0_
M5/DW!I-[B;QCB?,=S4]ILQ;.4]AE9R];XS:;XQ"0/3A95ZJV1?G>U?"+SQZ3
M&^RMYKWDVW,?[&I5_5-%/0M1/>9&,N*45;?M[% =N& *.9LX%>K=&_L5. >G
M1)>RO""S30D5.-L.5TK672R28XL:T9'S08C>YS^^4N2YWU2@%P>^*(;L+?&^
MS;[7K.]SL/ _%[,V]>Z?.)TWF*_FGZ.*I\OIBG_TG+^<__6:EM-%^207HV+6
M;02!#I:CEZA9+JE&8*'(RD^R0%.'R"T'6,N8C.M05!P%#_J'F9\B QF2C,0A
MM#*%(X,DVQ AXT!95#(+GV48K*AW?3"V5X,VL7!:!^5S]HFSQ>;<R$6Z$&V5
MMK8&$:E2BWT0(B4'OE )R-%\HM[.Z*N QF3 #^/#-5W;G?30C?#_I#FO<,:(
MGI:3Z7RZ6K?UOMO*)1%SL 0UM!.F07$:65.%J*/-&$HNW6O:MT :DU'M2X^>
MNNCKYU]=6VAH]2-A4U9%:XZEV4 ;W8;-FIP!V72C4S&([FWP7T<TJAI-7WYT
M5,4][;BW_OT7L\7[83;7/[_[L/OH-ZRBTY9Y>_<KYQPNG_9A^W#Y&UNO/(NA
MF!K+=BKP.9W]RU_/3LN&AOD-SO^BWW@Q/]5*><U>Q]KD,V?$NO5^6.$!2_$@
MC$L%92M]]*X]''>%';+;!N'U<O%NRMK]\>.?3(V?YY^>PZ>9;?2G&3')*6D
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M3/L&E_0C;M+VDU83V0APXG*(HIT 5P4W$QPMQ^1,_4C1"2](R^X'S:Y',J8
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M70Q!H,.KER#<L%=\]\_>A4'N6V#0,72S8_WE_/OMK\0 _O&W_P=02P,$%
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M*,D]6711#,&3C5 ^ QX-I[6[/),#\>R?87R.JP'K$*W6SH"UM&\K1N=!GT0
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M\HQ9LKMB!K!T;X/Z:30^)_/\Q$2M9#VIF4+85$UG]DYR^M%IQ[31'%L[B-9
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M%LLAN"+!Y<"<#LZ(T+K&<5]L3XDX@^BC81'U56;E"EH_:%V>)&ECX 4A919
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M?.'S/+YL+_/6[7<JB"7_^L!HV6#GZM7[;Z&SI?!OJV\'R;7NC',=CLM2EFS
MNF1 99<ARI@AH?8F!62L7U.U0ROPGNXVC?6W@< :Z^UWDM39^>460)B#-:8
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MDC)!T"ZOZ@V/0@..Q@%8BXYQ3(7)7DF7&Y"L)?[]7Z -2I8[[58.I.FUEO2
MV89_5#E6Z*US!^\\N'DFX/W0CS*O+X945*T@E5RI9=P56>4R!1#*"42?<FK>
M5.FH\OIJ$][YM7YKOWSZ8_227E3WD\5[T\4/)]PIE$9$4"%;4%PZ\"0?\$('
M(53PP;3>A?MB>^QQT9MP\/;2.(C^!@C36(7S3Y)(&(_^!W--SSCA6AK#0X&<
M5,WASQ%BT!;JQ0?+7G'3/$3C853?N-5,9\<=4X\R%B<9Y) 0%!DK$')&X+8D
M([4+Q7YKH'(TS#R,W@\=4U_O+2^++;PN%[/S=YR?=ODJ^N_N;Q&_^AJ"3IRC
MD) P\KH1"*@#A,"4*"S%8FVONOX/>&!VP?@$+@(W851W ,TV=@"NP[6\/N^#
MK*&/^'XT^W<,[T^KW: JV2]I9$GHI$6@_R8ZHRL%GM=DUB0Y6AF,MRT*$!Z"
M+/?XAX^1*YMHHK7S^/7\%*=7P[\,8T>K@V)D<BYP%((5I2M@@T3Z??0F]&NB
MN/+Q^_5"MA1^UU1R^X@VT[0M%F<8)%83<GD($%!*R$QYR3G+17Z+-FMM9NRL
MB=959WL[XON ?,;19AOI<*M HFT4<+!H,V>+=)9;,))6/,6-AI!\!L*JE& &
M66A2P_AQ19L-3Y)-Y-[:8'CSXN7[-Z=A>A9>3=)E RHG#(N!UWK,AC8]&GMD
MSD,D6\"[:)WO6<)CQ<./-61I(QUT#04XL+_L-]H@L8F#;,V3=O&(]0'7R 7V
M&Y+U@(L7_H2S-!U]7.)<7JTEL@RY\*(V/S?U+(#@G!& 62J'WJ72O,+" Y!V
MO>A]3386B77R8?&&E]UL?N(B)DS:TX$G^%KRE\XZBEE(BF?KLD].\\:#O(MB
M_^Z!EKJ_?:VZHY0'<!O],TQ'U=R] B20>XZA-FJOV5N8%3C"!I;.- YML4JU
M#M2X ^)I:7TW&0_@U;E)P__&6N4)\XM/]-L/M$U4@5W^L7;.X'06PIPUY\!K
MV*7BA?8[K)TSM&4LF52":!W%NBG&IT69034T0 +WO7A_&LU2M:-J4Z<W=)2O
MWO+DN"(S68!5N8;;:X0H,=%AFW&+BC.%K=V!FV)\1HS:54,-$^0N\?Z!\[<$
MHZZ;+Z88:)]DTAI?0-8D3B4($^V,!C*7*)W'Y&*OY*8-"',+PM/BPR[R'2 8
M_MTY :%QTK&H.\,3--&)C!&TC(0FN!I#F.JUNZMN;9\3EL;:OHG@:2E[!^G>
MU;7>.5,&)V$R?W7V<=I]NHAKI#-P$"5R"5YI46,5'$13:LF (E'X@*+TNJG>
M)$WF#HJGI?,=I7Q7[V97O:\>[<5M>U#68BP(7-<6)4QD($/80!&>%B3A#%G%
M>SE1[S7@9TC]MY+VH8-R+L?S%L>UX<E%#/JU\/<?OUS_R\4EK&3&U@[FQ2^<
M>60,NZ02:,X\"L.\L*TKT_5'=RC/6#,^='O1RP#'WNMX+CTN/1 -E%-W%\UA
MTN:&TM\]--E!^/NA!6J34.0$/-:X $9V<!#:@@X851(B,&Q]];DO.CR0]'8X
M-FPB\X%9<-EYFH7 O%=@HJYU_LE"#D'6 &QG?4P)L5\]C2U9<*C$LUUU<X^J
MMQ!LXSB9=W,"4\V17['[, T?3T<I7%0M0T&F%>,);&:L5BWS$)@)@%8IG56*
MWK4(EED+X*G8!>VDW#@0YMV%'7H=TM?J8P^#:ACXLA;( :)GVRBJ&TK*C:-;
MUH/CWF?C30(7D@/%$X*WS$"..2>: D'*7AZ.XU+]?;&P>]3\)L)M7JVZ.Y^?
MO@N37Z:U.>8L=2_#>%2ZZ604+N,OI([9J RUK0]]"06B41JR%4+)K#'E6U</
MZ\KM//2J_8:S--)'-Y@P]Q("RXMS(I!5NJA%RFP"[VC02:9LK?/%WPYF?O0A
ML$-LZ#O+]F E%/N ?,Y!K9OH<+N@UBT4<+"@5EF0!4<XI94%5"VX[VRRM6>V
MXC0](JIG6$)Q>))L(O?V%L*$0%PV6P@:9;$>++>T0$H"$D0PH'TH6%PBDTCV
M- :NGGJL8:P;2;UK(;*!XU??S;OTK]-N3$^>7:3^[!#"NOYANT2Q]H38*)#U
MY3C,9J_+XJ57;B4NA6:65(1:(*@0)<2(%IC/B4Q\8[)J79-E)9!=[^S>$#:<
M3C$O'OON-$QQ]H(LU-J8!?.)TEY[3W:ML]7=B:Y 2(&!XQ*%X626,M%XF/<C
MVO]=WN[ZOWV=UU#F X2SWD3W)DQ?3Q<'W;S("7N#TP7@D^BC,5)Q0$[8E(H.
M?$))/Y))[(LTL5]BW-;,6(?LZ3&DB0X&N.]?Q>/7Y_/9/$SR:/+AQ"$KGC9!
M8+EV7<I)TT%6,-K:3/32,.E<ZV(Y#T!Z>MS83>H#A+&^[,[.NLGJE0VE*>B%
MA4*K& U;"/#($T3B+W>I."_:%S!<"^<ID*&5M >(/KT&;>T"IDH(+A<&G#LZ
M%94:Q*_(F+8E.$D R?QM'<+< ]83(T83Z0\0KWJ'N]=7L4C'8LV1%C"!BPJ8
M6$O!"2A"<<Z2K-UGAEXJGMC&T4S> \2SO@NUI,@"V\MN,AOE1:1]5XL,X.A3
M+3=P+9+B!(WWGM8V"(9V-QHW@YA% 5V(TI)+&6Z[&W8/;=X$X%-@RW ::1@6
M>Y$0?)%M$3X0WLKQT:Q>T?U",OHYI-/E.!:$/Q'2^>R2!<MDM8TP0*CQ$]P;
MYX*R9#;=.LZN2[3N_<['S(4AQ7N7!7;G1>1K;:+%V'_\LI#$A==&)>=R,(PV
M-\=!,3I4Q\3)-@I&)QF99KIU/.L]</85'#W LM!(QH<.B5Y[41]$L*96G[#"
MUI \38.0M!%J79QE2B=VN_GRH_=V-M/I0][.361[,/]5'Y#/V-NYD0ZW<F1M
MHX"#L24FS661#(PW@8SG@."22) "<R$'5USN=8(];I9LZNT<GB2;R+VUM_/7
M;IS/PN0=F3^U.MJ/77EQV3]+.2^"H;.3S*[NK @AY0(&I32,CMNB]+,OU[[B
M6/V@&^FC:R[, ?P@[\XCG7I&8?KEVE%HP6[)E(RU&[-V.9*9FPT$)1TD':RR
M3CEYNUQ3B\S:U6">BLW05NH#W&M?@U-I_[I<._Y>Q@+T0#A0)M3#Z Z3&=5(
MG>OO)EKJ8@ 760^D=-Q*&*TCI=;V!$Y;B,'7K3,+)832(;0NA'4HMCR0.'4P
MLFRB@M;&Q(OY^U/\/4S_A?/7I6"MH+K<_VB'*RYI >A+JH,NX)S-H*+A41,J
M?;N*U!IC8NTK]G\WU5H977-)#F!)K.Z"YZQ0BGD--4H,E%:J]O@RP))U(AJ,
M0;:^Q#ZJMJ9#61"[2WL 9^BFG>CZP/W6J'0G)>_86'(;#1U!HU*I&5IK:PTJ
M(4$9+B%HE\"C]:PD+5UH78;N* BU5:/2??)I$\6TMD&60;2CV7PZBN<+85\>
M]Y?H3,B&5F':,@E([<S&P(N<@:0092G.R-O];=?8(@^^ZOB[A&ZDJ6XP,>\C
M#CR&&>:7W=E'FD8+[V^+NL8]G[QSA/B&X!N%BR]<H3_>?O4UCOWXY>HC;\*7
MQ6+S5YCF*_^<U)%E'02X*&LU:R3K!YD#XYASM0<&$\WOEW9&O?-)>5L$?YS7
MJ7/I@[X6_Q8E%E&S;D7B=)#(C$/4NM: 4A:3BLZF7IW$]B'&=8,XP EMO_R]
M<UH_* V&N$:N>.XL17<'%&\/Z.?/'T<7(3=OZ"S;Y1,CL^ L,Z(=C4'9Y*J
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MG,_/I_AJ-CL/DX0GOB1I4PY@L?IF594<CPA,EJ"P;FZF]7W-QB"?'26'5>,
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M6IS1'KFX=KOVJY.<>%3*TR"#BU"KKM281 0;F?#2BNAU:X=>+V!/C![ME3&
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M2> /R!G-0:ZC'%4BD:0(!I17!$I:!D[9##'*D$EY&W&4^NRM'3A*CJJ%_Z8
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MH0;WM]!BO29$FY,I7.>UT_PL3^U>.'UP4SEVQ"-Q\O516TK /M@"/T0 Z B
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M2[>W2@'SB*!$7;1[B8"8HQK=.U]EW)]%\I>9Q3QT1F5O9CS"Y2N]BM,K8(D
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M&?9U/P)P2T=X263YV(/*+W TL,:22'O1!ISX;P0 P O8C%4$]"+P\>7@9;G
MZNQAD=;49/^WI%\&EYK$(D O#T.AI)^3GZ"2>R\X'G5&O.8=GK]_7,@[84JW
MBV&RF==4#36-PRR>>F&8T#PF(<$#*^03BFZ/C.BRC!8*\NX5DXVDWG'H6O\A
M%G=:(4XRC-'H6J%#44;D<:&T8AT*G:Z-],P,DX<+C?7*&0/LKG1U0[>_>9XS
M=AF$X=EGGZ-!49W\/[E-:MS[D>U-D]*%V5>?W7WAD\ JPBQ?\LIEYD,!99M(
MS/B7PHPP<J:4NSO4-?F*R?-*IXZS'E&E'W WOB=VB:2SO7E%*59N'R-41P "
MN,_9XV2H0(A\&HQEM\7#(,;7C<&W&?4CTC)GKFN[T:9/121(;)S=^M%&^[^0
M3G_*Y\ I8#S1Y(OY_ &FNFC9N;- _@6_ZS:!EIVG8\K\[IZC<MG['PH860E
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M= %\Y,O/3 #VI,7PX4W81:*UGPC@!_,9=;8VIN#Z#W;@3*"U@L[+4SA1K&G
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M'/\KEWMF=B4J>HZE$J^+TO"$+K:_8UIIS+XJMDO/:FC.^O]DIL!&3/=V1 @
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M1$?(=:S.3^IN#:H97FRUO).@6F PYWH:ND$)U%XQL\)&Q6$<3@<NZC<OWAQ
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MYM?N#!]X3L4S+=4P>WHS9#A8]I\D@QRUPV&D1\B]ZPM^@Y!+2 ^X/?3L%AE
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M[=DJOX?W/( _"_,Z\S_&?JP+]/QP^H(SK3]L)$;ZD_IB%5R9#& B\*/!*60
M1P."MNE#8E40TG!.]/BHGEJJOR/CRV+]K?6U"D5:$VC9?Q*5#W"3!A,\.Q19
M>=6CL>HA)]BILS:$YCGM-4=(M;+ZI0WJGPG53WZ:@7WE]?T>8F4RW6N"7I 8
M3?2[[HEP*M95_O@66RS\[D;?(D\%&LZ.<^ZQE!Z*5X-^6G!I>U(TTFSVO.1F
M>9G-%VYUP+8!==X9\D0*9[\&C035-T6B#.)^B,;4EH_"13Y7?KT]P#=S6P?1
MD9RK;-(>X5L8_*6FNV:!]>0-EG:/$ZMGV*;WE3;R3_!ZY,/Z*P_NLZG")H9_
M#&LHL00;WJ>._FC4SNN\+_"1HFBYB>D-[=.U%'3ZIE>7W%C2/%EC>U.[.%CP
MYJEUJNXI,!K:@.@^2,Y0:.XSX)S;/HTK'7VWXOV"+<"[_GOMM\>!=B5 VRS<
M)":'1 ^E,$$0[D+?($P*&X",E@TP9]E<,%#4#Q0:N!&3N@?\]7"C7N*K8;79
MN[,ZVNXN#8Q!/WAN"#VZ$MVH&CO18; :\F8]8?N[EJV/2$R0"*^5N\25<L!1
M!-673QOW6XFOQJ$JI&]@;AF86B@=9JQ?7_^)@E7<\H(AG6+-_)[U@/ '/BJQ
M<4'^2(?&,':+NA1AM%,\' V-(4EB-E]'6"V90;H:PKF;8K*#!.0OUMUD8/ZN
MI>Z.:4?]S;!$IR9)#]9@X4]2>SC*5:70CSN[?+<7^!Y>5>]R]AIX"+_'9F+\
M.0]<")JG!! 4@D+8^SYJ2 0)]V?NM#TJD+KE=M/V0?KHY<4[\6+:27N.1]R/
MJW]HH9YK^9Y]?+_#@X@-2.2'/V@-4=?4+U3-#UX3M95X;[>UK7V_DHJ=> '>
M8Z)QVU6#'7>+MI?!-5O??3"S3^IS:B<'PO'&R#.-_$V=<;_35Q21 8U&TFOP
M[B XNT1P(:O(V&+GCAFOM4@?;N:';X?EX/5L]@6=X55/__S,AD.[>*>&XM14
M2W=ZY:[^K+)KG7U9\S8< \L=\'QB)7E''B\9PO!D@;'!E07X\"X;\,N33_V?
MR^IO2 1>>Z(%40/0^CVJ28=[01/( ,P'I!.2??ND/EBEK/GJ>"7='6\-'-L+
MD[GB*(C@J:4K%6&'-+G";K6F/03G"KV78B*=O+?3YS!VX=LLG2=&U2N9^BHX
M+A,Z#MJ5P!23V,5W)U<];V^#Q!_/%*M,8809-U< XQ5,(VET::E/%"CW&@5=
M7J'<RX"6H.8RDOTR>AL2DC)MBAKU&_/H3RHB X+"H3,WA!XD\KDQ7P4 N !,
MKRZW=D7U![ 96;S^SXIX9&OED&<:^9<L7*3@]W]U!?#_^:\D-*&7@CW:X'5,
MJ"<98/VGAJAD-?/G&#HB2V#S(QG0#JX<C^F2 9,!G=9*;*EQEW7R+<)M^FX8
M<',/:J,ES^.)T6"7:]@C5%C4_,!8 3J587<RP&9(5EB(A%X_U?!W$#E-MV;*
MPK53'"2<Q0U1J]1[D'I^L=75/^9G0Z>#'1F0$ZR@5];XE@QH%7XS>ZSZP]]R
M$VY/!LQ?[ *$^DPV2INB!E93K^Y-!O@8?$G7[1MN4:^G>?/TY>XR[7*%V];K
ML)6_[2O( !-,/G$O\,Q\"HH37CDG Q)!^UOP[^>5\!Z[.4M@5&6Y8(%/A IS
M(D\-A2R$4/@-UH&X!#Q;,8;2G2.: HZ&_L?D@CCI,CL>LOVWXRR;Y1;I2JMB
MH20V*6-^_GLYT-WS<J2?3V&*TOMK:Q=/J;-J>FOF9DX"L0=[VMC+\"M!SS>D
MI]F4\K)+7UA,T,U]MJ@]@@C7GIDI.V3H4+WYQV$JN?[TUW]'C70-32@D"_?S
M.#8U%BWW?'0]C1.)V)Q_F,=M^.>9OZ@YR-#];/CO.@&JH%">6$BX1$$5>01+
M'WJ/9Z#81M.SV&+,0]3Q09IX_LV@T\^FJN'6D0U)65M(5"ZR@3:N@Q4+FT0M
M%P>*D#BQJ7GI=W<MI+W7DDM2S'O LGEL@RC@FRSQ_1_H*G])1&WA36(MTBF5
M*B@%WVLKA5TJ3:DI^V;?VLQL_<_3+-CAK01Q0^W[<CVHF<\$#5PZ"IJPS)LZ
ML )4>*,P*F0A<$V-!@4!+6N94F7%W.L#^-S;>@B[1K%#8[!SYJH!CP4A&+/4
M)%_#=GM^.YQVF*F8)S2#SY]UL(,,:$J"#">LPE%YR(: FEYXO!F<,10*RR[D
MQ,9=%,WM?>C^H;=\^+G!9;&[#@Y+'1V8ZQL36X%@?PT)PDN<)L;(PV  Q+K@
MPOCQ0/'K]0R(*/-:L#G:S(.Q3YSKZXYU2B+>"O9=XQJFJWY-7WS(]/;6,LC=
M']D2D"U[K7JV$E 25QW:6WEI2AWXKN87ZTD];B\0KQGJ,=WAR=HZ7N3]^3>S
MHM8P%U?<]\GQTJ<3GW>_:]^5/ ;>(T:&FE*((A87\JZJL[P?R&YKOM.,QB;I
MJG6<F7JLFG^,$1>G8=[,^45S]7GU^]:S=WC/H+5>!#.%"1WP!$UVG[]^V17_
MH0"\>VKD12^>5;[P +=(=6;#;<#_$)9'ZEYI..B&1J_4E^6ORL8)R-6/!\1Y
M'Y2&N$:5]NJ)K8-O,'\YK1GT3H0R=!AAH&BF"LSD8 15Y=:R-N(D6&T6.2&H
M%S6/LR9DR 3MI-L2,<XG/+@U[$KWC]#[&*'?L9"6/!?./3,G;J7N!:L;S"UC
MC]SF39F)ZCB'?A((BXC=57NR:K75J"[^.-ZYJ35J/\5\X1WM6>07-0'W%QU*
M)VXXUZI0 1PGB@R(61;.DTPV>-!P:U'^BJ7L;8B Z6.GRSHV>+_PMV:MIE+U
M:V#<=3 A][1?]OQ7.1GP>W >F8^(M&6<U! *M<(XOVK\Z!1I@.6H=2A?A'A]
MJY<R,REYY"!3_>Z50\3CI&/:4KC."L80?B9W$ <]'C.@!*WD1KC"RN50=\X^
M>/PR*RY2O0*JO=II.F;D'N#+JROM9*%[23!:NIF[9ZC4G3'>>7^%H (]\2,#
MWJ4.P''<E"CT16$+08]$O85>( %#-<>[1(/@IMB+I-)WNI-6 V%^;B>;]Y->
MM0VXLQ:TU]U<2Y-+[SEK)@G@5U//Q0(1.#F*:$PRFP75>>]EO8--*=F*?)[L
M4/)=74 PE3:4.K981>?*7$E,>\+J:OPV0OG+9NGB2P$$EO?D Q%!8@F*)XAC
M@8,OVK1J6412/<;'I.+J&+^8:_+N+2H#CE+<ZW!0+&(U<#!9\< 4!T5+AL'F
M>Q\FH/HZ+<7MLY@R;K3M U#ID9$I,<A;?\\]H*B3K]/^_."3*,Q4TTXGM\/G
MZ2Q:69>]Q) (VJ 2;^E4D8J:NUEG>W@&T@]M%.<0 T.5[:^O&&1\DVO;9X>H
M9!'OQ<7"OB]IZX7O;Z,"WFEMF8%+D/%P#A)?*/^X$!;4/_IRY>[DOMC5AR+X
M^ QC!L\'#YT=7D&Z[_"[I^&@>#W"%=Q8E750X&I.HN?QJ.XT=8!HF[:\,=V3
M+.[N//DO5[:9Y)(2","_9]'!?CBLF0U^)8#?V00O<V(,<LOG7BNGN!?T[9E1
M\UW]_HXMY;+09_P@$@)'O:%,:QP7@.GU3B0)-1T>'_ )Y1NN,5YZ'>MO_@>O
M"90_N2Y\D,?GSS]6&>J+MR9]!S,2C )02!X<>E)_NM+"-,2![_!-[L^;3.-:
MV^4T?*Q#+_="?;$+%&OM@U\VQZT,+DO53LI[FHH6?G/*#&Z/_Z'2V.$;DV'X
M)/R,O44(F3>VD$]Z-(36)D8)4\1<4 7O:FHO*!71.!./GB2HU.V(:]8WUKDO
MS(562&M\7Z(QQ7+V7+Y0,\SG9M'E- ]S*O\BB>A\"2:P:9]H3P?(3ZQA/S:X
M<@GI!=@'7Y$R\!/6;*1MWV,_<<K]Y-JV7.!9L37C"S5?UJKK46.J&_@OI51,
MC'!1J #<Z2 !7I_2[OP^%%*;(O\SO:2AO3'S>V,+G<^J2&_:<'JKQ9-7@FLT
M/$0.RF,V)OC]].R 5!)H9FH$;#3.:7\VQ*TKFSM';6Y>QX??4,I->34X5,&7
MPN-"CVAM_'\='Z\/5? Z'WR/I* ]D)BA@/\Y.3E8UFO!-.4^S-LB#+;@D4Y0
MGXL.2RUQY]&.DQ_V=+_7&6D\>7 5<G&T(5'^]KNM+UNZGS6*9H[^S_H15357
MO#J.D23BJB$:.S"OD*C5%K.@55\XJ_LM7M! T0Y[8%<9>*&5UI5;<AS>(P=W
M 3('B:.)Y3V=6OL0@NP:2$$H?+;.<F6(%\)7&P&#RDLD=X-NW3!8>C=@27&-
M][IG8VCXGBM>E<#_4V2\(V3-2D__D8Q(?;.%MXR#1H:V1X:\,Y'8B()CC&3G
M]<QQK)CJL;YEAC9%6PGLVXR%'I^H>&G/:X9>8DFI[6(VS$"CEL_*1M!7('H-
MYM#[N+.U+Z',*%7-#]NGX;_R+*PK#?OICL0+-0L^,%PIA(@ &*[2<RUZ(B9H
MHY#>8W/@096DE_HY*>\_M^9&E)\D-PZ\?I"9XI2G$ ]'/9)<T1 D/,798VKN
MUV&5^D$LEB[SMJ5" ^YJE19B3IJ"AR>7I"XGK5]Q0 HA$>!X)$:?,M[5L5AH
M?[;A;Y),S)+2V*5DJ4D;+<!ZI9PFJPYM2<B;XX6$<WNP(S09) "W'XLJY)UP
MT./WZVL^?SOJ7M&071>6$A(?9;Z8I 4P3NAFC&(>I%(VM"8TX7:J737$<$M8
MAOX\QF_+KGG-<8WN[1:3JHX1(:W/DF<$^6Y_%A;NA&%APXC&H=T5%'+NH-N6
M%6N0*N6_!_UG\EK$YO(]&5R)]885G3;(DA2B9K\:9M)-DIXFL%=[D,8QQ./O
M"+\-11P!#[&44&RZ9/;\+=]SR5WO6#C& #C/B89'-$!!02ZNPKHS51.;BV-!
M7\6SB4H?DC^'M5:XLJ3^KOZ^/V/8$$$:?%(XO\%A7G*?FY_/R]3XCF!DFGNW
MA@1LBA*-5GHJ3B<T!(.^3PR;I/+NHBQD90P+(W2J,K12A1%O9=D/3_<*L,,V
MQ"RD,Y">H(ZIPAEP[7 8NEZUU=)Q$:QM3I:I+AZ[=FAD^/8JU&?#%YJ K*_9
M/5A;F4]%LY&X,!O?K"JO>RM(Z^[6ES#7V]4[;&9H.QQ6/Q\22:.^&2U0J@@C
M;($QAF3 G#"T4U]=S<U#-&W/M*.V/4+N./W];/'2&[/9<ZW:DJ#(?YJF&WAG
M%:0UL#1IU@LZ]9HW!))2HBJHMQGARO"&%0)K_2"B?N75"EHK$VT>:E-LWN#^
MP;/!77DOJO)#!LV1$U#@Y/*0CV3:B_2,3L[_1^O-?$^JH_W.16I>PX1A"\AZ
M4._>4S@P*'_PL]XGJUL0S]UK>6?% :M9RTL""G9!-T;HU!\&00EL-2?ATUU7
M"6*?,691,LM#-MB1S+M>0D_K>NR]./<N<CVONI8N3/O!>/WJ76&,TJIVKS=_
MJ#NVM/Q5EX#KD-&4UU2)8%JZ)DO8F6,:)JX5D/DSK5CJKHC#3XJ7R)3BC4-I
M<1N86#13/F9A(/L\IA04&^#L+F&L9U55X2IF85]@5*#]//S5OOM9%@9.2&X3
M)\*MX%M3-24:RJ0AN #8J8(7RA94-\W])S<N%6\ *=B,H7_&=;@A*IQQ>ZY;
M]/ZM.U<,V(_@E.BU[CD.WCE?( .TJJS-GEH0WXX_9(__5YVM:,G3_ZT:U?(/
M;BJP= ??3V[-MRPL+(7UY(_:AMB,BH95VZ]^*GH.N<-&]3R!L(;+H01,#6)!
M!_"#?DF0:P"0>[%[@,=&0SYE3+A:/#>MY<_UI/+ZIQT(BL:+:"/(YV&TJW ,
M9@V-TI&BG0.=?=''L\N&8TT'@Q59";]V2ME7031P5W#D2H,80F&E3]_7:[^*
MV79ST/^FK57,G8MHKXI"I7?/QGCK;0],[/]C!9W9&++1K!_,&GJ=B AUQM+V
M3 Q=JB^Q'#R9T./*8EXOO)/(YOTZC2^-2<LW39M-4"/B/1(!FBL^P1#+"9[8
M7SVVC-C4A/=3#9Z!)A'?-Y?^[%SWXQMRO8'1Y(U0B6RO,=1FQUO@[X::)Z*\
M>U98"8\SAO$/&R3]7?:&/5A&U3[2Z(Y&1A^)V/1?6;NS^7&PMW7WL=DJL&\,
M=V-EH,IL*$\C9TWV\I;W.S?.-*L1*>-MR0]KN;V<VAG!1KE^;]EX:Y.2UF$'
MQFY]+7^K=J_7_*H_22=V(-V %PDOL,V1'=?0+0U5O/>FO#RJJB8?U>4PW]W@
M]!N[D@(9A"S-%/%+GEB=6.&BT08)2( :)Y9ZX%!;L;[2HG[Q*]M3D4"(K7H/
MYRL=0QTN[N\ OB=W9LW43_YS/Q+#KW[>K)7/O\7M_>  ((H^?O@W1<IOL09)
MH<*H,%F\]V#;4DIX.2TSL=RP-6&:?R^#<R0KZ[F/CUQFPB F<$ V!GIUO1 $
MP#5#L"+9GWB>37H7M;N\?GMAAZ'6T."^.Y:3=+D'"\7#T=ZQ7<R_C[P:,57O
M.CJ>J(4UX2XD]$T)/G8D ZK+.L$D>A"FS?P=MGS0_>>-^MT?NZEW>W07ET"^
M"$'J;:XGA[]]K8GE[Q-N7/I?WZP6RD!X3K'5< (7[B*6XW0U)Z&ARL]HRG^K
M*#MP$M44Q+G''&\4J._'RC'[S6 XY>5Q61K(WPB: \:<_!_<O6=44]^[+AH$
M101$E-XB15!#4:K2 BH@(B H'8Q(!P$!P2@AH4CO**"HY"<@14KH72(=I$D-
MA)8$!*4F("&0PHWGC#/&_N]R]CEWW$_W0SZLD96,-3/?^;S/D[<A9Y88T2@^
M)AU68#)SV=$C (\7/1?\RYYDSC@V_7=TGZZU(-BB&#7P^6_Q$'SX9[BN*.E.
MY,OW#A)@$)9^FN)+8M6CE.!TSA'DHFFCG]?)_<& CS?N?)GC#SX>[G8^*D9:
M.M)(-8>UX;\>,R"M7"S?"PB6#1=(2+B$^VBB+]7'+FQYDG[9_C^MM[]\Z0@P
M8<SXS;!2^%]%G^%7:/]2VHG1P9L?"&X< >;!A[P5,?\AJ .6_)O#QU8A<892
ME$?3 Y^%3WKEK4T=YLTBW)YDZ/MK#DLIAQ5'#\]_)@.=OI;N#4,EFR--?-Y.
MV;I;IB2Q@D!<9_1QD9H)60F^<_)P%6\PT?BX.?](&5-U!'FI']N8L[_U+%^&
MW >$>5X0]&K*%V(A-DE?$P?M11$$.Y$G859$IR- N#;B47-%<DE> >GJ11-)
MKHJR5\J:E5R?S?3YYT9O/K$&\]&\F \9>]9;4 /" Y>,*YOOC\'<KY(G%;GY
MQ+FR].WM6+]GTG**C.+L] IIO\N4G&!(41T0K[ZVQ39^^P9BL1"%7;NT>Z6*
M"*3QF9C5C8%=P&>\U"];+WPWE3H9<5U2NB7ZP;G%"$@JI JQT8U'8Q,M2$71
MP>6680)4D\K(M9X=_K-E@;4M0B:<_+MGHOJXBLZ?Z4Q#A!T!O-%1(B.]VY$B
MJYT\/(OMA6LBK[']?!C]P?.S9J_/4%D>"5T2!N#(J!PFVYE&]R)J>.*U30E
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MPPT71[0;MBEXHWF/ )Y##ITV B0'KS9V.9/:KCLUUSM:QXQE-2J].*8+-JT
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MU=IB\C5@[[47/?,=GW&@'Y>N/S9<)V1[9KNA+BR4ZL@81!(G<H^-T41R)8\
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M1H\ ^?FHE2!<-BW+GP4QC;AS!!AK7+=]8C+'Z/39U2+G,K$[C:*%*XK?ADM
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MX:\VI+C"Z7)I5JAIVO[8YLRMB,#04UWT;/#RK*[ $6"ZI@#Q6R9X%=R0U41
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M:,Z$]WUU(V)K9PYX5"7;AEPXSSP$A>%4!,_[IV<: RY_29Y]S]P]929U-,.
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MDZT<A'+OX3!IAXCR+1=3W05US]EB+L'+T+7KXJ7A]'35>80EO1 NDGIZUCA
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MO?Y ,Z-^3/F#6%(,(/4&BQAF1Q]W!#@0?69^R*@_ HR60AH7ZS T/AO\"TK
M%R@K+OD72;V*8&+\9/7KCFO*U'<L_M1M!*S8]6W^F7^XOYC9+C_Q[T2R,]WO
M;!X"L]? 2+8_'X&<&>*SL./[S_Y'1!QA_NOR&]1J"^.4$?7^NJX6B;[_;>3D
MH@XZ&J:D]+KX0"D"42S+6?9V7;P%%L$C\<C]>H?+?F]W\QH%TM$\$O^1+;'
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M,'_KK;9SE!<%)N5KF^<&%?"7@0.IHN]7+U]1UL)LK-+.0<A!% PQE,">V&I
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M&3QXO_*,%C7PDB!-& &R0VH4LV$]X>(30U:6UA8C6ICYO P-"986Y2[@2U-
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M0 -"O<<,&R5U!Z_$=O"Z#^J_S@XT [KJR5\Z;/NN9\7S6+;5==&<G]]L3VP
M&MT %%!G#8*N&Y0$+WH\.9:M6"ZDH9?KDC!DVQ4-O"#BGOF%]+=CTZHI)AD#
MW1;K@R#U0(LF]]K391@'BX,2Y\2&L^AJO;Z'>.O%W*[:Y8EK]PL'_+6\9[,G
M.J#UI^ZWP+%^';4*<HHGXX()O!):NB=RR<&"F7B:OTC^ODI)8,;(KSGWX)77
MYUY6M>6I=P6JPJ,41_:@<B_>7&C1%L[O!%1<C*#J)P+JRW!LF]V(.L9:Y5X@
MA9ON.H3[ZWNKM\(RCN%?"AZ7TAUI"P'(+L=^X2]0G?LYRB&>.G $KB"IPW6$
M6Y[ZKZH]*84J \4;;):_KY9KE[/%PX"/J19)\DL-Z1)'N*@Y_0*M2\SX@1D7
MG;?M5;-]7Q)&?*[TXQR>$.)=*K;MOJL.KXWU2 *C('1M-Y$#!FUA=YB8%I,@
M=3H%O,Y2UJM/1:XZV=W96O/)F&U72I2@? $: ,=Q ;G"F8-JUZOR%LV7,9'=
MEB[.KU@3Q'NTK&14 B^T\F_>H"H)!P(Q(H@]GGQ5[75#'%T'$;#%2XAUJ3!V
M,07E>V/\2%\1 7>!,2"DW)^W+*]<B( X/<($[%@68T($D,D0 6>4B((<\:-/
M-4<#NY7($$L, U*LAT2F[@M/2(4KV#TDP9,N]_FILMQ7<B=-K4MW7V8]U!60
M_!E\M=Q>G8ZT6:FA)(F,<<<J_E[4?+UB\V%3UT0K@NSHA5SDJ3YT_\WC(K$:
M'W \N,:L&XJQ M;%18>J^#+EE;I.$0%NJY%R"*>:WE9S2("NTCW(*GP2C!$W
M[ (O C?%H&T2,*8V:5]XD*76%,Q^2?5>U4EOU?:^UK.>4Y^>J$:!9\$O?P&1
M^F,+OOVKY,>K[)CMC=14OS"(E:S%$\LA5%N-Q5WL(/>91U?H BVN>/OTZ=I%
M^<* >^UCT_>O%M;^DP&3?#N!V%*L@LSI((YI?U7^XR? K_)_8^DD40AT.VGQ
M83A'S#IJR1)3M!9FHFDM_R1U])Y9[1@]2JV^+F"76X15G'R@B7EAF]QG;#>&
M?>J3^=D2VA@#@H=285C6$3$$L=:&CAF%HH"C81?K]]]\_:76_CK6?W7Q?JK&
M1ONFV:3?-XAN^WA]KD/;U FW0T-3I,;K+)Y'146,ZZ]?N6LEW@ZG#24!\T@]
MW$-HG_(8<J!W47$@SB$M?\9?UTNH-5'IIOD6B^50ZB.?MNO?DO>L-CI0^&@B
MP '"$3Z<HYWX ]4 =_S@MG(U?83[^$BXB][TCC6B+?.RDY.\DE8G)27-(+RC
MO.*Y74U7J#[&=>T@:85FN@.(.>P%_SPOI$B3KY]XO:\K[#/4<IW"/' G+0T<
M#V*#K&6L<AR'W7]!X,#\::OSVOQ-84? Y_:'AK3S9C'(6PW'8]91)>'X"=W[
MG1.XZ05(ERS";>D#[L-QE=RH+U3.6NMRTPE^!3VPGH-GP/])+('97,+#.H1Z
M4"8#'5?J$#/2GLZ-D0,&NKSD[C'S7X^&6'+I7K%KW;SYK9_IMS[[\KPY3A%S
M1C+=*'QYN&RH'<JP5R\OI.?TV8[R9[5*O4!?/DVG,L\Z38I:S\,-VN*+/4+O
MWFT1WH0/PFI'RW;GD(G#G9-Z##\:?257W!J?41[^:,D@H[:2Y-Z\7=Y,=D,Z
MPCSQW"W10,/^D S=^5?)N>&-T[XD>,(JM4Q=)?N<L/9TE<SW+#)T']\3E^2'
M0\4Z!7I140A?WU:H,SX*0?)8I#75WL44&6!B/KH&/J&L^S1*D1<]93"QHGU8
M5S82*_IP8MV2/&NQN7\"7,1N\B.$ CH&6P*C+R6AW[HS\02!C*,T45F97IXO
MFTVQBKM\C2*^MRB#%N7,*V.\N#]P=X&'YTE,RX;52^5 YW-6M5/Y-_>DRYG$
M!)NH'09P9.HS>!&C.QFW)S97_W3=DX1'@2G;Q)%#!)3,?AV?+/U4/W7*=R=7
MH--^0*P=EQ KX(N Y+Q+8;%S(F$"3/,#LXFT[ /12</-#)KFGJ;8YG4YZ+Y_
M*P8-XM^3X69(?68@B2()9)<H$> R@MH T=H3.@X0?]D8B=<Y'-#M7(* #%8+
M,CY ,E?TB#_F"@U:."+0?$#!UP/[8=2XNRAPO*K:M<SUG:VVMU)EK5GKN/?W
M*Z0::L2D(W1]7J;+:3'MU;/[?JK!'&%M"3V(NL ]!E0I=N")>F.A[GL13G2+
M8_O,:*_<D@;OQ=]?&O:;79-3=>SS>DJOJY?CXR$."T2 $Q/%[\J-I"3]NWTK
M0GDV^QLCK3T"=4+Q3U.V[ME'6BSO\3@-7-( >1OIY;XWQ_7CFX@ 6WT(.AYE
MD(%B6T_YD5?F/M&%UM>56=&Q;TZ4?R-BFG@3%!3Q6: G<^G+4M1H>"^HIFR/
M#*N$,VQ'R2365W%CO!_5A+@OJ:@D_,AR9=]_V=W&\EZV(=QN@78$<)82#C<R
M?+O+"<H$_:WMSU('+XF7ZJ':J!YT(+*Q[R"6=YJF^C?EF8S?GD;RLT&T>W.!
M=N-;CH:&WH=&_32#*[?,$@G?C/2X]AQ1W/=CZ,#W>IX)2\RBF+5"6"81ST%K
M[R9TN79?KKV48%\^+Z)/=A"XLTD>PMNL<LG2Y#"I!XC4@RXZ6TQOUL]EZXY+
MG88?;KAWJ;/[B_-?& ;>O@\UED1OHCWP[U0YL I!U$$JW1_G&K.]Q*;]>1Y)
MS66\C+@?>><R(\N%2UJZHDFRYYR)<5?ZT_Z_93F.X(FK=*I\*%AG2W;/F* %
M'JX[/4VY&*#''N_+7Z/.N,#23$4>(/1!B,"+T_HK4G$?/['(7>^H*<7 =)W4
M#6'BG]L>_R:/[RK<+#4U"-ZSR<133=S)?%ET1@HC<:R-Z/@Y[PUH7W:.=JS'
M<]4%P;5O(UR(;';:Q_''KLPA<_O@3FA4,%,G**9%N?N <7DXS+.$QF+?&:"K
M.O5E\LMWLQB*-S%&[ZZ2B40:PB?N9CQ-.W/$.D.ZU XZ;F*ZP8D(VA,5??E>
MY9H^P0+'D!:5D-*$ *D=*;?OHO,<%O<Y/,B:#0)#N4B([!K(%7_7Q%)-4R%,
M;BF ]X?E@>S%TZ<UPLUH"NT.R7.-PI@KG*I1-ACQ-00/3J 1([V9!-D+XU2[
MM=@UCTOWJD\QOEEDFYXN_G!(^V[7ER^@9,A_?OO^8L>'SR3VV8?/-)J<F?QZ
MXIBS+>C0DJSILX-MWX/V*)[S8?G^2'[;72PH5"-NHPP:JN\*J7BR..9-D?HN
M78%ZCJXF;_NUL!*7T-7DY[ZMR<#IG*N^MO;#'7*AEY"0 5!<2UD/E*][TO4\
M,?*SUIU1[UN^_!.R7QCCTEYI\)A2Z%(A<P? 2#VF12Z-F1]Q76:WG!,51@<&
MWUC1W1QRABJ)?ZJ8_\VI+7B"YS#Z0RZR=0V,8\WM,^/]WE&+.C)MJ)V47E9Q
MS7&HDN[[.I67;EAO+*(VQ&5W@X*1VS>-1+F4^HV%4$U];8,9'(CS)66Q6$+'
ME)^CY>/<8*C4$NR=&/>*5M"W5/?3R<2;\^;_E-_^#P-('/^?)HN0C7;(+0R7
MXX107V&4H4M5="8) 2?+Z,]7!SKT(0*9^(^#_,_[)^X73'29&LM1JS)K0BXA
MZL2ZK0W7XOJ!;*$WI^T<D@Q: FK37EYT%S? OM!0"]32>F; S?%5HTH\0_@\
M#9]7[ZX6N ;LR3/MC*(G"$XBJ30=ZU,L(&M2M+"2$-%P]O!.<*-V%($78P"*
MA/%X\^E/296D'><]K-2EUY7G"G'MOCA$GCP"C:3<J*J[*G8B;X&OACA)4^G?
MJCKHW:,TO\.UY![&L3PO$*WT0Y<&O01SRQ;0>GML'5J/O4>80U"1['3Y6CVJ
M9&0QMOT%,)<R\VFEZ-0] W)H<^;EY%>WKW4V,([/WS@$18$:3Z/"54*#H>M<
M+T/5_/%0Z:J1B=^G<M3YNM)S$,X"7?-YLEA7,K^AU$P,&&NUD[,:#W*%)V2W
M8%NM[E:O/M$"5BPMWA^W+$>S7+9[9U_]?N%<K(JTAV!_K29_Y';/#;L(5H[J
M$Z5 V_G,5 JZX^7P^K-FK$YHX#3(92S!.%1W1B%(0>^#IU!]D/26*TM;<L3W
M-V3IU,"8\)'P7LAGZ.Y$52@Y<KM7W_WV)U1X[<?N*?#RZL:/&Z)F3V=WZ-CX
MPTVO/V]-&!2)!. J\$W^,E%/X@8J?ZI36KK.K@A,50G596 ER!MK0[XDG8UR
MISSF?W[!G]ONALC3W)06UK&9/[TKIE-)(04TGN/-JWSQ-EHF6[2D\$M,NONA
M'OH'$9!1@R%)I"TU$7"<+X%W)ZG= \A@<U 2H;]U#'^I!CYH^,]>YX/T_,K
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M'!8*^P),0X8+5 0#R#H4'^=!VME;!"C( W2F>)" 0).38.FX^UD/_A5D:YO
M303,!XR10"#\YQ&ZAR0.-G_R-I_JP?&4[QIO-X#>@A<."'H'/898GCIOO'0B
M@L3^M?+S)5?PY\WYB[=G_2OI[NXSZ_D2 77N2%]T"!&0CD5.$?H]209:SP[^
MDXY :[;.=\!.&#KOFX5=:((PK5JX&7"EUPAS.X0&2PSI'@/RI_7\Z.Q1<6AJ
MI%?V)F2QL?,\H)YUS-5>NK_0WH-YTL)R4%55L"GS8=I/R?.,?.IK[],7?RC^
MA7,BAH9ZR)F#A%*I%7%IX2,@3L\.*EP ,KNW7=/Z&'_M>SI2JQ6VVRC;WM9G
MUBJA8Z']G *B0U#&?R("G W)@U@-@7J;8?*F];)9C0U3U87-;<VA/OS/A+T9
M\OF"'L+Z35_/%K"=5>"+VVX6!MW=/.T%T@=Y34@IM"M;=D0NKJCN)HIF-A1N
MWWC,?V'>[/@%EA8R6(*[003 >1#'I6X$QW")H'U((I U5!_%^6/&PP$E6. ;
MZCF1]-$F))NF::UAW.<=_4GG+_#X:J> LSER&\>6,]6K+B#54OUV7<WIQWC9
M"EOWM7PYM1Z Z]C3>T!!$NN+8!0==#MS'8P3TEZASAMT5"[[]I_]$B=I,F(3
M];*^'7U8CW;!ZER*?ZH9ZAM&!%"$HCS2:Z;"^<R[.(,L_'D<GZHMV"8#AQ#"
M.#57VTI,QH-/<S+A?8XA@?1FROIC&>SI%.DFL/T/4KZ_P%/O0+4RNV"D_3HV
M"&J-S(I6$)";UU<JJ^S/WKO\ZOH/7=SHWB5L153Z;<TM6EZ=:Q#9<-%9R+HP
M2K!R UA;!4>7+)_:W&<U!:G?P;+GZUBMF9W48I6_'!*^$@%T)6E)*AC+>R+Y
MNE?Z^3/ @]DI!PKZVOW!A(+U\FA>S=D"?^G7;OGF>LZ9.:+4ZC^I;R\ME4 L
M(+5@7&Y9]QB60P&$OQ2;^)+M+!!?C-C:Z! GR?%,->27WPQ>BM /.W0'TQ,!
MNPQ4)_ ?K>B\NOQA-!130M&]Y[L19G<;M)!^:&:"J20#MP-KQO88D)8&^"Q5
M[OQ+J-*TPF473HA=>R0:S?>B((N'1\L^+4I@)]:*[%70MA#K/,M1&8[CR+JE
M$5G6 Z8O2O.$A'RPN866<>67+<!1](3[GSECE0CC.:N[,YNM<&!0B&;-++S:
M0_33XXXCI=[/@WRU!2FO8WM#?'_J'( _PI"FAO2#&S+1!#),4G%:H&WQ;[8[
MDWUQAI+&,38WE>E3HCO?"T9_.N$X:\<R!@VLS<6H*XF6#5@+WY_&R5<OZ#E<
MF=FS;:G_W'(M75.%9J*;K*90YF5CN'D,9?PND^]/* NDZS%!')/=<PZ+\VYC
M*^#S-)UUUWWN9>Z11^_9E4$5-8F0:[OI7VZ.B=-KGS0J[FALB=1A>>&4R<].
M)C!\(9'PV1/B?+ 02>CS5P'&KC VU?JOU&H7_3I@L6EFO-PE> :_->4%LH4R
MA6I.X,36\2J=:()\\SO1Y"<!,+LYW1OD$2*-\6>& WQO=?>FC8UW7Q;MG!-\
M$6OE, XB8%T9<T85\='I2.'@XD)5,^![^%( IWLL\-[AJW,Y7L)+G.\&7K)3
MD'Y.U:=::11T^W-3!^P=:Q8J6P*TZ/&4<>LE>.!'^\>@I(U J,S)4KW[-]^^
M6\D9G\6NZ.4.ZGD:[>]%@&B%6J*A2W",R&HW=-<[CG %TU5^-PG*LIQR:_#-
M<VFIYLS7Y[KRGNHHLYV\%] N2!PGF+J#'6.V7I\ZV4(1K71X"RD"XRO+("S>
MMR ">(]_Q^X/:?Q'%<C_"+4^0I@A7QBQA";$857B (H*%W& V$DB B0 ]:60
M+TI3A*8!(N!]8OLCOW]\,O9O*RB3'542:!.(@"OU('RL'Q& _P!.!7\*Q.4A
M>F#G.!+(G-2M1"O_;W]BOJNW3"BO/)K;7,6Q^ZXU=H4%GW8MBE:-)>,TGNX)
MC 08I#W1D'LVH?M\J<-?]7H*T)5<EIX:#E=7VKDU$*?.$'3TWRW0^]_92C'J
MR'P^"\$_%LC]C %Y4A(+W]"7Z[%JQW)D[BW+6GU35G]@K,.I:P!I*:X9*WD@
M[-,0W@2&=(%5+44^^JW&SE[7S.>TUK(P9PHPMZ<ZA'\Y8-T!(=,PT,<HIH79
M.:SQ?@A<E$82"+L4EF@H<NV9Y+E?'-H1GT2@#P5YL^QTL(['1I5:TI1.GP1-
MXHN-*?D'06_;BT'^#Y_K4+>]!(\@_A-6P\IS/ MB@:@-A<KL'B!;++AK$3%U
M=W2WTCUL!Q5QY7^_1G^,^&<;@\B4(>WGH>F?1O6V[7I$P'V'$L:B-/SU\#^%
MG421VVA/I-4*;QV+=5"N?MW,"5TL8-C']P7K4.!U,DENSWB5JR<B^2$$6K8U
M:?N!U<]CB=)U?(&M[1/Y2X^8!T[S)2TNO-OL^&*Q*F"P<K,OA.E?+M[?@M9*
MB0 6U<=KH(5!CS9IA:RHOEO%MQ[OHK987$78]$1LXX1'#[N!CZ14IJ7[Q_KA
M\ZWHF E2=(Q('MZ$L)H/AQ6Y*;&Y9L.<::=ZV"<UKV8IVA4DMDFF-3GJ#MS@
M.&G<F\/ZX10QOY"S4^N0[AWWX?BR]L1#].$A\-)CZ5./5)%EB[=O8J5N ^CI
M,PYQXEAU#&A-.Z5^SU +L[TIB2!?JO_<D/>"7#!4VK>-4K=36\ACT.0P^<2V
MT[LIE ,K$=X%7&36W0 O4DH_N21TA3UK]8$V8-N]K<,6<"S"H1YMFB*Y_-J2
M%-/=Q]!9MV)*-N )3M^F[DW594_B-JBU6UOR>2+%?_8)QV>1E7X7X^%!(C#B
M7JW^E839CLM3^_QUP:)9;YVI0=U0MVP1)@S_+H27$!W.\!-!W79SS5*-;BW)
MM6H]Y,XPR^0^ZV^V2]^3'J1^WU+E=+(;2,[!,9"F+0BZA>U9K=L;B/^1TC&\
MD2<W]%M<]C"KT?#SK>V9T$R1 'HUS?N!]NYWH_$Y$"\@#REJIYM6Y5D'T[L^
M*70S.X!(CZZ^NR(UH<U\Q]Z?XI%V)O=:S4D5=)$/C45M[W$A?QO&"5Y!-F24
M/5&;YK+;F/\Z)=QIH/0B]9$#*\W '<TP&B* ?&D6X01C=;DUT+V:1.!#?M].
M[%CV.E[*<^N?=+VV]SV!HVHC:T-)M#!HV.-;NL@0-+/R)-<$0X.5=LF2_K #
M8@SELW6*DE;K3RO39!8L61%Z'ZZP9#;/"B*'K.5R/8E![/FNNWA,Y//E6ANH
MI-^2NO/5C!S[(C'JMV;X:TC7$]#6MU!E(L#^<1GAU:K9S"JE(FQ!Q0AE6E,2
M>C&J>Z?JU_B'#L^+7Q<Y#RT:DD>]>3\FM5;//F64GS8;!B%-)77W0<X,C$'9
MXNX;(3=%U!,]#IB!V%\1.%>PT3%(#;26#3GT:R "T)33(/1]0MK.622)ZR]P
M&DAX#VS176M&U;&\I_C78DS>=^ABM94FN?%(;M&10#PMSZMKACS"ZO7X2QCG
MC;@>"._OTQ:JJ#:C4O><U%Q>/5^*E&4S&=J;W=DLM?9B<TO3QOEKJ;\3KY9S
M_[U$ZJ/_D7E1\201<L(*:8%D FPQ)@1-+.C4D!#M7E =\D\)&?_\@O=[\&D_
M^"+&VZQY0E$O*::E_I(#C;M"(LV%)D=C)JKZX!+V*>M[8^Q$0.Q+# D]D; .
MAL*'".@U(@(8R)!SA' O(@!)NTD$Q,/="ZM1N[SYXO_R31&!EVH=CL/]J>''
M07(8+#9SFES0I],H0XP+,!9Q=!1(!$28 7&:0.0XB &R_>. " !4@S")Z):K
M;2&498F0GMLX12( EHO 722Y@8VK_T*.6?V$YN:\HJK)WZ?2QBDP]8#/SEJ)
M@$Y)*.%R>W6BC&#7APW8WZ8"K;\/YR4"QD97"1>L("B./3^C(#2#X7]RX4D#
MG]R"ROXV%?1OJPNQ9K=1BS+I^]M4[']?G>3BS\+_8N3_;QEI\W(=R/M34/ES
M#A'0<Z@K8GKXPO!'+_+5/,-$I\C3D^KJ1/V!0HIG_]CH]=^-%V.)'1(8E:Z<
M-Y.*@]MZ&;S#\57?7WO:W3Y+TQD3D,SY=P29O@NA^T^QK>R_MNR_9/^_&/G_
M,B,E)]MD-O+X^GF-=VZQ0T5K5:[8*"=$R3Q\W*DX/F&\^/.EU3^>E?/_<RKA
M/S\_^EN./<?;JIU;X#@%$NN8=P+I7,M< PZ_68V<+;$S7WK!ORE&^SXC$3!5
MV'&YCA2\)(5_R<Y)#O8+5_23:]+,TE<ZNSQX@[SVMA+T.4# D .]IQ1!HN/V
M_V6,S(; #88#!RSAHT0 %63]*<;,H'[ZA,>?+H1[L_V(GO:*!7^KE$?R/,L:
MH*?:MY]I %QS@&-GVB@;6$U&@^E#?=Z[-#0$Q]1/#ZKG"8S(::%1;RGO38UP
M,\NF,MT<LYL.CAF;DY#<(@(6>]!PY,%NU7H5T'1&P;4>KP?.-_^XN_'6<_HC
M;95DVT=XW;43?F%6\X!!.!"?^:<J8P<07]P63 0P>H>**L?4NTJ7-#?8!LG8
MOM&(_&DY&)/6D-[S72CB!14@R];W^$[BU>+_P3,*]U85%0Q#_3'+\IUOQIJ,
M9;\9-9W,,?8]3QQ67:;\<O5T-;YBWJ<JC<T\XEW^[V^Z_I^FL?5Z\_FE?X3G
M_[/Q?P=LAV^YHPN)@(QT3 DI>%:'$P$ES\U.AL%?YO8TB0 Q490>H3^,!"[O
M;U6))VK+%(:",6-%/YF#5'KR%>=V_<SO2CT)*RWRYZB(L]OEY-ZB5I;GO,&?
M;FAB'=@#7:C</.CWM+B,A$8K2G8%8(L1+0E[>UP^9_EZ;QL*5+<B^J WR.>.
M+_UK6A=6/4[6_$P%?1>?K0!9@*QOM? TZQOVM@R7]%>%1D2_8&;AEW6@/"PD
MW_LVS.DDY$6+R(4@S1!G_ 1^R+SZ7P5M^L M]9C'1 !%"!&0-K8^@(\BZ>6Q
MQZ/"$[[Y'Z3]R" "2,!W8RQ^11JUCW"1492A6EI@4- ATZ9O[']Z1"&,M_NH
M\A"]/%!-C3^#]X(QP@>X:'4)(F!.FHL(N-,&7ZHP66;!V04U6K>@M!-/X&S@
MF^G;9NW-;9E0TY $7BU0@AN> T.:G4(-DX'<[,P'(AF3UJH8/H:JV7K;LK$]
M_[CCS:V_R_G Z[FR[+ZN(M*P#TH%#E7'Y&W R=UDZWQ_YN1]^T OFYEJ2MVS
M,$=?UB0T=P#;]77'7L9Y8]36F\9>MET")1U7<DN=A.BE2'3!]4>H+[O',G&>
M6J#/7O:'H\CWZ25U6:']D$5?- PEMJ>QP<#7:R,V(:40DL<[L\>V:V,K)XQX
MH_R6!SJDNT@IF[$#+H$@=21;C]97$]"^ESB9O[D^[]_>?^N0NG6?JND1%&0$
M#L,@UIUWO9&$OGH9_B#YSAR*BLC0X3WY!XU4P&]'PGS0]SQB]8&K%(K@R,7M
MR/Y*)*^ A S]H(\$I+=P1FIO!/5.]\V$\%G+<[.TJ"]]=[-BS E:./VJ;YC<
MWAQX@LSRH&_%M[% 2<$JD4,>;M@'-\)GR)_WCZ[YU/@\@@ F1#?!-D%!3S)!
MZ=@]J2EK@V1[7PX+*V^"AV"]8W]Q+V$#3/9;MLZ,E[/(WZDK5NY26J9YB%Q$
MY[%0I.0Y/SX1Y Z,L5' "*S#Z(*R>UO"XS8@M/,]I=9/P%8#;I/:+OF/3'H=
M'5DE>Q.MJ@,:- !/<]X4AN%][!T#1=BLEP84LN _[GU]F>P=J7Q)^/L-$0??
M*/#KO^=:'3NG(KP1$00.3,SZ6&R' $+]^O3)Z)W%?M>Z1EV/W9B1).9 F(J(
M4$. EOF:0)_!A;,Q NTV$2"2VP5$\Y$D4S>_5-*H=@N$$67"O<NO(0+L1@\(
MF0MS<["_S70(Q+'&$0P,S8F &J=3DIKN[NR,821AN'1O<LB\ER'^2C#)$L5]
M@2#O \]NJMD3^G)7\9*U<#AHK1IRJ-O&0@38-H..W^[\[^<Z#GO_,Q1$TM4N
M)#069X9]P-.F:<MQ-E[G7J4U<E]9RLQGS)OU/E>!@P6?ET97#].;BZ"P\)L_
M6R#Q'71!!YHSERVJJH_5-'G,'9QW]Q]!_8680Y@9PKD@75<A6ULG4"RG-^2X
M^BOB!4&2"!B41D'Q+^N9\&+!;[T4((+!JE!.N+V4,WU&;R<VEMSLQ =K2_H5
M/%2?1)SH'"$*/'0EFPBXI&)XO@<D1$N>M_ZY'-F:Z[A"!,RS_LE-JLCZJ4-P
MA#@CSF00#*!=IPG$<8,$?IKD!S_L-#XQW!UV+UMJ?C3;IF'O?AW8QZOIXQM%
M!)#%&*Z#8R"UJ[CLU5@86OZOW*3P/ZU'#$(%PC;@"\^/'M:DE*CSS'C4W^30
M,GQ-GO5Q_MC(I^D<8/A@0GI<&CH PX@1 =%U8]SAL^I4=;.7+?;JSJ[Y"Z2,
M#SM[BXP#,?1#*1BS$V'PE]/='I3;TEK@@#=-J-XT2_'4<6M6*NJAE_=G:RWT
MT>=R[$C")7^!^0O@J01\*<BY#]F-^8+3'(]-GS@K-&SL05 $>AXVONAP GW/
M'SW;] HJ46!1RZ'CD[1P;JIO3.7Q>J/Z-9ZC^*E2['-*\PC X!Z8-WP"W.C<
M!5U8?9S1W0)=5-7>B'[LJH!7L<6JKS>K3\F_JLFBNJ2U#8A\=)'F%Q'@#%\\
M6"<"]L0WO+E^VERH:4M=ZN[^5M32_#C99N!F6N" 8* 0I3K9VJO.5V5"D&OJ
MTK,G<%9,F1F**T'DA;^UP7Y(;@.DS3ES6/?=Z;+^U8&F)9#5"0@C>1"_]38U
M!3DYN2*SSL7[+D-Y^G6D+,;L.Z)?)H$+R$6X@HG:L%Z!<6:#XJ^I3XG62=G<
M6*[XT*-$,\BSW0S_Z;P&V<W%"F,LU_9C-G803#\)EQM@#V()!T]F&JRUK_R,
M&A27SV W2@U_3,O.E/LN \."U79;93Q93164F5%GZ_+V7!>'RY:5?+RXR"3.
M\O#-QH6 RAM._/11[WS-^/S80 5C&+%HJ-AN(/*LV*Z7X:'#^;4R/P .T =1
MAI <P=9'S!*A)SB;\'H0/,F$8VLD/-A>/\7W08Y_!8)'3_N(@#-)=262E*Z0
M/%N)G''J+@_^8?@P[- 31@?9M9@$':??.@U&0A=\"?JUZ][XI%O:A'1MFP.+
MSY'_$*;\&53R&P=G%Q%X/Y*'O\OQY^7Y/W[\-]66>$ARJD&B<*SC$F1.C:2Y
M!DHS:,=09Y)'HB*Y6W5,#!%@=4P$X&\LF5A&@;+W)!]-'^L;3%E,7/OQ:5K*
M47=O7WK+I33695Y.E^]/$ML%8VJA0\D)?Z@ SA-3^J'$G7 )Q924^?;.TO*W
M;ZN1G;@F;>=MM1O54?\F/6GBR9#I)>&S&GPN9"T?Q$60VFEX N\-N[;=%<Z8
M,JN7(,/<%>;+K3K@[;49G 4\G-2DO;"LG$:*4^\$KR25!'FOYQ>L[S$N2!WO
MR>OD+"Y2][->M6V\&E\T\0@@V5IMW[]Z>(44]:*96HB "7V+9JMBZ*8$XO,J
M */=$TZ.=(*N ZGG-4M=;SG6^6AX,W=7;(KD[X[H.MGI.HFDZUY!I$@0IA4.
MSJB6(',B?UJ5/=:X1W"&K!4'7X,5$69MKH2IBT:[*<UR&<=P4YHU:CH-5'H.
MGHCDER(,(6NO/ZL01F^EUWR!]F97J,4M5!D>74$H_77@?>B_B,!'^1W@V<#%
M)!-\1WMWJI)93CO!.X@4\&C6E4F_] JAVN/ !H1RX_-.+%0ER_%%O>%7-4TS
M#*<:@+7[?!E[\C?I>)X^9_=Z1BUZ6P@6^;_0F"WG)/]V]]X.\1F<YH:NH+69
M26O^CSW8 <_WYY/.:J=LX$FQ3B)@01FMC6SL^D;7-Q<.G,!I>JJ_9<"OU%=Z
MM*3J3U"E&SM?N5K$CZM@OPI4OBEJ(=2,.PJUPZ3YH" ;WO'JHM]^H5Q],9&;
M>W*6=_HV4X8JWLD_?9>6'Y)#@"+6\EE5836K/3_2DI@5-3)^MN2-DR').' H
MPL1B8T][X&9<THEA--)R*>B^^XCK+W= 0]30O4=7;D185WSEB2,3VN:?.Y8G
M^9<]DO#<Q(01 3Y_ND5.Y7<V@B@@[DP1@M?^=-)[,JF8Q,-U9[IZNWE2)I.Z
ML;D^K;&BTN_H,CWGO:\:/-@2W5/OB%6DL6$*B-IOB8D64TBMZKF^1*YCE[J7
MK#S>_4Y"VZ_@,_LSU>E7FP!F2DGT0?<J#\2)%",]Z$"FIGW\)7B]46I0_6T(
M,ZOZ2,K&XB^.!6VCRQ_(RF_^*29T%;P;A31<*XN14A<)56J^1?&C(+1AM%#U
MATN9MJE3UKS.@P_?7RDG?[:-55JC9.M(E@JO_7-17#?78[AHUB/OGD^>KR/C
MH21-R/.[^.V)_+;76G&E\)Z*@"X5]XVGC\*922JKY[]4!4;7HSAAS[X734C5
M#=_0(+"'/&H6@G1NVV-FLW%L7&8S"@>+90\^U3AS+I;FEFL$5!A,L6INB]ON
MB;A"@TE0F.(.TO\T#N&Z!&49Y0O+[KOEF#EM;/]=V@OFX#]6<2:AL\L=G,A:
M2U73'3X*:F1*1CB!*'X+TB/AL0I51HJ2IXBL'P=?V3A=BN(OR;9$5@@/)3\S
M/Y\=V&/ AF&.T$D8?[$>*%N0I>Y4E>!ONAH?#V?7M#4Q/M4!"3D:\LV"RQW1
M)+_JN0.N-4Q0$+!?]R9900;,\Z,^L)=RL.?7>GM7A>R P][$692>#Q_KA*IC
M@]<@JZ/VT,SYZ <<.3ZK3H]S^@06I\[PJ58C*W]39ZHPGLGX@/DAB)?O/W4?
M -'//#+L2G%&&TR'/O[H"@:\1[;L!/M)>.?>KFV(:<OR+)*W[*^\O+]3_X8L
M^83CN/[>FW$CS1=$0&*'%$X2>>U]CF$*SK$0$WQNWCOH7?Y;:3:]SN-^'(U\
M)8<(,Z/LJS )K7!^R/\JAPB>#UHK5[^!-(.JRV/L39#*\0I$ (M%USIF/=WS
MUCY?4[I1X+,^GG6G"Y\ZU]ZM1:VT&Q)H3%#"Z]L]F XQ)L&@HOO(!80GWRX)
M:9J-6YRM/&Q?_7[VM;5AWWK^JYS\M"E\7>P#ME7S^0H[:BPR](6S4M&:-[/K
MRN6ZQHRA_YAA\@'E_"C==89(1IJO#/Z*:1I_]P__X5+^(7NI&482OX&O:40
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MBH_[A[C"=S+?G.TYAE0:K] EB7(_%?#Q=;)/T>;S 4]F91VEY5YHK&R,7Q?
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M)I0A719DL2Z L=>J0JAT7>DF97:*R]I.QN9X_>:UVP&&Q1) C_\#]4?N)UE
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MK2C<#;Q$,V8HEV9IRT^&5E^JKPI::]LHH7"I+XZ%S>>7?'A3&C+#(!K*W:9
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M!3!Y]).,VB=4>^9BT5YZ3.OU7&"J\V7ZZU9]E_19,X2G4-V C*BC_QJ["F,
MC_K.,^TKR'@&5I>HSH<BDRHW1P.*[K8VUDJ/^24):,-[.1 [7"O:708T>#&T
M6>GJ$L?#7OO"S6NM%4,=]V*IOK$$]&P*WC0Q_"9(!NTM>B,7"&<"HHRF*IC9
M.,O'IZ3RUT\VO-<8'NI??2QPJHP1;O%;@0+"!<T3.+8F>'ME-/N17_S"@ZIC
MNR:\^\DOP!SUEH$KR  -"_<U2Y*HV[4WJ,S*XW>X9&LC>/]!XJU'9<]T5+"(
M7\@5Z=?2*N1_EEW&@[B*<^-)2.O>,YM<=G&E.43&]9T35OP)<1AV  WAA$T/
MYL,VGYBLT!%K6P668=3^#%_K'U*CX]//?\C=Q 1<F^UZI<7<MG/0W20QF-Q%
M^M.'B2S5(E\?PLE#?H 95<1RODH>+D L6_5<TB-BA!.;M=KZV$6QK 3?J8,
MG"/LVRB>A*TJ!TBN\-TY[4-RW+EY/1_<E2#E9..FB"\K=&>@%\K;KPT!D/C)
M("%7C=7_[?)4]QF(">#J,DMXZH$03IZ8YDF_[-WD(AR7L&BF(1-X[6K(HUO$
MMY!E./+ !<P V8X[ Q$_2KF/XFV7$V:VL<7H\33.\9?:\<]Q'+RL336-NH6U
MF?D2?I?WU^_,D%]E=R;GB]&=B>]=&VYG *Z&-*!XP/?043UPAOHFQ\<L+S8_
MNPY4+088OOKL&(KA+J,R,T^XN<:DBYB!OCX#L1.Y\4_1M2'7 />R[E(+YNI;
M3;KE/[?L,X0[>Q8'%+E+KJHCOGK.^6 9?B"=/>DZ, KM2H=3V>#&+WJ*3Z2Q
MF>]Y'9UN<Q>SW(7S4[#2Y5-)?F-?0NL-LV];,>Q*,T24;7@5^6?>;XG98C1(
M&W3G:(R>?CX?P2ZVPQ/E3>LJ]UP</DKYOYZC^5>>H?E7-Q\U*=+CB)^!_I2\
MNVXK]\_7_S__./\9*"%+@-@V=L*Y6?H7S/<?;UF'J4'09L@3Z<7+)/ACQT"0
M;$'\4D+"P8 X%)^^3PN;KJ(BIBU,='K)HLY )%];Z]QC\"II"Q,DC*'",FVW
MJ;>2,%1=TV_Z^C.0.%'-+OWITG7BGFRV3Z@%C%%-/,@26$58/?0_ ]FV8;0*
MD$UU<<1'A<,+D>SMFA)>B3'4J[-(D@-;3H71A_ $J=<#[Q=5T16I*\:/3B$S
M0T7VE*BH ;9,/%(1[+1;VL(^=/XE#:$8O=0)CVJC3_R^? :BW7S)7-GA3BLJ
MJ0NV2'+[6-:5=,)#\@*'A&@56Y0GBQ7>#^CXU)8D&?ODN:W,SQ?S)]4EMWU4
MG-]C2Z[<>(ST6M38M5U8^BNB":F=6FOXZT?_$+;^NX#5.)@T>!%+LVJ72+.)
M]H*/?,*S4_UMT;6.YW25LK#J9 '$I-4)C$A- C\B(F6PZ9K ,U#A"U^<'TX3
M?SUA%=S!P(Y7.NA*5ZI[#7<85@^X*%P/49<1#J[1_W*G'D*-7'X/8X:@J GY
MQE_]O'>J,'6QDX+,$3@3\EW&Z\<GO'+'R5]DB33?,=(XSY7T2#4VR^_-2YV7
MZ0.>Y:"EZLZSF_&6TKETSM[>AKY?I,'<+T<?]YR*Q-:VVX\'*<,\ YGJ34[J
MJZ//-52)AZG*B%< &(R\9RR,/<@:(W-KD[<%)E&_*;(4/W&=IUF>FD/'E&4U
M-J;4W0MZ^\B'2 U&MS@VQ*G)+-T>*.>-LEN#T>PV-O<$,CT")6B(_P[']F+T
M-]Z>@=S T599V^GNMDX;!O>]*5[Z!">!#KGL6 F\(=](;P^),@@9SJ9%WT&?
M*& L)2?0 G32TM39CIY&L3BJZABBYQGH"81NT=\ FP.D?WJ8J]4XN8>8$N!(
M>.!9UZ-=9:DIVE+U)6$> @BG=P:S=2S52"6MM 3ZVEKWR"X\7+QG$A#!G[6[
MG.!G&Y.T3Y[C;#\_94L"G)1 8)[_-O8AQG$O_YS<&2C27M^HQSNG549C>YU2
M)%'P334C@R+51YK?2X PM#N!P;\7ZS]&Y!6:M_^#S*_96+/Q^E@;* _3H5[N
M$#83!/+YAV1D1TC@09,HY>^'.M[90/C?7]^#[.YS7+&PM*+B=;\S*M;X#K%X
M,'I-_8F]S]6-C.S\7S (O&:RQ0\%3P SR'V_+"Y9@?R4#8GF1+%.Q0\4E&#E
M"'^T6C1A:T.ML*-1Y.&F*W08N=.PC%OB(8Y &%04[#D2OY5;SNN%?K2>U9$2
M\?PJ.CUUR$'J'V.D+M(>^8:6*>WJC7J^EU)%;KIXT*!)@X8VBF'GC^:B+7J.
M^!6*T[I++-L^D2<D^'Y1Z%RJW>^,,S?/DBQG-HN43]9@91GB%)(P #WU2O;G
MV3[M5&"4V'8;%?TP7ITKX&7X2H?GF8R,JPFW ;SM!EZ#D*5&![7 ZP-MLZ:1
M+=Q.M+1-'DRKIB[CR?8-TPEJ[8-#\U?2UF*G>C)(<ZUHV3&KLS,7@$+'DZAY
M':(]GI;';]$-3:LM@]WPJ82:(#\$@,-^ $(#$?<.Z$5,6T8][.U>=+H7]?_0
M*B[:"Z]M(B^5Y2V8VC3822!-]=\ >#4A/)L'^("1W,/?+O9/6]K56.1*JZ]K
MB*VB93]XT3<$.OD61-YN&)N2*E1<$>(4,@GE4I'%J>,?MP"9J#A>#R:N;3T7
MI\CE?)W?UH@T!V&UBP]$>0#$-!(0W!T8(PZ>KAE5.39@-%?XB%N9R@J]A,,N
MHMR)+.XI0(X"=S+$'V?3 #))G?F;DR^V?5C,C6S?(*J)WC>26V,YM!:^M_Q4
M><0=0WCTSR6C_F@S!9&1WI<N"?SF0K 4E6>@'X6(?R>G<IYD"/]IYM&0]%4A
M18::K'\78;$9(H$%_G)W8C/IS>>8Z__U^@&5_O_.(L_O5=)CDKA:,@'EB;M,
M"KJC<\W'"8 0//(0R1'$")2B>+PARO<G]R;[?T*^T'?G:ZT23^P?,OS]KE,H
MD9J91 V7>I>PETE!8X05,2-2 GQ8A="YP^E:@\L [0=.X:;HH5RY_&9'G;1)
MH]P?1QWB33J[8>+84FP]H502KX^C!?2,1RM,Y1 Q29K.WE4?V;NS(;78,U"U
ML#HUS^3=$WLB33H:061<BL?"&,MR9QZO9@JE3M,QU,]01CY2]@$G]XY7J1V=
M('TKW(Y)%AL5X"<XR6E];[*RJE_CZ077NQ?G^L-"WAV/:R] T?K("#":Y/-=
M>90?MD4-C.(OT6Z-)JL9/RO0=FO:^6KV6YO@(T?Z01_2Q++\#)N6O4_JE>FI
M*<DT6P##,] %[79%?& P0WHQL(>I(!.@QXIK_)@K.45F+!^;LYZ4DL9(D60
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MAK$UX%8*1#\!#O<#7;W;$JN&!+HC]<F;*52_/:G/YN;(NV;D!AT\.HI6-<L
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M?J7""-V3?EBPR)?^51MQXQ14NMK.*SB_N\T]/\?C'_78(UO+2Z)XJ?AKJ48
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MN*)POH,^LKSL=IQ)Z7M&AFR?;6@T F?*Q-CY59QJ"'/XC7)BPY%;D,MRZ\;
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M&9HE.1R!W'@ )EVB&Z,<RLW%^E7] OA=JF2I>\HKQ6V'<[@NV41M<3^Z#<Q
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M;#7?4/,1M?#EJ'?1;.ZIF%?R%\HZ,$7J.PS]2)FW3LPL9YJ$DQ]9SEIBXJG
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MX"UUS]6Y<I^+9N'UEVVSF0*>^6^ALIVA@[\:)+)SG_ZSQ.O_K25>S?<(A11
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M%36]#</YCT",[?GU->1+6Y5_G+YE-=,E5F]/ ;C97L2/)\-:+Y/EGALOR%V
M<(R69=?]1C6K?WWGOF"[PHN^G6;_\"CZ\KE^!C7( 0/P*U0&4Q:T"&?9@+)A
MC=+!Z^J=WU/&KX+T(K6"%4?/CY[O5A,.IH?20QY3Y:$;>0AX1L,28H010AM?
M<*ZM\L,I3LV*97YU"DF>X<UFV1S2D#'TGFB2B$DO5SSA\-$?SDT(+@XV$ ?0
MC*:3[4 >;!$XH!#(>;,59:=L=>.*M,VI-L,W%\[41<Q^[#"_&&*L6'Q._PGM
MV9IUOCHJ_Q4 +RC5:[ AM-%1&2I+?HHZGMZ<I0HY+)PI9HGRE\X?A<@S- 64
M$/AAK=?!"]SO2\E21,?ZNE&(P1/(P'6C6DVWF@_?T<X.PDR7P2AFE:SCH&=3
MIKGQ:4>W-<][ * #(BUEVJ#P[Z)>N*?=SVK*]SZNSA0IXX.H.[:$ DA*IR*E
M"G\"!:!G-7[ O1BCL&^%L47F.&\(;5  Q@UUH0;,+(D=W5^26GI$DL!Q,(PQ
M?-)X<;45&9O:?!6?MF V=)"0,VO)E+DQYC;2)R-37,)2*=^M>^V'VF9W;]1P
M#+PFF=@+_3V_!TO?)84?Q)$X7<$C-E!.\A"\@@+8/K_H,0TTP<<LP)D^S;/:
M;IPXCOJT[0VS]P2K<>DZ^*5H5><XN/5T 98<0DY#-\S1J40N[H(V8T(<;#L4
M.C:^/$CD0. @^";L+[;P)(C4$+\MN=7MD:V4,9TL<(K<LRQ@+/HV: ]^W3/:
M<_1!+&HP"_8$?*QD' X[W/:C /+&.7&LD'G")5^&3M@9"L!)CMZ7_0<./#FU
MDNJA5E^W?P$LFU>?8DJ/?G;KS;>?/"?FOS@R_R2[/_B+D,^_X_IIVE6/J46R
M410:1@J40QZ8()8JD5]!?_VH)JRCF]P._<N@C&W,6R?GPLG!@OFV5*YQD^H'
M'2@%#7>5RG*-<UJMG*L@.MA2%)Z!W$F2I@ ,1!#&I9-Z>^:$A\3SC20X6<65
M F#K!>$LDK;]K;\FK:P?T56+BQ?=Y?E\Y.5R4H*S(%6(XK4(\I#[>)C/V^5-
MLW.DG/:;=8,K&S*R*^<I@'$&QV^TS=;C\W#,0W @'%,)9=/#@F[5[2O/TWAD
MVN2LIMY- CY_&-ML<,HD,U*T2Q;\,\:EYO8+U^?^5[ZB UZWMS>(-<YM^'_M
M,*L=*I"3V?]VVV2G_R9B,P0'Q6OE09CP.@OS8?[/Q@,49OCK/]AO<R<2CRZ<
M+.2*N_LQ<[XU7]0C7AA$B1/%YL]YL\6<D&I)<FW7:D?JXE*,[C@<?WZC>=L(
M_BR!YW4-@6"B.O1*KY6*+Y''2O +U*ZOI%%7^-7XOO-"W#&O%_R$$$(!Z,K"
M#&#_HU>L59B 4_0<)A8?J$U3$GLE#C7/ZM(LBV5!C]\=_OKL>_T'*O=<O>BC
MN0I ^:S?!,:",6; &,)#*BH&5!O&6KDC2D)OA#WXQ=5%/*O[D *X.Y@'=23W
M@QC<-=6)'IBN]H'H,6[S4P$ZXR*.H<A=\6N"9R0F"@C]-9T0,#ZY%/(4_PD-
MBO!?O[0)_I[X\MW.WE-">1M;KDFHUE8-08?Z[5R\-"D(9>.Y"$6<GAYDU_<B
M7?OX6L8-?/2SX-?C'R,4@'7X5[=*D3?0&(C+2!Z(5L,O=RVA5 %XUB7>ZA*+
ME.K$DD4+[1<! #T,Z$TJFK.TVN#RG+ 53CSS<4J2X\#A54TXFA4F2@%4^[2
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M"TT'],7Y-KL9WQG3EIWK<=&@)_.QMBIX2<)-9R#K(>^J$6TG7^3:25B:8H*
M:M*WX&O);$Q2AC460?N7'^%$3FCQ7[&#"QZML+-SOE%=9.&:<JM'=BES+C6S
M[8'ZD3Q:<SL3+8 GWJ( (Y@:J H:5 8)(%4<W'"]5RE59RNB*=I\'VKXUL*]
M>?+*"N")5XSQ'ZMCF-N[4/$D#=&&G"K ?25E:\H1K; ,6\,8D;N-Y74C<NY*
MDS\^\M:<6:3]N.QWF6=/=N]:JTE=ZNO<0M)H*:MX6R;7D#>KGMG0P5M9=8)%
MTL^F;[5UL;SN>63BST@^W2,[HUMO).$]L*ZX0+("*1/R,-]7L2MQ6A-1Z!R_
M\5KOQ8IIH+%HQ?LT#*WZ\6.[>NO/I_3$3U+P#!2 J/3"("G*7X^<T D.I0H*
MT\'C:S;2Y,X2.9)D(V*6+1"V=ZM9@ K[ZW)AZP*FGA/ZA^D2V54\?R_E[=%#
M"J PB31"++;\5Y<'X"G^W[@VRMZVP??D)BF !MB!B WK?TJ!GO]*[7^^7L]K
MX+GOES,U,6P1D#-B/97&Y]=3TYT_BW^TXX[_+M;FZ.,V^]G!B:>[K#D20#PA
MQ8.>IB$=D;R;T*L-V$A\PJ$56[FHI)W;*<EDL2L6@U>,NT]?53]$#%E*Y$\(
M*6(W43XA%,!SXW#N^;,0!R$U)\?TJ0UAEK%4D]6^= UL/),9PZZT O;S>#L5
MBR&)[&;C**?.;7YT9M;BV/B/=TYOW^H?S%=Z)%IDGAN\^.U3Z-E[0]\_>T:'
MG,3H,)57].!76\A<^*0%6>.6.>5R(^/;8Y?VW-UFDL_6LS Z7DQ.#G1\HL5"
MPW )*?8=1I5;44-ENTN->,?%GNII)SNSD4<UW&(T6^(1BVJ" /FDV-Q,9&7U
M_4]:]IC==B1&_\8;@]_$Q]A+4W.<'FDR7D=I:9Y#&E6Z' GSKO9#XQN@%H_)
MG 70UG+V0![QVLCC*[NF]"M9K\G>RV,_,^U1]":?W^D\8LBH[T$$9(=?[GR"
MB$ ^1TQ<1W5M,Q7VH3_E?FK7E/PD]"RO@,H;^L)/ K)/'XL*P\Y-K 9:!-('
M5.DP11/E&JFFG1:^X@K. F)0F3(NOIIZ+^6:_/32X\].9'K;=4P5F4D;@VCG
MQFS V8EZ/HM<H74!L3S(JJ_\4T:5!HIL1PYWCQ8C2=9_8$ST+%#O%^1&WN,U
M2\[/EM",@HYXJ^F68+7L2/D:D_,O.6_R ,P7F^NHTQ0RXN$=-3T 1$>GJ"CV
M[[)^;[B:@8Z)->4S>2NTEQ,SS:V93%#6$9W8@DI0 .V9L(VO%, R+070S'F@
MNM5*)8 )Q[W"EWA@U<%"\/,U-5\[&RQC9!['C#-SU,?/&K?PHB1Z;KR\"KLC
M4=#?:2]N,U3MP;XVGBF$Y?R@GI)6V#$T8V4MG"AI_RK,S*Q;>'S9O%,.+[K:
MCCBW\7 #SDQ\Z+F@E%87$+8!W#[C,(CI6-%?-J4  G(UR?"O7@_NO@&Q*@WB
M18$1N0T_JK!2/\^\G'4[6!=[C=1+O\J&=CV@Q?F1PJ#,T$%5K.\G_6#8.=]L
ML2?I^=FFF:R+K@&9HJ?4*IGXRP>#=8D7I+<:).OE+:C +"'T/^ZS9]BW(5!A
M>$\/?I#<\)BJL 0X]\4"5/_V&?1K()D>I',,S'X*"F73.:;2M=&[^5\@R_AO
MLHYW07\3[/Z[ 7 ]#@J 2PA>M/=9FZA_0AT/6 :"^4>F-?^GUH'Y?^6M$M8L
M P5F<)U3'>.<:V\?X[:,:>N@B6]W9K^[H"7,-57 *Y).9, BB1QZN"+\(/J:
M%UNPI4,ZZ_=W'V6JH^2V9746&4H3E5Y?\'?HXJ,9R2PX8<">#LW%%VB-?E=$
M6$4U*9K7IO_<N' GXLDW;8'W=^)O.MHI,&J&U;.%P1C)_!"!(88P*)\O=%JK
MO/O*Q0<.R>%8(\641+/M^LE8M?5'Z;><]G,0T&$JNAULXR>XZ?TX68VHYJI_
MT:'\Z4+YG9L]IH:%=]V"1FFZ:J#5T YX[1:L.MW65_S'V)L3XQBO0JY72_+G
M7,[1UBQ'\(L),MFLUW^[GAH=>E*""\+HA35?)')CXT*)CST$<(K.J0_"7L$O
M6]@Y7THS?A8S>E5S+HV3N$8!M&HBE,\83^VW *F*V=]/+CO^C;QR-&'_@%9D
MAOGK4-R&1OR7*@&:GLO(LTCG>;RD3\P5HHT/AH![L?>ELO;C% 7PXEC:Y]5;
ME3>P;-V%'(LC!VG.-U#>-UCX,-MT*EKLJ-UX,N1'PURRM'8AN%4HS7WM9>_X
MGLS9ED-Z.R?A6"U:H9IC*C/2Y>#U<O$E:& $5'*SUO6UA@C=.><5'?H'>YAZ
MYT? Q5BU;H:ZM,QO%W6<7U7]5/80^!.6U5#,!<4IIWVW<2[0 6:(5DZ%")C$
M&AK01!^[,#SH!@BZ;B(FVLG,DF7$VUCO\#:/6+B3>F8I6E#5(HB+1KGOB2CW
M>6%&/NTV=7HJ</:;!9<G$QO),Q0 RS;T-'F4[[OF6>.M$L&;5J[IK[4^$.0_
M)\[9:JY9O5^2X [EH<U3&F$'%49*A^&?HA<6*8"P.0YL-XWQ>R_J?Q2NY6_0
M?8AKJ96N+^UEEL;J#E*WU[X<D8.IF;T'G:IYC@)XEV(C1[B^A2.;3YJ_#IU=
M/DY;O%[G/@C]3; Q*OG#9X$2" U\!9;_+EX/L]@!O.#]R1GQ@@AR&5?0/CVO
M<I.1QOP5;:*>Z'@O!7#F7TX;G];PP\QWP-@A^E7XZT:8Y7ZSLM32Q!Y/F>Y?
MNBGKYV5%XK_NA2[RKB<*!J_.>IDO[OS+U0N8&[7%&%^/A96L0N?>#IDCU6'+
MWK[-95'/H(-]Z2W89"-N&*]'N--S)6:A"ZZ#E:U^]EBI$5,B_>/;#$;]0F+V
MZN>G70\"/;6C. ?+UK*1-Z!7J2MS!^:T&WJ2-Q[NI>BS:&0VG'Y--[VP-J$[
MG-YRY4%6<X5,R+R2J.*!5"31O9*J/I&^SPQWY4SP3G[TF; QG:(NF6\40)F;
M!]56[MH\T,9!2?F:7.1?_O0_JS![.Z;U(Y&RVZ%3C&7;=],FF[0<'5\(ED7W
MOM1]S4A+[<475S20F3P/H]< 8XN@],XI?#/^BQO<?';6?6ZG)I4[Z[U?*,PH
M-1K<XO@8_B+(1FX;1'CJ*X*S_(8YA$=6NVE;?.HP]!2]U==[2KE6/NR*H_=R
M= C *>NGVN#^"&9_43<"M3OE/[V8MQW:<6*MOCU7[&8OB0OA;._N_1S?&(;-
M?&7*$^)T" ?3P5IU-?2P;ZF&*(V;-UO(D65RS.(F%Y;:%8,$]^S*JS\-YMD&
M^7AO/TW3WU(,UEK2Y*3.W-UF3N(C?,07B/H(4;9TPL8W;%UF(=.CJMI9]+/D
MRT2N5C6ZP%=CS36DK&;UYZ"JNG97>(3FQ9$R;\/G5X1K+63O,/&NOCAE& _@
M$<TTKI%^'(2=)[++=8+Y-1ZB@%R#6'<*P'QT6[BISD9AT<(Y+[F*/VWLFE-?
MI>0>OH?9H.LA.+]FWV.KBV#HZX&#8]QS%ME8UU7]%9Q]!NQE5)^IB'4X2S@^
M[Z'7?WD-L,1WPOU@M'J;W[C^]^';PM+2%SG.!9E.YSLYGJLJ-M:>*@Y*-&CA
MR/MV:9OSV!DK1V:NPCBU-91.&0=Z\5, O&?>2(T_'6L;[MYEUT=(LQS)2^PH
M7"LUIH6U6C9S;5KFJFAJ8* Y"Y^</THVU&4H\Z![EG/OQ_=4^TR4S44Z[Y77
MGPSH//6U[R +8?.#[-$(9I=S&PVZ!1<&W#QI&6)ONZ/BM%L9XK7H3C$BX" 7
MX%1<.U4QAGNYP3K\E>=J2'5>N&&]Y\/Y(WP>SY[%DP  8%MR6("6#D0:+8>7
M4&U!,D/$J>S4Y%:60NA4&?!TRKHEDGI_(E%#++?]_6*<_]6S_:IL#4QT;!^5
M=O'2\R'+HV.R5@M-I-J,;[1*?.\>]G/7GZLVD=2<>W(RLFQ73V W]4 (CVR5
MR>T8G)O6W:NG%7<YU17WI8QM =P91T-\CO$NB&T6W(@H6O<!2XHLIS#=I,]*
M5^Q_?47W$4XXNHB.^(E@"IVQ!9#@1#U0V\#;6Z,U1GH/?D%'5BV/+_&,+?5=
MD%10KQ#.$J?E$4GT?!?_,PD%VI['>.#"L/L0=8P9_.OC#9A3^KKHJ.R76*8+
M N[,P]9W6E!+[B;'6+"+^5XXX2+1>PCF!(Z^3]3'7L[P+'[<9>_I\K1:0FQ6
M[3[;+G/9Z6LKR)<4@-,N7D*\'3;%CM9!M-]@:$\O2X;YT>UW*H_'#P.K\G$/
ME[O[F>Z_?#5J5VRR)3K8_!Q!AS\B&!!E2)\AH+-U6"[2+S3!M[*\UEAE9SOG
MQP*?@\29A-0WIKRTUX2!/S<'\=*K[WX1]9YBIG"N5_;Z"CLY_@@#US,(,NA!
M=MOJEB/GOOC6),$<HD0JJ&ZZL]HJZ?.T<*W9?+K4P_Y1RD65[=BRZ.ZU3IY3
M9W4U':VC2:K:VE0\2I4RJ?A=7#0&V>G!.@&Y]INHE>-K9W/IVOD#9W<W= I^
MYJ[8!0-W<\]BQO+2>S1T-$G@FF1LW+8.P=GW.LYZK/H&0X<F$#FVX]WH=^7^
MU'?]A"[^K:7Z'CO/%IZC L&.02-2<HT<T!58-1]T*!=Y>OF[T2O[AFW$H[P^
M-OD.(XD7*KBHIV+UUWJ6TD].?T.$D=5&FB_[,K3/GZM^+U9;B>6,YA[JU!R6
M<59G8"88\/*VMEYJUL-O$OSP["B]SC[8N_35L$/9.SOZVPZ)*[-9%D,V\%27
MQE.=>N(%!4W2-D%';IS'% "60&:6Q5BA,NL\%UBE>(E.Z#.7Y6?:GZREU/Z2
M;->3[7/P"SQ\9#[UFJ>(!R&,]Z0J #N\#=H-.JV'/0J5@XBY>J%!=6*]\ZU,
M]C$C- (*4F>73;L/NI2.+:Q)X.PBYX84>.DZ;JHVP9MS.V;+68F]#:V?%ZE5
M;R-HP%+**!P2++6MW_;W@CB4T7]@9:*2&9NIQX5OZQ/I;YPI-SD9K>@3Z!8+
M;<_Q<KS&L*;#17/P2'%&RXTW944G@@%[C1FD>)N;Z\CDN/97:3<L@N<JL9/K
M#/M?(]W_K74@S??>8@O:&N)BJ6@)Q(<7T4N4\"!J+[[=5I]=E:D0'?>/:HNY
M:/J,F3?(CN.S%QT6/,8)DVN((^92S8^M0CER9JCSW;L;FJ*P5F6D<USX%/WX
M>W2($=:T*9%7+$KO6XIK8,@N9YCO4Z<N:^%G!Z?3_MAWOZ%TTT3WD6J/*'7&
MIK'=%9TACQVQ66</?]#O'[@E>CF15QS15B\^W;RO_XIT97S_!G4OG,:KS].!
MGO=\UUEX_A.>BR^]4O-D*$Y&RPO(S<3+TVH0_A'P8_A2T*_/C@%TPZ2KXWL+
M?V*F81:@%VSO#>1[G)6.&$@I(U\_0F^BD5F[DXWHW\@NMN!,3GQ\=/ZN2?6C
M9M.6O=TOFJ9MB^7[',G 6>$CQ \VO-1\^]M!-J+K<+.H#C?1D/BX0%16&+AW
M_ 12]P"V&:439PV\\]%=!8K#J^-8#=O4A7)<LIXV5-0F ]8XT68 Z.D&=7PX
MC@&_FTVTPY_)6ONQ;=61R5H;;CCJU@<]$#VS/#T8TO/8SF0?!E';!GL\JHB?
ML=9Q]I =W:Y5,\V(RR[L 27#I)$5=XV+R>-@-LM9E=W?HO#G6T4LE4*9@7RD
M25(]\KDL.\JG5?#9L!PGY"&ZQ+EZ6VK6ZJ@^ U+O_O+:F5/R;EW!!'-\R=X1
MF<D44WS4 >=3!D7ZG$O(]]7LU<_^@&!]"\T7,[VA:0'Y-;'DZ'E4O%@AYWEX
MALQ,U?F7WV+/D 94*8![9C5X,8(*N8<".(]T.8V]0 2-5C=IX)];?HK;EBR(
M@DUKS,OH+;6JO%JJW9Y^E1"]'S<WCY<P)Z;M=L@=*<V3KEF.M\,P>LA#JF4'
MFAVB #(.S_O3SA#G\%B"+-&>E'%%%K1@OZ[?$$#@J!N5%=W?6HX_=1?ZC,:\
M152Z.)%&^!P38AJ.O_RS!"-N@=?VEFL;8'P.%:U*5(/<3.K#?:I_-G7W0=I[
MNE9A%OO[Q<6M+=;! X>K7?!W#7I=;._F1/"N)9><3&M?N4I'DS*QIS?]PE]5
MWF3J,NT]N(S,1$X\1&?F8+AQF>5#W_4MV[ILTX@WBMLOMD0Z)3G<7?PB;RT5
MW)6=NIJDLQ-B?^*9'2FM$+=J16:NIP#$I?-@$S6.%$">JC<A"\-&UC=OAQ.X
M#N)((I'(/^"W!+[WNL&<%&4&/GGH VX  BB I5#(-0J@PD.? OBE5F+PXEW<
M8RI)^;_K(] !G42 9D&]>?]?#;'[IX%_62EL];LD!7")!"=0W[BE/#3TWS\>
MS=D-T<)>\E5ML17%0MY)K?F[+6/%OW -?4<29 %0;W(+&&L!>4+*(LLB=R^-
M:>C@K,P/PJZ5.4QG4@ B[<?F&X)0;UBK'$3E1'6K5:A.XK+QA4WU4*QGSU->
MPWM-QX'D:XAARR)W4:J5^W?%[3^RL?7#\%*RAS_S,'4M\ZQ>*]-^Z'EVJ]LY
MA!Z.UY?E*0 ;L6@RYXG54T>/?(MIYS'7RC,6OR3&A\_1F^!IP!_G:\*)YL#:
MU:U5S!!DT2#=QGMQRU2,W2'NKH7J)K@PV?@I=44>7/W?';O^/Y:P_\^,C7]F
M;% ;!C8%Q(5@]+8646?B^/#-8'6TT;#SB?]5]GGKQ4M*/U_FA(@DO+/U$WL4
M"!FA*E5^TI=2378B9R/F=)J:YF7LEL)$)U_= &L(:]W#JP*!O9"\]10[W3=7
M$1%4Z?=AG@YQ"!-TH0 $O5T?--B&T*6_^202[9<Z+LR4P?:*@RX'-FX2&];L
MA.$.^I<KO;6:0;:;#<OM>G2QB2X^"\:37HT _5A&#FPCKT7.S\>56U#"^$$J
MYJA%B MO@QH0;]%DKN)25XEA#&/L$CUR>D,6?R.6$2?3D7F8,VR1,1@(0Y6H
M?YH@#UBZ9:_RQ;W?RO+(GIXU(BYR]L-:1=TX-1GP#<2 ]>^WL?#<-V^V0 ?J
MF]1>%Z<_:HC;ZG/RX>E=AUZL^ 9S?.XN3'X=N1^'%[6MH^]JVQ7T=;/@+?7^
MZ#[Y-K2QSF*4?'D6*05V"# >9R;24 %]W=0/.)^&H#_W:FH[6N'5J)[/-5K-
MZ0$HU<3=_TV=1(?Q)T@\:6'[PFD6+P1;ZPIJK]+8\[J;)EQ8&S_,V@HO!E;!
M.H!G(!JD: WZ1230Q3EW+=TLPN7*E;R93;[4<S^N!GU,['P$8.JAY4!BYI&5
M0!*'(8QXBLK%2_YY*.,@/O%.\$1X*_PTQ/Y&9W(F8F'[TN/<6JFJ=N$]!+?[
MH6/W2UJJ%:+7!%FE ,[&XV4I .VX]Z#KQF1YW0SMA_OI@^BN]C6D1RV^Y:2!
MC0'.T5<8@.Q+]9A\_#%"HRGSV;7U*LW?!*K:8R40J'M\^'8=!= BO4O60[1&
M>00*\<-QK:"J'!=5^]M\Q'2]J:Y4'$*2B8:\,S #\Q'Z?9+QUQ\UE?:^4'_B
MBAKD\[5" \->0!Q17W5EK71&D]/G-@2VXD6JW6):A'COQ.O1\6U(]VNR$*6&
MH(Q$Q2$RM^\S-'K7:"CQ4:Q5OEE:_XC&3K^IJ9\?/P  :$$8ET9J6I.H/+#T
M6U,,-B&)/+ SWU\GB$+[TX^VM197,?WF!7<Q*]%%WL6S12S8KHM2$<Q"+)7)
MPA=4"NEC7W(BOR"GP62CAVAS4O GJFP0@[I1-ZDP;.GIG^LN;!O Y/!7EGIV
MMJMKWH@M<8+4%/XV7LWW]$\+2SE9A.B5\>7W*\8U7/N<58.]MV*#7G5":?"$
M=EL14C321;=J>,=V8['5/[EI^\..1I7W\XVJ2\US\J+W[),$G%XB-L:0G\%X
M*:\4!,'X=BT%L,FN5?X8.;\O+D(!"$C?YE&"W9Y2*7%%K-6JSZ9 !XJL.E]Q
M^5Z_?'-SI)D5&@ 1H^Y"!_+@/%M9[BCQR14-O[<K7*'>;+.6'?7'>I-H8?V)
MA>CH7O]0RY/Q!=L\CP7@Y%$;7U?D#GTIGUSHP?%N?E*NLX=#C&(M@PZS 1K)
MJRG\ASMASL:QS2!-6M*G4M'ATEVQYUM/JFL-,QZL*/4H&(H&_;H8]&V+^9SW
M:QH7 \T0IPUD!W"B$?<"N_MN5T.1 F 42L@R4I*)!SNGF#R>F>X)J;R)D>*>
MFDE^;=IP57@<#2:R+UJ-:0J1)Z9 [^86LJ/^'^*^.ZJI;ULW% 61)E5J4%"4
M*KV(1$":"$CO1 4$1$0%I!@20.E-0$!1B @(BA!Z)Z&C%)$.H8?>$VH@[<7S
MQAWCG'M^]Y7QSKGOCSU&]H;L[+W6FM_\OK76G--</3L9$FLRH5%X*9E&>$C[
M=3#4?U\;V@_$6OJP?YY]I'D=-21VC^TMY-;OY.P.;[O4I&)(!N$\>GT45-WU
MZG'5&C,Z"UD,$QJJ.(X?RF]J3HZ#-QK1^LX6F]N?@0\@VE'A8"9-N9)L%&>C
M@B<&N)E[H4KE0HW.BO<>;9K$TTE>4=4YFSUO;!153+SR1TPZ]\PCB_.[_.>_
MX&X<Q)0_[U3PYDJ5T#,)8*=-/,:@OG:3W31/4]VFSG?0YO,_->K\]C\I0W?Q
M1H>FI"R-LQA)( _>M#GX15;1&F+9P?%B@X9IN(K,H:B(,*OJNAHB"S5'I7"[
MCXY0ASQ4I-V_C/A]0L12^Q%. ?PLFJ$ QAU,J4B>^47VKD;/W[:.BUET @^O
MU9!3M!Q!1.ZH!>NB/$^D )[OLV-5HWJOOM6(]D>^>X;,+\H$833)8B^$NL7S
M X!80[;CB]G7J PT K6?PH1/(C/E'";A/<<U=NI(82Y+%$#=<C^<^-(?C.;5
MV?KSJX<7\$XNV();^ *<Z<TJG$JTAL63C-]:,/XI>WN[OKW)UQ$M>BFWT)N]
M9_B8:END!\B3\#+W5NF N9UHI A1$[N4$4$TFC=2JQ)!^UWU/#725'Y<<ZZ/
M^?:Y#SW65UITG@#<Z6/Q_<WP,M36$$:6#A_0+LR)SZRN%RXHL'>RU4:*#'\^
MAS9F:KPB:G#XR5+$VYE!J\-/!56:M'7\=<+1$YW1/KZ])9,;^"42?.Z1J6!R
M+?K'^@![=_,;K?.BK_2=.@/@6$-0;'W3E+,L7J'0:,76MC.S(UI\.;HA^LE=
M6&E[9S,S8#+)6FGDGZL4#D-;465L';(371CGB@4*(-H^^[V42O"=S,?*)Y#!
MWM[!?N:.J9]<-R6BGP)^BAUV::#^4VY;HZVS.7LVFQ<(S&LP0<4E?!W.+=N4
M45>RQ:6@XZH^*H5'4O3VJHX^TS4);@/W>T%60-#4;)7/YB6LOAU>"</B.X^*
ME&Y4P/BPVAG#/"]%RTDW5^F(MLB[%AU'YTG>NQ92\$*%;NJ?"ZJ#(;HT2&!@
MEJVKD,P^D(#=_YC5F8P/HJKO--QV40'1&@=N>_$V2])NT.2SJ$9$?7FFZDC&
MD)^OYJ8_NFY5\J!KP6>3@'7!9%%A+A8J$FC2;S>RZ3?Q*7+][H:$/G]C=$[R
MVWF[=TG:)I(X<?(9%ZH2NB%+"OU3GLR5F\026$/6=7(G-Y; ]ATLTN>J053=
MCQ=?:8/30\Q).<7$JS@&@RB'0?"=IG>3I@WW4ZXU."R)+#Y$?:( HBB "G S
M/"(8CS-MVSEMNUI?&C//>ZWH/8^:7"WMYO@O-=&/SX:4\,9_,KA0 *D%5'0O
MU<LAIJ#ROED\B"%2+:=%O\I)QX*$.,@"M>_>SC3YX)/?XEVY+?GP$-=W(5Z8
M9D_L[<*7X+&MG5"4.V+"R K_\HONW"Q]H*\#=FFI7*EIHKRFX>5K45J]6G]/
M/I)M]5S@7#R;/*D4]0#,0AXJM<>GWD:!V?!#=UZWL$Q>)KPLU)HJG?I&'#<W
MZ7*V>=9=V@Q,/$&$@[Q!XP_(Q@\['4B<>GM:7CUG3FTG/)U@^N+QPZ/E2=R*
M7M*:J9\ L E\&N2V\QH&@.AB3-F)<F5P8TUQ=JG#_NO&/DS-3J&AFDXZO&*1
M+U9IYYZ!=6Q6X)NZA">(K2LUV8RXXGAU<(+?!UAEJG>M ]BAB#[(Q5JL<]5.
M)^<!:\#53BN8C@3PO8$DUIW,1#7D2^+-H,,S5-$Z&$M:1K3 \9(UQ+=PJB =
MOTQE ;<E<FK?G[01+L-^EA-EJ>CPD@HV Y+@2!C6HEQ_RZZ0_:E>1@%LM0)<
M!R]W)WZ0;:4.<=Y*"H#$485WIW(:#6IG% W#-KG__)/)]9C-D!7")5B+6N.I
M^1VFB<"%A5]9P!@-HV_M%5^R%'C+2Q.UTFRL5#,?L/URN%(009^PTHR:RYTM
M%V]#1"!Y!J&R1(G!,>WJ%)P?Z78G+;3_?7(VWX+>K[:W5^:$"B2TP\_#IV19
M83^:\BF L>_ $P#BU9\M<_> $Q;F8GXCBAC0SGQ>WO9U/C#6""6\CI0E?0!K
MC^0KJ+P^\$I0G\HVJ I<J$LPW*G*]Q>.!0@RD801/_OQ8@'$Y%E^V'@@;$W*
MZJ3KMD,XTU]4$F"@C/SUE"'B#<K#9_+ZO$_SF;S?,@'XJ XMN@3Y@?!CATB;
M+05V:ZG$FS1P>J%W(J-C6T&X:3(-1*01Q_KV!T3GVP\IQ2H(>\6/O,J.E]%W
M>1;O58]H*,&45(Z.T,4'G05?IPP#@@)$C10'RX+$DG\M/W1)L4U-,;4_T4B]
M;#56680EN]>EN3TJ7_E:LPR-#TPE,P7@VLSKW^!]= ?\O'2.N#]GKE/I6K!>
MFB7Y7*Q[Y)^V @ON3^9I7AQ4]'XX''+ WN-]E0)X<>MM(=%%:1A"_R>'Z8:P
M"G:K( XIL\&)?WYVW^[>D+>+1?#%9VF>V7>M+XMF?3@_1^PPL0R.2H3-I=MS
MKNT98\<Z ^3 (KU/UP?$DD$$:2FF>+B90(CD<)9CN?RAMVP=V3U'_1TC4B_C
M8#DDB:!,'A6F)>5YRVSY&7E6AL#N)+C5#Y4P/A=UJ>F-M&I.N=9^5=6:/KZ0
MGO- &GJ#W (#0&6(%TB?($;B2<3KOOEVDQZ^Z+AJI]$,#B/_)ZL7LIZGN+D\
M;%:[JWGO3 >TU:9WN?*JQ?<%W1GQ5^_,"IB*+8*%E7 4 &8KHWDV@G^V_64A
MSZ[7*8,M[_?59[8?/A/T3/XE'Z"LAF:!ZE$=JL!"S',7[%B4E4+SM1G.) 0Z
M:A=A0FV7/,B=/1F(.#:RT_DBVW?G0E#[Y*=JABDVU3<AEF.+6\BP[],> <A+
MU95!BGWJ+U]ZQ30?7TQ?<_6P:B!B>%O6NF[H03,N=7O4,^7;3E=,=9>O/XG-
MTGW1ORIZJ$(JH9J>)_W8O@^W9WJ]2=-G*8MO:-[=$NG\2T82!K^Z7>[10=J%
M-A(/CB[!%(%E\/99O!6J4B7BP.$]I/BZS=LUE;R/LJG!VE==)LS!TOWE8_LH
M9^&780E,,YAR][0/\]P2R/6!M.WMSV65F8=SR=SUBHDW?Z)?B2=]0G2P.)"9
M/N#X#@0B?Q,%\G7N.1Y+/M_KN68R.2'$!7>\PDU0PX"/>97 )_OP/Y6CR;I%
M-5%/%8NNUB<W%9]DV5WFR')V-W,>!9F"YM? /!3 JOEO*IUQ_Q/I;3:/PDMD
MQ& :S3 4 *W=%#K[_/BT(7W<-GW1%9\O-AOVL(J=31IL'&:L)8F9>&NLJNGY
MD,7H7(J=2W7FR#UKPVRY,N>)R?-F(_U*>T=;;@0.,+0_^!(JL5'A.[)A_FL)
M#_J^QH/K'PS%Z#L="WZLMI^K/=7&?LTW<_^^J4R6OGZ&4WU66>1IWT/'^JUA
M4C3^',$$(D7ZM'^4VE)3[%WD<)F0);,I%9!\1<2'Z8R=Z$^@.L?IF]YY&&0D
M8NGLO'A[EN\\L-V)#7,Z3$'_6=Z49#W"\)-/NL>[ #OV-)!CXDTEDE/N]^CR
M"U/?:>@#3C<*;DC9>I;H;U?\Z'O*]#I#IM<?TD>PA;P8 ;G#([P6LCA-7EF@
M:E$U99&2*:TB;C;)[ZO9N\[R 6C51-? =\:BH;_!='ZR:,[Y8RQK4XCR!WXG
MG2#N=J;O:U(7,K9KZ+E? !.]^EK5'WUW D>>?%1U/V4N\V7:M-L''VS3@3KA
MJ@01J>YV81C6-HBD,H+?^3E43M-/ 0@CGE/=JTV@ #FJR8@"H+E/ ? 3FTFY
MFERVQ'/XMA*BPI#/XO!69=@C<XRK90!!M]+BX[?%IZXB+YD(=RY)(1OKKG;N
M0 N&[W^=^]:3?FYL.80JB=ANXZG:3SN=ZK930<3@I']\AA',;-G.9E4.>8@#
M7W+#RZEN #8OY, !=X\1V],<=?^UM>CB\U8NR9[@0Q9RFG,FJP^CL#Q 7&'[
M]^JWTVI=5NO&_F$%XF>ZP.]/S*A,N .(_1C(U@95W-7L(:&^3*P+F_@ND;YQ
M93Q\N34=NU$$QV9$;FH(S#L)M/*;N;CE3#B,-SN&+TMZC(I-Z9U^4=CGQXWC
MK%%8&C\V1&]/G@J<[80E@5B0=(%!2E1JIQX3.L7CX&!@T]=0[\]W\<JNJJ#;
MNV_,\:5B[DVX@C@_&$V@OBVN(%ILMW*+8]2AKO]Y\E7OHO6^^"O;!MS$.H@+
MO@(#3X""AHDP3)UA;1-$!_#@056-!:%6E.$SE=D@$VUW#1$NE[N1%9>7\LS6
MEH(":E*?3P!#\ MDIB0<Z\G6 CYHWOBZ806S-O+3X(Q)SSA&.8(]>X$M\?T-
MKWX_*H6Z&K#%[?[\<L.K6\BX%W>>V_W(%0[MDD\^SJ2:E=N?O;"=H,H;#?@O
MY"/RN7[&M@O1SHIZ=B5Y.GO2C:Z%%TQ9+CRF:V;6H3G2+/L3P(%W5XHQINL,
M;LK?'HJ1R:VIC0MP6?JL/7XXBQ]#V2U5NFWF<\/T^A\4-0]"?QF"=ZXG38R1
MF<[.L\61+Y9B>1,47V"[HOW%V=$_!;-#TGJ[MCO/1P1FU4N4WC,5V+T)^LR-
MYY[O'V]8*&@U18LWTX9<.&CB87EI4D<>'4K+KS:0WN:PXW]"IVW%E=H(,&7J
M R.K]B8ZA5^+\]V?21"6<=>+=\WBS662_(@#Q4,NS66IKI/E1K_O7[^0O.(\
MI>_#)_KQ])M0T]+E1B,R/^'0G6 Z 9N_O_:!%(#L)^P\F1UM1 <&I]K$.QP+
M7LM5\SI?'7)!UQ?)AX-%:'@5L(!;3OJR:QZ8:! DH[=%^QUYXDL9QO><N%V'
M3'K[OE2Z[Q7]V>Q=7P<_S,,)<M[>U??Q+A"[W6N@JYPLQ\1VTS8U;"H5_(#*
M-25*2ERQ8^V2*FEHQB>51P8]'+&_4B-%_$Y5QR>/T0TBJ;HW/)PJX(8#"\BU
MGJ@379:0.&KC4Y7>&V [[.1X"+1_-I;PD6J:KSO6@+]/INPI@'O.<?L:<62F
M5/_GL[R0JZZ#=37&9UQMCX3"T.M/>WF_&-P]LQ.V1N5GX?;3CH@..,^$5(GT
M[*T]_AM=]_WJ7DMRK[TY'_J2-N01@L@M2C92B4!M N G-L_^?,,!]O,!#DP*
M=:!2OD^?9[$9NR0=\CU-\%?"!UTNFU;XQ7]?T,@2F,B%I]+&FKW & VVXBPQ
MXBVG6\X)Z@N;*!?R"&=([J^)I6-G<!_JA=P,*M=>(E<28-,,PIK!PM0+.L%A
M1=\"+8PS+'$JKV72#P?/>O36<$[V1)?<3^#B:"^9N';:-!WP4Q6!*LQ[!TR&
M88TD3>.@K*4X!%6*">$=K <4C;&/K,W7>2S0G3+@:_W\?,DZ/%8)I>K>8@>(
MW_U)<#H-(8(.1*T)'[!PR2/W??I+A]I0!;MI/<9$C[V6YDMVIC/F-J)JP@.Z
M+!M/0>]A/.0?%$#5T6;+ AT&3&OW2.5S?\#$ 9R%[_+TN76QV LK(J("([\+
M&EB]OH G@60F;C'0N*=FX9CM9&W@"SK?>)>"B6#"5G\3S,#2RO>(.VFYIIE*
MNC.VO G&^.; (HQ?P(D&[P?C7V48A8O]2ZQQW)6O[XP#G[W(<_FR=!XQBPB'
MGX;P8GGG#^'8C>92Q1?*02EV>1<*ZFLA0:F]S<P-]_P  -I0+L"-![$F-O1)
M*13 DR26P*@."J <D4B\,>\DOV([(N-2)F>/OK77+Q)+GM&?X*?MJ^)^%ZI.
M!^:#M5R%"A)O8F6)4CT(@4 O<RS1/NI0?5(YQU.IX.-]POW4GCVK@,<S#64?
M7=V+H<T#VNGI9T_!-,!4;[#9A&,S)'TZ8!.$*&-+OGY?)4O?&K8WEO_EE5:#
M$O=N58NP+;J.^*@0OZ.Z^HS$.F!XG26W&WHZ\%5'M@3^QAP)UI4).0%'E^Q/
M^A8Z3-_ZW5LCT>#JGM#L*M.,')2GZ8!:D'^#!6!SGV> ^'[,-._\EZ@2^%F[
MF<9@+UN\I\_6S#A-6?H<V@CU= GI&RGV+)X-O7[E#ML2##-+%0G>P$1G\;A.
M$"<2B"^R&?E49:3X+O Y9HI1U-W?Z8V#7J-BO&_\WEB8,VZ> D@ 8BT09SW4
M?2(50:SXS[/&@](Y%=7Q^)N:/Z1_Z_-O>W%T,7UR33'US23'7OFVPIVDAM?Z
M&MACA[>:9W' "#78X[/W;E=D6,0:O&;-\&%ZKW-+KJS&73*L$A<6;Y-KIGOS
M+]?(/L-)M^#;\"7SX?\(7"BD8_N'" 7?&2X*(!G:3Z+*W1S^58__>FT J44J
MI "\)&4G!BI]V#S)7,,0!PR",R_*J+)*N]1@@/T[OQ7K4IB;IJ-'KQ8?FE'I
M.+4$.H:J&FN=1=.U:,J0/A>7:"C-9QD$]>5HQW%_'7IRODWR75JV7B80R?-P
MCSMTWJK44S=V92<?DDKPQ\/)YT 3((S0"7)"5BIW:#C IZ9?J(*& @ DQQR>
M1I94UE>CJB)/NJVR9^9Y#!:U^80$W>P,YL)9M1!],+R$7A'5S=%#%.:<%)>/
M.J"BE366Y%U]P6(*(/>.96ZMPCIH@JT-B(TB]\)9_,RS'81XT%MC.6P0S>$Y
MPO;;E1EDPO<^WMM5ORN]6%A_/)@UJ8F=N;#ZYI,NZ93G[TZN_RH/QK_CD$C/
M#Q'.*'!Z9*$O5D8U,?E;D8;G]?*C;SG;):K2I00BNA#1P.K9K:NX-OTQX*$I
M]M1AUGSQY3/+]6/;.?JU<C?S\W9O16VN7?[]C/]]OH8W3>V7M&92RF>4&FSN
M([@2^A57,!]!=1H:/E][ON)K6BV@AYAE';&C%S92?<S?^WKDE5?'#VGDGX^<
M*.G<A#I[ ''.5&]E3M1Z 0MB:YME%C-#W44HFM'FSJJ40_50=S=V]PZI8![;
M?QA%RD5*@OJY?]76^W_,\F7VG1)T)]?E*9U$F6AKZ7)9QO^K5R"7(3H4 %!=
MGQ12L*OTI^3=WY6A^ZN&S?WJB;[Q^N1+L3]W6MHWOLO9 ;:8!"[7B@;V;X!U
MPPX(&+.#OY*TF3,O,$8UCWGID$>!%0T$^5&O=WM;RB,QR&^+%@9L-1Z(<.*?
MK2572*D'&[5;,A"=H-S* IJ=Q^*V+5MUG^UH2:;"7Y!#V)HXB.Q" L=L>S;K
M2+%_L<3F0\D/AM8>'X9/:^OI:ZN_:EF.#%WU^%OTI>-1G'],XXUY8R]PC6ZZ
MDWSW\MJYO:K,\Q/-JBOTB1YT.9]1XK '/I,%F+$M7ESX'A5@$O>;^,=,G60P
M)VJ*>/%8JQ2^BW?S>C0^?>40C'=772D$?;=$ESK^97#G70,Z\5#)16 TJB9@
M$X7ML:K]K80X?SGG*QHGQ>_*,;-U?^1.V=77US2X]^39[E[-8Q@;MFG+9J5R
M@#AHM_,U9)*Q#Y=1CJD<4Y1E9?K,1=.C+S08K>WMW!GDV-#!61;[3A93H[K8
MW5]K/ 8/(T8-\A(BK9*'WW3KB[QZI7/3\6_Y>OYL(@*?@4[/5JXD@1Z"&?#N
M=MA3Z?"@@!*PD<_589=T2P-,$NQ'F=&Y*<-UP_-;4\%=FTFXU':X,/F4!XQ3
MP\G+R_W;.L=TA[R=9!YP]8B-(\U.6(_/BGXI2:V3@6;2**(_WP/Q!N2!F'29
MY]WLQQA?;]54J1KQE[8QJ^+]+"3/Z+9;C-9/L-?+]-"S2\9RI7:ITKNO^D3"
MSVDHX=R;,U7:P8R&8IEZ=0QPFC2-.@"S6=J8.//W?),S?((<:I^; Q3_8(+D
M$M5%+Z!B* !W\"L%R"UL1$)VSM>S!"_%Q&-7#P#\V4-)SL[VT$9 6[$OJ)0"
MV+JPP(;VFL\NH])N@;51_A<Y^>N(>[PF=N:\"?=B[W8\3+%F><\(4E859'HQ
M.!>2\_?%/OZNGFYQ[-]7V@60O5"/8<=J(#X*8,P(1!(-1[HBOE  _W1MI!38
M7+"*$MV_(X[-646)?(Z5+%S];\.U_XOCQLJA(U46QN&?40#W)X$D?LF3.,32
MT%]<C,; ,6U#!YH6T; 8X$WJ"RTE9?^?_(+:/Q:I'/F' )!_[VZ"NBP!LH[]
MV-\J<]XLR?R'TT^LF7^U^0"$+\()W,+K8S? ^%2,4I B53ZCFWJ3VVE2M*]]
MY5])^+5DR=DL+AY+=H!*$#UP#%LW<.&R7$3K,8N;0S(/V?5F',=XT%:)FUNQ
MY].RM1G$ 7R"2[&)-B=I^!SL0AN*5X.FF*B"<_^HF!7,=O%%S=/4*\Q"=N<C
M:=+>GDL3%7VCSWU\\+>*U1\I@%47')A\VA:VR^)HK^T1T.*#WCADPK/,20*C
MR'0X*:S=),O>G1,G7/;V?"B;QK:(0%;9_EW:0B: < TOD2O@4#O3,H[,>=7B
MY:DIM!O>+#4^=?'I#:\?J']*BU! 99STF:2/+FEB/NR!WW3-SU@WEK?1C&^5
M,S",O]K1"_MZ:+-U%5M*?(+GQNQ$6;NQS!2[(7^^2T!YU;AESRYO\M^Z:YJC
M1#PF=Z(JC;LVLW!)9E%=RC9R'L&?LU3LJQEU.[Z7&KPP6A+DP"*7W#2VW)NE
MP\!#^QYE%]M?,84";D1 @G!'A_QX7H+6H^>!&>"*VM]$?8FPR_GY]3I2A$ +
M=?7&Y^RJ4Y::UU3N,5]!A@[HM,]B[R9-&+7-"*2V\R#EC1^"K_QD24AKW/)7
M<'D]>?%B9Q<YLYQF:FR>')&/7SC<(A4];,J<P B+-CG$+<<M&U\WJ)D SJR]
MF[?2%1=8%&VP6;.*(G(HS-^Q03[,7TAXA!E[JNEHYJ!->)FPY I,G&U%:2'/
M$FGP-EB&FZE4N<*\;SDT.A=95_="?GJJ?%^^=U:!YM?(>:N?Z-S+68/CUC=>
M#(ZB.T<%!%3;KSE\[N*_TOI-I+50.)39*O9*X14RY+L&[\(YJF=3#3%8M<'T
MDSG62B [%49+00R^9P*V)BM\KE?$!R!6E6.OUCS]DU$.* -%_UEXA'.@-KEF
M3^0DCU=(;V&>L^>@O4!VA_9TGC:+WP>61B'V71?L/>ZF( 22=WOXQ$H"U22"
M%V$ZP&H4,;.@'4$XI4*.OTU\2_4OGL3+>!@N>PB#"$>*KIU[=.(ZBK8HA'Q_
MTRV\*%7ZH]9CRG7^[?X/-?I7>2\N;4,S?E(?EH/T-J,%@5DEVO;+MSMZPMW>
M@=_+M6LZ]WV(67A! <@BB;[@"!MY_.3A!*D0'2AM+[##MW[FK;:K XLFM^7/
M!Z>MS_K]5!6(GG,+10SWS.+% EH]_96SVSK1(\CL7H.PA9H4*^'L)QV"P9N(
M6B@MM ?%"',74G_I$Q7LE:5]H.WTR";Q<E.6U@_K-Z>L[H2^T/N6%VH@GBF3
MWO+@:.O<_-DMW\.GN)U7&K*<5;W9PDWA@^=;W-]TT4PPA?V4K;EW,C;73^2L
M60AH0X0#^94$=F(L2CZXE:PA"CH*U=.-[.X,_*#_H"61\KCE\7T#Q_GG^OLH
M,!S$!YO[  .0I?"Q.QWHE[.!.E:H@/05@M*"<H7QA:E!18[<4P^"CQ_'!B=G
M>^KNNWBLDA5A+3=A[JB(&5ZX&78ENEC#J^0G'T$8GG]'W.9-TML^]2>)8@P"
MY48+V[G\1&M2G%(<_!P4G7T6=PKSV?%1</[!<&SH:S:EIK;2NX:J]+@4KP.O
M>0218VA.Y95_M#^"]Q%_4GSF]*M+Q0-&+Y5%DY?UV6>(%,"95,_5;GWN#2@_
MZ37T7*#%PASIDY\7R83%7+)NY\%0VM:0::SA@D?W12F:]D>"FW<7!)G?R!DK
M1KAL!9/MJU#L*IL4 ,'O$?+*6'$^0262Z.8;('^*M#'>X]??1--I-(G<WWRN
MUM(',Z_"]6]Q$MB(?*3< P^B!48NZ'-@PCF7$!UC/_TL=F_=+#%]?495^E.0
M>T_0@*]QI1,5\[.3/H</<;!8/^#I0)O.L]_6R:)9WEOW(P<W2"[QA<G9ERS[
M3=\=G @&[A"IDHEL['Q$;D7#R*]'C.;@1$Z;>?V6': GZ%P>CK4(\4A=L!4S
M>/76-8?OWUA'_75E.@Q_T#3_6#S7$>+U)Q@Y N7A$Q4 9"&" P)<[FM@IV*^
M.RN^=PTKKY47B]7Z2<^]]OM5'[\C6SAJ+@6XJZMQGP)P.0M;$^-NAK78(L\^
M0N<C(I'J'M5]SWSRM?VR+#\OMG$:N%:EE?WJES<\%S/'HS6#TD6YLTTTM, K
MQ%_[LS'@9<@4@-DKBR:5(:-"#5/Q=RX&I4C+9X5W"U5%/JYDA[[LS/VR=M()
M]\U_-%KF/.&L-V!*_T,LUG;J?O) &'.>(+L>8T%?<2N:BC)E;%LD["057E@4
M$:_A_ ?BOW<@:KP3W_VON@1YETASD9?%Y205?3C>O'J^>25W>;J%D-L.K&';
M_#K?=*/J+"JZWG\PXD=B3V]C6LPJ[<U$K9,YUD6;?@J '367#JO8B?._Z@]F
M<E[/9@]Z5U9=E28CS97=()IEK[M2FNJQ"CA?(GF+B@P&$)&J6D,-K84;/G=C
M3&[?K!Z=;(KQ6%(]Z%J^\ML>[@+]!:IR#P5YCN*N!S*UW:UXU<8QJ2\ZVR7X
MT*V>@\O/=C&5[LBX[=[^@0A$EPH: 11 2A"6VJVM-> 3$9M55$M2*.PL%.#!
MB7\Y'YFH..[CY%J?MAA44)=,PS1H>$%LCC/BO%EJJ+S7&U(>!? 02 \=F@$.
M^K'QK_-'9F9*]TRU7,[&2?(D*\O7IJO1. 8#?&>KQ$8Z@]B(G"YD8X'6V8.#
MKQ3 FFL5U9&VFQZ+DR]3 *5..^3HX"4H U$ .]9L&GGBTP8\XSCM[(EV,=E0
MVA#]M?5,\O92O"?_@B\[P"PL?G'/.:-H+1T]FO8RUWF;<(/(X?"S<K[Z=KX
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ME:#7(8KI@VS1,]R9% #P89)5F6? 4XTR=9[^:LE]8>';JB9NRR'9MXNCZO=
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M2.R)A)MMIO3Q ND)5:9SV\@^K2,Q#X#[538'"/<A7J1LJ(P6%K9P0%KJC^K
MV();BGX,3JW)+$KT"_ZR:\SO+G/JC02]!XAQDIAISY^V>!/,G_[]3)PN3!DN
M!+V!WYEWW^K @+DOEWUU'@_T=>8H^2C[)?',_1B;HU,!W.=*CPW0>F?FQA0\
ML7N'?:0:67_96.O?3AO6AI+?3970=K:=/12 E%1NYJT[XCH5(D#D9,SE.MJ5
M_05=2 R!+1"$R0BE -Q)"FT@WOF&ZK%B'UE [.ZS9U(OEDVG0]=_T1Y(J BK
M/_7:J$]7V.,D,T7@4.TP%DVNU1D MJK-SA%_XE H4Z 3Q<,3!X1S)'<??W&U
MOC'T_ B1@'H 'F=HI0"$(*<UI2#FPSLB SOBF2R:G2TIXF\=:C+$RKO7\4[S
M;RZ&0AW3N[@/"HC<#O-Z-0NRK\E ?$P.^@,*K_VD0"5'+7!S)UTIZ-FTN4'N
M]"KK=FCRKOBF$,$/_W(.&CW+2);LD(*>3UE:*1O^I"-II[$BGS=08I<CO4<;
M6EX&DJ1+JZI^W=1? +T":[E,%GB4Z5@#9"0:AN2L=Y\Q\%=V:%!C<Y.*3NG*
MWGHO1T(3H@[OX"TPB' P "*'[>_,8'=\=*(_J;%<G9S_^LSV<A:WT(@AC:#[
MTGDU(36$&S8JH?$"CNY65'LVXZBWTK0,K.Z9NWR?\,NO$B;G RS"U=DE"PN]
M$UMTH4[D&0J@YG0Q5GT9])H"8')-@-SWI^U_"5DO3U#G.^UBF1!FG:VU!VE^
M?4<HKU3R>):J40[-2644P*,L(>C%]>#>-M-A^=&C;-'A)Y93B(>1URH,EZAP
M52UQ[LB0:UA[9?^K+NR:L_QO"N"Q[+A/.SJD8Z8N),]A6L[+*\ZHNF'P2;>_
M?N*=SEX&K-'YQ\]/JR&F4.-'AQ_*2 6:?$#VJ<FN^Q@G?MVJD:V+XCUVM@_5
M/O\RB+UWYJZA1$N&^!.,ZCBG)I5\AC=0 #\U\# *X+X#@L0NN8K 7^XB9JI$
MH#8VJ%1T\*?7"A@OB2*F]D=1'Y^[G@(8H$7&4K_W&/8S-]"!C*P"D:32BS:C
MS$W1&8><V*2MZPO2"ETV9+$&[&&^BVLZ!^-]0TSF^<44R^NV.3:G]>@7P^6Z
M!$F&V*CY]#BLSWQU&+:G;:_/__XGA^.K4HM\KE)]H@W> )9?[7/,K&G'+%1^
M[(0KB(>H+>S0V@:^=$(-;N4-R5P*+'[B%L9O"A*(S04X )BSO0XD#YV'#X3<
M#_WP/M_6C\QGG:<]E-D4]QH,I1+O.U8T<-AF+W[,-#ED+6@8 *? L'=G)TW;
M9YFJKI"9(&)-Y/ZQY1K# Z?;&GS%HN\>JE[X<=W-[\+$R;>TR4@U<!A2&-I)
M 53-=B6QZ.(>H)?:[4,5T(Y>_&^_!@06D.V[&E[.HR+RKIR'-*>))-^2@7Z!
MM5 U[>(8D-QF#>RVGZ,ZB!3PKC;1@0)P$82?Z'N#TV9YH%+006=>K'4^01[B
MI^)[*7^D:M'P6ZK2=%G4B]G+*[Y!I:HN2>^'[ST6<06. /%B&<0W?[)*CW>)
MDY,G+1[],%R'?J.2_?=:_\$N_GY[I\/?;?RTI"&.0<<I@-WG4*H&*4F'G>B?
M@OP$&Y/_^5K1/5"8Z0!4?_6=Z;S. )1Z:QNSW_^_<]O^U?&R?_-/\@Y>[ *Y
MK1ITHFASP ON*?CG:^<Z0!U1!>N0 BK/XM ,H[Y/#U#CWYM0]__U\%57(496
M(4[6>,EA3DI_?W932.G_\F;"IPCF^.OM,':0.THH4*55V?WNJ+^Q&J:ZAKG0
M[8U\]>]?5EHB@JZQ>##Y#!Q+M\#0DF#151_53@&P],WC_3W\\,5W=F_U26H/
MO;]6UL#.);][DT'#/9/D]CDS/?U/9OR\?W4ZC?\Y4SOVUS.U."\RT_LYAS@8
M3^!US!WV5.\0=YDTC5!(D71E@J)6T[0;)/BU9MKQ$584\QC% )4)=,'(BQJQ
M)ONQM'LF]'O)OROA]NU<X*R>.NJ &<P*0UE6P4)(OG4XFW_U+O_BF>_;-W]6
M-T8#)>Y>#S6T%AIXY^JN1!P@FN$M%N"OLB7KL %)E6.ER-"4A!Z=9\*!Z7QR
M47H'@HGQ=+0,TXNJM=8YFY?JAT: X%2,J'E26?K&+NB;*0L^51L7^<H% V.>
MZ2A<"WYKI-34+ETGIK>J=2#$J/'JS4V1V$G$DN\\G*JZXV$,U@9(0?R7#8/J
MM)JJFI\WREQ&&F-&,%,OJZ<(8YX+P$F&PQ3<].MZ9]3"AX[*C]Z!FX,"[#W3
MAE4&[UY-<6CM.#_&VQ>H-%SR:9_/8#/],)U21A)8 W.0@1M(6226-0XC($D!
ML*\E\VU_O_?>-?-\&_VEUM3*(OEP-E%1$5>;17<B-R?&_3 I3D,.F]WIV);;
MC,["O&JIK>O6_@YJ3"ZZ=IA22P'@+^M%?#?$)8%QJ0[UJ_4O8IZQ="S07K#+
MSV2PE!UZ9OFPZY/X(/(J?AK' 8L#\D L<$P/.I3BUL1"5:RJ3:<G<XYLTWBQ
M)=]KKB9(N1A.ZT*E5IN7NK,O3<RF0:7F]N%L&^@]@TR>#[Z%E2)\IRIEY6Y.
MJSQFX&OI]/(A<\^V T]XE$R)M' *(!HQ^>=I$&U)>%U-1B<\9ELZ(UN^*<@J
MND4YW;6-'70XU'=__;S-:I:S0LR-+#N+>%D?$/[4@XI9=[-6N::D11]++#S6
M[_JSH&*/L7H(<PM]!L_NK8AHL2ON=^5O:KRT*8/V@#EA\^;$ "P\KB#CYQ!Y
M6&HG1A5<[D1>UO,Q.W]??$07>D(>!;/ YA]! +B R$]Q?:CPX=D)@/RL9SEI
M]QOA!U?7O@NX5S?8#JJNVBUO;KTZ,!G>\=U*[:JD'Z@$SD$!_*C[1@&,Y5$
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MD1^BYO+5N2.C"#8;0VLX*1 ZW9HW)>+\:>O7>GUATXVEIE]_KGL=P1?TXZN
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M3DK@)1I.?.GM@..D^:-;!4*,*"]+%U.(NW\9[)JCPK1#:((8E^E1*=T^R1
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M<.I+"W_G)W'T7IQ?,)0#9WNI=ERMK,W^2)-6RA+3F93\_.1TFW8Z85%&\7+
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MO%75('& N-X=H&:SZ^-_J\%58R)+H^1QB;J[:0V%BPQ]G]*'S&,TL:8X!DQ
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MOK^ZYMNOPI807RX1,\..2G?9?H _RO'$R7.-70U]XIUY(W13*4,1L!L28KO
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MJU$R8(8LPRXOU*2U%J 9VI[Y?YBCGXA6J\\748'?%$S>%\3)8;\2'^O+DT;
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M?!) !H8-AF%H#25,'DG08H&=R"/"3P9HG<F (.FV3'GKJZ9,O W,E R@1V
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M=?Z'KCHRN[@3Q426)K[$.<U2"D-@/%)D?7+7A9L%\*JJ[6Z8KX!MS)U^]48
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MYTA_+7KF,P*_@4-0*.X'#S"M(-R=O@---SH1V.>A 89,IY^C.&R7]DY!LF@
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MN>8ROS5E]<NZX12EC)*#7L#"I.!CR%+X"E<U&4WM U9B8T&.8,%I(EMC[:A
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ML0/+A'C HL4\!R"@45V%_,B<$/KAF5F6$&[SW6PQ1SO&L#IL4 SKWQ/$Z(2
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M:,M-2VP-^.BKVD"/5+*K9&U$ ^Q^N8L;-CEU2LND+2#E3B.7L8[H?SJH(;O
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M.\>!"=O$;WB3&Y1<3^SI95N%D:IODLT_6V\X.?BK5$D_J8G3TQ"S/Q:M*)$
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MZ))ZP2RKY0\L.>K.R07(O@VSX>Q'W5K?WIF'D&TA.'-4HO-E<'T5KN,-1XJ
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MS\&;+\ 4'^2PXY/CP*[H4S[E=3PS3G9Z2JUZ85[;SE/[BU]"PCF.=7/:(,=
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M2#%+2/I;I9.O1)4ZE'+DT%X[2,( I1JJ2U(,;KV"^Q2U\-3)G^3<CKR?M;R
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MZ'"/S$4E#&R >)]L?*[C_L6=@GB3*_>DGE-?&SZWGU?%,T/1)4;BCL_OM]$
M-N-YM #1H@5[4^GUPO;[)"'O[RV5]2\^?'3=L'HV$:$L=Q!.^=3(TDW2)KN,
M487@'B<LI@9Z<\;F$TL(XVP2"487@!3=J8GYE)3F)NIWN8,\NFQ9\.X)+PB!
M8QB^>Z7@&#<X+U& >F4,M+<E0 V7NUE^"7+ : <?KX<< L4:T;=LY;"H VXM
M/3J&6D=1N$='_\.)D=/@=R#B.4/RN\ _6\'-TA':M?'=4D@?F,PC3KU91X=D
MWWSH/.2CUZ'=EQQ,+)&.\YCH792*FD>2&%2IZ2:0;Z"R%7*V>PN:Q/\DF2*1
MA#H-GB^Y0@-:YG"6+I$?+I!+\I#CJ,E[US()#XBW!]\^6RB6@?-57H&;ZTT>
M44-/)U--P1A#2F0F#3#LA+R#X^@R'+"3S>E8,4R<!NC5(@?-_O%%GZHX"L8@
M_[%BY4H0F:><8( KZ-0VM""^PX/H>#$&JOJDJM03BOF]<Z_WS2%LB2]SD7G%
M)?I E_.0_B@F, U(LVV@M[L*00,^J(1DDKGUJ$8%">"-N[X4B8@H7.SO, CI
M.JP/Q=YXCLR+9X[&XI:B$@G9!0.7T_R\O465'6X[=@RPZ E:B$MXWP?)6 3W
MLU"?@-W SX9A/VF 8 4\.H+LF5%]UB2^+L%U:&S&]^6U"[HI,3TU\SQI+Y4@
M8P)T;K'H/ I>'X-3@/$=^H<YVDH7JF@8M<'WF0X/2Z\YAP_,^;+!^A%'H2+S
M <2 W&!54^^3[4NFHH3!_GUUIZ\[76L.AG='7Z\, PR0?MLVLQ.&I(NPR>'5
M.;XWF]Y0&8R<9M'%5 =-^RRYUQC),CN6^RQM*X_Z0\?W=/_$2F_207X[AMZ%
MQ$'P[JS[-<&+AYK$%*P<) ;.66^"G1[EUEN8O;QUZ[Z4"+6/QXA'YZLMX\SX
MCBY)D7Q^!.5% Z;LFK&D0J2\3];*[?$"V\GS+XL2/E9;[TBFJA&;K21*+L=1
MP^$/U11\P*Y;L:53*\&#"F_GW1?U9V@ <57E0.0?6$?SB8>48=Q^Z\"18+/6
M0?H/!BH=K@AVX9+_>AG_51_H_/'](/:4R?V<O#3(<Q3.@@9,QK? 60/Z># %
MK0W:EXI![3Q]WF&>+*R^3-O(UXEL#,_M7ZI+Z]RZ-<^.0;VO)9?1-:T2,MF.
M.]YR^/!YV!=LVS<3P:[^KJ^_(U/00&WD'N_'O6-/062> DQ@+OXBX?[@N/V[
M$M]Z.7^=6(D28[>D20LC9;/]N^D\VH3Q!1JPZ9>[IG.&\@T:\MX#EQU/,7/F
MK\(?84CUK#HK+1&NW,9Q4VXOALJJY.K/O$%GE";=5E]MG26^;^^0=>7E=<6G
MM<)TD7WH!-!VBB:2=&IWBR(34:)9JIT\B9@<($@2]7#N"WM5B1@(IV>C#%Y^
M]_I4\1[E:]#=I;L[^BQO["3D]J\  AW+B_/NL FQ(T/UK"0!J"X.U?).;%JO
M+'I.O:_XU57I-OD0WLR'?&I"\2$Z<Z/[IVSJRRM&O*6&MQ9,LAU?>>3'Z7.D
M&F"]Y&3F(UB/BK%\_6V=W 0A2J+:%"/FV/')L15HT(![?G"!M:/KD.)6W$?!
MSM?GJI/<6SI^7Q>]+Z3!G@Y0I\C&1!4<$LN?E>7;AF2?#(XXVIRXDKP_N$^9
MZ;*Y-A#V]2(ZCEQ.W*%__T\5(\@2LB&.V3'>E(<_C21@J7#W:H@<T]#6(W!M
MF=S3+B:H^?Q6$KK2?4,/^YK,A4D+.I6>,9:I.RHZX*I2)^I3^9*?A8-C\K1W
M7;3@9;;1RC!S3=#PPPOMOFR.31%JF%M?WM^1_=P$A#)8V KAUCLU5-L&CGB
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M:U/'?1)/=)XJ/ZLDUF:[PP@996Y&18AQ$Z5P6U2^@NB"NH9A8>.E5)-)ON7
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MA5J<:Z!DJ*:@$4C#:)WMN -?DFUUI1?VH/EWXWR+AQV?Q M-$0:6/$M3O&3
MJ?L!4@BJ<V,6$>4@J)Z1_7HT]ZF"\,3G=[P]M1T)W*%7S7G2'Y_N/OU%,=K<
MT$1D-XL,= @VDSY0G/-7>O=^7STA3G%%^?Y8^LL:- T\$BY_?,+!PK/+V.M<
M;S!K1TO%[O&>CLALL;A"=BV=5QS?FTG,%+F1LL^!#ZN9D8$>5:*LU2<D16,<
MNT=6IBMCT#/J.+^9E#[_Y&A#<]</M56<[<>;"W)Z:S9.?Z2;RUR!F P8C1N!
M$!",I<^CT?KR&20S =)[U'UMB^'%I?YSTHY":A(.S)?4C]64*&I->';!'9&X
MXWFA]=P$A1*<!3:TC9BD,YGF3WSJ>5MD9.2EKI)RMG1L>GY7%4^#1L WM)]/
MX:UR8^FMB0N3&K7&^:/2F<ET"1^/Q"JIOSOZ-"R4J9$'4_R!XEV&B4_]/UML
M&]:![^5&@8+M1J8^/>&Z_Z#X6KYV]%GA=Z=?YQ2Y\((ITN[1/6;0#BZ_.4'0
MQ)EE3RY-,O5=?V'V 2%06QOZ\2)*:RKE@@&=3B#3+F<M_;.*5H@/Q92"*0%W
MG440@Y= ^\(#L-=!:CMN..%IC@.>('9-Z1GC8.'#+:=*;)8O%!VMJHMP4JSI
MNF/]Z4ZA[V9<M82O02-\I'1Z897@;X6SR*Q(DJR<CZD,?AN3\D0'W05")^R$
M3TX%"G2?:6C\5'3]_:8"@9L,D$P<=DE-HW#2HX'O$(P1Q]ZQ# KZ^W#T5B(+
MD0^7A\EN@ MJ'@4_A(DMH4?35#8,E,])IAP0?_R-7U,VGDD;I\7!DXP)G@YL
M5G@P*5*#03>MB2^IAZPUUJ;;WBL6-(H^X2VG7,N1S'W]T.FE1".KWD8O4QTL
MB! SFD>\WTT&7@F2?'^NQ +?\+\?2 PM!Q%Y9?8O9C 57T\<]><0*C![NG6B
MF0YVK-X39X$'P;J1]-!K4#_,7+/<:T_MJT_$/P<'WN8ZX_O!0C)YZ*6C.!>C
M[N"C+0;$:\^]!.(']#RN#D*9X02E2"\*5_:]4<^T16%M4Z65K1R/N0BFV,KP
M4<H\I29':W+Z0VV4A*>3]:R<T)T":'YT'<V3,]TJ>L."VH^P"I%;4[Q!?A:8
MXI((>[!-64;G-YI&-V\QQ0[E'X6>>YY!VC*P)G09--#<CF,-<K#[Z(-/A7+^
M&LQA!A\,VQ:_Q6;H=)Y>8'\&&@BYAVKI#IMB@RDNKF1"33#?7J/=!205M Q3
MN.X_>WVNI,WT3JSRY./.AA[,3LS/Q^F)+U!0L$ANX9BGNG>.&(,QIUMIY3-&
M&:&"V5,"^,)6I3-'[W-TPD?!<U.4Z<V+#,34R,?-'&2XX7ZKVS7371&V$;#Y
M3$#R65B9X0QW-;]AC[X1RS52/27GIFLC/LVIQ5]PMWUI-H^4\!> HE_;*5"F
M2*N^*>:?J_^":5\E*D1H\Y;W?$\_9^R_:1)X(K[;5_$>RT)Z;<7"J[R[%:S<
M:!=T6  9H-%FI0S;+,.DB27,<Y_7%]=2-F9BD]Y))6:^\'!-+RC''?[=XV96
M6T.0DY[@]^C5]5F.:!"FJAS"6C8IK?;>0W)NK=+SB'V#1:(N2Z=8QPGVB=I+
M9QBEQ)T.@DR'NL 5C.WH0Z0O(.;#LPH16R]";B[@+PQ^GJV6%[-^S6X?=8X)
M+&JA17/=4$MFV:,%"XJHTYH[R+O2#)/I\]H..;$78.H9R/69+>;E@X[IL% :
MH=NW#52/NRX$/@1/OT&65CZ^^VP!FZ.>&JXJBO[P<&UT0WAXH3,%,%:X;JNB
M/;#W''^'U%LO1"P@'<4YFN(<<^RU4J*$*@)ZNP[Q!>[R)4IU)AQU&68Y'F<T
M;JS6J1Q-]!CZN8/"5 FL$CHT2 +5]0:F?^;)R%1O,87*%DE^#>$# EJ#.9I\
M1CAV[N.D\^/\&F"<H<(VOA7[:_-UU8A)J71DIU1UK'SP@.23PB^I.[<P#+F8
MVFFUAW6,17G);]QMK[$&BNC>"U3B..4T7LWH6"NOT]C.L[9E=OGD/WJSO7]P
MH7V.#20\A)!J],A 9O32V]\>_JD(E*HY"- ET/8.LF/(Y%KW8_C<@B$90)61
M]/_D_8]DGO>@YU6+X$.&Z"T6RC7_<@0LY?^])WF 2\4:-$ 8"7(*<=KB'DM9
MBU^[A.0TVL71=4]G>,PE F^&/)T^8 JDK:^T:6M"63$^:YS3 MK"0=\]N[RT
MBF_4VMP2-RSFLO8K>VLD]":4/Y1%A(/_M.A9:""6#.S,$5.@KAB-]DE.3'>\
M^:[EX%VM<[V]-#=@$3;?'_:JC.\L9\N>[3K$Z =) V,NH>+ ;/6,!!LL7Y2V
MM*>N;I]/F9'<T>17&2&;+YZ),U<PS=_8R!9ZPBCL!Z'X",P2?*2;% &FI%O3
MSI%D0)1B7ME3B2_)P*(C%D)BL(9O''3W]V2]L@H*AY2K-9C&98@BF]!LFC8B
MY05C=N5CC3N>;P,VS)(%&JNB3PZ[7CXKOOGR9EW[[_=I*%L?V=P1P.GA3^$&
M%]HSF/JWBW3-JTL2&^(NS$X:)DK;B]]\2U\G%>!(*YX0B\TP^ KB)_$$!<\%
M-GMYS@1&YU57]&ZW1#FG]"1(Z;)]5.=VM8*@!1=.W%$Z<;<*E 3^[1:^L)&A
M+E I>#4)0XF>':(%A'FT?#\E3R'J(&H4<CF1=U1.<TI6_UBT)KS8:^1+4)MB
M=_^6T42HML#/%[[@'U_ANDBU[O#]VZ'U)O\Y^7/,1A*A2^!]^@%8)O063F<&
M'4]QKOZ0<))<54U9GZHCK6:%=Y2Z:MU')1XE\9C=)TX\9P06[XGXXE5(G1FT
MQ-2[:W>:&]7CL]\@#QG3I2IY<!Q.V+D]<X I*Y9FL\(OT:T^A=4C1./G,EN$
M$$J=";!AP?50B1<[P3A_L>%EOL$WDJ7Y1\?$ W:!Y(I'\;J&+SN(3\,=C!UG
M(<.IUL2GVD=68K#&<T./"9_AIJGJED]5\+7/O-+5[2_V-'5LN!+-0\^%;&ZN
MC>P3L6,[=#@%O$X0"1XE(M]?_D'#LCJ47])>_?OD::=#\BTW2\<NZGH!0B?Y
M:6/GD4?(0*0QZ0M\2Q%'L?FTLN ]AC(3ZQ<BY62 XRCQ"7KQ-I(R(P:2 <+-
M#V/3Z#40!K[ST,2FGL?3U=+K4)-\SUI>A5MK&QF0G;UKTEBA)O/2\:4ODJ)W
M,[UDH!1)9(/)D(&&+@Z2#BH?[4(&1A1F4*MUJIO3K&OF)%-.XHLUA3>?V7+U
M4,^_/6XYV0005PX_,9I+2[V!S*#T74MPZ'[N7)#G7$7<K;[1D48BHD!)6OO"
M7IQ$(0HQ(R?69CU']ZI;U!*]JH:_3U#Z"N-;0C+#5#S:=?HU3R%=WJ'3SHB,
M?O_$=3-N\N2D78NV3A7]<;Z#M<?0D/)T/D.L2%)@IN?.Y65U?X+7P=;R)MGW
MQA3?67/RZ$-A'9Z]W#D43@+< .=<]O-PX!Q4]6$I;*D<<0SZ4?0D"?GD8KV;
M2)ON6K3[6YOP>-:=+Y0V#26<K,,Y%D*5<%(%Z7!KK#B'LW\(M[F!E[OG\9'3
M'"<R[SF=LP@X4,#LU?" 0^#GJXZXPP5C]BM(T#;>,K0W.*"W+&3EX:F%@_[J
M"R^EXVY:"G$Y@9H==BF=G,1LCV%MJLE11\6HREUIK=>QY*WDDBA_>\AO,^>$
M^(VU[S3#89"<?8?4UXMI_A6(;%L]1T=7P5;Z.J;WK=QN)_,?OSJ1+P0PT!]\
M:T./2 1[F8[>)7U"L]T<* MVKL."'XLG=AL;,=R(&E S\CU.DGC,&4Z2/*'N
MA%@8FB9V-Y&!QQ ^22QBS6B.-<9+XKO:T.?Y\0G[Y:12U\ZI ^"42-R8:/C>
MY0.!"EMA>'U8UQ0[VGWBB&%/O>BU95Y=W0RCM==]+M'2.LGG:BK3N3LL*M[@
MJSOXM?PV( 1UR(X?9?I!M,)Q C<HXU!%+^>@2%(.&6BDI)XWUQB-RWI43+G*
MXY$WN'1\?-@30H3,]/A'\Z/? =PT#^CO^S2#QR [/KC:.0T0$,37LGZOV./<
M%2^Z%+6 65TV+YD'&RWY3'J.H?J^#[_00_O^*'WW$8T(G!2B4>$AFG,+%2W"
M.U".)UKI;]9W"Q,_EXY]#W)@D'TWVM+R**#]<^PV0^3U_EW08V1)]RH9P#JV
M) 8US_*%R?G'N5CW2E7?DXR;.,9_=O+J8W9&(.'E=5? ZB 98!/&BU.RKC.E
ME'$0@R:!(==ZK@1H@!Y2NK<Y:F1W>KT1PAXDN#L3&''CJ^2 _+ICM5O.\T\Q
MW+[<C)\#VUA%GJ&RX=>G1@*G00BX*Y*18(B-#"ORAW!^^+P:%ZC\R5BU?.L-
M[V)+J!*/F3[+]-S+H1%X&6JU=!HR&FG8<Q<IN*P>\4Q%(#=CTD1KUE+2V>+V
MK/4\'32;OY%G$4)7?RC(9QK<;"\S W_T0[YXZ[/XEX]R<V)?UGR5/WV+=8O9
M??G@0"R;O^: GYN,2!%%O=C^WGF7//BOO='Q?Z?\OR\X7BVGI'K+XG]YO_$$
MT(S)(\3LP'\@B4Q#NM=V?_OJXY]J@OX9R__>QI1_+;_VD.%?^LXK5MM?;C<,
M&%PD T^\\HB^E&1/A^?^_PC;&20?O(-BL'ZN"\7_\UOCWQS^R57_KVT/6YU^
MA*1K._27QT+/4J[ZU\-7[&G_$SO3_KWOX9*'J/)&E3>JO%'E[=]3WKY2Y8TJ
M;U1YH\K;OZ>\]5#EC2IO5'FCRMN_I[SU4N6-*F]4>:/*V[^GO/UUD^#\Y4 E
M&_?*P 3 @2DG0?>NQ-6$EP&H%@5<$+)]?6^W!X[A@I# 5BS>=H>E):KQJ7HP
M07AS"PD,[ZZG7-:#1#* W0?/S,)!Z(4I/3+08 3'$=VW[QU>,_O[_A=D]23X
M*NQ;#R0"B<&"$5.;ZUED8%H<38 A?HM@,# O,@"JOFLUDT?0-)W;)> 7T3AF
M!<H8S":)2&'QI) M"($NE0P@>K;O,98;_+#GP;F3 8[#."(9T-Y7(!TPIO2+
M13(0&46 D0%D"!\9H)$@ W-;(0XZ5%HJ+97VGXQV\)=W6ZQF77_'4S $QUQ&
M(:PJ2D9-?+)O)5^HD!/_PD&LR%[>X/! C'O]NBPK02&2Q"*,W6!R#-4(X;OE
MP>W2Z_#@.KS+(Y7:!%1:*NW_$NU?5S-&L\-_5ZDJI8HL,,C^PI$0/C8FRD>,
M@LG F(<V2G0GGUCX:QX""><%8R[#$8(A.0&6._MJJ8<:/N<\VO C UH%"[_G
M^ ]IJ)'!]/V>Z(]1VZ\+&\W>E8\FJ/R-^/TA:O]!UI6%/OB'^/T^:F\[M K
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M!S[4=)V]USJ(*G(;M++RH[-N23+F*JUHH;&2>GD<" "LW@UU0TI<"2\4FL@
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M)9YVW7L^DCC<=LYW3^>[ JV(QI-\*JU^[1H]TL(6*+9#B-,[G6:)$)P8?7
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M#D'^W/HN6]>BGODQ<1]=CG\>3G:FJ*-:#71EJ'Q#:TV"\PBS>5/6<;GV(]<
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M%TK+ T0X7V:)#I7Y?LAMRNA"!"5_[%&5BW]2\?"KQ7!XZ)1CM )3\\!5GF<
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M_UL!Q7)9U X#2AE-C_IU<A1*TG!''6@& AFK^SY#2*-[!&_25@.1,UID<OF
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M]P69J#QLI#[R2.G4./(XP8FKG?D08E&X/+ARJZTP.^.IBH#N\QSZ9?MT*B^
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M$JJ?D]I"S40#+**$X.J3BM@XM;$UE>\*-:7G8:L?HJP.(2=QO_N?Z_($F+:
M.KVNR^DJK^S*]X3;K:?YXM#K?,MCW\E=)(7OAC>5 R ^#NE7SX]9DS-) ;3G
M !_0.ZU93P[%<[A8#U>SK/TJM][\5>N:+/M.-/Y4F++=N6?'?&*)0Z*U?UNW
M:\[%'*$5(47G8"^AE3/Q3<)X894/",V"MT0[NXC;RE\$[5Q=Y-XG'E.^JK4B
M06P$6 H)F:"]=0691C>SDA/RKI8LI]BYW<C>JK@L$Y18T7X*G^N3$F$^)+[
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MFYS@/AV(9.1O5H4.PL6.";V]QU>^U!=$[LY)=0_IFII>%F2QFE4Q_[H)DZ(
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MYU*<;Q;X>KU1CN2+>NW"8)C1#>8"3+^[,XWO994'S"?:?=\MJE;JJ35W_*0
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M_=S!9[O\P:<Q-:S[K.)W[5J+OI^K^9K@_184O$SODY-GGQ,HWK^:'4L,)2'
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M]>*071=+HIE.WM-DIEO/<SY(BBSYH]#HA]Y1F(-F8+@P$.^[$).-O#/HR:?
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M<&U^8*Q1'["9RE9H=?06!&CC*S?ZO(R?3&KL6O+>CWD?=\"X6P<T[UOK**(
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M+:32J@D=!6,9T66'7JV/;N%/^9DGL=60XZ-F^Z.XK#U"\^.:0$?I?*[,6T/
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M)B+]<?LJZLB'I^$38F9D,T@%!5#!G?FXD-PQHU)>83Y$ 31+Z#Q5-#];N<L
MNOGQ[2H#D9T4YPGC"4;MOS#C(@_8;L67)']L>US4B:D?S.4Y"D\\:2#Z^NE2
M??P%R,+$95IGJSU!L/OL9/JE.WCD?",]@/7Z+ 40BUI)VY?%GYCSQA@LI.9@
M"1W\E;\2!;5NCX_U.^+DDOI8!CX@#@I$P.)Q$S1@Z8NG8#GPEMP&.JK-FUH
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MZX&"LV;E"#)P"\S[\!9_SSGQT+R^%*0!5C.D^R9 9I2@ ,05V]#[%[HH@-S
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M^ NG31WLG)-\%!SLXBDJ2O8SQ1:>\8;OG7P/GT$A=UE?)MS2_#:Z5HP:JS'
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M75GS-64WIPELF20]MGKX^C)RS[6J@+-Y&YQ+,:9*)/X>2_B7-0CS;OVT(2E
MTAFQR51&^>H<A2:<*#+A^Z6*_<UM<K'39&!(F[1$,I%4!^^%@[^ .P+._CB1
M?8*(P%-(S679OE%&6Z$V._>X8I-#-=2/!PIVM^"]&H1NP/N[F>!B-QE0X=V2
M\=W_;/^S_<_V/_L#?V;Q2\O9^EKAIJ[+PCFWTF:-Z_>V&-9^>Y_0?]7^*/ZJ
M_\KP>H'Q(3R&_,F&?!WQ@VC\\O)WO07JGTB-]<^&]>_JDA)_T8^<ERV CVHA
MOS-0GOD75\!2[A_ 9_:7]H_6H,T]4UB0[_:FMC91H+)2(UY;^&9N6)!$5UL
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MUCVO03G<<-:9J3\$+FJ\;@Z(4!^N]U>)SWK6OV%C<B7F)MF+7-2BC04+A([
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M=:A006[UX[J]W]RXN[)""FF8[X>T8[CD1*%#N9-K"8:XC+U%=+NGZ"+[C_T
MV//0=])9]7*B@RK0UJQB3<?<K"5-*8Z7A4$A?'/E4LCVO]4Y[E&^&1#TCB>C
MK##^;)WKOTF-ZX*;C5^U0ULWCK#SRA+S<BK-@Y9VQPN.'_)24ON<=J,.:3 5
M[FE+..JNG]<F*'Z<^9W>]";ARD3Z\].>(B[2.4;2"79]#7LK;Q22GPQH5L2?
MH9WN$3K.>Y_5[;SJ%TDISBL'#!>1P7(T-^_S.%;,R\@4E/^#)XI3NOH.?2>V
M6T*PP_Y77+HG_9&/*F<D%;-KS+6T7^^"=AOE0([%H"\SQE_(S'FQ9O&)UGDY
MLN'/[DDFF517,MXSZF 0/RE97-&#3$3A;H)Y3;$>P\#"HT+G8[/]"KGO.]GO
MD\<"1]+9WFOU"_UN/N078JA7A-<^NYT=,4HB(" 4E@3BM8V,4G^*?.9-W#RJ
M^>ASZY>FUS*!%WM.GLUL8/M]Q:A\CT;2<::0F%'$!U>*\,9S>YIU-3!<<@_@
MU?=KN1'N)*'O]9O>1*S8_$D!_1<U8I$^3)OC[I .]X+I#GNPT#==8;A=G_2O
MU$6BO?B])8;N[QVN=9OK)]DLJI>=Z9$FI-M0@C1JB\$[@K,,X>=Y]&!(J1PY
MF),;.IBU5+\QCP:*"PJTN69[EFU[F ("W4M0=FRP%<ZMET2V8!O"*CYV":L1
M=J!X]KS2EN+["_,CJBJ2[<V<+&RQ%KBK/W.FMH%[<@79X7W]Z"I4NS=_Z%<J
MB$5)AW-)85#[I\F&1<.XT%0-\I14U761#VL\ZN=U2E%O.)ZH3.21:53#>8<]
M=$SW=,W/ '("-D$,,J5\Z'T-.7A5*UX@ 7D&^8Y3\DQU_<3^G1 OYKTRX.]>
M9W*1IQJOBZ=+X7R[4)@O_W'I#4YL=VSR RJH,>,8UH'!F=HV0Z-F]N<O3'IZ
M!WL&NHZN/>G^_B'3Y?*9&.G79]*LVA4Z&>U2:K^>)+_)*\F.>T-Z0TZ".,#C
M,/1MJM8D0WQ=?GY_D;6MO?[*](CJF/:(<,(3\9/C<E^-%5%>"+)'7FS:MC9C
MJ#=E%EP5D("F16?!W_=5<3*?BZQ_NAV"IX^XUJ&JKE^26XI_XWHN?G5^</7.
M+!/:2"Y7F^YO(36.,G(NY+<##DUAQ "[_&#<.F:&E_(*S$H%+=@?_2TZL3/,
M;[=II7N6'$WC#U!ARO!](;S2NZ400RBZ=5+Y[#NFK-U^'GVVAP:_,N1L?<XC
M9E^ 5E.00YS_<:$5N%Y+^EL]YI9$$L3-,NG;I_Z\J52I!Q?8Y32O_,%FB>>Y
M7"%>">TY0M=$==C#>]NX)_+'@J$%&RKWS@N^("=B&>O#+1E'[RT]^:XQ_(KA
M 1?Z><W^"$$F?>MR2'%9]LJ'U*)V:WI?M>.:!\^W8NY#2;YJ1T@23[4\[X)A
MC-2S<Q78RX?)FH_OS;Q\B<D@:^0.#)T/3B&>"^UOXR>_JV']$+M!=.D1:2IN
M&S=Y?#ON2SA#OP*7E[&L;Y; PKER\%8]\3)BY!")$X]:I(+HYZ>F,:['8<T.
MH;N&8DDU9L*G1OO.LK$P,SXQ"#Q-^9Z71S:I^N-'Y OM ?C0+NB88R0R.+!X
M[:[-G-M=-_QU)]4Q$^<T5^>YV<6$:V'<OXW[Q6 #*-Q=SD26)>68)R3P6.E[
M@?NL#P/+A]R]I%H:HK7SC Q68KC?\#.S+2EF?T1B3I'.DM'HA]"8.\%6$[H7
M$0KZ*#O<3C3#W;DXN1FWTFW)&,>4H9BG1+&BMV(GWE<Q"PDWM/KQ3OV"/ ((
MLFVY>,QB 9B'=!5;03!45+OL;*\K5*8_UL^G-*J3_,CZ\)?^@Y+^]OYUA53R
M)XB#)^S0"Q=2A%34N2<8O?]Q>ZDZ27Q\>H0ON:2:2Z??<G+Y\F5SS87XI"7X
M*<"#$XFA5WV%0X4'7YMHNOE4FU6T&5$N$6MX.23<0E'<5NK3:Q:II&2S._C5
M7LX9SL/<B?.J /<\!E&.91[^D.WDSN"^U;M27Z?'ZI2PR>H4CRVQ3<G=-R3Q
M0K$<K8LC,R*S[1/U/( SHFYB73O39^B1K9$X5MYH<X#[#=A0 NT N$&G7[:C
M:RI>O1_3N;'SP4/+:Z]H_8E<H.?@TE,M'H8D=:9E*;'X$OE?;=?)86@G;WZ2
MS(]50BO>9LK:(WFVM2Z[R N6/'/9YY?917.]I#>>%LSG"NN?/D%_4N-Y_MO<
M< ^#11%D9+>X\^_W@Z.*ONM<=TM9Z><?K7]=X8G_&LN/?.\O?H#* SI4 +<0
M\V?(.TBCT27OEB.-V4YD89.)<<7O\-C+4T]1DI0O0/41204<X><I<V0K\NMC
MA9VACZ^4CY!#_(U(<\V.1X]ZK=,TOX;^[H-<#)U&57'V>",! 2="Y(*]J7'B
M< TQR/#5L5ON.^?(K&3UZQ*I9Z.TP[XB=N"?:LQ_!44BD8!CQ?1>#Q7T.;V+
M'=JIJ]Y:W3KNIVAEKQ<2MIPLE;#PZDQA@5'_XU[CSJ6D_O*XPU:"-!9.D\],
MVSITBZ*#IHHWYVWM>R=+UUA/FGJ9C^972FDPNRT_6"H^#H^%32Q!) #GD2D5
M+,V?X0E-D.X1D?7GVFXS-V'NCI]S HN2RA67P_Z"% @NE38BU*=VW(Q5YG1M
M._^M@J2"U=8\8%>VB-S:]EP1-I9X[?D0$N7S9?UR68:<UZ(37A*[0^(9[+$Z
M+NLMQ-EV"]1G.)=^31/)U]'@"D<DR.@_>\/1T^UR^FF@+KT@B=?WL"#9EW5-
M)-CX[RL'[T144+1,0U/)(J.67WL&0J]3AB&X6\K"P9<)">^#36F4U93KF+'S
M9Y=#T?F4=])Z_BPRJ8ZG^"N-+!XO"0M_(=OA-:)4O840 7=Q1=&>$SLW?VRM
MU#;&-.G<E3<0[V-^.2[^O_'VG6%-==NZ09!>!.DM2!&E*ETI$>DBABHH)2H@
M( ("TD-"D2I%0$"E1*0J)=*E2.@(B"A50%I0D)Z A@5I-Y[SG.?L;Y][[][W
M/&??'^O')(LUVYACO&...<=KY&ME/3_@BC/!*I-X=E?$4ZN=4/%'92BLHF"3
M#^7+^89V5F2\H?MYGO>:\J3Y8/25(S:"$CD!(0\7!JJ9>JF@Q&D-_B=?9[\9
M<)0VC/CK9#K)YN:>,KP7;:9S7GHE[??1C)'>77EP ;)9>2L++T!X,JDC7Q7*
M2 59-%T4%3@'Y2/5=3M^<G-W\\0^!;?J,_G=]VA*V%(FGB5=(K^@@I;/M>&W
M*05!RHEQR5WB*.FZ+?Z.,%<I,UX'V1%!>EU."T2,E8E&CE@Z-W"(.]D%:=",
M+L'!4C*PGJA/=>\3Q"-+.QF8KN*&]'N*EA.*6'OPZ?U@W%7E62;#"9GT[N9P
M^R2% /AKZZ79(?LFH(S.+OW5AY4%S,LW9ZS?OH PZ(%I\J"DI[(9GF*!9W(8
MAZN7Q8O[94FYS&=\DY1P:%G/DJ6A[X.3G1V<8WKB@*H!3BFV?7V6(Y_?4LC4
M2TCB4G1^%!U-\*,8H2![>R-9^1A](UYKP7\R_S2="+*FB0JJP2-_7FY+7OY;
M>JG_O)L(XZ!,44&TUV(Q=U7]EO,L=("L?DV<T$K=#4/+.<-K/.:Y(L]\+YQ)
M;KG%>>48"S$3DPU-&]?'CLZ9]SV!&Q4LC?OJN,ID?W^T7#S^JIU_*?:K8EUJ
M^6?6BLHDU*5OR*XK2&\JB*?A!2KA%UEC=NS;JKYKJ;G:%5VQ'V&F-(\W+I*;
MJ$D;)&B[\PJ7^$\P)T(I]-XG RS;7.1%#A/S17HC]8\Q9SY^OC(F_SI8)%G%
M1S3.-YO(L8SA#(WHOBF&2H#+EW>5KFN<3]S>KLYP3583._8&OUNXEC42IOP8
M<S<]FJ*)[TC%RSKC2M$DZ5F.[YJ$@REB=6G8]C<S(=2@W&FZ"5%3D;*+/&RK
MSE$']\Z@U0$4/F$9U57 ')J.#4GT:1"1E7'=3_*Z>WOR=AR]^5FA0>:2Z$'L
M2X]2*UB>_2+.#CR3-H:;<YS;/*B-,4%QI%Q688*;7]3C(K80T,5Z[)3I11!"
M>T$I=0G*\W+JN3F'!D&CH>T6(S2G[K:[Q#'HT]'HP<[RH>ZU<772"!SV+A_9
M9;3CSG/N(;[I!;W;=SI_$ A\NP]YM9$T!*<AJ*=)\\BON^7(]:M\EKSIZX7V
MGM@00Z6ADC@Q,_KR%5@4LGYT>X4(!0X(:;CR.!UHM5'8*R#6SMR\0,&+\*7D
MW%"OQH#IHZ5>%7TO+BA*2IT,LN^%<&'N*<\H]Z%$N*)(?-[L+IKO6UJ;!+Q+
MPCC4<)4-Q=O:] '<+??I-T?.Q.HMO$H^'%[QVW;&:1,0H5L=IS:QNC?=]J7&
M?:2\\_H-OKQ0PZI#NMW<.#ZQ]%G$1XK 1OQ(O$,$/,2;XVK)GO), UFM+UYJ
M6,_4+PN56QBZ.X(H!J!_.':4 )1#NFE[VR1<IUZCKV6B*MMG+U3DQ8)9<BQY
MU9+)^A)Z2!DX*UY:O@ENY"Q]LZYIY3+CO![N]':4OBK#7&0NIB:MI/*L: PG
MA]?QUPJ4[%_!'F,*SH-W/26E"\UD3$XW>*L:44%/U!/($30S\))UO&K&9%5@
M>YSH1;(E/V\/6]YE!=A,QOP4U9W5%H;U2CEZ2P;7="*D]CP><13171@\3+A&
M!7%103TS2!JB/ *%.E)!H%WDH0:FR*NZNN8\(3'3^;WFF?L>X^H#P*;%>$*,
MSF6CJDNI%W<! 4IH<Z.UYW4((W)Y"]. )(-T%*F@J! ,*<^$I)M+H)F9ETQQ
M&!PG#5UF>8_2<.;SSP;^Q.M>+#K>DJG:5EJWF$<S([V/+"D?QY%K4\I$ F;9
M3OZ45"_R+E?R+!74OQOM(@ 48R/.J&U#G<S+<MAN;;(>"EAWEC+$Y;'7QG\O
M;!>]\WZGPP-8)#J0^,D%ZLZJ/1ANM*^/G[IVH#_#]:;,:PQR?9H\Q9Z'T2 /
MG8?K+OAE"*]GAR:N(V-%F?.JKUIUP!C;G!FKBD#,,D-&[76ZI]FWNT!IOSEX
M'_+:B^'I!PJ% =>E$<>!A7/OO)W!1H]& R6-Q]Y>C1,T9,@T T5&R@]1&"@3
M8&8JR+.GR@0W=(1==6:^[)NY.K,]<WTE-#7:5_"DR,,+@M\#SKP%7_[B<AN/
M7&&*IC "<D@P7+\E9]HLQN&E(KNB6JKT '/1"0^43?2N2\A+!$UWT07MQIV$
MW].3=E;M?NLT>'?<I1<WY.M*EV+&R9YYX3J#PNTDL$%,9Z2L$<+_3^3^"CFW
M9/):(14TEW%)!.SM?7R/^9/F[;LJ*YBC=J)',C&O&\(#9UH993+",W7?W*XI
M7IXI#C/:,^67=J!00<]@7BEEG+@EOIWC''1S7V H%YI;'O.<,KS /57RQ4>Y
M49DG3+%VYV&;4>;7<TO;F6&G%I@.GJ@4]B8?09:0VU*XQX3XL9T@KOCPT=FU
MVCE"Y=G/72%^;46A>6\*HS_7>:3.,%C=%="=398?0<B2;@,>.(_+XE)  5;$
MAW%PT(&$O7GC69##[4MC0\8!E\]*!(26,/V/:R(U*YC"-\0,^-@V0A7=Z=6H
M780M>V^A?:OA:1?A-6@.G)<28"K4_^U@0,V!ZW4%.HXBA^PRQ-S=C=,[TX*+
M_/'[(#&(3>"\,]+-L;3WW)5R]E2%S-Z4X2\Q_%T?M&Y=.G)=.NCG8B %XM3+
M>Y5!4(4CN[E!@5WLN:',WCEG,>B#2!:FVE>=X7%\^/0^R-PFP0NPJ'8*];/#
M,[R8JO3*4!,V/+UEO+14;)Z=$"IU'/[Q]?);[QR< (DWC^",__2:,\._T@6X
M$Q'/(G*/\$K07#RZ+&XUE8EX;:BXI3@[;O3]SQ*&<^SE$GO,I?^>#_QO,\$X
M_DV.&%LZ((1X!3EX'Z],G,(<F?.%.D>4;Y^E@F3J>S&[-ZF@=06[Y2 BX@9E
MVYPDOP<9%5>B@C*:E"D=4"KHRFTC7GNO_:+_5KX 7DNF&M*?NV?32^E$MIO(
MGUVPCJ#_3>**-5$?DF<XHOQWPI=]BA&0CD>398[S6L%XD?\P$X_HZ&/,=U8J
MZ,^Q*G9["Z>_%O_GJ3__4O5?&%+^>L[LOS5:__3C]"F5YL!7>_\;+\Q+6K?_
M4K9DLOA75O[_*@+4B?]ZN@S8 @9K1K'ICPO5\6(?X[W4%;TMWRE$)"F))2S1
M=8K%(7[0P)0L2<J]%,X\W>XB!?:=;FR1"ADXS:;EZI"KB]NEB6^T_7)"'YD3
MR4YRP*,2:ES/#9=M7HQKL9D;>A=$>H?%/, L9;FHU4[JL87F=O8;$1&Q5>J#
M5_<)WC]MAN\CITU+^!H(I\#7$%.8QIPLHMS/0O#$;CM$.7$';N"O=EY?K+.1
M.>=GU8[3@&R()>-"P#7C"T @!4Q?@ORBB**"F-BHH _9!P+;/L33Z\C&ZPG+
M9)7]7I70@+6>Z9,6O.OWE6)+N^5:>56,TJQ,?;[=2A'%'P;A#R@L1;=QT&6F
M)+VS!GA6"^=?S*Y/;VH\>\L2\C'#]:. <K/(?D%YJ>%]S<!O#T<!^;6XM0F?
MHDF*\/S,C$YRO05_65:[?]:^2K_/"N>E-9%<O<:C171HKBEN+>XW6'##>GOL
M5]L%].H3=NP"\\>:3F0K"WJ%%?,&.CMJ^6X<Z8H4=7+DYSPZUAW\>P:2>Y(B
MXK VF__D-%(=)H20#\U=\>A-]<.:))=YM$V6WTU3"<@A;/:>,_E96\8;OG?-
M3)K23/D(PUT=!86F+Y=EK:!3FS7W-SHDFLT_/"3>,&JXGK.O]/-1@K?VD&V\
MKZU2<+8T#_*$]V8E=*Z'4%_;&-\_CN7HM71\-2#,IJT@)]$=34SKM%,[8A$[
MV!XABL\@/H:OIE<!%PDKECA4XL?:'D)UM6[IQU/FACM%!I6OOZ4VB#(R:7U;
MZ**"&%X#[]^$(K&?RG'A.\LH$[Q=5?-U7,ZA*Z;>^<<3\;PE3K!8\&G$-EP5
M#R5D ?-XM%G]9\J9T%?.P?W=R(8NT2>.O3S.I9KT[)[0H=Y;^?:--''35BOP
ML"17DTY&ELX.JUT,F?O1FLW[-/YT[;OTARE:EGTQ*;^EZ0:+JM4YRS?227RN
M%(MBFH*L31NF@LQV*@\GTBZ<SC@5Q_;AN]R;E$PH"'0Q"_8%]E_>PYL3K%*E
MR:440>ED,6ABPP+S!VR06M';&<)T-PJ0@?0BA4.5(#P L>\$H&K]/L7<KZPQ
MS^5J<H\\(>>DH:3K/.\%)]+76[:( +@-X(5%QE)!)]31\93S29*3#1?:7U]U
M:PB0/Q/Z/>4)BQEW]L033N8/3,F4 ?E#FF\44]3%"VE4_YA1P:&77MZ6,1\5
M-$CB9962?^M)C*6P*.(%;*<[A #,<D?1V9S%[I"F XV\U@'.,AE%02K(S9P-
M,SE:';Y(XDU?J7F-2UA*<1'&C0S?]"Z\^,*<X3FGN/R9S^IS15N]*B89'WAX
MF"6$#[4IS"0HH;GO5"&[,(02%^*T2.);M'R7A57N(2L^#N,_LIL8@B3 Q^/N
M1V#51Y>O+. >0K0H#"3QZ0X=DO47/<'0<'T?C4HIH9H;YJ6-[5=<O)[K"\U&
M+;GYWE<R]CX0IBTG*%'7?-E^[+ZZ[CT.[Z%3ZK+OTJ"+/LLON!0MRW:N<)2+
M^C&]((D!7GB;@46F=C,JB 79$WFCP=FIFT #<:;8[/;7S KOLL7"9B_T1V[^
M! -^Z-E=2K+,*(7N*Q6TIVL#?9FQC^I%'O-&LI$BT7 ]/#.]%8[\O2FSCCQ]
M7H.?IG#=I]D[>NU_#1)92"X3%!7*)W'P=! QOFWJ84BNV?OG<X'#,F4ZS0%A
M2I\;[O?N.60M8)[M"@/3O500-]RF(G2Z/V3D]>;-RB0EWQO<["EO3O#4OJDX
MM.4$H1>1@ Q_5M4ZIOY3B__KF\,^/A6AR=@(&\ELG@&"N:W*:<1>SN6V!"%K
M;6&;KYXD&+D2^?T'Y0P5]'7@-<VL&TQI=NY&@[DAGGXB)DNH!,)CA8U"GY&)
M[Z75^?3I*AYTB6)/03?26;E\4+/-E&LP;#HY)1Q%>:J+H&'WKC,-/G+3A/ I
M];8(AQ4,9KI&ZEV^\JZTJ43"T'7?4IL('S&Z.^%9%FVG'&U&('>I($!6LW<W
MF@IJ$(A#R&PL2(\%6; 9"*A8$ )U0BRDF^JZ*VH;(EAWGO!<13T45XUV6MR^
M060D!0!K1.O-0E5<]\Q- .:<3%O<#;X[M@J,"U/R85+GRM:?UW.[=_MHQSL$
MIL\.D7;^;.4OO2SD)!?^?@VG6[8X%UK9?^)-WK./'7:E:3@APT\OZS_8QOZH
M.<?UL1-OF==B(7YC61F03N\6D6<>2"7=KMZ8!@YG>QV_=F7]S#1Y0$)B1LOO
MD?;)S4C73<B,G^-G-%RYTND>11@O47!+,UIOTD^WJ1O_X4N<";NHRENC'>:E
MD^^Q- =N<=NNZEO[K$MIF>?Y6FD3C_(^R8I?(].% _OH?+USE'&4"$+WJ]<1
MK ]V(O7>])7LU29]#R^?'X.2VZYYH:ZN3\['2]N5'&5N19K3M%D+GH;.=V?M
MX/+L50IPNS+G+K4;AS?-;8E7_=)WSZ1.B'?E36%HZ,)[]ZOD(B$:/S+0UP83
M0G&9^Y26J-[40!%JY6_NWMJ4>)?@^^.4Z>R\:J$_+ >%NZ9\J,-U'#FM:$,%
M61SPD15#*RE&J:Z4]AW(+T?;P0TUI*#ZT3 NB\(2J-D'B7<1!-(P/+E7Q:7?
MQA"W,%]7_61'+>=T1IM.;WD(S:JNP[+LR%Z4#[1%<1_)#MFB<Z6"7L79/LL\
M'P2+GT(Q44&N[Y'+V=DK][B!B&[ATMH6M[V/GQ16/;)N*3:H\ES>T1)U^XW^
M(8QY"TN'[!D@)&EBVD*;S7711E*D==1WI#.&'6Y0%FI"\,6ADG^_9K^)>+RL
MS3:72R]SN^FMF;06P4Z=5 ?W!!JQZ32TPZ..2A)7>/9^X?79\T;YI8VM^08,
MKG7&[\37% )ZL\A,),\));510%:Q;^3UJ<6N<%M9/^>L'C^:S7-:F\4\WY"(
M,=GPV"JEC?YB*S"YY U)PO#\7B=!BN\MZJ&\/(35)W#';#_N2L@+UX(E9OL2
M/CXX7^A-Z/MS#<8%,:HG!$O2HY^2G2:=94_BV)M_HSB?=Z5+,N!+G)E4R"DS
MUE*'BBXFJ2-6G'BV>U$HN*?U=#Z?CQKYXMC"B5A6J60^HUDF_>B^,-CVC;*9
M>YAZDSX1Q]_V23H77G^B!YD\]_/=-P[;$>--A]ON:Z<_I=Q&T,%O32..P^T_
MZTE[9K;6H!X\#F,55[I?$/4N.GII]^J*KJ \IZW][Q7O(+](;X[MXJ1;[XPR
M-<6$1-U-"1+3>'O85\W.L+560 RWL_%]U:M=NT0[B[Q:GUC8_KO<T@KR9/YO
M.9Z/Z@E.Y!2*%&5\.D3@R&GP9>C-;JC<FGU+:HF-$MUYQU[6YR6@F)Z -^GM
MG=E,/W3_P@]=A+GE, :9$5C^:L36.KN5S^Z6-[.':+0.OFQ*,B!78^Y ^2C#
MP;.P1&13,1X2WW@C]<V"3$MCIDAU%?;L'>4S(AEFQIR!C=%LT84F! G@\1NX
M)KD<SA%1/F3-$4 1X]^&Q#NHRSH\6!@^9<9$-.5 C".[KMU*]ILQM\LT.OYR
MXM?:Y8CSN;XF2[WV2[*=/"8#R 0&46[LOQ-!OU+Z&3Q!Z?1\E=S[\O\G&21:
M'EC$S5#.P4_C37JTT/TYE%/UWNXMYP]?G98^=R<O5TJJT"B\E)<.!]N"$47N
M8>H:UY(;.1Q[<4 ,E'O BZ>$?^18KV)*E=G=X&^.']>C4X(NK.Q>.5,VWWGF
M_T(L^J\\I_(O>T8Q8P_?6\IM!#^8?T1\Y3EUU6/\@58UZYEC(A$1$0[7%Z9D
MXJ4%;8U87T;0=;ZN^,]_5%'GXOIYL?[P15F>3^B2J^KE3-%(!^%F]_+UH_LN
MQ@4^?%4>!;62KRA70)5/_V6^#H//WW"9RB?X_9Y:_+V@3&:V]_]/S_'/N< N
M(X@K5!"2T@A.7V1_N!X4J6IGEWNC/DI(2=&7^W)CM['>W;B)8\0 J^;SAUS#
MQ"(CM:W3Z:O[!%^:^DF#6P&*Y3.AJOU3Q?V%?'5V\0S9I$JB:6Y4!C2>,_FB
M=%0^Z,U&,1\Q%B=+* 0@1,/U]"#<KOU\A:-$1+7*.CQO\T'HL+$9>\L*_/YZ
M5NH,MGUE97I+&2>UTNJ\$1)NB5M,JE'IN3[.=R>C!-*G(\4]FG7P&/3]@9CW
M(1%_$$,Y0^E?%!>XED:ZN4D1>2$_S+898&BOL14HFA=8D'E&7MH'A37(&&P[
MK9B^L>@R]6N7PS,\/?%W$OPQA]RL=UO2Q:UX!A5M!&O)]-Y^4 0>0B"0R^[4
M111S]+_7>7R_+B?"1_YJE.K2F6U15UG!?6F=)Z,OR%^ E95#G1 B&Y"+5<J/
M.8F%,K,UI:GX"[YOMI'S0 ^)/25S(&CVJ$NZ6J$$F,=NSI@2;<7%W5+ .V8A
M= %Z<;8(-1.C!QZ+"'':"+HAAH7M$UZ--1:<)CI.,-QVFSB->1=_/4NT;H"M
MY(KJA^,B8BRZWGORA&YR[F_D#!BKE/$:,+_^+N_2Y/Q.@_=\O_;PC>H;YD;2
M&7'B;N[9F4;]2X%1^NAUPA]2PVH-@A\1 MS=N!I9IGS2L<2C8Z"N38FIR<[L
MB-4JZ]VLWEOR$SVU>7@XP+*\*'9OJ[I:(G/ 6NY8?%NCMA!.2_S>=A8]R+=S
M'19'!0E"?DB&P C:ZXM'-L<1:;3^R4@7=-"%OM(<S2P\G5]>MN+NU08N1?C_
MW9:ZU<VD+:1%$&D(\=<49N/._Y7^SCK!JOY('!C%\R\NRW:C^.!F+2D65! S
M!:7[T;_)7WKH7;QJVJ4PUM>Z];"1A"T\SJ\?TH0:J/Q*LJD<J0L\78V^9[%_
M]=3"&VN%F%<F"CSGC"<L38_;>)';:2.=LN@\@_C@HL[_QO1=I,99022[#Y).
M%M\)Z^_0H_T,F9U)U<:FXKI:5=:Y"R\X=,]SQ^Z8C7ZV3J.AW,)Q/!.%Q1W'
MY8@KR8%PE6%P"QAVCP_M.3]VL#F7M(B&UD@V\3+=1T&@7Y!8)*^>&#"^#$EM
M!"<4ZC5Y6\",D#)/:T-G5?>E>@=V#3="3@E^T(D*D">*HE>S**Q>5)#L[6KD
M5VU:5[\<RQ=40YH)*Y.BJR";M.4*NEYPUQ.SQ_B6"D*'8G[1W0QB?UEC/X#<
MDPY-H'1-(X]D*M_\M5QQ"7D1@KN:?GAQ6XK2U9I.24*OW\&\0 *G34@%P1E4
MT*UY$RK(</I7K9UNWTF<%(5UA0J207;!",?\R'(YF%L0]]%#C=$X#$%A'7QD
M)H: T.;:"?D=#<A3.FE-++6>WJ2"MIH"B1IPQ0$RVT4H)=/$8.:8%GHNG6(!
MP9J08W.I(),!6 $21ZOHD)UD16M[I!059-"*_@+]QR^5-7&63\%P-*!XJ!ZQ
M2&2CC<_127M:([<*B.="J2#"ZRG7SVX3OFJC=(#O]9R]]:30Y9P5K]!J5[\G
MWZY4M*4;60KM[\DC.I%=T#]9!'>16XI_CCY;N+C3$-83*BCS[ H74="1Y@)+
M%.DR')Q#>OH!IT.Z+426&6NQRH]\*FX 63U- 2YRWYQ$GF+,W92E?:M -\3T
M9VWN[73*QPY\3^CZ!4SB>9NWMG']1^M;.NYA[-,WP_6&/2(>(".U05?ZA$EC
M@;&-9NQ#SRCU.E;"%LL%+D*V*KJEW6]UF<^_E<3D8X#38%*!2P%M-JII_3=*
M]@^G-_F)C(,L9<..W8=SMD(>_^8PM\4K?$$<V,0@3TD^0Y/>QA[7./M3>F&@
M1:B35(QC"ZTDF)!K%=3"E.##Z>R;E>7.6A^]0FX'8#7OM&CQ=$D$,6F;V4QZ
M'Q6B5[4)>X:/"<OXT!2?D:GD;^$%%S]F'>Y?42+&FOQJ1GN'A\0WZ)KTAO=V
M&,5G^ZC/]Q8$&QP3$L,<M_8^#&M]#Z"($8CQ\S=TO\2ON!0:-=TPUVW*+KLD
MA.,-3CN?E1*6*6[J,8+41S9Q3(Z@MC!X#>_+!DT)(4)=73-R6\@>;U&B_7<_
M$L^5L2%HZH+2^Z?IC?K+JZ9=E.^Y#P2D?MJ9K%S1=A(Z6$S +#T'U_5G+_]L
MJ/8PZYCZ32=X0YT%O7,JNV1 H;9[G2=EC\YXX#+T)BF9_!;C3H813(#')?<0
M/),UIS^KAT14"Q_XI^U->5^W_F(F?=ODN9"[6X;_.]&E$]Y'D>AA*"!O\3Z/
M,DH1:LT">SWNG5H7VJW=JAF.WLZV1L0D#G[S 3L@/H"%?3MTX0RXW;3&X.M3
M3\Q<7_/1&3C/%J0 HESJP8/149JW'J+7,(36R49G-D(;$%?Y,]?Z!FQV4T5'
M]7*?="JA1D@P0#!8*F,68X]<RLR\M@AJMQ)9&X2>O&8S[E_7,)\^AM'2._^*
MAD^/GVA/,^),7_'1.2<E$>O/J/]OJC(RB7@1V:74KHXFZ37A308JMZ^,WIRZ
M<Z-HO$HZC=Z5-_;LFEK&AYMWF&4>'(L<$UP#7X-;XY1)YYNWU%=@7"3E2>6=
MLEKC<PM7+9UZ@\S?O<R8Z'\C,&S&PO[RA/%R[/@OC7=44*(X(XX*ZAT][NU"
MA[<]'2GKW)0YM6R[?:M&RTWW^34AZ!VZBE6Q]$X_FAN]-8F+6%FMQ(Y L2^:
MJBCB_*\6KYP<]*UI%K^[_OV\BFG7E>-T#B#H2'XTK C&"UEZ!JYO3MGJPLDY
M P)6UEQYWFJY.;NCVDLM&>G7\J2O1AR0)H$,HN"?E'5UHX]A_500:TG'E!J1
M_V[SE!H/=EU2)_M=XV4WJ^C]%!W#H/O^+BLX 0IK,98L:]V(6]MF*AMXL[[5
M?58]0O"1P)-@9?56[(5+D%!CJ5LJEURC?!8?2B-6O0C^ZU/\L_"K-Q3OF#YM
MEGYD^1*%D/MA.?;;0MMQ7%&]0')5>Y@-R(P(P]["#_.^$1(3?&#W-(9Y0X[L
M9OD/.*818I0QU)ZCCCGE-YJ2V><BX++^=^$,Q&(.LLV:UBU2^O[ 8\QW'QI\
M1V=106//K(SX9N$__UFBZ[\_>+") =&462,@1>F>0AV=L]\M0##"_SZ><3@@
M@A061[TFW_X%IX(R$%(D;YJ6TS?BM>\#?_Z'F^.JV-W#8QCR0UJ+#?C^W$[_
MV^*_=E_^+S?A6U GJ*"!3S13!?,BI3Z<^.^,US_]V*L6(S]XW_SW^_]_>OTW
M15ZZ\7]EU?^O(D"=_*_!B\/9/WG?X"P3.DSX= K_U'/?[64J2/2XEYO=H<1$
MT:7,?M/UU5=)]K(*5Y\M6\"SB.J(SQUGR7EZ,G.A^SUX<M.8H<9L:JQ>;UMC
M -OI+;&:$D:3KAY.?>M.*L@6QDT1#=7&CL8&@>E"#Z 64..)SPJUY^6&A@+2
MTLY9?8F2Z_PN3#H![-+LZ@ PL"1"++!9UA+7PNUK"Q8;FS:>D=I@R-"8S!73
M-#3S[;B9)N\P7"Q3_'MW&;F-IJ$'V['E]^-P#_=7+A=C9=)J51R<^N>G#S[R
M7-9U#1$G>_=!?#'IM"_74$$>7$*A\A;XCJR*S=:/)WJ\/=Q#Q+Y]VO0_63!,
M%QE[+RMW5FOS!041M!@'X=4Y[R]3GD@Z5;D>>/G!9N!M?Q;PP2QK=2E) WA<
M_8V<;H1KJD3ZYX<%$U2'#D5=[YU2"Y!HZ;/__1Y?WA6"Y(;<1?.%*E\SSCFP
MQ6U]F9-,R7WG&(E#DUB-K(#I)7#W*"!;OJV*EZ1,;+B(()G7550.F\/;V$)2
M60X3FP8+\L3H+JEVW9["E,N;>VYMWZY/T'-BKJT)T[**1@T]_2J-Y'O$)^-P
M*XU9G7P=,802[A BA0/V11LWM;\V)RK<7TJP&_^0\FW.R;A([#GS-]=@ZP]
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M+Q:R;Y=Z:S9I3$T)Q_65<.M[JQI&F;"]66-E$W4KM+!U]== 7E&SWXO!B-/
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M,^?DD5W9$>O *G)KGV@#]R<_[U!W).D S:\W-(49-'N@4P_?&]]M]=;]+EM
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MW@E*$VE*[Q&4)B*"2H>@H@B(- 64D"!(;P("BD"4(DB59NBA(Z(@O4EOTA/
M$"#E#<^=^?T>GW?>F7MG[G-G[GSRQ_KCG*Q\]]GG[/W=:YVUSUH,=4I6Z-9\
MNTX^)(M-^V.W!]DYWX6%"UX?<K_&D#B&3 UU"+HV00(<4&.QY$%8KK.%$VNI
M?N+KTW;N8I\>XP.[0:P\M]<AMU>V1PUUQV(F7\H!8[ \7,=L9VSPP:;;:QCZ
MWAZ9'/*4&O)H%&(S$%#X9&9/1ZWA >D$-<7R+T,882*^+NVCUU]+RZO]>* Z
MI>X\G*1( N[,2D:O&L$-414E-%A'W',]P1](\-ZQRYFYHK G>!'RH,UPL9J,
M%OJ *WGKE*(7>JSN>^^XY6/B$WF.#<E[^<(Q1;W5M(DPR*O04[4YK7#T]<FH
MH?13*8N-*<=CW_W(7?R$K(EP>35R:/9KW)THAY@:=H\^L4+8W:4]?VPAW#7;
MZ;G&P/S<>\83;=GI!@[VN1&9\5_T 1^%_=OH%2+=G:G'4)K[DVP*A$M@#MN,
MCM-]6<&NA5Q1N^<-V$),Z[B1@/$XX.F4%;A*8$6[M6K(7,.)O\'?PJ1^NV?F
MLR?UKO#)>NM-Y-:4I0W5]\0C'^H,ICR-8'9X<W*O\NQ:WW?G0#G1Y2PC+:WD
M26*Y1?>:YDC2*&=41GJ>E;;^<IYO'@AM<O >I*D,YX4>PCJB*_HS+Y5^B+ N
M7-OOF/IPXV,YBVN#8.FGU7.!RUF'GD+.$%O 99JO]G6A.BAC#O7WTVZ,S>RM
MFTUC C,&J6%2.S$F#G1"<C+*VH<.A]#I/&@LZUU%3>6BRHWJOJ6L&*$)_3I/
MSU5D-T7Y (4-0LM>D+>@,J:UK2E$+$^+P!&,+H($T!9'2A_:5[\+4>S%O& Q
MXZ8ULSPK*^31C2X3$"<![*BIM$E _=K4ZS7P-#%076;FM+W;A_%F+X]3KZ[>
M,75(,3<W5Y<#I5(_'\!OCXX[$[D&9VK+XPV/73.HM&0>FH_G#0,)QNKJ@IZR
MK;ZT10QKOLVU6%+D5"UZ[YZ4Y.VAWF<D<3A&.=.T:[4](.^0<'H@2H H2::7
MZUEE@W?[8 RX6PQCM RG48/JC8O//:JDIA_>N3)5_CI,/2]=8@Q^'QQNA8P@
M 3<9P+Q.#N0Q3N?_,5)D,3%QA'^PXX[QU7I[6G^M]@N0%- 'I:;B0W@;W(Y
M*.8X[4;YFIQ19?^ITA<S:C5A#N$L2D#TYPS=Y\47RACIY]BY"H?'-((,R(\T
M%^K]\64:I'D"5/]L<5[_P1MW/^CD/8]8'-.LK3 $?6,C_-9%.5^0_KU&WL"O
M[EDQ4RSM-),T2W9(LC'%C3N"/MC?2"L)]9N687(B<@ZN5?#Z*;>E,7K'C>O(
M5OE.G&[*E V>X'TPQ18UE8+K(]+MHI'30ZTD(.I)3K"FB*^_PIKFI&X2\<26
M,6>B/"?'#ZY=6<$[-T\>L3B[M)%4Z!)Y#5N,C<<MO8>RX;B],+>U^T[UD\>
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M1'[M>SAF4/M&:FS]JWKX%@<L-T*WIY/ER@"/=>#]V5IF\NRX@JO)6?%>;)\
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M!C]- LK;\:G&+9/[W INA#/QJ/P(H@D)<(K=54:$H["RSI-[-T2<+IN"+4G
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M4:L.!Z7A2ZV(\7"'[EU%1,@D]G#YP6N^721N]X!T9Y3(I(LB)AE">O567Y$
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M1K1SWO<&*=$ RMQ<,UPPO[7O*6X&$Z(W%1-="EG6K)^D8)34A=UH_K[J?H,
M$!IYV2DS3IR&+=[GPFQVP!AD#*."L:U7BS-S4QX_GY*%LP\\EB(+[4AHW"3W
M5D"$(/K!<R]</&&>L.@SIB/1*GWY6 Z.6TY.'FIQW-=(\P4QM4P+*>Y2I9D@
M .I:+<MFMS+YNV$N[8U)<V+[:<S0\K+TR#>?L.8/+$7HF9M:-(-FXMK%\6*8
MQ+;HY;=0ZZ+MT9U4T=-$V04]<1Z?C#30QTUU(+5T^TD5;/7PQK8=5SWV92E:
M16Y(HVUV#3P22!E0_3>\^M6'][R>@-3(?M+\GP45^:7;<TEY9;^M=[(-)LWK
MS5VJ-92IJS7Y7DF7)Q66"=V)H*:R=[-3PJ@F5LY!K"VP3#D.Y<M[%RH)9]X]
M_O+OYTV&HM\K>=H_[%!0)A<E,]?DX5'C0U&?K#6 N51O62P3 $Z+N MU^!I'
M$76!U]'W5<K %<.JNU$1FQ5C-M096.N5@+82C4*7,*FQ.O;=]'J1$ _U)5='
M;F?RN/6W'0)O;.<'[N@W:]U2=/Q$SD9T;*3)3?[G8CD>1"$S/_'5355ZS,.+
M(4-RJ&2>+SSI<\$#!;S('_K3"MPREAA]V)-Z\0#*UY@F(M/$%MH?82BZ; <;
M<DI["(G@U)!0-_U0?6-UK%6! " 9Q^BYI"8SX6J,/IH[&N^_^-[W*HWV#Z"Z
MH*5$^89>^@SQY_G90L0];7F'X_KQ@_&K.:4AUC3T;:VU-#GJ!!4-R@C5C!?M
MQ)>?"("7>7 "H.:LYV/_"RSY+A<0\6J#CTP*5GA@*!%:QD3!O;FIKF:SEK"/
M:, ;H<7D?ZBR34%-RT%9#H56OP*E#M<[HN<YUZA5=A6T1M331?17P:2=Y<G4
M(P@+[;+[PA1RS7$VS%[-[48>?Q50#MG;97]SION2\>JR$G.<3\=Z?- W$OT*
M-U34G\ZX,2?= $AM'\&OWH8Q0S9&T.9=2"#DH(](MNQ!L9/=H]>I;QVN%5"'
MU7"\LDC<V$$IQZZTW)6- S'OW[(E<Q':"9U_:\:W$$PU_'#@N#)4E1>JDAJA
MC0X5>W]\X_2&X14(3 +KU/^ 7+&%:/IV3CD^V$\E-I= 2> $9KK ['A)S$A\
M<MQ)B)BAW;@H(N]*92U"H?*SK@7)40:<U"$<_.!P*?JF>SWUDU/M';_7?"75
MW9UC'<(=:S3!-)JJ2"8"P'F9'O_P\A/(=0P#M)@"/QT].(S)$R5I2+-:(9ZW
MZ4[,$WLOS40<<9ODDQ!7;<;]Z%A6&\%\>$0$?&3*/U1$_7N6Z?3A\XF]SX !
ME>YX!IW;':('ZDFA!D%7\=@&U%G<B>GH,1>[R\S9P3S=+:_/@:EM-*1_"0"4
MPK76U6'9^\Z9?QS>=,M5P4I^J%WDI]V@X0[22=-,5"\5OBW:5<KX$5. SHL)
MDX9(+_>ITEE'31PX9O);EW2_CHFNKS>U[+-[?Z\U[W2$ $AWPB(O?6H)@/%^
MD4$"X$4R,\2Z$U9#^K$,UV)>._8JY@NTW7]MF\0IH9B<M9\DM\/7K.!@X>-.
MZ+;%U7^2TJ>YHMIY<<1]W_91"-KM\Y6W@3KU@5(_M^XG-/,RV84^K 2M'KZ!
M"F&Y5LSJ5L!LN_HKBW=A]W3]R=(>I!%3EFP-CZ=\U ?<XG-6IO%VHYLQRHU>
M\6*&@'OGU-VO:*8\ZA(5M1PM]YTL'19:I==U.SDZ-YJ%,5S_<>)OD]?#O;TF
M:]N&22\90_KMX"@V+:J]S+/O>IE-P\H;VG=!S<LA', O7Z>;;RBQB?S$*V#S
M5@3BZ]2^X!QZ%9^4EDCQ>.P?\J29]]G"V24( *)?GI 6-/!-*[$'XW)BW04'
MM=  [<>AJ*A^[:=OXL22<*09[P\"&,R55A#,.)/>  $33$R-<\6<T)Q3=6/2
M"F-53F&O!?%>4"4\Y2;C1C8!T N+"F.:I$Y'@UBWSOUWFK0B0K;H'CV?5,P<
M=)BJLFU/KG1IY_EN8-)U'MU>['1/W=!=V(#>H9+CMLG?B>\VD_E-R72X:P2F
MU ]2?HYP/:=;DM*ANIPTRS>S<>3)R/)A926>_JYLB(6M@"-.GHWBK=&+$CJ3
M=T2"F,U]-+G-+LH'?V605;TBUGQO,X[-ZO8B@JHDC8/O[)Y:T2W?%R4]\HO]
M)90XKT&;TQ*S.NKH7%+9O(1>.E@2:=$U<[EG"EG3HDQ*D"XOOS;R:ASNJXBY
M&M3RC^1X'YR#*2YRM05&6I$\1S=N62FV"M\6.)J-"#H(3ZW3$38D2X'T37.R
MC;^2 5*[6C&]V] 74QRG<&%)Z<F/D8Q[_4#AJ0+#G!G=PGQ^ZV$/%[,J$TYX
M;_M*#.N946A;>?_FKS6CG_*4$0YBC91W-EDJ"[J6!##+\7[K4WB1;W.[3.+>
M C4Y LF\]5L#K*>[>EU-39J,AD\G_2[O#=MJ/VN"#T\3->M^O?:^G.4_'Q+O
MN!*]AF/["0 7KS?22]<;O[B;BO+G$S+\8^XYP\^A%[ZX&42/J$EW>@=:9XTH
MXUU$>:$CC38)K<%79K[\IAAL0R1]]Q"J8>;X!$M1>3)A, GV$*GYV1\9^"$Q
M,B#@>+/H=0,!P'YUO<X)2* )MCW1O52KA_.V%TI;F^O'K#<C<O;!ORJ#1OEE
M%8ME<_%K']AFTW_2Q=PDI\V9;_;H4]B&XULO"V"N.2':EY_QP"*H+':Q"O-N
MS'6_)!0>XKH?.! B;+BI)__F(J7ES?/HSE6%;U'L ?0!(./=Z E5 ;S2--34
M'Q4JT)W)',9=+2TZ+67#:\/[R.?N.S(%C;-8TT-XS<IA7!X0;PTY#XR&&A3M
MROM\R?A2W1:QH9E 0Y&1^#N:Y,TG![[@F8%E2E4 E -3O,]: ;EXB%U31+Z%
M[E[$CFGVU(RX\\_3RK^/Z[6Y=U3P.L'1,7W2: DU>\;(>'-JJBZCMB&KAK^M
ME=Q.E\\^#E[ _R$) /"_U_H%YL+U)AGRBJR;BFS8KN!";T%B(N"RZ?27WN-
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MHA?6*#]QBJ"0O\E6(R&K'350<>S-@70K3#ZQF\WZQL3[%<6CQY0!7)J"*FY
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M='E)'IFRBO[T!A"7RH3GPH\8+S^'D:JL?.>BD>%2"$[>%_%&&LR?;L[+3KF
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M@&W+X@Y7RS(H?9VHKY^GB8OM#0-BTOAR169>R9BFT'T]W1&Q[PAF9?5]@B$
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M45\W8F=)R+#+.3?R+/E>0XV3_]-,>^W*LR(K_#*OS>JXM_.-B(+!&5T%YZ@
M5Q [[(=55E' ;;[\;4^DKZ/EMM_U0?:5J'V'65M=Z#-2"Z7.O!=U]J]2]J@"
M1O4 )QQCYTE61=AGMW[YCNR,.R,2^4IQ;\H?Z>A/?C]C+;@F)+EU?: \(TB[
M_6:M!HVNODRD 7J&KU3 U^U22FP#(B<@93KH\2CL-(%QT;R])/VHA[_NK;=G
MT.T2.P.PLHAU9WU!S2WU-$JY__&/Q^O>?S]U(S":$1R792/RN0@0XD.H2N90
M[5QM"UHL:6D"][I0*K*%ARESLUVJD>_!MKZ,J9^*%RP#UE]059'2MBU)84=P
M;K7@*DM9IMX)C4S=(UP]FZ+C<&<?V,@+SKZ"M/E'YCX1RD%HQPPGS9^JPB%B
M)G5VB66#)C/Y$^MW%CA>)/M61#3JW>)K(ZW]?=D# <_94HBDD/@_ZC+,>CM9
M)W7U<:CHX628VN:+Z.*E%':19A_OYX5;2_9\07T#E&=O1$%M*/_39Y93:+NM
M0@6DNG0.GVQ_ID4_I5\GYHL+QYPW02>X.IJS--#*>&3&='5NN%]VRCXX9A&\
M'5(&90[3K*QI7FVN>:[_)+6=SM;:J/J6Y06WFL,V7_E@Q:.8;1ZB4L$T]WZG
MG+O&U8:1&D^NM= R/=%YKP?-2E59]K%_.,._IX3WTE7"I,#'^BAR2P%9'OT1
M-@OD1UY>AREBT6T+T2<9?]#\6X\,?0+HDR[\0#^NN=AQU<[QP6<7R?X^OC:1
M\0Q?PW,>._Y(F@F_A$-Y8MJL/F-+9[8.F]7TG>H:LU8&A"U2J\H_/;ED)LKH
M:J*0MFZQ@#5$"4#X%\))1HO;.IA*Z1:U ,\KG_P*KJMU9]SX3/GCFG!J\MMA
M>2X50! ?CBHG*00A@JF WI,\\F%F33W'@PL^=\KC+?:5<V9T5*[$((0D:;X\
MCE*X!").Z^XU%\TM'39(3\2D$))ESY,LR+4D30P-&S2UY,!BW$("G%Q3E-/8
M#/SJ)H!RB_?2$3_TVIUO_5@="MO&P"?K,;(O8:($^!(XW$O6_^U--V%P55Q2
M=\N2WA3CT-5GX-;TH(NZO$(0R#)J*P4[O%PQ!CF)R+V'$VZCB?G-U4>%9\7C
MD):GDT\Q6/,*? 4@7JI?*B<YD%,T0,&A&.%O""&_3M79B7#K7>?Z4(.IQ-.N
MA= W5W3-KCQ9S&R7*N*7_=XZP5VW]H$R15'%@;L*$BE \ML66=BT<X':C#31
M>TIPS#9UPQF0--+.+2BA_DW]F03B\3C('CQ% 9_52"G9,)>#O!34_=PZZ>!,
M%QT,_[4E_>L.(^.IZB%H O%^L/+=";CG5 VKD)W1TP^$].4'YHUQF6+)$A4.
MX?+59==.:_?<3P6HK.><S/R#%)9,ZT/LK>H_]%(![;<UQ(+?[K0\QIIWU1L&
MY@/!-5->J?TK4KXA'%VOJ(#!V]U\=]KHZP5Q)VJR"5#)"RD7IH=>^UZZ/H!F
M^ZLBBNFY-I0*P"KC#0D!6*8N\_EKV#Q*,3P,[NXQN6# \>7NJ%@BET.\AL'E
M/;^Q1#\[B2_P]EL4CHT7>?-%%-&)94ACT9M/H;Z<?=U?S\6(\^U:]G<WSQ;[
MIZ"D%&UE376R#5JB<1<Q.7S<=U@_7'\HN>=-.==.!5QA6@*20S5IX6,>N4=@
M)*H2C/"A7R>DH-*?[#;HK+(DKD!Z$C/W3%]&[8V 6OS>H=MI7I7U^!KX(A6P
M.<U*%CY8]K*T$/ZC[DD%2%P;I3U<[:0"#/]7A4=VYY:]C_5ULJD L!+PQ,OJ
M"/5W?X:H9?-W&5+MW5;[O XZ!:7#2BZ.Z8<N,UL_J*]KSA^3O8+(397&S Q/
M"PKK40%FJM UB<.CK;?$ZY,DEE$4YCKNX> P_\;S[;?M<T*OC5[:QQXXB['>
M(*9%'?M:[[O\I[Z2,DCB)31CAI/AK)Y01\RZ>MS5Q\R_D5O];OZ,PWP:4[-)
M*6_U;@F=,M=^7X@L_3V?YQE&]*2,G'RWDYIP'FMAPPPK8NHM[V[7)749%VE6
ME4FM>*=AG\LK=,0?&$V;XT$$\T7OZ/J"BQ2.^:$2=Z0@VZRZ#O:[>*)JM).4
M05%<WL:3B';>?GIH(U$.>@:KW+T;QT\%=!;$YF3BL\-*.D5G*G*[!0:OM"!M
M!J"31?V/_"(BPXWN^!PA_DF<S26NM79ECFRCOAUU,X.74#2O;X6[T+-F.N:4
M_; I+]?O.YYX7V]EO[7PV:R16?\N^)%Y&I2+((LQBM!@S6C/OYB_L3H:^EE6
M+ LWJF_GQG7QW<?+X=R* (;M3;MFFVKW$_Z*E/[=&:,EUB0-4>C3$9 SF'Y.
MW\U;S:KWQ9??9JM+1Y#WN=Y7KSE>)Z@_2]><+FE]L4 Y-X1]"I5O<OI1_$6_
M/,3"4]-)6SAPH45DTMQY)S#=6M![6'$_IBOL+KH-CC4V,+H8'&\DT[%*-/*1
M:KE>//0ZL+U?G4%7S.4KV)V<7E$JSIE^26RF\?@4\7(PH@?. '+->XSWQ-V>
MF5O/5K"U[HI*R>0::KJ)F[U7_K [7U'%>+PJHZ]\@7#-M*<:@MMO-[<3"N$P
MC3&H#56*(;LV6$\E:H.F61-#QVJ8FKWC@%CCQMH4%N4\1Q>XJ/Y-QVL\#[_N
M"57=FA[MK5'6:G"L\(+-@O;\X1=H2C_SD H82ZR%+!OU97_; #*#%O.17%]'
M_<$7"4<VX^#NG\/,AVUUZ;+58O%+6BS"RB[MF(+G_2N 6QHW:'9R*MLV$O\*
M*S7/DX:9>&Q8HV0DP!#0R%,=HFV!/0NUSX]&.93MT>'W4#6C*#=03$XQ*=^T
M(B\S<;21?CM9[=@R^8P1@*-;6Z5>^GZZONL+*B *OIAGQ]B +0-U)049(W&>
M)V^]9+9+C#D54&+7TG@'HT$**H.'I_SL9&G8)Z:[X P-^Y A^!!TY?RR44L6
M?E8W_1)/H*NSP9M?R#]9O'UM*SL/UEP1Z!DFHI!9S\+C,1G1YIKF)*=HUS?J
MOCK+UP<Z15ZR:'(1<(M,,^!8FN @K:&:<(V."<KQM,6Q25:6D9<-6P\Z%2"
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MF%WR5G^Q))=890HM3K@"H^<%"/I$7D)I&XR# ^[LAKL[DANS?^6JYUT)BVK
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M3"F) ]U1Q_\P80DHO)F30&CBPR ;N$>U\<_2;/2>=O9L$=05=OC4PQD9!ZD
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M%LGC'0L6.IS3>H0SBG?D>5N?ISLUX70A:BZ3U"^G<Z?CVO&=6T,AO5O6(4O
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MGL[\<SCS1"DO^W$4AJNV.6OIFI/E>2/(N=>=5SONJRR++(9K%JV)OQ\WT5#
M>I,X.C'=93;N8(Z .:WNZ>+QQ#T]P>E[!H([]OSZEL.!\G[K8#%H* 'B1KP$
M]<$&Q2/Y%FPZGP;5K8N^/6KB=3JG?B5<8,G?7FYV3U,\TE:Y/24&S GR5-L.
M[06Q04-"2_],*-O=G;:JYMH7"GJ#>=5 HU[W]Z.E%\2E[4!$<\HPY2+AU)(L
MLRN%=T*F5C_ PBD?XS4M*A8J9'K6XI<><];FN^7DZ"91&$3IV?^RP'2M?JN"
M*&E#"L%V%\13KD*4#3#,0J4UHUO2OT]-OKV0<5'O*2?,\=VB5^#P=8#X@?@_
MK\I-)(=3 2NS_L,GE+]P2>WK9^,W;[IO$026LSN#R$E(9<+C;CA+@&1&B:UG
M<Y0SM(]>GJ&Q+BU5AC"GM\7"&]DW"Z>Y(DA* GJ!D<+DSH^/%,\NVQB]FNMX
M/=_A_^#N/:.:[KX_T2@(*EWI("!%D*KT)A&1)@*"TI$@'2,@(#TD%.D=!!0$
ME")20T>*"3WT4*3WT)2:@(9H"H/_N7/7S&_67>MY7LR\N"_R(EG)=YV<L\OG
ML_?9>V>M/4TL6A+2=3[[!A<&(7MF3?)@J%- -_+/9CGLN_G4+@QK(B6+.5R5
M#O^LE9[%W5NA1WLWW<8H/&4\EC_)CE25T;@7Q+\W3N0(M,%DAWTDE.#\_U#P
MQST>PG@L"IC5);6'>#7!/'IXG0<E<"YQ(R.EE$)-&1C!,F&JX9@4^L!D&S3=
M\^ 0FP2ZQ-^[*EE*.OX/=06TS2\OF$5C;B=FK% &[*Y/JNL2U0-OA,IJ>SL[
M-#T6_Z5?I9_4S=B3UK;(',Q]\J[1\.8OJK5U&'WP^QKY74\1$^^-".;!VFW_
ML1Z&V0[ARX-^(O[QB2:$M5(;$'0!U@"MYTA0>-=P2!WH.Q+H,?VHS:/(F]6=
M^47YD K/!H27/A%;^/7JOTG72/^KBIW0W3,X/T>0.(/SM+' 0_*9'1:</DI/
M6'Q=G>)!3D&(/3\%L%%HW:UG8EV45*MS)5O]ONTMY+LVSYOJBN;M\]S !#<9
M!Y/"_GE+UT69".0%TDVL:.=1H%S7U27;>6,_D8WT955]B1'!PJMO[C\ZW_<!
M\/4K^+CT/_O %,HVRVDKU+DNG *H3@'.Z'.D\S,*'N#.YC]1 U/[F.; 0Z?X
MNQ&*4IFW45P;OVA/ 5/'!6%(%YD$RC4RW(\I,3AOI 6[,9]<&K0M->!>TMRN
M?__66RS3P-=SM)L\@:,7H*GFIKNM0CM)'S]]])R/9QAY(:*E;.MZ0_V@3^6'
ME7B*:8M)A3:KN3-_ 1!K:OS[>@X_.=$?^4<W"*1-^9]],^+5F>RFPP;HQ\X0
MO6/CF>JH#?Z1P9\!UXP@+!,YXB.EL9[ 0H=1+\*3SC[SG@+N_CD3=)WXWQ(]
M!=2P-2=H=SXM;C3.:PN\S-387G!9P[V28;$OD+#CB'J+"+M%)06RIJP4''FJ
MEI)AEF>N;_QIP9YGG.C>P.K;C4>#TR=W(V0O*ODZL1C)-EP]IJE&WR''0Y5@
M71,$;=&H7Q4I<CT:++'6PY:;6PWSVNV+1WJ /E1&YB(4"\]'GB%>W F.ASPB
M\7O)XFT@R@A)3@ ^=VM<DE8"T8+;EEC.S<_[33H$TE;8:'#1^/CW&2_#C<_^
MK@,,M=+C=2(/W_:S?B"1V?CM]2^]OSSFK2*:D\#5BAG\?F8YGE1']H*PCU9B
MQ]V.SPZ0=,OCRF9FQ%.[14-UDUK>V\;UW>_].B'F3"36-HJN\7G83.8,)>D!
M.<39PC292H*>.8B:.T:XL#J^OJWV-]T9)\=I7/RF#L/(L.[^(7S!;96P5C"\
M*3?)Y^(U])9M^>V4]D['+,B,^NC2 AK6J7,HW6B<I,&*1;]KXOP9^%3I987(
MU+?^D=\Z+7_,F7KVE32QL/WUC_,D&;U]7?QTJDO$9&S1E[QUCMMA[6+.CEMB
M'3QOO<>"^4FLS9W-8X3L+GZ6ZSJ*S>PI)0,"/WAK]"9[+OWR%DJC_*CBZ"OP
MT1C2W37/_C3W?=[Y4UKI_>L-M='*UY-TV(3B[I6'J0( ;,'MV:LIO1Y7U_F[
M\X3ZK U[O+SEQ9IKA&C X,9'(DDHD^@!V_#,ZZW<AR1M#(@I4%<_UPYG5.)5
M_&.:<"PM76Q99/N3YVUXQAAC,58BK32$QW:AL'YCJN%+PWCE2 "K/XU"]C[C
M3FW0BW/FRT:W?&[YFEH^9^>N*@>Y9]^VLS'(2^_:%51D9.32IRT(UKIJ6M,T
M]8I8)?W+P&;Y/K;_7.=-P<QG^8O<)%%RX2G ]? \1(;P>Q4=#>5,/R8*]3#_
M.'PY.5CWD'L';Q,PNP#@%Z1W-F)2_PE?MB;%D1N?VI.K-;AL'_K?SVK5E P&
MM+[?H-QK_O!+L'",&+)ZLO<1"U^-B;^!@T4:DG)>X^%NADM=@Q$JUZ[55'#[
MON'-F%3XG4M\X@Z5GH&]6'I\%RLTP-=249*42*,XZQWPC%?V_$K7)R7[[;J-
MF0.S_P3 \:8!'GC6K"R->(()\2($2'"O)KCV(1=RD@YC7]VD/N;M:<HP:(A@
ME^/R>V3,KZ*!6%$E_"\/0-KN'LG]S_<P&AYG>*S4;%353OS?SU]-^CR_W/6O
M\U?P_ZBK#=K^)VT'[&+^=T0-QB2(%FFLXE)ZJ E66!H8_UOM[N]_Y*]H\_!*
M#..*O27X#]YQ:1XF9_Y&$F4IZ'FE?0YV."Y[O:_9N[QQ<Z&3GL%W4WV$T_1(
M;_7@HER=O.$'>WP'O/84\)Q!>MN<G*P0*Z7D%?-PXN"BW0_JZ2.-T(@R8!1$
MFRA.&4!>I-PAJ>3VS&^UE"^ %972YY=LYH8\TSX U V;]*XAG.\$V*=ZC\7'
MNK,/9FWP-X"ZVH!S,GUG;K((JV69LSR_XZK3!$Z11PFKV?8-7W2-<.YWAOQ4
M3]4!@EZE\!!@)MBM)(Q:VZRDX/3>:GN4RSOF-SD*J?:U7!W/^N&QNJ2KKJO5
M03.D_U%I^E47 ]]SQZYC*ODX&[\I&!H;QG0%.UD;EB_HLS!X <XI_4ZKE01L
M)+I.O-GD\-#)T)W$+XMAI_9^@%TKK(WE8RZGH7GD^.^>&X /,!'$>':]SV@J
M#8Q!#[M+]VF>1U3GXJZ/S*>C^-H.:HV+HB6AVJO\LSQK*=V'W&[+2I.-^W8[
MN_=;DG?$/H%A4OE"F0Q-S-[Y7X1V06K_V>FIP=0@5],(_^W_7EF/D9R/T>I4
M3FWM_U\:RRR+C%4#GX,6+"RP3$D*7*O8P^C\'<[]=8_7FHY13@DJYSZ].7#M
M% E^91NZ](^[XH%RYDNRDQ$2E!F$P@R4QLXZT!4T[ED:XJB 2I\Q=!MRO9FH
M6M?VT&<O\?R^,.^)X&2&&[>_?E[,?BE1DJ1(4%D=$4*!F.[CSX=L3&XW9+GD
M\0_'Z[/?=Y==B\G2HD_5Y*3B):\314@*V()(#;H?UJC7A5_J"OK8S5NC5O)D
M<LS75@%OCVB8KSP@\NG#,WZ!YC+P-8130/4/,/%N8/*,\=C/&:G-CK'ZL)><
MO0QUDBZZO%YI")/9E#>4A,#X4X ^01=;_^C;JR'[5J_(GT%\RRO"E)T^JDU4
MOO%]NIRX(6V>16_K1<)*)Q)KS!3#7N5=!C&<\6/B>)YM*C<@X.O.(NG;$N8N
MXGIG=@!= DG#':Y5E>Y%X5"=R^($UU!?AJCEA>)DU^7OS]X(8[, 7G'C8=V^
M ]3Y#*]6:#2N01Z1&PX;#WE)VKC-@X(BRZ4@.O?GPQ;#?LN.T5<PRD7:$J.<
MS9#WC8&G@'T0$4C06J6-;5<H(CA:MDZ)3#W+"HEJ<TM,V_-[<MW13$#1IMHW
M695[6FFKWNE.==J?<*(UZ2)6I@=.M:L!Q'',9YMAH^/*C%WLWP@[%T9],A',
M].A037[->Q7]$,)#Y*4,(1F@J@096QQ3T@;2)@_XB+V63G]"^(A4#$D=;Q&5
M#/F)8OO3B!NQ0EPB:9IQB7;/UP "@$Y9".DS-.1NP$5PQ?1K,>Q65+ LTC0G
M4A%6*6;OA7]S>4@[K.POK"7)=(+J#J/;KQ?2/@7J?/M)U*-.:B%]\7#57EQT
M6O7QGFY)B04Q&J? [)DN/V=/"\JFL$U6_;*L4;E]G\N3=NS^\/;2A6!=$JLK
M14\JAASC ?RIW1N2O3?E[%Y&&<F_-.F%N;KP]/MXKZ3'8+O/^<K2V<CX!^;Q
M4/OI*CXK(C7I_BG@]>3JTZ;P &GB*>"2[9W("*BCY\K79J\/YK=33B0V#N?%
MAHA:T+E@VBX#)=D?UD+=CAK='6;\SY'>WSOE^*<N^(+J3P&)&/(;*!"BB>6/
MW[I9C ('(U46MA#Y27XNIP"K9XOE:@UAC($:56<([A<VZR,&S4%864?%HO+\
M?.6STA[H,OB> 6CW-N_\UU2<M./]?Q9LJ_ISEX3]5IH/>PM8OK,O7R-(K);E
M=\%82G/]L<@WZ!>VG6Q?!!*%D]I@#Z.H4BW-#Z.1]J"PIGRF! .<3M$="E)8
M"(V,QMZ_XJ!RJW?0X_%DH(,WVM9B](Q1,@@N0=4"#1Y/;V3=$20^:(ZP,&Z/
M.T/;'N^HG83#DIG.C#$#^&RE& )/B ?;9D&<PH\/>>QZ&P8).A8Z7.;4UJL1
MC)HEKPH;:TY>',%FUWORA0G&1$U"!M[G6Z-0V??A$[#'<08W&OS.W#);6":7
M';.CMBZZN?VK#G&'H$MDA4@25-8K9&(U^+\U@O<-C/2S6-MS:.(>XAH>]CI$
MR!KUV<O.;BO_ #TS-W/*;96^5%*&!?ZOYQO(M+= 9)^#/,::Y^&NKO-5A7B#
M0SW+2BP7T)%LA4XZ:"':>=4W2;=8?8ST30[_LYAL;Z5.\6L1&%D_$ZF3%G1M
MTAT/=G_YV6<,S=+=MUY>TZ_^BYJEDZ9*_[.;8496Z9922KM,!;1[I4$GIB+0
MP+2U!;M_U.L=Q^F5WS]0MS7M\=%DSCM3[2Z73L<SD/L9ZK[H%983<K-?=?\C
M-6R&+OYW-^6R2OE"8 S&*X)TM;B@82<K*YU+R/AM#"+37%AYV_OH./F+?<C,
M&7/"/EJ U4'1UH8?'"A&C4ZY*8^;EE==X 'LO4O\ZI31@MH/A+G560TADL.T
MPL6J0P],TX1]4QJ[B?OS",YB_S3A<^<_6XZ)_=;!Z E8M$&_+<NTD=\B75,8
M2)($&,R;[> #8\$%G'TVR_Q"V'%KW86>1*M'S#145R[:,X1*$:5. 0/M!%I*
MYZ-3@#6A@'+9NV1QX!GV[,W3ON5+"A(!E.]!YK2@GMB%H^+BQ;W."EVMD%74
MWATLE+AVD%L-,6G/?HRC:?3,]HD]5'_3>/Q-M?"UBNLCJ(M#1]/+VW;ZV(^-
MH#DO?'O"VHV,2OTR@G&/KY8GR\:%IU[,H?DZ9K_5OV]TL0,\;=?/U=RQZ0#5
M\'<4\!(DM'!),7$*<_;3DJNM-"K[_I&"YX=&:H7 SGKJ$;>"X.98W3U:+*P#
M<6N\W?59!3@@._C:-XM4;>\[R#<NX9%]MKJ>B7?M&:GHU_/%_ON]^CM,__@*
MMX;$^@I!]*0S$'*AO.!R* )M4]^090-^Y_GPXV8<G?A@U#TVAUO^44(J?)DC
M_ZH=\13RS#!""-;H;J7@DQ02K&QEQ<K&P%N^ \5ZN;\D12ZHJL$QW3(8-_'&
M,[V-9VH/#.M4)'E4@J%4.&!D(T_TER;L_E1#UL=1R.=#]H=]I<2/A9*T#JAI
M!!C':\=&J"6""9'=IP!^OR!Y,N/$T<[@.)^7H&#6MD>EQK...!'0^[2(8>^\
MD1P\$^&&Z)^4,Y1]Z,X_>("H(1P2A4ARA-U7\Y0/+N/JNC6B^*A/E]Z(=5W"
M>&7=+0K3-.^CV0/<;!%1%(:S.A! >"F"P6I!+(6?D+W*D[!TPY!;-WNOT-';
M2SE=4?-8_QW'H5->#TL?K?5O$)[\=]+!I>_&N P]HNGN\O7IU8@?=H^FB4Y-
M[V8+/?J%>TH/6692C"2ZN-%],K/'ZR<Q")9=;MR,NES5B-L%!!X<T/#U;<>-
M>*6!B"=^#F9&EVRO#&K"2V&KQ>*H5?/DN_T@YOF,/8TA?S$+4^O(QG=11%5*
MW\I%/WZ:0%I,[_J.*=B8(:O<8E],@'@O\PU#A/K>(BU/??*O/T [-N+M(=Z5
M^L,P/D5ZFK07+7SE;7JDB[TA58XF3;^D);2V@/.[F*V/6-]51%&U6_*9]ED]
M?EC[AI?3Y8N%RQM80UI1W2F@,1$'XH2.\-<&1"%N!E[FCP=Q>,$/O=1U)HR]
MZ'U_OQ!<'MHVO$Y_<,32[@/@'-57QGL1Q"COO .P!KK?K@\8,/C0I#*&"S?G
M4?$7,0.Y3U+F)'I47<_.QC6%&OU)KUJRTGS0V:Y,H>SVEV>SZ4HA$4Q:UJ)N
M3Z^V-RHS_9N*B*,Z2B>4 :>;0M)>1\=1A)$XNEV.R<5N+Q:B;"]KM950^CVG
M@-F+9O./ +2<& 0FUV;\PS=8[18BW(_I>C5TV FDWO%:XH'0Z%%8*ITCEX ?
M'"5#!>PU7LC%0!$*0$Y;@E=7SEVKJ+QZC7Y,VJ 6][UK9L7VQ>W5^K1-%Q]I
M#RPM>DC%PQH/]_;7T'.C7G2D^P3CH(!/<0?S0CS#3F[2@B#%FX*I2=T"BEI7
MQQS+V/YX8$#,AACT7(89SJSC_%/7SN/E+U14?GWY3LK76IZ3RLE50&?T!<@Y
M+"*N\GLP^:"L[/E,$EUOX-@Q=Y]5L9FV^5I3A+Z ZZ+%CZ0"TKM*?KP G))3
M7EK^\.T!>@@TIX4/F$:Z*7M6MFM6V;I3J,:DAX]M.M8A)_5]Y?>?^Y1#&IY.
MR+ZG%X],U[4A6E)&@UWW)H/64F*1E_W4%O1<6VX[6 48>@0P'PL%%C\J!8N]
MB!R#F_)0?3\DW(@A9: Y3@&SYC)DYL8S"GA![!20KK*&)C)IGP**F]F,O/*[
M-FV;-<XDIZ\9B]K[AN05B>+;\;@R^D<9N?FN%:'7\R!D_\J@K.HJ-^F0G'T*
M<+$$NDMX.*XS]2594RAJ%<T1;%;^0[[B%V0-A(MO7VR9+?_@PR0 8#IS)FP-
M0TF/*9=62DJ:#!8"87>_" 3HY<P5:'3ZP"[OG )6"S2N3RJ YBC7N*>UE8*E
M/P:P=3&UTZ.WA5B^#Q)H9Y/[/KJSCQM;N.ABB7BI6H(V#GZ?D(+=[;%@_FX^
MX)/=&CHN(YD@*1U?(7C!PG#3LJ):\Y&F*.?OC'5/.(9I/@9?"@I/VSDL(AAT
M'^M3=RA?:ATWL!U]E%=U\T4OGV^#_:ISQ:_!78N)%UXO?BXLS$H=_#J_ZT&?
M+JZOIM.VJ/,Z8O/)%?_(\ $,DDX*P1KX&+72Y)J@P4W2_B;]<]?#PG+*CJMJ
M22AS*UWW2[C!@V2D*I_R1NJY#:=2B:99_5>Z,_SLL&<%$8HKC H&*S$GOI;@
M/V:5S;<&I+;?9TM=YK@]6-6Q3'/N[A=E92&!$U -4V]H"(:IFT&W&RK2&K*+
MOFR+HG\\N+D)MHF2NM+R(OU1Q6=A\EA1HP.LNPEZ^10PUHEA.D.+[J> _L:?
M 1VPN:&.4T#]4G6MU^INV^[,#!_-E_0_>DNUGKPZY8+)MP#'G/F75'8[2FY6
MV]BM%AY [X&7+^ *>DX!\T,H)&,[UZMI+PR#HTDSXLT5(1O6UN,2=^_$PK=3
M3=M;]A7+R$?0?SQ;IA_Y'Y,JR+ZEYE[WF>,722N$;.)M" BGN^]="K$?/_!
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M)?$JR,_$M'C"S?\R"4V((3(29K0)X4H]L#E4[VV"Y]:6O@O8:B-]I=_=Z*E
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MF)L((<C=*<<9=4N,64R_-%9SF]Y ])UX9?J#U;0O48"KG:)"WV7FJ5;W"U#
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MX2$)7:W?!N=G8@\\!._'1#D^'U _ KR$-(K35EN!#ZU_MV%T]R;78/$K;.I
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M?"8FA?Y;2'H&2\W)\!=0]06['[MK"T%2Q8$Y5MHK!U+4U-0LK,(U_;__A.!
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MQO&2_J+9*DO&211KYG]=*TH9(!;,&>-["$GT4'9"'HY= ;MSZTIT>_[W_O)
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MVN0\I!<D:H:=X-"5KUGKR2_RE(M79I#11>5)2Y/#9?Q=K>J/Y^P1\AK!I\Z
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M\2HXR$ !T!IZO$Y>R7-3FHF!((3V4_KL]0W8ASZI%(\]BE =H*Y23$WZ0@'
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MH+&=S?ZO==D*8_^N@!>&\;Y1%E$F0I;1\>DJ'/G:W1O76)1RYFZ$LNO ML\
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MFHI& <B*UO_S=_]_F3T-&KF0B8=CGWZ\EHYFXY^_NB3^)7DQ!L)X4T5JU=F
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MV20'Y*[!NP:OQI[^Z-2P'RYU??H'5\][*6C O-7QG=0;:GW4*\@W*3V^7;I
M!*L$P6/M#!#>^O3C6DYE)\.4TE9K4_-S,6"MB)O]4^;"N_#C2Q:JXT(5FV<
M@N0XZ9T-&Y%U ?$S+O9 G>;<\RKSDF.:D*>&LG8=T\8G&M<6\1\(;/YK69U7
M^M%[_M^?MX0H*B6;<"7Y\,LD"'H;\(^*T?F#1(799CY#Z?'5!":<A'5T;SX?
M[LXY$)/7]SQ\GOVCQ*N;_\F3%R&2GJA)I#SR1<%\=6\!__9T^V/,X,JV%I:T
MQ^'V^3 L).N1HE)\L]2;NQO7F5%\(C<$:LFM2)=Q*I+$%.DVY@P0-0.:,_0/
MF F\=/?0X?@NW_,,C;ZT9^QONKO77E\47ZU+^&NP%=!RFH4#HL=[5R."/:NJ
M<9R6=L*3^,>T-R8,;_VESA"1D3SX[B\F?$(X(?*3K DVV#, &A'7[HN[]R3)
M.)MRP49UA:'T:FG!2 XD72!=G"I%"Y-D33:9;+^R-KY ?]ZQ8<J@F%,CZ^U%
MI3TA_1BF3XM9!VG?N@:&= W9XS&_JX=7YR#KO+T%L?8*N/3HI'K+D[A0A16>
M)@/Q=%JG3:<7ZDVV6,"VTN/:N.;-D*+? IC*V?U9''!M*Q6]&I-=H;.VN/CM
M\"6DDF-=W"/3BNNY6$SQL*1W=]'!V$7NJ7&'-;O;^"<_]BE\WYRQK02PJ0>#
M 'P[YJ#$<W2++G3$0,*;7N)#=?X9  )F<86SD;.50,P$]U$9I0XUJ_K8E8O'
MC4J7;'.I#2124PS$9\]'C&+D+D?DA"!^9UCGA)3]33S-OW(&H%UJ:YRB7(8N
M4(ZTN3L:"VN_;1<6VD2]"'W-5WV)7(1P8V,C%.##L:"83B'HT %)]I-.*;FE
M<N%PA1OZRRGHS]VAR*04"_'KW[JV+U?[G'>9IXW-"DD15YFW],)28CI%E3WJ
MGIC-ZR[B)1_P'?@T\F*G( &(3\/RAJE?+T25N@:W\SO8V>@><:>-(Y04.$;Z
MHS8>M;-/)7J8>P6^$OIK>EJ"/<;'$)1Q8-O47C@ )^K>FG93>?BN[.$533.%
MBIN*]V.]+;U9@W;B)X#GWM^*= \-8KH=*Q)MALU];%PN/F',:%/2'L<5,2SN
M(9 L5K[.%R,.8+'!LG6!(H!,)S$P[340BW:QN^+=F0,EB'1-3)95YI_$+L?/
MZK[]<-4ED@22\(/H0!CNXIF-ZIG\93-=TIEE,M+X;HG7NV+B_;N/VK07NL6H
M:^-%%V4'BTZJUYL.0%@P>C8&W*-)/[-R_,1RQ3S1T&J=0P^XXN3&KL?W4U]S
MV7VU#[1@LY;4L[@]"7- YT"5+Q-"]'D,R[Z?]!8S;BDF>A/=D;W(^:0U5 _R
MDC6AHNM4P-*]L7'<8SNG;/.8P\CK1JW:%8?$CWI'J&Q#XC7X*(4'=ZT)1X.^
M,*J+L>W,WV]L"$A>O/N'U=$Q@3XM7N&A^NBVT&[H8M+C-BSO@1.6$ZU;PQ9-
M4D6_G7K<HO:BJ2W*YFER$I5IB;FNP_P]'HW(X-M]27$(5@K[#CZ[M,_XN5^(
MQU^CFXHZ,OT;YDM:EJ:+;Y;B+3:B#XK6?LV? ;2B>RE2!*&R'7EWW<VU]OJ)
M7X7O)9DZK[=_+G9@?VJF * 7:ZZ>VI.C(4ACQGL@M*LDDTFQ6<V)3W.[(D9C
M)2[-C;H!(R]+\U!B*N5I''4_KTK4_*T@\E(FA8'8&PWH'8H"8>A0+81PD%"Z
MR'^(58H]XF.,L K(94_QR2;S$*+1)F_ O'#J7?MKN*=?O.#"RW1!U<\-,'ZN
M-ZBEI2*.[S&D,;]4_2WE<0S"7R+H8+?1C4B, .3M'9G@$>N7/)5>M>J?Q134
MW[P]6O9]5U05VC:[@JP_]ZHP^36V><[^3BYL0'ZV?:H+=TOLBD+_DT$$9\TP
M1U_&BZ!K586V"UY&<@Y3".<#N776=&SGC%P8KQD8ZFP3LV&UR1$C7A PSQ23
M<IO6D^;PS6OY/6L\N)ZM>_$,P$D([YZ 9E\\ 3.BE!:R302_ZWD*G4_3+U-#
M<>R,A^4!+1LX>R"1ZAR&->\4G)!#SP!%'L=CH(@$7!-^"-?T>G/:QNAK@>4/
MB8X4T$F")UVW\WW!,F?/YN4NT"U6@,*'G$"@<DK-J9LG\25\]/:=FDG>_IY;
M+%^-KY9,=HWF^ER)<P4>",IUA!IX^'N$>G(?I WZ0+SCQ%_I=D],1)FG1VG3
MOKJX-KN=>2! !,+XOE/H/;)GPY1,]A,<>F\E!'$/&<HD*6@?/ZB#.+.UT BN
M79I#\=%7G"__8&C!HUD*56<.0C[-E;]R-$V@19HJ43K2]O1">LU/E9]T1A\J
MH0FW0Q1_0F+ ]?0];!&/44Z87QS:I2M#;3,_> SC$DH_RM^M&F)[T44S-_M^
MGK($K+NZ9.\!;5_,Q3@V\GY$ZNN3/=9!\^!N>UX"F:@-/>Y#\C[G[S_XF+&K
M)O!IJ>KHH</5*9""UL='<LL"F8ETC\B=FIPD90(8#;ZXNT(]Y?F[(N'YC83E
M>+%+["\G@EY=?//W]B^G*]X"$)HK,0T/;F\ZMK39DH.QP#X@/<D8NP^7QMXJ
M;/V4KMANJ%"<3,+EWI26*F(&FOZN&FJNCEYAQHZ_)DF[?" \UH^[5XO*]7PQ
M^"0#G'5DF?(0NC'K80D2>WRDN,9&*J9!(4^.J\X /W'@0GLF A&;A ;&04A,
MYX'FTE5*RR<&ZQ 'NKZK]UG%4CT,^<4.7E MH&9+E?\N8NDI9E28U=._LXC?
MT"H;#+,L40F^<.K2)^U_TS7XH,==@?T/+&[R.[CZXY6X;_0OJVNJ8K1O0\3$
M]Y/FLYP2+^:[O1?W"1L9\08(II@\DQZ"\\-\"1:X,(QI \&WBN6%G;BNEU93
M<_2SM*]WF2<^/'M0T)9?\. 8LLB&5B"I$ZC0 GL&8?9[GUO-/]*GS+Z.84Q>
M?LYQ4ZR9>VL5:[(:=0; 1I-X(#PK.K5G@ %>6?^4FSTSS/W4!2\"F_$^5I+$
M)J=5&^&=(O@4@MJ?+&$WZ_>+UX8<WNO) 1Y5>KSXQ43>A[\ZCY^/Z?VB:Y*/
M"J;!UYZ37(-P2>+;^TKPU<>9]8?XH57H?K3C)X;VO:D'I:2H#;J8M25>2Q^E
MXLT)3*4P*"'KB]N*>$<*D.UGA-V*35^_8ZN#F+AIF(KIL!>D_<+=M<;-4R;\
M%CE'DQ^F@A5.POR*#C;[6:L3G,'[J.]P8EBPIDT\0NV6D+6ZHS_+F#YW1:G
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MNIQ[0SR=^X*)EB70G32$U:W#'N.CR<7JVAAD4KY(_52[JENGH8U'VT<(U\0
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M5H?8B[=M=W_XA1!"N'_1Z%UD:A;IR2O?M.J?YOT4OS=AZ77N7&PAQTL;S=[
M#M;6$:(*@9BTXA]=)%(]7LF'I.CY?8O:;GSHFH"3=I%[EPV^*FP)-[D=^!L%
M)*EAH:P4^2SLG[)WT/  ^R%_U3"+G[J; 8-C+QXUY+O+K'$VD )CH-R;?[>4
MFU2W_58>D.X23FRB"3=Z!V(?O"Y2U;/9OM*?WA[:[R%NIONLT&Z-4V>^C*&R
MI FT-$@2105?W_^D:7*(#B ^P_<8ZG*(*9XV:%\5UEV^%W;*LNSIBVXZ@,N)
MI$)DSD.+///EWBDN\5*:-UZX$QSH-_:6#@CI R6H8'NW0#A%0/@K15'*U2E7
M0GZ5[_D1O^KKCQI2W;3X-16E;F"C;0)/Z7S0E/KMGP'B'NE>2M3>1;_]N\'L
M_N\-YI?_O<%<OOH\E[GH\]$2D3-& >%>P.FE4FT_9,"CJ>G%KD9@L+;@LHYB
M(E14UP8_T#W&K4T'W+6LZE[/D?"7<W?;BZ#)<,V9!#4*@VTVPK88-R8&Q093
MJR7!C]]/V6$B?FJ< -7$ND?-<*!NNI2'!6\[*1'VB9?PD)Z,"(I'F?<=DGW7
MW><:&GQ&Q&2_4Q>M/>);P@, HL\3(V,CWEHX5DS<4C3< *4B>)\H)BR>F-+U
M0<Z7M6A'M63P-[-X56!@[V^#6G9F ' ])N1P%NF"?P)R):F'IMJ8D#L<[/7(
M_QRY6A?NFL=$PWK2 ;L??U0Q\CXT/,EFPC>I"Y(2)E+^PK-=3@DM=<.%;>?=
MD.QG6_'.>CUN> 9)M'U1B.2/BU1D"U?O?D*]W&&:*2V=(A>FHJ)N^S(%G!MD
M<6$L(WMKKAFB\*^-M&.<G(^J)2=UFL72#RBXIX%F5.)'+=QD U+2RDN"9(N%
M[VZI/; ZPETE4C*(:]'';W9\AXML,_U<#5QP7\PZJZ-X-@R7U)GALV+"\'"4
M@''*P/OX>N(EM:ZIXHW\L>WPFM,YN3M-EWF"&S)-1S8BX>CBZN-+8?B\R^_[
M9*Q0 "8ZP'=39F5WRQ&+R+#;#!^QF"C#MZ5<D%U?, 05"_9TG_H"EEY!1P.X
M*EMX#'2S."%?-;JVG95*PS^M<*]-959(F+P(O')1)R+(80LZ+?'GTZNGBUT7
MY][^"7V+SVK7EMDBK"@RP22J,_4T;,9#5$Y@A@^O^31)>N[_5/D^/)=S5[2Q
M9W&2$3<4 ?M>.SF1L%24F.,\6*2T0>FWT*C6J?&W60//)'7S)+KE]$3U&ZG<
M)'/\B!$)PM"'-T@1;RS5)O.?2<_)=]R5;1FK';[UXPUL. " ?1@\00DC^!-/
MX*?383;!*_Y)3N?R.L],!ZEUU=/,BDX&K-;HWJPVQN_(@+G;0=\ RR7*=N5W
M+8VSZF V!-%V&NNWL<^ZMI_G-J;M%@9#\V]_[QK0'?MJQ)[*Z1((J%>OA#O+
M[H?13H6=3IS##;;#4H^K\WX]L..%B(D<9"6T?;5XD4CQJB"1EVW2%6!WWWL%
M=P<S7\S@C_AQ)7RPN@^<J_V):UM4.\CT.^0F_ >4":9#ODI2AG#Y:%B6+\Q:
M$--D9[)-?PS4?N"*SR!\A2CO.&3S&%],2W=]W5$^^AO.W5HW03GW]K?Z'0[?
MG<^^91D3J\JZ-^[%ZAD@^T8P+G>F4>JTJ6/_=GD7VSP3_%!9=UFU9.?;B.VQ
M9;/00K;GAQ&!0M_%'@89''-B$5O6R]"$8MY:B+!/D7Z4,QJ=&%K[U11LVE<D
MDTP]>NER-LC46FLC9ZH9B5$D:N/7>_5"@2(;=EU%(@0YTYR^@)R(T5M549V_
M1-3Y+V(U_:)/\+"*.=QK8 O- I)VR3+P(00;C7MS4<JU2-Q9U";K5M'>L2%X
MN@P1^DE$T,0Y0O("@#G[M,A.&[9@:>]:'8)\UJ_M('^JJ56%QN#&R,H^Z</N
MI>1IVJ4F\XB2.F/^:D.I<P]6/?(]PNYI^LN'ND9SNDA2C<CJ,"[$++G=QNE4
MGJW(BN-O_J67W6VSL4<Y1D)#1:XO>Y\7KK?=NM3ODS_=^"RD-2ON;^,'VKN-
M.D<'3->"CO4V_PRC#*D%"+=$:G&+T;)%!,54K0-YWOB_+@3<R!S)77Q<D+*0
M&8MJ^?R[3\M14/#M$911IM5^*)3]/1N<_,[%UU?^3^%(UG,GMU33&+T4OKX_
MO77P&(H883&%((4K3FJQ?>L@W65S/R#%^H$ =Z<D?Q?VB>OC6(A$_'UD%R,Z
M3S,TN^@N,VEX8L&KH2-(,-5,]"U#?ZT\#]&-^W$@&6M ^5E,XQA8ME#X'8E@
MAUGDC]QL!IN)8KYGU7SUOQQ0'3B?(#%I5B&J+JNZDS7ZFG.9(<&LOOC Q?!3
M5:R?/H0_,?9_6W_!D.-%Z*0<:^>L,8LA?^FCKSZ$%:QEK WQ!ZEOV9\/YC2M
M8">O+]UDKNG*_E,+C,DQRKYFR M0G^P#B\6:0<I!-0U;DSC+V94;$^=&=]<G
MZRQ<^LEN\^W&G\\M5+FDF+&_BY2P_2MOP 4 VUQIFSEKL1*)%*-($,IZXV2:
M<]:N@/W)+YZM=0D8@OV2@SMY \<UVWGX4[_=O&,Q<U1!G"!)XQ6QJ(0W7DO
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M^$^!D_2)?_+\'_R#_^0X29_]+U!+ P04    " #.@6=7Z?0Q"!KH   X_ D
M%0   &QY96PM,C R,S Y,S!?;&%B+GAM;-R]Z7+DMI8N^O\\!>[N&WWM"&&;
M SCM'DZH)K?BE$LZ)=G[=%3<R,!$B=<I4IO,E$O]]!?@D,E,93(!)D#1_</E
M*HD$UOI ?, "UO"O__/[XQ(\\[+*BOS?_N+^U?D+X#DM6);?_]M??KW[!.._
M_,]__Q__XU__+PC_S[NOG\&'@JX?>;X"[TN.5YR!/[+5 U@]</#WHOP]>\;@
M9HE7:5$^0OCO]6OOBZ>7,KM_6 '/\?SNL>ZWY=_B*$B(XSO0#U(.4<HX3'"
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MU)+6U[M25HWJ.<<!'9[6YF"R/+</(S2F"NMQJ#0J#!F!;*+20IH?EUXMH9-
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M0.H@)R[^R<;49-4;7K5;.\N#9GDUZ6JX#F63:7"7";H%_;4*M15>@97L F=
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MZ#/'\2U#/X>QG5_HYQ%Y_ZRAG\/P6PS]/-&Q?J6NF[)@:UH'/]R*;C/*.[Y
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M+^QBCGW*F.] E*8>1"%.(?;<"")$9*T3EO"(Z'""6?'FQB>]O&TR6]M&3_#
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M3WFDTEV,B1_VLH<77?;P%A[PL_CTE .&+'T?BNO?FXVZ[56N-^ #*]G.N%V
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MY 4^Q$F<0(*(CWG (U>FLM'(HGZ\K[GYW;T_\QYY"%;5FQ,C8%F_*5&Z#;X
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M6Y-:L:7GB)!;1CR5'$OI+3D5G#GJ"O=&\QQ+VSRM[VJPYU8 -MI?@.ZC:
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MOOVA B1 B3LE4DN6U*W]]0<@656L&PF@ (I])F+:MD0"F0^(1"*1>%(]RJP
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MD<Q+(@]2C!%$'G,@27T&.?#8\8.8D0QW>%\7]#W0WG1K\V25V@=:;K_Q%Z$
M/\7]O3!+_JV"B,$[=.]+ ZZB]*D;<H8IP#=-WZX?6753O+*6][E>IJ(@%F($
M.G'(($(H@'QEY$8["8B?I:%/U?B!#CN8VR+8R ?RG8!JAN$(/SEC< DJE@U
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M"OMY=(=GL0&P)CK.XP UQWF-E* 5$WSH!)5,V!R!2N'.OQ'()KKYKPN=&@_
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MJ@1\9NV?-\4Q!]>/<K7Z4E8BIV#I^C0,<!+!%&/*/1@O@01[#F0HQF$4.EY
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MQ._?:#WY>UVJKRM**Y%;4/*=\>K_SY^;KREE"7+%B7X<-V0^40)CW^5_\Y/
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MQO/I19^;8>PD!VT=$" ^.G!S=PLHEW7:S#.%X9?P&F<[J);ML]FLM,W7T6(
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M3_J&=&=/?C7#HS@.<G;('KJ6S=(@L/8.^2[#S9#-4NQ\4A.F!\RA1=-L1<_
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M9O!2B,@NZ_3H?OC<:=)PXJL6C=$9,\D]J^V1L+T/;<!M%0"M!EU1KT6[MUR
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M!VWPX$2AN>E.2=1U/#@2T7A=-W)L3?YY4Q1;1C]M14WQ^FJK;OO\JL4W#VE
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M_HYZF-TB4H>X-5(ZE9@.EU,U].\8R&&2-P*/93I61D8C_*]'^POB_XY;G#@
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M^YZ'0=(,[GG90G2 B,Y=;_/R 97LGO'O8UXNHMA%01)C0#&E (8Q!6GDQB#
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M+OGZ.04.LJV??>""B*R3;"VG3O?XV.E^M^0+A\F[C+_]O,YK8X#Q+TQ>+M*
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M \X$0Q%#HLCU!$[/G@ :>(MJ J"&@N\ 1IN-]=7\,ZV*>MBQFF2559$.0:I
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MPL;=!(<#5F.5C(BSFJXW>7>>4FT,%KY4E^&^V";!UTM?BC)+%K(6^=;C]%Q
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M=&ZUJ+H, [.Q5FB2 3EUY-H5$2$DCF!%J6VQC=6\=1!UCXAQ(=- L8\W CM
MRAW Y)'A8)?,>,%XB:F6\!6*,JT4$*,W)!_GDLK):M,Z.^I)@L8-P=O#IYWT
M>X#2\U.\KM>(01,T.86FEK9S^BKP>L@5R2%4BJ<06R=X[DS<N-7B T!L$*UT
M +?MH5R77'!D/G$RN*4F$RH3B0LF.,B4:B-B(SEOW0CS84K&K09O#Z0&\NX
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M:+F0 "1ZY*U;G.Y/92<IC\<BZ '?:DAU=>" W?4>%7H3'3I@H5IDQLDB1R7
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MDD6A%8DEE=WJ2P[-V1X$*2V5]ERB]CX2'!L!#^_X*%@4% T#L>)!L2S!%YX
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MI_J3*(PMF4(,'9PGT2BRP*@#Y)P$>8 RN^9)6=LT='C<?*!^%PV%W0%8+H[
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MWDV C[?99UDH)Z;6>RL(DB;FMJN<(\L51C&$E-OF&4I*I\9N(:41IZYN>*Z
ME!H V]743F;PY<S&SW'Z?>2!11_2AMW-KF#)V>8?K1QH9KS'-BE$O*;YBLZ0
M%H(B&933Q&"F7>ECN"3]E:,L)0#5-2+=!I#]^^>KZ<(8/'JCOSL0%.7)4X&2
MEP9Q(?/Q0B1RE*HDX+1PIO05>3LU=5%7#R'=(.)J GB_=-_C=++0X"\1>+4^
MF/*N>I10H[./S;B-N8+#@Z--';(&PZ:$C,R7'D#5E[:Z=^N&0#F *!N Z.MN
M^JV;VGG<N!FB*"&+$R>"]\T5,<@%;O,MD <%3K1(I9^%=Q)4U]UL!HSEA-8
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M&'.B"(*3$R-NDD9&YF9A+%))@2>4]_)A]PG^\4?K^*?%!'\T_QIP.,NFH*I
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MB<O3NG)3>,)U")KY6#J5X4 2ZU[Y*T#P&-%<&O( 2O&:*$YYD@2LO+)YFE1
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MZ2CKT<,&:"2&1#BEM<FG= P<:=@+F%820;,2W!U+)^4](Z+%Z$L9Q)S&[P8
M\Q3R_QES$_L87GV'O_T2EY7C=S^\BM,;<DWRE$E!"")YM!XG22 ;!4:@&1A[
MZ9.EI=/1#Z6QQ3O7$ :JL+1:1^//J\3[3W8>/\9I3N*X]KD\5V**% ]YE+R(
MR+'H4;"8J,@)YL4KJ@^EL45?ZPQH/%5:#:#Q?9Q_RK("^_YJ&BWX IC!C28A
M\$3A2D-A#W#Z2Q0(BTR;Z+4K_=RU1D+M$M7AL'0*KQN RN=;('R96];=Q.LH
MG:8A.B28 ^KA1HQT\+DEN,Z]LDSPL702T%,*:M>=#@>4$SC= $ZNXL1.YN]N
MODV[[\O),]=$6YH<8<AP07/S-(V<3!A)GEBDQD::>CV-'H"5YU34KAT=#B\G
M<KRY?G*?YYW_\VLW!HG,EKWS3D@LW;[8:;FE/8DLE%ZZ_,)]FB'77!OC."(F
M3V' %$P"SY.VJ,%.&B68+=UV]RD%)Q\F]S,H%GS\Z<?KL9VM>MERKW6P$B.5
M=-Z<3LAYHE"R4GCFL,"B=$;@#G+JAH).D/NS4Z40RUM\_;34*IE;OBN:TVZ]
M /H9&%,ADE:8"X]9K_:G0[U^#H:/8D+=]_IY"(<OYO73>4%8RC,_32[+HA8.
M74\]\A9K&ZQ..O2Z6K_0U\^#9'[4Z^<A JC]^OD+G/4W=O+9^J^YF?!/77JU
M>LMS8)2IE1$9%C3X;BXBZT-",C(F<;+@BM%];LKN3US"N^A!LNR*,[:!FP_<
MVV:C,++3'Y_MO4E>:!+#G#DM,!(Z.,1#D,ARII$75G$%ASI;'[A1XK*\F9BZ
M+Q6E#ZRRO&\!1 _D9^7ZD!YE[*\T3<J<[:8T"#TW"]="(6=--M.!<DJYL+;T
M8_M^JBK[067$OPZJLK*H?8*]FE]]C;_9Z9]Q_B'!YT>3+RM#"Z8T:2\HBB;Y
MS*2$M%8!<2>)$WD6^OH+ZI83;.LG*L.CL""[XEQMP/)<P;_[D!Z-^U[HCU:4
M<VP$RJE-B O.$2B21-@K39V,SK+2<=Z-A-1]\1SJV#J=YPT YQ'YL^44#?OP
M-X\+SE9ZP02.2JG\*$89XI(P9(7VN7NBP<D+IFWI]_4#2:QKK0J HCN?A&J?
M:JO@ZV@VGX[<[4)&=S>5U6ZD#1*T$@PO$)['_6!D: @(N.982EHR[7J=;GL_
M51<W@TJY&XSE#5BPA35?V?:'-QG"J,#*2A0%C?GZR5!N<8BP"9Z+ !X#+QUE
MWTA(W?2*H8Z^TWG> ' ^WGUWL8W/7X&CLU>W\Z_=-(]VNN;""&.P1%KE9[@(
M_+'>8J0)BU02R04NW4IW-T5U#50!D7>#\;\Y-'VTTP_31:ED6,PQ^QBGBPU>
M.^.D9)R@2& OG#N-C(\,_L@Q-8F!B2W]G-Z/LKJAI:'1540>S:%LJ3,?;N>S
MN9WD1E+7.N)D"-4(!VGR7!J!G*0862J=81(SK4O/$MQ#4MV[WWFLUK$2: !0
MN1U9-]EL@2.3*1H*+@%86V 3I>!>$H\<Z K1/FE#2^?F[R"GKB=5'DBE.-\6
MB+8:6IZLU2%A1(@6B*=<>,"E ._3:@8;,C:53H7N05;=C-5!055$$FV!Z[FU
M=3XH02(86AISB_(8\S1@BA+EA&#/##&E(YR[Z*F;UWH&&W4L[QO T:-WA-?=
M9#8*B^J ;G+78?/#Y%&8Y3I*8PS88&0EG.# )XQ<H F)!.K#"&-VO5E'R7>Z
M_036S8@MC[3AI%.U)_,BY+:J+[%?8(>+]J^S&6SB+7#UC?5?5SM?J-<U9=H$
M[152F&7O,5ID<U\M8J36EBMP+/NEH_3_9MW!*.60-"2KVTRS=G86 ^SR6P3%
MR$N5:.;;<^4""=@'DE\H&SL7?HV[/$!^@9#[CZ]:V^4BV=D"(0OR[L8Y/0S)
M,$3#N0:6Q[N .'8Y4\I:1")QUGH,."H]^N$TB@MF>^=O_+0NM,</%S_]>/@W
M*SI>_66G81EP]B*(Q=L\U38W9 &%<XECI*2UPEN&E2G-NF+$UXV]GA&S.S+/
MSRC^!MS%CV,[>>@E%"1W#,,M' X@H)U3Y%@>">$$X8[2@(TK#-W'WV\F3_V<
M$%B/NQTKCX:P=->!%9L8XZ+] E&(:T:1-I2B$+T2..;NK,7? )Y04!=/QTMR
M"R2.8&OMQ(>KO[JKK]WM#*[25W\!SWY\F,3ER_S]^(>\N[N&4\IA(W!NY4RS
MJTHX,AC<81VUUI%SN G97K>"@S[;!DJ.$6YW%DXWB2%P\;L?,2XC@*OL_T?[
M$RE8:2Q&0H'QY9H[9(DU2))@<J:M$4D=CZ3='Z_[PC@HG@IRO2%4O5ETS(B3
M[>IB%"B'=1Q1R<!ZYRBRDX&AR*35@CC)C3P43GN_6O=%<0 <E>5S[0J^[ LN
MCG:L UPSI$::4XUXRA5 -,$O@DJ/G<%,ENB1??_!9HIC*GC)QW.^!;C<H1RT
M16D1D*(V(2Y( K*Y1E8&39@G4=(27?@??;)B;=YQPEH7]Q&<JRSPW^S?HYO;
MFSO"4Y*<X8A84KD-*U@WZY1#P8>PZ"?/(BX@\B<?K2ST8T36E>!? Q?AO:9Q
MFV5\>!I@PN$@+!RSCDE0EYB0BU@CJ;'6/.L++5Z.>3+5S13 5 S@G%GVEXSV
M][=9N>]>JA[E!3D6$\TS-:@G%*ZGF" G1.XYQ%7TW&GE92O@W[:)RL',,Z.P
ME!(4@40K.O'LY>\Y ]PZ ][\_6VT3 GX&*>C+EQ+%BC! 0-D8<]<^3RNGG%D
M(R?@.&'G]" '00GB*U]5&M"!LT.@=ESE:*:_F_CILJ/@F@WX;D?C?"J_[::_
MP"KSQ[D/S[.U"(M>>[AFL$ <2,R"IRAS]8^7D5&JK(W]"NDJ;Z2R*U5'=5I@
M_$$(:N6D.>6H?17"*/\G=OSLT)7."&T(1KE) .+4@<WQ"J0);&"*:<K6NP;5
M]\.V;Z=RC6(#IU$#,+G8\VG[_M>LS6P].:^;/#<RP>#$%88C/>2P"$L.1"D3
M,H3E&R96W@Y\3!7=3]WZ@HL\K>KAZ9(/K<4O?\19[G>_]([)=;2&D&1S%WL6
M$8_ !<V<12)2[Q2-(O+2Q8 EZ:];3'&IQ]*I0*B:+K^A[N2U_3::W]F"3X"!
MZ?<8P&%]>SN_G<9WL]FMG?AX;9)GR@>+5,Q=FGCF-7$1898LC_D8EJ4C8P<3
M6;=FHS*@AQ7I)9ONU8O.?1+)K;OO,9^GDUQC9;ACAB,?<_JN\Q89YQ@*W(#>
M*AF2*MW*9*B]U*TUN5237A(@K2C*,?&_^\RJZ<@_N'R+G*O5!!]LHT_$!S 4
M8#=XP Q9S1/RSE*=&%%*#J(J@^RFE[*8EZPL]4%RL;?RE<U8GK&+(W71\XFR
MJ))W2%AM\]1;DDMV-=*>$<*)"V:]EW'IV_5&NOH]">(7!O7: KYT;-]U;%T]
M!IF 24C8()-T3J@)"CGC"4K<^\!=[MN:SH+MIW3UP_9+>^^N+>!6W)QC=O^@
MTC&\NWOJ-)P2:?,SO\DSI@RCR$D/'"",!$]=BK1X\63)#?13@Q?]Y%T%"PTH
MPOV]!>[YX)-MYL7[;O(]SO)\SKSMV54WM^/'/\\UKN^[^7_E.8R^^S)9O*]X
MDA@6.B(F&0>+($$XC CDA-;2@57GK'309[#-]%.0E_:PW19&7K*R+&W'VVZZ
M^JO\[\BU)20890)2(L"9FE_WM=4,!&=E\DPKJ<BE:-#&'?93JY?ZN-TPFAK0
MM:.%\V$1>YLM<F9F=\?RVH#IQ0]_MO/XUHZFBP9LU]03$Q56R"<&[(F*(ZLI
M08$%'B5UV/+B/:7.N\5^VO;2WKLO 4\%G_6&[6%T5ZS0K5J6K__\S=_YM]$M
M6YF/TL@O_KIXQZ,3Z1BB/U))UC3234D2C[EQ*%AOX,"P&EF%&;AI@FJ/1?2D
M=+R^E6Y*O8[F5^/%DO"[#VG]\%U0NBS+P<0F!H &4Q5=;O"C\TNI1X)Y08./
MW*R781?LK%1P(Y?=9>D +&_OLE0+%@VX8^\F8/_BHF-MYNROJRTNBF1]2M%'
MQA!.6.9Q7!@YEC2*5%-MG97"E$YEVD%.*_V8JH&E&T9R[8)PU>U!I$AIRNUA
MG ,FQ6"1UI@B9F)21.ID<.GK\DZ"Z@*QF-C[P>D(&30 J)S?! 1\?34)/\?O
M<=Q]RWM:N6IW5=R!&RP#13*QW$0$=$\S&Y&DE DAJ2*A=*/]'F0U":YC0- -
M*Y$&0/9+G, E<0P[>A5N1I,\W,OF%C)/-V6-Y7D,!8H,;HD\:8N<(0QIPZDA
M00GI3&&8]2*L;C7D<$ K+Y4&H%;&YW@(N%AGN-5"9Y<#W&;%&3*1$T2%#\)9
MKP@K/5"R\!9:Z3O4BC=8$R$-*,AJ9S%LWOA*^:\UXR8Y"LR5X!MQZBFR1D<4
M.>/6$^/$^F#+TP>I]J*L[K%?%3SKDU?+2_)"&LD_1!K!69I/1WZ^FG?U^V0T
MGPT8:]WUN6%#JKTWVDCD5&./-7%(&9HG1#F%##BEB!/.)1.,P@7LA49.]SZS
M[&EBY*P*.H*6,JPIXF >D..)H>0D!M. K92E+_'_]*$_%+/#]:$_1/PMN!,+
MRN$?+\(J/( _9BU%F$I@7,JYZX)09(*A)MI B"O=>. ) :U$/L\*@G6WX&B)
M- "GXQGWL.U)6&N"2XD6)JF$/ TT=P8!'N \C)P;T&WG#79G+S0^8A^5)\ ?
M#ZM#\Q"&EG$#.-_DSGWZ_/M=FW=+,0DAH$ASSU5'/=+1121<" 03Y3$N_6"Z
MDZ#&>^(-CI?G$=I"PFL B062DG30@1J/$0'MAVNFR6Q,!@$/ P4>)QV;:?O8
M7%BLIJMP9ME?,MKOFM^#YM\NI/)A_C5.K[[:R2H[[CY-]5,W'K_MIOD_NL9,
M $=4/B:9SNU=.-(LCX1,@G(0CV&I&<TX:H>-GPR%\5M*?88'T[^'JBT[+EU'
M2JR2<(*;@/, .>61C;E%O=.61L*]MJ4'5IUM<Q>J8&= ^/F5\0BX':V'WQ:O
M!9_G=CIO7!N?IH5?6^,\BT$AP2)#7!N0(2$!)2:)YU@D14J_XI]K;Q?:%ODE
MZ>()8'O11^(?"_G=\T4*I:*.&.4QU6"B9,B53AP9+[S&42GB+T<)G^[M0ALL
MOR0E/ %LARNA62KA)'[);SB-JR'(+<718^90+"1.2B!*7&9.%$CC))%/N3,\
M=\RMS\9L6!.?;>]"6S._)&4\#7*GZN/5!9R-Z_Z[38HEY3GB4:CE.Z_%UJ$D
M:5#8&6)3Z=2FMJZ+[16XOB2%/ 5N)UX7WTQ:/R#OF;.W?/BQH&,*4@FK$<L%
M;!PS$#3F&@$'@^?6>FSUY6GL(2RXT*OGQ<19!X/CB[YU]F??== Q)<\3<BJ/
MYDL6+@D*N!>58\()ZQ)O9BYBP7V_^/#M<(K3H!$X",7_=J'?_>P#'C$?-454
MY-:VC!ED _;(*N]="CX&?CG/H4/TGFGO!/^WL@1#XOE%.P)/(X+[&4<4IR[W
MH2 VYMD)B2+'*4-14JI,P%CZRXF*';CY%Q_ ?@&&8$@\OVA#L(I&W@*J>WA3
M</'CA!$D(]&(:VF1#I$@'K@AA#F9Y.7<"0[9^8L/F[\ $S 8DE^T_A]PE^(N
M&,,514)SF4M?!=*:2!0<#7DR@&7A L/P973_DB/T+T#W!T)QT>C^6=M<+OGR
MRL]'WX%S0S>SW/RU,[2L[+'--LJK8U2>4AR1""Z"VGB!#.4)2:< <=XZ1G%A
MVUFYO/I875]I]*.9JX_-C]#&!T,"BDGD64N>(T>M0D00+IAWD=)F E([=W+1
MA=>'H+ET4^,"P+ADA^XY%U:OUD;$8)UG2# ,?JR, L&?)+)4:ZRPH%HT,T)^
MVR8N]/&E(#*'4Y8C8'+Y#R(;P\2_3+O9[!ICK(,,#%%/<D-)$)"UG"+G3%!:
M"1=4:_JR81L7^DC1KL:<"I46SI;L&2]'//U\^S#O;+'MV2.W>?;F[SCU(^##
M-74L<DDE8L%FCAN+\G4(6>\M9582XXM/DCB8R@N-PP^(]6$%?=FIW\^C@J\F
MX<W?WT;3Q0H/)2DR@M<JJ$": -^7?=:I5T@'SZ(,(3K=VD&P=U,7&J]N]U@H
M"Z,7H5G/?4MI;;1>)13LHA]7@FNABQIYRRA)GF!9O*E^G2M(>]'>=C7G-)A<
M>G[UTP,X]_]8,2& 1%C@#@6<!RM'BI&5N2F(L(1'II-WQ9L&EMY$W<O'!<>P
M3H-#"U>,<D9A[<7FSE7].!WYQ<-36MDP*KA3/'$4\JG*L?3(*1T1M3Q9RY06
MJID*V:-W6?>*<\$:-3"@_GU4[AH\504L -G)F+NA.8*T3A%%2;3BUE(9F^G-
M<MC67DQT>1"$UU'(@^!V.?'HK2W@^N0MKS&(6AJ]\TB#=<W5B EI)L!O5C%9
M3HRW].Q9-^6V]V+BUTWH9"787<+IN(\U=[OOQYUHDK9"!R2\ 9XD(L%J>8-4
MQ(Q906+Y 5OGW>&+B;5?A%X.![Y+4,U30Z\[F<5-PH0#B[ /)/=^X\A8(U"(
M)F*J.07+UI@[>]*&7TSDOPG%;0::+T"/^]X(N!)28&=1R.^4/,$OAG*#I& X
M268-4:4'N+5T ;V$MX5+T,TAX/;R7B-VL@:<"I&DL7 W3P)QYF1NUJ@18=R)
M)"R1S;V,]]Q:W5/R@N.L0T#G!9QMKT(8Y=_8\8-L'P1FE4T!*XR$R X[LPR8
M(1C<I0TVC'&ADFA,CW9NJ.XY=L':4PXFK>C,LP*=Y\QP!Q_0GV*>^ )__[J;
M+%AS:\=7<7I#KXE.7AL'C(G) XMD0D8)@XB,WM(@#..#W.;.N\W+?J@H"/)-
MZM<PXEZ 4FX_W[>QB%P+SS0),1M3FWMZ<X^TI#8_YA@=P;9J,4AOD/-N\[)?
M*MI5RJ$1UXI2GB"\97.3980IYBEF5UW^JWOQ^62(%M$@RS-/<F=O396$&RT)
MS$C)4VRFVV:_+?52-OF/ASDH5%Z YCPZ\=^!#1E-9B._; .@@[=:6HHHF!+$
M35#(*>$1W$Z5HR$HK%I[%]BZF<OV%XM"=K@@X@GX:461RIS23QE!KGEBW&IJ
MD(=](^Y#0AJ'B%S2E$:BL1RF._L@N[EL+V]P5:J/H&*Z=*YV+*]FL]N;)0M^
MAW\TFOPTMOY/^#G\Q[,E;W+(%"S,;UV(^>GDS6P^NH%5)E_NN]8\:7>R3..)
M8<"N+L,3/6QSF#,SO8T>,XIZI1F+R%@F\_ "T&YF#=(^:L6IPM*5?JZYT!XS
M]R)^A)-/H]F?;Z<Q&Z<(@)Q_@@U<,\.3X"H@B6,"5YY09&WRB"5C#'>)@8%J
MQ4OLNZF+[CQS",:+.8.#P*45I[ 40^Y<CC\Z$.1H/)K_6+!$!>J3)@0QZL%/
M=N!\N,@ITLEYDK0*3#53$]I_6Q==^=:,#A6 3"M:=(QCO(LERS@G#YKYH"+2
M <3%!?QB8V)@680G A/F]"#*,\AN+KJV[62=J0^05E2EM/7X>?1]%,#]7MB.
M:!F77D8DX;:3;8= QC"2IQ8I%ZSU/#33H;KOIBXZ6:FYP^9HN#07>5A) ,0X
M_W$%/)D!O_-.W]MI3D/^'D\($/1>^[1[_'%;*'3=7GW\X_K'[['K J,!$XZ<
M=SE!6UMD!%A7X9R2G 91/O]Q'TTG6^!5B.1#VO:EGWX\^4F.UUU'38G4<)&A
M-AC$I=7(T*!1M$&+X)FSJ7CM_3&$UKW:%L73,ULXN. :\ _Z;>W5WZ/9M>-:
MF23 5$LF$%=P4S *#+GWU!"9; J^=$/E_M15?I ;'BK=6>36&")_[G(^RG4,
MEEHA.=)6 *-,HLC*E'T&C D<H8SST@T2GE/1IJ4[5=X[8'4$\QN#SV]QT>DG
M84TI3Q*Q%,$ASLWBP,^T>091]#S&(%SI9)WG5+0#GV/DN@,F1S"Y(DQFT_GU
MIWR96:B*Q"I)AS4*2<-E'GP%Y*PA<%]R1$3-*8N]'M)AU4>H@#\](.+)!RN_
M=9_ME#J>RRU XP[1T0/E.B&BI$8\.(,,(1CL*+<:8_@/=:^. WW 4=-&G""L
M=7$?P;G* O]M-!G=W-ZL".>86N<PSNW@0DYUC7D./4%$*T>-B4[X7K&L/2)_
M\M'*0C]&9%T)_E46_(>_)K#.U]&W!>JQ]=2G@%$@/J,>)^28=0@VHW"(R6M=
M0O!//EJYX<=9#X/CN=T*3%9>DXN&8"(Q(LXO:I<=6,8\U#*IH(@B4M(2A\+:
M9^O9B!,$MTG\1W"Q(@!RZ/3ZUQP_?7=S<SOIOGVUTQN[LG4.1Q]M3+F#1 (W
MEV)D-*-(*?" N1*.8O84"<]COKL^T(#,CY%65YAU%<4?XNCZU_C%CM],YJ/5
MY5I2[I1G"BE&[H:Y1)L?SBT/A,I@U:Z#8A;]__[2??\/6'JI_O";!\W?\,'*
MS67.=DB<RNO*,%E2O=(7)0*HBXKY32M;20Z7:@W[5Y1@RI7CG.TJ/M^/D<=?
MJV,F3A975X!WM4^&7\;V[^[SS6C^]?_"SQ=Y:>-Q7!3-?9QVWR(HQ/M._#J"
M?[%($5_\^U^FW>VWU=^MS"%C3!K#!<+..7"=#9A#&H%QCBD9/1C8*'N=)(4(
MJ@>IXZ'0599+93?U=7>;LR(7K[KO[<WR*L^C\T*R@%2("G%G.-(&-J&=$EI;
M' SOE<NTQU?=].W*?9?.>K<YF?>U8U[QV^W4?[6S^.K+-"ZR/-:WM-+(I)QE
M)D:$,<\M9HQ 6AF*@D]141PQ%KTJ^/9%Q/H25,]%/EWFW= "J'TZ?NXFW;W'
MKS@&KT  I<R ;CD9D#%6H9B8D]YAZ5+H=<0]7K5BY&P8B74EV%=;[K]\_K\K
MJBUC 'GCD6<AAP23AKW#-<]R!VP)R?!D^_DU=TO6>3\YD\2/8UQC3ZZ/#ME?
ML^\UCS>S:YJLADWD#G]YFJ.#X]6PR) 2X$]1X9A60S[ ;J*I;KN#9O)%CI-1
M YA['^>?LL2 +Z^FT5X[G'BT,2":%%OVE'2&,@2JJ)UVQD12NCWX&@GM//"?
M+M^N'+,;P,I5G-C)_-W-MVGW?=D<_-IS$YS@$C&.8Q[/)I&UT2$=35*<LD I
M*PR7YU34S088%#$GLKP!T+SR?GH+7QU9E^ND1HM^TQ_F7^/TT5]=!T\<YP:8
M8K5#W!B9'SPC4@Y3PQ1UIG@CKEZ$U7U;'!1:Y073 -K6Z7_?3?SM-//ZFM*0
M&.&P$XX]G/H"=B*H0E9[+;"+4=O2F>#;J:G['#$HK@J)H $P_3::=-/1_,==
MH?3]>]['./597E_B3S_R]G*3MVX,RWQ9_I/K8&@.87A$2 AP=TE@GAU32(-G
MJ9-*@>K2C66.)K9NB'%0*)Y'@ T@]:[-X'^.YE]?W\[FW<V#"OZXUB0F&3!%
M- 3P&#AFR&G,<UZ1X981$F/I@:T[":I[9QP4<>4$T0"J/L7O<7(;WP(+-^WK
MS=]^?)O[B[V:S2+\+US9OZ^YH %V(E!T%N[6.#&D.:?(*^F2T,!'73Y$<3"9
MO1"H+A*!0POM8FI)'UHJ775S.WX'5OXFOIK/IR-WN[B"S[ME;/CS+?S!SH:H
M.3V:AF%J4\NPY%PUK-&#0;3:(B*U0)RZA*Q3&FG-B,4 /1F&K%9JIX:561$M
M$P;9%/*$;6YSJP2*C-+21J58-,7GVK[ &M9#\%2FAO40P35QWO>NC4L*3)\
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ML[ZV [/I]( 3/>^P_&W@;N$^,#"#'99'WP?6^-*"Z'Z?A.GXQY?/T=].ET-
M;N:GRVWCJKU.=UQ?:KM8TH+(WOP]]1^G(U] OQZ6ZB6<!I[6GFV^!8G\ B?
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M*XU$E4^4\P[^#6_15S_(OS@[B__G?_U_4$L#!!0    ( ,Z!9U>Q!B@.Q1\
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M(?6'7U Z8)IAQPVB4,3<]T&.)AG>7]8Q9,3)W\J JW-:%GE&"$K%F@0I?M9
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M<-S"RI:P)0B.5P;>:39!FGN5SUY=OS;SWBD'!3H2*[-&Z1^%MS/)15O(@K@
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M*85T1*( @P_!3_J5C UWB$@$&!TVW$TRY&"PKO@-?X=H..#(ES'S*#7_=H7
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M'+IT__QV?'U<*<[I\?QFXR.D\3DP';AD,=MUX$3GT$B,A*'&,E0C@C!!VGV
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MM,A9J.+9R[-87C(9_[0C>30:3WAX(.#O/M^;',=B?!B.AX?'HZ$X"B?_'>W
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M=TP<=P!4B#)S::T0+5!E/9+<[G=P?:K@2O*MX\CS*I;V1AV\P8XF&PWVFY)
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M%N_SY<K8SZH]]P5A(I9N^#TM65M4-)^Z<!_KMBR6NWSC4F#UT]U/W+?W(O\
M4$L#!!0    ( ,Z!9U?@RMW,&0@    I   <    ;'EE;"TR,#(S,#DS,'@Q
M,'%X97AX,S$R+FAT;>U:;6_;.!+^?K^"E^+:!+ =O[:-DP9P$_=JH'"ZB8/N
M?3I0(A41D40M*=GQ_?I]AI1C)W:N+K+;]057H$DD#H<SG(?/#"F>Q$6:G)[$
MDHO3OYW\O5YGYSHL4YD5+#22%U*PTJKLAGT3TMZR>KV2.M/YW*B;N&#M9KO#
MOFESJZ;<MQ>J2.3I0L_)H7\^.72#G 1:S$]/A)HR)3[LJ:,H$$'[J!,(T>IV
M.F^/N'Q_U.Q%02A[0G1[_V[MH2O$?1];S!/Y82]563V6-'Z_V\N+XYD21=QO
M-9O_V'-RIR>1S@H,9M#9_^EUK&OBY@;*"IWW6VUH*N1=4>>)NLGZSK\]KVHA
M'NI$F_ZKIOMW3"WUB*<JF???3%0J+1O+&;O4*<_>U"S/;-U*HR(O:-5_)&S$
M(.YQYNU_!SV)RN3"GU:;G!C>Q2I0!>NT&NV''FQG>XB9E^8O,OYL>#D9?1J=
M#2:CBS'[>GUY=3T83]CDXDE/=L7RR^LOPRO6ZO!ZJ[O/#]A@?,Y:/5$]78_/
MAY=L\GG(KH9GUY>CR0C"PU_//@_&_QRRP=F$77QBK:-.M[;SC@ZNV.#\XNMD
M>+X:'_++Q:S3;),OSM7!Y<?!>'A5O_CUR_!?"R_;S>;6N/S37>QN='%48V<Q
M-XG76.BLQD)I"A7-61'SXO6KWOOCK9=6SH4 #=83&4'_^\5B4YE %/MU>O,7
MN=EJ+)SX^:,_FI9FHT?3,&(QGTIFY%3)&1)($2O+?BNY =R3.=[GVA1,9^R3
M-BEK->N_,!VQ+W.9)&R4IF6F<\0MY34VRL(&XG3T$N+4WKDX?>06T4$<TCF[
MS?0LD>)&UGRXJB )#1,RC6( (W"5,9[-69D5II3P .6!JQ00/<Y2/!G%$Q;Q
M$*\,TRGR5Z&]W)I )D-I+3=S$DGYK<2X*SHMW@D8@R$35V9@#!((E4%9 ;$,
MW6&)D(;-8A7&S);T8]E_)HVLE) #J;()Z@\J96:JB.&@S67H#"2].4S3 FY.
MT4VP8+XZ#2\%@IW_'0A*%JD,02:\+(-: _X@CF:STJZR"$3""P4]*@N34D G
M@+,2P1I IXA\<L2=($M0!MW<8[*"@WTT-& O%"FND4290 ! U$"+&\XZ>T)N
M8Q8E>F87*#7R1MG"< S$Z:6W&U;65L!F%\:L6?M2\-;=.;Q-'@3GC:VP5-4%
M1 XZBA0>]^V!B]F(<2,=.A!M%222HL@D(!DDRL;4@\12<"/Q(ST+9<-$VQ+]
MB#6-3CQ,<J-#*?#:LGV@0DC S(=^>!?&/+N1; !"NBRI8G$E:&]?>BM<"4I/
M_E%1X9AY>))^1JRU@EJ/(K)EZX&B!P-%&(C\?(QE2%!J?T;IU.ON$#Y1T^\*
M0-\VCEHT#^?28F^ :+ET]GTHU2C3AKRTVW>AE!=(P*(:R2=171HH #--E75\
M!RF9.3U4+2^9<I5MC4RXPUF519=8J55,3(T*K E;K$Z4<"<*M@RL$HH;10XH
MG^L=_V>DJ;24?]W*M"Y9.W;45L*@ FQ,G7)4DRHL$TZD#K><$<L\CAZ^*E@M
M9O!7($D0O(O^4CR#9W<+Q\$.X;C37<?QUH2U!N?MJ6YK5&,E3)4@L'*K,TZ<
MSBV 3B4E(9@;L4 3\*UXH!)5S"FU;QJ6UI8#GL.47Q8/1%=*4I<Z[BJ'\M+D
MP+1UI4@8:B.< :XXO9$9*HP$T$:+S&G-D @*;P]?K"V5@[U?#(##'0*P)^+A
ME">E8RN*KHPB5(=JBKC8#54>"HDM>-<_;B[Y'%+1$9QI?6$9Z+)X>NQM,@._
MEY94-4??W^BP8%&/N\4G_1S '@<T&N E@$WL$-@JMO317$<%;;>KDLVU/ +=
M#[ CY7 =AJ6AJ*\DS ?Z4FT+O*&326BQ(514YS9L?TTX F3!58_D*C.Q)Y+N
M7(".#++RWI8#;TG,[7U%02SG("Z%HW_G?47-<^S^;V52'1(\DJ\]8T*>">B=
MVF;U7L(VRQT9BL4ZJ"V9B(AQ%9=+4B)\_4!EL5:CPBZ."K70QMZG<?<"RM)4
M%864&ZD^T"@1J$4HV.2Z[P.W8%9+S(W?5"$O%IC\K50PV2VI,@O=L<'!_W=0
M?UKB'B2HN5 #*@",-JVT_0V5!!RJ%'R_DYE)?DLYU==@+JNZZM$=7BZ.>'X(
M9-6FPQ\9;* P+M#1RGL&VP#(JMJ$,+"%HK#F4[I%/K=E"F1@>IP;58;8> SV
MHM+U[FUN!LC*D0%5U!!PZ:@-D'&GS!6V:C[-J6RJDZFD7)?QF^JPW%1L*-,\
MT7.)UEFL/?_Q!\@%TIZ9]AL_\(FN<#NAJCD \J2I8Y(3GEO97_QQ#(;.$S[O
MJ\Q-E>MT7"D+=%'HM$_?XZ?$]"@+JD^=#DN^N?I4?]1M=(XZ]+6^,/@O%@-7
M'_(;[D/^82'6V[IO&]U6^\GF9J/U9-M_4]MIO'_7^\.U.F,[6ZD]=!/A)P/3
M;7.>?=CK["TZ5$#LM_,[UGKXK9^P^7C&_62O7H;XB0NG0Q-RCJ7@TAP; YYI
M(,WK5ZVWS>-W-7=EY-&UC&IVGN\X$/WSB<HY_''^,*O_82ZMQG)WKGYLGH37
MK[KOCJW[R<X^#R[I.L5X^&UR,=X0\"TAWV0NL6\SHUN(5M3F9B['_-"I)*.)
M.7X185F[[N'"\O BQ*Z$XF5.N+\"%2L9L4_W*?G"[W=V_E[0_E=_N B3E\93
MN3E8GC]6OAP\!:-#5Q5L<'+UQEZNK?NPVO??$*9R[0[?<L&ZLJ*Y[,(#K-JR
M6._RG6M_U4]_ _'0W7S\'5!+ P04    " #.@6=7+8K7+M5]  "Y!00 &P
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MI:./5RHJ[9 *'!+D2-[>JL4B.E\NUWFQNDK*9:+W93Z;1 ?UE1*S],7QL?6
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M"@V<Q:TC5VC M>]T4"$6))F!=82;B+>CN]=B$=U90GY:Z\5BL"#E]\_:OX_
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M UFTVJ!.Y!:R92)7B!T#V/T]6![:1P+< PJU.6E N@7Z8TTOWFW@*=1D;#0
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M7!^MH7'?T0:2(C(O1V.-3<.WR;7#6!L,@HLKYG)^A<D?5Z6:JQ(" H0!\-K
MZ]$3>9>M--CP=DXI>J,IKXF'&S_,\!SAS)[G,R<:N2>QI*OAQ)*D4+$9Y16
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MM*QG\R7FN09G79+V1=%30,1'? !Z!O;%U1F0IR,0WT%Z.@'2MR&X.0X;&I=
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MZ.E6]E\K0EP7JQ\?:4,P$&V=:GF"._SPY_KJ(9,BB$OVU\1((F_:K?I\-05
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M\WOZ<>4]QK:60\(G%WY=8"DOE0W47$"B)3YW)L8MCD7ER&V?G2H(L_^G:I9
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M%%>7O"J6*Z6]_8>O*MA ILE[Q(Y68N69Z7315P_3%4)Q*KJ0S?&Z#R]&D9C
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MI8=73RJAE2#926D[X0ZJ?L9NIU9/,I4J-Y T!K^\DO0L<,@IK:XNG;\JXGS
M& W<:@1.C<"I$3AUW\"IDQ$X];T#I^QI$*.MI^TV;>ZI:S!'F78^OVV:?[[A
M!Q&P/+-]M ,F.MNZ]Y(]&VN\O$X.RDD)#,B\@;R-::\$(L6F-W5SX625R[\/
MCY>D#3@28*539V&A+T8_HI*F3-!GG=G#R18_2(@W?,J,SEDE6!;Z_O@I58BY
MH/8L!S.BHOIJQ?^&9UE8AF/R>''1,A)^>\7.*/2,EIX8;D+IXY4QG*ZR5?-&
M'.EDXAUS2P[6$W])95Q%J?IP*$X,M0F[/M D?K&F7BHNWXFAF?!>HH=\8M(;
M*7%F4;I54;27>2V8 %YO]2Q=)XOV&\NR=CP :7'\$*_PXPC=%](H-7E=O)DP
MZ]OJ -&P9!O+U3&F<(<1"TKP>HRX@N.^1HS@3/*];=\1VX56FWZ6TT;F*I@(
M=K.Q><I]6=*,9H'?F'OS^3>>F;X!B5=UF;BWK(W8XIORVTBBQ,!6_9%):W?O
M)5#&J*]&;&!&A,:5>L7F8YPZ1P&9T.Y=YTF>+8LU>/,V6D>>SL:D0;C=C'1Y
MP+7@.:'V9WUKLB]'V@"+*P=%^]'K)K=X+KO)/D)6DG3Y\_UTQTUW&Q>$3C2;
MTQ)Z !3<&B?"%'XZR<.$$ ;;] .3ZK"V/4B!2*S98OR>: 5#,'*I7Q0CD PI
M,VU?&C?*6QP<A:&%:\PC<I'K-^5;8P496/F3+UVI4/EKP/AM\"]01,.OIVV2
MJYC)#6(X0Y/)#[%\#&XV\N$VJ-X&#[D'X:#,_'1P<_*PG95(8>$<6E7[UUN4
M1>,%S?PY29P-WT.C%)-4D*+$2TKEV@H*("W<C*G:/**MB[0G46=AJ&]'==6#
M;B";'$ UJ-<[<_CEH"WTH,N&W)\E<D.=DNX1+ *%/FWZRM4EVY&O-&S38+8G
M8(*9*6],EDR4Z=F%9E8 P>LT2MUDT_:BC!T^ OLP_RWV#3XQP,8IKTT3M.U:
ME(-PO%5)&IWK:5TIG%OS]<,:>WMBS ^PP G<Z2V)I;@',3CS*?'Q+MKGGM_Y
MNS.&P"U"MY)+T_O8IJ;().<$%>B4(E] .&.6H=#RF6&Z*-JL5[*HBIY;P0]M
M8HQ;$F)0U2"J.P=HHP\MLW)?G-$!EL7L(+\0<.(TOW,!&PI)CH5WHO;$M*'J
ML$(ZY[5_4,5BKVU'VE@!:TP:O!4B&U1YK9@GF>-/?;<[&"3:J>L0><@CI!3,
M$VF>SG..3&-1<L6U:H<*@F+03I_[BL4DT54%&;:LNB)KU**5-S!]WL&MM]HG
M=]K6>PB6V0#;T+PO+Y,\^]< "A>@JA#[!33L?$>];2TYL536)M[O(?!"+0.@
M9,K$SD ;5QS#I8=T[DE7=7=OW*V?TT6.>8!#ES<_]%XG?$7CQK^0UM"#"MQ*
M7L#^J''ULJAJ("#+]&__#G&"WMNU,PB.KT@S#^YF3Q=S[B( OOXVA9R^]8>*
MT;D;:=6^=A8Q$]$YJ3$>.@$)3['%,P13^^YBR>(,DG_$%HW8HA%;=-_8HB<C
MMNA[QQ89/\/H4#X8Z M"#*4%5.RQP<C?D])'ZZ"A]N58P+0ML&LV-/=7TD(,
MH@GU8'I0/YT\=UM0OW_SYOS5V;YUH#X>8.\]-O>JZ+5Q\1\>TU7(H )&$FU*
MJFV5=!5GA+>)4NQD\_=8U VK./9@.;Z)RS<RII][WS=9#LVVDH6QNR6N^!'0
M0^L2DLQ]6*@%U2 C&,4=0MODE!B@_<8\@K'SUOTV"X!E09<(G,.:V2:HWOKI
MAFHX56I)12NK,DNHYZ;II];_,A52PQ$ AM%$>F:PUAP1-.X+\K+9D?8,88*M
M\>!J7G-X&C87 ^O<YJ;H9D&QXY01\BE!]%.:ZU*?N1FR4>OG7673K):N<Q@K
MO0L"&)RT*EG8132X#5N\VYR0SKUC.K1/A4#;22YO%>GC-.I]%+'O6^YL@/TJ
M/ZH<&@V"&-DTFIP#^Q+.'V U\E^5WF!.R[^'"8H!($E41+O+(D,65@LZ&39D
M5"F67Q/7A_1-] I8-S1.]*#:=/[0V""B??3\IVK++HI A&^5G\%X\Y%*K2<K
M O'6#<PP=[ED?"]'F[DY[X-H0 G-P<%N 10]!HV)@'?WQ<F]8WVL"/V6D%(7
MJA!<H8>WM[M$QX.ZS/!'EIN@6YAL3MK;WYA"7Z^ V80X_FV#=VJKD==EL>A6
M.7&S%OR2%&K 'D5(3NA)L5,#'X<>ZQ7$]]E2#&>=Z0V@5Z',%FB_%K,,][5A
M!#-Y^I[UCSYZI ((Z>P.S!NPI\T#$/3=":JW?T/DB*9.OFJ62<D"V7LXC(EZ
MNE+W6OYM]_MLE"E)^?E@APUS*6?40R,>]@6R,[R2,JLKC1P^I'(T,,KF 1K8
M@YW';R!;U+'1]E++?FLE:^:56Z(TYWEGS?,-5<\!8UP[8TX&XQ.6-7BJ?5^8
M.4@:HT0D2PE^'/[[8+H&6&!D-5PC2/C ;F$S+<_QN+44!["D8P+=O$(CYQ\J
M^TO$J6G^FMI@Y$JR+M9U\U $Y+,9KN6^YX.\3Q7"\S._MVB'F=)^ZT$8)ST*
M8I-^*#;KB*VA),U9^3?0%\/K_F;5A46.^$%\\_G#NY&]X!;>%%A-LQVZNC_V
M1/>3MHR4I]6'*Q"P5\*]9@B8)3@CL6YD/(ZF1?$I9'9L!OSPTR^=_C3$]PF;
M'=2=J 7K7Q7SK=\Z]+L1"30B@48DT'TC@9Z.2*#O'0G4134=)!DG9AAJPTO-
M5;?4_&+7F?IN,>N\XMQFC,UF;@<5\=IL58)1F1=]6.':Z4^TN_W8%S'\^N<C
M?PJ^[=>@<9'"8QN/R-YU&X_(@85@-RT@+=ARA-^_MW+?<K4G?LE\.'[)T\GC
MXU!6JP5D>GAWI MA16+S2:D5ELQ3>3T2\7X""@ ,4(IG *W-UI8NN4G%'T%^
M%OMTLL<!O5<82>,Z*=C>3N_HVI*0P>WF9FS=U,OP'-QTIJ5+ C^#SIG8_<!G
M%=X9Q<9[U(F:]DQ=*]",UOT.L6142^FM.#GS-3 KX$3I@0$31!!\U3NF40MN
M<;IVYQ?;\]F=7S1XP:_(+]I[;)M?[-8LW[E6OQR.5A>(DM7J=ITZ,*.#8,C:
M.B_7%O.NO%Q 0&U>SBKL'B@-Y9V:]QD55(^"NE?[/^YV .PB?;&U;V_1+EIL
M6_OFUT%K?Y29'61FOX#")X^'!Q1^33!%3JR?2L.-A[?LNWA;6Y1W K1DE  *
M=5$Z.]B%B3);< ,J64H[+7W4P!XSK,'P6\,+''$+L#T3RJ/A">4'BP!^Z)RY
M(SO$J8OE*QY7W:V0\]DLT7:,=VP"?[,")M'H?0$G*J,1R++!8=NVD/,Y"(Y^
M!I9C49,YZYO*<*4VLR*L=,&'DLQ01:2'3GOE!?:<)]9L4W(C1389$0X3YIK(
MY.%AH0$""MP9I#!JVML'://LT\0/IW'2]"4S8 U,FAP%[8=3QMW602%%8_()
MFA_9$='\!J=6&CBN2O7[.G48)S%T7WFTC<T PAJC#Q0 S[60:2O(& OT,"+'
MN'/G:@@:['B(&HR*%@:EO+!G^1+;K.(Q:NM!1)G%D<KP:$3A*4HCDQA!B[=C
M\\52$*>LH9V2X>(,!!9FA3V(D6W5:@ON S8WE.M8TF=*3B 53T3^G</ZO@NW
MSX<BUD>3QT_<TNVS_SU[]>O'\_?OHO=OHE?O/_SR_L/IQ[/H_-W%QP^__GSV
M[N-%=/KN=?3W]Q_/W_T5?G.A?__A_./YV47T_K=W9Z^CO_PC^OBW,W.MOM6>
MZ:23X>DD-@^X3H$/#Q6=8[?:Y</C$[NM?CS]L[H"9QM,%T(B"P\VP7V4UC<4
MQ;0>)8)O\-]%>>N:^X)'MFUS'<MEA.&,,)P1AG/?,)QG(PSG>X?AL(N''.=4
MS0)M#\ _UEI4Y:G6WMAI:*JTBS,/E[> PR(G469.(@S@%+,UE? QM2C>N.]N
M&,,W=\NA'$+LUT6F35#+XP8#!N'7CZ06PN@R5;VW=_GCH6K:N(\NZWJC/W"#
MY"&V'!S*'L8EGU%0BVV<P6E&$2@TB9L^^O=F*X7%!\K49U=J]HD+CDJ]T2KX
MOQM:YR3_5-GS.55X?A(]!O2;PKPR>\C:*$BS8 :?$%K2Y8!3_?W$&; :M)H.
M&:$;TMA45]B.4=J.RE5!+%5!4VN:S#Y=EGJ$Z2->A#G^YR=G2>9S?TE.2_UB
M7T5,C.*0 L@:)^)'C"7 K^Z6N/P!):TKXD.4+MMTJS%RB)>[B(P0\8O9W*0.
M.1+(&E%:<V^C^YB^I5?K"7DN1IB@?U22K^&]T%N?)[-*J[X% M,.=FMLWJ1M
M6!7Z%Y)-0N1]JE66V0ZSQIC04==[CP;6WA2'C="H48)[HMXD?6T#(4!FD=04
M:>R5-#BU)--XJ8"SPH1"DER<%^QN9/Z-"0R4LN5J4=SZ3=4QC=%NJ@Z J(RI
MJ%R)XCB.B22B[%Z:KO)X?*X6*KU4Z)2)\L7/&0>5P9&+TB1,'*9]2FD^2I:@
MC+^[Y=[@^3\9GN?_]T*XD2\L!NO]C:/Q0M;%P\0LM<S:OIQT]/O ,3S1M<96
M58T()*'),B]0D<#6? 6^)C+V+D*O2R#NNE*+>2S"R1&!I,0[9&RG)JMDIK=-
M;"T%*$1*R:@C<N'B,UR P5,@?$'M"=8BJ%"302%+.8T;.1-'48B1 +]P6Y1O
M8*YN81.(98WORT;L+ESJ.[+CT:[VRRV_\PCL8$*P)\>3DQ=N#/;B;Z<?()SZ
M)KKX^/[5_]DS)?IT>$KTC6!S_3BJY?@;0/A4*YDRS&UHU$^IF!*=E/_,&3]N
M8?/#=>Y\ES);E>OKNIJI]#J*=2J4B3=?IM^7'3:J?IOI-(-Q =+_MOT*@?Z2
M>M=B+V@GQ=O+-(G'DV?>3Z(S;)I -:EFWN4$<>6F1US^;=?!'N4Y\I8B\309
MVNX$.8$$2\&)4:G _F2;N[[Q&.'Z>%,.LIJI$-!AURM8I(3[1L2A7''WYWS[
MD&^@:IL-$9PO?/B)%.V%:J',)"=Y8$90=9!72GY%=1CSW-]*'T/B?+5- V>+
MI$+;D'K!4_M+UCPW;L2'MT5[-S#';$DE@7,GOX2.L(0@'1$0KD%QP[4&/,^U
M*5DI%Y86$RYHK@P0#17JI9Z4,BFQH3>@GEF>D%4#7"GKW-L HD%'<^\EC!\V
MQ-(ZAC/H7IYR98S+S;AA1-R?DUHB.K?.0$-5:S!NLUI>GCZQR@IY:C@J "IM
MKDWSZ$:5.XV 22RE83T^8]\\R0'V9'P+35Z&8_.<1KF^DRN!4.WEFACZ[X8A
MPUO>FA8DGEGNMVCONRG[=+@'^/* 8PD=6R^=PP&WY4)/8 S'[4)1*B+5?FQ9
MW,*6,;'^9?+)=-:%LK$L3:XEO*T%?PY!&=]YU+I-:P)IX.I; W2VTQ[O?CP7
M8#6">!SII,[>8'H08S=@U+1V<7H5PC08C-P7KPH=$*"-;3?F[B'W/<)4O>'-
M#-4L0(47UJC!S#WFKY++4F%H$O;_,M?JH+-(3VK_'#)RGB:.@2%E2$L:(C@"
M:ZT1]20&"OXP%L8W=6L9*AF1OC2Y3"!.3/()*T[RP'IVF4!;2_Y)\_%^3*)H
MR<F.PBJGWT[+WJV?1V3%B*P8D15WA*QX/B(K[@Q9,3B;<(#=(#^RG3[V%;C'
M-M<RQP2'1D(TQWT5(Z\O\(?F ?:91CL3,G=$@<"6I!"4,4@;\PD6^P#Q";UX
M9:Y: &_TL$WZ 7U;,Z#N\)%C[FK#B-.&:$40Q0*T$Z"$>:^=1\G$:)%]4DZ3
M%YJ7?9''H;:M;DD96HZ4:/815FYY+69^P=I>FA"FWZ''H\N3^CVG*Q#&<903
MR>F5?\Q):ZLUHUR<C2ILMWVV>[X7/O+&S\E#]AF@1,CI(,0[[_5?7[W=M]C%
M -N@O<D^@X?\@;3GZWZ/Y/O2$ ,\L<YS9HY!%S4$6O(!_-ZN<0/K7#-(F7_]
M-R3=I6;)Z?KL:PT&F*2_%^LR7W+!(!UK'; ;+"[./NNSA(_7% \IJCET/G**
M_3@(8@.17+\DG6&<!-F<9(\^M?<".MZT6&WH9D?-[X+C\-AZFE T+DA$I:57
M(8^>/=:?E1&S+.L/CA[K>]U6$L]U(ZH4ZI#NR.>=/*U5@9W&*G_B\%B6!98W
MWV*)>Q8UIB$Y:X"D!\S=\<7/%G%RW]>CH@Z\LY%<6!P^5K!RM>:Y^*H1V=GP
MQ\2</E3*2LM$IEE[\:@BAJ;1HSBYTVE"L<B+ID2;QG-]R::^@>RN"CH5@<TB
MU9P#*L@\->T)V ;5VR#*EDN5 M,&]OF#O2W3 M^:K=TJ8A8B#/GX)H&2Z/@N
MG^DNJ'X"8)DFT:F9-6.K-&TGGN:[F$30+K="H.!J5E_>_OB'IR]_,CB!6+L5
M-\#_'MMSH%?Y0@CQJX4485 T0@#$R@9*G, KNBF.&L&GAS?NMANU]42;[<+S
MR/8YPX!KQ<%\W"V[OR88EC,8*(9?;9L,8:O@G+$6%FN3:3MA7RR> ?I$=V;Q
M,*E"M$IN7;"X7BO(MJ=.300D0[.IP>!H:2YJ]Q)B#I!42.<#U6=5SC+.2?,U
M66[2!9(1TQ;#I3:)9D6N-W3%SU2?Z7,'O<,H2A1'0?W.'=X5;9S,UTCF;ABY
MNG4"!A:2]!K$/'XHZZS7!D/2!_U S\Y"LVJ%U>V"GZ?W[3LT=SP:!4?MXB!V
M._&\"0FQ*L/K5\WIHL0,31CD0??-=QU@/]</"'Q04'-RX8C PR,.@Z'&AC(K
M+G,H?:+2D]E"R^$UDYIPP(^BC*5]1R\^R<>RS0I3U,91E*(9V5<RED#%B!*X
M,G;8TM@QFD*EE3]&V$Z0RZ7\GU&TG&PM7/"Y,25P/ R==&!  !_W]1Z_Y\V5
MPC\+B@>9)#)&S]1G")@Z=6]L9!CWE8L0DZJC A$>+<TH7NN->I-\AQ4U_1OT
MR0!YU$YM+_-?F(/,<9D?=I^>YZ;5NI9A/LO<PEA#SL?T:97"#KK:I&PPO'8>
MUJWX+V(:W$HC9$*"'Q%[TGK!A61ZUZ\77+?1ZN^N=X-VB,"@T4;'3)7&-D;4
MC86(Q7(K1(>),]3*$VR.]X*UH364<<+6=':&(436XFE0)C>-< KQQKRC=VX5
MSP#&1J_X#I.)65%Y0H#MIP&DJ[RY8D&5]!)-I(/\H27#V?(A4!!Y24H? ND1
M9/E/A?O^\0]/GO_DVBP6SN>.882)C#"1$29R[S"1%R-,Y.MA(D,I4QM,G=KQ
M\PF'A;A.[?W'OYU]\ C WNPW]=>3 1*J>B5K[]$*L97 #U_P"Y#8"AB]IGH-
MB5/ %/]:BH3>_A%B7&'\)6"O',RT)502SMM6&1[& IZUM3KW4C43+HZE@CN'
MDILK@2L9E5/XTIE/H8#[/:\AWO%'[19KRW6+56V'_Q]4QC @2[0]QO8$F7-$
MSO'UFP+GUB+I]8#@!KD!O"1$N&&MX)C[WI:**#:J*@,K,41U$5, I"ZU*E/*
ML+A&I,U@6*MU"0CKFGAT(53WY:.7TIQFV=+<J22H#&,)>G"UWCLFE>'>&]HC
MY+N/A>4:7;CEJJ3V#0Y)2;NF:NZR\&#Y%(=?9@4$="MP>/1&3SAO4GS1"L?M
ME;6K J4/D&&MDBQU2E)]C>%U&= K&.P_$*0G^MK]3]2KX(O9&:5H$<6A0E5B
M_JP&:]*PZLQQZVWQ&0F%HM*]G2:YMW+-9!G9K<07(/(;LZ29O_A>[Z'.6C8W
M0;[3OBE"+^T\$6LD4K7(\&2)=]\-V!E;?XE8 UER'P_RJA$'X'(CXKGD)U.$
M%%M4V8U,ZT?C=_.0FQ; OMFZ<B3I*DDQ6MD]RP$N\>^9^^'\?X=BQ379=U^?
M__W\]=F[UQ=[9C</D,;[M9HM$AM0?"UYAH<UF<TP+(1ZEJS ..N):VX,4>[(
M(6!)&EAQI3A7O6S<SLCYHI4^4[&M=E)=$>(<P=]\6&2Y$VIMO&(9) >Z]]?>
MMU3* 'FJ14BB#PHZ!ZF'W6Q_(>.A XL1TP%IO$@%F;D,"BW6YK?$5!DP_I+K
M)%L8DC23Q.2LXGI)UN&RCW"RQ:IGJ+(EQAWFS*ZDD65"P$V<:*9Q@7]B@!]@
M3,@"I]=(Y;.,JVIAL.J?VN7)_@4FMY-\Y2]+I;=UR:R'2VV9BW7.[71P@X=]
M>(?8@4UB2QLG3 \;^3<=F V:*5"VO)YA42X7*QO^L- @A"^B(\&R+%*H#@:;
M<%HLLNK*ZPF"\YA)&3>"_DWGDDP[H0GRY8&3\5U;1X,QCIY.GKNVT9OSBU>G
M;Z-_G)U^V#-%/4!:P3=:L^@#^1_:87MX(,J<!G.KDJ"C;=QV@T[>AECO^]ZC
M@TD*-#V8\W>OSWY^=_[F_-4^QO\'R%UWSJ068.8:7\;$CUK!:_T9)0GLWV=,
M*TNA^=-+KUW(=XXE_E;54[LTZ;403,LXZ"S0Y$$)T+C7]'R]6$ PCOFD&5[O
ME#M:AFF*; L2QA!_]0!B6KK;$K.@&6F#7"-<9(2+C'"1^X:+O!SA(M][OY:L
M8A((T,3HA.8FE$_D40A:OA6@LPLQSO+K8@&= P\P8G"3U;D+4X;?'(KV_P5Z
M U A&]K9B9-&1^XRS,>ZS34RHKW'6Z=\]%%QB1Q\A=-U6GO3H$:IJW2T^:)_
M6Z+2(+[53+690.FF^L\UG.:A0)4[Q;%="^DU$)L6RG#U:4['^AFHJU690>-(
MH24[^[Q2.<1P#BS.5GA%*F9IB^;:S#QDN=$*XQ8PN6MI]'B5+8G-'0,KLT(;
M&C/+<(9"9>5OQ$9LAXT(6UQ<)F&ZG7CL>!0%[=EUH>5I:(>#@ECVI;H!-(@V
MN20%[VH(+L@^R XE$^Q[-%JLN71B<>N-6'1;H%7+098=_O$/1\\>_T18'3,N
M5$0V]<[A/&D:0ZGRG@8>@5VG'R7/ZAJ^'EU97/?E3SKPZACNU1:J'^IU@2,.
MM/^:LMAX5=,J9XQ2R"C']C'9=??DAZ:<;E^MIQ7+P$%ZV*I*??(4L%F+!;5'
MAK8UH :.'__T4+LVK,=?,7R,/6G A9P;6;6B\XU(L<-[&2?NZ*>QQO?N_7*I
M\=TI+/)@L=!-S$Q6BQ_XY2[F%UQPBP4X>%Z#:2=N?9.!WMWAL] ./T0517K%
MMEY5WMQ);4J[^FBC<II$704QSLM[KY<J((+E#K$M$@4IT&NJ.1-#1MX'#VO&
MIQ07Y[7.PLH4 5M&=[_Q[ Y9K7W9WK/A;.^3R0N"29.T#W 'QW*.WU?0378\
M2W6_:0=A-S"2R$L4MY'^VNA:-HQ 4R2/;Y=!!25$P#CX)C:/O2"&%/)R56L[
M;Z[MAN(&;B+."QJ2<W!28,NH[;T-U\78RK1-U5Q1B\[6^X2I3S);"2C6$I;;
MR<P+O,!1N<Z0-@_HBCP[A!IRJZHM?&/MS^>$[&,I8K"BW,$DK]%;!*81L^S$
MV=@RU9T2RCC8?U7NA*)@^]5-M<C,M5&Z6B3Y82=M)8,>;T5@6EQ])/4U,:@?
M@#AHD8*($,XUVY;.;\1HBD.]%KW7PD+Q%918 DYU28U$*W-68HL<4[ZZ7M39
MDFA]IO:(H<DB(?]=3Q$V)4VU6X%L&@CF,'P,R"T/3!'S=8EK0A7SQ/,%^&OW
MY?0R\ZO1S9,4;X_S(F\8#+O RKOE^MAKAX\]YJ7A?K4LE:)4?!/>C0-]=Q"I
ML!Y^5]0@O0#B-O810($N"Y<AS$;(G#5V?2^M]I++,EE=D?<7=H&PEZ-H8%_T
M SA@WCBMK1R(W!RP1;(I#A?0*,&07/L)1D%H58<T>_I"\\Y.( 'IHP(A0L(1
M-HPPU"XF_(/S<"#^,VK#9?([598CT8,>5FJL)3R;8/<@"0SW\&-MX3X6QLN\
M7?J&_UP7Y7H9DY_K/6I6+/$\M:AY^ZQ4$7Q:E'1K6/[O^:&,U;8T?,W'9X=\
M6D#!"KY)ZT:R+^U8M":B/U"3P?Y9*=Q$W/0 .A]7:D&6_$T)KZ2E897E3,+#
M8: Y-L+^E!<WN<R:**A'W)>"3G*7^(Z&TEQ"7#>M2XH<J_*!BP8HL*CO#[ (
MZ8-"WP]8Q9J:*9EQE&*:0'T(>!F$!S5.2.N2-$LY8K7(U+4RRDQX-HH5H,=2
M>:DI47AT \'VQ<Q.AV-FBQ=]EFM%2A;/PR:R?V/S!)8^5S.](3-")F*J#<GV
M<M&VQ,LB37')P&2N+,>E%E\1C6U2Z/A]ZB7T PYB^%PU9P'089@36@8!96<T
M!*F$@? >^*^Y6PDR55J'J<VF8! _C;<E$.@::Z$X@FBZ _,<B#IUMR06BS!7
MQ!<]W5+VF [7#HR3&DE9/XB:21DRG+EH##/4J:IOE&HWN1/$9^\ J?F7,<*:
M"P[Q"5EO??;EIH;'7U"0I@CM>BH*!4IL9'+KFQJ'6 DW#GIM':W!>>J!( H)
MPQ"7BH.6/K;%FHB)M%"L%$[>[^LRJ[2Y2(I[;L]:+"U [B.:S.Y7SN PS#-%
M1/#Z#";Z)$#TZ].B<:[F1=/%(TY&?)(<'-P$^R5SJ2&9I>_D3:(P$*6GL3F!
M2_!!8)\)A9.R"LG0TI$L@TX LKK@2P4)KZ2J 6DEZRL30X,WT+)9X>)*124,
MA,KO IF2SIGO@L@TJ;<2Y/3#C0_>:J6\F!6]J#WYS:Q #SDDM%/T!9K 24D@
M=@)3L^V(I#Y9[=6Y[I!4$); AG'KMV :X3TCO&>$]]RS(73\>(3W?._P'J._
M1:UR3SG\'!K\]1XS&/?<+:@0\.7O+<YP2&RG;&[L=@":TR^I0@<@>J4-GU2;
MLU#4A,2+PW--"075Z.B'2UE"%TC@(+3QZ(X7D,BLB;- $>FZXL'Q..%2-Z[,
M9S^L%I'X3K3P9O45'_AZ-A9,+]"2&1N!AUQ@B,:@.V0!\PNQ5H?Y]-!T*N3T
M@A]]\)(*$,%13H2]9?VT#-MYPTPTY7+2Y"@K9^LEV$5@^VK_"F?NBEE J0NO
M6$^.S2.&E&M'[9SMC+&'0X+KN$X6C1</A OO8>I[34::WMZW=DQGSS;%^9J)
M<T&%<M@12E7KY<HN6*>IVO]85(&T_:%Y=@EAN)HB=[NZ9-C?")T&J)_L<0HI
M?-"5XP%/!@UF8O&P(PJ8Q<!2>TW\,%VW:X)^0#*J=EZ$U.=TK2W4G-V2:Z,J
M-CK"F],&<>327H?'&F^12;!24K1[<>])>$X-)SS'6?!W1?[HC'F:.1SV 6,\
M#UQT<J4DUJ2W\UR53!3M5(,$XBT>DM&R3WN\S+Q]F^<D%/OB"4.GG^)$VXQX
M486KZ;:A<^HU$-,;GH%M: 9BPZYK^J+%-H/0Z&NDW4<Q#?3[V["BNV^T'5:
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M VO:V)'SI2HHM %SVX>-WI*RS^HU&"0=V=#FS[ 7@_/!(9*HEE-*]]-7!9J
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M4U-$6*6BD6#]G )=$H<N(DC]2V<%W ERX-*5!'-H9.M)]8VQ*L:%B7:/'+@
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MZD[Q0-]E_@U02P$"% ,4    " #.@6=7>JQ^M)X0 @!JO10 $0
M    @ $     ;'EE;"TR,#(S,#DS,"YH=&U02P$"% ,4    " #.@6=76_LQ
M^AH0  #]K@  $0              @ '-$ ( ;'EE;"TR,#(S,#DS,"YX<V10
M2P$"% ,4    " #.@6=7 ;X:8+\8  !M\P  %0              @ $6(0(
M;'EE;"TR,#(S,#DS,%]C86PN>&UL4$L! A0#%     @ SH%G5ULMQR\B5
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M;"TR,#(S,#DS,%]P<F4N>&UL4$L! A0#%     @ SH%G5[$&* [%'P  4)H
M !P              ( !OR$* &QY96PM,C R,S Y,S!X,3!Q>&5X>#$P,2YH
M=&U02P$"% ,4    " #.@6=77L/MNK8+  !$3@  '               @ &^
M00H ;'EE;"TR,#(S,#DS,'@Q,'%X97AX,3 R+FAT;5!+ 0(4 Q0    ( ,Z!
M9U=O'U!Y(0@  !XI   <              "  :Y-"@!L>65L+3(P,C,P.3,P
M>#$P<7AE>'@S,3$N:'1M4$L! A0#%     @ SH%G5^#*W<P9"    "D  !P
M             ( !"58* &QY96PM,C R,S Y,S!X,3!Q>&5X>#,Q,BYH=&U0
M2P$"% ,4    " #.@6=7+8K7+M5]  "Y!00 &P              @ %<7@H
M;'EE;"TR,#(S,#DS,'@Q,'%X97AX,S(N:'1M4$L! A0#%     @ SH%G5^EY
MQTY9!0  TAP  !P              ( !:MP* &QY96PM,C R,S Y,S!X,3!Q
A>&5X>#,R,2YH=&U02P4&      T #0"' P  _>$*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
